<SEC-DOCUMENT>0001654954-23-015760.txt : 20231219
<SEC-HEADER>0001654954-23-015760.hdr.sgml : 20231219
<ACCEPTANCE-DATETIME>20231219160319
ACCESSION NUMBER:		0001654954-23-015760
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231219
DATE AS OF CHANGE:		20231219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KNOW LABS, INC.
		CENTRAL INDEX KEY:			0001074828
		STANDARD INDUSTRIAL CLASSIFICATION:	MEASURING & CONTROLLING DEVICES, NEC [3829]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				900273142
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37479
		FILM NUMBER:		231497245

	BUSINESS ADDRESS:	
		STREET 1:		500 UNION STREET
		STREET 2:		SUITE 810
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-903-1351

	MAIL ADDRESS:	
		STREET 1:		500 UNION STREET
		STREET 2:		SUITE 810
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VISUALANT INC
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Visualant, INC
		DATE OF NAME CHANGE:	20050106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STARBERRYS CORP
		DATE OF NAME CHANGE:	20020918
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>knwn_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:knwn="http://knwn.com/20230930"><head><title>knwn_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin:0px 0px 0px 15px;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-10-01to2023-09-30">0001074828</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-10-01to2023-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2022-10-01to2023-09-30">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2022-10-01to2023-09-30">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2022-10-01to2023-09-30">2023</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">5000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" unitRef="Shares" decimals="0">30000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember" unitRef="Shares" decimals="0">20000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0">80358463</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" unitRef="Shares" decimals="0">48156062</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" unitRef="Shares" decimals="0">17858</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember" unitRef="Shares" decimals="0">10161</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember" unitRef="Shares" decimals="0">10161</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" unitRef="Shares" decimals="0">17858</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" unitRef="Shares" decimals="0">17858</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember" unitRef="Shares" decimals="0">10161</ix:nonFraction><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="From2022-10-01to2023-09-30"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">Estimated</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">Useful Lives</p></td><td style="white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">June 30,</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">September 30,</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Machinery and equipment</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">2-3 years</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">961,529</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">1,510,265</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Furniture and fixtures</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">5 years</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">26,855</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">26,855</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-align:center">5 years</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">3,612</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">3,612</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less: accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;;">(691,899</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;;">)</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;;">(677,755</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;;">300,097</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;;">862,977</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2022-10-01to2023-09-30"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tr style="height:15px"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended June 30, 2024-</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total remaining payments</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;;">204,534</td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Less imputed interest</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;;">(1,822</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total lease liability</p></td><td style="width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;;">202,712</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></table></ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0">80358463</ix:nonFraction><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">213330</ix:nonFraction><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2022-09-30" unitRef="USD" decimals="0">1510265</ix:nonFraction><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2022-09-30" unitRef="USD" decimals="0">3612</ix:nonFraction><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">21366</ix:nonFraction><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2022-09-30" unitRef="USD" decimals="0">26855</ix:nonFraction><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">153371</ix:nonFraction><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-09-30" unitRef="USD" decimals="0">677755</ix:nonFraction><ix:nonFraction name="knwn:TotalRemainingPayments" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">153401</ix:nonFraction><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">1396</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0">154797</ix:nonFraction><ix:nonFraction name="knwn:GrossProceedFromPublicIssueStock" contextRef="From2022-10-01to2023-09-30_knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" unitRef="USD" decimals="0">8280000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" unitRef="USDPShares" decimals="INF">0.001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" unitRef="Shares" decimals="0">4140000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" unitRef="Shares" decimals="0">5000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" unitRef="Shares" decimals="0">200000000</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption1Member" unitRef="USDPShares" decimals="INF">0.88</ix:nonFraction><ix:nonNumeric name="knwn:StockOptionExpiryTerm" contextRef="From2022-10-01to2023-09-30">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='knwn-20230930.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2022-10-01to2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-10-26_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-09-01to2023-10-26_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-10-12_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DigitalassetsalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:ParticleIncTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DigitalassetsalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:ParticleIncTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-09-01to2022-09-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-05-01to2022-05-13_knwn_PeterConleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2022-03-15_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2018-04-01to2018-04-10_knwn_MrBosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2021-03-31_knwn_MrBosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-04-01to2022-09-30_knwn_MrBosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-05-01to2021-03-31_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2018-04-01to2018-04-10_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_PeterConleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-11-01to2022-11-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-09-01to2022-09-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-09-11to2021-10-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-11</xbrli:startDate><xbrli:endDate>2021-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-05-01to2021-05-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-04-01to2017-04-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-04-01</xbrli:startDate><xbrli:endDate>2017-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-01-05_knwn_ThreeDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:ThreeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_srt_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-14_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-15_knwn_PhillipABosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-11-04_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-15_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-12-01to2022-12-14_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_AIMindMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:AIMindMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2019-11-01to2019-11-04_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_PeterConleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_PhillipABosuaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_RonaldPEricksonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:NineteenEmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:EightEmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-01-01_knwn_TwoZeroTwoOneEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:TwoZeroTwoOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-10-15_knwn_TwoZeroTwoOneEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:TwoZeroTwoOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:NineteenEmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:EightEmployeesAndConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_EmployeeStockOptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:EmployeeStockOptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_StockOption3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_StockOptionsTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_StockOptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:EmployeeStockOptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockOption3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockOptionsTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockOptionsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_knwn_StockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ConvertiblePreferredStockDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockAtOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:StockAtOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_StockAtTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:StockAtTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-09-01to2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-09-01to2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-20_knwn_CommonStocksOfferingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-09-01to2023-09-29_knwn_CommonStocksOfferingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-29_knwn_CommonStocksOfferingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:AuthorizedCapitalStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ThreeDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:ThreeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-27_knwn_MrStruveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_MrStruveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_MrStruveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-12-01to2022-12-31_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-08-01to2023-08-31_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-08-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-16_knwn_ConvertibleNote7Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote7Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-16_knwn_ConvertibleNote8Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote8Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertibleNote1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertibleNote1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2018-03-16_knwn_ConvertibleNote2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ConvertibleNote1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertibleNotesFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNotesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertibleNotesFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNotesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertibleNoteTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertibleNoteTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertibleNoteOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertibleNoteOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ThirtyFirstDecemberTwentyTwentyThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">knwn:ThirtyFirstDecemberTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">knwn:ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">knwn:ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_TechnologyEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_TechnologyEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_TechnologyEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_srt_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_StockOption1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_Warrant1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">knwn:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_Warrant1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">knwn:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-10-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_knwn_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStocksSeriesCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStocksSeriesCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_SeriesDPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001074828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentType">10-K</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the fiscal year ended: <span style="text-decoration:underline"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">September 30, 2023</ix:nonNumeric></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from ____________ to _____________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File No.&#160;<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityFileNumber">001-37479</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:90%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:14pt"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityRegistrantName">KNOW LABS, INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:90%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">90-0273142</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressAddressLine1">500 Union Street</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressAddressLine2">Suite 810</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressCityOrTown">Seattle</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Washington</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityAddressPostalZipCode">98101</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:100%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:CityAreaCode">206</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:LocalPhoneNumber">903-1351</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Title of each class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Trading Symbol(s)</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of each exchange on which registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:TradingSymbol">KNW</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE</ix:nonNumeric> American LLC</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(g) of the Act: None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160; Yes &#9744;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#160;Yes &#9744;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160; &#160;No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2023 (the last business day of our most recently completed second fiscal quarter), based upon the last reported trade on that date, the aggregate market value of the voting and non-voting common equity held by non-affiliates (for this purpose, all outstanding and issued common stock minus stock held by the officers, directors and known holders of 10% or more of the Company&#8217;s common stock) was $<ix:nonFraction contextRef="AsOf2023-03-31" name="dei:EntityPublicFloat" format="ixt:numdotdecimal" scale="0" decimals="0" unitRef="USD">32,309,758</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 19, 2023, there were a total of <ix:nonFraction contextRef="AsOf2023-12-19" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,346,524</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DOCUMENTS INCORPORATED BY REFERENCE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Know Labs, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Annual Report on Form 10-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year Ended September 30, 2023</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">TABLE OF CONTENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="#P1">PART I</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1">Item 1.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1">Business.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1a">Item 1A.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1a">Risk Factors.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1b">Item 1B.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I1b">Unresolved Staff Comments.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I2">Properties.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I3">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I3">Legal Proceedings</a>.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="#P2">PART II</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I5">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I5">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">35</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I6">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I6">Selected Financial Data.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">41</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I7">Item 7.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">42</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I7a">Item 7A.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I7a">Quantitative and Qualitative Disclosures About Market Risk.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I8">Item 8.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I8">Financial Statements and Supplementary Data.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9">Item 9.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9a">Item 9A.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9a">Controls and Procedures.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">49</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9b">Item 9B.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I9b">Other Information.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">50</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="#P3">PART III</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I10">Item 10.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I10">Directors, Executive Officers and Corporate Governance.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">51</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I11">Item 11.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I11">Executive Compensation.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">58</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I12">Item 12.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">66</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I13">Item 13.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I13">Certain Relationships and Related Transactions, and Director Independence.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">68</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I14">Item 14.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I14">Principal Accounting Fees and Services.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">70</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="#P4">PART IV</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I15">Item 15.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#I15">Exhibit and Financial Statement Schedules.</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">71</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Item 16.</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Form 10-K Summary.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INTRODUCTORY NOTES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Terms</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as otherwise indicated by the context and for the purposes of this report only, references in this report to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;our company&#8221; are to Know Labs, Inc., a Nevada corporation, and its consolidated subsidiaries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Special Note Regarding Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This report contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our goals and strategies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our future business development, financial condition and results of operations;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">expected changes in our revenue, costs or expenditures;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">growth of and competition trends in our industry;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding demand for, and market acceptance of, our products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">fluctuations in general economic and business conditions in the markets in which we operate; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">relevant government policies and regulations relating to our industry.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A &#8220;<em>Risk Factors</em>&#8221; and elsewhere in this report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Trademarks, Trade Names and Service Marks</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this report are listed without the <sup style="vertical-align:super">&#174;</sup> and &#8482; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names. This report may include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report are the property of their respective owners.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="P1">PART I</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1">ITEM 1. BUSINESS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Know Labs is an emerging leader in non-invasive medical diagnostics. We are focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique &#8220;signature&#8221; of said materials or analytes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device will provide the user with real-time information on their blood glucose levels.&#160; We recently announced our Generation 1 working prototype device.&#160; This device embodies the sensor which has been used in internal clinical testing.&#160; We have also announced the work our R&amp;D team is doing on the Generation 2 of our device, which is a wearable format and could be a final form factor, ready for commercial application. We are expanding our testing, both internally and externally, and will refine the device over time, which will require FDA clearance before entering the market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Following FDA clearance of our non-invasive blood glucose monitoring device, Know Labs plans to expand its sensor technology to other non-invasive medical diagnostic applications. As a platform technology, it can identify numerous other analytes in the human body that are important in medical diagnostics and human health and wellness.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While medical diagnostics applications, with blood glucose monitoring paramount, are the focus of Know Labs, the Company&#8217;s proprietary radio frequency and microwave spectroscopy platform have broad applicability outside of the medical diagnostic realm.&#160; Over time, as resources allow, the Company will explore those opportunities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Corporate History and Structure</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Know Labs, Inc. was incorporated under the laws of the State of Nevada in 1998. Since 2007, our company has been focused primarily on research and development of proprietary spectroscopic technologies spanning the electromagnetic spectrum. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Know Labs has one wholly owned subsidiary, Particle, Inc. incorporated on April 30, 2020. AI Mind, Inc., Know Lab&#8217;s former wholly owned subsidiary, was incorporated on September 17, 2021 and dissolved in early 2023.&#160; At this time there is no material activity in the Particle subsidiary while the Company gives all of its attention to its focus on its sensor technology and glucose monitoring device development.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The Know Labs Technology</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have internally and under contract with third parties developed proprietary platform technology to uniquely identify and measure almost any organic and inorganic material or analyte. Our patented technology utilizes electromagnetic energy along a wide range of the electromagnetic spectrum from visible light and infrared to radio wave and microwave wavelengths to perform analytics which allow the user to accurately identify and measure materials and analytes.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our technology provides a unique platform upon which a myriad of applications can be developed. As a platform technology, it is analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. Our radio frequency spectroscopy technology is an &#8220;enabling&#8221; technology that brings the science of electromagnetic energy to low-cost, real-world commercialization opportunities across multiple industries. The technology is foundational and, as such, the basis upon which we believe significant businesses can be built. While we are pursuing our core focus on commercializing our glucose monitor, we believe non-core clinical, non-clinical and medical research applications represent a multitude of opportunities for strategic collaboration, joint development, and licensing agreements with leading companies in their respective industries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe an important competitive differentiator for our sensor technology to be its ability to not only identify a wide range of organic and inorganic materials and analytes, but to do so non-invasively, and in real-time, which potentially enables new multivariate models of clinical diagnostics, and health and wellness monitoring.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Know Labs Sensor Technology:&#160; Hardware and Software</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our sensor technology embodies two key components: hardware and software.&#160; The key hardware component includes a sensor which both sends and receives a radio frequency signal.&#160; The data obtained by the receiving aspect of the sensor is analyzed by software.&#160; Today, the sensor portion of our hardware development is complete. This sensor is currently being used in our internal tests, and has been for the past several months, gathering millions of data points to further refine our algorithm. It is the core component in our Generation 1 working prototype device and the Generation 2 device under development. This sensor technology will be the core component of future versions of our devices. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a consequence, a significant amount of our focus has shifted to algorithm development.&#160; This involves sophisticated development of algorithms which derive meaningful information from the raw data obtained by our sensor.&#160; These algorithms are developed through the utilization of artificial intelligence (AI) and machine learning (ML) by means of training various models. We will continue data collection to further refine the accuracy of the algorithm until we feel confident that we can be successful in FDA clinical trials and bring to the market the first non-invasive blood glucose monitor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Early Results</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We previously announced the results of an internal exploratory study comparing tests between our sensor technology and the leading continuous glucose monitors from Abbott Labs (Freestyle Libre&#174;) and DexCom (G6&#174;). These results provided evidence of a high degree of correlation between our technology and the current industry leaders and their continuous glucose monitors. Our patented technology is fundamentally differentiated from these industry leaders as our technology completely non-invasively monitors blood glucose levels. We also believe our technology successfully addresses the limiting qualities of non-invasive optical technologies whose diagnostic capacities may be inhibited by skin tones and other factors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are currently underway with an internal study comparing data from our sensor technology and lab-based reference devices, the Nova Primary and Nova Stat Strip. We have also expanded our study to include participants with diabetes, an important step in clinical development. These studies will allow us to further refine our algorithm and obtain results compared to lab-based reference devices, which will be required for future FDA clearance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We continue to build the internal and external development team necessary to commercialize our technology. Our ability to obtain exacting results from the data collected through our sensor technology is enabled by our trade secret algorithms built through our machine learning platform. We have been refining these algorithms so they can accurately determine blood glucose levels across a broad population. We believe our algorithms can also provide accurate measurements for blood alcohol and blood oxygen levels, which we have identified in preliminary tests.&#160; We expect them to provide the analytics for the long list of other potential analytes in the human body many of which are set forth in our issued patent USPTO 11,033,208 B1.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Validation and FDA Clearance</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are also focused on building strong external validation of the technology. This on-going initiative should provide additional evidence and support as we look to approach FDA approval. Over the past year, we have announced several significant validating studies.&#160;&#160;They include: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The results of a proof-of-principle study titled, &#8220;<em>Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions, Implications for Non-Invasive Physiologic Monitoring.</em>&#8221; This study was conducted in collaboration with Mayo Clinic, sponsored by the Company, and its results were presented at the 2023 American Physiological Society (APS) Summit. The study demonstrated the accuracy of the sensor in quantifying three different analytes in vitro. In the peer-reviewed publication, it was found Bio-RFID achieved 100% accuracy in quantifying these three different analytes in vitro. The study was peer-reviewed by Sensors Journal and American Physiology Society.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The results of our technical feasibility study titled, &#8220;<em>Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6&#174;</em>.&#8221; These results were presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle, WA in ___, 202_. The study was performed by the Know Labs Clinical Development Team at Know Labs Research Laboratory in Seattle. The purpose of this technical feasibility study was to demonstrate hardware and software infrastructure stability, and to collect additional data to determine the accuracy of the sensor at quantifying BGC<em>&#160;</em>in vivo non-invasively using radio frequency by means of training a neural network (NN) model to predict readings of the Dexcom G6&#174; as a proxy for BGC. The study was peer-reviewed by the American Association of Clinical Endocrinology.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The results of a new study titled, "<em>Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs&#8217; Bio-RFID Technology.</em>" The study demonstrates that algorithm optimization using a light gradient-boosting machine (lightGBM) machine learning model improved the accuracy of Know Labs&#8217; Bio-RFID&#8482; sensor technology at quantifying blood glucose using predicted readings of the Dexcom G6&#174; as a proxy for BGC, demonstrating an overall Mean Absolute Relative Difference (MARD) of 12.9% &#8211; which is within the range of independently reported values for certain FDA-cleared blood glucose monitoring devices. The study was performed by the Know Labs Clinical Development Team at Know Labs Research Laboratory in Seattle, and reviewed by members of Know Labs' Scientific Advisory Board.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The results from a new study<sup style="vertical-align:super">6</sup>&#160;titled, "<em>Novel data preprocessing techniques in an expanded dataset improve machine learning model accuracy for a non-invasive blood glucose monitor.</em>" The study demonstrates that continued algorithm refinement and more high-quality data improved the accuracy of Know Labs&#8217; proprietary Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.3%. As with all Know Labs&#8217; previous research, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6&#174; continuous glucose monitor (CGM) as a reference device and proxy for BGC. In this new study where data collection was completed in May of 2023, Know Labs applied novel data preprocessing techniques and trained a light gradient-boosting machine (lightGBM) model to predict blood glucose values of Dexcom G6&#174; CGM using 3,311 observations &#8211; or reference device values &#8211; from over 330 hours of data collected from 13 healthy participants. With this method, Know Labs was able to predict blood glucose in the test set &#8211; the dataset that provides a blind evaluation of model performance &#8211; with a MARD of 11.3%. The study was performed by the Know Labs Clinical Development Team at Know Labs Research Laboratory in Seattle and reviewed by members of Know Labs' Scientific Advisory Board.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As the Company successfully completed our foundational studies, created a stable sensor that delivers repeatable results, and developed a software infrastructure to manage and interpret large, novel datasets, it will continue to expand its testing and data gathering with larger and more diverse populations in order to continue increasing the accuracy of our algorithms across diverse populations.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have also begun the internal and external process to pursue FDA clearance for our non-invasive blood glucose monitor. Our Chief Medical Officer, medical and regulatory advisory board, our entire executive team along with external advisors guide us in this process. Additionally, our third-party quality assurance and documentation consultants help ensure that the rigorous requirements of FDA are met. We are unable to estimate the time necessary for FDA approval or the likelihood of success in that endeavor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Product Strategy </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have announced the development of our non-invasive glucose monitor and our desire to obtain FDA clearance for the marketing of this product. We are currently undertaking internal development work of this product for the commercial marketplace. We have also announced the engagement of several strategic partners and advisors focused on sensor technology, product design, data science, machine learning, manufacturing and regulatory affairs, who we will work with to bring this product to market.&#160; The announcement of our Generation 1 working prototype device was a significant milestone for the Company. It has been used in internal clinical testing and will gather significant amounts of data with diverse populations which will allow us to refine the design of the next generation device. We have also announced the work being done on the Generation 2 prototype device, which is a wearable format and we expect to be a potential final format that would be presented to the FDA for market clearance. We will make further announcements regarding the product as development, testing, manufacturing, and regulatory approval work progresses.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our efforts are entirely focused on productizing our sensor technology and collecting high quality data for validation purposes, including third-party studies, and appropriate and required clinical trials. At this point in our development cycle, the hardware continues to be miniaturized and optimized, the product form factor is moving in the direction of a final product that will be used for FDA clinical trials and the algorithms which provide results from the data collected by our sensor are being refined to improve accuracy.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Sales and Marketing</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While we continue with our internal development efforts and the move toward clinical trials for FDA clearance of our non-invasive blood glucose monitor, we will explore the several potential avenues for moving our first product and potential follow-on products into the marketplace.&#160; The avenues being explored include direct to consumer, initial launch partners, broad distribution partners, licensing partners and private label approaches to the market, among others.&#160; As part of our growth strategy, we have begun discussions around joint development agreements with potential biopharma, medical device, and consumer electronics partners. These would be strategic collaborations that could help us accelerate development and commercial launch. In parallel, we have begun to build our internal commercial and marketing team in preparation for detailed strategic thinking about the optimal approach to the marketplace. We attend and engage in conferences focused on diabetes management and technology, which are valuable for building Know Labs&#8217; reputation and network in the space.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Competition</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The technology industry, generally, and blood glucose monitoring and other medical diagnostic markets in particular, are intensely competitive, subject to rapid change and significantly affected by new product introductions and other market activities by industry participants. To compete successfully, we will need to demonstrate the advantages of our products and technologies over well-established alternative solutions, products, and technologies, including legacy providers of blood glucose monitoring technology, as well as newer ones that are working to achieve a non-invasive solution or more acceptable blood glucose monitoring solutions which may or may not be similar to our technology, and convince consumers and enterprises of the advantages of our products and technologies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We group our competition into three large categories. Those are (i) large global technology companies who may enter the blood glucose monitoring and other medical diagnostic markets, (ii) legacy providers of blood glucose monitoring technology, and (iii) new entrants working to achieve a non-invasive solution or more acceptable blood glucose monitoring solutions which may or may not be similar to our technology. With regard to companies in each category, we perform due diligence from all publicly available sources of information on their relevant technologies and their product plans. This information informs and refines our activities and underscores our sense of urgency as we work to bring our own technology to the marketplace. As it relates to all competitors, we continue to focus on building the world&#8217;s most robust patent portfolio in this space. PatSnap Research and ipCapital Group, two leading patent analytic firms, have ranked Know Labs #1 for global patent leadership in non-invasive glucose monitoring patents. We have retained both organizations to perform patent related work.&#160; We continue to build out our patent portfolio and grow our trade secret AI and ML driven algorithms. Patents issued, pending, and in-process increased from 107 to 259 YoY (+142% vs. market +35%) reflecting our high rate of innovation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">With respect to our planned non-invasive glucose monitor, we will face direct and indirect competition from a number of competitors who have developed or are developing products for continuous monitoring of glucose levels. These competitors include DexCom, Inc., Abbott Laboratories, Medtronic plc, Roche Diagnostics, LifeScan, Inc., Ascensia Diabetes Care Holdings AG, Senseonics Holdings, Inc., Integrity Applications, Inc., Nemaura Medical, Biolinq Inc., and Profusa, Inc. Our planned solution will also compete with traditional glucometers, which remain an inexpensive alternative. We also compete with companies who are seeking to create non-invasive glucose monitors, such as Movano, Inc., Hagar, and DiaMonTech AG. &#160;Because of the large size of the potential market for our products, it is possible that new or existing competitors may develop competing products, procedures, or clinical solutions that could prove to be more effective, safer, or less costly than our solution. The introduction of new products, procedures, or clinical solutions by competitors may result in price reductions, reduced margins, or loss of market share, or may render our products obsolete. Many of the companies we will compete with enjoy significantly greater name recognition and have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and sales and marketing of approved products than we have.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mergers and acquisitions in the medical device, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Other small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. There are also several academic and other institutions involved in various phases of technology development regarding blood glucose monitoring devices.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Competitive Advantages</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe our key competitive strengths include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Through first principles, our sensor technology&#8217;s ability to not only identify a wide range of organic and inorganic materials and analytes, but to do so non-invasively, accurately, and in real time, which potentially enables new multivariate models of clinical diagnostics, and health and wellness monitoring.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our sensor technology is non-invasive, using radio waves to identify and measure what is going on inside the body in real-time.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our sensor technology platform can be integrated into a variety of wearable, mobile, or counter-top form factors, and we believe eventual interoperability with existing products from current market leaders.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No needles nor invasive transmitters in your body, making our sensor convenient and pain-free.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No expensive supplies, such as test strips and lancets, are required to operate our device.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A core focus on accessibility and affordability for the populations we will serve around the globe.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The current prototype sensor collects approximately 1.5 million data points per hour, which allows us to potentially build a deep understanding of health and wellness that other sensors may not be able to.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;Know Labs is the world intellectual property leader in non-invasive blood glucose monitoring, according to ipCG Capital and PatSnap.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Growth Strategy </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The key elements of our strategy to grow our business include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Initially, entering the diabetes glucose monitoring market with our non-invasive glucose monitoring device.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Following our entry into the glucose monitoring market, entering other clinical monitoring markets for continuous, non-invasive hormone, medication metabolites, endocrinology components, and biomolecular monitoring.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Applying our platform technology to lifestyle analysis, clinical trials, and chronic illnesses. We believe that potential use cases include real-time wearable medication monitoring and detection of, for example, ovulation and hormone deficiency.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">With an ever-growing body of non-invasively determined analytes available from individuals utilizing our technology we believe, over time, with longitudinal data we will be able to engage in so-called &#8220;predictive health&#8221; and provide early warnings of the onset of disease.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significantly, every new application will function utilizing the same sensor. We expect that hardware changes will not be required to target new analytes, so you will not need a new device, but an updated software algorithm will be required.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each new application provides potential new opportunities for monetization of the platform technology. Each additional analyte we identify over time may require its own subsequent FDA approval.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Research and Development</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our current research and development efforts are primarily focused on improving our radio frequency spectroscopy technology for the monitoring of blood glucose. As part of this effort, we continuously perform clinical testing of our devices following IRB-approved protocols, and we conduct on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. As resources permit, we plan to focus on extending the capacity of our sensor technology to identify new analytes and applications. Our current internal team along with outside consultants have considerable experience working with the application of our technologies. We engage third party experts as required to supplement our internal team.&#160;We incurred expenses of $7,727,000 and $5,386,000 for the years ended September 30, 2023 and 2022, respectively, on development activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Intellectual Property </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The cornerstone of our foundational platform technology is our intellectual property portfolio. We have pursued an active intellectual property strategy which includes focus on patents where appropriate and a diligent protection of trade secrets. To date, we have been granted 32 patents and 22 design patents. These include 13 patents on our early work on the visible and near visible portions of the electromagnetic spectrum, which were a point of creative departure as we explored and invented our current radio frequency sensor technology. We currently have a number of patents pending and continue, on a regular basis, with the filing of new patents. If we include pending patents, our IP portfolio reaches 215 patents issued and pending, which positions the company as the top worldwide IP holder in non-invasive blood glucose monitoring, according to ipCapital Group, a leading IP and innovation consulting firm. We possess all rights, title and interest to the issued patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our issued patents will expire at various times between 2027 and 2047. Pending patents, if and when issued, may have expiration dates that extend further in time. The duration of our trademark registrations varies from country to country. However, trademarks are generally valid and may be renewed indefinitely as long as they are in use and/or their registrations are properly maintained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The issued patents cover the fundamental aspects of our radio frequency spectroscopy technology and a number of unique applications. We have filed patents, which are pending, on the additional fundamental aspects of our technology and growing number of unique applications. We will continue, over time, to expand our patent portfolio.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, significant aspects of our technology are maintained as trade secrets which may not be disclosed through the patent filing process. We are diligent in maintaining and securing our trade secrets, in particular as they involve our AI and ML driven algorithms.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We shall also have an exclusive, perpetual and royalty free right to any patent(s) or other intellectual property which Phillip Bosua, someone working under direction of Phillip Bosua, or any successor or assignee develops, relating to Know Labs&#8217; technology within a period of five years after January 23, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Related Patent Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inherent in a platform technology is the ability to develop or license technology in diverse fields of use apart from our core focus. We focus on human health and wellness with a first focus on the non-invasive monitoring of blood glucose. We plan to pursue the identification of a multitude of analytes in the human body that are important to diagnostics over time. We also plan to identify, over time, opportunities for our intellectual property to be deployed in areas outside of human health and wellness.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may, although we cannot guarantee that we will, create other such subsidiaries over time.&#160; Additionally, we may license our intellectual property to third parties so that they may pursue activities that are not a part of our core focus.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employees</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, we had eleven full-time and part-time employees. Our senior management and other personnel are co-located in our Seattle, Washington offices and remote. The Company expanded its utilization of consulting firms and individual contractors to supplement our reduced workforce in an effort to reduce fixed expenses and extend operating resources.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Government Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our operations are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our research and development partners do business. The laws and regulations governing our business and interpretations of those laws and regulations are subject to frequent change. Our ability to operate profitably will depend in part upon our ability, and that of our research and development partners and affiliates, to operate in compliance with applicable laws and regulations. The laws and regulations relating to medical that apply to our business and that of our partners and affiliates continue to evolve, and we must, therefore, devote significant resources to monitoring developments in legislation, enforcement, and regulation in such areas. As the applicable laws and regulations change, we are likely to make conforming modifications in our business processes from time to time. We cannot provide assurance that a review of our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that the regulatory environment will not change in a way that restricts our operations.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>United States FDA Regulation</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Know Labs glucose monitor will be designed to allow our sensor technology platform to generate a glucose value and provide the user with real-time information on their blood glucose levels. A patient&#8217;s glucose data will be displayed via a companion app and will be transmitted directly to certain compatible mobile devices, including iPhone&#174; and Android&#174; devices.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our medical diagnostic products and operations, initially the glucose monitor, are subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and its implementing regulations, guidance documentation, and standards. Our products will be regulated by FDA as medical devices. FDA regulates the design, development, research, testing, manufacturing, safety, labeling, storage, recordkeeping, promotion, distribution, sale and advertising of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. FDA also regulates the export of medical devices manufactured in the United States to international markets. Any violations of these laws and regulations could result in a material adverse effect on our business, financial condition and results of operations. In addition, if there is a change in law, regulation or judicial interpretation, we may be required to change our business practices, which could have a material adverse effect on our business, financial condition and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the FFDCA, medical devices are generally classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk to the patient and/or the user associated with each medical device and the extent of control needed to ensure safety and effectiveness. Device classification also depends on the intended use of the device and upon indications for use. Additionally, the class to which your device is assigned also determines, among other things, the type of premarketing submission/application required for FDA clearance to market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Class I includes devices with the lowest risk, present a minimal potential for harm and for which safety and effectiveness can be assured by adherence to FDA&#8217;s &#8220;general controls&#8221; for medical devices. This includes compliance with the applicable portions of FDA&#8217;s Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I devices require premarket clearance by FDA through the 510(k) premarket notification process described below but most are exempt from 510(k) premarket notification requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Class II devices are moderate risk devices that present a higher risk than Class I devices. Class II devices subject to FDA&#8217;s general controls, and any other &#8220;special controls&#8221; deemed necessary by FDA to ensure the safety and effectiveness of the device, such as performance standards, product-specific guidance documents, special labeling requirements, patient registries or post-market surveillance. Premarket review and clearance by FDA for Class II devices is accomplished through the 510(k) premarket notification procedure, though certain Class II devices are exempt from this premarket review process. When a 510(k) is required, the manufacturer must submit to FDA a premarket notification submission demonstrating that the device is &#8220;substantially equivalent&#8221; to a legally marketed device, which in some cases may require submission of clinical data.&#160; If FDA determines that the device, or its intended use, is not substantially equivalent to a legally marketed device, then FDA will place the device, or the particular use of the device, into Class III, and the device sponsor must then fulfill much more rigorous premarketing requirements. Additionally, unless a specific exemption applies, 510(k) premarket notification submissions are subject to user fees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Class III includes those with the greatest risk as they sustain or support life, are implanted, or present a potential unreasonable risk of illness or injury. In other words, Class III devices consist of devices deemed by FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device. The safety and effectiveness of Class III devices cannot be assured solely by general or special controls. Submission and FDA approval of a premarket approval, or PMA, application is generally required before marketing of a Class III device can proceed. The PMA process is much more demanding than the 510(k) premarket notification process. A PMA application, which is intended to demonstrate that the device is safe and effective, must be supported by extensive data, typically including data from preclinical studies and human clinical trials. Additionally, as with 510(k) submissions, unless subject to an exemption, PMA submissions are subject to user fees. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To determine the classification a product may be subject to you can use three different methods &#8211; searching for an appropriate product classification via FDA&#8217;s Product classification database; searching for a similar device by clearance or approval via FDA&#8217;s 510(k) Clearance Database, PMA Database, or De Novo Database; or searching for a similar device by device listing via FDA&#8217;s Establishment Registration and Device listing Database. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are also De Novo and unclassified device types. Unclassified device types are pre-amendments devices (i.e., marketed prior to the Medical Device Amendments of 1976 but were not classified by the original classification panels) for which a classification regulation has not been promulgated. Until the unclassified device type has been formally classified and a regulation established by FDA, submission of a 510(k) premarket notification is generally required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">De Novo classification, described in more detail below, provides a marketing pathway to classify novel medical devices for which general and/or special controls provide reasonable assurance of safety and effectiveness for the intended use but for which there is no legally marketed device upon which to base a determination of substantial equivalence predicate device (i.e., no predicate product, new intended use, or different technological characteristics that raise different questions of safety and effectiveness). Devices classified into Class I or Class II through a De Novo request may be marketed and used as predicates for other future submissions, where applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>510(k) Clearance</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To obtain 510(k) clearance for a medical device, an applicant must submit to FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; (i.e., as safe and effective) to a legally marketed device, known as a &#8220;predicate device.&#8221; A legally marketed predicate device may include a device that was legally marketed prior to May 28, 1976 for which a PMA is not required (known as a &#8220;pre-amendments device&#8221; based on the date of enactment of the Medical Device Amendments of 1976), a device that has been reclassified from Class III to Class II or Class I, a device that was found substantially equivalent through the 510(k) process or a device that was granted marketing authorization via the De Novo classification process that is not exempt from premarket notification requirement. A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics, or (ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise new questions of safety and effectiveness and is at least as safe and effective as the legally marketed predicate device. A showing of substantial equivalence sometimes, but not always, can require clinical data and non-clinical bench performance data, including engineering performance testing, sterility, electromagnetic compatibility, software validation, biocompatibility evaluation, among other data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Before FDA will accept a 510(k) submission for substantive review, FDA will first assess whether the submission satisfies a minimum threshold of acceptability. If FDA determines that the 510(k) submission is incomplete, then FDA will issue a &#8220;Refuse to Accept&#8221; letter which generally outlines the information FDA believes is necessary to permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information before FDA will proceed with additional review of the submission. Once the 510(k) submission is accepted for review, by regulation, FDA has 90 days to review and issue a determination. As a practical matter, clearance often takes longer. FDA may require additional information, including additional clinical and non&#8209;clinical data, to make a determination regarding substantial equivalence.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If FDA agrees that the device is substantially equivalent to a predicate device currently on the market, then it will grant 510(k) clearance to commercially market the device. If FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the De Novo process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, PMA approval. The determination as to whether or not a modification could significantly affect the device&#8217;s safety or effectiveness is initially left to the manufacturer using available FDA guidance. Many minor modifications today are accomplished by a &#8220;letter to file&#8221; in which the manufacture documents the rationale for the change and why a new 510(k) is not required. However, FDA may review such letters to file to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>PMA Approval</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A PMA must be submitted to FDA for any device that is classified in Class III or otherwise cannot be cleared through the 510(k) process (although FDA has discretion to continue to allow certain pre-amendment Class III devices to use the 510(k) process). PMA applications must be supported by, among other things, valid scientific evidence demonstrating the safety and effectiveness of the device, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data (e.g., study protocols, adverse reactions and complications, device failures and replacements, patient information, patient complaints, tabulations of data from all individual subjects, results of statistical analyses), and non-clinical laboratory or safety studies (e.g., microbiology, toxicology, immunology, biocompatibility, stress, wear, shelf life, and other laboratory or animal tests). The PMA must also contain a full description of the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Following receipt of a PMA application, once FDA determines that the application is sufficiently complete to permit a substantive review, FDA will formally accept the application for review. FDA, by statute and by regulation, has 180-days to review an &#8220;accepted&#8221; PMA application, although the review of an application more often occurs over a significantly longer period of time, and can take up to several years. During the review period, FDA will typically request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside FDA may be convened to review and evaluate the application and provide recommendations to FDA as to the approvability of the device. FDA may or may not accept the panel&#8217;s recommendation. In addition, FDA will generally conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the QSR.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If FDA evaluations of both the PMA application and the manufacturing facilities are favorable, FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure final approval of the PMA. If FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted. Once granted, PMA approval may be withdrawn by FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In approving a PMA, FDA may also require some form of post-market surveillance when necessary to protect the public health or to provide additional safety and effectiveness data for the device. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and makes periodic reports to FDA on the clinical status of those patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New PMAs or PMA supplements are required for modifications that affect the safety or effectiveness of a PMA-approved device, including, for example, certain types of modifications to the device&#8217;s indication for use, manufacturing process, labeling and design. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>De Novo Classification</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Medical device types that FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the <em>de novo</em> classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. Under the Medical Device User Fee Amendments of 2017 (MDUFA IV), FDA&#8217;s goal is to make a decision about a De Novo request in 150 review days. Review days are calculated as the number of calendar days between the date the De Novo request was received by FDA and the date of FDA&#8217;s decision, excluding the days a request was on hold for an Additional Information request.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It is our current belief that our glucose monitoring product may require a <em>de novo </em>classification request. This will be further refined as we continue working closely with our regulatory consultants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Breakthrough Devices Program</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency&#8217;s mission to protect and promote public health.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Breakthrough Devices Program replaces the Expedited Access Pathway and Priority Review for medical devices and offers manufacturers an opportunity to interact with FDA to efficiently address topics as they arise during the premarket review phase. FDA considers devices granted designation under the Expedited Access Pathway to be part of the Breakthrough Devices Program.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All requests for Breakthrough designation must be submitted prior to submitting a marketing submission and can be revoked by FDA at any time. Additionally, devices eligible for Breakthrough Device designation must (1) provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions; and (2) meet at least one of the following: (i) represent breakthrough technology; (ii) have no approved or cleared alternatives that exist; (iii) offer significant advantages over existing approved or cleared alternatives; or (iv) whose availability is in the best interest of patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may pursue the Breakthrough Devices Program for our glucose monitor product.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Clinical Studies</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When FDA clearance or approval of a Class I, Class II or Class III device requires human clinical trials, and if the device presents a &#8220;significant risk&#8221; to human health, then the device sponsor is required to file an IDE application with FDA and obtain IDE approval prior to commencing the human clinical trial. If the device is considered a &#8220;non-significant risk,&#8221; IDE submission to FDA is not required but must still follow IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and complying with labeling and record keeping requirements. Instead, only approval from the Institutional Review Board, or IRB, overseeing the investigation at each clinical trial site is required. Human clinical studies are generally required in connection with approval of Class III devices and may be required for Class I and II devices. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an IRB for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may impose additional requirements for the conduct of the study. If an IDE application is approved by FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by FDA. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The sponsor is also required to comply with the applicable FDA requirements during the clinical trial (e.g., trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices, or on making safety or effectiveness claims for them). The sponsor may transfer some or all of its obligations related to a clinical study to a third-party but is ultimately responsible for compliance regardless of whether these obligations are contractually transferred. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The clinical investigators in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, FDA, or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA or the IRB at each institution at which a clinical trial is being performed may suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable health risk. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance or approval to market the product in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Post-Marketing Restrictions and Enforcement</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After a device is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reporting of potential device shortages in some circumstances, including during a public health emergency;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Compliance with QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">unannounced routine or for-cause device facility inspections by FDA, which may include our suppliers&#8217; facilities; </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">labeling regulations and FDA prohibitions against the promotion of products for uncleared or unapproved &#8220;off-label&#8221; uses;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">corrections and removal reporting regulations, which require that manufacturers report to FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy a violation of the FFDCA that may present a risk to health;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">post-approval restrictions or conditions, including post-approval study commitments;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulations pertaining to voluntary recalls.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Advertising and promotion of medical devices, in addition to being regulated by FDA, are also regulated by the Federal Trade Commission (the &#8220;FTC&#8221;) as well as comparable state consumer protection laws.&#160; Recently, promotional activities for FDA-regulated products of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating to advertising claims. If FDA determines that our promotional materials or training constitutes promotion of an unapproved or uncleared use, then it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an unapproved or uncleared use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged, and adoption of the products would be impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, under FDA medical device reporting (&#8220;MDR&#8221;) regulations, medical device manufacturers are required to report to FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a judgment by the manufacturer. If FDA disagrees with the manufacturer&#8217;s determination, FDA can take enforcement action.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The MDR requirements also extend to health care facilities that use medical devices in providing care to patients, or &#8220;device user facilities,&#8221; which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient treatment facilities, but not physician offices. A device user facility must report any device-related death to both FDA and the device manufacturer, or any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to FDA) within 10 days of the event. Device user facilities are not required to report device malfunctions that would likely cause or contribute to death or serious injury if the malfunction were to recur but may voluntarily report such malfunctions through MedWatch, FDA&#8217;s Safety Information and Adverse Event Reporting Program.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA also has the authority to require the recall of commercialized medical device products in the event of material deficiencies or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed devices fail to meet established specifications, are otherwise misbranded or adulterated under the FFDCA, or if any other material deficiency is found. FDA requires that certain classifications of recalls be reported to FDA within ten working days after the recall is initiated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The failure to comply with applicable regulatory requirements can result in enforcement action by FDA, which may include any of the following sanctions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">warning letters, fines, injunctions or civil penalties;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recalls, detentions or seizures of products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">operating restrictions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">delays in the introduction of products into the market;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">total or partial suspension of production;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">delay or refusal of the FDA or other regulators to grant 510(k) clearance, PMA approvals, or other marketing authorization to new products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">withdrawals of marketing authorizations; or</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">in the most serious cases, criminal prosecution.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by FDA, and these inspections may include the manufacturing facilities of subcontractors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Federal Trade Commission Regulatory Oversight</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our advertising for our products and services is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission (the &#8220;FTC&#8221;) as well as comparable state consumer protection laws. Under the Federal Trade Commission Act (the &#8220;FTC Act&#8221;), the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>International</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 24.5pt; text-align:justify;">Any future international sales are subject to regulatory requirements in the countries in which our products are sold. The regulatory review process varies from country to country and may in some cases require the submission of clinical data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1a">ITEM 1A. RISK FACTORS. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>An investment in our common stock involves a high degree of risk. You should carefully read and consider all of the risks described below, together with all of the other information contained or referred to in this report, before making an investment decision with respect to our common stock. If any of the following events occur, our financial condition, business and results of operations (including cash flows) may be materially adversely affected.&#160; In that event, the market price of our common stock could decline, and you could lose all or part of your investment. </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SUMMARY OF RISK FACTORS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks summarized below. These risks are discussed more fully in the &#8220;<em>Risk Factors</em>&#8221; section immediately following this summary. These risks include, but are not limited to, the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Risks Related to Our Business and Industry</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We might not be able to continue as a going concern. We believe that our cash on hand will be sufficient to fund our operations at least through June 30, 2024;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are still in the early stages of commercialization, refining our technology. Our success depends on our ability to conclude development and market devices that are recognized as accurate, safe, and cost-effective as other options currently available in the market and cleared by FDA.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to extensive regulation by FDA, which could restrict the sales and marketing of our products and could cause us to incur significant costs;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Risks Related to Ownership of Our Common Stock </span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The market price of our common stock may fluctuate, and you could lose all or part of your investment.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may not be able to maintain a listing of our common stock on the NYSE American.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not expect to declare or pay dividends in the foreseeable future.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Future issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market price of our securities to decline and would result in the dilution of your holdings.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Future issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely affect the level of return you may be able to achieve from an investment in our common stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to Our Business and Industry </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We need additional financing to support our technology development and ongoing operations, pay our debts and maintain ownership of our intellectual properties.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are currently operating at a loss and using substantial cash to fund our operation. We believe that our cash on hand will be sufficient to fund our operations through June 30, 2024. We may need additional financing to implement our business plan and to service our ongoing operations, pay our current debts (described below) and maintain ownership of our intellectual property. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations and/or divest all or a portion of our business.&#160;We are seeking additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to our then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay, scale back, eliminate the development of business opportunities and our operations and financial condition may be materially adversely affected.&#160; There can be no assurance that we will be able to sell that number of shares, if any.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We need to continue as a going concern if our business is to succeed.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because we have generated limited revenues and currently operate at a loss, we are completely dependent on the continued availability of financing in order to continue our business. There can be no assurance that financing sufficient to enable us to continue our operations will be available to us in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have cash and cash equivalents of $8,024,000 and net working capital of approximately $6,264,000 (exclusive of convertible notes payable) as of September 30, 2023. We anticipate that we will record losses from operations for the foreseeable future. We believe that we have enough available cash to operate until June 30, 2024. As of September 30, 2023, our accumulated deficit was $121,841,000. We intend to seek additional cash via equity and debt offerings.&#160;&#160; As a result of not having at least twelve months of cash available and not having any firm commitment for debt or equity financing, substantial doubt about the Company&#8217;s ability to continue on a going concern exists. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have financed our corporate operations and our technology development through the issuance of convertible debentures, the issuance of preferred stock, the sale of common stock and the exercise of warrants. During the remainder of 2024, we expect to raise additional funds through the issuance of preferred stock, convertible debentures or equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The proceeds of warrants currently outstanding, to the extent not exercised on a cashless basis, may generate potential proceeds. We cannot provide assurance that any of these warrants will be exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>As of </em></strong><strong><em>September 30, 2023, we owed approximately $2,980,000 and if we do not satisfy these obligations, the lenders may have the right to demand payment in full or exercise other remedies.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We owe $2,762,000 under various convertible promissory notes as of September 30, 2023, including $1,301,000 to Clayton Struve who owns 100% of outstanding Series C and D Preferred stock, and $1,461,000 owed to entities controlled by Ronald P. Erickson, our CEO and Chairman. Mr. Erickson and/or entities with which he is affiliated also have accounts payable and accrued liabilities $218,000 as of September 30, 2023 related to accrued interest. We may need additional financing, to service and/or repay these debt obligations. If we raise additional capital through borrowing or other debt financing, we may incur substantial interest expense. If and when we raise more equity capital in the future, it will result in substantial dilution to our current stockholders.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We have a history of operating losses and there can be no assurance that we can achieve or maintain profitability.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have experienced net losses since inception. As of September 30, 2023, we had an accumulated deficit of $121,841,000 and net losses in the amount of $15,289,000 and $20,071,000 for the years ended September 30, 2023 and 2022, respectively. There can be no assurance that we will achieve or maintain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and adversely affect the price of our common stock and our ability to raise capital. Our operating expenses may increase as we spend resources on growing our business, and if our revenue does not correspondingly increase, our operating results and financial condition will suffer. Our businesses have produced minimal revenues and may not produce significant revenues in the near term, or at all, which would harm our ability to continue our operations or obtain additional financing and require us to reduce or discontinue our operations. You must consider our business and prospects in light of the risks and difficulties we will encounter as business with an early-stage technology in a new and rapidly evolving industry. We may not be able to successfully address these risks and difficulties, which could significantly harm our business, operating results, financial condition and common stock price per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We may not be able to generate sufficient revenue from the commercialization of our technology and related products to achieve or sustain profitability.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are in the early stages of commercializing our technology. Failure to develop and sell products based upon our technology could have a material adverse effect on our business, financial condition and results of operations. To date, we have not generated revenue from sales of our technology or products. We believe that our commercialization success is dependent upon our ability to significantly increase the number of customers that will use our products<em>. </em>In addition, demand for our products may not materialize, or increase as quickly as planned, and we may therefore be unable to increase our revenue levels as expected. We are currently not profitable<em>. </em>Even if we succeed in introducing our technology and related products to our target markets, we may not be able to generate sufficient revenue to achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We are subject to extensive regulation by the U.S. Food and Drug Administration, which could require us to take significant time and could cause us to incur significant costs.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our KnowU and UBand glucose monitoring products are subject to extensive regulation by FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution and shipping. Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States, it must be cleared or approved by FDA through the applicable premarket review process (510(k), PMA, or de novo classification), unless an exemption applies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The KnowU and UBand glucose monitoring products and substantially equivalent devices of this type that may later receive marketing authorization are similar to products referred to as integrated continuous glucose monitoring (CGM) systems. Integrated continuous glucose monitoring systems are generally classified by FDA as Class II devices and have established special controls outlining requirements for assuring CGM accuracy, reliability, and clinical relevance. FDA also has descriptions of the types of studies and data required to demonstrate acceptable CGM performance. Though it is our current belief that our initial product, the KnowU and UBand glucose monitoring products, are appropriate for a de novo classification request (i.e., a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device that is described in more detail below), we expect similar classification, special controls, and testing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we receive 510(k) clearance for our KnowU and UBand glucose monitoring products, we may be required to obtain new 510(k) clearances for significant post-market modifications. Each premarket submission and review process can be expensive and lengthy, and entail significant user fees, unless exempt. The classification and special controls for all other products using the Company&#8217;s proprietary radio frequency and microwave spectroscopy platform will be dependent on product type and explored as applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, regulatory clearance or approval by FDA does not ensure registration, clearance, approval, or certification by regulatory authorities or notified bodies internationally. While the regulatory requirements for marketing in international markets may require that we obtain clearance, approval, or certification by an international specified regulatory body or notified body. Complying with foreign regulatory requirements, including obtaining registrations, clearances, approvals, or certifications, can be expensive and time consuming, and we may not receive regulatory clearances, approvals, or certifications in each country or region in which we plan to market our products or we may be unable to do so on a timely basis. In turn, this could limit our expected international growth and profitability, which could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>The clinical trial process is lengthy and expensive with uncertain outcomes. Results of earlier studies may not be predictive of future clinical trial results, or the safety or efficacy profile for such products.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical trials are generally required to support an application for clearance of a new device type such as our KnowU and UBand glucose monitoring products. All clinical trials must be conducted in accordance with FDA&#8217;s Investigational Device Exemption (IDE) regulations, which govern investigational device labeling, prohibit promotion, and specify an array of Good Clinical Practice requirements, which include among other things, recordkeeping, reporting, and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with FDA&#8217;s regulations for institutional review board approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Results of clinical testing may be unfavorable or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for FDA to grant approval or clearance of a product. In additional, the commencement or completion of any of our clinical trials may be delayed or halted for numerous reasons, including, but not limited to, the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">we may be required to submit an investigational device exemption application, or IDE, to FDA, which must become effective prior to commencing certain human clinical trials of medical devices, and FDA may reject our IDE and notify us that we may not begin clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost of clinical trials may be greater than we anticipate;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">patients do not enroll in clinical trials at the rate we expect;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">patients do not comply with trial protocols;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">patient follow-up is not at the rate we expect;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">patients experience adverse side effects;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">patients die during a clinical trial, even though their death may not be related to our products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">we may not reach agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">institutional review boards and third-party clinical investigators may delay or reject our trial protocol;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">third-party clinical investigators decline to participate in a trial or do not perform a trial on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or other FDA requirements;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">data collection, monitoring, and analysis is not performed in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">changes in governmental regulations or administrative actions applicable to our trial protocols, including, for example, recent legislation passed by Congress requiring clinical trial sponsors to increase engagement with FDA on matters related to appropriate representation of racial and ethnic minorities in clinical trial data for pivotal studies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA concludes that the results from our trial and/or trial design are inadequate to demonstrate safety and effectiveness of the product.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the ability of FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, the availability of industry-paid user fees, and statutory, regulatory, and policy changes. Average review times for product approvals at FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disruptions at FDA and other agencies, including those resulting from global concerns (e.g., the ongoing COVID-19 global pandemic), may also slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, if a prolonged government shutdown and/or government employee furloughs were to occur, or if FDA&#8217;s response to a global issue diverts FDA resources and attention to other regulatory efforts, then the ability of FDA to timely review and process our regulatory submissions could be significantly impacted, which could have a material adverse effect on our business, financial condition, and results of operations. Further, in our operations as a public company, future government shutdowns, furloughs, or public health emergencies could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any of these occurrences may significantly harm our business, financial condition, and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Moreover, even if our products are cleared in the U.S., commercialization of our products in foreign countries would require clearance or approval by regulatory authorities in those countries. Clearance or approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>The safety and efficacy of our products is not yet supported by long-term clinical data, which could limit sales, and our products might therefore prove to be less safe or effective than initially thought.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Given the regulatory environment in which we operate, we lack the breadth of published long-term clinical data supporting the safety and efficacy of The KnowU and UBand glucose monitoring products and the benefits it offers that might have been generated in connection with other marketing authorization pathways. For these reasons, clinicians may be slow to adopt our products, we may not have comparative data that our competitors have or are generating, and we may be subject to greater regulatory and product liability risks. Further, future patient studies or clinical experience may indicate that treatment with our product does not improve patient outcomes. Such results would slow the adoption of our product by physicians, would significantly reduce our ability to achieve expected sales, and could prevent us from achieving and maintaining profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, because the KnowU and UBand glucose monitoring products have never been marketed, we have limited complaints or patient success rate data with respect to using these products. If future patient studies or clinical testing do not support our belief that our products offer a more advantageous blood glucose monitoring, then market acceptance of our products could fail to increase or could decrease, and our business could be harmed. Moreover, if future results and experience indicate that our product has potentially recurring malfunctions or causes unexpected or serious complications or other unforeseen negative effects, then we could be subject to mandatory or voluntary product recalls, suspension or withdrawal of FDA clearance, as well as significant legal liability or harm to our business reputation and financial results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we choose to, or are required to, conduct additional clinical studies and the outcome of such studies are not positive, then this could reduce the rate of coverage and reimbursement for the KnowU and UBand glucose monitoring products. This may slow the market adoption of our product by physicians, significantly reduce our ability to achieve expected revenues and prevent us from becoming profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe that publications of scientific and medical results in peer-reviewed journals and presentations at leading conferences are critical to the broad adoption of our products. Publication in leading medical journals is subject to a peer-review process, and peer reviewers may not consider the results of studies involving our products sufficiently novel or worthy of publication. The failure to be listed in physician guidelines or to be published in peer-reviewed journals could limit the adoption of our products. &#160;Unless specifically stated to be &#8220;peer-reviewed,&#8221; the studies referred to in this filing are not peer reviewed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We are subject to extensive regulation which could restrict the sales and marketing of our products and could cause us to incur significant costs.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Medical devices may be marketed only for the indications for which they are approved or cleared. Further, clearances can be revoked if safety or effectiveness problems develop once the device is on the market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The current regulatory requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply with present or future regulatory requirements that are applicable to us, we may be subject to enforcement action by FDA, which may include any of the following sanctions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">modification to our training and promotional materials;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">customer notification, or orders for repair, replacement or refunds;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">voluntary or mandatory recall or seizure of our current or future products;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">administrative detention by FDA of medical devices believed to be adulterated or misbranded;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">imposing operating restrictions, suspension or shutdown of production;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">refusing our requests for clearance, PMA or <em>de novo</em> classification of any new products, new intended uses or modifications to our products;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA refusal to issue certificates to foreign governments needed to export products for&#160; sale in other countries;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">withdraws or suspension of 510(k) clearance that has already been granted, resulting in prohibitions on sales of our products; and</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">criminal prosecution.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations and could result in stockholders losing their entire investment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, any relationships we may have with healthcare professionals, clinical investigators, and payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens, and diminished profits and future earnings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Healthcare providers and payors play a primary role in the recommendation and/or prescription of any product candidates for which we obtain future marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, payors, and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to Centers for Medicare &amp; Medicaid Services (CMS) starting in 2022 information regarding payments and other transfers of value to physicians, certain other healthcare providers, and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported will be publicly available on a searchable website, with disclosure required annually; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. In addition, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, then we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, temporary or permanent debarment, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, then they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may seek regulatory approval of our product candidates outside of the U.S., and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">differing regulatory requirements and reimbursement regimes in foreign countries;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">foreign taxes, including withholding of payroll taxes;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">difficulties staffing and managing foreign operations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">potential liability under the Foreign Corrupt Practices Act (FCPA) or comparable foreign regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the U.S.;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">business interruptions resulting from geo-political actions, including war and terrorism.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We may face difficulties with respect to coverage and reimbursement by various payors.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales of any medical device depend often, in part, on the extent to which the product will be covered and reimbursed by government payors (e.g., federal and state healthcare programs), third-party payors (e.g., commercial insurance and managed healthcare organizations), and other payors (e.g., foreign government healthcare programs). In the United States, various glucose monitoring products are covered for individuals with both Type 1 and Type 2 diabetes by Medicare and Medicaid in the majority of states and by commercial insurers, subject to satisfaction of certain eligibility and coverage criteria. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">But significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. For example, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by payors, that an adequate level of reimbursement will be established even if coverage is available, or that the payors&#8217; reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Decisions regarding the extent of coverage and reimbursement amount are generally made on a plan-by-plan basis meaning one payor&#8217;s decision to cover a particular product does not ensure that other payors will also provide similar coverage. As a result, the coverage determination process can require manufactures to provide scientific and clinical support for the use of a product, and require providers to show medical necessity for use, to each payor separately. This process can be time-consuming, with no assurance that coverage and adequate reimbursement will be applied consistently or even obtained. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Payors are also increasingly reducing reimbursements for devices through continued implementation of cost-containment programs, including price controls and restrictions on coverage and reimbursement, which could further limit sales of any product. In addition, payors continue to question safety and efficacy while also challenging the prices charged, examining medical necessity and reviewing the cost effectiveness of devices in an effort to avoid coverage and reimbursement. But decreases of this nature surrounding the reimbursement for any product or a decision by a government and third-party payor not to cover a product could result in reduced physician usage and patient demand for the product.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Moreover, in international markets, reimbursement and healthcare payment systems vary significantly by country, with many countries have instituted price ceilings on specific products and therapies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of FDA or another governmental authority, could have a negative impact on us.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to FDA&#8217;s medical device reporting regulations, which require us to report to FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the initial use of the device. If we fail to comply with our reporting obligations, FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, seizure of our products, or, if premarket review is required in the future, delay in clearance of future products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA and foreign regulatory bodies have the authority to require the recall of commercialized medical device products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects, or other deficiencies or failures to comply with applicable regulations. We cannot assure you that product defects or other errors will not occur in the future. Recalls involving our products could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Moreover, medical device manufacturers are required to maintain certain records of recalls and corrections, even if they are not reportable to FDA. We may initiate voluntary withdrawals or corrections for our devices in the future that we determine do not require notification of FDA. If FDA disagrees with our determinations, then it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability and malpractice claims against us and negatively affect our sales.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We may face difficulties from changes to current regulations and future legislation, both in the U.S. as well as in other foreign jurisdictions where we may be operating.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Existing regulations and regulatory policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of our product candidates. Legislative changes may impact our future business and operations, including those that may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our business, financial condition, and results of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Both before and after a product is commercially released, we have ongoing responsibilities under various laws and regulations. If a regulatory authority were to conclude that we are not in compliance with applicable laws or regulations, or that any of our products are ineffective or pose an unreasonable risk for the end-user, then the authority may ban such devices, detain or seize adulterated or misbranded devices, order a recall, repair, replacement, or refund of such instruments, and require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health. A regulatory authority may also impose operating restrictions, enjoin and restrain certain violations of applicable law pertaining to medical devices, and assess civil or criminal penalties against our officers, employees, or us. The regulatory authority may also recommend prosecution by law enforcement agencies. Any governmental law or regulation, existing or imposed in the future, or enforcement action taken may have a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We cannot predict the likelihood, nature, or extent of any legislative changes will be enacted or government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. Similarly, we cannot predict whether FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, then we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Our industry is highly competitive and subject to significant or rapid technological change.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our fields of therapeutic interest is highly competitive and subject to significant and rapid technological change. Accordingly, our success may depend, in part, on our ability to respond quickly to such change through the development and introduction of new products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If our product candidates are approved by FDA, then potential competitors who seek to introduce similar product candidates may seek to take advantage of a shorter and less costly development program for a product that competes with our products. Our ability to compete successfully against currently existing and future alternatives to our product candidates and systems and competitors who compete directly with us may depend, in part, on our ability to attract and retain skilled scientific and research personnel, develop technologically superior products, develop competitively priced products, obtain patent or other required regulatory approvals for our products, be an early entrant to the market and manufacture, market, and sell our products, independently or through collaborations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We currently rely in part upon external resources for engineering and product development services. If we are unable to secure an engineering or product development partner or establish satisfactory engineering and product development capabilities, we may not be able to successfully commercialize our technology</em></strong><em>.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our success depends upon our ability to develop products that are accurate and provide solutions for our customers. Achieving the desired results for our customers requires solving engineering issues in concert with them. Any failure of our technology or related products to meet customer expectations could result in customers choosing to retain their existing methods or to adopt systems other than ours.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Historically, we have not had sufficient internal resources to work on all necessary engineering and product development matters. We have used third parties in the past and will continue to do so. These resources are not always readily available, and the absence of their availability could inhibit our research and development efforts and our responsiveness to our customers. Our inability to secure those resources could impact our ability to provide engineering and product development services and could have an impact on our customers&#8217; willingness to use our technology.&#160; Moreover, third parties have their own internal demands on time and resources which may not always align with ours.&#160; Hence, our own expectations for development and product timelines may not be shared by third parties upon whom we rely.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are in the early stages of commercialization and our technology and related products may never achieve significant commercial market acceptance.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our success depends on our ability to develop and market devices that are recognized as accurate, safe and cost-effective. They must be safe and deliver the required level of accuracy under any condition, regardless of the user, as determined by their intended use. This will be achieved through continue refinement of our technology. Before presenting it to the FDA, additional development is needed to increase its generalizability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Many of our potential customers may be reluctant to use our new technology. Market acceptance will depend on many factors, including our ability to convince potential customers that our technology and related products are an attractive alternative to existing technologies. We will need to demonstrate that our products provide accurate and cost-effective alternatives to existing technologies. Compared to most competing technologies, our technology is new, and most potential customers will have limited knowledge of, or experience with, our products. Prior to implementing our technology and related products, some potential customers may be required to devote significant time and effort to testing and validating our products. Any failure of our technology or related products to meet customer expectations could result in customers choosing to retain their existing methods or to adopt systems other than ours.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Many factors influence the perception of a new technology including its use by leaders in the industry. If we are unable to induce industry leaders in our target markets to implement and use our technology and related products, acceptance and adoption of our products could be slowed. In addition, if our products fail to gain significant acceptance in the marketplace and we are unable to expand our customer base, we may never generate sufficient revenue to achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, we may not be able to penetrate or successfully operate in international markets or encounter difficulty expanding into international markets because of limited brand recognition in certain parts of the world, which may lead to delayed acceptance of our products by consumers in these international markets. If we are unable to expand internationally and manage the complexity of international operations successfully, then it could have a material adverse effect on our business, financial condition, and results of operations. If our efforts to introduce our products into foreign markets are not successful, then we may have expended significant resources without realizing the expected benefit. Ultimately, the investment required for expansion into foreign markets could exceed the results of operations generated from this expansion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are dependent on key personnel.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our success depends to a significant degree upon the continued contributions of key management and other personnel, some of whom could be difficult to replace. While our continued operation and ultimate success is not dependent upon one individual, our success does depend on the performance of our officers, our ability to retain and motivate our officers, our ability to integrate new officers into our operations, and the ability of all personnel to work together effectively as a team. Our failure to retain and recruit officers and other key personnel could have a material adverse effect on our business, financial condition and results of operations. Our success also depends on our continued ability to identify, attract, hire, train, retain and motivate highly skilled technical, managerial, manufacturing, administrative and sales and marketing personnel. Competition for these individuals is intense, and we may not be able to successfully recruit, assimilate or retain sufficiently qualified personnel. In particular, we may encounter difficulties in recruiting and retaining a sufficient number of qualified technical personnel, which could harm our ability to develop new products and adversely impact our relationships with existing and future customers. The inability to attract and retain necessary technical, managerial, manufacturing, administrative and sales and marketing personnel could harm our ability to obtain new customers and develop new products and could adversely affect our business and operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We rely on the timely supply of components and parts and could suffer if suppliers fail to meet their delivery obligations, raise prices or cease to supply us with components or parts.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The manufacture of our products is complex and requires the integration of a number of components from several sources of supply. We rely on numerous critical suppliers for various key components that are used in the manufacturing of our products. We can make no assurance that we will be able to maintain such supply arrangements. If we are unable to maintain supply arrangements, our access to key components could be reduced, which could harm our business.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, if demand for our products decreases, we may have excess inventory and inventory that may expire, which could result in inventory write-offs that would have a material adverse effect on our business, financial condition, and results of operations. We may also encounter defects in materials and/or workmanship, which could lead to a failure to adhere to regulatory requirements. Any defects could delay operations at our contract manufacturers&#8217; facilities, lead to regulatory fines, or halt or discontinue manufacturing indefinitely. Any of these outcomes could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This reliance also adds additional risks to the manufacturing process that are beyond our control. For example, the occurrence of epidemics or pandemics may cause one or more of our suppliers to close or reduce the scope of their operations either temporarily or permanently. In addition, these suppliers may provide components and products to our competitors. The medical device industry&#8217;s reliance on a limited number of key components and product suppliers subjects us to the risk that in the event of an increase in demand, our suppliers may fail to provide supplies to us in a timely manner while they continue to supply our competitors, many of which have greater purchasing power than us, or seek to supply components to us at a higher cost.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The failure of our suppliers to deliver components or products in a timely fashion could have disruptive effects on our ability to produce our products in a timely manner, or we may be required to find new suppliers at an increased cost.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Moreover, our reputation and the quality of our products are in part dependent on the quality of the components that we source from third-party suppliers. If we are unable to control the quality of the components supplied to us or to address known quality problems in a timely manner, then our reputation in the market may be damaged and sales of our products may suffer. As a result, we may experience a material adverse effect on our business, financial condition, and results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We have limited insurance which may not cover claims by third parties against us or our officers and directors.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have directors&#8217; and officers&#8217; liability insurance and commercial liability insurance policies. Claims, however, by third parties against us may exceed policy amounts and we may not have amounts to cover these claims. Any significant claims would have a material adverse effect on our business, financial condition and results of operations.&#160; In addition, our limited directors&#8217; and officers&#8217; liability insurance may affect our ability to attract and retain directors and officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our inability to effectively protect our intellectual property would adversely affect our ability to compete effectively, our revenue, our financial condition and our results of operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We rely on a combination of patent, trademark, and trade secret laws, and confidentiality procedures to protect our intellectual property rights. Creating and maintaining a strong patent portfolio is important to our business. Patent law relating to the scope of claims in the technology fields in which we operate is complex and uncertain, so we cannot be assured that we will be able to obtain or maintain patent rights, or that the patent rights we may obtain will be valuable, provide an effective barrier to competitors or otherwise provide competitive advantages. Others have filed, and in the future are likely to file, patent applications that are similar or identical to ours or those of our licensors. To determine the priority of inventions or demonstrate that we did not derive our invention from another, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office or in court that could result in substantial costs in legal fees and could substantially affect the scope of our patent protection. We cannot be assured our patent applications will prevail over those filed by others. Also, our intellectual property rights may be subject to other challenges by third parties. Patents we obtain could be challenged in litigation or in administrative proceedings such as <em>ex parte </em>reexam, <em>inter parties </em>review, or post grant review in the United States or opposition proceedings in Europe or other jurisdictions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">any of our existing patents will continue to be held valid, if challenged;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">patents will be issued for any of our pending applications;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">any claims allowed from existing or pending patents will have sufficient scope or strength to protect us;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">our patents will be issued in the primary countries where our products are sold in order to protect our rights and potential commercial advantage; or</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">any of our products or technologies will not infringe on the patents of other companies.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we are prevented from selling our products, or if we are required to develop new technologies or pay significant monetary damages or are required to make substantial royalty payments, our business and results of operations would be harmed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or interferences against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could have a material adverse effect on our results of operations and business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Claims by others that our products infringe their patents or other intellectual property rights could prevent us from manufacturing and selling some of our products or require us to pay royalties or incur substantial costs from litigation or development of non-infringing technology.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In recent years, there has been significant litigation in the United States involving patents and other intellectual property rights. We may receive notices that claim we have infringed upon the intellectual property of others. Even if these claims are not valid, they could subject us to significant costs. Any such claims, with or without merit, could be time-consuming to defend, result in costly litigation, divert our attention and resources, cause product shipment delays or require us to enter into royalty or licensing agreements. Such royalty or licensing agreements, if required, may not be available on terms acceptable to us or at all. We have not been engaged in litigation but litigation may be necessary in the future to enforce our intellectual property rights or to determine the validity and scope of the proprietary rights of others. Litigation may also be necessary to defend against claims of infringement or invalidity by others. A successful claim of intellectual property infringement against us and our failure or inability to license the infringed technology or develop or license technology with comparable functionality could have a material adverse effect on our business, financial condition and operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The analysis of our patent portfolio by PatSnap Research and ipCapital Group is not a legal analysis and does not predict the outcome of any legal challenges we or others might make in regard to patents, nor does it constitute a view on the overall legal strength of our patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If we are unable to secure a sales and marketing partner or establish satisfactory sales and marketing capabilities at our company, we may not be able to successfully commercialize our technology.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we are not successful entering into appropriate collaboration arrangements or recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing our technology, which would adversely affect our business, operating results and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may not be able to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales and marketing infrastructure, we may not realize a positive return on this investment. In addition, we must compete with established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to commercialize technology without strategic partners or licensees include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We may engage in acquisitions, mergers, strategic alliances, joint ventures and divestures that could result in final results that are different than expected</em></strong><strong>.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the normal course of business, we engage in discussions relating to possible acquisitions, equity investments, mergers, strategic alliances, joint ventures and divestitures. Such transactions are accompanied by a number of risks, including the use of significant amounts of cash, potentially dilutive issuances of equity securities, incurrence of debt on potentially unfavorable terms as well as impairment expenses related to goodwill and amortization expenses related to other intangible assets, the possibility that we may pay too much cash or issue too many of our shares as the purchase price for an acquisition relative to the economic benefits that we ultimately derive from such acquisition, and various potential difficulties involved in integrating acquired businesses into our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, we have also engaged in discussions with candidates regarding the potential acquisitions of our product lines, technologies and businesses. If a divestiture such as this does occur, we cannot be certain that our business, operating results and financial condition will not be materially and adversely affected. A successful divestiture depends on various factors, including our ability to effectively transfer liabilities, contracts, facilities and employees to any purchaser; identify and separate the intellectual property to be divested from the intellectual property that we wish to retain; reduce fixed costs previously associated with the divested assets or business; and collect the proceeds from any divestitures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we do not realize the expected benefits of any acquisition or divestiture transaction, our financial position, results of operations, cash flows and stock price could be negatively impacted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>We may make strategic acquisitions in the future, and if the acquired companies do not perform as expected, this could adversely affect our operating results, financial condition and existing business.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may continue to expand our business through strategic acquisitions. The success of any acquisition will depend on, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of suitable candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">higher than anticipated acquisition costs and expenses;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">competition from other companies for the purchase of available candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to value those candidates accurately and negotiate favorable terms for those acquisitions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of funds to finance acquisitions and obtaining any consents necessary under our credit facility;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability to establish new informational, operational and financial systems to meet the needs of our business;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability to achieve anticipated synergies, including with respect to complementary products or services; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of management resources to oversee the integration and operation of the acquired businesses.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may not be successful in effectively integrating acquired businesses and completing acquisitions in the future. We also may incur substantial expenses and devote significant management time and resources in seeking to complete acquisitions. Acquired businesses may fail to meet our performance expectations. If we do not achieve the anticipated benefits of an acquisition as rapidly as expected, or at all, investors or analysts may not perceive the same benefits of the acquisition as we do. If these risks materialize, our stock price could be materially adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Government regulatory approval may be necessary before some of our products can be sold and there is no assurance such approval will be granted.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our technology will have a number of potential applications in fields of use that will require prior governmental regulatory approval before the technology can be introduced to the marketplace. For example, we are exploring the use of our technology for certain medical diagnostic applications, with an initial focus on the monitoring of blood glucose.&#160; There is no assurance that we will be successful in developing glucose monitoring medical applications for our technology. If we were to be successful in developing glucose monitoring medical applications of our technology, prior clearance by FDA and other governmental regulatory bodies will be required before the technology could be introduced into the marketplace. Our devices leverage Machine Learning (ML) and Artificial Intelligence (AI) to process the massive data collected through the Bio-RFID sensor. ML/AI also controls the sensor operation, enabling the device to emit and capture data, and, ultimately, to identify and measure blood glucose levels. Machine learning-enabled device software functions (ML-DSF) continue to be evaluated by FDA, which recently released new guidance proposing a science-based approach for AI/ML-enabled medical devices to be modified and improved more quickly. There is no assurance that such regulatory approval would be obtained for a glucose monitoring medical diagnostic device or other applications requiring such approval. FDA can refuse to grant, delay, and limit or deny approval of an application for clearance of marketing a glucose monitoring device for many reasons. We may not obtain the necessary regulatory approvals or clearances to market these glucose monitoring systems in the United States or outside of the United States. Any delay in, or failure to receive or maintain, approval or clearance for our products could prevent us from generating revenue from these products or achieving profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We or our manufacturers may be unable to obtain or maintain international regulatory clearances or approvals for our current or future products, or our distributors may be unable to obtain necessary qualifications, which could harm our business </em></strong><em><strong>thus limited sales to the U.S</strong></em><strong><em>.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sales of our products internationally are subject to foreign regulatory requirements that vary widely from country to country. In addition, FDA regulates exports of medical devices from the U.S. Complying with international regulatory requirements can be an expensive and time-consuming process, and marketing approval or clearance is not certain. The time required to obtain clearances or approvals, if required by other countries, may be longer than that required for FDA clearance or approvals, and requirements for such clearances or approvals may significantly differ from FDA requirements. We may rely on third-party distributors to obtain regulatory clearances and approvals required in other countries, and these distributors may be unable to obtain or maintain such clearances or approvals. Our distributors may also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals or clearances, which could increase the difficulty of attracting and retaining qualified distributors. If our distributors experience delays in receiving necessary qualifications, clearances or approvals to market our products outside the U.S., or if they fail to receive those qualifications, clearances or approvals, then we may be unable to market our products or enhancements in international markets effectively, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Foreign governmental authorities that regulate the manufacture and sale of medical devices have become increasingly stringent and, to the extent we market and sell our products outside of the U.S., we may be subject to rigorous international regulation in the future. In these circumstances, we would be required to rely on our foreign independent distributors to comply with the varying regulations, and any failures on their part could result in restrictions on the sale of our product in foreign countries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cyber incidents can result from deliberate attacks or unintentional events. We collect and store on our networks sensitive information, including intellectual property, proprietary business information and personally identifiable information of our customers. The secure maintenance of this information and technology is critical to our business operations. We have implemented multiple layers of security measures to protect the confidentiality, integrity and availability of this data and the systems and devices that store and transmit such data. We utilize current security technologies, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, threats from malicious persons and groups, new vulnerabilities and advanced new attacks against information systems create risk of cybersecurity incidents. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These threats can come from a variety of sources, ranging in sophistication from an individual hacker to malfeasance by employees, consultants or other service providers to state-sponsored attacks. Cyber threats may be generic, or they may be custom crafted against our information systems. Over the past several years, cyber-attacks have become more prevalent and much harder to detect and defend against. Our network and storage applications may be vulnerable to cyber-attack, malicious intrusion, malfeasance, loss of data privacy or other significant disruption and may be subject to unauthorized access by hackers, employees, consultants or other service providers. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud, trickery or other forms of deceiving our employees, contractors and temporary staff.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that we will not be subject to cybersecurity incidents that bypass our security measures, impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our customers. As a result, cybersecurity, physical security and the continued development and enhancement of our controls, processes and practices designed to protect our enterprise, information systems and data from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any cybersecurity vulnerabilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the U.S. may institute additional cybersecurity requirements especially for medical devices. For example, the data security requirements in the Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;), enacted in December 2022, that among other provisions, requires developers of certain &#8220;cyber devices&#8221; to design and implement plans to monitor, identify and address cybersecurity vulnerabilities of those devices and to submit those plans to FDA as part of every new 510(k) or PMA for a cyber device. &#8220;Cyber devices&#8221; are defined as devices that include software, connect to the internet, and contain any technological features that could be vulnerable to cybersecurity threats. This provision entered into effect on March 29, 2023, and FDA has indicated that it expects sponsors of cyber devices to begin to comply with these requirements as of October 1, 2023. FDA has stated that failure to comply with these requirements will result in FDA denying approval of the cyber device application. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We are subject to corporate governance and internal control requirements, and our costs related to compliance with, or our failure to comply with existing and future requirements could adversely affect our business.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We must comply with corporate governance requirements under the Sarbanes-Oxley Act of 2002 and the Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act of 2010, as well as additional rules and regulations currently in place and that may be subsequently adopted by the Securities and Exchange Commission, or the SEC, and the Public Company Accounting Oversight Board. These laws, rules, and regulations continue to evolve and may become increasingly stringent in the future. The financial cost of compliance with these laws, rules, and regulations is expected to remain substantial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We cannot assure you that we will be able to fully comply with these laws, rules, and regulations that address corporate governance, internal control reporting, and similar matters in the future. Failure to comply with these laws, rules and regulations could materially adversely affect our reputation, financial condition, and the value of our securities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risks Related to Ownership of Our Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>If we are unable to comply with the continued listing requirements of the NYSE American, then our common stock would be delisted from the NYSE American, which would limit investors&#8217; ability to effect transactions in our common stock and subject us to additional trading restrictions.</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock is currently listed on the NYSE American and the continued listing of our common stock on the NYSE American is contingent on our continued compliance with a number of listing requirements. If we are unable to comply with the continued listing requirements of the NYSE American, our common stock would be delisted from the NYSE American, which would limit investors&#8217; ability to effect transactions in our common stock and subject us to additional trading restrictions. In order to maintain our listing, we must maintain certain share prices, financial and share distribution targets, including maintaining a minimum amount of stockholders&#8217; equity and a minimum number of public stockholders, as well as satisfy other listing requirements of the NYSE American. In addition to these objective standards, NYSE American may delist the securities of any issuer for other reasons involving the judgment of NYSE American. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have been informally advised by the staff of NYSE American that, given our current stockholders equity and history of net losses, we may be subject to the equity standards set forth in Section 1003(a)(ii) and (iii) of the NYSE American Company Guide, and that we may not satisfy these standards or the exemption criteria for these standards. There is no assurance that we will be able to maintain compliance with the NYSE American continued listing rules and/or continue its listing on the NYSE American in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the NYSE American delists our common stock from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect the common stock would qualify to be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a limited availability of market quotations for our securities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">reduced liquidity for our securities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">substantially impair our ability to raise additional funds;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">result in a loss of institutional investor interest and a decreased ability to issue additional securities or obtain additional financing in the future;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a determination that our common stock is a &#8220;penny stock,&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a limited amount of news and analyst coverage; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">potential breaches of representations or covenants of our agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements, which, regardless of merit, could result in costly litigation, significant liabilities and diversion of our management&#8217;s time and attention and could have a material adverse effect on our financial condition, business and results of operations.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The price of our common stock is volatile, which may cause investment losses for our stockholders. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The market price of our common stock has been and is likely in the future to be volatile. Our common stock price may fluctuate in response to factors such as:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Announcements by us regarding liquidity, significant acquisitions, equity investments and divestitures, strategic relationships, addition or loss of significant customers and contracts, capital expenditure commitments and litigation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Issuance of convertible or equity securities and related warrants for general or merger and acquisition purposes;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Issuance or repayment of debt, accounts payable or convertible debt for general or merger and acquisition purposes;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sale of a significant number of shares of our common stock by stockholders;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">General market and economic conditions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quarterly variations in our operating results;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investor and public relation activities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Announcements of technological innovations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New product introductions by us or our competitors;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Competitive activities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Low liquidity; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additions or departures of key personnel.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These broad market and industry factors may have a material adverse effect on the market price of our common stock, regardless of our actual operating performance. These factors could have a material adverse effect on our business, financial condition, and results of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The sale of a significant number of our shares of common stock could depress the price of our common stock.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, we had 80,358,463 shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of 14,506,158 shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 20,866,313 shares of our common stock, 8,108,356 shares of our common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 3,040,219 shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, we currently have 9,020,264 shares of our common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures. Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock. Future accreted dividends will be settled by issuing additional shares of preferred stock which can&#160; then be converted to common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Significant shares of common stock are held by our principal stockholders, other company insiders and other large stockholders. As &#8220;affiliates,&#8221; as defined under Rule 144 under the Securities Act, our principal stockholders, other of our insiders and other large stockholders may only sell their shares of common stock in the public market pursuant to an effective registration statement or in compliance with Rule 144.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These options, warrants, convertible notes payable and convertible preferred stock could result in further dilution to common stockholders and may affect the market price of the common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Future capital raises or other issuances of equity or debt securities may dilute our existing stockholders&#8217; ownership and/or have other adverse effects on our operations.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to our articles of incorporation, we are authorized to issue 200,000,000 shares of common stock. To the extent that common stock is available for issuance, subject to compliance with applicable stock exchange listing rules, our board of directors has the ability to issue additional shares of common stock in the future for such consideration as the board of directors may consider sufficient. The issuance of any additional shares could, among other things, result in substantial dilution of the percentage ownership of our stockholders at the time of issuance, result in substantial dilution of our earnings per share and adversely affect the prevailing market price for our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to our articles of incorporation, we are also authorized to issue 5,000,000 shares of blank check preferred stock of which 30,000 shares have been designated as our Series C Convertible Preferred Stock and 20,000 shares have been designated as our Series D Convertible Preferred Stock. &#160;Such preferred stock is senior to our common stock in terms of dividend priority and liquidation preference. Any preferred stock that we issue in the future may rank ahead of our common stock in terms of dividend priority or liquidation preference and may have greater voting rights than our common stock. In addition, such preferred stock may contain provisions allowing those shares to be converted into shares of common stock, which could dilute the value of our common stock to current stockholders and could adversely affect the market price, if any, of our common stock. In addition, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company. Although we have no present intention to designate or issue any shares of our authorized blank check preferred stock, there can be no assurance that we will not do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of the modifications of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock (see <em>Description of Securities&#8212;Preferred Stock</em>), assuming no changes in the amount of outstanding Preferred Series C or D ownership, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock. Future accreted dividends will be settled by issuing additional shares of preferred stock which can&#160;&#160;then be converted to common stock.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the future, we may also attempt to increase our capital resources by offering debt securities. These debt securities would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions on our operations, including liens on our assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because our decision to issue securities or incur debt in our future offerings will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings and debt financing. Further, market conditions could require us to accept less favorable terms for the issuance of our securities in the future. Thus, you will bear the risk of our future offerings reducing the value of your shares and diluting your interest in us. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The exercise prices of certain warrants, and the conversion prices of our outstanding convertible notes payable and our preferred stock may require further adjustment.</em></strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If in the future, we sell our common stock at a price below $0.25 per share, the conversion price of our outstanding shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock would adjust below $0.25 per share pursuant to their respective certificates of designation. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 7,684,381&#160; shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,439,707 would adjust below $1.20 per share and warrants totaling 4,484,725 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>If our company were to dissolve or wind-up operations, holders of our common stock would not receive a liquidation preference.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If we were to wind-up or dissolve our company and liquidate and distribute our assets, our common stockholders would share in our assets only after we satisfy any amounts we owe to our creditors and preferred equity holders.&#160;&#160;If our liquidation or dissolution were attributable to our inability to profitably operate our business, then it is likely that we would have material liabilities at the time of liquidation or dissolution.&#160;&#160;Accordingly, it is very unlikely that sufficient assets will remain available after the payment of our creditors and preferred equity holders to enable common stockholders to receive any liquidation distribution with respect to any common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business, and we do not anticipate paying any cash dividends on our capital stock in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I1b">ITEM 1B. UNRESOLVED STAFF COMMENTS. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I2">ITEM 2. PROPERTIES. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Corporate Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 13, 2017, we leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. We lease 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expired on May 31, 2022. On October 31, 2021, we extended the lease from June 1, 2022 to May 31, 2023 at $2,986 per month. On April 26, 2023, we extended the lease from June 1, 2023 to May 31, 2024 at $2,908 per month.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Lab Facilities and Executive Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 18, 2021, we entered into a lease for its lab facilities located at 914 E Pine Street, Suite 212, Seattle, WA 98122 and leased 2,642 square feet. The net monthly lease payment was $8,697&#160;and&#160;increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 11, 2021, we entered into the First Amendment of Lease and added 2,485 square feet for $5,000&#160;per month.&#160; On September 20, 2022, we entered into the Second Amendment of Lease for additional space. The expanded space will be utilized for research and testing. The Amendment of Lease expires on December 31, 2023.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 22, 2022, we leased lab facilities and executive offices in Yucca Valley, CA from Phillip Bosua, our former CEO. We leased 1,700 square feet of the total 2,134 square feet of the premises and the current net monthly payment is $7,000. The lease was to expire September 30, 2023 and could be extended on a month to month basis. We paid $91,500 in rent on September 28, 2022 for the period September 1, 2021 to September 30, 2022. We paid $28,000 for the year ended September 30, 2023. The lease was terminated on January 23, 2023, the date of Mr. Bosua&#8217;s resignation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 22, 2022, we leased an additional 1,800 square feet of lab facilities at 123 Boylston Ave, Suite C, Seattle, WA 98102 with a net monthly payment is $2,250. The lease was set to expire on November 21, 2023 and has been extended on a month-to-month basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I3">ITEM 3. LEGAL PROCEEDINGS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="P2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I5">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Market Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Number of Holders of our Common Shares</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, there were approximately 190 stockholders of record of our common stock.&#160; In computing the number of holders of record of our common stock, each broker-dealer and clearing corporation holding shares on behalf of its customers is counted as a single stockholder. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Dividend Policy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the near future. We may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any future determination to declare dividends will be made at the discretion of our board of directors subject to limitations under applicable law (including Nevada Revised Statutes 78.288) and will depend on our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant. See also Item 1A &#8220;<em>Risk Factors&#8212;Risks Related Ownership of Our Common Stock&#8212; We do not anticipate paying any cash dividends on our capital stock in the foreseeable future</em>.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock do not accrue or pay cash dividends. All future dividends will be accrued and paid in Series C Convertible Preferred Stock or Series D Convertible Preferred Stock, as applicable. See &#8220;<em>Description of Securities&#8212;Preferred Stock</em>.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Securities Authorized for Issuance under Equity Compensation Plans</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Item 12 &#8220;<em>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</em>.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Sales of Unregistered Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended September 30, 2023, we had the following sales of unregistered sales of equity securities:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, we closed an offering of our common stock pursuant to which we sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, we received net proceeds of $5,472,791. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description of Securities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Authorized Capital Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description summarizes important terms of the classes of our capital stock as of September 30, 2023. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation as amended, restated and supplemented to date, or our articles of incorporation, and our second amended and restated bylaws, or our bylaws, which have been filed as exhibits to this Annual Report on Form 10-K. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Authorized Capital Stock</em>.&#160; Our authorized capital stock currently consists of:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:78%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">200,000,000 shares of common stock, par value $0.001 per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:78%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:78%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">5,000,000 shares of &#8220;blank check&#8221; preferred stock, par value $0.001 per share, of which:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:78%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">30,000 shares have been designated as our Series C Convertible Preferred Stock, $0.001 par value per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:78%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:78%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">20,000 shares have been designated as our Series D Convertible Preferred Stock, $0.001 par value per share.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2023, in connection with the Series C and D Convertible Preferred Stock 1 for 100 reverse stock&#160; split, the authorized shares of Series C and D Convertible Preferred stock were each reduced to 30,000 and 20,000,&#160; respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Outstanding Shares of Capital Stock</em>. Our common stock is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. All outstanding shares of our capital stock are fully paid and nonassessable. As of September 30, 2023, there were:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:77%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">80,358,463 shares of common stock issued and outstanding, held by holders of record;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:77%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:77%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">17,858 shares of Series C Convertible Preferred Stock issued and outstanding, held by one holder of record; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:77%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="width:77%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10,161 shares of Series D Convertible Preferred Stock issued and outstanding, held by one holder of record.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. Our articles of incorporation do not provide for cumulative voting in the election of directors.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors on the common stock out of legally available funds. In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any preferential rights of any outstanding preferred stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock, including our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Preferred Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our articles of incorporation authorize our board of directors, without stockholder approval, to issue up to 5,000,000 shares of preferred stock in one or more series, and to determine the designation, preferences, limitations and relative rights thereof, including, without limitation, such matters as dividends, redemption, liquidation, conversion and voting. Our board of directors has the discretion to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock, or which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of our outstanding voting stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series C Convertible Preferred Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Of our authorized preferred stock, 30,000 shares have been designated as our Series C Convertible Preferred Stock, or the Series C Preferred Stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">With respect to dividend rights and rights on liquidation, winding up and dissolution, shares of our Series C Preferred stock rank senior to our common stock and our Series D Convertible Preferred Stock. Holders of Series C Preferred Stock have no preemptive or subscription rights and there are no redemption or sinking fund provisions applicable to the Series C Preferred Stock. The rights, preferences and privileges of the holders of Series C Preferred Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any other series of preferred stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to any class voting rights provided by the Nevada Revised Statutes or the certificate of designation for the Series C Preferred Stock, holders of Series C Preferred Stock have the right to vote, on an as-if-converted-to-common-stock basis (but subject to, and after giving effect to, the conversion limitations described below, applied effective as of the record date for determining the stockholders entitled to vote). Further, as long as any shares of Series C Preferred are outstanding, the Company shall not, among other things, without the affirmative vote of the holders of at least a majority on voting power of the outstanding shares of Series C Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series C Preferred Stock or alter or amend the Series C Preferred Stock certificate of designation, (b) issue any other class or series of capital stock ranking senior to or on parity the Series C Preferred Stock as to dividends or up liquidation or reclassify any shares of common stock or any series of capital stock into shares having preference or priority as to dividends or upon liquidation superior to or on parity with any such preference or priority of Series C Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each outstanding share of Series C Preferred Stock accrues cumulative dividends at a rate equal to 8.0% per annum of the Series C Preferred Stock stated value (currently $70.00, subject to adjustment as provided in the Series C Preferred Stock certificate of designation).&#160; Dividends, whether accrued, declared or payable are payable solely in the form of additional shares of Series C Preferred Stock and shall not in any circumstances be accrued or payable in cash.&#160; Such dividends are payable only upon conversion of the shares of Series C Preferred Stock, or when, as and if otherwise declared by our board of directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each holder of any shares of Series C Preferred Stock has the right, at its option at any time, to convert such holder&#8217;s shares of Series C Preferred Stock into shares of our common stock in accordance with the terms of the Series C Preferred Stock certificate of designation.&#160; Further, we may also require, upon notice, the conversion of any or all shares of the Series C Preferred Stock into our common stock provided that the shares issuable upon such conversion meet certain resale eligibility requirements, and our common stock has been approved for listing on specified stock exchanges, all as set forth in the Series C Preferred Stock certificate of designation. However, we shall not effect a conversion of the Series C Preferred Stock, whether voluntary or mandatory, and the holder of any shares of Series C Preferred Stock shall not have the right to voluntarily convert such holder&#8217;s shares of Series C Preferred Stock, to the extent that after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of 4.99% of the shares of our common stock outstanding immediately after giving effect to such conversion.&#160; By written notice to the Corporation, a holder may from time to time increase or decrease such percentage to any other percentage not less than 4.99% and not in excess of 9.99% specified in such notice; provided that any such increase or decrease will only be effective for that holder and will not be effective until the 61st day after such notice is delivered to us.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Series C Preferred Stock also has price-based, &#8220;full-ratchet,&#8221; and proportional anti-dilution rights, based on issuance or deemed issuances of our securities below the current conversion price of $0.25 per share, all as set forth in the Series C Preferred Stock certificate of designation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Series D Convertible Preferred Stock</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Of our authorized preferred stock, 20,000 shares have been designated as our Series D Convertible Preferred Stock, or the Series D Preferred Stock. With respect to dividend rights and rights on liquidation, winding up and dissolution, shares of our Series D Preferred Stock rank senior to our common stock but junior to our Series C Preferred Stock. Holders of Series D Preferred Stock have no preemptive or subscription rights and there are no redemption or sinking fund provisions applicable to the Series D Preferred Stock. The rights, preferences and privileges of the holders of Series D Preferred Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any other series of preferred stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to any class voting rights provided by the Nevada Revised Statutes or the certificate of designation for the Series D Preferred Stock, holders of Series D Preferred Stock have the right to vote, on an as-if-converted-to-common-stock basis (but subject to, and after giving effect to, the conversion limitations described below, applied effective as of the record date for determining the stockholders entitled to vote). Further, as long as any shares of Series D Preferred are outstanding, the Company shall not, among other things, without the affirmative vote of the holders of at least a majority on voting power of the outstanding shares of Series D Preferred Stock: (a) alter or change adversely the powers, preferences or rights given to the Series D Preferred Stock or alter or amend the Series D Preferred Stock certificate of designation, (b) issue any other class or series of capital stock ranking senior to or on parity the Series D Preferred Stock as to dividends or up liquidation or reclassify any shares of common stock or any series of capital stock into shares having preference or priority as to dividends or upon liquidation superior to or on parity with any such preference or priority of Series D Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each outstanding share of Series D Preferred Stock accrues cumulative dividends at a rate equal to 8.0% per annum of the Series D Preferred Stock stated value (currently $70.00, subject to adjustment as provided in the Series D Preferred Stock certificate of designation).&#160; Dividends, whether accrued, declared or payable are payable solely in the form of additional shares of Series D Preferred Stock and shall not in any circumstances be accrued or payable in cash.&#160; Such dividends are payable only upon conversion of the shares of Series D Preferred Stock, or when, as and if otherwise declared by our board of directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each holder of any shares of Series D Preferred Stock has the right, at its option at any time, to convert such holder&#8217;s shares of Series D Preferred Stock into shares of our common stock in accordance with the terms of the Series D Preferred Stock certificate of designation. Further, we may also require, upon notice, the conversion of any or all shares of the Series D Preferred Stock into our common stock provided that the shares issuable upon such conversion meet certain resale eligibility requirements, and our common stock has been approved for listing on specified stock exchanges, all as set forth in the Series D Preferred Stock certificate of designation. However, we shall not effect a conversion of the Series D Preferred Stock, whether voluntary or mandatory, and the holder of any shares of Series D Preferred Stock shall not have the right to voluntarily convert such holder&#8217;s shares of Series D Preferred Stock, to the extent that after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of 4.99% of the shares of our common stock outstanding immediately after giving effect to such conversion.&#160; By written notice to the Corporation, a holder may from time to time increase or decrease such percentage to any other percentage not less than 4.99% and not in excess of 9.99% specified in such notice; provided that any such increase or decrease will only be effective for that holder and will not be effective until the 61st day after such notice is delivered to us.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Series D Preferred Stock also has price-based, &#8220;full-ratchet,&#8221; and proportional anti-dilution rights, based on issuance or deemed issuances of our securities below the current conversion price of $0.25 per share, all as set forth in the Series D Preferred Stock certificate of designation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Equity Incentive Plan </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, we have issued stock options for the purchase of&#160; 14,506,158 shares of common stock at a weighted average price of $1.546. The expiration dates of these stock options range from now to May 30, 2028. There are unearned stock option grants totaling 3,869,825 shares related to performance targets. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Warrants to Purchase Common Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, we have issued warrants for the purchase of 20,866,313&#160; shares of common stock at a weighted average exercise price of $1.063. The expiration dates of these warrants range from January 30, 2024 to September 26, 2028. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If in the future, we sell our common stock at a price below $0.25 per share, the conversion price of our outstanding shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock would adjust below $0.25 per share pursuant to their respective certificates of designation. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 7,684,381&#160;shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,439,707 would adjust below $1.20 per share and warrants totaling 4,484,725 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clayton A. Struve has warrants to purchase 6,269,715 shares of common stock that have a beneficial ownership blocker at 4.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The proceeds of warrants currently outstanding, to the extent not exercised on a cashless basis, may generate potential proceeds. We cannot provide assurance that any of these warrants will be exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Convertible Promissory Notes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We owe Clayton A. Struve, a significant stockholder, $1,301,005 under convertible promissory or OID notes. We recorded accrued interest of $94,062 and $86,562 as of September 30, 2023 and 2022, respectively. On December 7, 2022, we signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2023.&#160; On September 15, 2023, the due dates on the notes was further extended to September 30, 2024.&#160;For accounting purposes only, the September 15, 2023 extension required us to increase the value of the convertible note by approximately $230,000 and record a corresponding loss on debt extinguishment because the extension of terms results in a de facto debt extinguishment but does not change our cash obligation required&#160; to settle the note.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We owe Ronald P. Erickson and J3E2A2Z LP, (J3E2A2Z) an entity affiliated with and controlled by Ronald P. Erickson $1,460,926 under convertible promissory notes On March 16, 2018, we entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. We recorded accrued interest of $218,334 and $287,290 as of September 30, 2023 and 2022, respectively. On December 7, 2022, we approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to January 30, 2023. On January 25, 2023, we approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2023. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. For accounting purposes only, the September 15, 2023 extension required us to increase the value of the convertible note by approximately $277,000 and record a corresponding loss on debt extinguishment because the extension of terms results in a de facto debt extinguishment but does not change our cash obligation required&#160; to settle the note.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Securities Subject to Price Adjustments&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If in the future, we sell our common stock at a price below $0.25 per share, the conversion price of our outstanding shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock would adjust below $0.25 per share pursuant to their respective certificates of designation. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 7,684,381&#160;shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,439,707 would adjust below $1.20 per share and warrants totaling 4,424,425 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Anti-takeover Provisions</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Anti-Takeover Effects of Certain Provisions of Nevada Law and our Governing Documents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Provisions of the Nevada Revised Statutes, our articles of incorporation and our bylaws could have the effect of delaying or preventing a third-party from acquiring us, even if the acquisition could benefit our stockholders. Such provisions of the Nevada Revised Statutes, our articles of incorporation and our bylaws can have the effect of enhancing continuity and stability in the composition of our board of directors and the policies formulated by the board of directors, and can also have the effect of discouraging certain types of transactions that may involve an actual or threatened change of control of our company. These provisions also may have the effect of reducing our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares, or an unsolicited proposal for the restructuring or sale of all or part of our company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Nevada Anti-Takeover Statutes&#160; </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Nevada Revised Statutes, or NRS, contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling interest&#8221; in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. These laws will apply to us as of a particular date if we were to have 200 or more stockholders of record (at least 100 of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately preceding that date) and do business in the State of Nevada directly or through an affiliated corporation, unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a &#8220;controlling interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply. These laws may have a chilling effect on certain transactions if our articles of incorporation or bylaws are not amended to provide that these provisions do not apply to us or to an acquisition of a controlling interest, or if our disinterested stockholders do not confer voting rights in the control shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Nevada&#8217;s &#8220;combinations with interested stockholders&#8221; statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business &#8220;combinations&#8221; between certain Nevada corporations and any person deemed to be an &#8220;interested stockholder&#8221; of the corporation are prohibited for two years after such person first becomes an &#8220;interested stockholder&#8221; unless the corporation&#8217;s board of directors approves the combination (or the transaction by which such person becomes an &#8220;interested stockholder&#8221;) in advance, or unless the combination is approved by the board of directors and sixty percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any person who is (1) the beneficial owner, directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation, or (2) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then-outstanding shares of the corporation. The definition of the term &#8220;combination&#8221; is sufficiently broad to cover most significant transactions between a corporation and an &#8220;interested stockholder&#8221;. These laws generally apply to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation may elect in its articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation&#8217;s original articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and associates, and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with a person who first became an interested stockholder on or before the effective date of the amendment. Neither our original articles of incorporation nor our current articles of incorporation include such an election.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NRS 78.139 also provides that directors may resist a change or potential change in control of the corporation if the board of directors determines that the change or potential change is opposed to or not in the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant to NRS 78.138(4).&#160; The Nevada Revised Statutes also provide that any director may be removed from our board of directors by the vote or written consent of stockholders representing not less than two-thirds of the voting power of the issued and outstanding shares entitled to vote, and this standard is also reflected in our bylaws.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Bylaws</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our bylaws contain limitations as to who may call special meetings and also establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Authorized but Unissued Shares</em> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our authorized but unissued shares of common stock are available for our board of directors to issue without stockholder approval. We may use these additional shares for a variety of corporate purposes, including future public or private offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of our authorized but unissued shares of common stock could render it more difficult or discourage an attempt to obtain control of our company by means of a proxy contest, tender offer, merger or other transaction. Our authorized but unissued shares may be used to delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares held by our stockholders.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Market Price of and Dividends on Common Equity and Related Stockholder Matters</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our common stock trades on the NYSE American under the symbol &#8220;KNW&#8221;.&#160; Trades in our common stock may be subject to Rule 15g-9 of the Exchange Act, which imposes requirements on broker/dealers who sell securities subject to the rule to persons other than established customers and accredited investors. For transactions covered by the rule, broker/dealers must make a special suitability determination for purchasers of the securities and receive the purchaser&#8217;s written agreement to the transaction before the sale.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Period Ended</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">High</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Low</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Year Ending September 30, 2023</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.17</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.92</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Year Ending September 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.44</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.85</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.71</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of December 15, 2023, the high and low sales price of our common stock was $0.94 per share and $0.8375 per share, respectively. As of December 15, 2023, we had 81,346,524 shares of common stock issued and outstanding, held by 190 stockholders of record. This number does not include approximately 5,690 beneficial owners whose shares are held in the names of various security brokers, dealers and registered clearing agencies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transfer Agent and Registrar </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have appointed Equiniti Trust Company located at 6201 15th Avenue, Brooklyn, New York 11219, telephone number (800) 937-5449, as the transfer agent for our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I6">ITEM 6. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Summary Financial Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the following table, we provide you with our selected consolidated historical financial and other data. We have prepared the consolidated selected financial information using our consolidated financial statements for the years ended September 30, 2023 through September 30, 2022. When you read this selected consolidated historical financial and other data, it is important that you read along with it the historical financial statements and related notes in our consolidated financial statements included in this report and prior 10-K filings, as well as Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(dollars in thousands</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">STATEMENT OF OPERATIONS DATA:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Revenue</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating expenses-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,727</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">General and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,571</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling and transactional costs for digital assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(274</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,430</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total research and development and operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,024</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">16,934</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,024</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,574</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total other (expense), net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,265</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,497</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Loss before income taxes</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,289</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20,071</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Income tax expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,289</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20,071</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock dividends on Series D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,627</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Deemed dividends on Series C and D&#160; Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,527</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(20,443</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(20,071</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Basic and diluted loss per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.41</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.50</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Weighted average shares of common stock outstanding- basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,581,467</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,370,473</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I7">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis summarizes the significant factors affecting our operating results, financial condition, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this report. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this report, particularly in the sections titled &#8220;Risk Factors&#8221; and &#8220;</em><em>Special Note Regarding Forward-Looking Statements.</em><em>&#8221;</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique &#8220;signature&#8221; of said materials or analytes. The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. This device will require US Food and Drug Administration (FDA) clearance before entering the market. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 30, 2020, we incorporated our wholly owned subsidiary, Particle, Inc. Particle was focused on the development and commercialization of our extensive intellectual property relating to electromagnetic energy outside of the medical diagnostic arena, which remains our company&#8217;s singular focus. Since incorporation, Particle was engaged in research and development activities on threaded light bulbs that have a warm white light and can inactivate germs, including bacteria and viruses. Particle is now looking for partners to take this product to market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 17, 2021, we incorporated our wholly owned subsidiary, AI Mind, Inc., for the purpose of identifying and capitalizing on market opportunities for our AI deep learning platform (discussed below). The first activity undertaken by AI Mind was the creation of graphical images expressed as non-fungible tokens, or NFTs, utilizing the AI deep learning platform. During the year ended September 30, 2022,<strong> </strong>AI Mind, operating our AI deep learning platform, began generating revenue from digital asset sales of NFT&#8217;s and had sales of $4,360,000. AI Mind was dissolved on July 25, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Developments</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2023, Phillip A. Bosua resigned from the Board of Directors and from his position as our Chief Executive Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2023, our Board of Directors appointed Ronald P. Erickson, the current Chairman of the Board, to the position of Chief Executive Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 27, 2023, we announced the following new officers/transitions: Leo Trautwein, Chief Commercial Officer, and Jessica English, Chief Marketing Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 21, 2023, we announced the publication of a peer-reviewed study in Sensors Journal. The manuscript described the proof-of-principle study of Bio-RFID technology that quantified three different analytes in vitro. In the peer-reviewed publication, it was found Bio-RFID achieved 100% accuracy in quantifying these three different analytes in vitro. This study was conducted in collaboration with Mayo Clinic. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 5, 2023, we announced the results of a technical feasibility study that was presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting. The study demonstrated that the Bio-RFID sensor can deliver stable, repeatable results in predicting blood glucose concentrations obtained by a reference device.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 7, 2023, we revealed the portable Generation 1 prototype for non-invasive glucose monitoring. The Generation 1 prototype is a portable research lab, designed to be a powerful data collection device. This device should allow Know Labs to scale data collection, including testing across more diverse participant populations and scenarios.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In June of 2023, the Company issued 1,402,784 share of common stock as dividends&#160;&#160; to the holder of Series D Convertible Preferred stock as settlement of cumulative unpaid dividends through December 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 26, 2023, we announced the completion of a new study demonstrating that continued algorithm refinement and more high-quality data improved the accuracy of the Bio-RFID sensor technology, resulting in an overall Mean Absolute Relative Difference (MARD) of 11.27%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 9, 2023, the Board authorized the Company to file a series of amendments to the certificates of designation for certain series of our preferred stock, and the restatement of its articles of incorporation, as described below, each of which were filed with the Nevada Secretary of State effective August 11, 2023. Based upon the June 2023 issuance of common stock dividends&#160; to Series D Convertible Preferred Stock holder and the modified terms and conditions&#160; of Series C and D certificates of designation, it was determined that Series C and D preferred dividends need to be accreted for the cumulative unpaid dividends . As of September 30, 2023, cumulative unpaid Series C and D totaled approximately $770,000 which converts to approximately 3,040,0000&#160; shares of common&#160; stock. The value of the 3.0 million shares of common totaled $3,526,653. The Company recorded $3,526,653 in cumulative deemed dividends related to Series C and D Preferred Stock which have not been paid.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the amendment and restatement of our preferred stock, we effected a reverse split of our outstanding Series C Convertible Preferred Stock and Series D Convertible Preferred Stock by a factor of 1-for-100. No changes were made to the 5 million total shares of &#8220;blank-check&#8221; preferred stock authorized in our Articles. Prior to such reverse split, there were 1,785,715 and 1,016,004 shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock designated and outstanding, respectively. To account for the reverse split, but in order to provide the ability to issue &#8220;pay in kind&#8221; dividends in lieu of cash dividends, at the time of the reverse split, we designated 30,000 shares of Series C Convertible Preferred Stock&#160;and 20,000 shares of Series D Convertible Preferred Stock, of which 17,858 and 10,161 shares were, respectively, outstanding immediately after such reverse split. In order to maintain the economic rights of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, the definition of &#8220;Stated Value&#8221; was multiplied by 100, to offset the reverse split factor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 15, 2023, we signed amendments to the convertible promissory or OID notes, held by Clayton A. Struve and Ron Erickson, to extend the due dates to September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, we closed an offering of our common stock pursuant to which we sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share via an S-1 registration statement. After deducting underwriting commissions and other offering expenses, we received net proceeds of $5,472,791.As part of the offering,&#160; the Company issued common stock purchase warrants to the Underwriter Representatives to purchase an aggregate of 1,960,000 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments. The Representatives&#8217; Warrants are immediately exercisable and may be exercised at any time and from time to time, in whole or in part, until September 26, 2028 and may be exercised on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Principal Factors Affecting Our Financial Performance</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our operating results are primarily affected by the following factors: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability of our research and development team to produce an FDA clearance quality technology;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to recruit and maintain quality personnel with the talent to bring our technology to the market;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the production of market ready products that can sustain FDA clearance quality results;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the clearance by FDA after their rigorous clinical trial process of our products for the marketplace;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the receptivity of the marketplace and the addressable diabetes community to our new non-invasive glucose monitoring technology; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">access to sufficient capital to support us until our products achieve FDA clearance and are accepted in the marketplace.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Segment Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Financial Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic 280, <em>Segment Reporting</em>, requires that an enterprise report selected information about reportable segments in its financial reports issued to its stockholders. The Company considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology with a first focus on non-invasively ascertaining blood glucose levels. Previous segments included (i) Particle, Inc. technology; and (ii) AI Mind, Inc. sales of NFT products. Particle commenced operations in the year ended September 30, 2020. It is now looking for partners to take the product to market. AI Mind commenced operations during the year ended September 30, 2022. AI Mind was dissolved on July 25, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth key components of our results of operations during the years ended September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years Ended September 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">2023 </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">2022 </td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">$ Variance</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">% Variance</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Revenue- digital asset sales</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(4,360</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-100.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating expenses-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and development and operating expenses-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development expenses</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,727</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,386</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,341</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-43.5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Selling, general and administrative expenses</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,571</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,547</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Selling and transactional costs for digital assets</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(274</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">3,430</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">3,704</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">108.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Total operating erxpenses</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">14,024</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">16,934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">2,910</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">17.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating loss </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(14,024</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(12,574</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(1,450</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-11.5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other expense: </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Interest income</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">112</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">746.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Interest expense</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(390</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(8,034</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,644</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Loss on debt extinguishment</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(507</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(507</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-100.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Other (expense) income</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(495</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">522</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(1,017</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-194.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total other (expense), net</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(1,265</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">(7,497</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">6,232</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">83.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loss before income taxes</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(15,289</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20,071</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,782</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="TEXT-INDENT: 15px;vertical-align:top;">Income tax expense</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss </td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(15,289</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">(20,071</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">4,782</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-TOP: medium none; BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">23.8</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Revenues</span></em>. Revenue- digital asset sales for the year ended September 30, 2023 was $0 as compared to $4,360,000 for the year ended September 30, 2022. We do not expect future activity or revenue from that source. Our Artificial Intelligence (AI) deep learning platform has generated revenue- digital asset sales of $4,360,000 from Non-Fungible Token (NFT) sales. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Research and Development Expenses</span></em>.<strong> </strong>Research and development expenses for the year ended September 30, 2023 increased $2,341,000 to $7,727,000 as compared to $5,386,000 for the year ended September 30, 2022.&#160; The increase was due to increased personnel, use of consultants, expenditures related to the development of our radio frequency spectroscopy&#160;Bio-RFID&#8482; technology. During the end of the three months ended June 30, 2023, we reduced our headcount by nine and operating expenses and used external consultants to reduce the future cost of the development of our Bio-RFID&#8482; technology. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Selling, General and Administrative Expenses</span></em>.<strong> </strong>Selling, general and administrative expenses for the year ended September 30, 2023 decreased $1,547,000 to $6,571,000 as compared to $8,118,000 for the year ended September 30, 2022. The decrease primarily was due to (i) a decrease of $1,466,000 in stock based compensation; (ii) a decrease in compensation expense of $451,000 related to warrants issued for services; (iii) a decrease in common stock issued for services of $183,000;&#160; offset by (iv) an increase in insurance of $420,000; and (v) an increase in other expenses of $133,000. As part of the selling, general and administrative expenses for the year ended September 30, 2023 and 2022, we recorded $305,000 and $380,000, respectively, of investor relationship and business development expenses.&#160;&#160;&#160;&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Selling and Transactional Costs for Digital Asset Sales</span></em>.<strong> </strong>Selling and transactional for digital asset sales were ($274,000) as compared $3,430,000 for the year ended September 30, 2022. During 2022, our Artificial Intelligence (AI) deep learning platform has generated revenue- digital asset sales of $4,360,000 from Non-Fungible Token (NFT) sales. The benefit&#160;for the year ended September 30, 2023 included an adjustment of our estimate for sales and use tax related to the sale of digital assets.&#160; Such costs for the year ended September 30, 2022 included digital asset conversion loss, consulting, bonus compensation transaction fees, taxes, royalties and other costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Other (Expense), Net</span></em>.<strong> </strong>Other expense, net for the year ended September 30, 2023 was $1,265,000 as compared to other expense, net of $7,497,000 for the year ended September 30, 2022. The other expense, net for the year ended September 30, 2023 included (i) interest income of $127,000; offset by (ii) interest expense of $390,000 related to convertible notes payable and the modification and extension of terms; (iii) loss on debt extinguishment of $507,000 related to the extension of convertible notes payable; and (iv) other expense of $495,000 related to the write-off of certain equipment. . </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The other expense, net for the year ended September 30, 2022 included (i) interest expense of $8,034,000 related to convertible notes payable and the amortization of the beneficial conversion feature and value of warrants issued; and offset by (ii) other income of $522,000 primarily related to the forgiveness of notes payable- PPP loans and other debt and (iii) interest income of $15,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Net Loss</span></em>.<strong> </strong>Net loss for the year ended September 30, 2023 was $15,289,000 as compared to $20,071,000 for the year ended September 30, 2022. The net loss for the year ended September 30, 2023 included non-cash expenses of $4,768,000. The non-cash items include (i) depreciation and amortization of $313,000; (ii) loss on sale of assets of $550,000; (iii) loss on debt extinguishment of $507,000; (iv) modification of notes and warrants- interest expense of $350,000; (v) stock based compensation- stock options of $2,956,000; and (vi) amortization of operating lease right-of-use asset of $142,000. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The net loss for the year ended September 30, 2022 included non-cash expenses of $12,164,000. The non-cash items include (i) depreciation and amortization of $321,000; (ii) issuance of common stock for services of $183,000; (iii) issuance of common stock warrants for services of $452,000; (iv) stock based compensation- stock options of $4,422,000; (v) amortization of debt discount as interest expense of $7,273,000; (vi) other of $35,000; offset by (vii) gain on debt settlement of $269,000; and (viii) gain on forgiveness of note payable- PPP loans of $253,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have cash and cash equivalents of $8,024,000 and net working capital of approximately $6,264,000 (exclusive of convertible notes payable) as of September 30, 2023. We anticipate that we will record losses from operations for the foreseeable future. As of September 30, 2023, our accumulated deficit was $121,841,000 and net losses in the amount of $15,289,000 and $20,071,000 during the years ended September 30, 2023 and 2022, respectively. We incurred non-cash expenses of $4,768,000, and $12,164,000 during the years ended September 30, 2023 and 2022, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have financed our corporate operations and our technology development through the issuance of convertible debentures, the issuance of preferred stock, the sale of common stock and the exercise of warrants. During the remainder of 2024, we expect to raise additional funds through the issuance of preferred stock, convertible debentures or equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, we closed an offering of our common stock pursuant to which we sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, we received net proceeds of $5,472,791. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the end of the quarter ended June 30, 2023, the Company made some adjustments to its staffing level, and the impact of those adjustments, plus the departure of our chief technology and executive officer, has significantly reduced our monthly burn rate. The Company will further adjust its cost structure if new debt or equity capital is not received. We believe that we have enough available cash to operate until June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The proceeds of warrants currently outstanding, to the extent not exercised on a cashless basis, may generate potential proceeds. We cannot provide assurance that any of these warrants will be exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Operating Activities&#160; </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net cash used in operating activities for the year ended September 30, 2023 and 2022 was $10,354,000 and $6,920,000, respectively. The net cash used in operating activities for the year ended September 30, 2023 was primarily related to (i) a net loss of $15,289,000; offset by (ii) working capital changes of $167,000; and (iii) non-cash expenses of $4,768,000. The non-cash items include (iv) depreciation and amortization of $313,000; (v) loss on disposal assets of $550,000; (vi) loss on debt extinguishment of $507,000; (vii) modification of notes and warrants- interest expense of $350,000; (viii) stock based compensation- stock options of $2,956,000; and (ix) amortization of operating lease right-of-use asset of $142,000. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The net cash used in operating activities for the year ended September 30, 2022 was primarily related to (i) a net loss of $20,071,000; offset by (ii) working capital changes of $987,000 related to Our Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue from Non-Fungible Token (NFT) sales and incurred certain expenses; and (iii) non-cash expenses of $12,164,000. The non-cash items include (iv) depreciation and amortization of $321,000; (v) issuance of common stock for services of $183,000; (vi) issuance of common stock warrants for services of $452,000; (vii) stock based compensation- stock options of $4,422,000; (viii) amortization of debt discount as interest expense of $7,273,000; (ix) other of $13,000; offset by (x) gain on debt settlement of $269,000; and (xi) gain on forgiveness of note payable- PPP loans of $253,000. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investing Activities </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net cash used in investing activities for the year ended September 30, 2023 and 2022 was $81,000 and $855,000, respectively. There amounts were primarily related to the investment in equipment for research and development. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Financing Activities</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net cash provided by financing activities for the year ended September 30, 2023 and 2022 was $5,865,000 and $8,111,000, respectively. The net cash provided by financing activities for the year ended September 30, 2023 was primarily related to (i) proceeds from the issuance of common stock for the exercise of warrants of $387,000; (ii) proceeds from the issuance of common stock for the exercise of stock option grants of $5,000; issuance of common stock for a common stock offering, net of expenses of $5,472,791. On September 29, 2023, we closed an offering of our common stock pursuant to which we sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, we received net proceeds of $5,472,791. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The net cash provided by financing activities for the year ended September 30, 2022 was primarily related to (i) proceeds from the issuance of common stock for the exercise of warrants of $838,000; (ii) proceeds from the issuance of common stock for the exercise of stock option grants of $27,000; issuance of common stock for NYSE uplisting, net of expenses of $7,425,000; and offset by the repayment of notes payable- PPP loans of $179,000. On September 20, 2022, we completed a public offering of our common stock pursuant to which we sold 4,140,000 shares of common stock, at a purchase price of $2.00. After deducting underwriting commissions and other offering expenses, we received net proceeds of $7,425,000.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our contractual cash obligations as of September 30, 2023 are summarized in the table below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Less Than</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Contractual Cash Obligations (1)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1&#160; Year</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">134,633</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Convertible notes payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,255,066</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,255,066</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,389,699</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,389,699</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">(1) Convertible notes payable includes $2,255,066 (excluding $506,865 adjustment for debt extinguishment accounting) that can be converted into common stock upon demand. We expect to incur capital expenditures related to the development of the &#8220;Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8221; technologies. None of the expenditures are contractual obligations as of September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Off-Balance Sheet Arrangements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies Involving Significant Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following discussion relates to critical accounting policies for our Company which involve significant estimates. The preparation of financial statements in conformity with United States generally accepted accounting principles, or GAAP, requires our management to make assumptions, estimates and judgments that affect the amounts reported, including the notes thereto, and related disclosures of commitments and contingencies, if any. We have identified certain accounting policies that are significant to the preparation of our financial statements. These accounting policies are important for an understanding of our financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require management&#8217;s difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because of the possibility that future events affecting the estimate may differ significantly from management&#8217;s current judgments. We believe the following critical accounting policies involve the most significant estimates and judgments used in the preparation of our financial statements: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong>. We determine revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">identification of the contract, or contracts, with the customer;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">identification of the performance obligations in the contract;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">determination of the transaction price;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">allocation of the transaction price to the performance obligations in the contract; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">recognition of the revenue when, or as our company satisfies a performance obligation.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, we generated revenue from digital asset sales of NFTs. Our engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses</em></strong>. Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements and Financial Instruments</em>. </strong>ASC Topic 820,&#160;<em>Fair Value Measurement and Disclosures</em>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Level 2 &#8211; Inputs other than level one inputs that are either directly or indirectly observable; and. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Level&#160;3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement. &#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have a money market account which is considered a level 1 asset. The balance as of&#160; September 30, 2023 and 2022 was $7,836,393 and $11,821,931, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em>. </strong>Pursuant to ASC 815 &#8220;Derivatives and Hedging&#8221;, we evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. We then determine if embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, we use a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. We determined that&#160;the conversion features for purposes of bifurcation within convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Based Compensation</em></strong>. We have share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of common stock at the fair market value at the time of grant. Stock-based compensation cost to employees is measured by us at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. For options issued to employees, we recognize stock compensation costs utilizing the fair value methodology over the related period of benefit.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Securities</em></strong><strong>.</strong> Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. We will evaluate our contracts based upon the earliest issuance date. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I7a">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I8">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The full text of our audited consolidated financial statements begins on page F-1 of this annual report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9a">ITEM 9A. CONTROLS AND PROCEDURES.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>a) Evaluation of Disclosure Controls and Procedures</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We conducted an evaluation, under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of September 30, 2023 that our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>(b) Management's Report on Internal Control Over Financial Reporting.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed by, or under the supervision of, our CEO and CFO, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (GAAP). Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of September 30, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013&#160;<em>Internal Control-Integrated Framework</em>. Based on its evaluation, management has concluded that the Company&#8217;s internal control over financial reporting was effective as of September 30, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Regulation S-K Item 308(b), this Annual Report on Form 10-K does not include an attestation report of our company&#8217;s registered public accounting firm regarding internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well designed and operated can provide only reasonable, but not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>c) Changes in Internal Control over Financial Reporting</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, there were no&#160;changes in our internal controls over financial reporting, which were identified in connection with our management&#8217;s evaluation required by paragraph (d) of rules 13a-15 and 15d-15 under the Exchange Act, that materially affected, or is reasonably likely to have a material effect on our internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I9b">ITEM 9B. OTHER INFORMATION.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have no information to disclose that was required to be disclosed in a report on Form 8-K during fourth quarter of fiscal year 2023 but was not reported.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="P3">PART III</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I10">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Directors and Executive Officers </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth certain information about our current directors and executive officers:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:15%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Age </p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:60%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Director/ Executive Officer</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ronald P. Erickson </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">79</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Executive Officer, Chairman Of the Board of Directors and Director</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Peter J. Conley</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">68</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Financial Officer and SVP Intellectual Property</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">William A. Owens </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">83</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Jon Pepper</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">72</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ichiro Takesako</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">64</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">John Cronin</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">68</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Timothy M. Londergan</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">50</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Larry K. Ellingson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">77</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Director </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Set forth below is information regarding our directors and executive officers as of the date of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Ronald P. Erickson</em></strong>.<strong> </strong>&#160;Mr. Erickson was appointed as Chief Executive Officer in January 2023. Mr. Erickson previously served as our Chief Executive Officer from November 2009 to April 2018. He has served as Chairman of the Board from 2004 to 2011 and from 2015 to the present. A senior executive with more than 30 years of experience in the technology, telecommunications, software, and digital media industries, Mr. Erickson was the founder of our company. He is formerly Chairman, CEO and Co-Founder of Blue Frog Media, a mobile media and entertainment company; Chairman and CEO of eCharge Corporation, an Internet-based transaction procession company; Chairman, CEO and Co-founder of GlobalTel Resources, a provider of telecommunications services; Chairman, Interim President and CEO of Egghead Software, Inc., a software reseller where he was an original investor; Chairman and CEO of NBI, Inc.; and Co-founder of MicroRim, Inc., the database software developer. Earlier, Mr. Erickson practiced law in Seattle and worked in public policy in Washington, DC and New York, NY. Additionally, Mr. Erickson has been an angel investor and board member of a number of public and private technology companies. In addition to his business activities, Mr. Erickson was&#160; Chairman and a member of the Board of Trustees from 2010 to 2021 of Central Washington University where he received his BA degree. He also holds an MA from the University of Wyoming and a JD from the University of California, Davis. He is licensed to practice law in the State of Washington. Mr. Erickson is our founder and was appointed as a director because of his extensive experience in developing technology companies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Peter J. Conley</em></strong>.<strong> </strong>Mr. Conley has served as our Chief Financial Officer and SVP Intellectual Property since May 2022.<strong> </strong>In addition, Mr. Conley currently serves as Senior Managing Director and Head of Intellectual Property Banking at Boustead Securities, LLC, a position he has held since October 2014, where he provides equity financing and M&amp;A advisory services to small-cap public companies. Prior to that, from 2012 to 2016, Mr. Conley was a cofounder and Chief Operating Officer of ipCreate, a global IP development and innovation services company serving large multinational companies. He also served as managing director of ipCapital Venture Group, where he provided IP strategy and venture advisory services. During his career spanning more than 35 years, Mr. Conley has held leadership roles at MDB Capital Group, The Analytiq Group / RDEX Research, Roth Capital Partners, and Lehman Brothers. He was on the founding team and Head of Equity Capital Markets at E*Offering, the investment bank of E*Trade. Mr. Conley attended the University of Hawaii at Manoa and the University of London, Center for Financial &amp; Management Studies, SOAS.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>William A. Owens</em></strong>. Admiral Owens has served as an independent director since May 2018. William A. Owens is the co-founder and executive chairman of Red Bison Technology Group, a company which installs and operates high speed telecoms networks and technology in large office buildings. He is the Chairman of Visionary Vehicles which is building a series of automobiles focused on electric and hydrogen powered cars, Kyrrex which is a successful and growing Crypto Currency Exchange operating in Europe, and Massif, an electric bicycle company.&#160; Owens serves on the board of directors of the Public Companies, Siply, Know Labs, and Compass, and is a director of the private companies: TruU, Tethr, ViruSight, Prism, Steel Grove, JennyCo, Axxess Capital, Versium, and Viome.&#160; Owens was the chairman of the board of CenturyLink Telecom (now Lumen), the third largest telecommunications company in the United States and SAP USA. Owens is on the board of trustees of Seattle University, and the Fiscal Responsibility Amendment (CFFRA) Association which aims to establish a balanced budget amendment to the US Constitution. He is a member of the Council of Foreign Relations. He is the Founder and senior General on a China US forum to bring 4 star generals together for China US cooperation.&#160; He is a Senior Fellow at Stimson Institute.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From 2007 to 2015, Owens was the Chairman and Senior Partner of AEA Investors Asia, a private equity firm located in Hong Kong, and Vice Chairman of the NYSE for Asia. Owens also served as the Chairman of Eastern Airlines. He has served on over 25 public boards including Daimler, British American Tobacco, Telstra, Nortel Networks, and Polycom.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Owens was the CEO of Nortel, a fortune 500 company, the CEO/Chairman of Teledesic, a Bill Gates/Craig McCaw company bringing worldwide broadband through an extensive satellite network and was the President of Science Applications International Corporation (SAIC). He also served on the boards of the not-for-profit organizations; Fred Hutchinson Cancer Research Center, Carnegie Corporation of New York, Brookings Institution, East West Institute, and RAND Corporation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Owens is a retired four-star US Navy Admiral. He was Vice Chairman of the Joint Chiefs of Staff, the second-ranking United States military officer in the US, with responsibility for reorganizing and restructuring the armed forces in the post- Cold War era. He is widely recognized for bringing commercial high-grade technology into the Department of Defense for military applications. Owens was the architect of the Revolution in Military Affairs (RMA), an advanced systems technology approach to military operations, the most significant change in the system of requirements, budgets and technology for the four armed forces since World War II. Owens was Commander of the U.S. Sixth Fleet from 1990 to 1992, which included Operation Desert Storm. Owens also served as the deputy Chief of Naval Operations for Resources and Requirements. Owens was the Senior Military Assistant to two Secretaries of Defense (Cheney and Carlucci) and served in the Office of Program Appraisal for the Secretary of the Navy. He began his military career as a nuclear submariner. He served on four strategic nuclear-powered submarines and three nuclear attack submarines, including tours as Commanding Officer of the USS Sam Houston, USS Michigan, and USS City of Corpus Christi. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Owens is a 1962 honor graduate of the United States Naval Academy in mathematics, holds bachelor&#8217;s and master&#8217;s degrees in politics, philosophy and economics from Oxford University, and a master&#8217;s degree in management from George Washington University. He has written more than 50 articles on national security and authored the book &#8220;High Seas.&#8221;.&#160; His book, &#8220;Lifting the Fog of War,&#8221; was published in April 2000 with a revision published in Mandarin in 2009. And his book &#8220;China-US 2039: The Endgame?&#8221; was published in 2019 in both English and Mandarin.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Owens has received numerous recognitions and awards: the &#8220;L&#233;gion d&#8217;Honneur&#8221; by France, and the highest awards given to foreigners by the countries of Indonesia and Sweden. He was named as one of The 50 Most Powerful People in Networking by Network World, one of the 100 Best Board Members in the United States for 2011 and again in 2016 awarded by NACD, and the Intrepid Salute Award in recognition of his business achievements and support of important philanthropic activities. Owens is active in philanthropy to foster Chinese &#8211; American relations including dialogues between the most senior retired officers in the United States and Chinese militaries. He is a North Dakota&#8217;s Roughriders recipients, the award given annually to the most prominent North Dakotans. Admiral Owens was appointed as a director of Know Labs because of his financials and governance skills.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Jon Pepper</em></strong>.<strong> </strong>Mr. Pepper<strong> </strong>has served as an independent director since April 2006. Mr. Pepper founded Pepcom, a company that become the industry leader at producing press-only technology showcase events around the country and internationally, in 1980. He sold his stake in the corporation and retired as a partner at the end of 2018. Prior to that, Mr. Pepper started the DigitalFocus newsletter, a ground-breaking newsletter on digital imaging that was distributed to leading influencers worldwide. Mr. Pepper has been closely involved with the high technology revolution since the beginning of the personal computer era. He was formerly a well-regarded journalist and columnist. His work on technology subjects appeared in <em>The New York Times</em>, <em>Fortune</em>, <em>PC Magazine</em>, <em>Men&#8217;s Journal</em>, <em>Working Woman</em>, <em>PC Week</em>, <em>Popular Science</em> and many other well-known publications. Mr. Pepper was educated at Union College in Schenectady, New York and the Royal Academy of Fine Arts in Copenhagen. He continues to be active in non-profit work and private company boards and in 2017 founded Mulberry Tree Films, a non-profit that supports independent high-quality documentary films and other publishing and creative projects that are oriented toward increasing the understanding of human potential and creativity. Mulberry Tree funded and produced the acclaimed documentary, &#8220;The Gates of Shinto&#8221; and is currently at work on additional projects. Mr. Pepper was appointed as a director because of his marketing skills with technology companies. Mr. Pepper was appointed as a director because of his marketing skills with technology companies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Ichiro Takesako</em></strong>. Mr. Takesako has served as a director since December 2012. Mr. Takesako has held executive positions with Sumitomo Precision Products Co., Ltd, or Sumitomo, and its affiliates since 1983. In the past few years, Mr. Takesako has held the following executive position in Sumitomo and its affiliates: in June 2008, he was appointed as General Manager of Sales and Marketing Department of Micro Technology Division; in April 2009, he was appointed as General Manager of Overseas Business Department of Micro Technology Division, in charge of M&amp;A activity of certain business segment and assets of Aviza Technology, Inc.; in July 2010, he was appointed as Executive Director of SPP Process Technology Systems, a 100% owned subsidiary of Sumitomo Precision Products at the time; in August 2011, he was appointed as General Manager, Corporate Strategic Planning Group; in January 2013, he was appointed as Chief Executive Officer of M2M Technologies, Inc., a company invested by Sumitomo Precision products; in April 2013, has was appointed as General Manager of Business Development Department, in parallel of CEO of M2M Technologies, Inc.; in April 2014, he was relieved from General Manager of Business Development Department and is responsible for M2M Technologies Inc. as its CEO; in March 2017, he established At Signal, Inc. which took over the entire business operation from M2M Technologies, Inc.; and in April 2017, he was appointed as Chief Executive Officer of At Signal Inc. Mr. Takesako graduated from Waseda University, Tokyo, Japan where he majored in Social Science and graduated with a Degree of Bachelor of Social Science. Mr. Takesako was appointed as a director based on his previous position with Sumitomo and Sumitomo&#8217;s previous significant partnership with our company. Mr. Takesako was appointed as a director based on his previous position with Sumitomo and Sumitomo&#8217;s previous significant partnership with our company. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>John Cronin</strong>. Mr. Cronin&#160; has served as an independent director since November 2023. Mr. Cronin is an experienced inventor and intellectual property strategist. Mr. Cronin is Chairman and CEO of ipCapital Group, Inc. (&#8220;ipCG&#8221;), a globally recognized IP strategy consulting firm founded in 1998, offering more than 45 different services. Mr. Cronin has authored greater than 1,600 patents and applications across hundreds of technology spaces, leveraging the ipCapital Methodology. Before forming ipCG, Mr. Cronin spent over 17 years at IBM and became its top inventor with over 100 patents and 150 patent publications. He created and ran the IBM Patent Factory, which was essential in helping IBM become number one in US patents and led the team that contributed to the startup and success of IBM&#8217;s licensing program. Mr. Cronin is also the Chair of the Board of Directors of AdrenalineIP, Chairman of IX-Innovations, and is the Founder of HarvestWeb, a 501(c)3 charitable organization that provides an easy online way to make donations to food pantries.&#160;Mr. Cronin previously served on the board of directors of HopTo Inc. (OTC: HPTO) from 2014 to September 2018, and ImageWare&#174; Systems, Inc. (OTCQB: IWSY) from 2012 until April 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Cronin has a B.S. (E.E.), an M.S. (E.E), and a B.A. degree in Psychology from the University of Vermont. As of the year ended September 30, 2023, we have paid ipCapital Group approximately $713,000 in professional fees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Timothy M. Londergan, Ph.D. </strong>Mr. Londergan<strong> </strong>has served as an independent director since November 2023.&#160; Mr. Londergan is a creative and results oriented business executive with 20 years of experience with early-stage technology companies. In May 2020, Mr. Londergan founded Tangibly, Inc., a company focused on helping companies manage their most valuable assets, trade secrets, through an innovative AI platform that can analyze patents and predict related trade secrets. Mr. Londergan continues to act as CEO of Tangibly, Inc. From May 2017-2021, Mr. Londergan founded and was CEO of WaveFront Venture Labs Pte Ltd, focused on helping leading Fortune 100 corporations incubate new companies based on highly promising, yet currently dormant technologies and was developing a platform to systematically evaluate and extract the most promising technologies trapped inside these companies and create paths to market for them via new company formation. WaveFront was acquired by Boustead Securities in 2021. From January 2018 to June 2020, Mr. Londergan was co-founder and CEO of Operem, Inc., a company that created blockchain based tools for managing intangible assets and was acquired by Abaxx. Mr. Londergan was recently named IAM 300 World&#8217;s Leading IP Strategist 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Londergan has 30+ issued patents, 20+ applications along with over 20 publications in peer reviewed journals and conference proceedings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Londergan holds a Ph.D. in Organic Chemistry, 1998, from the University of Southern California and a B.S. in Chemistry, 1995, from St. Bonaventure University.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Larry K. Ellingson. </strong>Mr. Ellingson<strong> </strong>has served as an independent director since November 2023. &#160;Mr. Ellingson holds a BS, Pharmacy, from North Dakota State University (NDSU), Fargo, North Dakota and an Executive MBA from Babson College, Babson Park, Massachusetts. From April 23, 2019 to present, Mr. Ellingson has served as a member of Know Labs advisory board. From 2013 to present, Mr. Ellingson is Co-Founder of the Diabetes Leadership Council and Vice Chair Global initiatives. Since 2006 to present, Mr. Ellingson has been President of Global Diabetes Consulting LTD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Ellingson retired from Eli Lilly and Company in May 2001 after having been involved as a leader of global diabetes for Lilly for more than half of his career. He has held several other positions at Lilly including Director of Pharmaceutical New Product Planning for gastrointestinal, skeletal, endocrine and infectious diseases, along with responsibility for marketed products in those areas in the late 1980&#8217;s.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Ellingson continues to remain active with committee work and board positions for a multitude of organizations, among them are NDSU, Research Park, International Diabetes Federation, Academy of Nutrition and Dietetics, Nurse Practitioners Healthcare Foundation and the American Diabetes Association&#174;. His contributions to the Association have been abundant and far-reaching and have spanned over 20 years. He has held numerous positions within the Association such as member of the Industry Advisory, Strategic Marketing Task Force, Strategic Planning Task Force, Big Ticket Task Force, Pinnacle Society and the Income Development Committee. He has been Chair or Vice Chair for an equally extensive list of bodies within the Association including the Board of Directors, Fundraising Committee, Executive Committee and Nominating Committee. He has unquestionably been a positive force and an integral part of mission delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Ellingson has been honored several times for his achievements in his field. He was honored by being the first and only non&#8211;scientist to receive Eli Lilly&#8217;s President&#8217;s Award and the Lilly Research Award for contributions to diabetes research. In 2001, Eli Lilly created the Ellingson Legacy Award to honor those who provide outstanding service to the customer. Ellingson was the first recipient of the award. The ADA, Indiana affiliate awarded Mr. Ellingson the J.K. Lilly Award in 2004 for his contributions &amp; service to the field of diabetes. NDSU awarded him the highest honor in 2007, naming him An Outstanding Alumni of the Year for his contributions to the field and to the University. The American Diabetes Association&#174; recognized Mr. Ellingson in 2006 with the Charles H. Best Medal for Outstanding Service for his exceptional contributions as Chair of the Board. The ADA recognized Mr. Ellingson with the prestigious Wendell Mayes Jr. Award in 2013 for his long-term service in diabetes. Mr. Ellingson received an Honorary Membership in 2020 to the Academy of Nutrition and Dietetics for his contributions to the Academy. He continues to be engaged in diabetes programs and projects through the Diabetes Leadership Council which he cofounded in 2013.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Term of Office</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our directors currently have terms which will end at our next annual meeting of stockholders or until their successors are elected and qualify, subject to their prior death, resignation or removal. Officers serve at the discretion of the Board.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Family Relationships </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are no family relationships among any of our officers or directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Involvement in Certain Legal Proceedings </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the best of our knowledge, except as described below, none of our directors or executive officers has, during the past ten years:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Corporate Governance</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The Board&#8217;s Role in Risk Oversight</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Board oversees that the assets of our company are properly safeguarded, that the appropriate financial and other controls are maintained, and that our business is conducted wisely and in compliance with applicable laws and regulations and proper governance. Included in these responsibilities is the Board&#8217;s oversight of the various risks facing our company. In this regard, our Board seeks to understand and oversee critical business risks. Our Board does not view risk in isolation.&#160; Risks are considered in virtually every business decision and as part of our business strategy. Our Board recognizes that it is neither possible nor prudent to eliminate all risk. Indeed, purposeful and appropriate risk-taking is essential for our company to be competitive on a global basis and to achieve our objectives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">While the Board oversees risk management, company management is charged with managing risk. Management communicates routinely with the Board and individual directors on the significant risks identified and how they are being managed. Directors are free to, and indeed often do, communicate directly with senior management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Board administers its risk oversight function as a whole by making risk oversight a matter of collective consideration; however, much of the work is delegated to committees, which will meet regularly and report back to the full Board. The audit committee oversees risks related to our financial statements, the financial reporting process, accounting and legal matters, the compensation committee evaluates the risks and rewards associated with our compensation philosophy and programs, and the nominating and corporate governance committee evaluates risks associated with management decisions and strategic direction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Attendance at Annual Meetings of Stockholders</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect that all of our Board members will attend our annual meetings of stockholders in the absence of a showing of good cause for failure to do so and all attended our 2023 annual meeting of stockholders in person or by telephone.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Board Meetings and Committees</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During our last fiscal year, each of our directors attended at least 75% of the aggregate of (i) the total number of Board meetings and (ii) the total number of meetings of the committees on which the director served.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Independent Directors</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NYSE American&#8217;s rules generally require that a majority of an issuer&#8217;s board of directors must consist of independent directors. Our board of directors currently consists of seven (7) directors, six (6) of whom, Messrs. Owens, Pepper, Takesako, Cronin, Londergan, and Ellingson, are independent within the meaning of NYSE American rules. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Committees of the Board of Directors </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Board has established an audit committee, a compensation committee and a nominating and corporate governance committee, each with its own charter approved by the Board. Each committee&#8217;s charter is available on our website at www.knowlabs.co. In addition, our Board may, from time to time, designate one or more additional committees, which shall have the duties and powers granted to it by our Board.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Audit Committee</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">William A. Owens, Jon Pepper and Tim Londergan, each of whom satisfies the &#8220;independence&#8221; requirements of Rule 10A-3 under the Exchange Act and NYSE American&#8217;s rules, serve on our audit committee, with Mr. Pepper serving as the chairman. Our Board has determined that Mr. Owens qualifies as an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules. The audit committee oversees our accounting and financial reporting processes and the audits of the financial statements of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The audit committee is responsible for, among other things: (i) retaining and overseeing our independent accountants; (ii) assisting the Board in its oversight of the integrity of our financial statements, the qualifications, independence and performance of our independent auditors and our compliance with legal and regulatory requirements; (iii) reviewing and approving the plan and scope of the internal and external audit; (iv) pre-approving any audit and non-audit services provided by our independent auditors; (v) approving the fees to be paid to our independent auditors; (vi) reviewing with our chief executive officer and principal financial officer and independent auditors the adequacy and effectiveness of our internal controls; (vii) reviewing hedging transactions; and (viii) reviewing and assessing annually the audit committee&#8217;s performance and the adequacy of its charter. The audit committee is also responsible for preparing a report to be included with this Proxy Statement. Our audit committee met 4 times during the last fiscal year.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Compensation Committee</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">William A. Owens, John Cronin and Jon Pepper, each of whom satisfies the &#8220;independence&#8221; requirements of Rule 10C-1 under the Exchange Act and NYSE American&#8217;s rules, serve on our compensation committee, with Mr. Owens serving as the chairman. The members of the compensation committee are also &#8220;non-employee directors&#8221; within the meaning of Section 16 of the Exchange Act. The compensation committee assists the Board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers.&#160;&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The compensation committee is responsible for, among other things: (i) reviewing and approving the remuneration of our executive officers; (ii) making recommendations to the Board regarding the compensation of our independent directors; (iii) making recommendations to the Board regarding equity-based and incentive compensation plans, policies and programs; and (iv) reviewing and assessing annually the compensation committee&#8217;s performance and the adequacy of its charter. Our compensation committee met 4 times during the last fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the fiscal year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Nominating and Corporate Governance Committee</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Larry K. Ellingson, Jon Pepper and Ichiro Takesako, each of whom satisfies the &#8220;independence&#8221; requirements of NYSE American&#8217;s rules, serve on our nominating and corporate governance committee, with Mr. Ellingson serving as the chairman. The nominating and corporate governance committee assists the Board in selecting individuals qualified to become our directors and in determining the composition of the Board and its committees.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The nominating and corporate governance committee is responsible for, among other things: (i) identifying and evaluating individuals qualified to become members of the Board by reviewing nominees for election to the Board submitted by stockholders and recommending to the Board director nominees for each annual meeting of stockholders and for election to fill any vacancies on the Board; (ii) advising the Board with respect to Board organization, desired qualifications of Board members, the membership, function, operation, structure and composition of committees (including any committee authority to delegate to subcommittees), and self-evaluation and policies; (iii) advising on matters relating to corporate governance and monitoring developments in the law and practice of corporate governance; (iv) overseeing compliance with our code of ethics; and (v) approving any related party transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The nominating and corporate governance committee&#8217;s methods for identifying candidates for election to our Board (other than those proposed by our stockholders, as discussed below) include the solicitation of ideas for possible candidates from a number of sources &#8211; members of our Board, our executives, individuals personally known to the members of our Board, and other research. The nominating and corporate governance committee may also, from time-to-time, retain one or more third-party search firms to identify suitable candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In making director recommendations, the nominating and corporate governance committee may consider some or all of the following factors: (i) the candidate&#8217;s judgment, skill, and experience with other organizations of comparable purpose, complexity and size, and subject to similar legal restrictions and oversight; (ii) the interplay of the candidate&#8217;s experience with the experience of other Board members; (iii) the extent to which the candidate would be a desirable addition to the Board and any committee thereof; (iv) whether or not the person has any relationships that might impair his or her independence; and (v) the candidate&#8217;s ability to contribute to the effective management of the Company, taking into account the needs of the Company and such factors as the individual&#8217;s experience, perspective, skills and knowledge of the industry in which we operate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A stockholder may nominate one or more persons for election as a director at an annual meeting of stockholders if the stockholder complies with the notice and information provisions contained in our Bylaws. Such notice must be received in writing to our Company not later than the close of business fourteen (14) days nor earlier than the close of business eighty (80) days prior to the first anniversary of the preceding year&#8217;s annual meeting; provided, however, that if less than twenty-one (21) days&#8217; notice of the meeting is given to stockholders, such writing shall be received by the Secretary of the Corporation not later than the close of the seventh (7th) day following the day on which notice of the meeting was mailed to stockholders.&#160; In addition, stockholders furnishing such notice must be a holder of record on both (i) the date of delivering such notice and (ii) the record date for the determination of stockholders entitled to vote at such meeting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Code of Ethics </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. Such code of ethics addresses, among other things, honesty and ethical conduct, conflicts of interest, compliance with laws, regulations and policies, including disclosure requirements under the federal securities laws, and reporting of violations of the code. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A copy of the code of ethics has been filed as an exhibit to our registration statement on Form S-1, as amended, July 29, 2022, and is also available on our website as www.knowlabs.io. We are required to disclose any amendment to, or waiver from, a provision of our code of ethics applicable to our principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. We intend to use our website as a method of disseminating this disclosure as well as by SEC filings, as permitted or required by applicable SEC rules. Any such disclosure will be posted to our website within four (4) business days following the date of any such amendment to, or waiver from, a provision of our code of ethics.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Communication with our Board of Directors</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our stockholders and other interested parties may communicate with our Board of Directors by sending written communication in an envelope addressed to &#8220;Board of Directors&#8221; in care of the Secretary, 500 Union Street, Suite 810, Seattle, Washington 98101.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 16(a) Beneficial Ownership Reporting Compliance </strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our executive officers, directors and 10% stockholders are required under Section 16(a) of the Exchange Act to file reports of ownership and changes in ownership with the SEC. Copies of these reports must also be furnished to us. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based solely on a review of copies of reports furnished to us, as of September 30, 2023 our executive officers, directors and 10% holders complied with all filing requirements except as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10% Stockholders-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Todd Baszucki filed a Form 4 on October 25, 2023 that was required to be filed on October 3, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Todd Baszucki filed a Form 13D on October 25, 2023 that was required to be filed on September 25, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phillip A. Bosua-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed a Form 4 on February 14, 2023 that was required to be filed on January 25, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phillip A. Bosua has not filed required Form 4&#8217;s and Form 13D related to the disposal of shares. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">William A. Owens-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed a Form 4 on May 22, 2023 that was required to be filed on May 18, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ichiro Takesako-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed a Form 4 on April 10, 2023 that was required to be filed on February 17, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed a Form 4 on April 20, 2023 that was required to be filed on March 27, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Jon Pepper-</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed a Form 4 on April 10, 2023 that was required to be filed on February 17, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I11">ITEM 11. EXECUTIVE COMPENSATION.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Summary Compensation Table - Years Ended September 30, 2023 and 2022</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to the named persons (our &#8220;named executive officers&#8221;) for services rendered in all capacities during the years ended September 30, 2023 and September 30, 2022, respectively. The Company meets the requirements of a &#8220;smaller reporting company&#8221; and has utilized the scaled reporting requirements available to qualifying companies. No other executive officers received total annual salary and bonus compensation in excess of $100,000.</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">All</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Option</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Other</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Salary</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Bonus</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Awards</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Awards</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Principal Position</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;"></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($) (4)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ronald P. Erickson (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:19%;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Executive Officer and Chairman of the Board</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">371,083</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">551,569</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">173,885</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,096,537</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">474,475</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,748,231</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,222,706</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Phillip A. Bosua (2)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Former Chief Executive Officer</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">519,583</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">181,715</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">96,440</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">797,738</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,437,926</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">865,601</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">91,500</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,395,027</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Peter J. Conley (3)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Financial Officer and SVP Intellectual Property</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">319,792</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">244,750</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">564,542</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal year 2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) During the years ended September 30, 2023 and 2022, the Compensation Committee and the Board compensated Ronald P. Erickson with a salary of $300,000 from April 1, 2021 to March 15, 2022 and $325,000 from March 15, 2022 to September 30, 2022. From December 14, 2022, Mr. Erickson has been compensated with an annual salary of $375,000. An entity affiliated with and controlled by&#160; Mr. Erickson, J3E2A2Z LP, was paid interest of $173,855 during the year ended September 30, 2023. Mr. Erickson was paid deferred compensation of $165,000 during the year ended September 30, 2022, respectively. See <em>&#8220;Outstanding Equity Awards at Year-End&#8221;</em> for a discussion of option award compensation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Mr. Bosua is party to a Separation and Release Agreement with the Company, pursuant to which he was entitled to receive severance payments. Such payments are described in greater detail below under &#8220;Employment and Separation Agreements.&#8221; During the years ended September 30, 2023 and 2022, the Compensation Committee and the Board compensated Phillip A. Bosua at an annual salary of $350,000 from April 1, 2021 to January 23, 2023. Mr. Bosua was also paid $400,000 in severance and $96,440 in rent and other costs during the year ended September 30, 2023. Mr. Bosua was paid $1,097,928 in compensation and $91,500 in rent expenses for services provided to AI Mind, a wholly owned subsidiary of the Company, in connection with the development of NFT sales for the year ended September 30, 2022. See the section titled <em>&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Digital Asset Sales&#8221;</em> and Note 4 to the Notes to our Consolidated Financial Statements, See <em>&#8220;Outstanding Equity Awards at Year-End&#8221;</em> for a discussion of option award compensation. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3) Mr. Peter J. Conley has served as our Chief Financial Officer and SVP Intellectual Property since May 2022.<strong>&#160;</strong>During the year ended September 30, 2022, the Compensation Committee and the Board compensated Mr. Conley with an annual salary of $300,000 from May 20, 2022 to September 30, 2022. From December 14, 2022 to September 30, 2023, Mr. Conley has been compensated with an annual salary of $325,000. See <em>&#8220;Outstanding Equity Awards at Year-End&#8221;</em> for a discussion of option award compensation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4)&#160; These amounts reflect the aggregate grant date fair value of awards granted in the fiscal year ended September 30, 2022, as required by Regulation S-K Item 402(n)(2), computed in accordance with the FASB Accounting Standards Codification Topic 718 (&#8220;FASB ASC Topic 718&#8221;). All assumptions made in the valuations are contained and described in footnote 8 to the Company&#8217;s financial statements for Fiscal 2023 contained in this Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The amounts shown in the table reflect the total fair value on the date of the grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, we entered into an amended employment agreement for Ronald P. Erickson which amends our employment agreement with him dated July 1, 2017. The employment agreement provides for a base salary of $180,000 per year, which was increased to $215,000 from May 1, 2020 to March 31, 2021, to $300,000 from April 1, 2021 to March 15, 2022 and to $325,000 from March 15, 2022 to September 30, 2022. From December 14, 2022, Mr. Erickson has been compensated with an annual salary of $375,000. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If we terminate Mr. Erickson&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Erickson terminates his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Erickson will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. On January 23, 2023, the Board appointed Mr. Erickson our Chief Executive Officer. Mr. Erickson was appointed to serve until his successor is duly elected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, we entered into an employment agreement with Phillip A. Bosua reflecting his appointment as Chief Executive Officer. The employment agreement provided for a base salary of $225,000 per year, which was increased to $<ix:nonFraction id="fid_1233" contextRef="From2020-05-01to2021-03-31_knwn_MrBosuaMember" name="knwn:AnnualSalary" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction> from May 1, 2020 to March 31, 2021 and to $350,000 from April 1, 2021 to January 23, 2023. Mr. Bosua also received 500,000 shares of common stock valued at $0.33 per share and was entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. Mr. Bosua was entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement was for an initial term of 12 months (subject to earlier termination) and was automatically extended for additional 12-month terms unless either party notified the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If we &#160;terminated Mr. Bosua&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Bosua terminated his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Bosua was entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2023, Mr. Bosua resigned from the Board and from his position as our Chief Executive Officer.&#160; In connection with his resignation, we entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;) with Mr. Bosua containing customary terms and mutual releases, pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#8217;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of our common stock exceeds $5.00 per share on the NYSE American (the &#8220;Stock Price Threshold&#8221;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 13, 2022, we entered into an employment agreement with Peter J. Conley reflecting his appointment as our Chief Financial Officer and Senior Vice President, Intellectual Property. The employment agreement provides for a base salary of $300,000. From December 14, 2022 to September 30, 2023, Mr. Conley has been compensated with an annual salary of $325,000, Mr. Conley may also be entitled to bonuses from time to time as determined by our Board or our compensation committee in their sole discretion. Mr. Conley is eligible to participate in all our employee benefit plans, policies and arrangements that are applicable to other executive officers, as such plans, policies and arrangements may exist or change from time to time at our discretion. We will reimburse Mr. Conley for reasonable travel, entertainment and other expenses he incurs in the furtherance of his duties under the employment agreement. The employment agreement is at will, meaning either we or Mr. Conley may terminate the employment relationship at any time, with or without cause, upon written notice to the other party. The employment agreement provides for severance pay equal to 12 months of then-in-effect base salary if Mr. Conley is terminated without &#8220;cause&#8221; or voluntarily terminates his employment for &#8220;good reason,&#8221; as defined in the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Outstanding Equity Awards at Fiscal Year-End </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table includes certain information with respect to the value of all unexercised options and unvested shares of restricted stock previously awarded to the executive officers named above at the fiscal year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="13"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Option Awards</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Securities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Securities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Underlying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Underlying</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Unexercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Unexercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Option</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Option</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Unexerciseable</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Expiration</p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(#)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(#)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">($) (4)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Date</p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ronald P. Erickson (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">11/4/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,865,675</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/15/2025</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">266,525</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,599,150</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/15/2025</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/15/2025</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">437,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">562,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/16/2026</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">812,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">12/14/2027</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Phillip A. Bosua (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.28</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1/23/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">304,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.53</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1/23/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1/23/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Peter J. Conley (3)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">312,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">687,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">5/20/2027</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) On November 4, 2019, we granted a stock option grant to Ronald P. Erickson for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vested upon uplisting to the NASDAQ or NYSE exchanges. Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $1,207,200 during the year ended September 30, 2022. On December 15, 2020, we issued a stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vests in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; We estimated at grant date the fair value of these options at approximately $520,869 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, we recorded an expense of $104,172 and a &#160;cumulative expense of $186,657, respectively.&#160; We are valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022. On December 15, 2020, we issued an additional stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $263,593 during the year ended September 30, 2022. The stock option grants vest when earned based on certain performance criteria. On December 15, 2020, we issued a fully vested warrant to Ronald P. Erickson for 2,000,000 shares of common stock. The five year warrant is exercisable for cash or non-cash at $1.53 per share and was valued using a Black-Scholes model at $1,811,691. On December 16, 2021, we issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On December 14, 2022, we issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $1.41 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) On July 30, 2018, Mr. Bosua was awarded a stock option grant for 1,000,000 shares of our common stock that was awarded at $1.28 per share. The stock option grant vests quarterly over four years. The performance grant was not earned as of September 30, 2022. On November 4, 2019, we granted a stock option grant to Philip A. Bosua for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon FDA approval of the UBAND blood glucose monitor. On December 15, 2020, we issued a stock option grant to Phillip A. Bosua for 2,132,200 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vested in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; We estimated at grant date the fair value of these options at approximately $595,277 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, we recorded an expense of $37,370 and a cumulative expense of $231,321, respectively.&#160; We are valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022. On December 15, 2020, we issued another stock option grant to Phillip A. Bosua for 2,132,195 shares at an exercise price of $1.53 per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $301,249 during the year ended September 30, 2022. On December 16, 2021, we issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. On December 14, 2022, we issued a stock option grant to Philip A. Bosua for 1,250,000 shares at an exercise price of $1.41 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Pursuant to the Separation Agreement, as of January 23, 2023, all of Mr. Bosua&#8217;s outstanding stock options listed above ceased vesting as of January 23, 2023, and his vested stock options will remain exercisable until January 23, 2024.&#160; Mr. Bosua forfeited stock option grants for 7,384,795 shares of common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3) Mr. Peter J. Conley has served as our Chief Financial Officer and SVP Intellectual Property since May 2022.<strong> </strong>On May 20, 2022, we issued a stock option grant to Mr. Conley for 1,000,000 shares at an exercise price of $1.48 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years, with no vesting during the first six months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4) These amounts reflect the grant date market value as required by Regulation S-K Item 402(n)(2), computed in accordance with FASB ASC Topic 718.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Additional Narrative Disclosure</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Retirement Benefits</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not maintained, and do not currently maintain, a defined benefit pension plan, nonqualified deferred compensation plan or other retirement benefits. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We maintain a 401(k) plan and/or other health and welfare benefit plans in which our NEOs are eligible to participate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Potential Payments upon Termination or Change in Control</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have the following potential payments upon termination or change in control with Ronald P. Erickson:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Early</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Not For Good</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Change in</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Executive</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For Cause</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">or Normal</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Cause</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Control</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Disability</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Payments Upon </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Retirement</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">or Death</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Separation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Compensation:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Base salary&#160; (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">375,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">375,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Performance-based incentive compensation&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock options (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,004,274</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,004,274</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Benefits and Perquisites:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Health and welfare benefits (3)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,446</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accrued vacation pay </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,406,720</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5,406,720</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reflects a salary for twelve months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reflects the vesting of stock option grants-non cash.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reflects the cost of medical benefits for eighteen months.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have the following potential payments upon termination or change in control with Peter J. Conley:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Early</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Not For Good</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Change in</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Executive</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For Cause</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">or Normal</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Cause</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Control</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Disability</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Payments Upon</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Retirement</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Termination</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">or Death</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Separation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">on 9/30/2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Compensation:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Base salary (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">325,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Performance-based incentive compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock options (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">673,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">673,063</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Benefits and Perquisites:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Health and welfare benefits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accrued vacation pay</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">998,063</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">998,063</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reflects a salary for twelve months.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reflects the vesting of stock option grants- non cash,</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Director Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our independent non-employee directors are primarily compensated with stock option grants and stock grants to attract and retain qualified candidates to serve on the Board, in addition to a $12,500 cash retainer in consideration of board services. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties to our Company as well as the skill-level required by our members of the Board.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">62</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The table below sets forth the compensation paid to our non-employee directors during the fiscal year ended September 30, 2023. Ronald P. Erickson and Phillip A. Bosua did not receive any compensation for their services as directors. The compensation disclosed in the Summary Compensation Table above represents the total compensation for Mr. Erickson and Mr. Bosua.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Option</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fees</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Awards</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Awards (4)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Earned</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Jon Pepper (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ichiro Takesako (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,480</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">William A. Owens (3)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">12,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,960</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">37,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">69,460</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The stock option grant for 20,000 shares of common stock was issued on February 15, 2023 to Mr. Pepper and was valued at the black scholes value of $0.799 per share. Mr. Pepper was paid $12,500 for board services. As of September 30, 2023, Mr. Pepper has stock option grants for 77,500 shares of common stock and warrants to purchase common stock of 40,000 shares.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The stock option grant for 20,000 shares of common stock was issued on February 15, 2023 to Mr. Takesako and was valued at the black scholes value of $0.799 per share. Mr. Takesako was paid $12,500 for board services. As of September 30, 2023, Mr. Takesako has stock option grants for 77,500 shares of common stock and warrants to purchase common stock of 40,000 shares.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Owens was paid $12,500 for board services. As of September 30, 2023, Mr. Owens has stock option grants for 0 shares of common stock and warrants to purchase common stock of 40,000 shares.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These amounts reflect the grant date market value as required by Regulation S-K Item 402(n)(2), computed in accordance with FASB ASC Topic 718. All assumptions made in the valuations are contained and described in footnote 8 to the Company&#8217;s financial statements for Fiscal 2023 contained in this Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The amounts shown in the table reflect the total fair value on the date of grant and do not necessarily reflect the actual value, if any, that may be realized by the listed executives.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Cronin, Mr. Londergan, and Mr. Ellingson were each appointed as directors in November 2023, as such they received no compensation as directors in the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2021 Equity Incentive Plan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 12, 2021, we established the Know Labs, Inc. 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which was adopted by our stockholders on October 15, 2021. The following summary briefly describes the principal features of the 2021 Plan and is qualified in its entirety by reference to the full text of the 2021 Plan, which is filed as an exhibit to this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Awards that may be granted include: (a)&#160;incentive stock options, (b)&#160;non-qualified&#160;stock options, (c)&#160;stock appreciation rights, (d)&#160;restricted awards, (e)&#160;performance share awards, and (f)&#160;performance compensation awards. These awards offer our officers, employees, consultants and directors the possibility of future value, depending on the long-term&#160;price appreciation of our common stock and the award holder&#8217;s continuing service with our company. All of the permissible types of awards under the 2021 Plan are described in more detail below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Purposes of 2021 Plan:</em></strong> The purposes of the 2021 Plan are to attract and retain officers, employees and directors for our company and our subsidiaries; motivate them by means of appropriate incentives to achieve long-range&#160;goals; provide incentive compensation opportunities; and further align their interests with those of our stockholders through compensation that is based on our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Administration of the 2021 Plan:</em></strong> The 2021 Plan is administered by our compensation committee (which we refer to as the plan administrator). Among other things, the plan administrator has the authority to select persons who will receive awards, determine the types of awards and the number of shares to be covered by awards, and to establish the terms, conditions, performance criteria, restrictions and other provisions of awards. The plan administrator has authority to establish, amend and rescind rules and regulations relating to the 2021 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">63</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Eligible Recipients:</em></strong> Persons eligible to receive awards under the 2021 Plan will be those officers, employees, consultants, and directors of our company and our subsidiaries who are selected by the plan administrator.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Shares Available Under the 2021 Plan:</em></strong>&#160;20,000,000 shares of our common stock were originally authorized as the maximum number of shares of our common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to 22,000,000 shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase discussed below. &#160;Shares subject to an award under the 2021 Plan for which the award is canceled, forfeited or expires again become available for grants under the 2021 Plan. Shares subject to an award that is settled in cash will not again be made available for grants under the 2021 Plan. As of the date of this report, all shares remain available for issuance under the 2021 Plan. The 2021 Plan also authorizes for issuance the sum of (A) any shares of our common stock that, as of the date of stockholder approval of the 2021 Plan, have been reserved but not issued pursuant to any awards granted under our 2011 Stock Incentive Plan and (B) any shares of our common stock subject to stock options or similar awards granted under our 2011 Stock Incentive Plan that, after the date of stockholder approval of the 2021 Plan, expire or otherwise terminate without having been exercised in full and shares of our common stock issued pursuant to awards granted under our 2011 Stock Incentive Plan that are forfeited to or repurchased by us, with the maximum number of shares of our common stock to be added to the 2021 Plan pursuant to clause (B) equal to 7,592,825. &#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Automatic Share Reserve Increase:</em></strong> Subject to the provisions of Section&#160;14 of the 2021 Plan, the number of shares available for issuance under the 2021 Plan will be increased on the first day of each calendar year beginning January 1, 2022 and ending on and including January 1, 2030 in an amount equal to the least of (i)&#160;2,000,000 shares of our common stock, (ii)&#160;four percent (4%) of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year or (iii)&#160;such number of shares of our common stock determined by our board of directors; provided, that such determination under clause (iii)&#160;will be made no later than the last day of the immediately preceding fiscal year. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Options:</em></strong><strong>&#160;</strong>Stock options give the option holder the right to acquire from us a designated number of shares of common stock at a purchase price that is fixed upon the grant of the option. The exercise price will not be less than the market price of the common stock on the date of grant. Stock options granted may be either tax-qualified&#160;stock options (so-called&#160;&#8220;incentive stock options&#8221;) or non-qualified&#160;stock options.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">General</span></em><em>.</em>&#160;Subject to the provisions of the 2021 Plan, the plan administrator has the authority to determine all grants of stock options. That determination will include: (i)&#160;the number of shares subject to any option; (ii)&#160;the exercise price per share; (iii)&#160;the expiration date of the option; (iv)&#160;the manner, time and date of permitted exercise; (v)&#160;other restrictions, if any, on the option or the shares underlying the option; and (vi)&#160;any other terms and conditions as the plan administrator may determine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Option Price</span></em>. The exercise price for stock options will be determined at the time of grant. Normally, the exercise price will not be less than the fair market value on the date of grant. As a matter of tax law, the exercise price for any incentive stock option awarded may not be less than the fair market value of the shares on the date of grant. However, incentive stock option grants to any person owning more than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Exercise of Options</span></em><em>.</em> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by the plan administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price. Payments may be made in cash or, at the option of the plan administrator, by actual or constructive delivery of shares of common stock to the holder of the option based upon the fair market value of the shares on the date of exercise.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Expiration or Termination</span></em><em>.</em> Options, if not previously exercised, will expire on the expiration date established by the plan administrator at the time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders of more than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder&#8217;s service with our company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods after certain terminations of employment, including terminations as a result of death, disability or retirement, with the precise period during which the option may be exercised to be established by the plan administrator and reflected in the grant evidencing the award.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">64</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Incentive and Non-Qualified&#160;Options</span></em><em>.</em>&#160;As described elsewhere in this summary, an incentive stock option is an option that is intended to qualify under certain provisions of the Internal Revenue Code of 1986, as amended, or the Code, for more favorable tax treatment than applies to non-qualified&#160;stock options. Any option that does not qualify as an incentive stock option will be a non-qualified&#160;stock option. Under the Code, certain restrictions apply to incentive stock options. For example, the exercise price for incentive stock options may not be less than the fair market value of the shares on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be transferred, other than by will or the laws of descent and distribution, and is exercisable during the holder&#8217;s lifetime only by the holder. In addition, no incentive stock options may be granted to a holder that is first exercisable in a single year if that option, together with all incentive stock options previously granted to the holder that also first become exercisable in that year, relate to shares having an aggregate market value in excess of $100,000, measured at the grant date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Appreciation Rights:</em></strong>&#160;Stock appreciation rights, or SARs, which may be granted alone or in tandem with options, have an economic value similar to that of options. When a SAR for a particular number of shares is exercised, the holder receives a payment equal to the difference between the market price of the shares on the date of exercise and the exercise price of the shares under the SAR. The exercise price for SARs normally is the market price of the shares on the date the SAR is granted. Under the 2021 Plan, holders of SARs may receive this payment&#160;&#8212; the appreciation value&#160;&#8212; either in cash or shares of common stock valued at the fair market value on the date of exercise. The form of payment will be determined by us. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Awards:</em></strong>&#160;Restricted shares are shares of common stock awarded to participants at no cost. Restricted shares can take the form of awards of restricted stock, which represent issued and outstanding shares of our common stock subject to vesting criteria, or restricted stock units, which represent the right to receive shares of our common stock, subject to satisfaction of the vesting criteria. Those may include requirements for continuous service and/or the achievement of specified performance goals. Restricted shares are forfeitable and non-transferable&#160;until the shares vest. The vesting date or dates and other conditions for vesting are established when the shares are awarded. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cash Awards:</em></strong>&#160;A cash award is an award that may be in the form of cash or shares of common stock or a combination, based on the attainment of pre-established&#160;performance goals and other conditions, restrictions and contingencies identified by the plan administrator.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Section&#160;162(m) of the Code:</em></strong>&#160;Section&#160;162(m) of the Code limits publicly-held&#160;companies to an annual deduction for U.S. federal income tax purposes of $1.0&#160;million for compensation paid to each of their principal executive officer or principal financial officer and their three highest compensated executive officers (other than the principal executive officer or principal financial officer) determined at the end of each year, referred to as covered employees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Performance Criteria</em></strong><em>:</em>&#160;Under the 2021 Plan, one or more performance criteria will be used by the plan administrator in establishing performance goals. Any one or more of the performance criteria may be used on an absolute or relative basis to measure the performance of our company, as the plan administrator may deem appropriate, or as compared to the performance of a group of comparable companies or published or special index that the plan administrator deems appropriate. In determining the actual size of an individual performance compensation award, the plan administrator may reduce or eliminate the amount of the award through the use of negative discretion if, in its sole judgment, such reduction or elimination is appropriate. The plan administrator shall not have the discretion to (i)&#160;grant or provide payment in respect of performance compensation awards if the performance goals have not been attained or (ii)&#160;increase a performance compensation award above the maximum amount payable under the 2021 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Other Material Provisions:</em></strong>&#160;Awards will be evidenced by a written agreement, in such form as may be approved by the plan administrator. In the event of various changes to the capitalization of our company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate adjustment will be made by the plan administrator to the number of shares covered by outstanding awards or to the exercise price of such awards. The plan administrator is also permitted to include in the written agreement provisions that provide for certain changes in the award in the event of a change of control of our company, including acceleration of vesting. Except as otherwise determined by the plan administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. Our board also has the authority, at any time, to discontinue the granting of awards. The board also has the authority to alter or amend the 2021 Plan or any outstanding award or may terminate the 2021 Plan as to further grants, provided that no amendment will, without the approval of our stockholders, to the extent that such approval is required by law or the rules of an applicable exchange, increase the number of shares available under the 2021 Plan, change the persons eligible for awards under the 2021 Plan, extend the time within which awards may be made, or amend the provisions of the 2021 Plan related to amendments. No amendment that would adversely affect any outstanding award made under the 2021 Plan can be made without the consent of the holder of such award.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">65</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I12">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Security Ownership of Certain Beneficial Owners and Management</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of September 30, 2023 for (i) each of our named executive officers and directors; (ii) all of our named executive officers and directors as a group; and (iii) each other stockholder known by us to be the beneficial owner of more than 5% of our outstanding common stock. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o our company, 500 Union Street, Suite 810, Seattle, WA 98101. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Name of Beneficial Owner</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Amount </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Percentage</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Directors and Officers-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ronald P. Erickson (3)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,210,540</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Peter J. Conley (4)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">William A. Owens (5)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">852,703</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Jon Pepper (6)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">510,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.6</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Ichiro Takesako (7)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">137,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">All executive officers and directors (5 persons)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,033,743</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13.6</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Less than 1% </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or group of persons is deemed to have &#8220;beneficial ownership&#8221; of any shares that such person or any member of such group has the right to acquire within sixty (60) days. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within sixty (60) days of September 30, 2023 are deemed to be outstanding for such person, but not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership by any person.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on 80,358,463 shares of common stock issued and outstanding as of September 30, 2023.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 1,488,085 shares of shares of our common stock beneficially owned by Ronald P. Erickson or entities controlled by Mr. Erickson, (ii) 2,091,525 shares of our common stock issuable upon the exercise of options exercisable within 60 days, (iii) 3,894,666 shares of our common stock issuable upon the exercise of warrants that are exercisable within 60 days, and (iv) 4,736,264 shares of our common stock issuable upon the conversion of convertible notes that are convertible within 60 days.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 10,000 shares of our common stock held directly by Peter Conley and (ii) 312,500 shares of our common stock issuable upon the exercise of options exercisable within 60 days.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(5)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 812,703 shares of our common stock held directly by William A Owens and (ii) 40,000 shares of our common stock issuable upon the exercise of warrants that are exercisable within 60 days.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(6)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 393,000 shares of our common stock held directly by Jon Pepper, (ii) 77,500 shares of our common stock issuable upon the exercise of options exercisable within 60 days and (iii) 40,000 shares of our common stock issuable upon the exercise of warrants exercisable within 60 days.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(7)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 20,000 shares of our common stock held directly by Ichiro Takesako, (ii) 77,500 shares of our common stock issuable upon the exercise of options exercisable within 60 days and (iii) 40,000 shares of our common stock issuable upon the exercise of warrants exercisable within 60 days.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">66</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares Beneficially Owned&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Percentage</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Greater Than 5% Ownership</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A.&#160;Struve (1)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,064,855</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="5" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Blocker at 4.99%</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Todd Baszucki (2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ronald P. Erickson (3)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,210,540</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.4</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Phillip A. Bosua (4)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,634,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 1,402,784 shares of our common stock, (ii) 6,269,715 shares of our common stock issuable upon the exercise of warrants, (iii) 5,000,000 shares of our common stock issuable upon the conversion of our series C convertible preferred stock, (iv) 3,108,356 shares of our common stock issuable upon the conversion of our series D convertible preferred stock and (v) 4,284,000 shares of our common stock issuable upon the conversion of convertible notes; and excludes additional shares of preferred stock issuable as accreted preferred dividends pursuant to terms of the series C convertible preferred stock and series D convertible preferred stock. All of the warrants, series C convertible preferred stock, series D convertible preferred stock and convertible notes held by Mr. Struve are subject to a 4.99% blocker pursuant to which shares of our common stock may not be issued to the extent that such issuance would cause Mr. Struve to beneficially own more than 4.99% of our common stock. The address of Mr. Struve is 175 West Jackson Blvd., Suite 440, Chicago, IL 60604.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Includes (i) 17,200,000 shares of our common stock held directly by Todd Baszucki and (ii) 1,000,000 shares of our common stock issuable upon the exercise of warrants. The address for Mr. Baszucki is 395 Del Monte Center, Unit 306, Monterey, CA 93940.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See above for Ronald P. Erickson or entities controlled by Mr. Erickson.The address for Mr. Erickson is 500 Union Street, Suite 810, Seattle, WA 98101.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(4)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Consists of (i) 3,005,000 shares of shares of our common stock held directly by Phillip A. Bosua and (ii) 1,629,600 shares of our common stock issuable upon the exercise of options that are exercisable within 60 days. The address for Mr. Bosua is 201 Galer, Unit 410, Seattle, WA 98109. Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Mr. Bosua is party to a Separation and Release Agreement with the Company, pursuant to which he was entitled to receive severance payments. Such payments are described in greater detail below under &#8220;Employment and Separation Agreements&#8221; and such amounts will be disclosed in the summary compensation table for the fiscal year ended September 30, 2023.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Securities Authorized for Issuance Under Equity Compensation Plans</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table sets forth certain information about the securities authorized for issuance under our incentive plans as of September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(a)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(b)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(c)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of securities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">remaining available</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">for future issuance </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of securities </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted-average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">under equity </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">to be issued upon</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">exercise price of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">exercise of outstanding</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">outstanding options,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">plan (excluding securities </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Plan Category</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">options, warrants and rights</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">warrants and rights</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">reflected in column (a))</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Equity compensation plan approved by shareholders </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:18%;vertical-align:bottom;text-align:right;">14,506,158</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">1.546</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">21,952,654</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Equity compensation plans not approved by shareholders</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">14,506,158</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.546</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">21,952,654</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">67</p></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 12, 2021, we established the 2021 Plan, which was adopted by our stockholders on October 15, 2021. The maximum number of shares of common stock that may be issued pursuant to awards granted under the 2021 Plan is 22,000,000 shares and all of these shares remained available for issuance as of September 30, 2023. See Item 11 &#8220;<em>Executive Compensation&#8212;2021 Equity Incentive Plan</em>&#8221; for a complete description of the 2021 Plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I13">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Transactions with Related Persons </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following includes a summary of transactions since the beginning of our 2021 fiscal year, or any currently proposed transaction, in which we were or are to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last three completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under &#8220;<em>Executive Compensation</em>&#8221; above). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm&#8217;s-length transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">to terms available or the amounts that would be paid or received, as applicable, in arm&#8217;s-length transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Transactions with Clayton Struve</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 3, 2022, we approved the Extension of Warrant Agreement with Clayton Struve, extending the exercise dates as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant No./Class</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Original </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">08-14-2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,440,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">08-13-2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">12-12-2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,200,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12-11-2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,785,715</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">08-04-2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,344,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">02-28-2024</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, we signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates. We recorded interest expense of $194,019 during the year ended September 30, 2023 related to the extension of the warrants. We recorded the original value of warrants in equity and as such, we recorded the extension value as an expense with an offset to additional paid in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Convertible Promissory Notes with Clayton A. Struve</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We owe Clayton A. Struve, a significant stockholder, $1,301,005 under convertible promissory or OID notes. We recorded accrued interest of $94,062 and $86,562 as of September 30, 2023 and September 30, 2022, respectively. On December 7, 2022, we signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2023.&#160; On September 15, 2023, the due dates on the notes was further extended to September 30, 2024.&#160;We expensed $230,005 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. We recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Series C and D Preferred Stock and Warrants</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 5, 2016, we closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the conversion price of the Series C Preferred Stock was adjusted to $0.25 per share pursuant to its certificate of designation. As of September 30, 2023, Mr. Struve owns all of the 1,785,715 issued and outstanding shares of Series C Preferred Stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">68</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, Mr. Struve owns all of the 1,016,004 issued and outstanding shares of Series D Preferred Stock</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 28, 2023, Mr. Struve converted $350,696 of accumulated Series D preferred stock dividends into 1,402,784 shares of our common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 9, 2023, the Board authorized the Company to file a series of amendments to certain classes of preferred stock, the certificates of designation, and restatement of its articles of incorporation, as described below, each of which were filed with the Nevada Secretary of State effective August 11, 2023. See Item 5. Based upon the modified terms and conditions&#160; of Series C and D certificates of designations, it was determined that Series C and D preferred dividends need to be accreted going forward. As of September 30, 2023, cumulative unpaid Series C and D totaled approximately $770,000 which converts to approximately 3,040,000&#160; shares of common&#160; stock. The value of the 3.0 million shares of common totaled $3,526,.,653 The Company recorded $3,526,353 in cumulative deemed dividends related to Series C and D Preferred Stock which have not been paid.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See &#8220;<em>Description of Securities</em>&#8221; for the terms of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Transactions with Ronald P. Erickson</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We owe Ronald P. Erickson and J3E2A2Z, an entity affiliated controlled by Ronald P. Erickson $1,460,926 under convertible promissory notes On March 16, 2018, we entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. We recorded accrued interest of $218,334 and $287,290 as of September 30, 2023 and September 30, 2022, respectively. On December 7, 2022, we approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to January 30, 2023. On January 25, 2023, we approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2023. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. We expensed $276,860 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. We recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 4, 2019, we granted a stock option grant to Ronald P. Erickson for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon uplisting to the NASDAQ or NYSE exchanges. Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $1,207,200 during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, we issued a stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vests in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; We estimated at grant date the fair value of these options at approximately $520,869 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, we recorded an expense of $104,172 and a&#160; cumulative expense of $186,657, respectively. We are valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, we issued a stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. Our common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $263,593 during the year ended September 30, 2022. The stock option grants vest when earned based on certain performance criteria. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 16, 2021, we issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">69</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 14, 2022, we issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $1.41 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 19, 2023, we signed an Extension of Warrant Agreements with Ronald P. Erickson and an entity controlled by Mr. Erickson, extending the exercise dates from January 30, 2023 to January 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Erickson and/or entities with which he is affiliated also have expenses and interest of approximately $218,334 as of September 30, 2023, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Transactions with Peter J. Conley</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 20, 2022, we issued a stock option grant to Mr. Conley for 1,000,000 shares at an exercise price of $1.48 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years, with no vesting during the first six months. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock Issuances to Named Executive Officers and Directors</strong></em>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, we issued 30,000 shares each to three directors shares at an exercise price of $1.70 per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, we issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 15, 2023, we issued stock option grants to two directors for a total of 50,000 shares at an exercise price of $1.24 per share. The stock option grant expires in five years. The stock option grants vested at issuance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Cronin&#160; has served as an independent director since November 2023. Mr. Cronin is an experienced inventor and intellectual property strategist. Mr. Cronin is Chairman and CEO of ipCapital Group, Inc. As of the year ended September 30, 2023, we have paid ipCapital Group approximately $713,000 in professional fees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Indemnification</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our articles of incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Nevada law. In addition, we have Indemnification Agreements with the current Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I14">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Audit Committee Pre-Approval Policy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee has established a pre-approval policy and procedures for audit, audit-related and tax services that can be performed by the independent auditors without specific authorization from the Audit Committee subject to certain restrictions. The policy sets out the specific services pre-approved by the Audit Committee and the applicable limitations, while ensuring the independence of the independent auditors to audit our financial statements is not impaired. The pre-approval policy does not include a delegation to management of the Audit Committee&#8217;s responsibilities under the Exchange Act. During the year ended September 30, 2023, the Audit Committee pre-approved all audit and permissible non-audit services provided by our independent auditors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Service Fees Paid to the Independent Registered Public Accounting Firm</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee engaged BPM LLP to perform an annual audit of our financial statements for the fiscal year ended September 30, 2023 and 2022. The following is the breakdown of aggregate fees for the last two fiscal years. Another tax firm prepares our tax returns.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Year Ended&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Year Ended&#160; </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Audit fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">220,420</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Tax fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">All other fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">98,440</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">69,015</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">318,860</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">235,300</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;- &#8220;Audit Fees&#8221; are fees paid for professional services for the audit and quarterly reviews of our financial statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">- &#8220;Audit-Related fees&#8221; are fees paid for professional services not included in audit fees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">- &#8220;Tax Fees&#8221; are fees primarily for tax compliance in connection with filing US income tax returns.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">- &#8220;All other fees&#8221; related to the reviews of Registration Statements on Form S-1 and S-3.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">70</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="P4">PART IV</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="I15">ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(a)&#160;<em>List of Documents Filed as a Part of This Report:</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s financial statements, as indicated by the Index to Consolidated Financial Statements set forth below, begin on page F-1. Financial statement schedules have been omitted because they are not applicable or the required information is included in the financial statements or notes thereto.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#REPORT">Report of BPM LLP (PCAOB ID <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorFirmId">207</ix:nonNumeric>)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-1</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#BS">Consolidated Balance Sheets as of September 30, 2023 and 2022</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-3</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#OP">Consolidated Statements of Operations for the Years Ended September 30, 2023 and 2022</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-4</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#EQ">Consolidated Statement of Changes in Stockholders&#8217; Equity for the Years Ended September 30, 2023 and 2022</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-5</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#CF">Consolidated Statements of Cash Flows for the Years Ended September 30, 2023 and 2022</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-6</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#NOTES">Notes to Consolidated Financial Statements</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-7</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2)&#160;Index<em> to Financial Statement Schedules:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All schedules have been omitted because the required information is included in the financial statements or the notes thereto, or because it is not required.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(3)&#160;Index<em> to Exhibits:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See exhibits listed under Part (b) below. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">71</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(b)&#160;<em>Exhibits: </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Exhibit No.</strong></p></td><td colspan="2" style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex31.htm">3.1</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex31.htm">Restatement of the Articles of Incorporation, dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, field August 14, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/0001074828/000165495421012914/knwn_ex32.htm">3.2</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/0001074828/000165495421012914/knwn_ex32.htm">Second Amended and Restated Bylaws, dated October 15, 2021, (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed December 7, 2021)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex34.htm">3.3</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex34.htm">Amended and Restated Series C Certificate of Designation, dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed August 14, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169716001036/ex_10-4.htm">3.4</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169716001036/ex_10-4.htm"><span style="text-decoration:underline">Third Amended and Restated Series D Certificate of Designation, dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed August 14, 2023)</span>&#160;</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex33.htm">3.5</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex33.htm">Series C Certificate of Correction of Know Labs, Inc., dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed August 14, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex35.htm">3.6</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex35.htm">Series D Certificate of Correction of Know Labs, Inc., dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed August 14, 2023)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex37.htmhttp://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex37.htm">3.7</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex37.htmhttp://www.sec.gov/Archives/edgar/data/1074828/000165495423010775/know_ex37.htm">Certificate of Withdrawal of Series F Preferred Stock, dated August 11, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K filed August 14, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495421013053/knwn_ex991.htm">4.1&#8224;</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495421013053/knwn_ex991.htm">Know Labs, Inc. 2021 Equity Incentive Plan (incorporated by reference to the Company&#8217;s Form S&#8209;8 Filed December 10, 2021)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495417004136/exhibit_10-1.htm">10.1</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495417004136/exhibit_10-1.htm">Form of Preferred Stock and Warrant Purchase Agreement, Form of Amended and Restated Registration Rights Agreement. and Form of Series F Warrant to Purchase common stock&#160; by and between Visualant, Incorporated and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed May 5, 2017)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169717000373/ex_10-1.htm">10.2</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169717000373/ex_10-1.htm">Securities Purchase Agreement dated August 14, 2017 by and between Visualant, Incorporated and accredited investor (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed August 18, 2017)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169717000562/ex_10-2.htm">10.3</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169717000562/ex_10-2.htm">Senior Secured Convertible Redeemable Debenture dated December 12, 2017 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed December 22, 2017)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000114/ex_10-2.htm">10.4</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000114/ex_10-2.htm">Senior Secured Convertible Redeemable Debenture dated February 28, 2018 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed March 7, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000142/ex_10-1.htm">10.5</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000142/ex_10-1.htm">Note and Account Payable Conversion Agreement and related notes and warrants dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2Z LP (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed March 21, 2018)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-20.htm">10.6&#8224;</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-20.htm">Employment Agreement dated April 10, 2018 by and between Visualant, Incorporated and Phillip A. Bosua. (incorporated by reference to the Company&#8217;s Annual Report on Form 10-K, filed December 21, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423006557/know_ex108.htm">10.7&#8224;</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423006557/know_ex108.htm">Separation and Release Agreement dated January 23, 2023 by and between Know Labs, Inc. and Philip Bosua (incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q filed May 15, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-21.htm">10.8&#8224;</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-21.htm">Amended Employment Agreement dated April 10, 2018 by and between Visualant, Incorporated and Ronald P. Erickson. (incorporated by reference to the Company&#8217;s Annual Report on Form 10-K, filed December 21, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-21.htm">10.9&#8224;</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495418014237/exhibit_10-21.htm">Employment Agreement dated May 13, 2022 by and between Know Labs, Inc. and Peter Conley. (incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q, filed August 12, 2022)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422012787/knwn_ex11.htm">10.10</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422012787/knwn_ex11.htm">Underwriting Agreement dated September 15, 2022 by and between Know Labs, Inc. and Boustead Securities, LLC. (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 21, 2022)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422012787/knwn_ex41.htm">10.11</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422012787/knwn_ex41.htm">Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 20, 2022 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 21, 2022)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422016317/knwn_ex105.htm">10.12</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495422016317/knwn_ex105.htm">Extension of Warrant Agreement dated December 7, 2022 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed December 9, 2022)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169723000082/ex_10-1.htm">10.13</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169723000082/ex_10-1.htm">Extension of Warrant Agreement dated January 19, 2023 by and between Know Labs, Inc. and Ronald P. Erickson (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed January 23, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169723000082/ex_10-2.htm">10.14</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169723000082/ex_10-2.htm">Extension of Warrant Agreement dated January 19, 2023 by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed January 23, 2023).</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012018/knwn_ex101.htm">10.15</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012018/knwn_ex101.htm">Amendment 10 dated September 15, 2023 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012018/knwn_ex102.htm">10.16</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012018/knwn_ex102.htm">Amendment 10 dated September 15, 2023 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">72</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex101.htm">10.17</a></p></td><td colspan="2" style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex101.htm">Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated September 30, 2016 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex102.htm">10.18</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex102.htm">Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated August 14, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex103.htm">10.19</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex103.htm">Amendment 9 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated December 12, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex104.htm">10.20</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012020/knwn_ex104.htm">Amendment 8 dated September 15, 2023 to Senior Secured Convertible Redeemable Note dated February 28, 2018 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 19, 2023).</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex11.htm">10.21</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex11.htm">Underwriting Agreement, dated September 26, 2023, between Know Labs, Inc., Boustead Securities, LLC and The Benchmark Company, LLC (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 29, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex41.htm">10.22</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex41.htm">Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 29, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 29, 2023).</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex42.htm">10.23</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423012435/knwn_ex42.htm">Common Stock Purchase Warrant issued by Know Labs, Inc. to The Benchmark Company, LLC on September 29, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed September 29, 2023).</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_14-1.htm">14.1</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_14-1.htm">Code of Ethics dated November 2018 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed November 27, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex231.htm">23.1*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex231.htm">Consent of BPM LLP, Independent Registered Public Accounting Firm</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex311.htm">31.1*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex311.htm">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex312.htm">31.2*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex312.htm">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex321.htm">32.1*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex322.htm">32.2*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-1.htm">99.1</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-1.htm">Audit Committee Charter dated November 2018 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed November 27, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-2.htm">99.2</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-2.htm">Compensation Committee Charter dated November 2018 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed November 27, 2018)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-1.htm">99.3</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000116169718000556/ex_99-1.htm">Nominations and Corporate Governance Committee Charter dated November 2018 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed November 27, 2018)</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423015070/knwn_ex101.htm">97.1</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1074828/000165495423015070/knwn_ex101.htm">Know Labs, Inc. Compensation Recovery Policy dated November 28, 2023 (incorporated by reference to the Company&#8217;s Current Report on Form 8-K, filed December 1, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex211.htm">21.1*</a></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="knwn_ex211.htm">Subsidiaries of the Registrant. </a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.INS*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because iXBRL tags are embedded within the Inline XBRL document).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.SCH*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Taxonomy Extension Schema Document&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.CAL*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Taxonomy Extension Calculation Linkbase Document&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.DEF*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Taxonomy Extension Definition Linkbase Document&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.LAB*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Taxonomy Extension Labels Linkbase Document&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">101.PRE*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inline XBRL Taxonomy Extension Presentation Linkbase Document&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">104*</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023 formatted in Inline XBRL (included in Exhibit 101).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">*</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Filed herewith</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#8224;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Executive compensation plan or arrangement</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">73</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="REPORT">Report of Independent Registered Public Accounting Firm</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the Board of Directors and Stockholders of </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Know Labs, Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Opinion on the Financial Statements</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have audited the accompanying consolidated balance sheets of Know Labs, Inc. and its subsidiaries (the Company) as of September 30, 2023 and 2022, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the two years in the period ended September 30, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended September 30, 2023 in conformity with the accounting principles generally accepted in the United States of America.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis for Opinion</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These consolidated financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Critical Audit Matter</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounting for the preferred convertible instruments</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As described in Note 8 to the consolidated financial statements, during June 2023 the Company declared and issued approximately 1.4 million shares of common stock as a dividend to the Series D Preferred stock shareholder.&#160; The Company also modified certain rights and obligations in the Series C and D Preferred Stock certificates of designation. The payment of these dividends and the modification of terms now obligate the Company to issue stock for the unpaid portion of the 8% cumulative dividend for both the Series C and D Preferred Stock. The Company recorded a deemed dividend for the value of unpaid portion of the 8% cumulative dividend. The unpaid stock dividend will be distributed in the future when certain terms and conditions are met and the shareholder requests receipt of such shares.&#160; The common stock dividend issued to the Series D shareholder and the value of the unpaid 8% cumulative dividend for Series C and D Preferred Stock is treated as a deemed dividend and both result in an increase of the net loss to be allocated to the common shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The principal considerations for our determination that performing procedures related to the preferred convertible instruments is a critical audit matter are due to the impact it has on the net loss and calculation of earnings per share for common shareholders plus&#160; the nature and extent of audit effort required to obtain sufficient appropriate audit evidence to address the risks of material misstatements related to the accuracy and valuation of deemed dividend after the Series C and D Preferred Stock terms and conditions were modified. The nature and extent of audit effort required to address the matter includes involvement of more experienced engagement team members and discussions related to the matter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included reviewing the modified agreements and determining the impact such changes had on shareholders equity and the loss allocated to common shareholders.&#160; Our procedures also included reviewing the calculation for dividend accretion and recognition of a deemed dividend. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ <ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorName">BPM LLP</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have served as the Company&#8217;s auditor since October 2019</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric contextRef="From2022-10-01to2023-09-30" name="dei:AuditorLocation">Walnut Creek, California</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">December 19, 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>KNOW LABS, INC. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="BS">CONSOLIDATED BALANCE SHEETS</span></strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022 </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>ASSETS</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CURRENT ASSETS:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" contextRef="AsOf2023-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,023,716</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_435" contextRef="AsOf2022-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,593,692</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" contextRef="AsOf2023-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,023,716</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" contextRef="AsOf2022-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,593,692</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">PROPERTY AND EQUIPMENT, NET</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_438" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,325</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" contextRef="AsOf2022-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,977</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OTHER ASSETS </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other assets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" contextRef="AsOf2023-09-30" name="us-gaap:OtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,766</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_442" contextRef="AsOf2022-09-30" name="us-gaap:OtherAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,767</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease right-of-use asset</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,090</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_444" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,930</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">TOTAL ASSETS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_445" contextRef="AsOf2023-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,265,897</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_446" contextRef="AsOf2022-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,758,366</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CURRENT LIABILITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable - trade </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" contextRef="AsOf2023-09-30" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,292,861</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" contextRef="AsOf2022-09-30" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">526,968</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_451" contextRef="AsOf2023-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,062</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_452" contextRef="AsOf2022-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,940</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses - related parties</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_453" contextRef="AsOf2023-09-30" name="knwn:AmountDueToRelatedPartiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,334</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_454" contextRef="AsOf2022-09-30" name="knwn:AmountDueToRelatedPartiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,264</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible notes payable, net</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" contextRef="AsOf2023-09-30" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,761,931</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_456" contextRef="AsOf2022-09-30" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,255,066</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Current portion of operating lease right-of-use liability</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_457" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,797</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_458" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,397</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_459" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,521,985</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_460" contextRef="AsOf2022-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,808,635</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NON-CURRENT LIABILITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease right-of-use liability, net of current portion</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_462" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_463" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,118</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total non-current liabilities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_464" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_465" contextRef="AsOf2022-09-30" name="us-gaap:LiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,118</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">COMMITMENTS AND CONTINGENCIES (Note 11)</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_466" contextRef="AsOf2023-09-30" name="us-gaap:CommitmentsAndContingencies" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_467" contextRef="AsOf2022-09-30" name="us-gaap:CommitmentsAndContingencies" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">STOCKHOLDERS' EQUITY</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock - $<ix:nonFraction id="fid_486" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value, <ix:nonFraction id="fid_492" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000,000</ix:nonFraction> shares authorized, Series C and D shares issued&#160; and outstanding as follows:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Series C&#160; Convertible Preferred stock $<ix:nonFraction id="fid_487" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value, <ix:nonFraction id="fid_493" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction> shares authorized, <ix:nonFraction id="fid_506" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction> shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_469" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,790</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_481" contextRef="AsOf2022-09-30_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,790</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Series D&#160; Convertible Preferred stock $<ix:nonFraction id="fid_488" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value, <ix:nonFraction id="fid_494" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction> shares authorized, <ix:nonFraction id="fid_507" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction> shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_470" contextRef="AsOf2022-09-30_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_482" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock - $<ix:nonFraction id="fid_495" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value, <ix:nonFraction id="fid_499" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000,000</ix:nonFraction> shares authorized, <ix:nonFraction id="fid_500" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,358,463</ix:nonFraction> and <ix:nonFraction id="fid_501" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,156,062</ix:nonFraction> shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_471" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,358</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_472" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,158</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid in capital</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_473" contextRef="AsOf2023-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,501,537</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_474" contextRef="AsOf2022-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,209,388</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_475" contextRef="AsOf2023-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">121,840,788</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_476" contextRef="AsOf2022-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">101,397,738</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total stockholders' equity </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_477" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,743,912</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_478" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,862,613</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_479" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,265,897</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_480" contextRef="AsOf2022-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,758,366</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>KNOW LABS, INC. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="OP">CONSOLIDATED STATEMENTS OF OPERATIONS</span></strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Years Ended,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">REVENUE- DIGITAL ASSET SALES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_512" contextRef="From2022-10-01to2023-09-30" name="us-gaap:Revenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_513" contextRef="From2021-10-01to2022-09-30" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360,087</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OPERATING EXPENSES-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">RESEARCH AND DEVELOPMENT EXPENSES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_515" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,727,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_516" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,385,586</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_517" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,570,597</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_518" contextRef="From2021-10-01to2022-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,118,137</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_519" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SellingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,019</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_520" contextRef="From2021-10-01to2022-09-30" name="us-gaap:SellingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,430,438</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_521" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,024,045</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_522" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,934,161</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OPERATING LOSS </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_523" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">14,024,045</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_524" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,574,074</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">OTHER INCOME (EXPENSE), NET</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_525" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestIncomeOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,145</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_526" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestIncomeOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,283</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_550" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,626</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_551" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,034,081</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Loss on debt extinguishment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_527" contextRef="From2022-10-01to2023-09-30" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">506,865</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_528" contextRef="From2021-10-01to2022-09-30" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other (expense) income, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_529" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">495,776</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_530" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherIncome" format="ixt:numdotdecimal" decimals="0" unitRef="USD">521,628</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total other (expense), net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_531" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,265,122</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_532" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,497,170</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">LOSS BEFORE INCOME TAXES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_533" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,289,167</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_534" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Income tax expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_535" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_536" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET LOSS </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_537" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,289,167</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_538" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock dividends on Series D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_539" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DividendsCommonStockStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,627,230</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_540" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DividendsCommonStockStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Deemed dividends on Series C and D&#160; Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_541" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DividendsPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,653</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_542" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DividendsPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_543" contextRef="From2022-10-01to2023-09-30" name="knwn:NetIncomeLossAvailableToCommonStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,443,050</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_544" contextRef="From2021-10-01to2022-09-30" name="knwn:NetIncomeLossAvailableToCommonStockholders" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Basic and diluted loss per share </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_545" contextRef="From2022-10-01to2023-09-30" name="knwn:EarningsPerSharesBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.41</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_546" contextRef="From2021-10-01to2022-09-30" name="knwn:EarningsPerSharesBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.50</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Weighted average shares of common stock outstanding- basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_547" contextRef="From2022-10-01to2023-09-30" name="knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">49,581,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_548" contextRef="From2021-10-01to2022-09-30" name="knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,370,473</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="37" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>KNOW LABS, INC. </strong></p></td></tr><tr style="height:15px"><td colspan="37" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="EQ">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</span></strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Series C Convertible</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Series D Convertible</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Additional</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Preferred Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Preferred Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Paid in</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;">Stockholders'</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2">Equity</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance as of October 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1259" contextRef="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1262" contextRef="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,790</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1260" contextRef="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1263" contextRef="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1261" contextRef="AsOf2021-09-30_knwn_CommonStocksMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">35,166,551</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1264" contextRef="AsOf2021-09-30_knwn_CommonStocksMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,168</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1265" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,530,684</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1266" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">81,326,494</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1267" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,242,163</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock compensation expense - employee options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1268" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1269" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1270" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1271" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,421,634</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1272" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1273" contextRef="From2021-10-01to2022-09-30" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,421,634</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Conversion of debt offering and accrued interest (Note 7)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1277" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1278" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1276" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,672,860</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1279" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,673</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1280" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,338,047</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1281" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1282" contextRef="From2021-10-01to2022-09-30" name="knwn:ConversionOfDebtOfferingAndAccruedInterestAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,345,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for stock option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1286" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1287" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1285" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,293</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1288" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1289" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,661</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1290" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1291" contextRef="From2021-10-01to2022-09-30" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1295" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1296" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1294" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,045,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1297" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1298" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">837,441</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1299" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1300" contextRef="From2021-10-01to2022-09-30" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,487</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1304" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1305" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1303" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">104,634</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1306" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1307" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,895</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1308" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1309" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock warrant for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1310" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1311" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1312" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1313" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,487</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1314" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1315" contextRef="From2021-10-01to2022-09-30" name="knwn:IssuanceOfCommonStockWarrantForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,487</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Isssuance of common stock for NYSE uplisting</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1319" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1320" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1318" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,140,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1321" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,140</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1322" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,420,539</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1323" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1324" contextRef="From2021-10-01to2022-09-30" name="knwn:IsssuanceOfCommonStockForNyseUplistingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,424,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1325" contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1326" contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1327" contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1328" contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1329" contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1330" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance as of September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1331" contextRef="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1334" contextRef="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,790</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1332" contextRef="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1335" contextRef="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1333" contextRef="AsOf2022-09-30_knwn_CommonStocksMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,156,062</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1336" contextRef="AsOf2022-09-30_knwn_CommonStocksMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,158</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1337" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,209,388</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1338" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">101,397,738</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1339" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,862,613</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock compensation expense - employee options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1340" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1341" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1342" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1343" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,955,933</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1344" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1345" contextRef="From2022-10-01to2023-09-30" name="knwn:StockCompensationExpenseEmployeeOptions" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,955,933</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for stock option exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1349" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1350" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1348" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">166,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1351" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1352" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,521</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1353" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1354" contextRef="From2022-10-01to2023-09-30" name="knwn:IssuanceOfCommonStockForStockOptionExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issuance of common stock for exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1358" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1359" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1357" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,632,727</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1360" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,631</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1361" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1362" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1363" contextRef="From2022-10-01to2023-09-30" name="knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,334</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Common stock dividends on Series D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1367" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1368" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1366" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1369" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,403</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1370" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,625,827</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1371" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,627,230</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1372" contextRef="From2022-10-01to2023-09-30" name="knwn:CommonStockDividendsOnSeriesDPreferredStockAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Deemed dividends on Series C and D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1373" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1374" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1375" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1376" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,653</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1377" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">3,526,653</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1378" contextRef="From2022-10-01to2023-09-30" name="knwn:DeemedDividendsOnSeriesCAndDPreferredStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Isssuance of common stock for common stock offering</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1382" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1383" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1381" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">28,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1384" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1385" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,444,791</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1386" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1387" contextRef="From2022-10-01to2023-09-30" name="knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,472,791</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expenses for extension of notes and warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1388" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1389" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1390" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1391" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,721</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1392" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1393" contextRef="From2022-10-01to2023-09-30" name="knwn:ExpensesForExtensionOfNotesAndWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,721</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1394" contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1395" contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1396" contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1397" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1398" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,289,167</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1399" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,289,167</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance as of September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1400" contextRef="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1403" contextRef="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,790</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1401" contextRef="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1404" contextRef="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1402" contextRef="AsOf2023-09-30_knwn_CommonStocksMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,358,463</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1405" contextRef="AsOf2023-09-30_knwn_CommonStocksMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,358</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1406" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,501,537</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1407" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">121,840,788</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1408" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,743,912</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>KNOWLABS, INC. </strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="CF">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></strong></p></td></tr><tr style="height:15px"><td colspan="9"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Years Ended,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_703" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,289,167</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_704" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20,071,244</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash (used in) operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_706" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_707" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,995</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Issuance of common stock for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Issuance of common stock warrants for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_711" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,487</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on debt settlement</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_712" contextRef="From2022-10-01to2023-09-30" name="knwn:GainLossOnDebtSettlement" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">50,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_713" contextRef="From2021-10-01to2022-09-30" name="knwn:GainLossOnDebtSettlement" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">268,872</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on disposal of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_714" contextRef="From2022-10-01to2023-09-30" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,431</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_715" contextRef="From2021-10-01to2022-09-30" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss on debt extinguishment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_716" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,865</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Modification of notes and warrants - interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestExpenseForeignDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,721</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestExpenseForeignDeposits" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Stock based compensation- stock option grants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,955,933</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" contextRef="From2021-10-01to2022-09-30" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,421,634</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Gain on forgiveness of notes payable-PPP Loans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" contextRef="From2022-10-01to2023-09-30" name="knwn:GainLossOnForgivenessOfNotesPayablePppLoans" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_723" contextRef="From2021-10-01to2022-09-30" name="knwn:GainLossOnForgivenessOfNotesPayablePppLoans" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">252,700</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Amortization of operating lease right-of-use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,840</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_725" contextRef="From2021-10-01to2022-09-30" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,963</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Amortization of debt discount to interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" contextRef="From2022-10-01to2023-09-30" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_727" contextRef="From2021-10-01to2022-09-30" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,272,911</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Other long-term assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_729" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,999</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_730" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Operating lease right-of-use liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_731" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">147,719</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_732" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">22,917</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Accounts payable - trade and accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_733" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,085</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_734" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,935</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET CASH (USED IN) OPERATING ACTIVITIES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_735" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">10,353,991</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_736" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,919,808</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchase of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_738" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,797</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_739" contextRef="From2021-10-01to2022-09-30" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,468</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET CASH (USED IN) INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_740" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">80,797</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_741" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">855,468</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from isssuance of common stock for NYSE uplisting</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_743" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_744" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,280,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock offering, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_745" contextRef="From2022-10-01to2023-09-30" name="knwn:ProceedsFromIssuanceOfCommonStockOfferingNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,472,791</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_746" contextRef="From2021-10-01to2022-09-30" name="knwn:ProceedsFromIssuanceOfCommonStockOfferingNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments for stock for NYSE uplisting</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_747" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_748" contextRef="From2021-10-01to2022-09-30" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">855,321</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Settlement of notes payable-PPP loans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_749" contextRef="From2022-10-01to2023-09-30" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_750" contextRef="From2021-10-01to2022-09-30" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179,103</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock for stock options exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_777" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_778" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,687</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock for warrant exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_751" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,334</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_752" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,487</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET CASH PROVIDED BY FINANCING ACTIVITIES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_753" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,864,812</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_754" contextRef="From2021-10-01to2022-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,110,750</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_755" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,569,976</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_756" contextRef="From2021-10-01to2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,474</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, beginning of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_757" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,593,692</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_758" contextRef="AsOf2021-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,258,218</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_759" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,023,716</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_760" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,593,692</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Supplemental disclosures of cash flow information:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_762" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestPaidNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_763" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestPaidNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="MARGIN: 0px 0px 0px 15px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Taxes paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_764" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxesPaidNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_765" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncomeTaxesPaidNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Supplemental disclosure of non-cash financing activity:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Conversion of debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_767" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_768" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,209,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Conversion of accrued interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_769" contextRef="From2022-10-01to2023-09-30" name="knwn:ConversionOfAccruedInterest" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_770" contextRef="From2021-10-01to2022-09-30" name="knwn:ConversionOfAccruedInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,720</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock dividends on Series D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_771" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DividendsCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,627,230</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_772" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DividendsCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deemed dividends on Series C and D Preferred Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_773" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DividendsPreferredStockStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,653</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_774" contextRef="From2021-10-01to2022-09-30" name="us-gaap:DividendsPreferredStockStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Issuance costs from common stock offering</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_779" contextRef="From2022-10-01to2023-09-30" name="knwn:IssuanceCostsFromCommonStockOffering" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,527,209</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_780" contextRef="From2021-10-01to2022-09-30" name="knwn:IssuanceCostsFromCommonStockOffering" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="NOTES">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_794" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Know Labs, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Nevada in 1998. The Company currently has authorized <ix:nonFraction id="fid_410" contextRef="AsOf2023-09-30" name="knwn:AuthorizedSharesOfCapitalStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">205,000,000</ix:nonFraction> shares of capital stock, of which <ix:nonFraction id="fid_411" contextRef="AsOf2023-09-30" name="knwn:AuthorizedSharesOfCapitalCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000,000</ix:nonFraction> are shares of voting common stock, par value $<ix:nonFraction id="fid_413" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share, and <ix:nonFraction id="fid_416" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000,000</ix:nonFraction> are shares preferred stock, par value $<ix:nonFraction id="fid_418" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share.&#160;At the annual shareholder meeting held on October 15, 2021, the Company&#8217;s authorized shares of common stock was increased to <ix:nonFraction id="fid_420" contextRef="AsOf2021-10-15" name="knwn:AuthorizedCommonStockIncreased" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000,000</ix:nonFraction> shares of voting common stock, par value $<ix:nonFraction id="fid_414" contextRef="AsOf2021-10-15" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique &#8220;signature&#8221; of said materials or analytes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device will provide the user with real-time information on their blood glucose levels.&#160; We recently announced our Generation 1 working prototype device.&#160; This device embodies the sensor which has been used in internal clinical testing.&#160; We have also announced the work our R&amp;D team is doing on the Generation 2 of our device, which is a wearable format and could be a final form factor, ready for commercial application. We are expanding our testing, both internally and externally, and will refine the device over time, which will require FDA clearance before entering the market.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_781" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. LIQUIDITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has cash and cash equivalents of $<ix:nonFraction id="fid_1" contextRef="AsOf2023-09-30" name="knwn:CashAndCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,023,716</ix:nonFraction> and net working capital of $<ix:nonFraction id="fid_3" contextRef="AsOf2023-09-30" name="knwn:NetWorkingCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,262,662</ix:nonFraction> (exclusive of convertible notes payable) as of September 30, 2023. The Company anticipates that it will record losses from operations for the foreseeable future. During the end of the year ended September 30, 2023, the Company made some adjustments to its staffing level and the impact of those adjustments, plus the departure of our chief technology and executive office, has significantly reduced our monthly burn rate. The Company will further adjust its cost structure if new debt or equity capital is not received. The Company&#8217;s ability to transition profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least June 30, 2024. Based on current operating levels, the Company will need to raise additional funds by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through issuance of equity securities, and proceeds from the exercise of warrants to purchase common stock and the sale of debt instruments. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company&#8217;s products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company&#8217;s products. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the twelve months from the date of this Report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Management of the Company intends to raise additional funds through the issuance of equity securities or debt. The Company is currently working on some capital fund raising transactions and while they expect to have something finalized by March 31, 2024, as of this date, there is no commitment. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company&#8217;s ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The proceeds of warrants currently outstanding, which could be exercised on a cash basis, may generate potential proceeds. &#160;The Company expects that portions of these warrants will be exercised but there is no guarantee any portion will be exercised. </p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_782" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_646dd2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_795" contextRef="From2022-10-01to2023-09-30" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation</em></strong> &#8211;These unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_796" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Principles of Consolidation</em></strong> &#8211; The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Particle and AI Mind. Intercompany items and transactions have been eliminated in consolidation. &#160;AI Mind was dissolved in July 2023.&#160; </p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_797" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cash and Cash Equivalents</em></strong> &#8211;&#160;The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $<ix:nonFraction id="fid_7" contextRef="AsOf2023-09-30" name="us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction>. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_798" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Property and Equipment</em></strong> &#8211; Equipment consists of machinery, leasehold improvements and furniture and fixtures, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally <ix:nonNumeric id="fid_34" contextRef="From2022-10-01to2023-09-30_srt_MinimumMember" name="knwn:PropertyPlantsAndEquipmentUsefulLife" format="ixt-sec:duryear">2</ix:nonNumeric>-<ix:nonNumeric id="fid_35" contextRef="From2022-10-01to2023-09-30_srt_MaximumMember" name="knwn:PropertyPlantsAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years, except for leasehold improvements which are depreciated over <ix:nonNumeric id="fid_36" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseholdImprovementsMember" name="knwn:PropertyPlantsAndEquipmentUsefulLife" format="ixt-sec:duryear">5</ix:nonNumeric> years. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_799" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Long-Lived Assets</em></strong> &#8211; The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_800" contextRef="From2022-10-01to2023-09-30" name="us-gaap:RevenueRecognitionLeases" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong><strong> </strong>&#8211; The Company determines revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the contract, or contracts, with the customer;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the performance obligations in the contract;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">determination of the transaction price;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">allocation of the transaction price to the performance obligations in the contract; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recognition of the revenue when, or as, the Company satisfies a performance obligation.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_801" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses</em></strong> &#8211; Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s current research and development efforts are primarily focused on improving its radio frequency spectroscopy technology and its first focus on non-invasive monitoring of blood glucose levels; extending its capacity and developing new and unique applications for this technology. The Company believes that continued development of new and enhanced technologies is essential to its future success. The Company incurred expenses of $<ix:nonFraction id="fid_12" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,727,467</ix:nonFraction> and $<ix:nonFraction id="fid_13" contextRef="From2021-10-01to2022-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,385,586</ix:nonFraction> for the years ended September 30, 2023 and 2022, respectively, on development activities.&#160; Included in the expense for 2023 is approximately $<ix:nonFraction id="fid_8" contextRef="From2022-10-01to2023-09-30" name="knwn:SeveranceAndOtherExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,000</ix:nonFraction> related to severance and other expenses associated with the departure of the Company&#8217;s former chief technology officer and chief executive officer, Philip A. Bosua, and other employees.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_802" contextRef="From2022-10-01to2023-09-30" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Advertising</em></strong><strong> </strong>&#8211; Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising and marketing costs for the year ended September 30, 2023 and 2022 were $<ix:nonFraction id="fid_14" contextRef="From2022-10-01to2023-09-30" name="us-gaap:AdvertisingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">305,292</ix:nonFraction> and $<ix:nonFraction id="fid_15" contextRef="From2021-10-01to2022-09-30" name="us-gaap:AdvertisingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,724</ix:nonFraction>, respectively. </p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_646dd2" continuedAt="cont_67fb54"><ix:nonNumeric id="fid_803" contextRef="From2022-10-01to2023-09-30" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements and Financial Instruments</em></strong> &#8211;<strong>&#160;</strong>ASC Topic 820, <em>Fair Value Measurement and Disclosures</em>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 2 &#8211; Inputs other than level one inputs that are either directly or indirectly observable; and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 3 &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities. The fair value of the Company&#8217;s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has a money market account which is considered a Level 1 asset. The balance as of September 30, 2023 and 2022 was $<ix:nonFraction id="fid_16" contextRef="AsOf2023-09-30" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,836,393</ix:nonFraction> and $<ix:nonFraction id="fid_17" contextRef="AsOf2022-09-30" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,821,931</ix:nonFraction>, respectively. No other assets or liabilities are required to&#160; be recorded at fair value on a recurring nature. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_804" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DerivativesMethodsOfAccountingHedgeEffectiveness" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em></strong><strong> &#8211; </strong>Pursuant to ASC 815 &#8220;Derivatives and Hedging&#8221;, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company determined that the conversion features for purposes of bifurcation within its &#160;convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and &#160;there was no derivative liability. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_805" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Based Compensation</em></strong> &#8211; The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. The Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_806" contextRef="From2022-10-01to2023-09-30" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Securities</em></strong><strong> </strong>&#8211; Based upon ASC 815-15, the Company has adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. The Company will evaluate its contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company&#8217;s inability to demonstrate it has sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_807" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="cont_2b899d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Net Loss per Share</em></strong> &#8211; Under the provisions of ASC 260, &#8220;Earnings Per Share,&#8221; basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Deemed dividends to preferred shareholders increase the net loss available to common&#160; shareholders and impact the net loss per share calculation. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_67fb54"><ix:continuation id="cont_2b899d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, the Company had <ix:nonFraction id="fid_18" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,358,463</ix:nonFraction> shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of <ix:nonFraction id="fid_25" contextRef="AsOf2023-09-30" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,506,158</ix:nonFraction> shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of <ix:nonFraction id="fid_26" contextRef="From2022-10-01to2023-09-30_knwn_Warrant1Member" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,866,313</ix:nonFraction> shares of our common stock, <ix:nonFraction id="fid_20" contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,108,356</ix:nonFraction> shares of the Company&#8217;s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately <ix:nonFraction id="fid_24" contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember" name="knwn:ReservedSharesToPaySeriesCAndDDividends" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,040,219</ix:nonFraction> shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has <ix:nonFraction id="fid_22" contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,020,264</ix:nonFraction> shares of its common stock at the current price of $<ix:nonFraction id="fid_32" contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share reserved and are issuable upon conversion of convertible debentures of $<ix:nonFraction id="fid_9" contextRef="From2022-10-01to2023-09-30" name="knwn:ConvertibleDebentures" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,761,931</ix:nonFraction>.&#160; Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately <ix:nonFraction id="fid_30" contextRef="From2022-10-01to2023-09-30_knwn_StockOption1Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">160,000</ix:nonFraction> shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, the Company had <ix:nonFraction id="fid_19" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">48,156,062</ix:nonFraction> shares of common stock issued and outstanding. As of September 30, 2022, there were options outstanding for the purchase of <ix:nonFraction id="fid_421" contextRef="AsOf2022-09-30" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,792,370</ix:nonFraction> common shares (including unearned stock option grants totaling 9,704,620 shares related to performance targets), warrants for the purchase of <ix:nonFraction id="fid_27" contextRef="From2021-10-01to2022-09-30_knwn_Warrant1Member" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,786,313</ix:nonFraction> common shares, and <ix:nonFraction id="fid_28" contextRef="From2021-10-01to2022-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">8,108,356</ix:nonFraction>&#160;shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has <ix:nonFraction id="fid_23" contextRef="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,020,264</ix:nonFraction> common shares at the current price of $<ix:nonFraction id="fid_33" contextRef="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share reserved and are issuable upon conversion of convertible debentures of $<ix:nonFraction id="fid_422" contextRef="From2021-10-01to2022-09-30" name="knwn:ConvertibleDebentures" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,255,066</ix:nonFraction>. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2022, calculation of net loss per share because their impact is antidilutive.&#160; </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_808" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Comprehensive loss</em></strong> &#8211; Comprehensive loss is defined as the change in equity of a business during a period from non-owner sources. There were no differences between net loss for the years ended September 30, 2023 and 2022 and comprehensive loss for those periods.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_809" contextRef="From2022-10-01to2023-09-30" name="knwn:DividendPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Dividend Policy</em></strong> &#8211; The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of its business. The Company&#8217;s future dividend policy will be determined by the board of directors on the basis of various factors, including results of operations, financial condition, capital requirements and investment opportunities.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_810" contextRef="From2022-10-01to2023-09-30" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong> &#8211; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_811" contextRef="From2022-10-01to2023-09-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on the Company&#8217;s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does believe such items are expected to have a significant impact on the Company&#8217;s consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_783" contextRef="From2022-10-01to2023-09-30" name="knwn:AiDeepLearningPlatformDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. AI DEEP LEARNING PLATFORM</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">On September 17, 2021, the Company incorporated AI Mind, Inc. (&#8220;AI Mind&#8221;) in the State of Nevada. AI Mind was focused on monetizing intellectual property relating to the artificial intelligence utilized as a part of the data analytics performed with trade secret algorithms. Since incorporation, it focused on creating graphical images which were sold as Non Fungible Tokens (&#8220;NFTs&#8221;). During the year ended September 30, 2022,&#160;the&#160;Company began generating revenue from digital asset sales of NFTs and had sales of $<ix:nonFraction id="fid_37" contextRef="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember" name="knwn:Revenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360,087</ix:nonFraction> of which substantially all were recorded in the three months ended December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">After the sale of the NFT, the Ethereum was converted to US dollars as soon as practically possible. The Company recorded the total value of the gross NFT sale in revenue. Costs incurred in connection with the NFT transaction were recorded in the statement of operations as selling and transactional cost of digital assets and include costs to outside consultants, estimated employee and former CEO special bonus compensation, digital asset conversion losses and estimated sales and use tax. The amount totaled $<ix:nonFraction id="fid_38" contextRef="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember" name="knwn:AmountTotal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,430,438</ix:nonFraction> for the year ended September 30, 2022. As of September &#160;30, 2023 and September 30, 2022, accrued expenses include $<ix:nonFraction id="fid_41" contextRef="AsOf2023-09-30_us-gaap_TechnologyEquipmentMember" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> and $<ix:nonFraction id="fid_42" contextRef="AsOf2022-09-30_us-gaap_TechnologyEquipmentMember" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,878</ix:nonFraction> of expenses, respectively, primarily sales and use tax and other expenses. During the current year, based on new information, we revised our estimate downward for sales and use tax liability resulting in a $<ix:nonFraction id="fid_423" contextRef="From2022-10-01to2023-09-30_us-gaap_TechnologyEquipmentMember" name="us-gaap:SellingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,019</ix:nonFraction> benefit that is recorded in Selling and Transactional Costs for Digital Assets in the consolidated statements of operations.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_784" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. PROPERTY AND EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment as of September 30, 2023 and 2022 was comprised of the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total depreciation expense was $<ix:nonFraction id="fid_54" contextRef="From2022-10-01to2023-09-30" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,019</ix:nonFraction> and $<ix:nonFraction id="fid_55" contextRef="From2021-10-01to2022-09-30" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,995</ix:nonFraction> for the years ended September 30, 2023 and 2022, respectively. All equipment is used primarily for research and development purposes and accordingly $<ix:nonFraction id="fid_56" contextRef="From2022-10-01to2023-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,260</ix:nonFraction> and $<ix:nonFraction id="fid_57" contextRef="From2021-10-01to2022-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" name="us-gaap:Depreciation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,637</ix:nonFraction> in depreciation is classified in research and development expenses during the years ending September 30, 2023 and 2022. The Company retired assets with a net book value of $<ix:nonFraction id="fid_53" contextRef="AsOf2023-09-30" name="knwn:AssetsNetBookValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">549,431</ix:nonFraction> during the year ended September 30, 2023 related to the consolidation of leased offices and the reduction on headcount. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="knwn_10kimg32.jpg" alt="knwn_10kimg32.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_785" contextRef="From2022-10-01to2023-09-30" name="knwn:LeasesOfLesseDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. LEASES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has entered into operating leases for office and development facilities which range from two to three years and include options to renew. The Company determines whether an arrangement is or contains a lease based upon the unique facts and circumstances at the inception of the lease. Operating lease liabilities and their corresponding right-of-use asses are recorded based upon the present value of the lease payments over the expected lease term. As of September 30, 2023 and 2022, total operating lease liabilities for remaining long term leases was approximately $<ix:nonFraction id="fid_428" contextRef="AsOf2023-09-30" name="knwn:TotalLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,000</ix:nonFraction> and $<ix:nonFraction id="fid_429" contextRef="AsOf2022-09-30" name="knwn:TotalLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,000</ix:nonFraction>, respectively. Right of use assets totaled approximately $<ix:nonFraction id="fid_426" contextRef="AsOf2023-09-30" name="knwn:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,000</ix:nonFraction> and $<ix:nonFraction id="fid_427" contextRef="AsOf2022-09-30" name="knwn:RightOfUseAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,000</ix:nonFraction> at September 30, 2023 and 2022, respectively. In the year ended September 30, 2023 and 2022, the Company recognized $<ix:nonFraction id="fid_424" contextRef="From2022-10-01to2023-09-30" name="us-gaap:LeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,000</ix:nonFraction> and $<ix:nonFraction id="fid_425" contextRef="From2021-10-01to2022-09-30" name="us-gaap:LeaseCost" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,000</ix:nonFraction>, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its estimated incremental borrowing rate to determine the present value of the lease payments.&#160; Recently the Company, as a result of certain headcount adjustments, has listed two of its leased premises as available for sublease.&#160; There can be no assurance such sublease will be successful or lead to a reduction in current on-going lease payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The weighted average remaining lease term for the operating leases was 9 months at September 30, 2023 and the weighted average discount rate was <ix:nonFraction id="fid_431" contextRef="AsOf2022-09-30" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">7</ix:nonFraction>%. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The minimum future lease payments as of September 30, 2023 are as follows: </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="knwn_10kimg33.jpg" alt="knwn_10kimg33.jpg" /></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_786" contextRef="From2022-10-01to2023-09-30" name="knwn:ConvertibleNotesPayableDisclosureTextBlock" escape="true" continuedAt="cont_b400cb"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Convertible notes payable as of September 30, 2023 and 2022 consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Promissory Notes with Clayton A. Struve</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company owes Clayton A. Struve, a significant stockholder, $<ix:nonFraction id="fid_1036" contextRef="AsOf2023-09-30_knwn_ConvertibleNote1Member" name="us-gaap:ConvertibleDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,301,005</ix:nonFraction> under convertible promissory or OID notes. The Company recorded accrued interest of $<ix:nonFraction id="fid_1033" contextRef="AsOf2023-09-30" name="us-gaap:DepositLiabilitiesAccruedInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,062</ix:nonFraction> and $<ix:nonFraction id="fid_1034" contextRef="AsOf2022-09-30" name="us-gaap:DepositLiabilitiesAccruedInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,562</ix:nonFraction> as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2023.&#160; On September 15, 2023, the due dates on the notes was further extended to September 30, 2024.&#160;The Company expensed $<ix:nonFraction id="fid_1028" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,005</ix:nonFraction> as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_b400cb"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Redeemable Promissory Notes with J3E2A2Z</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company owes Ronald P. Erickson and J3E2A2Z, an entity affiliated controlled by Ronald P. Erickson $<ix:nonFraction id="fid_1042" contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,460,926</ix:nonFraction> under convertible promissory notes On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $<ix:nonFraction id="fid_1037" contextRef="AsOf2018-03-16_knwn_ConvertibleNote8Member" name="knwn:ConvertibleRedeemablePromissoryNoteAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">664,233</ix:nonFraction> currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $<ix:nonFraction id="fid_1039" contextRef="AsOf2018-03-16_knwn_ConvertibleNote8Member" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">664,233</ix:nonFraction>, and (b) all $<ix:nonFraction id="fid_1038" contextRef="AsOf2018-03-16_knwn_ConvertibleNote7Member" name="knwn:ConvertibleRedeemablePromissoryNoteAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,833</ix:nonFraction> of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $<ix:nonFraction id="fid_1040" contextRef="AsOf2018-03-16_knwn_ConvertibleNote7Member" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">519,833</ix:nonFraction> together with a warrant to purchase up to <ix:nonFraction id="fid_1029" contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,039,666</ix:nonFraction> shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $<ix:nonFraction id="fid_1035" contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction> per share, also subject to certain adjustments. The Company recorded accrued interest of $<ix:nonFraction id="fid_1030" contextRef="AsOf2023-09-30_knwn_ConvertibleNote1Member" name="knwn:DepositLiabilitiesAccruedInterestsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,334</ix:nonFraction> and $<ix:nonFraction id="fid_1031" contextRef="AsOf2022-09-30_knwn_ConvertibleNote1Member" name="knwn:DepositLiabilitiesAccruedInterestsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,290</ix:nonFraction> as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to January 30, 2023. On January 25, 2023, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2023. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. The Company expensed $<ix:nonFraction id="fid_1041" contextRef="From2022-10-01to2023-09-30_knwn_ConvertibleNote1Member" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">276,860</ix:nonFraction> as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Debt Offering </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning in 2019, the Company entered into a series of debt offerings with similar and consistent terms. The Company issued Subordinated Convertible Notes and Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. As of September 30, 2022, all convertible notes and accrued interest had been converted to common stock. During the year ended September 30, 2022, amortization related to the debt offerings of $<ix:nonFraction id="fid_1032" contextRef="From2021-10-01to2022-09-30" name="knwn:AmortizationOfDebtDiscountPremiums" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,272,911</ix:nonFraction> was recognized as interest expense in the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Convertible notes payable as of September 30, 2023 and 2022 are summarized below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_814" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Clayton A. Struve</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1022" contextRef="AsOf2023-09-30_knwn_ConvertibleNoteOneMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,301,005</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1023" contextRef="AsOf2022-09-30_knwn_ConvertibleNoteOneMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,071,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Ronald P. Erickson and affiliates</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" contextRef="AsOf2023-09-30_knwn_ConvertibleNoteTwoMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,460,926</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" contextRef="AsOf2022-09-30_knwn_ConvertibleNoteTwoMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,184,066</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021 Convertible notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" contextRef="AsOf2023-09-30_knwn_ConvertibleNotesFiveMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" contextRef="AsOf2022-09-30_knwn_ConvertibleNotesFiveMember" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,209,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less conversions of notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1018" contextRef="AsOf2023-09-30" name="knwn:ConvertibleNotesConversions" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1019" contextRef="AsOf2022-09-30" name="knwn:ConvertibleNotesConversions" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">14,209,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1020" contextRef="AsOf2023-09-30" name="us-gaap:DebtInstrumentFairValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,761,931</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1021" contextRef="AsOf2022-09-30" name="us-gaap:DebtInstrumentFairValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,255,066</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_787" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_a944c8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Authorized Capital Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description summarizes important terms of the classes of our capital stock as of September 30, 2023. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation as amended, restated and supplemented to date, or our articles of incorporation, and our second amended and restated bylaws, or our bylaws, which have been filed as exhibits to this Annual Report on Form 10-K.&#160;</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_a944c8" continuedAt="cont_af32cf"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Authorized Capital Stock</em>.&#160; The Company&#8217;s authorized capital stock currently consists of:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_975" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="fid_963" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_973" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000,000</ix:nonFraction> shares of &#8220;blank check&#8221; preferred stock, par value $<ix:nonFraction id="fid_965" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> per share, of which:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_984" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" name="knwn:DesignatedSeriesCConvertiblePreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction> shares have been designated as our Series C Convertible Preferred Stock, $<ix:nonFraction id="fid_960" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_985" contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember" name="knwn:DesignatedSeriesDConvertiblePreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction> shares have been designated as our Series D Convertible Preferred Stock, $<ix:nonFraction id="fid_961" contextRef="AsOf2022-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction> par value per share.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Outstanding Shares of Capital Stock</em>. The Company&#8217;s common stock is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. All outstanding shares of the Company&#8217;s capital stock are fully paid and nonassessable. As of September 30, 2023, there were:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_1153" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">80,358,643</ix:nonFraction> shares of common stock issued and outstanding, held by holders of record;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_986" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction> shares of Series C Convertible Preferred Stock issued and outstanding, held by one holder of record; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_988" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction> shares of Series D Convertible Preferred Stock issued and outstanding, held by one holder of record.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. The Company&#8217;s articles of incorporation do not provide for cumulative voting in the election of directors.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors on the common stock out of legally available funds. In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company&#8217;s debts and other liabilities and the satisfaction of any preferential rights of any outstanding preferred stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock, including our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Preferred Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s articles of incorporation authorize its board of directors, without stockholder approval, to issue up to <ix:nonFraction id="fid_992" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000,000</ix:nonFraction> shares of preferred stock in one or more series, and to determine the designation, preferences, limitations and relative rights thereof, including, without limitation, such matters as dividends, redemption, liquidation, conversion and voting. The Company&#8217;s board of directors has the discretion to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock, or which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of the Company&#8217;s outstanding voting stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the amendment and restatement of our preferred stock, we effected a reverse split of our outstanding Series C Convertible Preferred Stock and Series D Convertible Preferred Stock by a factor of <ix:nonNumeric id="fid_991" contextRef="From2022-10-01to2023-09-30_knwn_ConvertiblePreferredStockDMember" name="knwn:ReverseStockSplit">1-for-100</ix:nonNumeric>. No changes were made to the 5 million total shares of &#8220;blank-check&#8221; preferred stock authorized in our Articles. Prior to such reverse split, there were <ix:nonFraction id="fid_969" contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,785,715</ix:nonFraction> and <ix:nonFraction id="fid_971" contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,016,004</ix:nonFraction> shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock designated and outstanding, respectively. To account for the reverse split, but in order to provide the ability to issue &#8220;pay in kind&#8221; dividends in lieu of cash dividends, at the time of the reverse split, we designated <ix:nonFraction id="fid_1254" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember" name="knwn:DesignatedSeriesDConvertiblePreferredStocks" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction> shares of Series C Convertible Preferred Stock&#160;and <ix:nonFraction id="fid_1252" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember" name="knwn:DesignatedSeriesDConvertiblePreferredStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction> shares of Series D Convertible Preferred Stock, of which <ix:nonFraction id="fid_987" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,858</ix:nonFraction> and <ix:nonFraction id="fid_989" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,161</ix:nonFraction> shares were, respectively, outstanding immediately after such reverse split. In order to maintain the economic rights of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, the definition of &#8220;Stated Value&#8221; was multiplied by 100, to offset the reverse split factor. All amount related to the preferred shares have been restated to reflect the reverse stock split as it occurred on the date of the first period presented. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Securities Subject to Price Adjustments&#160;</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If in the future, the Company sells its common stock at a price below $<ix:nonFraction id="fid_953" contextRef="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="knwn:PreferredStockConvertibleConversionPriceAdjusted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share, the conversion price of the Company&#8217;s outstanding shares of series C convertible preferred stock and series D convertible preferred stock would adjust below $<ix:nonFraction id="fid_954" contextRef="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="knwn:PreferredStockConvertibleConversionPriceAdjusted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share pursuant to the documents governing such instruments. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase <ix:nonFraction id="fid_955" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">7,684,381</ix:nonFraction> shares of common stock would adjust below $<ix:nonFraction id="fid_980" contextRef="AsOf2023-09-30_knwn_StockAtTwoMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share pursuant to the documents governing such instruments. Warrants totaling <ix:nonFraction id="fid_982" contextRef="AsOf2023-09-30_knwn_StockAtTwoMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,439,707</ix:nonFraction> would adjust below $<ix:nonFraction id="fid_981" contextRef="AsOf2023-09-30_knwn_StockAtOneMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.20</ix:nonFraction> per share and warrants totaling <ix:nonFraction id="fid_983" contextRef="AsOf2023-09-30_knwn_StockAtOneMember" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,424,425</ix:nonFraction> would adjust below $<ix:nonFraction id="fid_956" contextRef="From2022-10-01to2023-09-30_knwn_ThreeDirectorMember" name="knwn:ShrareIssuedWarrantToPurchasedPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.40</ix:nonFraction> per share, in each case pursuant to the documents governing such instruments.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_af32cf" continuedAt="cont_6dc0f1"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series C and D Preferred Stock, Warrants and Dividends</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $<ix:nonFraction id="fid_948" contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,250,000</ix:nonFraction> of preferred stock with a conversion price of $<ix:nonFraction id="fid_950" contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockConvertibleConversionPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.70</ix:nonFraction> per share. The preferred stock has a cumulative dividend&#160; of <ix:nonFraction id="fid_920" contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockDividendRatePercentage" decimals="INF" unitRef="Pure" scale="-2">8</ix:nonFraction>% and an ownership blocker of <ix:nonFraction id="fid_915" contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="knwn:OwnershipInterestInPreferredStock" decimals="INF" unitRef="Pure" scale="-2">4.99</ix:nonFraction>%. Dividends are due and payable in cash when declared by the Company&#160; or when the stock&#160; is converted.&#160; Series&#160; C Preferred stock is senior to Series D Preferred stock and is entitled to receive&#160; equal&#160; dividends paid to Series D. In addition, Mr. Struve received a five-year warrant to acquire <ix:nonFraction id="fid_951" contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="knwn:WarrantsToAcquireCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,785,714</ix:nonFraction> shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock and warrant and its conversion price, were adjusted to $<ix:nonFraction id="fid_979" contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share pursuant to the documents governing such instruments. As of September 30, 2023, Mr. Struve owns all of the <ix:nonFraction id="fid_1253" contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,785,715</ix:nonFraction> issued and outstanding shares of Series C Preferred Stock.&#160; Each holder of Preferred Series C is allowed to vote as a common shareholder as if the shares were converted&#160; to common stock up to the ownership blocker of <ix:nonFraction id="fid_916" contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="knwn:OwnershipInterestInPreferredStock" decimals="INF" unitRef="Pure" scale="-2">4.99</ix:nonFraction>%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2017 the Company closed a $<ix:nonFraction id="fid_949" contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction> Series D Preferred Stock and Warrant offering with Mr. Struve. As of September 30, 2023, Mr. Struve owns all of the <ix:nonFraction id="fid_970" contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,016,004</ix:nonFraction> issued and outstanding shares of Series D Preferred Stock. Each outstanding share of series D preferred stock will accrue cumulative cash dividends at a rate equal to <ix:nonFraction id="fid_921" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:PreferredStockDividendRatePercentage" decimals="INF" unitRef="Pure" scale="-2">8</ix:nonFraction>.0% per annum, subject to adjustment as provided in the series D preferred stock certificate of designations. Dividends are&#160; due and payable&#160; in cash when declared by the Company&#160; or when the stock&#160; is converted. In addition, On August 14, 2017, the price of the Series D Preferred Stock were adjusted to $<ix:nonFraction id="fid_952" contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember" name="knwn:CommonStockSharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share pursuant to the documents governing such instruments. Each holder of Preferred Series D is allowed to vote as a common shareholder as if the shares were converted to common stock up to the ownership blocker of <ix:nonFraction id="fid_917" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="knwn:OwnershipInterestInPreferredStock" decimals="INF" unitRef="Pure" scale="-2">4.99</ix:nonFraction>%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August, 2023, as part of a modification of the Series C and Series D Preferred certificates of designation,&#160; such preferred stock does not accrue or pay cash dividends. All future dividends will be accrued and paid in Series C or Series D stock, as applicable. As was the case prior to the modifications of the Series C and Series D preferred stock, although accrual of dividends is required as described below, no dividends are actually paid, and no shares actually issued, until a conversion of such stock or declaration of the dividend by the Board of Directors.&#160; Additionally the Series D Preferred stock will no longer be required to automatically convert to common stock based on listing of the Company&#8217;s common stock on the NYSE American, except if the volume weighted average price of the common stock is at least $<ix:nonFraction id="fid_923" contextRef="From2023-08-01to2023-08-31_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction> per share for 20 trading days and certain other requirements are satisfied.&#160; <ix:nonNumeric id="fid_927" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:DividendDistributedPerShare">The cumulative dividends accrued and paid in preferred stock will be determined based upon a $.70 stated value. The conversion from preferred stock into common stock is determined based dividing the $.70 stated value by the $.25 conversion price</ix:nonNumeric>. In June, 2023, as part of the anticipated modification of the certificates of designation of the Series C and Series D preferred stock, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of <ix:nonFraction id="fid_928" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:CommonStockDividendsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction> shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.&#160; In connection with this transaction, the Company recorded $<ix:nonFraction id="fid_932" contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,627,230</ix:nonFraction> in dividends, representing the fair market value of the <ix:nonFraction id="fid_926" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:NumberOfCommonStockSharesSettled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction> shares issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based upon the modified terms and conditions of Series C and D certificates of designations, it was determined that Series C and D preferred dividends need to be accreted going forward. As of September 30, 2023, cumulative unpaid Series C and D dividends totaled approximately $<ix:nonFraction id="fid_934" contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:CumulativeDividendUnpaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">770,000</ix:nonFraction>, which on a converted-to-common-stock basis represents approximately <ix:nonFraction id="fid_929" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="us-gaap:CommonStockDividendsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,040,000</ix:nonFraction> shares of common&#160; stock. The value of the <ix:nonFraction id="fid_924" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="-6" unitRef="Shares" scale="6">3</ix:nonFraction>.0 million shares of common totaled $<ix:nonFraction id="fid_933" contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,653</ix:nonFraction>. The Company recorded $<ix:nonFraction id="fid_935" contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:DeemedDividendsCumulative" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526,653</ix:nonFraction>in cumulative deemed dividends related to Series C and D Preferred Stock which have not been paid, net of the approximately $<ix:nonFraction id="fid_919" contextRef="AsOf2023-08-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember" name="us-gaap:CumulativeDividends" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,000</ix:nonFraction> of accumulated dividends with respect to the Series D preferred that were settled for <ix:nonFraction id="fid_925" contextRef="From2022-12-01to2022-12-31_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:NumberOfCommonStockSharesSettled" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction> shares of common stock as noted above.&#160; Mr. Struve is subject to an ownership blocker limiting his ownership to <ix:nonFraction id="fid_918" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:OwnershipInterestInPreferredStock" decimals="INF" unitRef="Pure" scale="-2">4.99</ix:nonFraction>% and thus the amount of common shares he can receive for dividends.&#160; Unpaid accreted stock dividends will be issued to Mr. Struve if he converts preferred stock or if the Board declares a dividend thereon, limited to his <ix:nonFraction id="fid_922" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="us-gaap:PreferredStockDividendRatePercentage" decimals="INF" unitRef="Pure" scale="-2">4.99</ix:nonFraction>% ownership blocker.&#160; Assuming no changes in the amount of outstanding Preferred Series&#160; C or D ownership, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately <ix:nonFraction id="fid_936" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember" name="knwn:AccretedValueOfPreferredDividendIntoCommonStockShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">160,000</ix:nonFraction> shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. </p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_6dc0f1" continuedAt="cont_ad7725"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_1215" contextRef="AsOf2023-09-30_knwn_MrStruveMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,632,727</ix:nonFraction> shares of common stock related to warrant exercises and received $<ix:nonFraction id="fid_1216" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember" name="knwn:ReceivedOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,334</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 27, 2023, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of <ix:nonFraction id="fid_942" contextRef="AsOf2023-06-27_knwn_MrStruveMember" name="knwn:ReceivedSeriesDPreferredStockDividendsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction> shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_958" contextRef="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember" name="knwn:ProceedsFromIssuanceOfCommonStocks" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,750</ix:nonFraction> shares related to the exercise of stock option grants and received $<ix:nonFraction id="fid_978" contextRef="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember" name="knwn:ExerciseOfStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,687</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, the Company closed an offering of our common stock pursuant to which the Company sold <ix:nonFraction id="fid_993" contextRef="AsOf2023-09-29_knwn_CommonStocksOfferingsMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">28,000,000</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction id="fid_994" contextRef="AsOf2023-09-29_knwn_CommonStocksOfferingsMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $<ix:nonFraction id="fid_995" contextRef="From2023-09-01to2023-09-29_knwn_CommonStocksOfferingsMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,472,791</ix:nonFraction>. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric id="fid_996" contextRef="From2021-10-01to2022-09-30" name="knwn:DescriptionOfAutomaticConversionOfConvertible">The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_998" contextRef="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,045,724</ix:nonFraction> shares of common stock related to warrant exercises and received $<ix:nonFraction id="fid_997" contextRef="From2022-09-01to2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" name="knwn:IssuedAmountReceived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,487</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_1000" contextRef="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember" name="knwn:ExerciseOfStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,293</ix:nonFraction> shares related to the exercise of stock option grants and received $<ix:nonFraction id="fid_1001" contextRef="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember" name="knwn:ProceedsFromIssuanceOfCommonStocks" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,887</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_1002" contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">104,634</ix:nonFraction> shares each to three directors and three consultants at $<ix:nonFraction id="fid_1003" contextRef="From2021-10-01to2022-09-30" name="knwn:ShrareIssuedWarrantToPurchasedPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.749</ix:nonFraction> per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 20, 2022, the Company completed a public offering of our common stock pursuant to which the Company sold <ix:nonFraction id="fid_1004" contextRef="AsOf2022-09-20_knwn_CommonStocksOfferingsMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,140,000</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction id="fid_1005" contextRef="AsOf2022-09-20_knwn_CommonStocksOfferingsMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction> per share, for total gross proceeds of $<ix:nonFraction id="fid_1214" contextRef="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember" name="knwn:GrossSales" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,280,000</ix:nonFraction>. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $<ix:nonFraction id="fid_1006" contextRef="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,424,679</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Warrants to Purchase Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, the Company signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_815" contextRef="From2022-10-01to2023-09-30" name="knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" escape="true" continuedAt="cont_ad5eca"><table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Current </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_830" contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">08-14-2017</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_826" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,440,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$<ix:nonFraction id="fid_842" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_834" contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">08-13-2024</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_838" contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">08-13-2025</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_831" contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">12-12-2017</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_827" contextRef="AsOf2023-09-30_knwn_WarrantTwoMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,200,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$<ix:nonFraction id="fid_843" contextRef="AsOf2023-09-30_knwn_WarrantTwoMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_835" contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">12-11-2024</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_839" contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">12-11-2025</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_832" contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">08-04-2016</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_828" contextRef="AsOf2023-09-30_knwn_WarrantThreeMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,785,715</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$<ix:nonFraction id="fid_844" contextRef="AsOf2023-09-30_knwn_WarrantThreeMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_836" contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">08-04-2024</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_840" contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">08-04-2025</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_833" contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">02-28-2018</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_829" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,344,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$<ix:nonFraction id="fid_845" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_837" contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">02-28-2024</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_841" contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">02-28-2025</ix:nonNumeric></p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded interest expense of $<ix:nonFraction id="fid_959" contextRef="From2022-10-01to2023-09-30" name="us-gaap:InterestExpenseOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,019</ix:nonFraction> during the year ended September 30, 2023 related to the extension of the warrants. The Company recorded the original value of warrants in equity and as such, the Company recorded the extension value as an expense with an offset to additional paid in capital.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_ad7725" continuedAt="cont_d5c119"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 19, 2023, the Company signed an Extension of Warrant Agreements with Ronald P. Erickson and an entity controlled by Mr. Erickson, extending the exercise dates from January 30, 2023 to January 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_941" contextRef="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,632,727</ix:nonFraction> shares of common stock related to warrant exercises and received $<ix:nonFraction id="fid_938" contextRef="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:ReceivedOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,334</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase <ix:nonFraction id="fid_943" contextRef="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantsToPurchaseCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,273</ix:nonFraction> shares of common stock at $<ix:nonFraction id="fid_957" contextRef="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantsExpiredPerSharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction> per share expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, pursuant to the Underwriting Agreement, the Company issued common stock purchase warrants to Boustead Securities, LLC and The Benchmark Company, LLC&#160;to purchase an aggregate of <ix:nonFraction id="fid_1007" contextRef="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,960,000</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction id="fid_1009" contextRef="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share, subject to adjustments. The Representatives&#8217; Warrants are immediately exercisable, and may be exercised at any time and from time to time, in whole or in part, until September 26, 2028 and may be exercised on a cashless basis. The Representatives&#8217; Warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the Representatives&#8217; Warrants. The warrants were valued at $<ix:nonFraction id="fid_1011" contextRef="From2023-09-01to2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember" name="knwn:WarrantsIssuedValued" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,080</ix:nonFraction> and recorded in additional paid in capital as costs form common stock offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_1012" contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">389,800</ix:nonFraction> warrants to purchase common stock to three directors and four consultants at $1.899 per share. The warrants expire five years from the date of issuance.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 3, 2022, the Company signed an extension of warrant agreement with Clayton Struve, extending the exercise dates as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_ad5eca"><table style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Original </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_850" contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">08-14-2017</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_846" contextRef="AsOf2022-09-30_knwn_WarrantOneMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,440,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$<ix:nonFraction id="fid_862" contextRef="AsOf2022-09-30_knwn_WarrantOneMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_854" contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">08-13-2023</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_858" contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">08-13-2024</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_851" contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">12-12-2017</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_847" contextRef="AsOf2022-09-30_knwn_WarrantTwoMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,200,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$<ix:nonFraction id="fid_863" contextRef="AsOf2022-09-30_knwn_WarrantTwoMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_855" contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">12-11-2023</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_859" contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">12-11-2024</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_852" contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">08-04-2016</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_848" contextRef="AsOf2022-09-30_knwn_WarrantThreeMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,785,715</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$<ix:nonFraction id="fid_864" contextRef="AsOf2022-09-30_knwn_WarrantThreeMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_856" contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">08-04-2023</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_860" contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">08-04-2024</ix:nonNumeric></p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_853" contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember" name="knwn:DateOfIssue" format="ixt:datemonthdayyear">02-28-2018</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonFraction id="fid_849" contextRef="AsOf2022-09-30_knwn_WarrantFourMember" name="knwn:NumberOfWarrantShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,344,000</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$<ix:nonFraction id="fid_865" contextRef="AsOf2022-09-30_knwn_WarrantFourMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_857" contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember" name="knwn:OriginalExpirationDate" format="ixt:datemonthdayyear">02-28-2023</ix:nonNumeric></p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_861" contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember" name="knwn:AmendedExpirationdate" format="ixt:datemonthdayyear">02-28-2024</ix:nonNumeric></p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded interest expense of $<ix:nonFraction id="fid_1014" contextRef="From2021-10-01to2022-09-30" name="us-gaap:InterestExpenseOther" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,260</ix:nonFraction> during the year ended September 30, 2022 related to the extension of the warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase <ix:nonFraction id="fid_1015" contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantsToPurchaseCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">122,018</ix:nonFraction> shares of common stock at $<ix:nonFraction id="fid_1013" contextRef="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:WarrantsExpiredPerSharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.918</ix:nonFraction> per share expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued <ix:nonFraction id="fid_1017" contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:CommonStockSharesIssuedRelatedToWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,045,724</ix:nonFraction> shares of common stock related to warrant exercises and received $<ix:nonFraction id="fid_1016" contextRef="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember" name="knwn:ReceivedOfWarrant" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,487</ix:nonFraction>. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_d5c119"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the warrants outstanding as of September 30, 2023 were as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_816" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="cont_1a41c4"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding October 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" contextRef="AsOf2022-09-30" name="knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,786,313</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_873" contextRef="AsOf2022-09-30" name="knwn:OutstandingAtBegenningOfPeriod" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.029</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_868" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_874" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_869" contextRef="From2022-10-01to2023-09-30" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,582,727</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_875" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_870" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">297,273</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_876" contextRef="From2022-10-01to2023-09-30" name="knwn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_877" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_878" contextRef="From2022-10-01to2023-09-30" name="knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,886,313</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_880" contextRef="AsOf2023-09-30" name="knwn:OutstandingAtEndOfPeriod" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.103</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_879" contextRef="AsOf2023-09-30" name="knwn:ExercisableAtEndOfPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,886,313</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes information about warrants outstanding and exercisable as of September 30, 2023: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_1a41c4"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Life ( In Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_881" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,649,381</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_886" contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember" name="knwn:WeightedAveragesRemainingLifeYears" format="ixt-sec:duryear">2.16</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_891" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_897" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,649,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_902" contextRef="AsOf2023-09-30_knwn_WarrantOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_882" contextRef="AsOf2023-09-30_knwn_WarrantTwoMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,512,207</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_887" contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember" name="knwn:WeightedAveragesRemainingLifeYears" format="ixt-sec:duryear">1.37</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_892" contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.20</ix:nonFraction>-<ix:nonFraction id="fid_893" contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.85</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_898" contextRef="AsOf2023-09-30_knwn_WarrantTwoMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,512,207</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_903" contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.20</ix:nonFraction>-<ix:nonFraction id="fid_904" contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.85</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_883" contextRef="AsOf2023-09-30_knwn_WarrantThreeMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,694,725</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_888" contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember" name="knwn:WeightedAveragesRemainingLifeYears" format="ixt-sec:duryear">2.59</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_894" contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction>-<ix:nonFraction id="fid_909" contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_899" contextRef="AsOf2023-09-30_knwn_WarrantThreeMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,694,725</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_905" contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction>-<ix:nonFraction id="fid_908" contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_884" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_889" contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember" name="knwn:WeightedAveragesRemainingLifeYears" format="ixt-sec:duryear">0.43</ix:nonNumeric></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_895" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.080</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_900" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_906" contextRef="AsOf2023-09-30_knwn_WarrantFourMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.080</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_885" contextRef="AsOf2023-09-30" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,886,313</ix:nonFraction></p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_890" contextRef="From2022-10-01to2023-09-30" name="knwn:WeightedAveragesRemainingLifeYears" format="ixt-sec:duryear">2.07</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_896" contextRef="AsOf2023-09-30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.163</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_901" contextRef="AsOf2023-09-30" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,886,313</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_907" contextRef="AsOf2023-09-30" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.163</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The significant weighted average assumptions relating to the valuation of the Company&#8217;s warrants for the year ended September 30, 2023 were as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_817" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonFraction id="fid_910" contextRef="From2022-10-01to2023-09-30" name="srt:FederalFundsSoldAverageYield" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction>%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected life</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric id="fid_911" contextRef="From2022-10-01to2023-09-30" name="knwn:ExpectedLifeMinimum" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric id="fid_912" contextRef="From2022-10-01to2023-09-30" name="knwn:ExpectedLifeMaximum" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonFraction id="fid_913" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" decimals="INF" unitRef="Pure" scale="-2">104</ix:nonFraction>%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk free interest rate</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonFraction id="fid_914" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShortTermDebtInterestRateIncrease" decimals="INF" unitRef="Pure" scale="-2">2.96</ix:nonFraction>%</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were vested warrants of <ix:nonFraction id="fid_940" contextRef="From2022-10-01to2023-09-30" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,866,313</ix:nonFraction> with an aggregate intrinsic value of $<ix:nonFraction id="fid_939" contextRef="From2022-10-01to2023-09-30" name="knwn:SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_788" contextRef="From2022-10-01to2023-09-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="cont_04e23e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. EQUITY INCENTIVE PLANS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 12, 2021, the Company established its 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which was adopted by stockholders on October 15, 2021. The Company initially had <ix:nonFraction id="fid_1094" contextRef="AsOf2021-10-15_knwn_TwoZeroTwoOneEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000,000</ix:nonFraction> shares of its common stock authorized as the maximum number of shares of common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to <ix:nonFraction id="fid_1095" contextRef="AsOf2022-01-01_knwn_TwoZeroTwoOneEquityIncentivePlanMember" name="knwn:NumberOfCommonStockSharesIncrease" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">22,000,000</ix:nonFraction> shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase described below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, the Company issued stock option grants to eighteen employees and consultants for <ix:nonFraction id="fid_1096" contextRef="From2022-10-01to2023-09-30" name="knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,158,333</ix:nonFraction> shares at an average exercise price of $<ix:nonFraction id="fid_1097" contextRef="AsOf2023-09-30" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.381</ix:nonFraction> per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over two to four years. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_04e23e" continuedAt="cont_b3cf2d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, stock option grants for <ix:nonFraction id="fid_1099" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,277,655</ix:nonFraction> shares at an average exercise price of $<ix:nonFraction id="fid_1093" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.647</ix:nonFraction> per share were forfeited. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, stock option grants for <ix:nonFraction id="fid_1098" contextRef="From2022-10-01to2023-09-30" name="knwn:StockIssuedDuringPeriodSharesStockOptionExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">166,890</ix:nonFraction> shares at an average exercise price of $<ix:nonFraction id="fid_1092" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.272</ix:nonFraction> per share were exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for <ix:nonFraction id="fid_1100" contextRef="AsOf2022-09-30_knwn_RonaldPEricksonMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1103" contextRef="AsOf2022-09-30_knwn_RonaldPEricksonMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction> per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for <ix:nonFraction id="fid_1101" contextRef="AsOf2022-09-30_knwn_PhillipABosuaMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,300,000</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1104" contextRef="AsOf2022-09-30_knwn_PhillipABosuaMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction> per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 20, 2022, the Company issued a stock option grant to Peter Conley for <ix:nonFraction id="fid_1102" contextRef="AsOf2022-09-30_knwn_PeterConleyMember" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1105" contextRef="AsOf2022-09-30_knwn_PeterConleyMember" name="us-gaap:SharesIssuedPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction> per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years after two quarters.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, the Company also issued stock option grants to nineteen employees and consultants for <ix:nonFraction id="fid_1112" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember" name="knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,336,000</ix:nonFraction> shares at an average exercise price of $<ix:nonFraction id="fid_1110" contextRef="AsOf2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.726</ix:nonFraction> per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, the Company issued <ix:nonFraction id="fid_1106" contextRef="AsOf2022-09-30" name="knwn:WarrantIssuedToCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,293</ix:nonFraction> shares related to the exercise of stock option grants and received $<ix:nonFraction id="fid_1107" contextRef="AsOf2022-09-30" name="knwn:ExerciseStockOptionGrantsreceived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,887</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, eight employees and consultants forfeited stock option grants for <ix:nonFraction id="fid_1111" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember" name="knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,132,457</ix:nonFraction> shares at an average of $<ix:nonFraction id="fid_1109" contextRef="AsOf2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.057</ix:nonFraction> per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock option activity for the years ended September 30, 2023 and 2022 was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_818" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Options </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of October 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1043" contextRef="AsOf2021-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,315,120</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" contextRef="AsOf2021-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,636,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.815</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1047" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,293</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1056" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.376</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1049" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,132,457</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1058" contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.057</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" contextRef="AsOf2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,792,370</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" contextRef="AsOf2022-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.618</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,158,333</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1048" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">166,890</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1057" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.272</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1050" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">10,277,655</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1059" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.647</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" contextRef="AsOf2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,506,158</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" contextRef="AsOf2023-09-30_knwn_StockOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.546</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes information about stock options outstanding and exercisable as of September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_819" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Range of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining Life </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Prices</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">In Years</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$.88-<ix:nonFraction id="fid_1064" contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption1Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1069" contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,161,875</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1073" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsOneMember" name="knwn:WeightedAverageRemainingLifeYears" format="ixt-sec:duryear">2.91</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember" name="knwn:WeightedAverageExercisePriceOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1081" contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,946,758</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.107</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1065" contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption2Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.28</ix:nonFraction>-<ix:nonFraction id="fid_1066" contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption2Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1070" contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">9,754,283</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1074" contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsTwoMember" name="knwn:WeightedAverageRemainingLifeYears" format="ixt-sec:duryear">3.00</ix:nonNumeric></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1078" contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember" name="knwn:WeightedAverageExercisePriceOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.473</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1082" contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,920,291</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.415</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonFraction id="fid_1067" contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption3Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.79</ix:nonFraction>-<ix:nonFraction id="fid_1068" contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption3Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.67</ix:nonFraction></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1071" contextRef="AsOf2023-09-30_knwn_StockOption3Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,590,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1075" contextRef="From2022-10-01to2023-09-30_knwn_StockOption3Member" name="knwn:WeightedAverageRemainingLifeYears" format="ixt-sec:duryear">3.05</ix:nonNumeric></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" contextRef="AsOf2023-09-30_knwn_StockOption3Member" name="knwn:WeightedAverageExercisePriceOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.186</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1083" contextRef="AsOf2023-09-30_knwn_StockOption3Member" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,213,750</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1088" contextRef="AsOf2023-09-30_knwn_StockOption3Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.151</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1072" contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,506,158</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1076" contextRef="From2022-10-01to2023-09-30_knwn_EmployeeStockOptionsOneMember" name="knwn:WeightedAverageRemainingLifeYears" format="ixt-sec:duryear">3.00</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1080" contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember" name="knwn:WeightedAverageExercisePriceOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.546</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,080,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.498</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_b3cf2d"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were stock option grants of <ix:nonFraction id="fid_1091" contextRef="From2022-10-01to2023-09-30" name="knwn:StockOptionGrants" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,906,158</ix:nonFraction> with an aggregate intrinsic value of $<ix:nonFraction id="fid_1090" contextRef="From2022-10-01to2023-09-30" name="knwn:IntrinsicValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_790" contextRef="From2022-10-01to2023-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" continuedAt="cont_b2a852"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Clayton Struve</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 7 and 8 for related party transactions with Clayton A. Struve, a significant stockholder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 27, 2023, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of <ix:nonFraction id="fid_1118" contextRef="AsOf2023-06-27_knwn_MrStruveMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,402,784</ix:nonFraction> shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. In connection with this transaction, the Company recorded $<ix:nonFraction id="fid_1117" contextRef="AsOf2023-06-27_knwn_MrStruveMember" name="knwn:ReceivedSeriesDPreferredStockDividends" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,627,230</ix:nonFraction> in dividends, representing the fair market value of the 1,402,784 shares issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, we signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates. We recorded interest expense of $<ix:nonFraction id="fid_1119" contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember" name="us-gaap:InterestExpenseDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,019</ix:nonFraction> during the year ended September 30, 2023 related to the extension of the warrants. We recorded the original value of warrants in equity and as such, we recorded the extension value as an expense with an offset to additional paid in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Ronald P. Erickson</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 7, 8 and 9 for related party transactions with Ronald P. Erickson, the Company&#8217;s Chairman and Chief Executive Officer and affiliated entities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 14, 2022, the Company issued a stock option grant to Ronald P. Erickson for <ix:nonFraction id="fid_1113" contextRef="From2022-12-01to2022-12-14_knwn_RonaldPEricksonMember" name="knwn:ShareGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1114" contextRef="AsOf2022-12-14_knwn_RonaldPEricksonMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.41</ix:nonFraction> per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 4, 2019, the Company granted a stock option grant to Ronald P. Erickson for <ix:nonFraction id="fid_1120" contextRef="From2019-11-01to2019-11-04_knwn_RonaldPEricksonMember" name="knwn:ShareGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,200,000</ix:nonFraction> shares with an exercise price of $<ix:nonFraction id="fid_1121" contextRef="AsOf2019-11-04_knwn_RonaldPEricksonMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction> per share. The performance grant expires November 4, 2024 and vests upon uplisting to the NASDAQ or NYSE exchanges. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and the Company expensed $<ix:nonFraction id="fid_1122" contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,207,200</ix:nonFraction> during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued a stock option grant to Ronald P. Erickson for <ix:nonFraction id="fid_1123" contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,865,675</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1124" contextRef="AsOf2020-12-15_knwn_RonaldPEricksonMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction> per share. The stock option grant expires in five years. The grant vests in increments if the market capitalization of our commons stock <ix:nonNumeric id="fid_1125" contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember" name="knwn:DescriptionRelatedToCommonStock">exceeds for 20 consecutive trading days starting at $100 million to $1 billion</ix:nonNumeric>.&#160; The Company estimated at grant date the fair value of these options at approximately $520,869 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $104,172 and a&#160; cumulative expense of $<ix:nonFraction id="fid_1126" contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember" name="knwn:CumulativeExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,657</ix:nonFraction>, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued an additional stock option grant to Ronald P. Erickson for <ix:nonFraction id="fid_1127" contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember" name="knwn:AdditionalStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,865,675</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1128" contextRef="AsOf2020-12-15_knwn_RonaldPEricksonMember" name="knwn:AdditionalExercisedPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction> per share. The stock option grant expires in five years. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and the Company expensed $<ix:nonFraction id="fid_1129" contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,593</ix:nonFraction> during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Erickson was paid interest of $<ix:nonFraction id="fid_1130" contextRef="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,855</ix:nonFraction> during the year ended September 30, 2023 and deferred compensation of $<ix:nonFraction id="fid_1131" contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember" name="us-gaap:DividendsSharebasedCompensationStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction> during the year ended September 30, 2022 that were previously accrued and reported but were deferred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $<ix:nonFraction id="fid_1132" contextRef="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember" name="knwn:AccruedCompensastionTravelAndInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">218,334</ix:nonFraction> and $<ix:nonFraction id="fid_1133" contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember" name="knwn:AccruedCompensastionTravelAndInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,418</ix:nonFraction> as of September 30, 2023 and 2022, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Phillip A. Bosua</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 4, 8, 9 and 11 for related party transactions with Phillip A. Bosua. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_b2a852"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued a stock option grant to Phillip A. Bosua for <ix:nonFraction id="fid_1134" contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,132,195</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1136" contextRef="AsOf2020-12-15_knwn_PhillipABosuaMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction> per share. The stock option grant expires in five years. The grant vested in increments if the market capitalization of our commons stock <ix:nonNumeric id="fid_1137" contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember" name="knwn:DescriptionRelatedToCommonStock">exceeds for 20 consecutive trading days starting at $100 million to $1 billion</ix:nonNumeric>.&#160; The Company estimated at grant date the fair value of these options at approximately $595,277 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $<ix:nonFraction id="fid_1139" contextRef="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,370</ix:nonFraction> and a cumulative expense of $<ix:nonFraction id="fid_1138" contextRef="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember" name="knwn:CumulativeExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,321</ix:nonFraction>, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued another stock option grant to Phillip A. Bosua for <ix:nonFraction id="fid_1142" contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember" name="knwn:AdditionalStockOption" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,132,195</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1141" contextRef="AsOf2020-12-15_knwn_PhillipABosuaMember" name="knwn:AdditionalExercisedPrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction> per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $<ix:nonFraction id="fid_1140" contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember" name="us-gaap:EquipmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,249</ix:nonFraction> during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Mr. Bosua was paid $<ix:nonFraction id="fid_1143" contextRef="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember" name="us-gaap:SeveranceCosts1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction> in severance and $<ix:nonFraction id="fid_1144" contextRef="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,440</ix:nonFraction> in rent and other costs during the year ended September 30, 2023. Mr. Bosua was paid $<ix:nonFraction id="fid_1145" contextRef="From2022-10-01to2023-09-30_knwn_AIMindMember" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,097,928</ix:nonFraction> in compensation and $<ix:nonFraction id="fid_1146" contextRef="From2022-10-01to2023-09-30_knwn_AIMindMember" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,500</ix:nonFraction> in rent expenses for services provided to AI Mind, a wholly owned subsidiary of the Company, in connection with the development of NFT sales for the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock Issuances to Named Executive Officers and Directors</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 15, 2023, the Company issued stock option grants to two directors for a total of <ix:nonFraction id="fid_1116" contextRef="AsOf2023-06-30_srt_DirectorMember" name="us-gaap:PrepaidRent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction> shares at an exercise price of $<ix:nonFraction id="fid_1115" contextRef="AsOf2023-06-30_srt_DirectorMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.24</ix:nonFraction> per share. The stock option grant expires in five years. The stock option grants vested at issuance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, the Company issued <ix:nonFraction id="fid_1147" contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction> shares each to three directors at an exercise price of $<ix:nonFraction id="fid_1148" contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember" name="knwn:ExercisePricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction> per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, the Company issued <ix:nonFraction id="fid_1149" contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember" name="knwn:WarrantsToPurchaseCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">20,000</ix:nonFraction> warrants to purchase common stock each to three directors shares at $<ix:nonFraction id="fid_1150" contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction> per share. The warrants expire on January 5, 2027. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_791" contextRef="From2022-10-01to2023-09-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_2966bb"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>11. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Legal Proceedings</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to the Company&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, the Company entered into an amended employment agreement for Ronald P. Erickson which amends our employment agreement with him dated July 1, 2017. The employment agreement provides for a base salary of $<ix:nonFraction id="fid_1228" contextRef="From2018-04-01to2018-04-10_knwn_RonaldPEricksonMember" name="us-gaap:OfficersCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction> per year, which was increased to $<ix:nonFraction id="fid_1229" contextRef="From2020-05-01to2021-03-31_knwn_RonaldPEricksonMember" name="knwn:AnnualSalary" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction> from May 1, 2020 to March 31, 2021, to $<ix:nonFraction id="fid_1235" contextRef="From2021-04-01to2022-03-15_knwn_RonaldPEricksonMember" name="knwn:AnnualSalary" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction> from April 1, 2021 to March 15, 2022 and to $325,000 from March 15, 2022 to September 30, 2022. From December 14, 2022, Mr. Erickson has been compensated with an annual salary of $375,000. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the company terminates Mr. Erickson&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Erickson terminates his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Erickson will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. On January 23, 2023, the Board appointed Mr. Erickson to the position of Chief Executive Officer of the Company. Mr. Erickson was appointed to serve until his successor is duly elected.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_2966bb" continuedAt="cont_466b15"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, the Company entered into an employment agreement with Phillip A. Bosua reflecting his appointment as Chief Executive Officer. The employment agreement provided for a base salary of $<ix:nonFraction id="fid_1234" contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember" name="us-gaap:OfficersCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction> per year, which was increased to $260,000 from May 1, 2020 to March 31, 2021 and to $<ix:nonFraction id="fid_1232" contextRef="From2021-04-01to2022-09-30_knwn_MrBosuaMember" name="knwn:AnnualSalary" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction> from April 1, 2021 to January 23, 2023. Mr. Bosua also received <ix:nonFraction id="fid_1238" contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">500,000</ix:nonFraction> shares of common stock valued at $<ix:nonFraction id="fid_1239" contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember" name="knwn:CommonStockPerShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.33</ix:nonFraction> per share and was entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. Mr. Bosua was entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement was for an initial term of 12 months (subject to earlier termination) and was automatically extended for additional 12-month terms unless either party notified the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the Company terminated Mr. Bosua&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Bosua terminated his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Bosua was entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2023, Mr. Bosua resigned from the Board and from his position as Chief Executive Officer of the Company.&#160; In connection with his resignation, we entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;) with Mr. Bosua containing customary terms and mutual releases, <ix:nonNumeric id="fid_1258" contextRef="From2022-10-01to2023-09-30" name="knwn:LeaseDescription">pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#8217;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company&#8217;s common stock exceeds $5.00 per share on the NYSE American (the &#8220;Stock Price Threshold&#8221;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.</ix:nonNumeric>&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 13, 2022, the Company entered into an employment agreement with Peter J. Conley reflecting his appointment as our Chief Financial Officer and Senior Vice President, Intellectual Property. The employment agreement provides for a base salary of $<ix:nonFraction id="fid_1240" contextRef="From2022-05-01to2022-05-13_knwn_PeterConleyMember" name="us-gaap:OfficersCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction>. From December 14, 2022 to September 30, 2023, Mr. Conley has been compensated with an annual salary of $<ix:nonFraction id="fid_1255" contextRef="From2022-10-01to2023-09-30_knwn_PeterConleyMember" name="knwn:AnnualSalary" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,000</ix:nonFraction>, Mr. Conley may also be entitled to bonuses from time to time as determined by our Board or our compensation committee in their sole discretion. Mr. Conley is eligible to participate in all the Company&#8217;s employee benefit plans, policies and arrangements that are applicable to other executive officers, as such plans, policies and arrangements may exist or change from time to time at our discretion. The Company will reimburse Mr. Conley for reasonable travel, entertainment and other expenses he incurs in the furtherance of his duties under the employment agreement. The employment agreement is at will, meaning either we or Mr. Conley may terminate the employment relationship at any time, with or without cause, upon written notice to the other party. The employment agreement provides for severance pay equal to 12 months of then-in-effect base salary if Mr. Conley is terminated without &#8220;cause&#8221; or voluntarily terminates his employment for &#8220;good reason,&#8221; as defined in the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Properties and Operating Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is obligated under the following leases for our various facilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Corporate Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $<ix:nonFraction id="fid_1217" contextRef="From2017-04-01to2017-04-13" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,334</ix:nonFraction>. The monthly payment increases approximately 3% each year and the lease expired on May 31, 2022. On October 31, 2021, the Company extended the lease from June 1, 2022 to May 31, 2023 at $<ix:nonFraction id="fid_1218" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,986</ix:nonFraction>&#160;per month. On April 26, 2023, the Company extended the lease from June 1, 2023 to May 31, 2024 at $<ix:nonFraction id="fid_1219" contextRef="From2023-04-01to2023-04-26" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,908</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Lab Facilities and Executive Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 18, 2021, the Company entered into a lease for its lab facilities located at 914 E Pine Street, Suite 212, Seattle, WA 98122 and leased 2,642 square feet. The net monthly lease payment was $<ix:nonFraction id="fid_1220" contextRef="From2021-05-01to2021-05-18" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,697</ix:nonFraction>&#160;and&#160;<ix:nonNumeric id="fid_1224" contextRef="From2021-05-01to2021-05-18" name="knwn:LeaseDescription">increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term</ix:nonNumeric>.&#160;</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_466b15"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 11, 2021, the Company entered into the First Amendment of Lease and added 2,485 square feet for $<ix:nonFraction id="fid_1221" contextRef="From2021-09-11to2021-10-11" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction>&#160;per month.&#160; On September 20, 2022, the Company entered into the Second Amendment of Lease for additional space. The expanded space will be utilized for research and testing. The Amendment of Lease expires on December 31, 2023.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 22, 2022, the Company leased lab facilities and executive offices in Yucca Valley, CA from Phillip Bosua, our former CEO. The Company leased 1,700 square feet of the total 2,134 square feet of the premises and the current net monthly payment is $<ix:nonFraction id="fid_1222" contextRef="From2022-09-01to2022-09-22" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction>. The lease was to expire September 30, 2023 and could be extended on a month to month basis. The Company paid $<ix:nonFraction id="fid_1225" contextRef="From2022-09-01to2022-09-28" name="us-gaap:PaymentsForRent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,500</ix:nonFraction>&#160;in rent on September 28, 2022 for the period September 1, 2021 to September 30, 2022. The Company paid $<ix:nonFraction id="fid_1226" contextRef="From2022-10-01to2023-09-30" name="us-gaap:PaymentsForRent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction>&#160;for the year ended September 30, 2023. &#160;The lease was terminated on January 23, 2023, the date of Mr. Bosua&#8217;s resignation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 22, 2022, the Company leased an additional 1,800 square feet of lab facilities at 123 Boylston Ave, Suite C, Seattle, WA 98102 with a net monthly payment is $<ix:nonFraction id="fid_1223" contextRef="From2022-11-01to2022-11-22" name="us-gaap:SaleLeasebackTransactionMonthlyRentalPayments" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250</ix:nonFraction>. The lease was set to expire on November 21, 2023 and has been extended on a month-to-month basis.&#160; </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_789" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="cont_19a16a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>12. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has incurred losses since inception, which have generated net operating loss carryforwards.&#160;&#160;The net operating loss carryforwards arise from United States sources.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Losses arising from United States taxable operations were approximately $4.2 million and $7.3 million for the years ended September 30, 2023 and 2022.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has Federal net operating loss carryforwards of approximately $<ix:nonFraction id="fid_1184" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">49.5</ix:nonFraction> million which <ix:nonNumeric id="fid_1187" contextRef="From2022-10-01to2023-09-30" name="knwn:FederalNetOperatingLossCarryforwardsExpired">expire in 2028-2042</ix:nonNumeric>. Because it is not more likely than not that sufficient tax earnings will be generated to utilize the net operating loss carryforwards, a corresponding valuation allowance equal to <ix:nonFraction id="fid_1183" contextRef="From2022-10-01to2023-09-30" name="knwn:EffectiveTaxRate" decimals="INF" unitRef="Pure" scale="-2">100</ix:nonFraction>% of the gross deferred tax asset of approximately $<ix:nonFraction id="fid_1185" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsOther" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">14.2</ix:nonFraction> million and $<ix:nonFraction id="fid_1186" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsOther" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">11.4</ix:nonFraction> million was established as of September 30, 2023 and 2022, respectively.&#160; The Company does not recognize the majority of state tax loss operating loss carryforwards as a deferred tax asset given it no longer has any operation in those states. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the Tax Reform Act of 1986, the amounts of, and benefits from, net operating losses may be limited in certain circumstances, including a change in control. Section&#160;382 of the Internal Revenue Code generally imposes an annual limitation on the amount of net operating loss carryforwards that may be used to offset taxable income when a corporation has undergone significant changes in its stock ownership. There can be no assurance that the Company will be able to utilize any net operating loss carryforwards in the future. The Company is subject to possible tax examination for the years 2017 through 2023.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_19a16a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The principal components of the Company&#8217;s deferred tax assets at September 30, 2023 and 2022 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_821" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1155" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,476,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1164" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,372,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1156" contextRef="AsOf2023-09-30" name="knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,174,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" contextRef="AsOf2022-09-30" name="knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,677,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Research and Development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1157" contextRef="AsOf2023-09-30" name="knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,460,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1166" contextRef="AsOf2022-09-30" name="knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1158" contextRef="AsOf2023-09-30" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1167" contextRef="AsOf2022-09-30" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accruals and reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1159" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1168" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1160" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,156,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1169" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,367,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1161" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,156,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1170" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,367,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1162" contextRef="AsOf2023-09-30" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1171" contextRef="AsOf2022-09-30" name="us-gaap:DeferredTaxAssetsNet" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance during the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1163" contextRef="From2022-10-01to2023-09-30" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,789,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1172" contextRef="From2021-10-01to2022-09-30" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,666,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">A reconciliation of the United States Federal Statutory rate to the Company&#8217;s effective tax rate for the years ended September 30, 2023 and 2022 are as follows. For the years ended September 30, 2023 and 2022, the Company&#8217;s effective tax rate differs from the federal statutory rate principally due to nondeductible expenses plus an increase in the deferred tax asset valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_822" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Income tax provision at statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1174" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" decimals="INF" unitRef="Pure" scale="-2">21</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non deductible expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1173" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" decimals="INF" unitRef="Pure" scale="-2">1</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1180" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" decimals="INF" unitRef="Pure" scale="-2">12</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1175" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" scale="-2">18</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1178" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" decimals="INF" unitRef="Pure" scale="-2">7</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other and prior year true up</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1176" contextRef="From2022-10-01to2023-09-30" name="knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" decimals="INF" unitRef="Pure" scale="-2">2</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1181" contextRef="From2021-10-01to2022-09-30" name="knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" decimals="INF" unitRef="Pure" scale="-2">2</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" contextRef="From2022-10-01to2023-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1182" contextRef="From2021-10-01to2022-09-30" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" decimals="INF" unitRef="Pure" scale="-2">0</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">As of September 30, 2023, there were no uncertain tax positions. Management does not anticipate any future adjustments in&#160; the next twelve months which would result in a material change to its tax position. For the years ended September 30, 2023 and 2022, the Company did not have any interest and penalties.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_792" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="cont_9988a5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>13. SEGMENT REPORTING</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The management of the Company considers the business to currently have two operating segments (i) the development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies; (ii) Particle, Inc. technology; and (iii) AI sales of NFT products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Particle commenced operations in the year ended September 30, 2020. AI commenced operations during the year ended September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The reporting for the year ended September 30, 2023 and 2022 was as follows (in thousands): </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_820" contextRef="From2022-10-01to2023-09-30" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Operating</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Revenue</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Profit (Loss)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Assets</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1191" contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1197" contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" sign="-" scale="3">14,298</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1203" contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentAsset" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" scale="3">8,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1192" contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1198" contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentNetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1204" contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentAsset" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1193" contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1199" contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1205" contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentAsset" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1206" contextRef="From2022-10-01to2023-09-30" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1208" contextRef="From2022-10-01to2023-09-30" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" sign="-" scale="3">14,024</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1210" contextRef="From2022-10-01to2023-09-30" name="knwn:SegmentAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1188" contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1194" contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" sign="-" scale="3">13,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1200" contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" name="knwn:SegmentAsset" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" scale="3">13,360</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1189" contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentRevenues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1195" contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">22</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1201" contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember" name="knwn:SegmentAsset" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1190" contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentRevenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1196" contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD">930</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1202" contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember" name="knwn:SegmentAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1207" contextRef="From2021-10-01to2022-09-30" name="knwn:SegmentRevenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1209" contextRef="From2021-10-01to2022-09-30" name="knwn:SegmentNetIncomeLoss" format="ixt:numdotdecimal" decimals="-3" unitRef="USD" sign="-" scale="3">12,574</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1211" contextRef="From2021-10-01to2022-09-30" name="knwn:SegmentAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,758</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>KNOW LABS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_9988a5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During years ended September 30, 2023 and 2022, the Company incurred non-cash expenses related to operations of $<ix:nonFraction id="fid_1212" contextRef="From2022-10-01to2023-09-30" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,767,809</ix:nonFraction> and $<ix:nonFraction id="fid_1213" contextRef="From2021-10-01to2022-09-30" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,164,418</ix:nonFraction>, respectively. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_793" contextRef="From2022-10-01to2023-09-30" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>14.&#160; SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to September 30, 2023, there were the following material transactions that require disclosure:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 12, 2023, the Company issued <ix:nonFraction id="fid_1242" contextRef="AsOf2023-10-12_us-gaap_SubsequentEventMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">30,000</ix:nonFraction> shares each to three directors at $<ix:nonFraction id="fid_1243" contextRef="AsOf2023-10-12_us-gaap_SubsequentEventMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 26, 2023, the Company&#8217;s underwriters exercised their over-allotment option under the Underwriting Agreement by and between the Company and the underwriters dated September 26, 2023, electing to purchase an additional <ix:nonFraction id="fid_1244" contextRef="From2023-09-01to2023-10-26_us-gaap_SubsequentEventMember" name="knwn:AdditionalSharePurchase" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">883,061</ix:nonFraction> shares of Common Stock at a purchase price to the public of $<ix:nonFraction id="fid_1245" contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember" name="us-gaap:SharePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share. The Company also issued additional warrants to the Representatives to purchase an aggregate of <ix:nonFraction id="fid_1246" contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">61,814</ix:nonFraction> shares of Common Stock at an exercise price of $<ix:nonFraction id="fid_1247" contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.25</ix:nonFraction> per share, subject to adjustments, with the same terms as the warrants issued in connection with the initial closing of the Offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 3, 2023,&#160; the Company appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan,&#160; as new non-employee members of the Board. Messrs. Ellingson, Cronin, and Londergan are deemed to qualify as independent under the director independence standards set forth in the rules and regulations of the SEC and applicable NYSE listing standards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 28, 2023, the Board adopted, based on the recommendation of the Compensation Committee of the Board, the Know Labs Inc. Compensation Recovery Policy (the &#8220;Policy&#8221;) for the recovery of Erroneously Awarded Compensation in order to comply with Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act, and the listing standards of the New York Stock Exchange adopted pursuant thereto. &#160;The Board has designated the Compensation Committee of the Board as the administrator of the Policy.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since September 30, 2023, the Company issued stock option grants to employees, directors and directors for <ix:nonFraction id="fid_1248" contextRef="AsOf2023-09-30" name="knwn:StockOptionGrantsToEmployeesAndDirectors" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,909,315</ix:nonFraction> shares at an average exercise price of $<ix:nonFraction id="fid_1249" contextRef="AsOf2023-09-30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.256</ix:nonFraction> per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:53%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: December 19, 2023</p></td><td style="width:35%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>KNOW LABS, INC.</strong></p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Ronald P. Erickson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name: Ronald P. Erickson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Chief Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Executive Officer)</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Peter J. Conley</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name: Peter J. Conley</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Title: Chief Financial Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Financial and Accounting Officer)</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>SIGNATURE</strong></p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>TITLE</strong></p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>DATE</strong></p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Ronald P. Erickson</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:48%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer and Director (principal executive officer)</p></td><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ronald P. Erickson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Peter J. Conley</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer (principal financial and accounting officer)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Peter J. Conley</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ William A. Owens </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">William A. Owens</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Jon Pepper</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Jon Pepper</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Ichiro Takesako</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ichiro Takesako</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ John Cronin </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cronin</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Timothy M. Londergan</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Timothy M. Londergan</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Larry K. Ellingson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">December 19, 2023</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">Larry K. Ellingson</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">76</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>knwn_ex211.htm
<DESCRIPTION>SUBSIDIARIES
<TEXT>
<html><head><title>knwn_ex211.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 21.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SUBSIDIARIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, the following was the Registrant's significant operating Subsidiaries:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name:&nbsp;&nbsp;&nbsp;Particle, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Country of Organization:&nbsp;&nbsp;&nbsp;U.S.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Percent Ownership by Registrant:&nbsp;&nbsp;&nbsp;100.0% by Know Labs, Inc.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>knwn_ex231.htm
<DESCRIPTION>EX - 23.1
<TEXT>
<html><head><title>knwn_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman; MARGIN: 0px 7%"><p style="MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">We consent to the incorporation by reference in the registration statements on Form S-3 (No. 333-268655) and Form S-8 (No. 333-261597) of Know Labs, Inc. of our report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) &nbsp;dated December 19, 2023, relating to the consolidated financial statements of Know Labs, Inc., which appears in this Annual Report on Form 10-K. &nbsp;</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px 0px 0px 0in">/s/ BPM LLP</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px">Walnut Creek, California</p> <p style="margin:0px">December 19, 2023</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>knwn_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>knwn_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Ronald P. Erickson, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I have reviewed this annual report on Form 10-K of Know Labs, Inc.; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td colspan="4" style="width:100%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: December 19, 2023</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Ronald P. Erickson</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Ronald P. Erickson</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Executive Officer)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>knwn_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>knwn_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Peter J. Conley, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">I have reviewed this annual report on Form 10-K of Know Labs, Inc.; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td colspan="4" style="width:100%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&nbsp; </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Date: December 19, 2023</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Peter J. Conley</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Peter J. Conley</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Financial and Accounting Officer)</em>&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>knwn_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>knwn_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with Annual Report of Know Labs, Inc. (the &#8220; Company&#8221;) on Form 10-K for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned Ronald P. Erickson, Chief Executive Officer (Principal Executive Officer) of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) &nbsp;of the Securities Exchange Act of 1934; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Ronald P. Erickson</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Ronald P. Erickson</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer </p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Executive Officer)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to Know Labs, Inc. and will be retained by Know Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The forgoing certification is being furnished to the Securities and Exchange Commission pursuant to &#167; 18 U.S.C. Section 1350.&nbsp; It is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>knwn_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>knwn_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with Annual Report of Know Labs, Inc. (the &#8220; Company&#8221;) on Form 10-K for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned Peter J. Conley, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) &nbsp;of the Securities Exchange Act of 1934; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:53%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Peter J. Conley</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Peter J. Conley</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>(Principal Financial and Accounting Officer)</em></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to Know Labs, Inc. and will be retained by Know Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The forgoing certification is being furnished to the Securities and Exchange Commission pursuant to &#167; 18 U.S.C. Section 1350.&nbsp; It is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>knwn-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/19/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:knwn="http://knwn.com/20230930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://knwn.com/20230930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://knwn.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" id="SignificantAccountingPoliciesAdoptionOfAccountingStandards">
        <link:definition>000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/AiDeepLearningPlatform" id="AiDeepLearningPlatform">
        <link:definition>000010 - Disclosure - AI DEEP LEARNING PLATFORM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>000011 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LEASES" id="LEASES">
        <link:definition>000012 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" id="ConvertibleNotesPayableAndNotePayable">
        <link:definition>000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EQUITY" id="EQUITY">
        <link:definition>000014 - Disclosure - EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/StockIncentivePlans" id="StockIncentivePlans">
        <link:definition>000015 - Disclosure - STOCK INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" id="OtherSignificantTransactionsWithRelatedParties">
        <link:definition>000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" id="CommitmentsContingenciesAndLegalProceedings">
        <link:definition>000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000018 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SegmentReporting" id="SegmentReporting">
        <link:definition>000019 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" id="SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies">
        <link:definition>000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LeasesTables" id="LeasesTables">
        <link:definition>000023 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" id="ConvertibleNotesPayableAndNotePayableTables">
        <link:definition>000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityTables" id="EquityTables">
        <link:definition>000025 - Disclosure - EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/StockIncentivePlansTables" id="StockIncentivePlansTables">
        <link:definition>000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000027 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SegmentReportingTables" id="SegmentReportingTables">
        <link:definition>000028 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
        <link:definition>000029 - Disclosure - ORGANIZATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
        <link:definition>000030 - Disclosure - LIQUIDITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" id="SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative">
        <link:definition>000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" id="AiDeepLearningPlatformDetailsNarrative">
        <link:definition>000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LeasesDetails" id="LeasesDetails">
        <link:definition>000035 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
        <link:definition>000036 - Disclosure - LEASES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
        <link:definition>000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" id="ConvertibleNotesPayableAndNotePayableDetails">
        <link:definition>000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" id="ConvertibleNotesPayableAndNotePayableDetailsNarrative">
        <link:definition>000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetails" id="EquityDetails">
        <link:definition>000040 - Disclosure - EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetails1" id="EquityDetails1">
        <link:definition>000041 - Disclosure - EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetails2" id="EquityDetails2">
        <link:definition>000042 - Disclosure - EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetails3" id="EquityDetails3">
        <link:definition>000043 - Disclosure - EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetails4" id="EquityDetails4">
        <link:definition>000044 - Disclosure - EQUITY (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
        <link:definition>000045 - Disclosure - EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/StockIncentivePlansDetails" id="StockIncentivePlansDetails">
        <link:definition>000046 - Disclosure - STOCK INCENTIVE PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/StockIncentivePlansDetails1" id="StockIncentivePlansDetails1">
        <link:definition>000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/StockIncentivePlansDetailsNarrative" id="StockIncentivePlansDetailsNarrative">
        <link:definition>000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" id="OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative">
        <link:definition>000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" id="CommitmentsContingenciesAndLegalProceedingsDetailsNarrative">
        <link:definition>000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000051 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000052 - Disclosure - INCOME TAXES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000053 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
        <link:definition>000054 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SegmentReportingDetailsNarrative" id="SegmentReportingDetailsNarrative">
        <link:definition>000055 - Disclosure - SEGMENT REPORTING (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://knwn.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="knwn-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="knwn-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="knwn-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="knwn-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <import namespace="http://fasb.org/srt-roles/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd" />
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <element id="knwn_AmountDueToRelatedPartiesCurrent" name="AmountDueToRelatedPartiesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_NetIncomeLossAvailableToCommonStockholders" name="NetIncomeLossAvailableToCommonStockholders" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_EarningsPerSharesBasicAndDiluted" name="EarningsPerSharesBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_StockCompensationExpenseEmployeeOptions" name="StockCompensationExpenseEmployeeOptions" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConversionOfDebtOfferingAndAccruedInterestShares" name="ConversionOfDebtOfferingAndAccruedInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" name="ConversionOfDebtOfferingAndAccruedInterestAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceOfCommonStockForStockOptionExercisesShares" name="IssuanceOfCommonStockForStockOptionExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" name="IssuanceOfCommonStockForStockOptionExercisesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" name="IssuanceOfCommonStockForExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" name="IssuanceOfCommonStockForExerciseOfWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceOfCommonStockWarrantForServices" name="IssuanceOfCommonStockWarrantForServices" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IsssuanceOfCommonStockForNyseUplistingShares" name="IsssuanceOfCommonStockForNyseUplistingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IsssuanceOfCommonStockForNyseUplistingAmount" name="IsssuanceOfCommonStockForNyseUplistingAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CommonStockDividendsOnSeriesDPreferredStockShares" name="CommonStockDividendsOnSeriesDPreferredStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" name="CommonStockDividendsOnSeriesDPreferredStockAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DeemedDividendsOnSeriesCAndDPreferredStock" name="DeemedDividendsOnSeriesCAndDPreferredStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" name="IsssuanceOfCommonStockForCommonStockOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" name="IsssuanceOfCommonStockForCommonStockOfferingAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExpensesForExtensionOfNotesAndWarrants" name="ExpensesForExtensionOfNotesAndWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_GainLossOnDebtSettlement" name="GainLossOnDebtSettlement" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_GainLossOnForgivenessOfNotesPayablePppLoans" name="GainLossOnForgivenessOfNotesPayablePppLoans" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" name="ProceedsFromIssuanceOfCommonStockOfferingNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" name="SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConversionOfAccruedInterest" name="ConversionOfAccruedInterest" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuanceCostsFromCommonStockOffering" name="IssuanceCostsFromCommonStockOffering" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AiDeepLearningPlatformDisclosureTextBlock" name="AiDeepLearningPlatformDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_LeasesOfLesseDisclosureTextBlock" name="LeasesOfLesseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConvertibleNotesPayableDisclosureTextBlock" name="ConvertibleNotesPayableDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DividendPolicyTextBlock" name="DividendPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" name="ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AuthorizedSharesOfCapitalStock" name="AuthorizedSharesOfCapitalStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AuthorizedSharesOfCapitalCommonStock" name="AuthorizedSharesOfCapitalCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AuthorizedCommonStockIncreased" name="AuthorizedCommonStockIncreased" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CashAndCashEquivalents" name="CashAndCashEquivalents" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_NetWorkingCapital" name="NetWorkingCapital" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SeveranceAndOtherExpenses" name="SeveranceAndOtherExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConvertibleDebentures" name="ConvertibleDebentures" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ReservedSharesToPaySeriesCAndDDividends" name="ReservedSharesToPaySeriesCAndDDividends" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_PropertyPlantsAndEquipmentUsefulLife" name="PropertyPlantsAndEquipmentUsefulLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_Revenue" name="Revenue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AmountTotal" name="AmountTotal" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AssetsNetBookValue" name="AssetsNetBookValue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_TotalRemainingPayments" name="TotalRemainingPayments" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_RightOfUseAssets" name="RightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_TotalLeaseLiability" name="TotalLeaseLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_GrossProceedFromPublicIssueStock" name="GrossProceedFromPublicIssueStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConvertibleNotesConversions" name="ConvertibleNotesConversions" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DepositLiabilitiesAccruedInterestsAmount" name="DepositLiabilitiesAccruedInterestsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AmortizationOfDebtDiscountPremiums" name="AmortizationOfDebtDiscountPremiums" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ConvertibleRedeemablePromissoryNoteAmount" name="ConvertibleRedeemablePromissoryNoteAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_NumberOfWarrantShares" name="NumberOfWarrantShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DateOfIssue" name="DateOfIssue" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_OriginalExpirationDate" name="OriginalExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AmendedExpirationdate" name="AmendedExpirationdate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExercisePricePerShare" name="ExercisePricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExercisableAtEndOfPeriod" name="ExercisableAtEndOfPeriod" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_OutstandingAtBegenningOfPeriod" name="OutstandingAtBegenningOfPeriod" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_OutstandingAtEndOfPeriod" name="OutstandingAtEndOfPeriod" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WeightedAveragesRemainingLifeYears" name="WeightedAveragesRemainingLifeYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExpectedLifeMinimum" name="ExpectedLifeMinimum" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExpectedLifeMaximum" name="ExpectedLifeMaximum" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_OwnershipInterestInPreferredStock" name="OwnershipInterestInPreferredStock" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_NumberOfCommonStockSharesSettled" name="NumberOfCommonStockSharesSettled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DividendDistributedPerShare" name="DividendDistributedPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CumulativeDividendUnpaid" name="CumulativeDividendUnpaid" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DeemedDividendsCumulative" name="DeemedDividendsCumulative" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" name="AccretedValueOfPreferredDividendIntoCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ReceivedOfWarrant" name="ReceivedOfWarrant" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" name="SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DescriptionOfAutomaticConversionOfConvertible" name="DescriptionOfAutomaticConversionOfConvertible" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WarrantIssuedToCommonStock" name="WarrantIssuedToCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ReceivedSeriesDPreferredStockDividendsShares" name="ReceivedSeriesDPreferredStockDividendsShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WarrantsToPurchaseCommonStock" name="WarrantsToPurchaseCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShrareIssuedWarrantToPurchasedPrice" name="ShrareIssuedWarrantToPurchasedPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WarrantsToAcquireCommonStockShares" name="WarrantsToAcquireCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CommonStockSharePrice" name="CommonStockSharePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_PreferredStockConvertibleConversionPriceAdjusted" name="PreferredStockConvertibleConversionPriceAdjusted" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WarrantsExpiredPerSharePrice" name="WarrantsExpiredPerSharePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ProceedsFromIssuanceOfCommonStocks" name="ProceedsFromIssuanceOfCommonStocks" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_GrossSales" name="GrossSales" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WarrantsIssuedValued" name="WarrantsIssuedValued" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CommonStockSharesIssuedRelatedToWarrantExercises" name="CommonStockSharesIssuedRelatedToWarrantExercises" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IssuedAmountReceived" name="IssuedAmountReceived" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExerciseOfStockOption" name="ExerciseOfStockOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DesignatedSeriesCConvertiblePreferredStock" name="DesignatedSeriesCConvertiblePreferredStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DesignatedSeriesDConvertiblePreferredStocks" name="DesignatedSeriesDConvertiblePreferredStocks" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DesignatedSeriesDConvertiblePreferredStock" name="DesignatedSeriesDConvertiblePreferredStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ReverseStockSplit" name="ReverseStockSplit" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WeightedAverageRemainingLifeYears" name="WeightedAverageRemainingLifeYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_WeightedAverageExercisePriceOutstanding" name="WeightedAverageExercisePriceOutstanding" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_IntrinsicValue" name="IntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_StockOptionGrants" name="StockOptionGrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_NumberOfCommonStockSharesIncrease" name="NumberOfCommonStockSharesIncrease" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_StockIssuedDuringPeriodSharesStockOptionExercised" name="StockIssuedDuringPeriodSharesStockOptionExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ExerciseStockOptionGrantsreceived" name="ExerciseStockOptionGrantsreceived" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ShareGrant" name="ShareGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DescriptionRelatedToCommonStock" name="DescriptionRelatedToCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CumulativeExpenses" name="CumulativeExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AdditionalStockOption" name="AdditionalStockOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AdditionalExercisedPrice" name="AdditionalExercisedPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AccruedCompensastionTravelAndInterest" name="AccruedCompensastionTravelAndInterest" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_ReceivedSeriesDPreferredStockDividends" name="ReceivedSeriesDPreferredStockDividends" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AnnualSalary" name="AnnualSalary" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_LeaseDescription" name="LeaseDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_CommonStockPerShares" name="CommonStockPerShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" name="DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" name="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_FederalNetOperatingLossCarryforwardsExpired" name="FederalNetOperatingLossCarryforwardsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_EffectiveTaxRate" name="EffectiveTaxRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SegmentRevenues" name="SegmentRevenues" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SegmentNetIncomeLoss" name="SegmentNetIncomeLoss" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_SegmentAsset" name="SegmentAsset" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AdditionalSharePurchase" name="AdditionalSharePurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_StockOptionGrantsToEmployeesAndDirectors" name="StockOptionGrantsToEmployeesAndDirectors" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_StockOptionExpiryTerm" name="StockOptionExpiryTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="knwn_AiDeepLearningPlatformAbstract" name="AiDeepLearningPlatformAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="ThirtyFirstDecemberTwentyTwentyThreeMember" id="knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="Warrant1Member" id="knwn_Warrant1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOption1Member" id="knwn_StockOption1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" id="knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertiblePreferredStocksSeriesCMember" id="knwn_ConvertiblePreferredStocksSeriesCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertiblePreferredStockSeriesDMember" id="knwn_ConvertiblePreferredStockSeriesDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCConvertiblesPreferredStockMember" id="knwn_SeriesCConvertiblesPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesDConvertiblePreferredStockMember" id="knwn_SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CommonStocksMember" id="knwn_CommonStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantOneMember" id="knwn_WarrantOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MrStruveMember" id="knwn_MrStruveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantTwoMember" id="knwn_WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantThreeMember" id="knwn_WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantFourMember" id="knwn_WarrantFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsMember" id="knwn_StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesCAndDPreferredStockMember" id="knwn_SeriesCAndDPreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantsToPurchaseCommonStockMember" id="knwn_WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ThreeDirectorMember" id="knwn_ThreeDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CommonPreferredStocksMember" id="knwn_CommonPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AuthorizedCapitalStockMember" id="knwn_AuthorizedCapitalStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertiblePreferredStockSeriesCMember" id="knwn_ConvertiblePreferredStockSeriesCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockAtTwoMember" id="knwn_StockAtTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockAtOneMember" id="knwn_StockAtOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertiblePreferredStockDMember" id="knwn_ConvertiblePreferredStockDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CommonStocksOfferingsMember" id="knwn_CommonStocksOfferingsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="WarrantToPurchaseCommonStockMember" id="knwn_WarrantToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BousteadSecuritiesLLCMember" id="knwn_BousteadSecuritiesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNoteOneMember" id="knwn_ConvertibleNoteOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNoteTwoMember" id="knwn_ConvertibleNoteTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNotesFiveMember" id="knwn_ConvertibleNotesFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNote2Member" id="knwn_ConvertibleNote2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNote1Member" id="knwn_ConvertibleNote1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNote8Member" id="knwn_ConvertibleNote8Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleNote7Member" id="knwn_ConvertibleNote7Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOption2Member" id="knwn_StockOption2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOption3Member" id="knwn_StockOption3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsOneMember" id="knwn_StockOptionsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockOptionsTwoMember" id="knwn_StockOptionsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmployeeStockOptionsOneMember" id="knwn_EmployeeStockOptionsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoZeroTwoOneEquityIncentivePlanMember" id="knwn_TwoZeroTwoOneEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RonaldPEricksonMember" id="knwn_RonaldPEricksonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" id="knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ParticleIncTechnologyMember" id="knwn_ParticleIncTechnologyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PhillipABosuaMember" id="knwn_PhillipABosuaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PeterConleyMember" id="knwn_PeterConleyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EightEmployeesAndConsultantsMember" id="knwn_EightEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NineteenEmployeesAndConsultantsMember" id="knwn_NineteenEmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AIMindMember" id="knwn_AIMindMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DigitalassetsalesMember" id="knwn_DigitalassetsalesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MrBosuaMember" id="knwn_MrBosuaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>knwn-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/19/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Fin Stmt Error Correction Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_3d56d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_3d56d9" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_92bdea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_92bdea" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_f99c65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_f99c65" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_133109" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_133109" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl_b1d6f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl_b1d6f4" xml:lang="en-US">Series C PreferredStockMember</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl_ec2c3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl_ec2c3a" xml:lang="en-US">Series D Preferred Stock Member</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_40b7e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_40b7e7" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_1f0d53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_1f0d53" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_18b5b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_18b5b0" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_2a58d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_2a58d6" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_5" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_ae6e44" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_ae6e44" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl_ca7075" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl_ca7075" xml:lang="en-US">OTHER ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl_441b2a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl_441b2a" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_dd4693" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_dd4693" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_f4e157" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_f4e157" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_10" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_7db74e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_7db74e" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_98ed2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_98ed2f" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl_648b19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl_648b19" xml:lang="en-US">Accounts payable - trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_6b0dad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_6b0dad" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountDueToRelatedPartiesCurrent" xlink:label="knwn_AmountDueToRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AmountDueToRelatedPartiesCurrent" xlink:to="knwn_AmountDueToRelatedPartiesCurrent_lbl_96e37a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AmountDueToRelatedPartiesCurrent_lbl_96e37a" xml:lang="en-US">Accrued expenses - related parties</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl_f52c09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl_f52c09" xml:lang="en-US">Convertible notes payable, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_d04a10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_d04a10" xml:lang="en-US">Current portion of operating lease right-of-use liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_6f9657" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_6f9657" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_18" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl_e64ba3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl_e64ba3" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_77d5bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_77d5bd" xml:lang="en-US">Operating lease right-of-use liability, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl_cf8277" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl_cf8277" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl_21" xml:lang="en-US">[Liabilities, Noncurrent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl_d61c66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl_d61c66" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (Note 11)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_487b45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_487b45" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_5e1f8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_5e1f8a" xml:lang="en-US">Preferred stock, value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_a5e44b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_a5e44b" xml:lang="en-US">Common stock - $0.001 par value, 200,000,000 shares authorized, 80,358,463 and 48,156,062 shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_350ba8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_350ba8" xml:lang="en-US">Additional paid in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_c3490a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_c3490a" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_de4657" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_de4657" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_28" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c83080" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_c83080" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStocksSeriesCMember" xlink:label="knwn_ConvertiblePreferredStocksSeriesCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertiblePreferredStocksSeriesCMember" xlink:to="knwn_ConvertiblePreferredStocksSeriesCMember_lbl_7a9310" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertiblePreferredStocksSeriesCMember_lbl_7a9310" xml:lang="en-US">Convertible Preferred Stock Series C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesDMember" xlink:label="knwn_ConvertiblePreferredStockSeriesDMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertiblePreferredStockSeriesDMember" xlink:to="knwn_ConvertiblePreferredStockSeriesDMember_lbl_6b517b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertiblePreferredStockSeriesDMember_lbl_6b517b" xml:lang="en-US">Convertible Preferred Stock Series D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_e5fb60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_e5fb60" xml:lang="en-US">Preferred stock par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_2f01ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_2f01ad" xml:lang="en-US">Preferred stock shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_0cf3ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_0cf3ea" xml:lang="en-US">Common stock par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_773a9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_773a9b" xml:lang="en-US">Common stock shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_35957a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_35957a" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_d56be8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_d56be8" xml:lang="en-US">Common stock shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_61067a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_61067a" xml:lang="en-US">Preferred stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_3c3de3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_3c3de3" xml:lang="en-US">Preferred stock shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_97ed7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_97ed7f" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_76f3b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_76f3b4" xml:lang="en-US">REVENUE- DIGITAL ASSET SALES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_c220c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_c220c9" xml:lang="en-US">OPERATING EXPENSES-</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_0bda68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_0bda68" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_c41019" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_c41019" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl_f1758a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingExpense_lbl_f1758a" xml:lang="en-US">SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl_6" xml:lang="en-US">[Selling Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_cdb1d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_cdb1d0" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_7" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_a644ef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_a644ef" xml:lang="en-US">OPERATING LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_8" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_a11ddd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_a11ddd" xml:lang="en-US">OTHER INCOME (EXPENSE), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl_b33141" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl_b33141" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_0b0231" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_0b0231" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_11" xml:lang="en-US">[Interest Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_4b18d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl_4b18d6" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl_827ca8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl_827ca8" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_092674" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_092674" xml:lang="en-US">Total other (expense), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_14" xml:lang="en-US">[Other Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_b88b58" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_b88b58" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_15" xml:lang="en-US">[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl_dc2672" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl_dc2672" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_eb1a3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_eb1a3e" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_17" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl_ed4d85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsCommonStockStock_lbl_ed4d85" xml:lang="en-US">Common stock dividends on Series D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockStock" xlink:label="us-gaap_DividendsCommonStockStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockStock" xlink:to="us-gaap_DividendsCommonStockStock_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockStock_lbl_18" xml:lang="en-US">[Dividends, Common Stock, Stock]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl_901da5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl_901da5" xml:lang="en-US">Deemed dividends on Series C and D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl_19" xml:lang="en-US">[Dividends, Preferred Stock]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NetIncomeLossAvailableToCommonStockholders" xlink:to="knwn_NetIncomeLossAvailableToCommonStockholders_lbl_373e7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="knwn_NetIncomeLossAvailableToCommonStockholders_lbl_373e7b" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetIncomeLossAvailableToCommonStockholders" xlink:label="knwn_NetIncomeLossAvailableToCommonStockholders" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NetIncomeLossAvailableToCommonStockholders" xlink:to="knwn_NetIncomeLossAvailableToCommonStockholders_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NetIncomeLossAvailableToCommonStockholders_lbl_20" xml:lang="en-US">[NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EarningsPerSharesBasicAndDiluted" xlink:label="knwn_EarningsPerSharesBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EarningsPerSharesBasicAndDiluted" xlink:to="knwn_EarningsPerSharesBasicAndDiluted_lbl_e670cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_EarningsPerSharesBasicAndDiluted_lbl_e670cd" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl_0a1d94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl_0a1d94" xml:lang="en-US">Weighted average shares of common stock outstanding- basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6969da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_6969da" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_c2bf8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_c2bf8a" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCConvertiblesPreferredStockMember" xlink:label="knwn_SeriesCConvertiblesPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SeriesCConvertiblesPreferredStockMember" xlink:to="knwn_SeriesCConvertiblesPreferredStockMember_lbl_029ae8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SeriesCConvertiblesPreferredStockMember_lbl_029ae8" xml:lang="en-US">Series C Convertibles Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesDConvertiblePreferredStockMember" xlink:label="knwn_SeriesDConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SeriesDConvertiblePreferredStockMember" xlink:to="knwn_SeriesDConvertiblePreferredStockMember_lbl_b679e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SeriesDConvertiblePreferredStockMember_lbl_b679e7" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksMember" xlink:label="knwn_CommonStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStocksMember" xlink:to="knwn_CommonStocksMember_lbl_d3426e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStocksMember_lbl_d3426e" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_701ea6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_701ea6" xml:lang="en-US">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_381444" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_381444" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_656687" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_656687" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_189f1a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_189f1a" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockCompensationExpenseEmployeeOptions" xlink:label="knwn_StockCompensationExpenseEmployeeOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockCompensationExpenseEmployeeOptions" xlink:to="knwn_StockCompensationExpenseEmployeeOptions_lbl_42bb3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockCompensationExpenseEmployeeOptions_lbl_42bb3a" xml:lang="en-US">Stock compensation expense - employee options</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestShares" xlink:label="knwn_ConversionOfDebtOfferingAndAccruedInterestShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConversionOfDebtOfferingAndAccruedInterestShares" xlink:to="knwn_ConversionOfDebtOfferingAndAccruedInterestShares_lbl_aad705" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConversionOfDebtOfferingAndAccruedInterestShares_lbl_aad705" xml:lang="en-US">Conversion of debt offering and accrued interest (Note 7), shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" xlink:label="knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" xlink:to="knwn_ConversionOfDebtOfferingAndAccruedInterestAmount_lbl_7e1c88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConversionOfDebtOfferingAndAccruedInterestAmount_lbl_7e1c88" xml:lang="en-US">Conversion of debt offering and accrued interest (Note 7), amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:label="knwn_IssuanceOfCommonStockForStockOptionExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:to="knwn_IssuanceOfCommonStockForStockOptionExercisesShares_lbl_7e1ab2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceOfCommonStockForStockOptionExercisesShares_lbl_7e1ab2" xml:lang="en-US">Issuance of common stock for stock option exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" xlink:label="knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" xlink:to="knwn_IssuanceOfCommonStockForStockOptionExercisesAmount_lbl_cae4f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceOfCommonStockForStockOptionExercisesAmount_lbl_cae4f6" xml:lang="en-US">Issuance of common stock for stock option exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:to="knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares_lbl_8951bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares_lbl_8951bb" xml:lang="en-US">Issuance of common stock for exercise of warrants, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:to="knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount_lbl_8914f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount_lbl_8914f6" xml:lang="en-US">Issuance of common stock for exercise of warrants, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f9f057" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f9f057" xml:lang="en-US">Issuance of common stock for services, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_7461e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_7461e8" xml:lang="en-US">Issuance of common stock for services, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockWarrantForServices" xlink:label="knwn_IssuanceOfCommonStockWarrantForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceOfCommonStockWarrantForServices" xlink:to="knwn_IssuanceOfCommonStockWarrantForServices_lbl_e12a2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceOfCommonStockWarrantForServices_lbl_e12a2e" xml:lang="en-US">Issuance of common stock warrant for services</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingShares" xlink:label="knwn_IsssuanceOfCommonStockForNyseUplistingShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IsssuanceOfCommonStockForNyseUplistingShares" xlink:to="knwn_IsssuanceOfCommonStockForNyseUplistingShares_lbl_51059d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IsssuanceOfCommonStockForNyseUplistingShares_lbl_51059d" xml:lang="en-US">Isssuance of common stock for NYSE uplisting, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingAmount" xlink:label="knwn_IsssuanceOfCommonStockForNyseUplistingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IsssuanceOfCommonStockForNyseUplistingAmount" xlink:to="knwn_IsssuanceOfCommonStockForNyseUplistingAmount_lbl_60c0dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IsssuanceOfCommonStockForNyseUplistingAmount_lbl_60c0dc" xml:lang="en-US">Isssuance of common stock for NYSE uplisting, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_01491e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_01491e" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockShares" xlink:label="knwn_CommonStockDividendsOnSeriesDPreferredStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStockDividendsOnSeriesDPreferredStockShares" xlink:to="knwn_CommonStockDividendsOnSeriesDPreferredStockShares_lbl_9c93ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStockDividendsOnSeriesDPreferredStockShares_lbl_9c93ed" xml:lang="en-US">Common stock dividends on Series D Preferred Stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" xlink:label="knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" xlink:to="knwn_CommonStockDividendsOnSeriesDPreferredStockAmount_lbl_197188" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStockDividendsOnSeriesDPreferredStockAmount_lbl_197188" xml:lang="en-US">Common stock dividends on Series D Preferred Stock, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DeemedDividendsOnSeriesCAndDPreferredStock" xlink:to="knwn_DeemedDividendsOnSeriesCAndDPreferredStock_lbl_efd6ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_DeemedDividendsOnSeriesCAndDPreferredStock_lbl_efd6ed" xml:lang="en-US">Deemed dividends on Series C and D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsOnSeriesCAndDPreferredStock" xlink:label="knwn_DeemedDividendsOnSeriesCAndDPreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DeemedDividendsOnSeriesCAndDPreferredStock" xlink:to="knwn_DeemedDividendsOnSeriesCAndDPreferredStock_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DeemedDividendsOnSeriesCAndDPreferredStock_lbl_19" xml:lang="en-US">[Deemed dividends on Series C and D Preferred Stock]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" xlink:label="knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" xlink:to="knwn_IsssuanceOfCommonStockForCommonStockOfferingShares_lbl_aa0372" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IsssuanceOfCommonStockForCommonStockOfferingShares_lbl_aa0372" xml:lang="en-US">Isssuance of common stock for common stock offering, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" xlink:label="knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" xlink:to="knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount_lbl_495b31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount_lbl_495b31" xml:lang="en-US">Isssuance of common stock for common stock offering, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpensesForExtensionOfNotesAndWarrants" xlink:label="knwn_ExpensesForExtensionOfNotesAndWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExpensesForExtensionOfNotesAndWarrants" xlink:to="knwn_ExpensesForExtensionOfNotesAndWarrants_lbl_9546fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExpensesForExtensionOfNotesAndWarrants_lbl_9546fe" xml:lang="en-US">Expenses for extension of notes and warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_e6c799" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_e6c799" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_0fb120" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_0fb120" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_b41daf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_b41daf" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_aa0aca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_aa0aca" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_5625f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_5625f5" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_0fa145" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_0fa145" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl_b839a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl_b839a9" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_857937" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_857937" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_d81e1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_d81e1f" xml:lang="en-US">Issuance of common stock warrants for services</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnDebtSettlement" xlink:label="knwn_GainLossOnDebtSettlement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_GainLossOnDebtSettlement" xlink:to="knwn_GainLossOnDebtSettlement_lbl_78ad86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_GainLossOnDebtSettlement_lbl_78ad86" xml:lang="en-US">Gain on debt settlement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl_cdeca7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl_cdeca7" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl_e6eddc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl_e6eddc" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl_10" xml:lang="en-US">[Extinguishment of Debt, Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseForeignDeposits" xlink:label="us-gaap_InterestExpenseForeignDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseForeignDeposits" xlink:to="us-gaap_InterestExpenseForeignDeposits_lbl_f4e7de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseForeignDeposits_lbl_f4e7de" xml:lang="en-US">Modification of notes and warrants - interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl_69dbc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl_69dbc4" xml:lang="en-US">Stock based compensation- stock option grants</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnForgivenessOfNotesPayablePppLoans" xlink:label="knwn_GainLossOnForgivenessOfNotesPayablePppLoans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_GainLossOnForgivenessOfNotesPayablePppLoans" xlink:to="knwn_GainLossOnForgivenessOfNotesPayablePppLoans_lbl_01e532" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_GainLossOnForgivenessOfNotesPayablePppLoans_lbl_01e532" xml:lang="en-US">Gain on forgiveness of notes payable-PPP Loans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_3cadc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_3cadc6" xml:lang="en-US">Amortization of operating lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl_df63dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl_df63dd" xml:lang="en-US">Amortization of debt discount to interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_d240b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_d240b2" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl_b1ede1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl_b1ede1" xml:lang="en-US">Other long-term assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_4df4ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_4df4ad" xml:lang="en-US">Operating lease right-of-use liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_ad8e07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl_ad8e07" xml:lang="en-US">Accounts payable - trade and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_16e291" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_16e291" xml:lang="en-US">NET CASH (USED IN) OPERATING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_20" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_e00bf4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_e00bf4" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_268243" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_268243" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_22" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_e197e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_e197e0" xml:lang="en-US">NET CASH (USED IN) INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_23" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_28d325" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_28d325" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_50c88a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_50c88a" xml:lang="en-US">Proceeds from isssuance of common stock for NYSE uplisting</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" xlink:label="knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" xlink:to="knwn_ProceedsFromIssuanceOfCommonStockOfferingNet_lbl_e10dfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ProceedsFromIssuanceOfCommonStockOfferingNet_lbl_e10dfd" xml:lang="en-US">Proceeds from issuance of common stock offering, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl_fa8619" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl_fa8619" xml:lang="en-US">Payments for stock for NYSE uplisting</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl_27" xml:lang="en-US">[Payments for Repurchase of Common Stock]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_146bc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_146bc9" xml:lang="en-US">Settlement of notes payable-PPP loans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl_28" xml:lang="en-US">[Repayments of Notes Payable]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_f8741c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_f8741c" xml:lang="en-US">Proceeds from issuance of common stock for stock options exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_602250" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_602250" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercise</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_65325e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_65325e" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_31" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_0832e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_0832e7" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_32" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1c4268" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1c4268" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_33" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6e1862" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_6e1862" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_d97b77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_d97b77" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_6fa26e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_6fa26e" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl_ea595a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl_ea595a" xml:lang="en-US">Taxes paid</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" xlink:label="knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" xlink:to="knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract_lbl_ad6ca7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract_lbl_ad6ca7" xml:lang="en-US">Supplemental disclosure of non-cash financing activity:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl_cc41d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl_cc41d8" xml:lang="en-US">Conversion of debt</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfAccruedInterest" xlink:label="knwn_ConversionOfAccruedInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConversionOfAccruedInterest" xlink:to="knwn_ConversionOfAccruedInterest_lbl_16c03c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConversionOfAccruedInterest_lbl_16c03c" xml:lang="en-US">Conversion of accrued interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl_119190" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsCommonStock_lbl_119190" xml:lang="en-US">Common stock dividends on Series D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl_41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStock_lbl_41" xml:lang="en-US">[Dividends, Common Stock]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl_4205f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl_4205f2" xml:lang="en-US">Deemed dividends on Series C and D Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl_42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl_42" xml:lang="en-US">[Dividends, Preferred Stock, Stock]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceCostsFromCommonStockOffering" xlink:label="knwn_IssuanceCostsFromCommonStockOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuanceCostsFromCommonStockOffering" xlink:to="knwn_IssuanceCostsFromCommonStockOffering_lbl_9a6e82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuanceCostsFromCommonStockOffering_lbl_9a6e82" xml:lang="en-US">Issuance costs from common stock offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_734a52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_734a52" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_8da997" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_8da997" xml:lang="en-US">ORGANISATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl_6bdf39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl_6bdf39" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_500eb9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_500eb9" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl_2" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_7a76d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_7a76d6" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_624818" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_624818" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AiDeepLearningPlatformAbstract" xlink:label="knwn_AiDeepLearningPlatformAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AiDeepLearningPlatformAbstract" xlink:to="knwn_AiDeepLearningPlatformAbstract_lbl_71a593" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AiDeepLearningPlatformAbstract_lbl_71a593" xml:lang="en-US">AI DEEP LEARNING PLATFORM</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AiDeepLearningPlatformDisclosureTextBlock" xlink:to="knwn_AiDeepLearningPlatformDisclosureTextBlock_lbl_3a7681" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_AiDeepLearningPlatformDisclosureTextBlock_lbl_3a7681" xml:lang="en-US">AI DEEP LEARNING PLATFORM</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AiDeepLearningPlatformDisclosureTextBlock" xlink:label="knwn_AiDeepLearningPlatformDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AiDeepLearningPlatformDisclosureTextBlock" xlink:to="knwn_AiDeepLearningPlatformDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AiDeepLearningPlatformDisclosureTextBlock_lbl_2" xml:lang="en-US">[AI DEEP LEARNING PLATFORM]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_bd01a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_bd01a5" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_ce1e14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_ce1e14" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl_a2d7db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl_a2d7db" xml:lang="en-US">LEASES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_LeasesOfLesseDisclosureTextBlock" xlink:to="knwn_LeasesOfLesseDisclosureTextBlock_lbl_bee9b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_LeasesOfLesseDisclosureTextBlock_lbl_bee9b1" xml:lang="en-US">LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_LeasesOfLesseDisclosureTextBlock" xlink:label="knwn_LeasesOfLesseDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_LeasesOfLesseDisclosureTextBlock" xlink:to="knwn_LeasesOfLesseDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_LeasesOfLesseDisclosureTextBlock_lbl_2" xml:lang="en-US">[LEASES]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl_6f5627" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl_6f5627" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="knwn_ConvertibleNotesPayableDisclosureTextBlock_lbl_02b5d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_ConvertibleNotesPayableDisclosureTextBlock_lbl_02b5d8" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="knwn_ConvertibleNotesPayableDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="knwn_ConvertibleNotesPayableDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNotesPayableDisclosureTextBlock_lbl_2" xml:lang="en-US">[CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_55adc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_55adc6" xml:lang="en-US">EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_f494e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_f494e3" xml:lang="en-US">EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_b7df9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_b7df9b" xml:lang="en-US">STOCK INCENTIVE PLANS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_c3edde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_c3edde" xml:lang="en-US">STOCK INCENTIVE PLANS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_e75197" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_e75197" xml:lang="en-US">OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_53ae3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_53ae3e" xml:lang="en-US">OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0199f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0199f6" xml:lang="en-US">COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_559a42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_559a42" xml:lang="en-US">COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl_63fade" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl_63fade" xml:lang="en-US">INCOME TAXES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_5363b7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_5363b7" xml:lang="en-US">INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl_fd65d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl_fd65d6" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_c0860d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_c0860d" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_2" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_fea43a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_fea43a" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_e5a18a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_e5a18a" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_399a9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_399a9a" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_719ac1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_719ac1" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_fceeb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_fceeb8" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_1ca595" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_1ca595" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_080b11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_080b11" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionLeases" xlink:label="us-gaap_RevenueRecognitionLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionLeases" xlink:to="us-gaap_RevenueRecognitionLeases_lbl_f8a29a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionLeases_lbl_f8a29a" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_419fac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_419fac" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl_1c8ef1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl_1c8ef1" xml:lang="en-US">Advertising</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_6b6be6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_6b6be6" xml:lang="en-US">Fair Value Measurements and Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness_lbl_d47d72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness_lbl_d47d72" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_c700c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_c700c2" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl_a3a526" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl_a3a526" xml:lang="en-US">Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_479082" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_479082" xml:lang="en-US">Net Loss per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_132e06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl_132e06" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DividendPolicyTextBlock" xlink:label="knwn_DividendPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DividendPolicyTextBlock" xlink:to="knwn_DividendPolicyTextBlock_lbl_c9c347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DividendPolicyTextBlock_lbl_c9c347" xml:lang="en-US">Dividend Policy</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_ee0d83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_ee0d83" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_e188a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_e188a7" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_df3f35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_df3f35" xml:lang="en-US">Schedule of Property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_374559" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_374559" xml:lang="en-US">Summary of minimum future lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl_4f1d64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl_4f1d64" xml:lang="en-US">Schedule of convertible notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:label="knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:to="knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_lbl_28be00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_lbl_28be00" xml:lang="en-US">Schedule of Warrant activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_f15ffb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_f15ffb" xml:lang="en-US">Schedule of Warrants outstanding and exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl_486145" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl_486145" xml:lang="en-US">Schedule of weighted average assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_86cdba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_86cdba" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl_1b52c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl_1b52c8" xml:lang="en-US">Schedule of Stock options outstanding and exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_790e04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_790e04" xml:lang="en-US">Schedule of Schedule of deferred tax</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_1678ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_1678ec" xml:lang="en-US">Schedule of Schedule of Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_5674b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl_5674b8" xml:lang="en-US">Schedule of Segment reporting</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedSharesOfCapitalStock" xlink:label="knwn_AuthorizedSharesOfCapitalStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AuthorizedSharesOfCapitalStock" xlink:to="knwn_AuthorizedSharesOfCapitalStock_lbl_728e2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AuthorizedSharesOfCapitalStock_lbl_728e2e" xml:lang="en-US">Authorized shares of capital stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedSharesOfCapitalCommonStock" xlink:label="knwn_AuthorizedSharesOfCapitalCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AuthorizedSharesOfCapitalCommonStock" xlink:to="knwn_AuthorizedSharesOfCapitalCommonStock_lbl_9a679c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AuthorizedSharesOfCapitalCommonStock_lbl_9a679c" xml:lang="en-US">Authorized shares of capital common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_a9e5c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_a9e5c4" xml:lang="en-US">Authorized shares of capital stock par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_5444d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_5444d2" xml:lang="en-US">Preferred stock shares authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_ae21e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_ae21e3" xml:lang="en-US">Preferred stock share par value</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedCommonStockIncreased" xlink:label="knwn_AuthorizedCommonStockIncreased" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AuthorizedCommonStockIncreased" xlink:to="knwn_AuthorizedCommonStockIncreased_lbl_374492" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AuthorizedCommonStockIncreased_lbl_374492" xml:lang="en-US">Authorized common stock increased</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CashAndCashEquivalents" xlink:to="knwn_CashAndCashEquivalents_lbl_83451c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_CashAndCashEquivalents_lbl_83451c" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CashAndCashEquivalents" xlink:label="knwn_CashAndCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CashAndCashEquivalents" xlink:to="knwn_CashAndCashEquivalents_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CashAndCashEquivalents_lbl_2" xml:lang="en-US">[Cash and cash equivalents]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetWorkingCapital" xlink:label="knwn_NetWorkingCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NetWorkingCapital" xlink:to="knwn_NetWorkingCapital_lbl_4d5588" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NetWorkingCapital_lbl_4d5588" xml:lang="en-US">Net working capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_1c1b31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_1c1b31" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_9770e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_9770e3" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_9d7dee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_9d7dee" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_80e4f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl_80e4f3" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl_99f457" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl_99f457" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Warrant1Member" xlink:label="knwn_Warrant1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_Warrant1Member" xlink:to="knwn_Warrant1Member_lbl_a27358" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_Warrant1Member_lbl_a27358" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption1Member" xlink:label="knwn_StockOption1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOption1Member" xlink:to="knwn_StockOption1Member_lbl_1e5200" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOption1Member_lbl_1e5200" xml:lang="en-US">Stock Option 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_d21800" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_d21800" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_61e1cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_61e1cb" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl_3809a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl_3809a8" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:label="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:to="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_lbl_9352ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit_lbl_9352ee" xml:lang="en-US">FDIC insurance</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeveranceAndOtherExpenses" xlink:label="knwn_SeveranceAndOtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SeveranceAndOtherExpenses" xlink:to="knwn_SeveranceAndOtherExpenses_lbl_0fe400" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SeveranceAndOtherExpenses_lbl_0fe400" xml:lang="en-US">Severance and other expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleDebentures" xlink:label="knwn_ConvertibleDebentures" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleDebentures" xlink:to="knwn_ConvertibleDebentures_lbl_37789e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleDebentures_lbl_37789e" xml:lang="en-US">Convertible debentures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_bc0a76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_bc0a76" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl_e78d38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl_e78d38" xml:lang="en-US">Advertising and marketing costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl_57b36d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl_57b36d" xml:lang="en-US">Money market accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_38bf51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_38bf51" xml:lang="en-US">Common stock shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl_e66366" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl_e66366" xml:lang="en-US">Common stock shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl_9" xml:lang="en-US">[Common Stock, Other Shares, Outstanding]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReservedSharesToPaySeriesCAndDDividends" xlink:label="knwn_ReservedSharesToPaySeriesCAndDDividends" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ReservedSharesToPaySeriesCAndDDividends" xlink:to="knwn_ReservedSharesToPaySeriesCAndDDividends_lbl_02f424" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ReservedSharesToPaySeriesCAndDDividends_lbl_02f424" xml:lang="en-US">Reserved shares to pay series C and D dividends</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl_285a52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl_285a52" xml:lang="en-US">Issuable upon conversion of convertible debentures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_479f55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_479f55" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_ad6913" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl_ad6913" xml:lang="en-US">Unearned stock option grants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl_2cb602" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl_2cb602" xml:lang="en-US">Common shares current price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PropertyPlantsAndEquipmentUsefulLife" xlink:label="knwn_PropertyPlantsAndEquipmentUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_PropertyPlantsAndEquipmentUsefulLife" xlink:to="knwn_PropertyPlantsAndEquipmentUsefulLife_lbl_08dbe4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_PropertyPlantsAndEquipmentUsefulLife_lbl_08dbe4" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl_0fbe82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl_0fbe82" xml:lang="en-US">Technology Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Revenue" xlink:label="knwn_Revenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_Revenue" xlink:to="knwn_Revenue_lbl_d08862" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_Revenue_lbl_d08862" xml:lang="en-US">Revenue Digital Asset Sales</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountTotal" xlink:label="knwn_AmountTotal" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AmountTotal" xlink:to="knwn_AmountTotal_lbl_4937fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AmountTotal_lbl_4937fa" xml:lang="en-US">Amount total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl_8d5143" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingExpense_lbl_8d5143" xml:lang="en-US">Selling and Transactional Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_586d8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_586d8d" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl_b95f50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl_b95f50" xml:lang="en-US">Machinery and equipment (2-3 years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl_037ddd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl_037ddd" xml:lang="en-US">Leasehold improvements (5 years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl_394ec4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl_394ec4" xml:lang="en-US">Furniture and fixtures (3 years)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6f7855" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6f7855" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_5" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_2a24b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_2a24b9" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_e05253" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_e05253" xml:lang="en-US">Income Statement Location Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" xlink:label="knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" xlink:to="knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember_lbl_46a375" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember_lbl_46a375" xml:lang="en-US">Research And Development And Sellings General And Administrative [Mmber]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AssetsNetBookValue" xlink:label="knwn_AssetsNetBookValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AssetsNetBookValue" xlink:to="knwn_AssetsNetBookValue_lbl_a0c373" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AssetsNetBookValue_lbl_a0c373" xml:lang="en-US">Net book value of assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_ff2c5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_ff2c5d" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TotalRemainingPayments" xlink:label="knwn_TotalRemainingPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_TotalRemainingPayments" xlink:to="knwn_TotalRemainingPayments_lbl_99bf45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_TotalRemainingPayments_lbl_99bf45" xml:lang="en-US">Total Remaining Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_e9eebe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_e9eebe" xml:lang="en-US">Less imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_218051" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_218051" xml:lang="en-US">Total lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl_ed910d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl_ed910d" xml:lang="en-US">Lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RightOfUseAssets" xlink:label="knwn_RightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_RightOfUseAssets" xlink:to="knwn_RightOfUseAssets_lbl_0041e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_RightOfUseAssets_lbl_0041e8" xml:lang="en-US">Right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_TotalLeaseLiability" xlink:to="knwn_TotalLeaseLiability_lbl_4d932d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_TotalLeaseLiability_lbl_4d932d" xml:lang="en-US">Total lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TotalLeaseLiability" xlink:label="knwn_TotalLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_TotalLeaseLiability" xlink:to="knwn_TotalLeaseLiability_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_TotalLeaseLiability_lbl_4" xml:lang="en-US">[Total lease liability]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_52be97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_52be97" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_dbabca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_dbabca" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" xlink:label="knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" xlink:to="knwn_ThirtyFirstDecemberTwentyTwentyThreeMember_lbl_d16eaf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ThirtyFirstDecemberTwentyTwentyThreeMember_lbl_d16eaf" xml:lang="en-US">31 December,2023 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CashAndCashEquivalents" xlink:to="knwn_CashAndCashEquivalents_lbl_354570" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="knwn_CashAndCashEquivalents_lbl_354570" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NetWorkingCapital" xlink:to="knwn_NetWorkingCapital_lbl_04bbed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_NetWorkingCapital_lbl_04bbed" xml:lang="en-US">Net working capital</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossProceedFromPublicIssueStock" xlink:label="knwn_GrossProceedFromPublicIssueStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_GrossProceedFromPublicIssueStock" xlink:to="knwn_GrossProceedFromPublicIssueStock_lbl_1c0152" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_GrossProceedFromPublicIssueStock_lbl_1c0152" xml:lang="en-US">Gross proceed from public issue stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl_b98960" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl_b98960" xml:lang="en-US">Debt Instrument Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteOneMember" xlink:label="knwn_ConvertibleNoteOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNoteOneMember" xlink:to="knwn_ConvertibleNoteOneMember_lbl_f2ec01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNoteOneMember_lbl_f2ec01" xml:lang="en-US">Convertibles Note - Clayton A. Struve</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteTwoMember" xlink:label="knwn_ConvertibleNoteTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNoteTwoMember" xlink:to="knwn_ConvertibleNoteTwoMember_lbl_2eebce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNoteTwoMember_lbl_2eebce" xml:lang="en-US">Convertibles Note - Ronald P. Erickson and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesFiveMember" xlink:label="knwn_ConvertibleNotesFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNotesFiveMember" xlink:to="knwn_ConvertibleNotesFiveMember_lbl_67e540" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNotesFiveMember_lbl_67e540" xml:lang="en-US">2021 Convertibles notes</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesConversions" xlink:label="knwn_ConvertibleNotesConversions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNotesConversions" xlink:to="knwn_ConvertibleNotesConversions_lbl_c69567" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNotesConversions_lbl_c69567" xml:lang="en-US">less conversions of notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl_98246b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl_98246b" xml:lang="en-US">Convertible notes, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl_5f6e43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl_5f6e43" xml:lang="en-US">Convertible notes, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote2Member" xlink:label="knwn_ConvertibleNote2Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNote2Member" xlink:to="knwn_ConvertibleNote2Member_lbl_91232b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNote2Member_lbl_91232b" xml:lang="en-US">Convertible Note - Ronald P. Erickson and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote1Member" xlink:label="knwn_ConvertibleNote1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNote1Member" xlink:to="knwn_ConvertibleNote1Member_lbl_74bdea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNote1Member_lbl_74bdea" xml:lang="en-US">Convertible Note - Clayton A. Struve</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote8Member" xlink:label="knwn_ConvertibleNote8Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNote8Member" xlink:to="knwn_ConvertibleNote8Member_lbl_5fb6f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNote8Member_lbl_5fb6f9" xml:lang="en-US">Convertible Note - J3E2A2Z Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote7Member" xlink:label="knwn_ConvertibleNote7Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleNote7Member" xlink:to="knwn_ConvertibleNote7Member_lbl_c50cd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleNote7Member_lbl_c50cd6" xml:lang="en-US">Convertible Note - J3E2A2Z Account Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentExpense" xlink:label="us-gaap_EquipmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentExpense" xlink:to="us-gaap_EquipmentExpense_lbl_30ffb7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentExpense_lbl_30ffb7" xml:lang="en-US">Expensed</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl_1e429e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl_1e429e" xml:lang="en-US">Warrant to purchase common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DepositLiabilitiesAccruedInterestsAmount" xlink:label="knwn_DepositLiabilitiesAccruedInterestsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DepositLiabilitiesAccruedInterestsAmount" xlink:to="knwn_DepositLiabilitiesAccruedInterestsAmount_lbl_24c05a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DepositLiabilitiesAccruedInterestsAmount_lbl_24c05a" xml:lang="en-US">Accrued interest amount</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmortizationOfDebtDiscountPremiums" xlink:label="knwn_AmortizationOfDebtDiscountPremiums" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AmortizationOfDebtDiscountPremiums" xlink:to="knwn_AmortizationOfDebtDiscountPremiums_lbl_afa11a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AmortizationOfDebtDiscountPremiums_lbl_afa11a" xml:lang="en-US">Amortization related to the debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl_01158f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl_01158f" xml:lang="en-US">Accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d7b680" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d7b680" xml:lang="en-US">Exercise price of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl_8380b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl_8380b9" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl_9e8979" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl_9e8979" xml:lang="en-US">Convertible promissory or OID notes</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleRedeemablePromissoryNoteAmount" xlink:label="knwn_ConvertibleRedeemablePromissoryNoteAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertibleRedeemablePromissoryNoteAmount" xlink:to="knwn_ConvertibleRedeemablePromissoryNoteAmount_lbl_a0ac9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertibleRedeemablePromissoryNoteAmount_lbl_a0ac9e" xml:lang="en-US">Convertible redeemable promissory note amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl_48dc37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl_48dc37" xml:lang="en-US">Convertible redeemable promissory note principal amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl_62e049" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl_62e049" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="knwn_WarrantOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantOneMember" xlink:to="knwn_WarrantOneMember_lbl_968880" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantOneMember_lbl_968880" xml:lang="en-US">Warrant One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="knwn_WarrantTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantTwoMember" xlink:to="knwn_WarrantTwoMember_lbl_d9f5d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantTwoMember_lbl_d9f5d4" xml:lang="en-US">Warrant Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="knwn_WarrantThreeMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantThreeMember" xlink:to="knwn_WarrantThreeMember_lbl_b5f3f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantThreeMember_lbl_b5f3f5" xml:lang="en-US">Warrant Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="knwn_WarrantFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantFourMember" xlink:to="knwn_WarrantFourMember_lbl_cd4916" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantFourMember_lbl_cd4916" xml:lang="en-US">Warrant Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfWarrantShares" xlink:label="knwn_NumberOfWarrantShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NumberOfWarrantShares" xlink:to="knwn_NumberOfWarrantShares_lbl_42506f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NumberOfWarrantShares_lbl_42506f" xml:lang="en-US">Number of warrant shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DateOfIssue" xlink:label="knwn_DateOfIssue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DateOfIssue" xlink:to="knwn_DateOfIssue_lbl_115330" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DateOfIssue_lbl_115330" xml:lang="en-US">Issue date</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OriginalExpirationDate" xlink:label="knwn_OriginalExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OriginalExpirationDate" xlink:to="knwn_OriginalExpirationDate_lbl_45ed12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_OriginalExpirationDate_lbl_45ed12" xml:lang="en-US">Original Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmendedExpirationdate" xlink:label="knwn_AmendedExpirationdate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AmendedExpirationdate" xlink:to="knwn_AmendedExpirationdate_lbl_7b54bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AmendedExpirationdate_lbl_7b54bd" xml:lang="en-US">Amended Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="knwn_ExercisePricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExercisePricePerShare" xlink:to="knwn_ExercisePricePerShare_lbl_18df68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExercisePricePerShare_lbl_18df68" xml:lang="en-US">Exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NumberOfWarrantShares" xlink:to="knwn_NumberOfWarrantShares_lbl_4e0f94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_NumberOfWarrantShares_lbl_4e0f94" xml:lang="en-US">Number of warrant shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DateOfIssue" xlink:to="knwn_DateOfIssue_lbl_6ac81e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_DateOfIssue_lbl_6ac81e" xml:lang="en-US">Issue date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OriginalExpirationDate" xlink:to="knwn_OriginalExpirationDate_lbl_2cfa2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_OriginalExpirationDate_lbl_2cfa2c" xml:lang="en-US">Original Expiration Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AmendedExpirationdate" xlink:to="knwn_AmendedExpirationdate_lbl_d2eeca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_AmendedExpirationdate_lbl_d2eeca" xml:lang="en-US">Amended Expiration Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExercisePricePerShare" xlink:to="knwn_ExercisePricePerShare_lbl_b9d977" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_ExercisePricePerShare_lbl_b9d977" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_lbl_ef89cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_lbl_ef89cf" xml:lang="en-US">Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl_3b617b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl_3b617b" xml:lang="en-US">Share Outstanding at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_lbl_3" xml:lang="en-US">[Share Outstanding at beginning of period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9b2259" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9b2259" xml:lang="en-US">Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_9802c6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_9802c6" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_0147af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_0147af" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5dafac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5dafac" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_7" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe_lbl_438791" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe_lbl_438791" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExercisableAtEndOfPeriod" xlink:to="knwn_ExercisableAtEndOfPeriod_lbl_9a903a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="knwn_ExercisableAtEndOfPeriod_lbl_9a903a" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisableAtEndOfPeriod" xlink:label="knwn_ExercisableAtEndOfPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExercisableAtEndOfPeriod" xlink:to="knwn_ExercisableAtEndOfPeriod_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExercisableAtEndOfPeriod_lbl_9" xml:lang="en-US">[Exercisable at end of period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl_7919c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_lbl_7919c4" xml:lang="en-US">Weighted Average Exercise Price:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OutstandingAtBegenningOfPeriod" xlink:to="knwn_OutstandingAtBegenningOfPeriod_lbl_75d295" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="knwn_OutstandingAtBegenningOfPeriod_lbl_75d295" xml:lang="en-US">Outstanding at begin of period</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OutstandingAtBegenningOfPeriod" xlink:label="knwn_OutstandingAtBegenningOfPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OutstandingAtBegenningOfPeriod" xlink:to="knwn_OutstandingAtBegenningOfPeriod_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_OutstandingAtBegenningOfPeriod_lbl_11" xml:lang="en-US">[Outstanding at begin of period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_101e49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_101e49" xml:lang="en-US">Weighted Average Exercise Price Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_5d4d31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_5d4d31" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_13" xml:lang="en-US">[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" xlink:to="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_lbl_9f9347" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_lbl_9f9347" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" xlink:label="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" xlink:to="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_lbl_14" xml:lang="en-US">[Weighted Average Exercise Price Forfeited]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_1880a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_1880a7" xml:lang="en-US">Weighted Average Exercise PriceExpired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_15" xml:lang="en-US">[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OutstandingAtEndOfPeriod" xlink:to="knwn_OutstandingAtEndOfPeriod_lbl_cfc6d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="knwn_OutstandingAtEndOfPeriod_lbl_cfc6d8" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OutstandingAtEndOfPeriod" xlink:label="knwn_OutstandingAtEndOfPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OutstandingAtEndOfPeriod" xlink:to="knwn_OutstandingAtEndOfPeriod_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_OutstandingAtEndOfPeriod_lbl_16" xml:lang="en-US">[Outstanding at end of period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_272eae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl_272eae" xml:lang="en-US">Minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_c679d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MaximumMember_lbl_c679d8" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_3c8838" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_3c8838" xml:lang="en-US">Number of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAveragesRemainingLifeYears" xlink:label="knwn_WeightedAveragesRemainingLifeYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WeightedAveragesRemainingLifeYears" xlink:to="knwn_WeightedAveragesRemainingLifeYears_lbl_f0e783" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WeightedAveragesRemainingLifeYears_lbl_f0e783" xml:lang="en-US">Weighted average remaining life (years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl_731aa5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl_731aa5" xml:lang="en-US">Weighted average exercise price, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl_368ea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl_368ea3" xml:lang="en-US">Shares exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_694efb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_694efb" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_FederalFundsSoldAverageYield" xlink:label="srt_FederalFundsSoldAverageYield" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_FederalFundsSoldAverageYield" xlink:to="srt_FederalFundsSoldAverageYield_lbl_f5961d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_FederalFundsSoldAverageYield_lbl_f5961d" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpectedLifeMinimum" xlink:label="knwn_ExpectedLifeMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExpectedLifeMinimum" xlink:to="knwn_ExpectedLifeMinimum_lbl_630dc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExpectedLifeMinimum_lbl_630dc9" xml:lang="en-US">Expected life minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpectedLifeMaximum" xlink:label="knwn_ExpectedLifeMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExpectedLifeMaximum" xlink:to="knwn_ExpectedLifeMaximum_lbl_df0fe5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExpectedLifeMaximum_lbl_df0fe5" xml:lang="en-US">Expected life Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_cba9a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_cba9a1" xml:lang="en-US">Expected volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl_920e19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl_920e19" xml:lang="en-US">Risk free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_e878e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_e878e7" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_0228dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_0228dd" xml:lang="en-US">Award Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_ffc5b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_ffc5b9" xml:lang="en-US">Title Of Individual Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_4596f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_4596f1" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrStruveMember" xlink:label="knwn_MrStruveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_MrStruveMember" xlink:to="knwn_MrStruveMember_lbl_221c9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_MrStruveMember_lbl_221c9c" xml:lang="en-US">Mr. Struve [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl_8d2e2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl_8d2e2b" xml:lang="en-US">Series C PreferredStockMember</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl_f551ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl_f551ea" xml:lang="en-US">Series D Preferred Stock Member</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCAndDPreferredStockMember" xlink:label="knwn_SeriesCAndDPreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SeriesCAndDPreferredStockMember" xlink:to="knwn_SeriesCAndDPreferredStockMember_lbl_10c643" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SeriesCAndDPreferredStockMember_lbl_10c643" xml:lang="en-US">Series C and D Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStockMember" xlink:label="knwn_WarrantsToPurchaseCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsToPurchaseCommonStockMember" xlink:to="knwn_WarrantsToPurchaseCommonStockMember_lbl_0f0631" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantsToPurchaseCommonStockMember_lbl_0f0631" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThreeDirectorMember" xlink:label="knwn_ThreeDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ThreeDirectorMember" xlink:to="knwn_ThreeDirectorMember_lbl_e0d8fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ThreeDirectorMember_lbl_e0d8fe" xml:lang="en-US">Three Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonPreferredStocksMember" xlink:label="knwn_CommonPreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonPreferredStocksMember" xlink:to="knwn_CommonPreferredStocksMember_lbl_c60963" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonPreferredStocksMember_lbl_c60963" xml:lang="en-US">Common Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedCapitalStockMember" xlink:label="knwn_AuthorizedCapitalStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AuthorizedCapitalStockMember" xlink:to="knwn_AuthorizedCapitalStockMember_lbl_780477" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AuthorizedCapitalStockMember_lbl_780477" xml:lang="en-US">Authorized Capital Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertiblePreferredStockSeriesCMember" xlink:to="knwn_ConvertiblePreferredStockSeriesCMember_lbl_49e22f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_ConvertiblePreferredStockSeriesCMember_lbl_49e22f" xml:lang="en-US">Convertible Preferred Stock Series C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesCMember" xlink:label="knwn_ConvertiblePreferredStockSeriesCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertiblePreferredStockSeriesCMember" xlink:to="knwn_ConvertiblePreferredStockSeriesCMember_lbl_110" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertiblePreferredStockSeriesCMember_lbl_110" xml:lang="en-US">[Convertible Preferred Stock Series C [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtTwoMember" xlink:label="knwn_StockAtTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockAtTwoMember" xlink:to="knwn_StockAtTwoMember_lbl_3192d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockAtTwoMember_lbl_3192d4" xml:lang="en-US">Stock at 2.00</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtOneMember" xlink:label="knwn_StockAtOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockAtOneMember" xlink:to="knwn_StockAtOneMember_lbl_d7bc82" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockAtOneMember_lbl_d7bc82" xml:lang="en-US">Stock at 0.25</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockDMember" xlink:label="knwn_ConvertiblePreferredStockDMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ConvertiblePreferredStockDMember" xlink:to="knwn_ConvertiblePreferredStockDMember_lbl_493efc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ConvertiblePreferredStockDMember_lbl_493efc" xml:lang="en-US">Convertible Preferred Stock D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl_461eec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl_461eec" xml:lang="en-US">Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksOfferingsMember" xlink:label="knwn_CommonStocksOfferingsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStocksOfferingsMember" xlink:to="knwn_CommonStocksOfferingsMember_lbl_6d0703" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStocksOfferingsMember_lbl_6d0703" xml:lang="en-US">Common Stock Offerings</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantToPurchaseCommonStockMember" xlink:label="knwn_WarrantToPurchaseCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantToPurchaseCommonStockMember" xlink:to="knwn_WarrantToPurchaseCommonStockMember_lbl_7a977d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantToPurchaseCommonStockMember_lbl_7a977d" xml:lang="en-US">Warrant To Purchase Common Stock Member</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_BousteadSecuritiesLLCMember" xlink:label="knwn_BousteadSecuritiesLLCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_BousteadSecuritiesLLCMember" xlink:to="knwn_BousteadSecuritiesLLCMember_lbl_d7f4c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_BousteadSecuritiesLLCMember_lbl_d7f4c8" xml:lang="en-US">Boustead Securities LLC Member</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OwnershipInterestInPreferredStock" xlink:label="knwn_OwnershipInterestInPreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_OwnershipInterestInPreferredStock" xlink:to="knwn_OwnershipInterestInPreferredStock_lbl_1f4e76" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_OwnershipInterestInPreferredStock_lbl_1f4e76" xml:lang="en-US">Ownership interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends" xlink:label="us-gaap_CumulativeDividends" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeDividends" xlink:to="us-gaap_CumulativeDividends_lbl_edd395" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeDividends_lbl_edd395" xml:lang="en-US">Cumulative dividend cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl_79830a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl_79830a" xml:lang="en-US">Cumulative Dividend</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_27ab22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_27ab22" xml:lang="en-US">Weighted average price of the common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_9f58f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_9f58f2" xml:lang="en-US">Shares of common stock issued during period</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesSettled" xlink:label="knwn_NumberOfCommonStockSharesSettled" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NumberOfCommonStockSharesSettled" xlink:to="knwn_NumberOfCommonStockSharesSettled_lbl_de2544" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NumberOfCommonStockSharesSettled_lbl_de2544" xml:lang="en-US">Number of common stock shares settled</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DividendDistributedPerShare" xlink:label="knwn_DividendDistributedPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DividendDistributedPerShare" xlink:to="knwn_DividendDistributedPerShare_lbl_198385" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DividendDistributedPerShare_lbl_198385" xml:lang="en-US">Dividend distributed per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl_c87ca5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl_c87ca5" xml:lang="en-US">Convertible common stock shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_507f00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl_507f00" xml:lang="en-US">Common stock shares value</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeDividendUnpaid" xlink:label="knwn_CumulativeDividendUnpaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CumulativeDividendUnpaid" xlink:to="knwn_CumulativeDividendUnpaid_lbl_de188e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CumulativeDividendUnpaid_lbl_de188e" xml:lang="en-US">Cumulative unpaid dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsCumulative" xlink:label="knwn_DeemedDividendsCumulative" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DeemedDividendsCumulative" xlink:to="knwn_DeemedDividendsCumulative_lbl_d7c077" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DeemedDividendsCumulative_lbl_d7c077" xml:lang="en-US">Cumulative deemed dividends</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" xlink:label="knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" xlink:to="knwn_AccretedValueOfPreferredDividendIntoCommonStockShares_lbl_41ab24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AccretedValueOfPreferredDividendIntoCommonStockShares_lbl_41ab24" xml:lang="en-US">Preferred dividend value accrete common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedOfWarrant" xlink:label="knwn_ReceivedOfWarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ReceivedOfWarrant" xlink:to="knwn_ReceivedOfWarrant_lbl_40cf0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ReceivedOfWarrant_lbl_40cf0b" xml:lang="en-US">warrants and received</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl_276b3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl_276b3e" xml:lang="en-US">Intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionOfAutomaticConversionOfConvertible" xlink:label="knwn_DescriptionOfAutomaticConversionOfConvertible" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DescriptionOfAutomaticConversionOfConvertible" xlink:to="knwn_DescriptionOfAutomaticConversionOfConvertible_lbl_280862" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DescriptionOfAutomaticConversionOfConvertible_lbl_280862" xml:lang="en-US">Automatic conversion of Convertible</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl_4df21d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl_4df21d" xml:lang="en-US">Money warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantIssuedToCommonStock" xlink:label="knwn_WarrantIssuedToCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantIssuedToCommonStock" xlink:to="knwn_WarrantIssuedToCommonStock_lbl_666d3b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantIssuedToCommonStock_lbl_666d3b" xml:lang="en-US">Warrant issued to common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividendsShares" xlink:label="knwn_ReceivedSeriesDPreferredStockDividendsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ReceivedSeriesDPreferredStockDividendsShares" xlink:to="knwn_ReceivedSeriesDPreferredStockDividendsShares_lbl_3dfe0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ReceivedSeriesDPreferredStockDividendsShares_lbl_3dfe0b" xml:lang="en-US">Series D preferred stock dividends shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStock" xlink:label="knwn_WarrantsToPurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsToPurchaseCommonStock" xlink:to="knwn_WarrantsToPurchaseCommonStock_lbl_866bb6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantsToPurchaseCommonStock_lbl_866bb6" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_72b3a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl_72b3a5" xml:lang="en-US">Purchase preferred stock</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShrareIssuedWarrantToPurchasedPrice" xlink:label="knwn_ShrareIssuedWarrantToPurchasedPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShrareIssuedWarrantToPurchasedPrice" xlink:to="knwn_ShrareIssuedWarrantToPurchasedPrice_lbl_5e218f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShrareIssuedWarrantToPurchasedPrice_lbl_5e218f" xml:lang="en-US">Shrare issued warrant to purchased price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl_b60255" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl_b60255" xml:lang="en-US">Conversion price</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToAcquireCommonStockShares" xlink:label="knwn_WarrantsToAcquireCommonStockShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsToAcquireCommonStockShares" xlink:to="knwn_WarrantsToAcquireCommonStockShares_lbl_091c49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantsToAcquireCommonStockShares_lbl_091c49" xml:lang="en-US">Warrant to acquire common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharePrice" xlink:label="knwn_CommonStockSharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStockSharePrice" xlink:to="knwn_CommonStockSharePrice_lbl_40319e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStockSharePrice_lbl_40319e" xml:lang="en-US">Share price</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PreferredStockConvertibleConversionPriceAdjusted" xlink:label="knwn_PreferredStockConvertibleConversionPriceAdjusted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_PreferredStockConvertibleConversionPriceAdjusted" xlink:to="knwn_PreferredStockConvertibleConversionPriceAdjusted_lbl_91509d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_PreferredStockConvertibleConversionPriceAdjusted_lbl_91509d" xml:lang="en-US">Adjusted conversion price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl_6a8e9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl_6a8e9f" xml:lang="en-US">Shrare issued warrant to purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsExpiredPerSharePrice" xlink:label="knwn_WarrantsExpiredPerSharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsExpiredPerSharePrice" xlink:to="knwn_WarrantsExpiredPerSharePrice_lbl_9db1f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantsExpiredPerSharePrice_lbl_9db1f0" xml:lang="en-US">Warrants expired per share</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStocks" xlink:label="knwn_ProceedsFromIssuanceOfCommonStocks" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ProceedsFromIssuanceOfCommonStocks" xlink:to="knwn_ProceedsFromIssuanceOfCommonStocks_lbl_9218d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ProceedsFromIssuanceOfCommonStocks_lbl_9218d3" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl_ab174e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl_ab174e" xml:lang="en-US">Interest expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_b4d841" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_b4d841" xml:lang="en-US">Authorized shares of capital stock par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_399612" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_399612" xml:lang="en-US">Preferred stock share par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_67e8fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_67e8fa" xml:lang="en-US">Common stock share issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_3b20a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_3b20a9" xml:lang="en-US">Net proceeds from sale</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossSales" xlink:label="knwn_GrossSales" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_GrossSales" xlink:to="knwn_GrossSales_lbl_6e807d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_GrossSales_lbl_6e807d" xml:lang="en-US">Gross proceeds from sale</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsIssuedValued" xlink:label="knwn_WarrantsIssuedValued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsIssuedValued" xlink:to="knwn_WarrantsIssuedValued_lbl_27e683" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WarrantsIssuedValued_lbl_27e683" xml:lang="en-US">Warrants valued</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharesIssuedRelatedToWarrantExercises" xlink:label="knwn_CommonStockSharesIssuedRelatedToWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStockSharesIssuedRelatedToWarrantExercises" xlink:to="knwn_CommonStockSharesIssuedRelatedToWarrantExercises_lbl_7d17d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStockSharesIssuedRelatedToWarrantExercises_lbl_7d17d7" xml:lang="en-US">Common Stock Shares issued related to warrant exercises</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuedAmountReceived" xlink:label="knwn_IssuedAmountReceived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IssuedAmountReceived" xlink:to="knwn_IssuedAmountReceived_lbl_bf06a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IssuedAmountReceived_lbl_bf06a8" xml:lang="en-US">Issued amount received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_eb80a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl_eb80a5" xml:lang="en-US">Common Stock Shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_936e39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_936e39" xml:lang="en-US">Preferred stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseOfStockOption" xlink:label="knwn_ExerciseOfStockOption" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExerciseOfStockOption" xlink:to="knwn_ExerciseOfStockOption_lbl_5b599d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExerciseOfStockOption_lbl_5b599d" xml:lang="en-US">Exercise of stock option</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_a94c7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_a94c7d" xml:lang="en-US">Preferred stock shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_49b71e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_49b71e" xml:lang="en-US">Preferred stock shares authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_b2021a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_b2021a" xml:lang="en-US">Common stock shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_765360" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_765360" xml:lang="en-US">Share issued price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl_48dc32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl_48dc32" xml:lang="en-US">Warrants totaling</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesCConvertiblePreferredStock" xlink:label="knwn_DesignatedSeriesCConvertiblePreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DesignatedSeriesCConvertiblePreferredStock" xlink:to="knwn_DesignatedSeriesCConvertiblePreferredStock_lbl_0887a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DesignatedSeriesCConvertiblePreferredStock_lbl_0887a4" xml:lang="en-US">Series C Convertible Preferred Stock designated</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DesignatedSeriesDConvertiblePreferredStocks" xlink:to="knwn_DesignatedSeriesDConvertiblePreferredStocks_lbl_751160" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_DesignatedSeriesDConvertiblePreferredStocks_lbl_751160" xml:lang="en-US">Series D Convertible Preferred Stock designated</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStocks" xlink:label="knwn_DesignatedSeriesDConvertiblePreferredStocks" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DesignatedSeriesDConvertiblePreferredStocks" xlink:to="knwn_DesignatedSeriesDConvertiblePreferredStocks_lbl_48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DesignatedSeriesDConvertiblePreferredStocks_lbl_48" xml:lang="en-US">[Series D Convertible Preferred Stock designated]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStock" xlink:label="knwn_DesignatedSeriesDConvertiblePreferredStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DesignatedSeriesDConvertiblePreferredStock" xlink:to="knwn_DesignatedSeriesDConvertiblePreferredStock_lbl_d99f41" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DesignatedSeriesDConvertiblePreferredStock_lbl_d99f41" xml:lang="en-US">Series D Convertible Preferred Stock designated</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReverseStockSplit" xlink:label="knwn_ReverseStockSplit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ReverseStockSplit" xlink:to="knwn_ReverseStockSplit_lbl_cb3539" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ReverseStockSplit_lbl_cb3539" xml:lang="en-US">Reverse stock split</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl_ac9403" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl_ac9403" xml:lang="en-US">Financial Instrument Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsMember" xlink:label="knwn_StockOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionsMember" xlink:to="knwn_StockOptionsMember_lbl_e1ab5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionsMember_lbl_e1ab5a" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_e7b0e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_e7b0e5" xml:lang="en-US">Share Outstanding at beginning of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9d7558" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_9d7558" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_478575" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_478575" xml:lang="en-US">Share Outstanding at ending of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9ec951" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_9ec951" xml:lang="en-US">Outstanding at begin of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_7a5772" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_7a5772" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_abf0b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_abf0b0" xml:lang="en-US">Weighted Average Exercise Price Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_10" xml:lang="en-US">[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_a7debf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_a7debf" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_6c8d26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_6c8d26" xml:lang="en-US">Plan Name Axis</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOption1Member" xlink:to="knwn_StockOption1Member_lbl_c08cb3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_StockOption1Member_lbl_c08cb3" xml:lang="en-US">Stock Option 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption2Member" xlink:label="knwn_StockOption2Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOption2Member" xlink:to="knwn_StockOption2Member_lbl_16064e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOption2Member_lbl_16064e" xml:lang="en-US">Stock Option 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption3Member" xlink:label="knwn_StockOption3Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOption3Member" xlink:to="knwn_StockOption3Member_lbl_5a9f72" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOption3Member_lbl_5a9f72" xml:lang="en-US">Stock Option 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsOneMember" xlink:label="knwn_StockOptionsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionsOneMember" xlink:to="knwn_StockOptionsOneMember_lbl_ce3cd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionsOneMember_lbl_ce3cd2" xml:lang="en-US">Stock Options 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsTwoMember" xlink:label="knwn_StockOptionsTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionsTwoMember" xlink:to="knwn_StockOptionsTwoMember_lbl_00ad23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionsTwoMember_lbl_00ad23" xml:lang="en-US">Stock Options 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EmployeeStockOptionsOneMember" xlink:label="knwn_EmployeeStockOptionsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EmployeeStockOptionsOneMember" xlink:to="knwn_EmployeeStockOptionsOneMember_lbl_e256a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_EmployeeStockOptionsOneMember_lbl_e256a8" xml:lang="en-US">Employee Stock Options One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl_ea0657" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl_ea0657" xml:lang="en-US">Range of exercise prices</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_def95e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_def95e" xml:lang="en-US">Number of outstanding stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WeightedAverageRemainingLifeYears" xlink:to="knwn_WeightedAverageRemainingLifeYears_lbl_4fce8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_WeightedAverageRemainingLifeYears_lbl_4fce8f" xml:lang="en-US">Weighted average remaining life (years)</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageRemainingLifeYears" xlink:label="knwn_WeightedAverageRemainingLifeYears" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WeightedAverageRemainingLifeYears" xlink:to="knwn_WeightedAverageRemainingLifeYears_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WeightedAverageRemainingLifeYears_lbl_4" xml:lang="en-US">[Weighted average remaining life (years)]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageExercisePriceOutstanding" xlink:label="knwn_WeightedAverageExercisePriceOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WeightedAverageExercisePriceOutstanding" xlink:to="knwn_WeightedAverageExercisePriceOutstanding_lbl_dc1013" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_WeightedAverageExercisePriceOutstanding_lbl_dc1013" xml:lang="en-US">Weighted average exercise price outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl_1cc7be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl_1cc7be" xml:lang="en-US">Number exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl_2a57ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl_2a57ae" xml:lang="en-US">Weighted average exercise price exerciseable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl_cc42f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl_cc42f5" xml:lang="en-US">Share Based Goods And Nonemployee Services Transaction By Supplier Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TwoZeroTwoOneEquityIncentivePlanMember" xlink:label="knwn_TwoZeroTwoOneEquityIncentivePlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_TwoZeroTwoOneEquityIncentivePlanMember" xlink:to="knwn_TwoZeroTwoOneEquityIncentivePlanMember_lbl_97a2d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_TwoZeroTwoOneEquityIncentivePlanMember_lbl_97a2d6" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="knwn_RonaldPEricksonMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_RonaldPEricksonMember" xlink:to="knwn_RonaldPEricksonMember_lbl_901cae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_RonaldPEricksonMember_lbl_901cae" xml:lang="en-US">Ronald P Erickson [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PhillipABosuaMember" xlink:label="knwn_PhillipABosuaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_PhillipABosuaMember" xlink:to="knwn_PhillipABosuaMember_lbl_e6c38d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_PhillipABosuaMember_lbl_e6c38d" xml:lang="en-US">Phillip A. Bosua [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PeterConleyMember" xlink:label="knwn_PeterConleyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_PeterConleyMember" xlink:to="knwn_PeterConleyMember_lbl_2a3341" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_PeterConleyMember_lbl_2a3341" xml:lang="en-US">Peter Conley [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EightEmployeesAndConsultantsMember" xlink:label="knwn_EightEmployeesAndConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EightEmployeesAndConsultantsMember" xlink:to="knwn_EightEmployeesAndConsultantsMember_lbl_0a985b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_EightEmployeesAndConsultantsMember_lbl_0a985b" xml:lang="en-US">Eight Employees And Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NineteenEmployeesAndConsultantsMember" xlink:label="knwn_NineteenEmployeesAndConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NineteenEmployeesAndConsultantsMember" xlink:to="knwn_NineteenEmployeesAndConsultantsMember_lbl_4b1887" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NineteenEmployeesAndConsultantsMember_lbl_4b1887" xml:lang="en-US">Nineteen Employees And Consultants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IntrinsicValue" xlink:to="knwn_IntrinsicValue_lbl_11f07d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_IntrinsicValue_lbl_11f07d" xml:lang="en-US">Intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IntrinsicValue" xlink:label="knwn_IntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_IntrinsicValue" xlink:to="knwn_IntrinsicValue_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_IntrinsicValue_lbl_2" xml:lang="en-US">[Intrinsic value]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrants" xlink:label="knwn_StockOptionGrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionGrants" xlink:to="knwn_StockOptionGrants_lbl_f20e14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionGrants_lbl_f20e14" xml:lang="en-US">Stock option grants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_193a40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_193a40" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_1e7e5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_1e7e5d" xml:lang="en-US">Weighted Average Exercise Price Forfeitures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_df5e05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl_df5e05" xml:lang="en-US">Average exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_1a3b5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl_1a3b5b" xml:lang="en-US">Number of common stock authorized shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesIncrease" xlink:label="knwn_NumberOfCommonStockSharesIncrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_NumberOfCommonStockSharesIncrease" xlink:to="knwn_NumberOfCommonStockSharesIncrease_lbl_334e18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_NumberOfCommonStockSharesIncrease_lbl_334e18" xml:lang="en-US">Number of common stock shares increase</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_lbl_87e76f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_lbl_87e76f" xml:lang="en-US">Unearned stock option grants</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" xlink:to="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_lbl_9" xml:lang="en-US">[Unearned stock option grants]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl_205809" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl_205809" xml:lang="en-US">Common shares current price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:label="knwn_StockIssuedDuringPeriodSharesStockOptionExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:to="knwn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl_c3ff70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl_c3ff70" xml:lang="en-US">Stock option grants share exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseStockOptionGrantsreceived" xlink:label="knwn_ExerciseStockOptionGrantsreceived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExerciseStockOptionGrantsreceived" xlink:to="knwn_ExerciseStockOptionGrantsreceived_lbl_b30e8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ExerciseStockOptionGrantsreceived_lbl_b30e8f" xml:lang="en-US">Exercise stock option grants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantIssuedToCommonStock" xlink:to="knwn_WarrantIssuedToCommonStock_lbl_e9d988" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_WarrantIssuedToCommonStock_lbl_e9d988" xml:lang="en-US">Warrant issued to common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_f59357" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_f59357" xml:lang="en-US">Stock option grants shares forfeitures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_MrStruveMember" xlink:to="knwn_MrStruveMember_lbl_744da5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_MrStruveMember_lbl_744da5" xml:lang="en-US">Mr. Struve [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl_34991e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl_34991e" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AIMindMember" xlink:label="knwn_AIMindMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AIMindMember" xlink:to="knwn_AIMindMember_lbl_957a18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AIMindMember_lbl_957a18" xml:lang="en-US">AI Mind [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareGrant" xlink:label="knwn_ShareGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ShareGrant" xlink:to="knwn_ShareGrant_lbl_3149fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ShareGrant_lbl_3149fb" xml:lang="en-US">No of share granted for stock option</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_6c4eef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_6c4eef" xml:lang="en-US">Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentExpense" xlink:to="us-gaap_EquipmentExpense_lbl_0ab06e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentExpense_lbl_0ab06e" xml:lang="en-US">Expensed</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ExercisePricePerShare" xlink:to="knwn_ExercisePricePerShare_lbl_92f735" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="knwn_ExercisePricePerShare_lbl_92f735" xml:lang="en-US">Share exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_a2fb8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_a2fb8f" xml:lang="en-US">Common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionRelatedToCommonStock" xlink:label="knwn_DescriptionRelatedToCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DescriptionRelatedToCommonStock" xlink:to="knwn_DescriptionRelatedToCommonStock_lbl_ed8a50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DescriptionRelatedToCommonStock_lbl_ed8a50" xml:lang="en-US">Company common stock description</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeExpenses" xlink:label="knwn_CumulativeExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CumulativeExpenses" xlink:to="knwn_CumulativeExpenses_lbl_d7e3a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CumulativeExpenses_lbl_d7e3a4" xml:lang="en-US">Cumulative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalStockOption" xlink:label="knwn_AdditionalStockOption" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AdditionalStockOption" xlink:to="knwn_AdditionalStockOption_lbl_895ef5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AdditionalStockOption_lbl_895ef5" xml:lang="en-US">Additional stock option grant</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalExercisedPrice" xlink:label="knwn_AdditionalExercisedPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AdditionalExercisedPrice" xlink:to="knwn_AdditionalExercisedPrice_lbl_ba1d22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AdditionalExercisedPrice_lbl_ba1d22" xml:lang="en-US">Additional exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_ee78f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl_ee78f5" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_11" xml:lang="en-US">[Interest Paid, Including Capitalized Interest, Operating and Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="us-gaap_DividendsSharebasedCompensationStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsSharebasedCompensationStock" xlink:to="us-gaap_DividendsSharebasedCompensationStock_lbl_898fc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsSharebasedCompensationStock_lbl_898fc4" xml:lang="en-US">Deferred compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccruedCompensastionTravelAndInterest" xlink:label="knwn_AccruedCompensastionTravelAndInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AccruedCompensastionTravelAndInterest" xlink:to="knwn_AccruedCompensastionTravelAndInterest_lbl_b4c9af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AccruedCompensastionTravelAndInterest_lbl_b4c9af" xml:lang="en-US">Accrued compensastion &amp; travel and interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl_0681a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl_0681a4" xml:lang="en-US">Severance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_f85f8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_f85f8f" xml:lang="en-US">Rent and other costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl_7eafa2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl_7eafa2" xml:lang="en-US">Share issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_WarrantsToPurchaseCommonStock" xlink:to="knwn_WarrantsToPurchaseCommonStock_lbl_c95e68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_WarrantsToPurchaseCommonStock_lbl_c95e68" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_e306a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl_e306a1" xml:lang="en-US">Price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl_562bd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl_562bd6" xml:lang="en-US">Rent</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividends" xlink:label="knwn_ReceivedSeriesDPreferredStockDividends" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ReceivedSeriesDPreferredStockDividends" xlink:to="knwn_ReceivedSeriesDPreferredStockDividends_lbl_1ccd37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ReceivedSeriesDPreferredStockDividends_lbl_1ccd37" xml:lang="en-US">Series D preferred stock dividends</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_4f41bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl_4f41bf" xml:lang="en-US">Preferred stock shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl_9e9c88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl_9e9c88" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl_22" xml:lang="en-US">[Interest Expense, Debt]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrBosuaMember" xlink:label="knwn_MrBosuaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_MrBosuaMember" xlink:to="knwn_MrBosuaMember_lbl_d23e14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_MrBosuaMember_lbl_d23e14" xml:lang="en-US">Mr. Bosua [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:to="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl_acb527" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleLeasebackTransactionMonthlyRentalPayments_lbl_acb527" xml:lang="en-US">Leases, net monthly payment</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AnnualSalary" xlink:label="knwn_AnnualSalary" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AnnualSalary" xlink:to="knwn_AnnualSalary_lbl_c3926c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AnnualSalary_lbl_c3926c" xml:lang="en-US">Annual salary</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_LeaseDescription" xlink:label="knwn_LeaseDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_LeaseDescription" xlink:to="knwn_LeaseDescription_lbl_ac4a9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_LeaseDescription_lbl_ac4a9f" xml:lang="en-US">Lease description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl_6dd215" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl_6dd215" xml:lang="en-US">Base salary</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_f4336c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_f4336c" xml:lang="en-US">Common stock shares</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockPerShares" xlink:label="knwn_CommonStockPerShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_CommonStockPerShares" xlink:to="knwn_CommonStockPerShares_lbl_f70834" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_CommonStockPerShares_lbl_f70834" xml:lang="en-US">Common stock per shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl_1a5213" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl_1a5213" xml:lang="en-US">Rent paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_da2793" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_da2793" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" xlink:label="knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" xlink:to="knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation_lbl_69a367" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation_lbl_69a367" xml:lang="en-US">Stock based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" xlink:label="knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" xlink:to="knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment_lbl_5765c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment_lbl_5765c7" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_98f889" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl_98f889" xml:lang="en-US">Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl_1b23f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl_1b23f9" xml:lang="en-US">Accruals and reserves</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_8d1077" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_8d1077" xml:lang="en-US">Total deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_c4ac9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_c4ac9b" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_8" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_e18217" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_e18217" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_c08cfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_c08cfe" xml:lang="en-US">Change in valuation allowance during the year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_10" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_03c61b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_03c61b" xml:lang="en-US">Income tax provision at statutory rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl_ed87ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl_ed87ff" xml:lang="en-US">Non deductible expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_ed77c8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_ed77c8" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" xlink:label="knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" xlink:to="knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp_lbl_9bd3d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp_lbl_9bd3d3" xml:lang="en-US">Other and prior year true up</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_17eaae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_17eaae" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_FederalNetOperatingLossCarryforwardsExpired" xlink:label="knwn_FederalNetOperatingLossCarryforwardsExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_FederalNetOperatingLossCarryforwardsExpired" xlink:to="knwn_FederalNetOperatingLossCarryforwardsExpired_lbl_e32647" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_FederalNetOperatingLossCarryforwardsExpired_lbl_e32647" xml:lang="en-US">Federal net operating loss carryforwards expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl_2908c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl_2908c9" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl_fc883a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl_fc883a" xml:lang="en-US">Gross deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EffectiveTaxRate" xlink:to="knwn_EffectiveTaxRate_lbl_465df4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="knwn_EffectiveTaxRate_lbl_465df4" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EffectiveTaxRate" xlink:label="knwn_EffectiveTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_EffectiveTaxRate" xlink:to="knwn_EffectiveTaxRate_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_EffectiveTaxRate_lbl_5" xml:lang="en-US">[Effective tax rate]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl_c6fea0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl_c6fea0" xml:lang="en-US">Statement Business Segments Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" xlink:label="knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" xlink:to="knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember_lbl_6bb35e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember_lbl_6bb35e" xml:lang="en-US">Development of the Bio-RFID and ChromaID Technologies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ParticleIncTechnologyMember" xlink:label="knwn_ParticleIncTechnologyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_ParticleIncTechnologyMember" xlink:to="knwn_ParticleIncTechnologyMember_lbl_f48588" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_ParticleIncTechnologyMember_lbl_f48588" xml:lang="en-US">Particle, Inc. Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DigitalassetsalesMember" xlink:label="knwn_DigitalassetsalesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_DigitalassetsalesMember" xlink:to="knwn_DigitalassetsalesMember_lbl_c6392e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_DigitalassetsalesMember_lbl_c6392e" xml:lang="en-US">Digital asset sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentRevenues" xlink:label="knwn_SegmentRevenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SegmentRevenues" xlink:to="knwn_SegmentRevenues_lbl_d6035e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SegmentRevenues_lbl_d6035e" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentNetIncomeLoss" xlink:label="knwn_SegmentNetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SegmentNetIncomeLoss" xlink:to="knwn_SegmentNetIncomeLoss_lbl_c3d67f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SegmentNetIncomeLoss_lbl_c3d67f" xml:lang="en-US">Segment Operating Profit (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentAsset" xlink:label="knwn_SegmentAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_SegmentAsset" xlink:to="knwn_SegmentAsset_lbl_8d98c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_SegmentAsset_lbl_8d98c5" xml:lang="en-US">Segment assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_028dbf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_028dbf" xml:lang="en-US">Non-cash expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_191ffb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_191ffb" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_d62584" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_d62584" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_1160f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl_1160f0" xml:lang="en-US">Price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalSharePurchase" xlink:label="knwn_AdditionalSharePurchase" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_AdditionalSharePurchase" xlink:to="knwn_AdditionalSharePurchase_lbl_c3251b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_AdditionalSharePurchase_lbl_c3251b" xml:lang="en-US">Additional share purchase</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl_d9355c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl_d9355c" xml:lang="en-US">Additional warrants issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_735630" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_735630" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrantsToEmployeesAndDirectors" xlink:label="knwn_StockOptionGrantsToEmployeesAndDirectors" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionGrantsToEmployeesAndDirectors" xlink:to="knwn_StockOptionGrantsToEmployeesAndDirectors_lbl_cd3068" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionGrantsToEmployeesAndDirectors_lbl_cd3068" xml:lang="en-US">Stock option grants to employees and directors</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_c6e59e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_c6e59e" xml:lang="en-US">Average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionExpiryTerm" xlink:label="knwn_StockOptionExpiryTerm" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="knwn_StockOptionExpiryTerm" xlink:to="knwn_StockOptionExpiryTerm_lbl_21f7ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="knwn_StockOptionExpiryTerm_lbl_21f7ba" xml:lang="en-US">Stock option expiry term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="knwn_StockCompensationExpenseEmployeeOptions" xlink:to="knwn_StockCompensationExpenseEmployeeOptions_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="knwn_StockCompensationExpenseEmployeeOptions_d">Custom Element.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>knwn-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/19/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://knwn.com/role/Cover" xlink:href="knwn-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ORGANIZATION" xlink:href="knwn-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LIQUIDITY" xlink:href="knwn-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatform" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatform" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipment" xlink:href="knwn-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LEASES" xlink:href="knwn-20230930.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayable" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EQUITY" xlink:href="knwn-20230930.xsd#EQUITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlans" xlink:href="knwn-20230930.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedParties" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedings" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxes" xlink:href="knwn-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReporting" xlink:href="knwn-20230930.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEvents" xlink:href="knwn-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentTables" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesTables" xlink:href="knwn-20230930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityTables" xlink:href="knwn-20230930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansTables" xlink:href="knwn-20230930.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesTables" xlink:href="knwn-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingTables" xlink:href="knwn-20230930.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OrganizationDetailsNarrative" xlink:href="knwn-20230930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatformDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetails" xlink:href="knwn-20230930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetailsNarrative" xlink:href="knwn-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails" xlink:href="knwn-20230930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails1" xlink:href="knwn-20230930.xsd#EquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails2" xlink:href="knwn-20230930.xsd#EquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails3" xlink:href="knwn-20230930.xsd#EquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails4" xlink:href="knwn-20230930.xsd#EquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetailsNarrative" xlink:href="knwn-20230930.xsd#EquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails1" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails1" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:href="knwn-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetails" xlink:href="knwn-20230930.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:href="knwn-20230930.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:href="knwn-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountDueToRelatedPartiesCurrent" xlink:label="loc_knwnAmountDueToRelatedPartiesCurrent" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_knwnAmountDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetIncomeLossAvailableToCommonStockholders" xlink:label="loc_knwnNetIncomeLossAvailableToCommonStockholders" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_knwnNetIncomeLossAvailableToCommonStockholders" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_knwnNetIncomeLossAvailableToCommonStockholders" xlink:to="loc_us-gaapDividendsCommonStockStock" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_knwnNetIncomeLossAvailableToCommonStockholders" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseForeignDeposits" xlink:label="loc_us-gaapInterestExpenseForeignDeposits" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestExpenseForeignDeposits" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaapExtinguishmentOfDebtAmount" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapExtinguishmentOfDebtAmount" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnDebtSettlement" xlink:label="loc_knwnGainLossOnDebtSettlement" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_knwnGainLossOnDebtSettlement" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnForgivenessOfNotesPayablePppLoans" xlink:label="loc_knwnGainLossOnForgivenessOfNotesPayablePppLoans" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_knwnGainLossOnForgivenessOfNotesPayablePppLoans" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" xlink:label="loc_knwnProceedsFromIssuanceOfCommonStockOfferingNet" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_knwnProceedsFromIssuanceOfCommonStockOfferingNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:title="000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatform" xlink:title="000010 - Disclosure - AI DEEP LEARNING PLATFORM" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LEASES" xlink:title="000012 - Disclosure - LEASES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:title="000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EQUITY" xlink:title="000014 - Disclosure - EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlans" xlink:title="000015 - Disclosure - STOCK INCENTIVE PLANS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:title="000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:title="000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxes" xlink:title="000018 - Disclosure - INCOME TAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReporting" xlink:title="000019 - Disclosure - SEGMENT REPORTING" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:title="000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentTables" xlink:title="000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesTables" xlink:title="000023 - Disclosure - LEASES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:title="000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityTables" xlink:title="000025 - Disclosure - EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansTables" xlink:title="000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesTables" xlink:title="000027 - Disclosure - INCOME TAXES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingTables" xlink:title="000028 - Disclosure - SEGMENT REPORTING (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/OrganizationDetailsNarrative" xlink:title="000029 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityDetailsNarrative" xlink:title="000030 - Disclosure - LIQUIDITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:title="000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:title="000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:title="000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetails" xlink:title="000035 - Disclosure - LEASES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetailsNarrative" xlink:title="000036 - Disclosure - LEASES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:title="000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:title="000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails" xlink:title="000040 - Disclosure - EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails1" xlink:title="000041 - Disclosure - EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails2" xlink:title="000042 - Disclosure - EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails3" xlink:title="000043 - Disclosure - EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails4" xlink:title="000044 - Disclosure - EQUITY (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetailsNarrative" xlink:title="000045 - Disclosure - EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails" xlink:title="000046 - Disclosure - STOCK INCENTIVE PLANS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails1" xlink:title="000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:title="000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:title="000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:title="000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails" xlink:title="000051 - Disclosure - INCOME TAXES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails1" xlink:title="000052 - Disclosure - INCOME TAXES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:title="000053 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetails" xlink:title="000054 - Disclosure - SEGMENT REPORTING (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:title="000055 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>knwn-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/19/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://knwn.com/role/Cover" xlink:href="knwn-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ORGANIZATION" xlink:href="knwn-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LIQUIDITY" xlink:href="knwn-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatform" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatform" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipment" xlink:href="knwn-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LEASES" xlink:href="knwn-20230930.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayable" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EQUITY" xlink:href="knwn-20230930.xsd#EQUITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlans" xlink:href="knwn-20230930.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedParties" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedings" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxes" xlink:href="knwn-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReporting" xlink:href="knwn-20230930.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEvents" xlink:href="knwn-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentTables" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesTables" xlink:href="knwn-20230930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityTables" xlink:href="knwn-20230930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansTables" xlink:href="knwn-20230930.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesTables" xlink:href="knwn-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingTables" xlink:href="knwn-20230930.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OrganizationDetailsNarrative" xlink:href="knwn-20230930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatformDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetails" xlink:href="knwn-20230930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetailsNarrative" xlink:href="knwn-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails" xlink:href="knwn-20230930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails1" xlink:href="knwn-20230930.xsd#EquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails2" xlink:href="knwn-20230930.xsd#EquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails3" xlink:href="knwn-20230930.xsd#EquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails4" xlink:href="knwn-20230930.xsd#EquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetailsNarrative" xlink:href="knwn-20230930.xsd#EquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails1" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails1" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:href="knwn-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetails" xlink:href="knwn-20230930.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:href="knwn-20230930.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:href="knwn-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_d8e8f9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_16a5a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_d8e8f9" xlink:to="loc_us-gaapStatementTable_16a5a1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c8bc0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_16a5a1" xlink:to="loc_us-gaapStatementLineItems_c8bc0b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_7a48da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_16a5a1" xlink:to="loc_us-gaapStatementClassOfStockAxis_7a48da" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_7e5aa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_7a48da" xlink:to="loc_us-gaapClassOfStockDomain_7e5aa3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_de7fb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_7e5aa3" xlink:to="loc_us-gaapSeriesCPreferredStockMember_de7fb7" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_534e1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_7e5aa3" xlink:to="loc_us-gaapSeriesDPreferredStockMember_534e1a" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_29a400" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c8bc0b" xlink:to="loc_us-gaapAssetsAbstract_29a400" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_1ed70e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_29a400" xlink:to="loc_us-gaapAssetsCurrentAbstract_1ed70e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_d28d51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_1ed70e" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_d28d51" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_6bd36b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_1ed70e" xlink:to="loc_us-gaapAssetsCurrent_6bd36b" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_f34a88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_1ed70e" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_f34a88" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract_830b95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_1ed70e" xlink:to="loc_us-gaapOtherAssetsAbstract_830b95" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_f9454f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract_830b95" xlink:to="loc_us-gaapOtherAssets_f9454f" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_166a96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract_830b95" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_166a96" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_a89eff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract_830b95" xlink:to="loc_us-gaapAssets_a89eff" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_36a519" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract_830b95" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_36a519" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_36a519" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent_c08e2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapAccountsPayableTradeCurrent_c08e2a" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_fb6030" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_fb6030" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountDueToRelatedPartiesCurrent" xlink:label="loc_knwnAmountDueToRelatedPartiesCurrent_7b7eb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_knwnAmountDueToRelatedPartiesCurrent_7b7eb2" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_4b5072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_4b5072" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_475baf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_475baf" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_26dea1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapLiabilitiesCurrent_26dea1" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d7dd6f" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_7cb7bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_7cb7bf" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_200424" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" xlink:to="loc_us-gaapLiabilitiesNoncurrent_200424" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_0f6f12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" xlink:to="loc_us-gaapCommitmentsAndContingencies_0f6f12" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_a782e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_026473" xlink:to="loc_us-gaapStockholdersEquityAbstract_a782e1" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_2e5a03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapPreferredStockValue_2e5a03" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_1f9908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapCommonStockValue_1f9908" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_fe33d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapAdditionalPaidInCapital_fe33d9" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_2cf736" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_2cf736" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_5d7edb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapStockholdersEquity_5d7edb" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_d86cb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_a782e1" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_d86cb9" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_dcfdef" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_6fe9a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dcfdef" xlink:to="loc_us-gaapStatementTable_6fe9a6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1e653a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6fe9a6" xlink:to="loc_us-gaapStatementLineItems_1e653a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_b24269" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_6fe9a6" xlink:to="loc_us-gaapStatementClassOfStockAxis_b24269" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_f7fe02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_b24269" xlink:to="loc_us-gaapClassOfStockDomain_f7fe02" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStocksSeriesCMember" xlink:label="loc_knwnConvertiblePreferredStocksSeriesCMember_9dc689" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_f7fe02" xlink:to="loc_knwnConvertiblePreferredStocksSeriesCMember_9dc689" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesDMember" xlink:label="loc_knwnConvertiblePreferredStockSeriesDMember_0b200b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_f7fe02" xlink:to="loc_knwnConvertiblePreferredStockSeriesDMember_0b200b" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_8747f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_8747f7" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_dcc4eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_dcc4eb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_d4e619" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_d4e619" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_0894b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapCommonStockSharesAuthorized_0894b8" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_f73d9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapCommonStockSharesIssued_f73d9e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_471732" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapCommonStockSharesOutstanding_471732" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_9fee5d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapPreferredStockSharesIssued_9fee5d" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_f7a3fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1e653a" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_f7a3fb" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_fd335e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_1e1ee9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_fd335e" xlink:to="loc_us-gaapRevenues_1e1ee9" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_4d191f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_fd335e" xlink:to="loc_us-gaapOperatingExpensesAbstract_4d191f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_3c047b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_3c047b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_74e7ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_74e7ca" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_59023b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapSellingExpense_59023b" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_8dac05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapOperatingExpenses_8dac05" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_c3fbe9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapOperatingIncomeLoss_c3fbe9" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_4d191f" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther_b22759" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapInterestIncomeOther_b22759" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_0d650a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapInterestExpense_0d650a" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_dcf62e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_dcf62e" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome_8b3333" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapOtherIncome_8b3333" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_947dce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_947dce" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e19fec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e19fec" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_941e1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_941e1a" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_e10409" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapNetIncomeLoss_e10409" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockStock" xlink:label="loc_us-gaapDividendsCommonStockStock_2b04bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapDividendsCommonStockStock_2b04bd" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_6d42cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_us-gaapDividendsPreferredStock_6d42cc" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetIncomeLossAvailableToCommonStockholders" xlink:label="loc_knwnNetIncomeLossAvailableToCommonStockholders_99b6de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_knwnNetIncomeLossAvailableToCommonStockholders_99b6de" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EarningsPerSharesBasicAndDiluted" xlink:label="loc_knwnEarningsPerSharesBasicAndDiluted_bb0c6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_knwnEarningsPerSharesBasicAndDiluted_bb0c6b" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:label="loc_knwnWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_8c4155" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_595288" xlink:to="loc_knwnWeightedAverageNumberOfSharesOutstandingBasicAndDiluted_8c4155" order="21" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_395304" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b4460b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_395304" xlink:to="loc_us-gaapStatementTable_b4460b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1cb988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4460b" xlink:to="loc_us-gaapStatementLineItems_1cb988" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_f23a8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b4460b" xlink:to="loc_us-gaapStatementEquityComponentsAxis_f23a8b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_dbdd9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_f23a8b" xlink:to="loc_us-gaapEquityComponentDomain_dbdd9c" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCConvertiblesPreferredStockMember" xlink:label="loc_knwnSeriesCConvertiblesPreferredStockMember_4ddece" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dbdd9c" xlink:to="loc_knwnSeriesCConvertiblesPreferredStockMember_4ddece" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesDConvertiblePreferredStockMember" xlink:label="loc_knwnSeriesDConvertiblePreferredStockMember_66966d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dbdd9c" xlink:to="loc_knwnSeriesDConvertiblePreferredStockMember_66966d" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksMember" xlink:label="loc_knwnCommonStocksMember_450685" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dbdd9c" xlink:to="loc_knwnCommonStocksMember_450685" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_d28e82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dbdd9c" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_d28e82" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_8a4bb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_dbdd9c" xlink:to="loc_us-gaapRetainedEarningsMember_8a4bb8" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_c3afa0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapSharesIssued_c3afa0" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_230125" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapStockholdersEquity_230125" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockCompensationExpenseEmployeeOptions" xlink:label="loc_knwnStockCompensationExpenseEmployeeOptions_0e08a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnStockCompensationExpenseEmployeeOptions_0e08a5" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestShares" xlink:label="loc_knwnConversionOfDebtOfferingAndAccruedInterestShares_0447e9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnConversionOfDebtOfferingAndAccruedInterestShares_0447e9" order="4" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" xlink:label="loc_knwnConversionOfDebtOfferingAndAccruedInterestAmount_e45f64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnConversionOfDebtOfferingAndAccruedInterestAmount_e45f64" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:label="loc_knwnIssuanceOfCommonStockForStockOptionExercisesShares_93313e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIssuanceOfCommonStockForStockOptionExercisesShares_93313e" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" xlink:label="loc_knwnIssuanceOfCommonStockForStockOptionExercisesAmount_517c23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIssuanceOfCommonStockForStockOptionExercisesAmount_517c23" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsShares_d6ba49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsShares_d6ba49" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsAmount_b54d6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsAmount_b54d6c" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_b44cf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_b44cf3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_2e2375" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_2e2375" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockWarrantForServices" xlink:label="loc_knwnIssuanceOfCommonStockWarrantForServices_9f35e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIssuanceOfCommonStockWarrantForServices_9f35e0" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingShares" xlink:label="loc_knwnIsssuanceOfCommonStockForNyseUplistingShares_5e3ee3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIsssuanceOfCommonStockForNyseUplistingShares_5e3ee3" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingAmount" xlink:label="loc_knwnIsssuanceOfCommonStockForNyseUplistingAmount_a0e3a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIsssuanceOfCommonStockForNyseUplistingAmount_a0e3a5" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_04bdae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapNetIncomeLoss_04bdae" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockShares" xlink:label="loc_knwnCommonStockDividendsOnSeriesDPreferredStockShares_857e7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnCommonStockDividendsOnSeriesDPreferredStockShares_857e7c" order="16" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" xlink:label="loc_knwnCommonStockDividendsOnSeriesDPreferredStockAmount_9f078d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnCommonStockDividendsOnSeriesDPreferredStockAmount_9f078d" order="17" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsOnSeriesCAndDPreferredStock" xlink:label="loc_knwnDeemedDividendsOnSeriesCAndDPreferredStock_2ce328" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnDeemedDividendsOnSeriesCAndDPreferredStock_2ce328" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" xlink:label="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingShares_024dd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingShares_024dd5" order="19" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" xlink:label="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingAmount_f29449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingAmount_f29449" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpensesForExtensionOfNotesAndWarrants" xlink:label="loc_knwnExpensesForExtensionOfNotesAndWarrants_0f86d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_knwnExpensesForExtensionOfNotesAndWarrants_0f86d3" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_3e10f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapSharesIssued_3e10f8" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_59c1d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1cb988" xlink:to="loc_us-gaapStockholdersEquity_59c1d0" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_583feb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d65594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_583feb" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d65594" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_016c08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d65594" xlink:to="loc_us-gaapNetIncomeLoss_016c08" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_d65594" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_20fc27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_20fc27" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_a03c1c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_a03c1c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_21de1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_21de1d" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnDebtSettlement" xlink:label="loc_knwnGainLossOnDebtSettlement_2a9b86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_knwnGainLossOnDebtSettlement_2a9b86" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets_6f238f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets_6f238f" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaapExtinguishmentOfDebtAmount_2075fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapExtinguishmentOfDebtAmount_2075fe" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseForeignDeposits" xlink:label="loc_us-gaapInterestExpenseForeignDeposits_4ba852" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapInterestExpenseForeignDeposits_4ba852" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:label="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_fd8762" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapStockGrantedDuringPeriodValueSharebasedCompensation_fd8762" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GainLossOnForgivenessOfNotesPayablePppLoans" xlink:label="loc_knwnGainLossOnForgivenessOfNotesPayablePppLoans_a30d24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_knwnGainLossOnForgivenessOfNotesPayablePppLoans_a30d24" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_ce55bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_ce55bb" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_999e90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_999e90" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d86aaa" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets_94d7f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets_94d7f6" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_0e2005" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_0e2005" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_afc49c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_afc49c" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_0ff98d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_0ff98d" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4695c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_c3927b" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4695c1" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_057aaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4695c1" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_057aaf" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8d87e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4695c1" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8d87e8" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4695c1" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_dbc21e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_dbc21e" order="24" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStockOfferingNet" xlink:label="loc_knwnProceedsFromIssuanceOfCommonStockOfferingNet_936811" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_knwnProceedsFromIssuanceOfCommonStockOfferingNet_936811" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_2de9ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_2de9ea" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_c3d07b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_c3d07b" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_724dbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_724dbc" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_3c190a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapProceedsFromWarrantExercises_3c190a" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4dc5e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_4dc5e5" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6b6147" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6b6147" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b26da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6b26da" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_803279" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_803279" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_cf251c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_2fe3ac" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_cf251c" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_2a7647" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_cf251c" xlink:to="loc_us-gaapInterestPaidNet_2a7647" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet_7c043b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_cf251c" xlink:to="loc_us-gaapIncomeTaxesPaidNet_7c043b" order="36" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract" xlink:label="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_cf251c" xlink:to="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_14e04e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_14e04e" order="38" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfAccruedInterest" xlink:label="loc_knwnConversionOfAccruedInterest_2d500a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" xlink:to="loc_knwnConversionOfAccruedInterest_2d500a" order="39" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaapDividendsCommonStock_df6dbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" xlink:to="loc_us-gaapDividendsCommonStock_df6dbc" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock_dbc2e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" xlink:to="loc_us-gaapDividendsPreferredStockStock_dbc2e7" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceCostsFromCommonStockOffering" xlink:label="loc_knwnIssuanceCostsFromCommonStockOffering_b3d1e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnSupplementalDisclosureOfNoncashFinancingActivityNewAbstract_f08a2b" xlink:to="loc_knwnIssuanceCostsFromCommonStockOffering_b3d1e7" order="42" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1653fd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_241e51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1653fd" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_241e51" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract_bcacbb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_d62290" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_bcacbb" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock_d62290" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:title="000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c1a320" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_4a86ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1a320" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_4a86ae" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatform" xlink:title="000010 - Disclosure - AI DEEP LEARNING PLATFORM">
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AiDeepLearningPlatformAbstract" xlink:label="loc_knwnAiDeepLearningPlatformAbstract_56787d" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AiDeepLearningPlatformDisclosureTextBlock" xlink:label="loc_knwnAiDeepLearningPlatformDisclosureTextBlock_d64733" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnAiDeepLearningPlatformAbstract_56787d" xlink:to="loc_knwnAiDeepLearningPlatformDisclosureTextBlock_d64733" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_9cad8c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_ea6fe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_9cad8c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_ea6fe5" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LEASES" xlink:title="000012 - Disclosure - LEASES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_e9c6fd" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_LeasesOfLesseDisclosureTextBlock" xlink:label="loc_knwnLeasesOfLesseDisclosureTextBlock_4b5463" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_e9c6fd" xlink:to="loc_knwnLeasesOfLesseDisclosureTextBlock_4b5463" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:title="000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_10e4ac" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesPayableDisclosureTextBlock" xlink:label="loc_knwnConvertibleNotesPayableDisclosureTextBlock_4733b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_10e4ac" xlink:to="loc_knwnConvertibleNotesPayableDisclosureTextBlock_4733b0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EQUITY" xlink:title="000014 - Disclosure - EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_d2b7a5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_cb7188" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_d2b7a5" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_cb7188" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlans" xlink:title="000015 - Disclosure - STOCK INCENTIVE PLANS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2203a8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_171046" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2203a8" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_171046" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:title="000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_3bfdfc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2412c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_3bfdfc" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2412c9" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:title="000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9dece9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0809d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_9dece9" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0809d4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxes" xlink:title="000018 - Disclosure - INCOME TAXES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_eb57c1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_b1055d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_eb57c1" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_b1055d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReporting" xlink:title="000019 - Disclosure - SEGMENT REPORTING">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_e72cbb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock_74202d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_e72cbb" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock_74202d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_5a507c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_ed792d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_5a507c" xlink:to="loc_us-gaapSubsequentEventsTextBlock_ed792d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:title="000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_fab3e0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_36cbb8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_36cbb8" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_75a4de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_75a4de" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_ccfc65" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_ccfc65" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_af1191" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_af1191" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d5de84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d5de84" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionLeases" xlink:label="loc_us-gaapRevenueRecognitionLeases_af3775" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapRevenueRecognitionLeases_af3775" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_e2c3cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_e2c3cf" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock_e33b01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock_e33b01" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_2976de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_2976de" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness" xlink:label="loc_us-gaapDerivativesMethodsOfAccountingHedgeEffectiveness_fa6dfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapDerivativesMethodsOfAccountingHedgeEffectiveness_fa6dfe" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_21c312" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_21c312" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy_fbe04c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapMarketableSecuritiesPolicy_fbe04c" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_675070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_675070" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_06bccd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock_06bccd" order="14" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DividendPolicyTextBlock" xlink:label="loc_knwnDividendPolicyTextBlock_cea325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_knwnDividendPolicyTextBlock_cea325" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_bc634f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapUseOfEstimates_bc634f" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_90c138" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_fab3e0" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_90c138" order="17" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentTables" xlink:title="000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_94c04e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_0c46f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_94c04e" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_0c46f1" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesTables" xlink:title="000023 - Disclosure - LEASES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_7e0fe8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_8601e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_7e0fe8" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_8601e3" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:title="000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_c1218d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock_5ed5c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_c1218d" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock_5ed5c5" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityTables" xlink:title="000025 - Disclosure - EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_5e033f" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock" xlink:label="loc_knwnScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_adb6bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5e033f" xlink:to="loc_knwnScheduleOfShareBasedCompensationWarrantActivityTableTextBlock_adb6bd" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_a2e44b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5e033f" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_a2e44b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock_e4981e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_5e033f" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock_e4981e" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansTables" xlink:title="000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cadba0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_df5015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cadba0" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_df5015" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_097444" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cadba0" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_097444" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesTables" xlink:title="000027 - Disclosure - INCOME TAXES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_2907ea" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e13059" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_2907ea" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e13059" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_73d859" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_2907ea" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_73d859" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingTables" xlink:title="000028 - Disclosure - SEGMENT REPORTING (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_9b33b4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_e2674f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_9b33b4" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock_e2674f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/OrganizationDetailsNarrative" xlink:title="000029 - Disclosure - ORGANIZATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedSharesOfCapitalStock" xlink:label="loc_knwnAuthorizedSharesOfCapitalStock_19bc76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_knwnAuthorizedSharesOfCapitalStock_19bc76" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedSharesOfCapitalCommonStock" xlink:label="loc_knwnAuthorizedSharesOfCapitalCommonStock_f9f447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_knwnAuthorizedSharesOfCapitalCommonStock_f9f447" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_980989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_980989" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_36adcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_36adcd" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_b6d895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_b6d895" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedCommonStockIncreased" xlink:label="loc_knwnAuthorizedCommonStockIncreased_a8d8d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1389e2" xlink:to="loc_knwnAuthorizedCommonStockIncreased_a8d8d1" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityDetailsNarrative" xlink:title="000030 - Disclosure - LIQUIDITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract_80189f" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CashAndCashEquivalents" xlink:label="loc_knwnCashAndCashEquivalents_6f0896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_80189f" xlink:to="loc_knwnCashAndCashEquivalents_6f0896" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetWorkingCapital" xlink:label="loc_knwnNetWorkingCapital_03bdbe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_80189f" xlink:to="loc_knwnNetWorkingCapital_03bdbe" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:title="000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c08aca" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_263254" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c08aca" xlink:to="loc_us-gaapStatementTable_263254" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0e48d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_us-gaapStatementLineItems_0e48d5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_c10eee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_us-gaapStatementClassOfStockAxis_c10eee" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_992e66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_c10eee" xlink:to="loc_us-gaapClassOfStockDomain_992e66" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_766aea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_766aea" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_45cb22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_766aea" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_45cb22" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_2b5f7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_2b5f7b" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_87e533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_2b5f7b" xlink:to="loc_us-gaapDerivativeContractTypeDomain_87e533" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_5c9546" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_srtRangeAxis_5c9546" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_fa6158" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_5c9546" xlink:to="loc_srtRangeMember_fa6158" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_b94904" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_263254" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_b94904" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_86216d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_b94904" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_86216d" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_34925c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_992e66" xlink:to="loc_us-gaapConvertiblePreferredStockMember_34925c" order="91" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Warrant1Member" xlink:label="loc_knwnWarrant1Member_c07fdc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_45cb22" xlink:to="loc_knwnWarrant1Member_c07fdc" order="92" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption1Member" xlink:label="loc_knwnStockOption1Member_a471cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_87e533" xlink:to="loc_knwnStockOption1Member_a471cb" order="93" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_e5763e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_fa6158" xlink:to="loc_srtMinimumMember_e5763e" order="94" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_dfc120" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_fa6158" xlink:to="loc_srtMaximumMember_dfc120" order="95" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0f0ea5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_86216d" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0f0ea5" order="96" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:label="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit_41ee56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit_41ee56" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeveranceAndOtherExpenses" xlink:label="loc_knwnSeveranceAndOtherExpenses_9de504" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_knwnSeveranceAndOtherExpenses_9de504" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleDebentures" xlink:label="loc_knwnConvertibleDebentures_e72224" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_knwnConvertibleDebentures_e72224" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_ee3823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_ee3823" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_55cfe5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapAdvertisingExpense_55cfe5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue_8e88c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue_8e88c7" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_c5671f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapCommonStockSharesIssued_c5671f" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding_205ef5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding_205ef5" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReservedSharesToPaySeriesCAndDDividends" xlink:label="loc_knwnReservedSharesToPaySeriesCAndDDividends_9da096" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_knwnReservedSharesToPaySeriesCAndDDividends_9da096" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_3ce333" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_3ce333" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3fba66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3fba66" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8787e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8787e7" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_6d2942" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_us-gaapSharesIssuedPricePerShare_6d2942" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PropertyPlantsAndEquipmentUsefulLife" xlink:label="loc_knwnPropertyPlantsAndEquipmentUsefulLife_5506da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0e48d5" xlink:to="loc_knwnPropertyPlantsAndEquipmentUsefulLife_5506da" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:title="000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AiDeepLearningPlatformAbstract" xlink:label="loc_knwnAiDeepLearningPlatformAbstract_9d3188" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_0ee3fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnAiDeepLearningPlatformAbstract_9d3188" xlink:to="loc_us-gaapStatementTable_0ee3fa" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5cb7b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0ee3fa" xlink:to="loc_us-gaapStatementLineItems_5cb7b7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_af2c8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_0ee3fa" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_af2c8f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_44d94e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis_af2c8f" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_44d94e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember_5fce52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_44d94e" xlink:to="loc_us-gaapTechnologyEquipmentMember_5fce52" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Revenue" xlink:label="loc_knwnRevenue_ba5341" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5cb7b7" xlink:to="loc_knwnRevenue_ba5341" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountTotal" xlink:label="loc_knwnAmountTotal_c9607f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5cb7b7" xlink:to="loc_knwnAmountTotal_c9607f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_2ad4ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5cb7b7" xlink:to="loc_us-gaapSellingExpense_2ad4ff" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_a12a88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5cb7b7" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_a12a88" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:title="000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross_bb961e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" xlink:to="loc_us-gaapMachineryAndEquipmentGross_bb961e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_5bdf5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" xlink:to="loc_us-gaapLeaseholdImprovementsGross_5bdf5c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross_cb1b2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" xlink:to="loc_us-gaapFurnitureAndFixturesGross_cb1b2d" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051ff1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051ff1" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_fdd6fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_a4b71d" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_fdd6fd" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_4cda8f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f87e59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_4cda8f" xlink:to="loc_us-gaapStatementTable_f87e59" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9b275c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f87e59" xlink:to="loc_us-gaapStatementLineItems_9b275c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_d348b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f87e59" xlink:to="loc_us-gaapIncomeStatementLocationAxis_d348b7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_cbab2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_d348b7" xlink:to="loc_us-gaapIncomeStatementLocationDomain_cbab2f" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" xlink:label="loc_knwnResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember_620195" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_cbab2f" xlink:to="loc_knwnResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember_620195" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AssetsNetBookValue" xlink:label="loc_knwnAssetsNetBookValue_6af35c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9b275c" xlink:to="loc_knwnAssetsNetBookValue_6af35c" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_00776c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9b275c" xlink:to="loc_us-gaapDepreciation_00776c" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetails" xlink:title="000035 - Disclosure - LEASES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_310a51" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TotalRemainingPayments" xlink:label="loc_knwnTotalRemainingPayments_164217" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_310a51" xlink:to="loc_knwnTotalRemainingPayments_164217" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3eca82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_310a51" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3eca82" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_5234a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_310a51" xlink:to="loc_us-gaapOperatingLeaseLiability_5234a0" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetailsNarrative" xlink:title="000036 - Disclosure - LEASES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract_6b2b01" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_bb1e5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_6b2b01" xlink:to="loc_us-gaapLeaseCost_bb1e5f" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RightOfUseAssets" xlink:label="loc_knwnRightOfUseAssets_ed1d4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_6b2b01" xlink:to="loc_knwnRightOfUseAssets_ed1d4a" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TotalLeaseLiability" xlink:label="loc_knwnTotalLeaseLiability_3df7f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_6b2b01" xlink:to="loc_knwnTotalLeaseLiability_3df7f8" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_bc2c21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract_6b2b01" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_bc2c21" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract_bafa1b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_29a00f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract_bafa1b" xlink:to="loc_us-gaapStatementTable_29a00f" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_efaf2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_29a00f" xlink:to="loc_us-gaapStatementLineItems_efaf2b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_e57ff9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_29a00f" xlink:to="loc_us-gaapAwardDateAxis_e57ff9" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_5e9a23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_e57ff9" xlink:to="loc_us-gaapAwardDateDomain_5e9a23" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" xlink:label="loc_knwnThirtyFirstDecemberTwentyTwentyThreeMember_d0f560" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_5e9a23" xlink:to="loc_knwnThirtyFirstDecemberTwentyTwentyThreeMember_d0f560" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CashAndCashEquivalents" xlink:label="loc_knwnCashAndCashEquivalents_eb41f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_efaf2b" xlink:to="loc_knwnCashAndCashEquivalents_eb41f4" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetWorkingCapital" xlink:label="loc_knwnNetWorkingCapital_62c9dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_efaf2b" xlink:to="loc_knwnNetWorkingCapital_62c9dc" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossProceedFromPublicIssueStock" xlink:label="loc_knwnGrossProceedFromPublicIssueStock_338889" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_efaf2b" xlink:to="loc_knwnGrossProceedFromPublicIssueStock_338889" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:title="000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_a81393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5b92ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_a81393" xlink:to="loc_us-gaapStatementTable_5b92ba" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5c2bfd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b92ba" xlink:to="loc_us-gaapStatementLineItems_5c2bfd" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis_f4710c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5b92ba" xlink:to="loc_us-gaapDebtInstrumentAxis_f4710c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_8f919a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis_f4710c" xlink:to="loc_us-gaapDebtInstrumentNameDomain_8f919a" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteOneMember" xlink:label="loc_knwnConvertibleNoteOneMember_db9b46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_8f919a" xlink:to="loc_knwnConvertibleNoteOneMember_db9b46" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteTwoMember" xlink:label="loc_knwnConvertibleNoteTwoMember_45f205" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_8f919a" xlink:to="loc_knwnConvertibleNoteTwoMember_45f205" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesFiveMember" xlink:label="loc_knwnConvertibleNotesFiveMember_49c6ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_8f919a" xlink:to="loc_knwnConvertibleNotesFiveMember_49c6ce" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesConversions" xlink:label="loc_knwnConvertibleNotesConversions_bc1eab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2bfd" xlink:to="loc_knwnConvertibleNotesConversions_bc1eab" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_8f83d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2bfd" xlink:to="loc_us-gaapDebtInstrumentFairValue_8f83d6" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_ba205d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2bfd" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_ba205d" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:title="000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_88d8da" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_460400" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_88d8da" xlink:to="loc_us-gaapStatementTable_460400" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0acc09" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_460400" xlink:to="loc_us-gaapStatementLineItems_0acc09" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis_aff0aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_460400" xlink:to="loc_us-gaapDebtInstrumentAxis_aff0aa" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_695c78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis_aff0aa" xlink:to="loc_us-gaapDebtInstrumentNameDomain_695c78" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote2Member" xlink:label="loc_knwnConvertibleNote2Member_c3a764" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_695c78" xlink:to="loc_knwnConvertibleNote2Member_c3a764" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote1Member" xlink:label="loc_knwnConvertibleNote1Member_a311db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_695c78" xlink:to="loc_knwnConvertibleNote1Member_a311db" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote8Member" xlink:label="loc_knwnConvertibleNote8Member_3b44e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_695c78" xlink:to="loc_knwnConvertibleNote8Member_3b44e4" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote7Member" xlink:label="loc_knwnConvertibleNote7Member_c458d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain_695c78" xlink:to="loc_knwnConvertibleNote7Member_c458d8" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentExpense" xlink:label="loc_us-gaapEquipmentExpense_8bf29f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapEquipmentExpense_8bf29f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f3e844" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f3e844" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DepositLiabilitiesAccruedInterestsAmount" xlink:label="loc_knwnDepositLiabilitiesAccruedInterestsAmount_e9bfdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_knwnDepositLiabilitiesAccruedInterestsAmount_e9bfdd" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmortizationOfDebtDiscountPremiums" xlink:label="loc_knwnAmortizationOfDebtDiscountPremiums_02bd19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_knwnAmortizationOfDebtDiscountPremiums_02bd19" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="loc_us-gaapDepositLiabilitiesAccruedInterest_d79df5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapDepositLiabilitiesAccruedInterest_d79df5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8e993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e8e993" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_814a39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_814a39" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_312dab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapConvertibleDebt_312dab" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleRedeemablePromissoryNoteAmount" xlink:label="loc_knwnConvertibleRedeemablePromissoryNoteAmount_bb10a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_knwnConvertibleRedeemablePromissoryNoteAmount_bb10a9" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_697176" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0acc09" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_697176" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails" xlink:title="000040 - Disclosure - EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_6099d3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_40577e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6099d3" xlink:to="loc_us-gaapStatementTable_40577e" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f10ddb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_40577e" xlink:to="loc_us-gaapStatementLineItems_f10ddb" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a3e6e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_40577e" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a3e6e1" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a3e6e1" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember_ac42af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" xlink:to="loc_knwnWarrantOneMember_ac42af" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember_64b0da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" xlink:to="loc_knwnWarrantTwoMember_64b0da" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember_4ca6ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" xlink:to="loc_knwnWarrantThreeMember_4ca6ba" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember_174c91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_965df7" xlink:to="loc_knwnWarrantFourMember_174c91" order="24" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfWarrantShares" xlink:label="loc_knwnNumberOfWarrantShares_db203b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f10ddb" xlink:to="loc_knwnNumberOfWarrantShares_db203b" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DateOfIssue" xlink:label="loc_knwnDateOfIssue_8b7b2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f10ddb" xlink:to="loc_knwnDateOfIssue_8b7b2f" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OriginalExpirationDate" xlink:label="loc_knwnOriginalExpirationDate_45178f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f10ddb" xlink:to="loc_knwnOriginalExpirationDate_45178f" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmendedExpirationdate" xlink:label="loc_knwnAmendedExpirationdate_de6f6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f10ddb" xlink:to="loc_knwnAmendedExpirationdate_de6f6a" order="4" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare_3db18f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f10ddb" xlink:to="loc_knwnExercisePricePerShare_3db18f" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails1" xlink:title="000041 - Disclosure - EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_af0f7f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fc44aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_af0f7f" xlink:to="loc_us-gaapStatementTable_fc44aa" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3f0d0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc44aa" xlink:to="loc_us-gaapStatementLineItems_3f0d0d" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_030716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fc44aa" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_030716" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_030716" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember_266dc4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" xlink:to="loc_knwnWarrantOneMember_266dc4" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember_219524" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" xlink:to="loc_knwnWarrantTwoMember_219524" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember_63c796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" xlink:to="loc_knwnWarrantThreeMember_63c796" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember_1202e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ad5202" xlink:to="loc_knwnWarrantFourMember_1202e3" order="14" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfWarrantShares" xlink:label="loc_knwnNumberOfWarrantShares_ef8ee2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f0d0d" xlink:to="loc_knwnNumberOfWarrantShares_ef8ee2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DateOfIssue" xlink:label="loc_knwnDateOfIssue_30d976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f0d0d" xlink:to="loc_knwnDateOfIssue_30d976" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OriginalExpirationDate" xlink:label="loc_knwnOriginalExpirationDate_8b4346" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f0d0d" xlink:to="loc_knwnOriginalExpirationDate_8b4346" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmendedExpirationdate" xlink:label="loc_knwnAmendedExpirationdate_183cfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f0d0d" xlink:to="loc_knwnAmendedExpirationdate_183cfb" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare_0d97d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3f0d0d" xlink:to="loc_knwnExercisePricePerShare_0d97d4" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails2" xlink:title="000042 - Disclosure - EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_0d4e9a" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract" xlink:label="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_0d4e9a" xlink:to="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers" xlink:label="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_6153a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers_6153a9" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8574bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8574bb" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_0dcf95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_0dcf95" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c291ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c291ed" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_850b0a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_850b0a" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe" xlink:label="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe_b3fd31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe_b3fd31" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisableAtEndOfPeriod" xlink:label="loc_knwnExercisableAtEndOfPeriod_21a8bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_knwnExercisableAtEndOfPeriod_21a8bc" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract_9bf58e" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" order="9" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OutstandingAtBegenningOfPeriod" xlink:label="loc_knwnOutstandingAtBegenningOfPeriod_39d484" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_knwnOutstandingAtBegenningOfPeriod_39d484" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1ae95c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1ae95c" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_21efd8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_21efd8" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice" xlink:label="loc_knwnShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_4d259e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_knwnShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice_4d259e" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bf53f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bf53f2" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OutstandingAtEndOfPeriod" xlink:label="loc_knwnOutstandingAtEndOfPeriod_e108ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_d959f9" xlink:to="loc_knwnOutstandingAtEndOfPeriod_e108ef" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails3" xlink:title="000043 - Disclosure - EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2c77c1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_fcd366" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2c77c1" xlink:to="loc_us-gaapStatementTable_fcd366" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5501cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fcd366" xlink:to="loc_us-gaapStatementLineItems_5501cc" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4b534b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fcd366" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4b534b" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4b534b" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_09f55f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_fcd366" xlink:to="loc_srtRangeAxis_09f55f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_d8cd69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_09f55f" xlink:to="loc_srtRangeMember_d8cd69" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember_18db72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" xlink:to="loc_knwnWarrantOneMember_18db72" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember_9d1052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" xlink:to="loc_knwnWarrantTwoMember_9d1052" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember_e163d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" xlink:to="loc_knwnWarrantThreeMember_e163d0" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember_af7766" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_43fba0" xlink:to="loc_knwnWarrantFourMember_af7766" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_823910" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_d8cd69" xlink:to="loc_srtMinimumMember_823910" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_88a2a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_d8cd69" xlink:to="loc_srtMaximumMember_88a2a1" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_520428" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5501cc" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_520428" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAveragesRemainingLifeYears" xlink:label="loc_knwnWeightedAveragesRemainingLifeYears_9f23d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5501cc" xlink:to="loc_knwnWeightedAveragesRemainingLifeYears_9f23d3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_22a072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5501cc" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_22a072" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_49cba3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5501cc" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_49cba3" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0b11c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5501cc" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0b11c1" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails4" xlink:title="000044 - Disclosure - EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_afae89" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_FederalFundsSoldAverageYield" xlink:label="loc_srtFederalFundsSoldAverageYield_265463" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_afae89" xlink:to="loc_srtFederalFundsSoldAverageYield_265463" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpectedLifeMinimum" xlink:label="loc_knwnExpectedLifeMinimum_f3423f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_afae89" xlink:to="loc_knwnExpectedLifeMinimum_f3423f" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpectedLifeMaximum" xlink:label="loc_knwnExpectedLifeMaximum_b1ee40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_afae89" xlink:to="loc_knwnExpectedLifeMaximum_b1ee40" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_15f2f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_afae89" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_15f2f4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_2ee828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_afae89" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_2ee828" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetailsNarrative" xlink:title="000045 - Disclosure - EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_6a0384" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f7ff0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6a0384" xlink:to="loc_us-gaapStatementTable_f7ff0e" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6d57ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapStatementLineItems_6d57ea" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_dfc74c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_dfc74c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_529af5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_dfc74c" xlink:to="loc_us-gaapRelatedPartyDomain_529af5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_8d1029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapStatementClassOfStockAxis_8d1029" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_774e1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_8d1029" xlink:to="loc_us-gaapClassOfStockDomain_774e1a" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_4162fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapAwardTypeAxis_4162fe" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fa439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_4162fe" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fa439" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_8647c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_srtTitleOfIndividualAxis_8647c2" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_637748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_8647c2" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_637748" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_e71b3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapStatementEquityComponentsAxis_e71b3a" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_47a4aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_e71b3a" xlink:to="loc_us-gaapEquityComponentDomain_47a4aa" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_0842c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f7ff0e" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_0842c2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_73ced4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_0842c2" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_73ced4" order="100" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrStruveMember" xlink:label="loc_knwnMrStruveMember_940aa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_529af5" xlink:to="loc_knwnMrStruveMember_940aa5" order="101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_6de045" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_us-gaapSeriesCPreferredStockMember_6de045" order="102" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_6025f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_us-gaapSeriesDPreferredStockMember_6025f5" order="103" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCAndDPreferredStockMember" xlink:label="loc_knwnSeriesCAndDPreferredStockMember_70b0fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnSeriesCAndDPreferredStockMember_70b0fe" order="104" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStockMember" xlink:label="loc_knwnWarrantsToPurchaseCommonStockMember_62a8ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4fa439" xlink:to="loc_knwnWarrantsToPurchaseCommonStockMember_62a8ba" order="105" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThreeDirectorMember" xlink:label="loc_knwnThreeDirectorMember_48d4a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_637748" xlink:to="loc_knwnThreeDirectorMember_48d4a1" order="106" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonPreferredStocksMember" xlink:label="loc_knwnCommonPreferredStocksMember_491fd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnCommonPreferredStocksMember_491fd2" order="107" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedCapitalStockMember" xlink:label="loc_knwnAuthorizedCapitalStockMember_3ac9b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnAuthorizedCapitalStockMember_3ac9b4" order="108" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_knwnConvertiblePreferredStockSeriesCMember_c15aff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnConvertiblePreferredStockSeriesCMember_c15aff" order="109" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtTwoMember" xlink:label="loc_knwnStockAtTwoMember_332b56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnStockAtTwoMember_332b56" order="110" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtOneMember" xlink:label="loc_knwnStockAtOneMember_453032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnStockAtOneMember_453032" order="111" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockDMember" xlink:label="loc_knwnConvertiblePreferredStockDMember_3381db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnConvertiblePreferredStockDMember_3381db" order="112" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_dc76d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_47a4aa" xlink:to="loc_us-gaapPreferredStockMember_dc76d7" order="113" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksOfferingsMember" xlink:label="loc_knwnCommonStocksOfferingsMember_0692a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnCommonStocksOfferingsMember_0692a0" order="114" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantToPurchaseCommonStockMember" xlink:label="loc_knwnWarrantToPurchaseCommonStockMember_b3fbf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_774e1a" xlink:to="loc_knwnWarrantToPurchaseCommonStockMember_b3fbf6" order="115" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_BousteadSecuritiesLLCMember" xlink:label="loc_knwnBousteadSecuritiesLLCMember_7f3c82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_73ced4" xlink:to="loc_knwnBousteadSecuritiesLLCMember_7f3c82" order="116" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OwnershipInterestInPreferredStock" xlink:label="loc_knwnOwnershipInterestInPreferredStock_0310c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnOwnershipInterestInPreferredStock_0310c6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends" xlink:label="loc_us-gaapCumulativeDividends_666ca9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCumulativeDividends_666ca9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_02a634" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_02a634" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62e744" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62e744" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_de4b75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_de4b75" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesSettled" xlink:label="loc_knwnNumberOfCommonStockSharesSettled_324065" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnNumberOfCommonStockSharesSettled_324065" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DividendDistributedPerShare" xlink:label="loc_knwnDividendDistributedPerShare_4d1089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDividendDistributedPerShare_4d1089" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares_b58b14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCommonStockDividendsShares_b58b14" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_b7ae3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCommonStockValue_b7ae3b" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeDividendUnpaid" xlink:label="loc_knwnCumulativeDividendUnpaid_175f1f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnCumulativeDividendUnpaid_175f1f" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsCumulative" xlink:label="loc_knwnDeemedDividendsCumulative_49ed46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDeemedDividendsCumulative_49ed46" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" xlink:label="loc_knwnAccretedValueOfPreferredDividendIntoCommonStockShares_f2ef33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnAccretedValueOfPreferredDividendIntoCommonStockShares_f2ef33" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedOfWarrant" xlink:label="loc_knwnReceivedOfWarrant_5200d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnReceivedOfWarrant_5200d5" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_knwnSharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_deb8f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnSharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_deb8f1" order="14" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionOfAutomaticConversionOfConvertible" xlink:label="loc_knwnDescriptionOfAutomaticConversionOfConvertible_a83e6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDescriptionOfAutomaticConversionOfConvertible_a83e6b" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments_98d710" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments_98d710" order="16" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantIssuedToCommonStock" xlink:label="loc_knwnWarrantIssuedToCommonStock_070bb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnWarrantIssuedToCommonStock_070bb7" order="17" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividendsShares" xlink:label="loc_knwnReceivedSeriesDPreferredStockDividendsShares_a90853" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnReceivedSeriesDPreferredStockDividendsShares_a90853" order="18" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStock" xlink:label="loc_knwnWarrantsToPurchaseCommonStock_bebaff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnWarrantsToPurchaseCommonStock_bebaff" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_526184" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockValue_526184" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShrareIssuedWarrantToPurchasedPrice" xlink:label="loc_knwnShrareIssuedWarrantToPurchasedPrice_4f3973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnShrareIssuedWarrantToPurchasedPrice_4f3973" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_c7b5c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_c7b5c9" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToAcquireCommonStockShares" xlink:label="loc_knwnWarrantsToAcquireCommonStockShares_72447c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnWarrantsToAcquireCommonStockShares_72447c" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharePrice" xlink:label="loc_knwnCommonStockSharePrice_462a5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnCommonStockSharePrice_462a5b" order="24" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PreferredStockConvertibleConversionPriceAdjusted" xlink:label="loc_knwnPreferredStockConvertibleConversionPriceAdjusted_431e8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnPreferredStockConvertibleConversionPriceAdjusted_431e8e" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_84b651" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_84b651" order="26" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsExpiredPerSharePrice" xlink:label="loc_knwnWarrantsExpiredPerSharePrice_b7f39c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnWarrantsExpiredPerSharePrice_b7f39c" order="27" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStocks" xlink:label="loc_knwnProceedsFromIssuanceOfCommonStocks_af1fc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnProceedsFromIssuanceOfCommonStocks_af1fc3" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther_394e4e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapInterestExpenseOther_394e4e" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_762806" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_762806" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_f2a7be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_f2a7be" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_9c0d59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCommonStockSharesIssued_9c0d59" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_5fa2e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_5fa2e4" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossSales" xlink:label="loc_knwnGrossSales_4aa7ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnGrossSales_4aa7ca" order="34" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsIssuedValued" xlink:label="loc_knwnWarrantsIssuedValued_fc9a67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnWarrantsIssuedValued_fc9a67" order="35" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharesIssuedRelatedToWarrantExercises" xlink:label="loc_knwnCommonStockSharesIssuedRelatedToWarrantExercises_31d758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnCommonStockSharesIssuedRelatedToWarrantExercises_31d758" order="36" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuedAmountReceived" xlink:label="loc_knwnIssuedAmountReceived_304e23" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnIssuedAmountReceived_304e23" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_268bae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapSharesIssued_268bae" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_9fcdf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockSharesIssued_9fcdf3" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseOfStockOption" xlink:label="loc_knwnExerciseOfStockOption_57f9ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnExerciseOfStockOption_57f9ff" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_c6b914" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_c6b914" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_05eda9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_05eda9" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_68ca33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapCommonStockSharesAuthorized_68ca33" order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_750209" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapSharePrice_750209" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_8fda61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_8fda61" order="45" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesCConvertiblePreferredStock" xlink:label="loc_knwnDesignatedSeriesCConvertiblePreferredStock_280c2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDesignatedSeriesCConvertiblePreferredStock_280c2c" order="46" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStocks" xlink:label="loc_knwnDesignatedSeriesDConvertiblePreferredStocks_522df1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDesignatedSeriesDConvertiblePreferredStocks_522df1" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStock" xlink:label="loc_knwnDesignatedSeriesDConvertiblePreferredStock_ff13ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnDesignatedSeriesDConvertiblePreferredStock_ff13ea" order="48" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReverseStockSplit" xlink:label="loc_knwnReverseStockSplit_bb670d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6d57ea" xlink:to="loc_knwnReverseStockSplit_bb670d" order="49" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails" xlink:title="000046 - Disclosure - STOCK INCENTIVE PLANS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_905087" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ae345b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_905087" xlink:to="loc_us-gaapStatementTable_ae345b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9c4e40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ae345b" xlink:to="loc_us-gaapStatementLineItems_9c4e40" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_2efc92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ae345b" xlink:to="loc_us-gaapFinancialInstrumentAxis_2efc92" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c9eff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_2efc92" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c9eff0" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsMember" xlink:label="loc_knwnStockOptionsMember_420343" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c9eff0" xlink:to="loc_knwnStockOptionsMember_420343" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d2553a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d2553a" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38b6be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_38b6be" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_15af4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_15af4c" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_222511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_222511" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e38a51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e38a51" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2193b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2193b1" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d98f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8d98f" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ba656a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ba656a" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ef2306" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ef2306" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d9204f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9c4e40" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d9204f" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails1" xlink:title="000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5aea5f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_7b5fc8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5aea5f" xlink:to="loc_us-gaapStatementTable_7b5fc8" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f1a620" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_us-gaapStatementLineItems_f1a620" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_40c8cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_srtRangeAxis_40c8cb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_4c349e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_40c8cb" xlink:to="loc_srtRangeMember_4c349e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_6200af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_6200af" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_4f0058" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_6200af" xlink:to="loc_us-gaapDerivativeContractTypeDomain_4f0058" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ecc20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ecc20" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0e3e48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2ecc20" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0e3e48" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_7e35f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_us-gaapPlanNameAxis_7e35f2" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_8ac184" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_7e35f2" xlink:to="loc_us-gaapPlanNameDomain_8ac184" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_517aef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_7b5fc8" xlink:to="loc_us-gaapAwardTypeAxis_517aef" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5922a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_517aef" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5922a8" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_6aa0b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_4c349e" xlink:to="loc_srtMinimumMember_6aa0b0" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption1Member" xlink:label="loc_knwnStockOption1Member_ea2540" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4f0058" xlink:to="loc_knwnStockOption1Member_ea2540" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_7d6d67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_4c349e" xlink:to="loc_srtMaximumMember_7d6d67" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption2Member" xlink:label="loc_knwnStockOption2Member_bc4975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0e3e48" xlink:to="loc_knwnStockOption2Member_bc4975" order="64" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption3Member" xlink:label="loc_knwnStockOption3Member_248c9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0e3e48" xlink:to="loc_knwnStockOption3Member_248c9f" order="65" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsOneMember" xlink:label="loc_knwnStockOptionsOneMember_63819d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_8ac184" xlink:to="loc_knwnStockOptionsOneMember_63819d" order="66" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsTwoMember" xlink:label="loc_knwnStockOptionsTwoMember_d67e32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_8ac184" xlink:to="loc_knwnStockOptionsTwoMember_d67e32" order="67" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EmployeeStockOptionsOneMember" xlink:label="loc_knwnEmployeeStockOptionsOneMember_cd7739" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5922a8" xlink:to="loc_knwnEmployeeStockOptionsOneMember_cd7739" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_adb76e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_adb76e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110471" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110471" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageRemainingLifeYears" xlink:label="loc_knwnWeightedAverageRemainingLifeYears_660c67" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_knwnWeightedAverageRemainingLifeYears_660c67" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageExercisePriceOutstanding" xlink:label="loc_knwnWeightedAverageExercisePriceOutstanding_efd238" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_knwnWeightedAverageExercisePriceOutstanding_efd238" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2e2628" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2e2628" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_037908" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f1a620" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_037908" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:title="000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2083dd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_316071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2083dd" xlink:to="loc_us-gaapStatementTable_316071" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6f80ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_316071" xlink:to="loc_us-gaapStatementLineItems_6f80ba" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis_b92c5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_316071" xlink:to="loc_us-gaapFinancialInstrumentAxis_b92c5f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b1186" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis_b92c5f" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b1186" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_6a7fd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_316071" xlink:to="loc_us-gaapAwardTypeAxis_6a7fd2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfd70c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_6a7fd2" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfd70c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_5659d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_316071" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_5659d5" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_7a7a0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_5659d5" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_7a7a0f" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_2a15b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_316071" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_2a15b0" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_f6e0e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_2a15b0" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_f6e0e3" order="50" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsMember" xlink:label="loc_knwnStockOptionsMember_cef8c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7b1186" xlink:to="loc_knwnStockOptionsMember_cef8c6" order="51" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TwoZeroTwoOneEquityIncentivePlanMember" xlink:label="loc_knwnTwoZeroTwoOneEquityIncentivePlanMember_e81732" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bfd70c" xlink:to="loc_knwnTwoZeroTwoOneEquityIncentivePlanMember_e81732" order="52" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember_28125e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_7a7a0f" xlink:to="loc_knwnRonaldPEricksonMember_28125e" order="53" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PhillipABosuaMember" xlink:label="loc_knwnPhillipABosuaMember_a2a638" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_7a7a0f" xlink:to="loc_knwnPhillipABosuaMember_a2a638" order="54" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PeterConleyMember" xlink:label="loc_knwnPeterConleyMember_c898a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_7a7a0f" xlink:to="loc_knwnPeterConleyMember_c898a1" order="55" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EightEmployeesAndConsultantsMember" xlink:label="loc_knwnEightEmployeesAndConsultantsMember_e98664" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_f6e0e3" xlink:to="loc_knwnEightEmployeesAndConsultantsMember_e98664" order="56" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NineteenEmployeesAndConsultantsMember" xlink:label="loc_knwnNineteenEmployeesAndConsultantsMember_3f5fcc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_f6e0e3" xlink:to="loc_knwnNineteenEmployeesAndConsultantsMember_3f5fcc" order="57" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IntrinsicValue" xlink:label="loc_knwnIntrinsicValue_09a2ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnIntrinsicValue_09a2ec" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrants" xlink:label="loc_knwnStockOptionGrants_e2327d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnStockOptionGrants_e2327d" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8cb56a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8cb56a" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_96f36e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_96f36e" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_6dc50c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_6dc50c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_46b7bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_46b7bf" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesIncrease" xlink:label="loc_knwnNumberOfCommonStockSharesIncrease_4de9e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnNumberOfCommonStockSharesIncrease_4de9e1" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" xlink:label="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_1d7986" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned_1d7986" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_602fff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapSharesIssuedPricePerShare_602fff" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:label="loc_knwnStockIssuedDuringPeriodSharesStockOptionExercised_87b163" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnStockIssuedDuringPeriodSharesStockOptionExercised_87b163" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseStockOptionGrantsreceived" xlink:label="loc_knwnExerciseStockOptionGrantsreceived_1bc2ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnExerciseStockOptionGrantsreceived_1bc2ff" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantIssuedToCommonStock" xlink:label="loc_knwnWarrantIssuedToCommonStock_5b1e85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_knwnWarrantIssuedToCommonStock_5b1e85" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9f06d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6f80ba" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b9f06d" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:title="000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_3f38ed" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_048e10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_3f38ed" xlink:to="loc_us-gaapStatementTable_048e10" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_23e07e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_048e10" xlink:to="loc_us-gaapStatementLineItems_23e07e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_98e605" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_048e10" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_98e605" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_2ecc7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_98e605" xlink:to="loc_us-gaapRelatedPartyDomain_2ecc7f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_1ddc8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_048e10" xlink:to="loc_srtTitleOfIndividualAxis_1ddc8a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b92004" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_1ddc8a" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b92004" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_551946" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_048e10" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_551946" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_d48257" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_551946" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_d48257" order="30" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrStruveMember" xlink:label="loc_knwnMrStruveMember_807fed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2ecc7f" xlink:to="loc_knwnMrStruveMember_807fed" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThreeDirectorMember" xlink:label="loc_knwnThreeDirectorMember_0db9cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b92004" xlink:to="loc_knwnThreeDirectorMember_0db9cc" order="32" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember_cf3253" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d48257" xlink:to="loc_knwnRonaldPEricksonMember_cf3253" order="33" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PhillipABosuaMember" xlink:label="loc_knwnPhillipABosuaMember_0e3fa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d48257" xlink:to="loc_knwnPhillipABosuaMember_0e3fa5" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_8bd341" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2ecc7f" xlink:to="loc_srtDirectorMember_8bd341" order="35" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AIMindMember" xlink:label="loc_knwnAIMindMember_0cd20a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d48257" xlink:to="loc_knwnAIMindMember_0cd20a" order="36" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareGrant" xlink:label="loc_knwnShareGrant_d78408" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnShareGrant_d78408" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_cf0adb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapShareBasedCompensation_cf0adb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentExpense" xlink:label="loc_us-gaapEquipmentExpense_e41fd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapEquipmentExpense_e41fd7" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare_cc4d17" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnExercisePricePerShare_cc4d17" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_568072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_568072" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionRelatedToCommonStock" xlink:label="loc_knwnDescriptionRelatedToCommonStock_83df49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnDescriptionRelatedToCommonStock_83df49" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeExpenses" xlink:label="loc_knwnCumulativeExpenses_2dbfd3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnCumulativeExpenses_2dbfd3" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalStockOption" xlink:label="loc_knwnAdditionalStockOption_3bea42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnAdditionalStockOption_3bea42" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalExercisedPrice" xlink:label="loc_knwnAdditionalExercisedPrice_730788" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnAdditionalExercisedPrice_730788" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_fd79f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapInterestPaid_fd79f6" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="loc_us-gaapDividendsSharebasedCompensationStock_0be76e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapDividendsSharebasedCompensationStock_0be76e" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccruedCompensastionTravelAndInterest" xlink:label="loc_knwnAccruedCompensastionTravelAndInterest_79779a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnAccruedCompensastionTravelAndInterest_79779a" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_de6ee4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapSeveranceCosts1_de6ee4" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_231f59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapLeaseAndRentalExpense_231f59" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_44dcfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_44dcfc" order="15" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStock" xlink:label="loc_knwnWarrantsToPurchaseCommonStock_fd2d0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnWarrantsToPurchaseCommonStock_fd2d0f" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_d28273" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapSharePrice_d28273" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent_6af052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapPrepaidRent_6af052" order="18" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividends" xlink:label="loc_knwnReceivedSeriesDPreferredStockDividends_f0937b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_knwnReceivedSeriesDPreferredStockDividends_f0937b" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_a5feb5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapSharesIssued_a5feb5" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_2fd282" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_23e07e" xlink:to="loc_us-gaapInterestExpenseDebt_2fd282" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:title="000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_96c6c0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_906fd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_96c6c0" xlink:to="loc_us-gaapStatementTable_906fd6" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_45f529" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_906fd6" xlink:to="loc_us-gaapStatementLineItems_45f529" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_3fc1f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_906fd6" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_3fc1f9" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_d1e4bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_3fc1f9" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_d1e4bd" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_4ae845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_906fd6" xlink:to="loc_srtTitleOfIndividualAxis_4ae845" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_ab4b55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_4ae845" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_ab4b55" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember_7c9912" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d1e4bd" xlink:to="loc_knwnRonaldPEricksonMember_7c9912" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PeterConleyMember" xlink:label="loc_knwnPeterConleyMember_6ddb61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d1e4bd" xlink:to="loc_knwnPeterConleyMember_6ddb61" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrBosuaMember" xlink:label="loc_knwnMrBosuaMember_394dc5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_ab4b55" xlink:to="loc_knwnMrBosuaMember_394dc5" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_16bf96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments_16bf96" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AnnualSalary" xlink:label="loc_knwnAnnualSalary_d72992" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_knwnAnnualSalary_d72992" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_LeaseDescription" xlink:label="loc_knwnLeaseDescription_5d9116" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_knwnLeaseDescription_5d9116" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_d3d5f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_us-gaapOfficersCompensation_d3d5f1" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_8f0878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_8f0878" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockPerShares" xlink:label="loc_knwnCommonStockPerShares_36a970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_knwnCommonStockPerShares_36a970" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_46bc55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_45f529" xlink:to="loc_us-gaapPaymentsForRent_46bc55" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails" xlink:title="000051 - Disclosure - INCOME TAXES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_4e32d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_4e32d1" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation" xlink:label="loc_knwnDeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation_06129d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_knwnDeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation_06129d" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment" xlink:label="loc_knwnDeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment_11fbd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_knwnDeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment_11fbd6" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_18a23e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_18a23e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d54583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d54583" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_6bbaa9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapDeferredTaxAssetsGross_6bbaa9" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_ccf4c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_ccf4c4" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_b17967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapDeferredTaxAssetsNet_b17967" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0c95b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_1c6487" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0c95b" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails1" xlink:title="000052 - Disclosure - INCOME TAXES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_449147" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abd242" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_449147" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_abd242" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_159d6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_449147" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_159d6a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_449147" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_571790" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp" xlink:label="loc_knwnEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp_12f27b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_449147" xlink:to="loc_knwnEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp_12f27b" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_ac4faa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_449147" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_ac4faa" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:title="000053 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_5ff058" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_FederalNetOperatingLossCarryforwardsExpired" xlink:label="loc_knwnFederalNetOperatingLossCarryforwardsExpired_d9dee6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5ff058" xlink:to="loc_knwnFederalNetOperatingLossCarryforwardsExpired_d9dee6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_b6e62c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5ff058" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_b6e62c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther_3ad53d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5ff058" xlink:to="loc_us-gaapDeferredTaxAssetsOther_3ad53d" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EffectiveTaxRate" xlink:label="loc_knwnEffectiveTaxRate_8ce74e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5ff058" xlink:to="loc_knwnEffectiveTaxRate_8ce74e" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetails" xlink:title="000054 - Disclosure - SEGMENT REPORTING (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_e64621" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e9a05d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_e64621" xlink:to="loc_us-gaapStatementTable_e9a05d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3763e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e9a05d" xlink:to="loc_us-gaapStatementLineItems_3763e6" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis_bfc0d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e9a05d" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis_bfc0d2" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_9874fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis_bfc0d2" xlink:to="loc_us-gaapSegmentDomain_9874fa" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" xlink:label="loc_knwnDevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember_80a0c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9874fa" xlink:to="loc_knwnDevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember_80a0c8" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ParticleIncTechnologyMember" xlink:label="loc_knwnParticleIncTechnologyMember_8e3333" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9874fa" xlink:to="loc_knwnParticleIncTechnologyMember_8e3333" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DigitalassetsalesMember" xlink:label="loc_knwnDigitalassetsalesMember_95f06c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain_9874fa" xlink:to="loc_knwnDigitalassetsalesMember_95f06c" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentRevenues" xlink:label="loc_knwnSegmentRevenues_b20026" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3763e6" xlink:to="loc_knwnSegmentRevenues_b20026" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentNetIncomeLoss" xlink:label="loc_knwnSegmentNetIncomeLoss_3af052" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3763e6" xlink:to="loc_knwnSegmentNetIncomeLoss_3af052" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentAsset" xlink:label="loc_knwnSegmentAsset_7ca092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3763e6" xlink:to="loc_knwnSegmentAsset_7ca092" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:title="000055 - Disclosure - SEGMENT REPORTING (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract_1c1d13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_caa773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract_1c1d13" xlink:to="loc_us-gaapOtherNoncashExpense_caa773" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_012d9c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_99b5a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_012d9c" xlink:to="loc_us-gaapStatementTable_99b5a5" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_e13143" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_99b5a5" xlink:to="loc_us-gaapStatementLineItems_e13143" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_00a1fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_99b5a5" xlink:to="loc_us-gaapSubsequentEventTypeAxis_00a1fb" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_79b58b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_00a1fb" xlink:to="loc_us-gaapSubsequentEventTypeDomain_79b58b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_66dc86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_79b58b" xlink:to="loc_us-gaapSubsequentEventMember_66dc86" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_067dcf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_us-gaapSharesIssued_067dcf" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_cbaeb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_us-gaapSharePrice_cbaeb6" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalSharePurchase" xlink:label="loc_knwnAdditionalSharePurchase_7c0a9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_knwnAdditionalSharePurchase_7c0a9b" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_c03bc4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_c03bc4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4d623d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4d623d" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrantsToEmployeesAndDirectors" xlink:label="loc_knwnStockOptionGrantsToEmployeesAndDirectors_2de6fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_knwnStockOptionGrantsToEmployeesAndDirectors_2de6fa" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d20bbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d20bbc" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionExpiryTerm" xlink:label="loc_knwnStockOptionExpiryTerm_c9c4ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_e13143" xlink:to="loc_knwnStockOptionExpiryTerm_c9c4ec" order="8" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>knwn-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 12/19/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://knwn.com/role/Cover" xlink:href="knwn-20230930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="knwn-20230930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="knwn-20230930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ORGANIZATION" xlink:href="knwn-20230930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LIQUIDITY" xlink:href="knwn-20230930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatform" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatform" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipment" xlink:href="knwn-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LEASES" xlink:href="knwn-20230930.xsd#LEASES" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayable" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EQUITY" xlink:href="knwn-20230930.xsd#EQUITY" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlans" xlink:href="knwn-20230930.xsd#StockIncentivePlans" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedParties" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedings" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxes" xlink:href="knwn-20230930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReporting" xlink:href="knwn-20230930.xsd#SegmentReporting" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEvents" xlink:href="knwn-20230930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentTables" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesTables" xlink:href="knwn-20230930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityTables" xlink:href="knwn-20230930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansTables" xlink:href="knwn-20230930.xsd#StockIncentivePlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesTables" xlink:href="knwn-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingTables" xlink:href="knwn-20230930.xsd#SegmentReportingTables" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OrganizationDetailsNarrative" xlink:href="knwn-20230930.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:href="knwn-20230930.xsd#SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:href="knwn-20230930.xsd#AiDeepLearningPlatformDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="knwn-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetails" xlink:href="knwn-20230930.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LeasesDetailsNarrative" xlink:href="knwn-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="knwn-20230930.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:href="knwn-20230930.xsd#ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails" xlink:href="knwn-20230930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails1" xlink:href="knwn-20230930.xsd#EquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails2" xlink:href="knwn-20230930.xsd#EquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails3" xlink:href="knwn-20230930.xsd#EquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetails4" xlink:href="knwn-20230930.xsd#EquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/EquityDetailsNarrative" xlink:href="knwn-20230930.xsd#EquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetails1" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:href="knwn-20230930.xsd#StockIncentivePlansDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:href="knwn-20230930.xsd#OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:href="knwn-20230930.xsd#CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetails1" xlink:href="knwn-20230930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:href="knwn-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetails" xlink:href="knwn-20230930.xsd#SegmentReportingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:href="knwn-20230930.xsd#SegmentReportingDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:href="knwn-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheets" xlink:title="000002 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsAbstract" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssets" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountDueToRelatedPartiesCurrent" xlink:label="loc_knwnAmountDueToRelatedPartiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAmountDueToRelatedPartiesCurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesNoncurrent" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" order="28" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStocksSeriesCMember" xlink:label="loc_knwnConvertiblePreferredStocksSeriesCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnConvertiblePreferredStocksSeriesCMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesDMember" xlink:label="loc_knwnConvertiblePreferredStockSeriesDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnConvertiblePreferredStockSeriesDMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfOperations" xlink:title="000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCConvertiblesPreferredStockMember" xlink:label="loc_knwnSeriesCConvertiblesPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_knwnSeriesCConvertiblesPreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesDConvertiblePreferredStockMember" xlink:label="loc_knwnSeriesDConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_knwnSeriesDConvertiblePreferredStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksMember" xlink:label="loc_knwnCommonStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_knwnCommonStocksMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockCompensationExpenseEmployeeOptions" xlink:label="loc_knwnStockCompensationExpenseEmployeeOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnStockCompensationExpenseEmployeeOptions" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestShares" xlink:label="loc_knwnConversionOfDebtOfferingAndAccruedInterestShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnConversionOfDebtOfferingAndAccruedInterestShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConversionOfDebtOfferingAndAccruedInterestAmount" xlink:label="loc_knwnConversionOfDebtOfferingAndAccruedInterestAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnConversionOfDebtOfferingAndAccruedInterestAmount" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:label="loc_knwnIssuanceOfCommonStockForStockOptionExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuanceOfCommonStockForStockOptionExercisesShares" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForStockOptionExercisesAmount" xlink:label="loc_knwnIssuanceOfCommonStockForStockOptionExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuanceOfCommonStockForStockOptionExercisesAmount" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsShares" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuanceOfCommonStockForExerciseOfWarrantsAmount" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuanceOfCommonStockWarrantForServices" xlink:label="loc_knwnIssuanceOfCommonStockWarrantForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuanceOfCommonStockWarrantForServices" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingShares" xlink:label="loc_knwnIsssuanceOfCommonStockForNyseUplistingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIsssuanceOfCommonStockForNyseUplistingShares" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForNyseUplistingAmount" xlink:label="loc_knwnIsssuanceOfCommonStockForNyseUplistingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIsssuanceOfCommonStockForNyseUplistingAmount" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="15" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockShares" xlink:label="loc_knwnCommonStockDividendsOnSeriesDPreferredStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCommonStockDividendsOnSeriesDPreferredStockShares" order="16" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockDividendsOnSeriesDPreferredStockAmount" xlink:label="loc_knwnCommonStockDividendsOnSeriesDPreferredStockAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCommonStockDividendsOnSeriesDPreferredStockAmount" order="17" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsOnSeriesCAndDPreferredStock" xlink:label="loc_knwnDeemedDividendsOnSeriesCAndDPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDeemedDividendsOnSeriesCAndDPreferredStock" order="18" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingShares" xlink:label="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingShares" order="19" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount" xlink:label="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIsssuanceOfCommonStockForCommonStockOfferingAmount" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExpensesForExtensionOfNotesAndWarrants" xlink:label="loc_knwnExpensesForExtensionOfNotesAndWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExpensesForExtensionOfNotesAndWarrants" order="21" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards" xlink:title="000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatform" xlink:title="000010 - Disclosure - AI DEEP LEARNING PLATFORM" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LEASES" xlink:title="000012 - Disclosure - LEASES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayable" xlink:title="000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EQUITY" xlink:title="000014 - Disclosure - EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlans" xlink:title="000015 - Disclosure - STOCK INCENTIVE PLANS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties" xlink:title="000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings" xlink:title="000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxes" xlink:title="000018 - Disclosure - INCOME TAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReporting" xlink:title="000019 - Disclosure - SEGMENT REPORTING" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEvents" xlink:title="000020 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies" xlink:title="000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentTables" xlink:title="000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesTables" xlink:title="000023 - Disclosure - LEASES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables" xlink:title="000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityTables" xlink:title="000025 - Disclosure - EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansTables" xlink:title="000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesTables" xlink:title="000027 - Disclosure - INCOME TAXES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingTables" xlink:title="000028 - Disclosure - SEGMENT REPORTING (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/OrganizationDetailsNarrative" xlink:title="000029 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityDetailsNarrative" xlink:title="000030 - Disclosure - LIQUIDITY (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative" xlink:title="000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="110" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" order="91" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Warrant1Member" xlink:label="loc_knwnWarrant1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_knwnWarrant1Member" order="92" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption1Member" xlink:label="loc_knwnStockOption1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_knwnStockOption1Member" order="93" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="94" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="95" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" order="96" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit" xlink:label="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTimeDepositsAtOrAboveFDICInsuranceLimit" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeveranceAndOtherExpenses" xlink:label="loc_knwnSeveranceAndOtherExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnSeveranceAndOtherExpenses" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleDebentures" xlink:label="loc_knwnConvertibleDebentures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnConvertibleDebentures" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReservedSharesToPaySeriesCAndDDividends" xlink:label="loc_knwnReservedSharesToPaySeriesCAndDDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnReservedSharesToPaySeriesCAndDDividends" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PropertyPlantsAndEquipmentUsefulLife" xlink:label="loc_knwnPropertyPlantsAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnPropertyPlantsAndEquipmentUsefulLife" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative" xlink:title="000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_Revenue" xlink:label="loc_knwnRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnRevenue" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmountTotal" xlink:label="loc_knwnAmountTotal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAmountTotal" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSellingExpense" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetails" xlink:title="000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" xlink:label="loc_knwnResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_knwnResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AssetsNetBookValue" xlink:label="loc_knwnAssetsNetBookValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAssetsNetBookValue" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetails" xlink:title="000035 - Disclosure - LEASES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LeasesDetailsNarrative" xlink:title="000036 - Disclosure - LEASES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThirtyFirstDecemberTwentyTwentyThreeMember" xlink:label="loc_knwnThirtyFirstDecemberTwentyTwentyThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_knwnThirtyFirstDecemberTwentyTwentyThreeMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CashAndCashEquivalents" xlink:label="loc_knwnCashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCashAndCashEquivalents" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NetWorkingCapital" xlink:label="loc_knwnNetWorkingCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnNetWorkingCapital" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossProceedFromPublicIssueStock" xlink:label="loc_knwnGrossProceedFromPublicIssueStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnGrossProceedFromPublicIssueStock" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails" xlink:title="000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteOneMember" xlink:label="loc_knwnConvertibleNoteOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNoteOneMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNoteTwoMember" xlink:label="loc_knwnConvertibleNoteTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNoteTwoMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesFiveMember" xlink:label="loc_knwnConvertibleNotesFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNotesFiveMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNotesConversions" xlink:label="loc_knwnConvertibleNotesConversions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnConvertibleNotesConversions" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative" xlink:title="000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote2Member" xlink:label="loc_knwnConvertibleNote2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNote2Member" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote1Member" xlink:label="loc_knwnConvertibleNote1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNote1Member" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote8Member" xlink:label="loc_knwnConvertibleNote8Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNote8Member" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleNote7Member" xlink:label="loc_knwnConvertibleNote7Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_knwnConvertibleNote7Member" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentExpense" xlink:label="loc_us-gaapEquipmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquipmentExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DepositLiabilitiesAccruedInterestsAmount" xlink:label="loc_knwnDepositLiabilitiesAccruedInterestsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDepositLiabilitiesAccruedInterestsAmount" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmortizationOfDebtDiscountPremiums" xlink:label="loc_knwnAmortizationOfDebtDiscountPremiums" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAmortizationOfDebtDiscountPremiums" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="loc_us-gaapDepositLiabilitiesAccruedInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepositLiabilitiesAccruedInterest" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertibleRedeemablePromissoryNoteAmount" xlink:label="loc_knwnConvertibleRedeemablePromissoryNoteAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnConvertibleRedeemablePromissoryNoteAmount" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" order="10" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails" xlink:title="000040 - Disclosure - EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantOneMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantTwoMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantThreeMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantFourMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfWarrantShares" xlink:label="loc_knwnNumberOfWarrantShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnNumberOfWarrantShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DateOfIssue" xlink:label="loc_knwnDateOfIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDateOfIssue" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OriginalExpirationDate" xlink:label="loc_knwnOriginalExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnOriginalExpirationDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmendedExpirationdate" xlink:label="loc_knwnAmendedExpirationdate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAmendedExpirationdate" order="4" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExercisePricePerShare" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails1" xlink:title="000041 - Disclosure - EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantOneMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantTwoMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantThreeMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantFourMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfWarrantShares" xlink:label="loc_knwnNumberOfWarrantShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnNumberOfWarrantShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DateOfIssue" xlink:label="loc_knwnDateOfIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDateOfIssue" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OriginalExpirationDate" xlink:label="loc_knwnOriginalExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnOriginalExpirationDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AmendedExpirationdate" xlink:label="loc_knwnAmendedExpirationdate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAmendedExpirationdate" order="4" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExercisePricePerShare" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails2" xlink:title="000042 - Disclosure - EQUITY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails3" xlink:title="000043 - Disclosure - EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantOneMember" xlink:label="loc_knwnWarrantOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantOneMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantTwoMember" xlink:label="loc_knwnWarrantTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantTwoMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantThreeMember" xlink:label="loc_knwnWarrantThreeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantThreeMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantFourMember" xlink:label="loc_knwnWarrantFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnWarrantFourMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAveragesRemainingLifeYears" xlink:label="loc_knwnWeightedAveragesRemainingLifeYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWeightedAveragesRemainingLifeYears" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetails4" xlink:title="000044 - Disclosure - EQUITY (Details 4)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/EquityDetailsNarrative" xlink:title="000045 - Disclosure - EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="110" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="120" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrStruveMember" xlink:label="loc_knwnMrStruveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_knwnMrStruveMember" order="101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" order="102" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" order="103" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SeriesCAndDPreferredStockMember" xlink:label="loc_knwnSeriesCAndDPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnSeriesCAndDPreferredStockMember" order="104" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStockMember" xlink:label="loc_knwnWarrantsToPurchaseCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_knwnWarrantsToPurchaseCommonStockMember" order="105" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThreeDirectorMember" xlink:label="loc_knwnThreeDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_knwnThreeDirectorMember" order="106" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonPreferredStocksMember" xlink:label="loc_knwnCommonPreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnCommonPreferredStocksMember" order="107" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AuthorizedCapitalStockMember" xlink:label="loc_knwnAuthorizedCapitalStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnAuthorizedCapitalStockMember" order="108" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_knwnConvertiblePreferredStockSeriesCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnConvertiblePreferredStockSeriesCMember" order="109" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtTwoMember" xlink:label="loc_knwnStockAtTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnStockAtTwoMember" order="110" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockAtOneMember" xlink:label="loc_knwnStockAtOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnStockAtOneMember" order="111" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ConvertiblePreferredStockDMember" xlink:label="loc_knwnConvertiblePreferredStockDMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnConvertiblePreferredStockDMember" order="112" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" order="113" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStocksOfferingsMember" xlink:label="loc_knwnCommonStocksOfferingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnCommonStocksOfferingsMember" order="114" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantToPurchaseCommonStockMember" xlink:label="loc_knwnWarrantToPurchaseCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_knwnWarrantToPurchaseCommonStockMember" order="115" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_BousteadSecuritiesLLCMember" xlink:label="loc_knwnBousteadSecuritiesLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnBousteadSecuritiesLLCMember" order="116" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_OwnershipInterestInPreferredStock" xlink:label="loc_knwnOwnershipInterestInPreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnOwnershipInterestInPreferredStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CumulativeDividends" xlink:label="loc_us-gaapCumulativeDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCumulativeDividends" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesSettled" xlink:label="loc_knwnNumberOfCommonStockSharesSettled" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnNumberOfCommonStockSharesSettled" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DividendDistributedPerShare" xlink:label="loc_knwnDividendDistributedPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDividendDistributedPerShare" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsShares" xlink:label="loc_us-gaapCommonStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockDividendsShares" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="9" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeDividendUnpaid" xlink:label="loc_knwnCumulativeDividendUnpaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCumulativeDividendUnpaid" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DeemedDividendsCumulative" xlink:label="loc_knwnDeemedDividendsCumulative" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDeemedDividendsCumulative" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccretedValueOfPreferredDividendIntoCommonStockShares" xlink:label="loc_knwnAccretedValueOfPreferredDividendIntoCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAccretedValueOfPreferredDividendIntoCommonStockShares" order="12" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedOfWarrant" xlink:label="loc_knwnReceivedOfWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnReceivedOfWarrant" order="13" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_knwnSharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnSharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="14" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionOfAutomaticConversionOfConvertible" xlink:label="loc_knwnDescriptionOfAutomaticConversionOfConvertible" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDescriptionOfAutomaticConversionOfConvertible" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" order="16" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantIssuedToCommonStock" xlink:label="loc_knwnWarrantIssuedToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantIssuedToCommonStock" order="17" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividendsShares" xlink:label="loc_knwnReceivedSeriesDPreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnReceivedSeriesDPreferredStockDividendsShares" order="18" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStock" xlink:label="loc_knwnWarrantsToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantsToPurchaseCommonStock" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="20" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShrareIssuedWarrantToPurchasedPrice" xlink:label="loc_knwnShrareIssuedWarrantToPurchasedPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnShrareIssuedWarrantToPurchasedPrice" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToAcquireCommonStockShares" xlink:label="loc_knwnWarrantsToAcquireCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantsToAcquireCommonStockShares" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharePrice" xlink:label="loc_knwnCommonStockSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCommonStockSharePrice" order="24" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PreferredStockConvertibleConversionPriceAdjusted" xlink:label="loc_knwnPreferredStockConvertibleConversionPriceAdjusted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnPreferredStockConvertibleConversionPriceAdjusted" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" order="26" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsExpiredPerSharePrice" xlink:label="loc_knwnWarrantsExpiredPerSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantsExpiredPerSharePrice" order="27" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ProceedsFromIssuanceOfCommonStocks" xlink:label="loc_knwnProceedsFromIssuanceOfCommonStocks" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnProceedsFromIssuanceOfCommonStocks" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseOther" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="33" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_GrossSales" xlink:label="loc_knwnGrossSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnGrossSales" order="34" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsIssuedValued" xlink:label="loc_knwnWarrantsIssuedValued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantsIssuedValued" order="35" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockSharesIssuedRelatedToWarrantExercises" xlink:label="loc_knwnCommonStockSharesIssuedRelatedToWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCommonStockSharesIssuedRelatedToWarrantExercises" order="36" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IssuedAmountReceived" xlink:label="loc_knwnIssuedAmountReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIssuedAmountReceived" order="37" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="38" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="39" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseOfStockOption" xlink:label="loc_knwnExerciseOfStockOption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExerciseOfStockOption" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="43" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="44" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" order="45" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesCConvertiblePreferredStock" xlink:label="loc_knwnDesignatedSeriesCConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDesignatedSeriesCConvertiblePreferredStock" order="46" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStocks" xlink:label="loc_knwnDesignatedSeriesDConvertiblePreferredStocks" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDesignatedSeriesDConvertiblePreferredStocks" order="47" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DesignatedSeriesDConvertiblePreferredStock" xlink:label="loc_knwnDesignatedSeriesDConvertiblePreferredStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDesignatedSeriesDConvertiblePreferredStock" order="48" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReverseStockSplit" xlink:label="loc_knwnReverseStockSplit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnReverseStockSplit" order="49" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails" xlink:title="000046 - Disclosure - STOCK INCENTIVE PLANS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsMember" xlink:label="loc_knwnStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_knwnStockOptionsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetails1" xlink:title="000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption1Member" xlink:label="loc_knwnStockOption1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_knwnStockOption1Member" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption2Member" xlink:label="loc_knwnStockOption2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnStockOption2Member" order="64" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOption3Member" xlink:label="loc_knwnStockOption3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_knwnStockOption3Member" order="65" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsOneMember" xlink:label="loc_knwnStockOptionsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_knwnStockOptionsOneMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsTwoMember" xlink:label="loc_knwnStockOptionsTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_knwnStockOptionsTwoMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EmployeeStockOptionsOneMember" xlink:label="loc_knwnEmployeeStockOptionsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_knwnEmployeeStockOptionsOneMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageRemainingLifeYears" xlink:label="loc_knwnWeightedAverageRemainingLifeYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWeightedAverageRemainingLifeYears" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WeightedAverageExercisePriceOutstanding" xlink:label="loc_knwnWeightedAverageExercisePriceOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWeightedAverageExercisePriceOutstanding" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/StockIncentivePlansDetailsNarrative" xlink:title="000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionsMember" xlink:label="loc_knwnStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_knwnStockOptionsMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_TwoZeroTwoOneEquityIncentivePlanMember" xlink:label="loc_knwnTwoZeroTwoOneEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_knwnTwoZeroTwoOneEquityIncentivePlanMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnRonaldPEricksonMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PhillipABosuaMember" xlink:label="loc_knwnPhillipABosuaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnPhillipABosuaMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PeterConleyMember" xlink:label="loc_knwnPeterConleyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnPeterConleyMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_EightEmployeesAndConsultantsMember" xlink:label="loc_knwnEightEmployeesAndConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_knwnEightEmployeesAndConsultantsMember" order="56" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NineteenEmployeesAndConsultantsMember" xlink:label="loc_knwnNineteenEmployeesAndConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="loc_knwnNineteenEmployeesAndConsultantsMember" order="57" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_IntrinsicValue" xlink:label="loc_knwnIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnIntrinsicValue" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrants" xlink:label="loc_knwnStockOptionGrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnStockOptionGrants" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_NumberOfCommonStockSharesIncrease" xlink:label="loc_knwnNumberOfCommonStockSharesIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnNumberOfCommonStockSharesIncrease" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" xlink:label="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" order="9" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:label="loc_knwnStockIssuedDuringPeriodSharesStockOptionExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnStockIssuedDuringPeriodSharesStockOptionExercised" order="10" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExerciseStockOptionGrantsreceived" xlink:label="loc_knwnExerciseStockOptionGrantsreceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExerciseStockOptionGrantsreceived" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantIssuedToCommonStock" xlink:label="loc_knwnWarrantIssuedToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantIssuedToCommonStock" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative" xlink:title="000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrStruveMember" xlink:label="loc_knwnMrStruveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_knwnMrStruveMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ThreeDirectorMember" xlink:label="loc_knwnThreeDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_knwnThreeDirectorMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnRonaldPEricksonMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PhillipABosuaMember" xlink:label="loc_knwnPhillipABosuaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnPhillipABosuaMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtDirectorMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AIMindMember" xlink:label="loc_knwnAIMindMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnAIMindMember" order="36" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ShareGrant" xlink:label="loc_knwnShareGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnShareGrant" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentExpense" xlink:label="loc_us-gaapEquipmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquipmentExpense" order="3" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ExercisePricePerShare" xlink:label="loc_knwnExercisePricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnExercisePricePerShare" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DescriptionRelatedToCommonStock" xlink:label="loc_knwnDescriptionRelatedToCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnDescriptionRelatedToCommonStock" order="6" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CumulativeExpenses" xlink:label="loc_knwnCumulativeExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCumulativeExpenses" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalStockOption" xlink:label="loc_knwnAdditionalStockOption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAdditionalStockOption" order="8" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalExercisedPrice" xlink:label="loc_knwnAdditionalExercisedPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAdditionalExercisedPrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="loc_us-gaapDividendsSharebasedCompensationStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsSharebasedCompensationStock" order="11" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AccruedCompensastionTravelAndInterest" xlink:label="loc_knwnAccruedCompensastionTravelAndInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAccruedCompensastionTravelAndInterest" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSeveranceCosts1" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" order="15" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_WarrantsToPurchaseCommonStock" xlink:label="loc_knwnWarrantsToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnWarrantsToPurchaseCommonStock" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidRent" order="18" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ReceivedSeriesDPreferredStockDividends" xlink:label="loc_knwnReceivedSeriesDPreferredStockDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnReceivedSeriesDPreferredStockDividends" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" order="21" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative" xlink:title="000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_RonaldPEricksonMember" xlink:label="loc_knwnRonaldPEricksonMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnRonaldPEricksonMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_PeterConleyMember" xlink:label="loc_knwnPeterConleyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_knwnPeterConleyMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_MrBosuaMember" xlink:label="loc_knwnMrBosuaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_knwnMrBosuaMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionMonthlyRentalPayments" xlink:label="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleLeasebackTransactionMonthlyRentalPayments" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AnnualSalary" xlink:label="loc_knwnAnnualSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAnnualSalary" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_LeaseDescription" xlink:label="loc_knwnLeaseDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnLeaseDescription" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOfficersCompensation" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_CommonStockPerShares" xlink:label="loc_knwnCommonStockPerShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnCommonStockPerShares" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails" xlink:title="000051 - Disclosure - INCOME TAXES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetails1" xlink:title="000052 - Disclosure - INCOME TAXES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/IncomeTaxesDetailsNarrative" xlink:title="000053 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetails" xlink:title="000054 - Disclosure - SEGMENT REPORTING (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" xlink:label="loc_knwnDevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_knwnDevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_ParticleIncTechnologyMember" xlink:label="loc_knwnParticleIncTechnologyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_knwnParticleIncTechnologyMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_DigitalassetsalesMember" xlink:label="loc_knwnDigitalassetsalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_knwnDigitalassetsalesMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentRevenues" xlink:label="loc_knwnSegmentRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnSegmentRevenues" order="1" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentNetIncomeLoss" xlink:label="loc_knwnSegmentNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnSegmentNetIncomeLoss" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_SegmentAsset" xlink:label="loc_knwnSegmentAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnSegmentAsset" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SegmentReportingDetailsNarrative" xlink:title="000055 - Disclosure - SEGMENT REPORTING (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://knwn.com/role/SubsequentEventsDetailsNarrative" xlink:title="000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_AdditionalSharePurchase" xlink:label="loc_knwnAdditionalSharePurchase" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnAdditionalSharePurchase" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionGrantsToEmployeesAndDirectors" xlink:label="loc_knwnStockOptionGrantsToEmployeesAndDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnStockOptionGrantsToEmployeesAndDirectors" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="knwn-20230930.xsd#knwn_StockOptionExpiryTerm" xlink:label="loc_knwnStockOptionExpiryTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_knwnStockOptionExpiryTerm" order="8" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>knwn_10kimg32.jpg
<TEXT>
begin 644 knwn_10kimg32.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !X AT# 2(  A$! Q$!_\0
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MH @^R6O_ #[1?]\"HH+:W:(EK>,G>XY0?WC5RH+?_4M_UT?_ -#- !]DM?\
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M.[59J%?^/Z7_ *YI_-J (;:WC:TA8M)DHIXD8=OK4OV>/^]+_P!_7_QHM/\
MCR@_ZYK_ "J>@"#[/'_>E_[^O_C1]GC_ +TO_?U_\:GHH @^SQ_WI?\ OZ_^
M-'V>/^]+_P!_7_QJ>B@"#[/'_>E_[^O_ (T?9X_[TO\ W]?_ !J>B@"#[/'_
M 'I?^_K_ .-'V>/^]+_W]?\ QJ>B@"#[/'_>E_[^O_C1]GC_ +TO_?U_\:GH
MH @^SQ_WI?\ OZ_^-'V>/^]+_P!_7_QJ>B@"#[/'_>E_[^O_ (T?9X_[TO\
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M2\CCLC'D>=$\(EWR,R;E&Z+ +<,.:YVSTW6/"T]IJ6JZ,\>E^$8=0=)XKBW
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MW'2O=,COO%OA**WE\>-HT%CJNZ]GM[Y+H!VC:.)IO+$R#*,%W%9"$4$L&&X
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M-W-'#>JNF65C=HCQ[A]F>"Y>22'<$P,00^9DMN5F4$@'I7_"&^(O^BL>*O\
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M_C;%'X=TO4HI=0Q_;$<EG+]CEBV'%RLV/+1QM1<*V6R0RD@%0#J/^$-\1?\
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M@TR_\-Z/-K&K?%KQ9%:QX7$=EILLDC,<*B(MB69B2   37HUQ_J5_P"NB?\
MH8KEO'D.EW7@O44UFPO+VT51(18I(\T3*<K(@B_>95@#E,D?3- &+HNCZIKV
MD0:II_Q6\6-;3=!)9Z9&Z'NKHUB&1@>"I (-:_\ PAOB+_HK'BK_ ,!M*_\
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MB_[]'_XJC;=?\]HO^_1_^*J:B@"';=?\]HO^_1_^*HVW7_/:+_OT?_BJFHH
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M/_Q5344 0[;K_GM%_P!^C_\ %4;;K_GM%_WZ/_Q5344 0[;K_GM%_P!^C_\
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M3)X3UB*;5'(OH(Y(GMD%G)(D@B=I/*;*RC?YC?)T'S': >J[KK_GC%_W\/\
M\31NNO\ GC%_W\/_ ,37S]J'Q \?7WA75/)O+&PE6729K._33)H5F@NKDQ-M
MC>?S-H*\.PB+#=A%#*U;L/C;7K/7=4T?[#H&FZW>^)(]'348[61X7/V-91-,
MN]&=V V*F\8RHW-MRP![)NNO^>,7_?P__$T;KK_GC%_W\/\ \37BVG?$+X@:
MQJ&EZ796'A^QFN++49+B\F6>9/.M+@1%HX@4)C;C ,F1NZ_)A_2?!>N3>)O
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MXK:-XDC:UOFO@UBD-W90M-IZI Q#VLP0.B_*0R,64^9D%>C 'HNZZ_YXQ?\
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M1_W9?^_3_P"%'VB/^[+_ -^G_P *** #[1'_ '9?^_3_ .%'VB/^[+_WZ?\
MPHHH /M$?]V7_OT_^%'VB/\ NR_]^G_PHHH /M$?]V7_ +]/_A1]HC_NR_\
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KGN:V-(U;4M4FN)-0\(ZEH@C5%0:C-:MYO+9V^1-+C'&=V.HQGG!10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>knwn_10kimg33.jpg
<TEXT>
begin 644 knwn_10kimg33.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !& 3X# 2(  A$! Q$!_\0
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MAN+656&,AHY@KCJ.HYS7,?%!I/\ A5\D,-C?WLLDEJ$AL;*:ZD.V5')VQ*Q
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MZ[XKN]9LO$=J;-2)_P"S8+1HX7GCD**L&WRR^%<[\A2OS,2P![Y]GC_O2_\
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M[X7W%S%JVM:/I>GZE!X8M6!M5U*TF@DMI2S!H$:8!I$"JIS\P4G:&*[0OK%
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MA_\ B:-UU_SQB_[^'_XFBB@ W77_ #QB_P"_A_\ B:-UU_SQB_[^'_XFBB@
MW77_ #QB_P"_A_\ B:-UU_SQB_[^'_XFBB@ W77_ #QB_P"_A_\ B:-UU_SQ
MB_[^'_XFBB@ W77_ #QB_P"_A_\ B:-UU_SQB_[^'_XFBB@#"T;1;K2I[EIK
M^?5;R=@SW-X\8<(,[8P(HD4*N3CY<\G)-;NZZ_YXQ?\ ?P__ !-%% !NNO\
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MZU/_ &;\4O\ H<O"O_A-7'_R?110 ?V;\4O^AR\*_P#A-7'_ ,GT?V;\4O\
MH<O"O_A-7'_R?110 ?V;\4O^AR\*_P#A-7'_ ,GT?V;\4O\ H<O"O_A-7'_R
M?110 ?V;\4O^AR\*_P#A-7'_ ,GT?V;\4O\ H<O"O_A-7'_R?110!CV>D_$:
M.>^GA\6>&M[W&V0R:!=ODX"\;M0.T<?=&!U.,DUL?V;\4O\ H<O"O_A-7'_R
M?110 ?V;\4O^AR\*_P#A-7'_ ,GTFEZ7XV6^6?6=<T?5+81.BPV=C/ISARRG
2<7^T2@C (V[1U!SQ@E% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524036640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 19, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KNOW LABS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,346,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,309,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">90-0273142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">500 Union Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">98101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">903-1351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KNW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Walnut Creek, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BPM LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Fin Stmt Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523681232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,023,716<span></span>
</td>
<td class="nump">$ 12,593,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,023,716<span></span>
</td>
<td class="nump">12,593,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">81,325<span></span>
</td>
<td class="nump">862,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">15,766<span></span>
</td>
<td class="nump">13,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">145,090<span></span>
</td>
<td class="nump">287,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">8,265,897<span></span>
</td>
<td class="nump">13,758,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable - trade</a></td>
<td class="nump">1,292,861<span></span>
</td>
<td class="nump">526,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">94,062<span></span>
</td>
<td class="nump">462,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmountDueToRelatedPartiesCurrent', window );">Accrued expenses - related parties</a></td>
<td class="nump">218,334<span></span>
</td>
<td class="nump">348,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable, net</a></td>
<td class="nump">2,761,931<span></span>
</td>
<td class="nump">2,255,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease right-of-use liability</a></td>
<td class="nump">154,797<span></span>
</td>
<td class="nump">215,397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,521,985<span></span>
</td>
<td class="nump">3,808,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease right-of-use liability, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value, 200,000,000 shares authorized, 80,358,463 and 48,156,062 shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively</a></td>
<td class="nump">80,358<span></span>
</td>
<td class="nump">48,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">125,501,537<span></span>
</td>
<td class="nump">111,209,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(121,840,788)<span></span>
</td>
<td class="num">(101,397,738)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">3,743,912<span></span>
</td>
<td class="nump">9,862,613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">8,265,897<span></span>
</td>
<td class="nump">13,758,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C PreferredStockMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AmountDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AmountDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523636240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">80,358,463<span></span>
</td>
<td class="nump">48,156,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">80,358,463<span></span>
</td>
<td class="nump">48,156,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStocksSeriesCMember', window );">Convertible Preferred Stock Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">17,858<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">17,858<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesDMember', window );">Convertible Preferred Stock Series D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStocksSeriesCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStocksSeriesCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524674816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE- DIGITAL ASSET SALES</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,360,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES-</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="nump">7,727,467<span></span>
</td>
<td class="nump">5,385,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">6,570,597<span></span>
</td>
<td class="nump">8,118,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS</a></td>
<td class="num">(274,019)<span></span>
</td>
<td class="num">(3,430,438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,024,045<span></span>
</td>
<td class="nump">16,934,161<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(14,024,045)<span></span>
</td>
<td class="num">(12,574,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">127,145<span></span>
</td>
<td class="nump">15,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(389,626)<span></span>
</td>
<td class="num">(8,034,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(506,865)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other (expense) income, net</a></td>
<td class="num">(495,776)<span></span>
</td>
<td class="nump">521,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense), net</a></td>
<td class="num">(1,265,122)<span></span>
</td>
<td class="num">(7,497,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(15,289,167)<span></span>
</td>
<td class="num">(20,071,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(15,289,167)<span></span>
</td>
<td class="num">(20,071,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockStock', window );">Common stock dividends on Series D Preferred Stock</a></td>
<td class="num">(1,627,230)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Deemed dividends on Series C and D Preferred Stock</a></td>
<td class="num">(3,526,653)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NetIncomeLossAvailableToCommonStockholders', window );">NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS</a></td>
<td class="num">$ (20,443,050)<span></span>
</td>
<td class="num">$ (20,071,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_EarningsPerSharesBasicAndDiluted', window );">Basic and diluted loss per share</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding- basic and diluted</a></td>
<td class="nump">49,581,467<span></span>
</td>
<td class="nump">40,370,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_EarningsPerSharesBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_EarningsPerSharesBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NetIncomeLossAvailableToCommonStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NetIncomeLossAvailableToCommonStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524219472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series C Convertibles Preferred Stock [Member]</div></th>
<th class="th"><div>Series D Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">35,166,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">$ 1,242,163<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 35,168<span></span>
</td>
<td class="nump">$ 82,530,684<span></span>
</td>
<td class="num">$ (81,326,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockCompensationExpenseEmployeeOptions', window );">Stock compensation expense - employee options</a></td>
<td class="nump">4,421,634<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,421,634<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConversionOfDebtOfferingAndAccruedInterestShares', window );">Conversion of debt offering and accrued interest (Note 7), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,672,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConversionOfDebtOfferingAndAccruedInterestAmount', window );">Conversion of debt offering and accrued interest (Note 7), amount</a></td>
<td class="nump">15,345,720<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7,673<span></span>
</td>
<td class="nump">15,338,047<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForStockOptionExercisesShares', window );">Issuance of common stock for stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForStockOptionExercisesAmount', window );">Issuance of common stock for stock option exercises, amount</a></td>
<td class="nump">26,687<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">26,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount', window );">Issuance of common stock for exercise of warrants, amount</a></td>
<td class="nump">838,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,046<span></span>
</td>
<td class="nump">837,441<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services, amount</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">182,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockWarrantForServices', window );">Issuance of common stock warrant for services</a></td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IsssuanceOfCommonStockForNyseUplistingShares', window );">Isssuance of common stock for NYSE uplisting, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IsssuanceOfCommonStockForNyseUplistingAmount', window );">Isssuance of common stock for NYSE uplisting, amount</a></td>
<td class="nump">7,424,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="nump">7,420,539<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,071,244)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,071,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">48,156,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">9,862,613<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 48,158<span></span>
</td>
<td class="nump">111,209,388<span></span>
</td>
<td class="num">(101,397,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockCompensationExpenseEmployeeOptions', window );">Stock compensation expense - employee options</a></td>
<td class="nump">2,955,933<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,955,933<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForStockOptionExercisesShares', window );">Issuance of common stock for stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForStockOptionExercisesAmount', window );">Issuance of common stock for stock option exercises, amount</a></td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">4,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount', window );">Issuance of common stock for exercise of warrants, amount</a></td>
<td class="nump">387,334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
<td class="nump">384,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,289,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,289,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CommonStockDividendsOnSeriesDPreferredStockShares', window );">Common stock dividends on Series D Preferred Stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CommonStockDividendsOnSeriesDPreferredStockAmount', window );">Common stock dividends on Series D Preferred Stock, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">1,625,827<span></span>
</td>
<td class="num">(1,627,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DeemedDividendsOnSeriesCAndDPreferredStock', window );">Deemed dividends on Series C and D Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,526,653<span></span>
</td>
<td class="num">(3,526,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IsssuanceOfCommonStockForCommonStockOfferingShares', window );">Isssuance of common stock for common stock offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount', window );">Isssuance of common stock for common stock offering, amount</a></td>
<td class="nump">5,472,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">5,444,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExpensesForExtensionOfNotesAndWarrants', window );">Expenses for extension of notes and warrants</a></td>
<td class="nump">349,721<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">349,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
<td class="nump">80,358,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">$ 3,743,912<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 80,358<span></span>
</td>
<td class="nump">$ 125,501,537<span></span>
</td>
<td class="num">$ (121,840,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CommonStockDividendsOnSeriesDPreferredStockAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CommonStockDividendsOnSeriesDPreferredStockAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CommonStockDividendsOnSeriesDPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CommonStockDividendsOnSeriesDPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConversionOfDebtOfferingAndAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConversionOfDebtOfferingAndAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConversionOfDebtOfferingAndAccruedInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConversionOfDebtOfferingAndAccruedInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DeemedDividendsOnSeriesCAndDPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DeemedDividendsOnSeriesCAndDPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExpensesForExtensionOfNotesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExpensesForExtensionOfNotesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IsssuanceOfCommonStockForCommonStockOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IsssuanceOfCommonStockForCommonStockOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IsssuanceOfCommonStockForNyseUplistingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IsssuanceOfCommonStockForNyseUplistingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IsssuanceOfCommonStockForNyseUplistingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IsssuanceOfCommonStockForNyseUplistingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceOfCommonStockForStockOptionExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceOfCommonStockForStockOptionExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceOfCommonStockForStockOptionExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceOfCommonStockForStockOptionExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceOfCommonStockWarrantForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceOfCommonStockWarrantForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_StockCompensationExpenseEmployeeOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_StockCompensationExpenseEmployeeOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772522208608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,289,167)<span></span>
</td>
<td class="num">$ (20,071,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">313,019<span></span>
</td>
<td class="nump">320,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock warrants for services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">451,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_GainLossOnDebtSettlement', window );">Gain on debt settlement</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(268,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">549,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Loss on debt extinguishment</a></td>
<td class="nump">506,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseForeignDeposits', window );">Modification of notes and warrants - interest expense</a></td>
<td class="nump">349,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock based compensation- stock option grants</a></td>
<td class="nump">2,955,933<span></span>
</td>
<td class="nump">4,421,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_GainLossOnForgivenessOfNotesPayablePppLoans', window );">Gain on forgiveness of notes payable-PPP Loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(252,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">142,840<span></span>
</td>
<td class="nump">35,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount to interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,272,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(1,999)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease right-of-use liability</a></td>
<td class="num">(147,719)<span></span>
</td>
<td class="num">(22,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable - trade and accrued expenses</a></td>
<td class="nump">317,085<span></span>
</td>
<td class="nump">1,009,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH (USED IN) OPERATING ACTIVITIES</a></td>
<td class="num">(10,353,991)<span></span>
</td>
<td class="num">(6,919,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(80,797)<span></span>
</td>
<td class="num">(855,468)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH (USED IN) INVESTING ACTIVITIES:</a></td>
<td class="num">(80,797)<span></span>
</td>
<td class="num">(855,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from isssuance of common stock for NYSE uplisting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,280,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ProceedsFromIssuanceOfCommonStockOfferingNet', window );">Proceeds from issuance of common stock offering, net</a></td>
<td class="nump">5,472,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for stock for NYSE uplisting</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(855,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Settlement of notes payable-PPP loans</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(179,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock for stock options exercise</a></td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">26,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercise</a></td>
<td class="nump">387,334<span></span>
</td>
<td class="nump">838,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">5,864,812<span></span>
</td>
<td class="nump">8,110,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(4,569,976)<span></span>
</td>
<td class="nump">335,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">12,593,692<span></span>
</td>
<td class="nump">12,258,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
<td class="nump">8,023,716<span></span>
</td>
<td class="nump">12,593,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract', window );"><strong>Supplemental disclosure of non-cash financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,209,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConversionOfAccruedInterest', window );">Conversion of accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,136,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Common stock dividends on Series D Preferred Stock</a></td>
<td class="nump">1,627,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Deemed dividends on Series C and D Preferred Stock</a></td>
<td class="nump">3,526,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuanceCostsFromCommonStockOffering', window );">Issuance costs from common stock offering</a></td>
<td class="nump">$ 1,527,209<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_GainLossOnDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_GainLossOnDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_GainLossOnForgivenessOfNotesPayablePppLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_GainLossOnForgivenessOfNotesPayablePppLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuanceCostsFromCommonStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuanceCostsFromCommonStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ProceedsFromIssuanceOfCommonStockOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ProceedsFromIssuanceOfCommonStockOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseForeignDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense on all foreign deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseForeignDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480513/718-10-30-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480843/718-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529057680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANISATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Know Labs, Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Nevada in 1998. The Company currently has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.&#160;At the annual shareholder meeting held on October 15, 2021, the Company&#8217;s authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique &#8220;signature&#8221; of said materials or analytes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device will provide the user with real-time information on their blood glucose levels.&#160; We recently announced our Generation 1 working prototype device.&#160; This device embodies the sensor which has been used in internal clinical testing.&#160; We have also announced the work our R&amp;D team is doing on the Generation 2 of our device, which is a wearable format and could be a final form factor, ready for commercial application. We are expanding our testing, both internally and externally, and will refine the device over time, which will require FDA clearance before entering the market.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772525433168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. LIQUIDITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has cash and cash equivalents of $8,023,716 and net working capital of $6,262,662 (exclusive of convertible notes payable) as of September 30, 2023. The Company anticipates that it will record losses from operations for the foreseeable future. During the end of the year ended September 30, 2023, the Company made some adjustments to its staffing level and the impact of those adjustments, plus the departure of our chief technology and executive office, has significantly reduced our monthly burn rate. The Company will further adjust its cost structure if new debt or equity capital is not received. The Company&#8217;s ability to transition profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least June 30, 2024. Based on current operating levels, the Company will need to raise additional funds by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through issuance of equity securities, and proceeds from the exercise of warrants to purchase common stock and the sale of debt instruments. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company&#8217;s products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company&#8217;s products. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern for the twelve months from the date of this Report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Management of the Company intends to raise additional funds through the issuance of equity securities or debt. The Company is currently working on some capital fund raising transactions and while they expect to have something finalized by March 31, 2024, as of this date, there is no commitment. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company&#8217;s ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The proceeds of warrants currently outstanding, which could be exercised on a cash basis, may generate potential proceeds. &#160;The Company expects that portions of these warrants will be exercised but there is no guarantee any portion will be exercised. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529046032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation</em></strong> &#8211;These unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Principles of Consolidation</em></strong> &#8211; The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Particle and AI Mind. Intercompany items and transactions have been eliminated in consolidation. &#160;AI Mind was dissolved in July 2023.&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cash and Cash Equivalents</em></strong> &#8211;&#160;The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Property and Equipment</em></strong> &#8211; Equipment consists of machinery, leasehold improvements and furniture and fixtures, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-5 years, except for leasehold improvements which are depreciated over 5 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Long-Lived Assets</em></strong> &#8211; The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong><strong> </strong>&#8211; The Company determines revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the contract, or contracts, with the customer;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the performance obligations in the contract;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">determination of the transaction price;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">allocation of the transaction price to the performance obligations in the contract; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recognition of the revenue when, or as, the Company satisfies a performance obligation.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses</em></strong> &#8211; Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s current research and development efforts are primarily focused on improving its radio frequency spectroscopy technology and its first focus on non-invasive monitoring of blood glucose levels; extending its capacity and developing new and unique applications for this technology. The Company believes that continued development of new and enhanced technologies is essential to its future success. The Company incurred expenses of $7,727,467 and $5,385,586 for the years ended September 30, 2023 and 2022, respectively, on development activities.&#160; Included in the expense for 2023 is approximately $859,000 related to severance and other expenses associated with the departure of the Company&#8217;s former chief technology officer and chief executive officer, Philip A. Bosua, and other employees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Advertising</em></strong><strong> </strong>&#8211; Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising and marketing costs for the year ended September 30, 2023 and 2022 were $305,292 and $379,724, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements and Financial Instruments</em></strong> &#8211;<strong>&#160;</strong>ASC Topic 820, <em>Fair Value Measurement and Disclosures</em>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 2 &#8211; Inputs other than level one inputs that are either directly or indirectly observable; and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 3 &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities. The fair value of the Company&#8217;s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has a money market account which is considered a Level 1 asset. The balance as of September 30, 2023 and 2022 was $7,836,393 and $11,821,931, respectively. No other assets or liabilities are required to&#160; be recorded at fair value on a recurring nature. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em></strong><strong> &#8211; </strong>Pursuant to ASC 815 &#8220;Derivatives and Hedging&#8221;, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company determined that the conversion features for purposes of bifurcation within its &#160;convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and &#160;there was no derivative liability. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Based Compensation</em></strong> &#8211; The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. The Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Securities</em></strong><strong> </strong>&#8211; Based upon ASC 815-15, the Company has adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. The Company will evaluate its contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company&#8217;s inability to demonstrate it has sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Net Loss per Share</em></strong> &#8211; Under the provisions of ASC 260, &#8220;Earnings Per Share,&#8221; basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Deemed dividends to preferred shareholders increase the net loss available to common&#160; shareholders and impact the net loss per share calculation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, the Company had 80,358,463 shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of 14,506,158 shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 20,866,313 shares of our common stock, 8,108,356 shares of the Company&#8217;s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 3,040,219 shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931.&#160; Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, the Company had 48,156,062 shares of common stock issued and outstanding. As of September 30, 2022, there were options outstanding for the purchase of 20,792,370 common shares (including unearned stock option grants totaling 9,704,620 shares related to performance targets), warrants for the purchase of 21,786,313 common shares, and 8,108,356&#160;shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2022, calculation of net loss per share because their impact is antidilutive.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Comprehensive loss</em></strong> &#8211; Comprehensive loss is defined as the change in equity of a business during a period from non-owner sources. There were no differences between net loss for the years ended September 30, 2023 and 2022 and comprehensive loss for those periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Dividend Policy</em></strong> &#8211; The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of its business. The Company&#8217;s future dividend policy will be determined by the board of directors on the basis of various factors, including results of operations, financial condition, capital requirements and investment opportunities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong> &#8211; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Recent Accounting Pronouncements </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on the Company&#8217;s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does believe such items are expected to have a significant impact on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529051856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AI DEEP LEARNING PLATFORM<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AiDeepLearningPlatformAbstract', window );"><strong>AI DEEP LEARNING PLATFORM</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AiDeepLearningPlatformDisclosureTextBlock', window );">AI DEEP LEARNING PLATFORM</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. AI DEEP LEARNING PLATFORM</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">On September 17, 2021, the Company incorporated AI Mind, Inc. (&#8220;AI Mind&#8221;) in the State of Nevada. AI Mind was focused on monetizing intellectual property relating to the artificial intelligence utilized as a part of the data analytics performed with trade secret algorithms. Since incorporation, it focused on creating graphical images which were sold as Non Fungible Tokens (&#8220;NFTs&#8221;). During the year ended September 30, 2022,&#160;the&#160;Company began generating revenue from digital asset sales of NFTs and had sales of $4,360,087 of which substantially all were recorded in the three months ended December 31, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">After the sale of the NFT, the Ethereum was converted to US dollars as soon as practically possible. The Company recorded the total value of the gross NFT sale in revenue. Costs incurred in connection with the NFT transaction were recorded in the statement of operations as selling and transactional cost of digital assets and include costs to outside consultants, estimated employee and former CEO special bonus compensation, digital asset conversion losses and estimated sales and use tax. The amount totaled $3,430,438 for the year ended September 30, 2022. As of September &#160;30, 2023 and September 30, 2022, accrued expenses include $0 and $343,878 of expenses, respectively, primarily sales and use tax and other expenses. During the current year, based on new information, we revised our estimate downward for sales and use tax liability resulting in a $274,019 benefit that is recorded in Selling and Transactional Costs for Digital Assets in the consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AiDeepLearningPlatformAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AiDeepLearningPlatformAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AiDeepLearningPlatformDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AiDeepLearningPlatformDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772530175088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. PROPERTY AND EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment as of September 30, 2023 and 2022 was comprised of the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total depreciation expense was $313,019 and $320,995 for the years ended September 30, 2023 and 2022, respectively. All equipment is used primarily for research and development purposes and accordingly $295,260 and $304,637 in depreciation is classified in research and development expenses during the years ending September 30, 2023 and 2022. The Company retired assets with a net book value of $549,431 during the year ended September 30, 2023 related to the consolidation of leased offices and the reduction on headcount. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523603184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_LeasesOfLesseDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. LEASES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has entered into operating leases for office and development facilities which range from two to three years and include options to renew. The Company determines whether an arrangement is or contains a lease based upon the unique facts and circumstances at the inception of the lease. Operating lease liabilities and their corresponding right-of-use asses are recorded based upon the present value of the lease payments over the expected lease term. As of September 30, 2023 and 2022, total operating lease liabilities for remaining long term leases was approximately $155,000 and $303,000, respectively. Right of use assets totaled approximately $145,000 and $288,000 at September 30, 2023 and 2022, respectively. In the year ended September 30, 2023 and 2022, the Company recognized $268,000 and $289,000, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its estimated incremental borrowing rate to determine the present value of the lease payments.&#160; Recently the Company, as a result of certain headcount adjustments, has listed two of its leased premises as available for sublease.&#160; There can be no assurance such sublease will be successful or lead to a reduction in current on-going lease payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The weighted average remaining lease term for the operating leases was 9 months at September 30, 2023 and the weighted average discount rate was 7%. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The minimum future lease payments as of September 30, 2023 are as follows: </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_LeasesOfLesseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_LeasesOfLesseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772528668784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConvertibleNotesPayableDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Convertible notes payable as of September 30, 2023 and 2022 consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Promissory Notes with Clayton A. Struve</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company owes Clayton A. Struve, a significant stockholder, $1,301,005 under convertible promissory or OID notes. The Company recorded accrued interest of $94,062 and $86,562 as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2023.&#160; On September 15, 2023, the due dates on the notes was further extended to September 30, 2024.&#160;The Company expensed $230,005 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Redeemable Promissory Notes with J3E2A2Z</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company owes Ronald P. Erickson and J3E2A2Z, an entity affiliated controlled by Ronald P. Erickson $1,460,926 under convertible promissory notes On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The Company recorded accrued interest of $218,334 and $287,290 as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to January 30, 2023. On January 25, 2023, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2023. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. The Company expensed $276,860 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Debt Offering </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Beginning in 2019, the Company entered into a series of debt offerings with similar and consistent terms. The Company issued Subordinated Convertible Notes and Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. As of September 30, 2022, all convertible notes and accrued interest had been converted to common stock. During the year ended September 30, 2022, amortization related to the debt offerings of $7,272,911 was recognized as interest expense in the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Convertible notes payable as of September 30, 2023 and 2022 are summarized below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Clayton A. Struve</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,301,005</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,071,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Ronald P. Erickson and affiliates</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,460,926</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,184,066</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021 Convertible notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">14,209,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less conversions of notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(14,209,000</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,761,931</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,255,066</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConvertibleNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConvertibleNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772630773760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Authorized Capital Stock</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following description summarizes important terms of the classes of our capital stock as of September 30, 2023. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation as amended, restated and supplemented to date, or our articles of incorporation, and our second amended and restated bylaws, or our bylaws, which have been filed as exhibits to this Annual Report on Form 10-K.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Authorized Capital Stock</em>.&#160; The Company&#8217;s authorized capital stock currently consists of:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">200,000,000 shares of common stock, par value $0.001 per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">5,000,000 shares of &#8220;blank check&#8221; preferred stock, par value $0.001 per share, of which:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">30,000 shares have been designated as our Series C Convertible Preferred Stock, $0.001 par value per share; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">20,000 shares have been designated as our Series D Convertible Preferred Stock, $0.001 par value per share.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Outstanding Shares of Capital Stock</em>. The Company&#8217;s common stock is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. All outstanding shares of the Company&#8217;s capital stock are fully paid and nonassessable. As of September 30, 2023, there were:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">80,358,643 shares of common stock issued and outstanding, held by holders of record;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">17,858 shares of Series C Convertible Preferred Stock issued and outstanding, held by one holder of record; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10,161 shares of Series D Convertible Preferred Stock issued and outstanding, held by one holder of record.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Common Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. The Company&#8217;s articles of incorporation do not provide for cumulative voting in the election of directors.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors on the common stock out of legally available funds. In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company&#8217;s debts and other liabilities and the satisfaction of any preferential rights of any outstanding preferred stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock, including our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Preferred Stock </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s articles of incorporation authorize its board of directors, without stockholder approval, to issue up to 5,000,000 shares of preferred stock in one or more series, and to determine the designation, preferences, limitations and relative rights thereof, including, without limitation, such matters as dividends, redemption, liquidation, conversion and voting. The Company&#8217;s board of directors has the discretion to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock, or which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of the Company&#8217;s outstanding voting stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the amendment and restatement of our preferred stock, we effected a reverse split of our outstanding Series C Convertible Preferred Stock and Series D Convertible Preferred Stock by a factor of 1-for-100. No changes were made to the 5 million total shares of &#8220;blank-check&#8221; preferred stock authorized in our Articles. Prior to such reverse split, there were 1,785,715 and 1,016,004 shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock designated and outstanding, respectively. To account for the reverse split, but in order to provide the ability to issue &#8220;pay in kind&#8221; dividends in lieu of cash dividends, at the time of the reverse split, we designated 30,000 shares of Series C Convertible Preferred Stock&#160;and 20,000 shares of Series D Convertible Preferred Stock, of which 17,858 and 10,161 shares were, respectively, outstanding immediately after such reverse split. In order to maintain the economic rights of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, the definition of &#8220;Stated Value&#8221; was multiplied by 100, to offset the reverse split factor. All amount related to the preferred shares have been restated to reflect the reverse stock split as it occurred on the date of the first period presented. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Securities Subject to Price Adjustments&#160;</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If in the future, the Company sells its common stock at a price below $0.25 per share, the conversion price of the Company&#8217;s outstanding shares of series C convertible preferred stock and series D convertible preferred stock would adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 7,684,381 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,439,707 would adjust below $1.20 per share and warrants totaling 4,424,425 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Series C and D Preferred Stock, Warrants and Dividends</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a cumulative dividend&#160; of 8% and an ownership blocker of 4.99%. Dividends are due and payable in cash when declared by the Company&#160; or when the stock&#160; is converted.&#160; Series&#160; C Preferred stock is senior to Series D Preferred stock and is entitled to receive&#160; equal&#160; dividends paid to Series D. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock and warrant and its conversion price, were adjusted to $0.25 per share pursuant to the documents governing such instruments. As of September 30, 2023, Mr. Struve owns all of the 1,785,715 issued and outstanding shares of Series C Preferred Stock.&#160; Each holder of Preferred Series C is allowed to vote as a common shareholder as if the shares were converted&#160; to common stock up to the ownership blocker of 4.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2017 the Company closed a $750,000 Series D Preferred Stock and Warrant offering with Mr. Struve. As of September 30, 2023, Mr. Struve owns all of the 1,016,004 issued and outstanding shares of Series D Preferred Stock. Each outstanding share of series D preferred stock will accrue cumulative cash dividends at a rate equal to 8.0% per annum, subject to adjustment as provided in the series D preferred stock certificate of designations. Dividends are&#160; due and payable&#160; in cash when declared by the Company&#160; or when the stock&#160; is converted. In addition, On August 14, 2017, the price of the Series D Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. Each holder of Preferred Series D is allowed to vote as a common shareholder as if the shares were converted to common stock up to the ownership blocker of 4.99%.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August, 2023, as part of a modification of the Series C and Series D Preferred certificates of designation,&#160; such preferred stock does not accrue or pay cash dividends. All future dividends will be accrued and paid in Series C or Series D stock, as applicable. As was the case prior to the modifications of the Series C and Series D preferred stock, although accrual of dividends is required as described below, no dividends are actually paid, and no shares actually issued, until a conversion of such stock or declaration of the dividend by the Board of Directors.&#160; Additionally the Series D Preferred stock will no longer be required to automatically convert to common stock based on listing of the Company&#8217;s common stock on the NYSE American, except if the volume weighted average price of the common stock is at least $2.50 per share for 20 trading days and certain other requirements are satisfied.&#160; The cumulative dividends accrued and paid in preferred stock will be determined based upon a $.70 stated value. The conversion from preferred stock into common stock is determined based dividing the $.70 stated value by the $.25 conversion price. In June, 2023, as part of the anticipated modification of the certificates of designation of the Series C and Series D preferred stock, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.&#160; In connection with this transaction, the Company recorded $1,627,230 in dividends, representing the fair market value of the 1,402,784 shares issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based upon the modified terms and conditions of Series C and D certificates of designations, it was determined that Series C and D preferred dividends need to be accreted going forward. As of September 30, 2023, cumulative unpaid Series C and D dividends totaled approximately $770,000, which on a converted-to-common-stock basis represents approximately 3,040,000 shares of common&#160; stock. The value of the 3.0 million shares of common totaled $3,526,653. The Company recorded $3,526,653in cumulative deemed dividends related to Series C and D Preferred Stock which have not been paid, net of the approximately $351,000 of accumulated dividends with respect to the Series D preferred that were settled for 1,402,784 shares of common stock as noted above.&#160; Mr. Struve is subject to an ownership blocker limiting his ownership to 4.99% and thus the amount of common shares he can receive for dividends.&#160; Unpaid accreted stock dividends will be issued to Mr. Struve if he converts preferred stock or if the Board declares a dividend thereon, limited to his 4.99% ownership blocker.&#160; Assuming no changes in the amount of outstanding Preferred Series&#160; C or D ownership, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 2,632,727 shares of common stock related to warrant exercises and received $387,334.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 27, 2023, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 3,750 shares related to the exercise of stock option grants and received $4,687.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, the Company closed an offering of our common stock pursuant to which the Company sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $5,472,791. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 1,045,724 shares of common stock related to warrant exercises and received $838,487.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 26,293 shares related to the exercise of stock option grants and received $26,887.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 104,634 shares each to three directors and three consultants at $1.749 per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 20, 2022, the Company completed a public offering of our common stock pursuant to which the Company sold 4,140,000 shares of common stock, at a purchase price of $2.00 per share, for total gross proceeds of $8,280,000. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $7,424,679.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>Warrants to Purchase Common Stock</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, the Company signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Current </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-14-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,440,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-12-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,200,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2016</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,785,715</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2018</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,344,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2025</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded interest expense of $194,019 during the year ended September 30, 2023 related to the extension of the warrants. The Company recorded the original value of warrants in equity and as such, the Company recorded the extension value as an expense with an offset to additional paid in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 19, 2023, the Company signed an Extension of Warrant Agreements with Ronald P. Erickson and an entity controlled by Mr. Erickson, extending the exercise dates from January 30, 2023 to January 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 2,632,727 shares of common stock related to warrant exercises and received $387,334.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase 297,273 shares of common stock at $0.250 per share expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 29, 2023, pursuant to the Underwriting Agreement, the Company issued common stock purchase warrants to Boustead Securities, LLC and The Benchmark Company, LLC&#160;to purchase an aggregate of 1,960,000 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments. The Representatives&#8217; Warrants are immediately exercisable, and may be exercised at any time and from time to time, in whole or in part, until September 26, 2028 and may be exercised on a cashless basis. The Representatives&#8217; Warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the Representatives&#8217; Warrants. The warrants were valued at $486,080 and recorded in additional paid in capital as costs form common stock offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 389,800 warrants to purchase common stock to three directors and four consultants at $1.899 per share. The warrants expire five years from the date of issuance.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 3, 2022, the Company signed an extension of warrant agreement with Clayton Struve, extending the exercise dates as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Original </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-14-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,440,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-12-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,200,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2016</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,785,715</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2018</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,344,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2024</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recorded interest expense of $244,260 during the year ended September 30, 2022 related to the extension of the warrants. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants to purchase 122,018 shares of common stock at $0.918 per share expired. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued 1,045,724 shares of common stock related to warrant exercises and received $838,487. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A summary of the warrants outstanding as of September 30, 2023 were as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding October 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,786,313</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.029</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">980,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,582,727</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,273</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.103</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes information about warrants outstanding and exercisable as of September 30, 2023: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Life ( In Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,649,381</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,649,381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6,512,207</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.37</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.20-1.85</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,512,207</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.20-1.85</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,694,725</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.00-3.00</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,694,725</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.00-3.00</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">0.43</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4.080</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">10,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4.080</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,886,313</p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2.07</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.163</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.163</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The significant weighted average assumptions relating to the valuation of the Company&#8217;s warrants for the year ended September 30, 2023 were as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">0%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected life</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3-5 years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">104%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk free interest rate</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2.96%</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were vested warrants of 20,866,313 with an aggregate intrinsic value of $0.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772616902752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK INCENTIVE PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK INCENTIVE PLANS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. EQUITY INCENTIVE PLANS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 12, 2021, the Company established its 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;), which was adopted by stockholders on October 15, 2021. The Company initially had 20,000,000 shares of its common stock authorized as the maximum number of shares of common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to 22,000,000 shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase described below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2023</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, the Company issued stock option grants to eighteen employees and consultants for 4,158,333 shares at an average exercise price of $1.381 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over two to four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, stock option grants for 10,277,655 shares at an average exercise price of $1.647 per share were forfeited. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2023, stock option grants for 166,890 shares at an average exercise price of $0.272 per share were exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Year Ended September 30, 2022</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 20, 2022, the Company issued a stock option grant to Peter Conley for 1,000,000 shares at an exercise price of $1.48 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years after two quarters.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, the Company also issued stock option grants to nineteen employees and consultants for 3,336,000 shares at an average exercise price of $1.726 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, the Company issued 26,293 shares related to the exercise of stock option grants and received $26,887.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended September 30, 2022, eight employees and consultants forfeited stock option grants for 1,132,457 shares at an average of $2.057 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock option activity for the years ended September 30, 2023 and 2022 was as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Options </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of October 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,315,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.565</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,636,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.815</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,293</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.376</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,132,457</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2.057</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,792,370</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.618</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,158,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(166,890</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.272</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,277,655</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1.647</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,506,158</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.546</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table summarizes information about stock options outstanding and exercisable as of September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Range of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining Life </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Prices</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">In Years</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$.88-1.25</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2,161,875</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1.105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,946,758</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1.107</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.28-1.67</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,754,283</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.473</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,920,291</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.415</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.79-3.67</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2,590,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.186</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">1,213,750</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.151</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">14,506,158</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">3.00</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.546</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">6,080,800</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.498</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were stock option grants of 14,906,158 with an aggregate intrinsic value of $0.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772628669408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Clayton Struve</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 7 and 8 for related party transactions with Clayton A. Struve, a significant stockholder.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On June 27, 2023, at Mr. Struve&#8217;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#8217;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. In connection with this transaction, the Company recorded $1,627,230 in dividends, representing the fair market value of the 1,402,784 shares issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 7, 2022, we signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates. We recorded interest expense of $194,019 during the year ended September 30, 2023 related to the extension of the warrants. We recorded the original value of warrants in equity and as such, we recorded the extension value as an expense with an offset to additional paid in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Ronald P. Erickson</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 7, 8 and 9 for related party transactions with Ronald P. Erickson, the Company&#8217;s Chairman and Chief Executive Officer and affiliated entities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 14, 2022, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $1.41 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 4, 2019, the Company granted a stock option grant to Ronald P. Erickson for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon uplisting to the NASDAQ or NYSE exchanges. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and the Company expensed $1,207,200 during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued a stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vests in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; The Company estimated at grant date the fair value of these options at approximately $520,869 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $104,172 and a&#160; cumulative expense of $186,657, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued an additional stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and the Company expensed $263,593 during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Erickson was paid interest of $173,855 during the year ended September 30, 2023 and deferred compensation of $165,000 during the year ended September 30, 2022 that were previously accrued and reported but were deferred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $218,334 and $295,418 as of September 30, 2023 and 2022, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Transactions with Phillip A. Bosua</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Notes 4, 8, 9 and 11 for related party transactions with Phillip A. Bosua. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued a stock option grant to Phillip A. Bosua for 2,132,195 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vested in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; The Company estimated at grant date the fair value of these options at approximately $595,277 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $37,370 and a cumulative expense of $231,321, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 15, 2020, the Company issued another stock option grant to Phillip A. Bosua for 2,132,195 shares at an exercise price of $1.53 per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. The Company&#8217;s common stock began trading on NYSE American under the symbol &#8220;KNW&#8221; on September 16, 2022 and we expensed $301,249 during the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Mr. Bosua was paid $400,000 in severance and $96,440 in rent and other costs during the year ended September 30, 2023. Mr. Bosua was paid $1,097,928 in compensation and $91,500 in rent expenses for services provided to AI Mind, a wholly owned subsidiary of the Company, in connection with the development of NFT sales for the year ended September 30, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock Issuances to Named Executive Officers and Directors</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 15, 2023, the Company issued stock option grants to two directors for a total of 50,000 shares at an exercise price of $1.24 per share. The stock option grant expires in five years. The stock option grants vested at issuance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, the Company issued 30,000 shares each to three directors at an exercise price of $1.70 per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772526477888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>11. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Legal Proceedings</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to the Company&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employment Agreements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, the Company entered into an amended employment agreement for Ronald P. Erickson which amends our employment agreement with him dated July 1, 2017. The employment agreement provides for a base salary of $180,000 per year, which was increased to $215,000 from May 1, 2020 to March 31, 2021, to $300,000 from April 1, 2021 to March 15, 2022 and to $325,000 from March 15, 2022 to September 30, 2022. From December 14, 2022, Mr. Erickson has been compensated with an annual salary of $375,000. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the company terminates Mr. Erickson&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Erickson terminates his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Erickson will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. On January 23, 2023, the Board appointed Mr. Erickson to the position of Chief Executive Officer of the Company. Mr. Erickson was appointed to serve until his successor is duly elected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 10, 2018, the Company entered into an employment agreement with Phillip A. Bosua reflecting his appointment as Chief Executive Officer. The employment agreement provided for a base salary of $225,000 per year, which was increased to $260,000 from May 1, 2020 to March 31, 2021 and to $350,000 from April 1, 2021 to January 23, 2023. Mr. Bosua also received 500,000 shares of common stock valued at $0.33 per share and was entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. Mr. Bosua was entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement was for an initial term of 12 months (subject to earlier termination) and was automatically extended for additional 12-month terms unless either party notified the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the Company terminated Mr. Bosua&#8217;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Bosua terminated his employment at any time for &#8220;good reason&#8221; or due to a &#8220;disability,&#8221; Mr. Bosua was entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 23, 2023, Mr. Bosua resigned from the Board and from his position as Chief Executive Officer of the Company.&#160; In connection with his resignation, we entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;) with Mr. Bosua containing customary terms and mutual releases, pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#8217;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company&#8217;s common stock exceeds $5.00 per share on the NYSE American (the &#8220;Stock Price Threshold&#8221;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 13, 2022, the Company entered into an employment agreement with Peter J. Conley reflecting his appointment as our Chief Financial Officer and Senior Vice President, Intellectual Property. The employment agreement provides for a base salary of $300,000. From December 14, 2022 to September 30, 2023, Mr. Conley has been compensated with an annual salary of $325,000, Mr. Conley may also be entitled to bonuses from time to time as determined by our Board or our compensation committee in their sole discretion. Mr. Conley is eligible to participate in all the Company&#8217;s employee benefit plans, policies and arrangements that are applicable to other executive officers, as such plans, policies and arrangements may exist or change from time to time at our discretion. The Company will reimburse Mr. Conley for reasonable travel, entertainment and other expenses he incurs in the furtherance of his duties under the employment agreement. The employment agreement is at will, meaning either we or Mr. Conley may terminate the employment relationship at any time, with or without cause, upon written notice to the other party. The employment agreement provides for severance pay equal to 12 months of then-in-effect base salary if Mr. Conley is terminated without &#8220;cause&#8221; or voluntarily terminates his employment for &#8220;good reason,&#8221; as defined in the employment agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Properties and Operating Leases</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is obligated under the following leases for our various facilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Corporate Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expired on May 31, 2022. On October 31, 2021, the Company extended the lease from June 1, 2022 to May 31, 2023 at $2,986&#160;per month. On April 26, 2023, the Company extended the lease from June 1, 2023 to May 31, 2024 at $2,908.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Lab Facilities and Executive Offices</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 18, 2021, the Company entered into a lease for its lab facilities located at 914 E Pine Street, Suite 212, Seattle, WA 98122 and leased 2,642 square feet. The net monthly lease payment was $8,697&#160;and&#160;increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 11, 2021, the Company entered into the First Amendment of Lease and added 2,485 square feet for $5,000&#160;per month.&#160; On September 20, 2022, the Company entered into the Second Amendment of Lease for additional space. The expanded space will be utilized for research and testing. The Amendment of Lease expires on December 31, 2023.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 22, 2022, the Company leased lab facilities and executive offices in Yucca Valley, CA from Phillip Bosua, our former CEO. The Company leased 1,700 square feet of the total 2,134 square feet of the premises and the current net monthly payment is $7,000. The lease was to expire September 30, 2023 and could be extended on a month to month basis. The Company paid $91,500&#160;in rent on September 28, 2022 for the period September 1, 2021 to September 30, 2022. The Company paid $28,000&#160;for the year ended September 30, 2023. &#160;The lease was terminated on January 23, 2023, the date of Mr. Bosua&#8217;s resignation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 22, 2022, the Company leased an additional 1,800 square feet of lab facilities at 123 Boylston Ave, Suite C, Seattle, WA 98102 with a net monthly payment is $2,250. The lease was set to expire on November 21, 2023 and has been extended on a month-to-month basis.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772630773760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>12. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has incurred losses since inception, which have generated net operating loss carryforwards.&#160;&#160;The net operating loss carryforwards arise from United States sources.&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Losses arising from United States taxable operations were approximately $4.2 million and $7.3 million for the years ended September 30, 2023 and 2022.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company has Federal net operating loss carryforwards of approximately $49.5 million which expire in 2028-2042. Because it is not more likely than not that sufficient tax earnings will be generated to utilize the net operating loss carryforwards, a corresponding valuation allowance equal to 100% of the gross deferred tax asset of approximately $14.2 million and $11.4 million was established as of September 30, 2023 and 2022, respectively.&#160; The Company does not recognize the majority of state tax loss operating loss carryforwards as a deferred tax asset given it no longer has any operation in those states. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the Tax Reform Act of 1986, the amounts of, and benefits from, net operating losses may be limited in certain circumstances, including a change in control. Section&#160;382 of the Internal Revenue Code generally imposes an annual limitation on the amount of net operating loss carryforwards that may be used to offset taxable income when a corporation has undergone significant changes in its stock ownership. There can be no assurance that the Company will be able to utilize any net operating loss carryforwards in the future. The Company is subject to possible tax examination for the years 2017 through 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The principal components of the Company&#8217;s deferred tax assets at September 30, 2023 and 2022 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,476,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,372,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,174,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,677,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Research and Development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,460,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accruals and reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">46,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">97,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,156,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,367,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,156,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,367,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance during the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,789,000</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,666,000</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">A reconciliation of the United States Federal Statutory rate to the Company&#8217;s effective tax rate for the years ended September 30, 2023 and 2022 are as follows. For the years ended September 30, 2023 and 2022, the Company&#8217;s effective tax rate differs from the federal statutory rate principally due to nondeductible expenses plus an increase in the deferred tax asset valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Income tax provision at statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non deductible expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other and prior year true up</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">As of September 30, 2023, there were no uncertain tax positions. Management does not anticipate any future adjustments in&#160; the next twelve months which would result in a material change to its tax position. For the years ended September 30, 2023 and 2022, the Company did not have any interest and penalties.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772525459856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT REPORTING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>13. SEGMENT REPORTING</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The management of the Company considers the business to currently have two operating segments (i) the development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies; (ii) Particle, Inc. technology; and (iii) AI sales of NFT products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Particle commenced operations in the year ended September 30, 2020. AI commenced operations during the year ended September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The reporting for the year ended September 30, 2023 and 2022 was as follows (in thousands): </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Operating</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Revenue</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Profit (Loss)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Assets</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,298</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,266</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">274</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(14,024</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,266</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,482</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,360</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(12,574</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,758</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During years ended September 30, 2023 and 2022, the Company incurred non-cash expenses related to operations of $4,767,809 and $12,164,418, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772616902752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>14.&#160; SUBSEQUENT EVENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to September 30, 2023, there were the following material transactions that require disclosure:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 12, 2023, the Company issued 30,000 shares each to three directors at $0.25 per share. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 26, 2023, the Company&#8217;s underwriters exercised their over-allotment option under the Underwriting Agreement by and between the Company and the underwriters dated September 26, 2023, electing to purchase an additional 883,061 shares of Common Stock at a purchase price to the public of $0.25 per share. The Company also issued additional warrants to the Representatives to purchase an aggregate of 61,814 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments, with the same terms as the warrants issued in connection with the initial closing of the Offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 3, 2023,&#160; the Company appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan,&#160; as new non-employee members of the Board. Messrs. Ellingson, Cronin, and Londergan are deemed to qualify as independent under the director independence standards set forth in the rules and regulations of the SEC and applicable NYSE listing standards.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 28, 2023, the Board adopted, based on the recommendation of the Compensation Committee of the Board, the Know Labs Inc. Compensation Recovery Policy (the &#8220;Policy&#8221;) for the recovery of Erroneously Awarded Compensation in order to comply with Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act, and the listing standards of the New York Stock Exchange adopted pursuant thereto. &#160;The Board has designated the Compensation Committee of the Board as the administrator of the Policy.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since September 30, 2023, the Company issued stock option grants to employees, directors and directors for 13,909,315 shares at an average exercise price of $0.256 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523296544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Basis of Presentation</em></strong> &#8211;These unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Principles of Consolidation</em></strong> &#8211; The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Particle and AI Mind. Intercompany items and transactions have been eliminated in consolidation. &#160;AI Mind was dissolved in July 2023.&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Cash and Cash Equivalents</em></strong> &#8211;&#160;The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Property and Equipment</em></strong> &#8211; Equipment consists of machinery, leasehold improvements and furniture and fixtures, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-5 years, except for leasehold improvements which are depreciated over 5 years. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Long-Lived Assets</em></strong> &#8211; The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionLeases', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Revenue Recognition</em></strong><strong> </strong>&#8211; The Company determines revenue recognition from contracts with customers through the following steps:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the contract, or contracts, with the customer;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">identification of the performance obligations in the contract;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">determination of the transaction price;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">allocation of the transaction price to the performance obligations in the contract; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recognition of the revenue when, or as, the Company satisfies a performance obligation.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Research and Development Expenses</em></strong> &#8211; Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s current research and development efforts are primarily focused on improving its radio frequency spectroscopy technology and its first focus on non-invasive monitoring of blood glucose levels; extending its capacity and developing new and unique applications for this technology. The Company believes that continued development of new and enhanced technologies is essential to its future success. The Company incurred expenses of $7,727,467 and $5,385,586 for the years ended September 30, 2023 and 2022, respectively, on development activities.&#160; Included in the expense for 2023 is approximately $859,000 related to severance and other expenses associated with the departure of the Company&#8217;s former chief technology officer and chief executive officer, Philip A. Bosua, and other employees.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Advertising</em></strong><strong> </strong>&#8211; Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising and marketing costs for the year ended September 30, 2023 and 2022 were $305,292 and $379,724, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements and Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Fair Value Measurements and Financial Instruments</em></strong> &#8211;<strong>&#160;</strong>ASC Topic 820, <em>Fair Value Measurement and Disclosures</em>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The hierarchy consists of three levels:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 2 &#8211; Inputs other than level one inputs that are either directly or indirectly observable; and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Level 3 &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities. The fair value of the Company&#8217;s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has a money market account which is considered a Level 1 asset. The balance as of September 30, 2023 and 2022 was $7,836,393 and $11,821,931, respectively. No other assets or liabilities are required to&#160; be recorded at fair value on a recurring nature. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness', window );">Derivative Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Derivative Financial Instruments</em></strong><strong> &#8211; </strong>Pursuant to ASC 815 &#8220;Derivatives and Hedging&#8221;, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company determined that the conversion features for purposes of bifurcation within its &#160;convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and &#160;there was no derivative liability. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Stock Based Compensation</em></strong> &#8211; The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. The Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Convertible Securities</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Convertible Securities</em></strong><strong> </strong>&#8211; Based upon ASC 815-15, the Company has adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. The Company will evaluate its contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company&#8217;s inability to demonstrate it has sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Net Loss per Share</em></strong> &#8211; Under the provisions of ASC 260, &#8220;Earnings Per Share,&#8221; basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Deemed dividends to preferred shareholders increase the net loss available to common&#160; shareholders and impact the net loss per share calculation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2023, the Company had 80,358,463 shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of 14,506,158 shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 20,866,313 shares of our common stock, 8,108,356 shares of the Company&#8217;s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 3,040,219 shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931.&#160; Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2022, the Company had 48,156,062 shares of common stock issued and outstanding. As of September 30, 2022, there were options outstanding for the purchase of 20,792,370 common shares (including unearned stock option grants totaling 9,704,620 shares related to performance targets), warrants for the purchase of 21,786,313 common shares, and 8,108,356&#160;shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2022, calculation of net loss per share because their impact is antidilutive.&#160; </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Comprehensive loss</em></strong> &#8211; Comprehensive loss is defined as the change in equity of a business during a period from non-owner sources. There were no differences between net loss for the years ended September 30, 2023 and 2022 and comprehensive loss for those periods.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DividendPolicyTextBlock', window );">Dividend Policy</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Dividend Policy</em></strong> &#8211; The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of its business. The Company&#8217;s future dividend policy will be determined by the board of directors on the basis of various factors, including results of operations, financial condition, capital requirements and investment opportunities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Use of Estimates</em></strong> &#8211; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on the Company&#8217;s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does believe such items are expected to have a significant impact on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DividendPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DividendPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining hedging effectiveness and if hedge effectiveness was assessed on quantitative or qualitative basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 79<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480682/815-20-25-79<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for leases entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772530171440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text">  EstimatedUseful Lives June 30,2023  September 30,2022 Machinery and equipment 2-3 years $961,529  $1,510,265 Furniture and fixtures 5 years  26,855   26,855 Leasehold improvements 5 years  3,612   3,612 Less: accumulated depreciation    (691,899)  (677,755)    $300,097  $862,977 <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524690256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of minimum future lease payments</a></td>
<td class="text">Year Ended June 30, 2024-   Total remaining payments $204,534 Less imputed interest  (1,822)Total lease liability $202,712 <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524690256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible notes payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">September 30,</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Clayton A. Struve</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,301,005</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,071,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Convertible note- Ronald P. Erickson and affiliates</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,460,926</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,184,066</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2021 Convertible notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">14,209,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less conversions of notes</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(14,209,000</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,761,931</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2,255,066</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529913696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock', window );">Schedule of Warrant activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Current </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date </p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-14-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,440,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-12-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,200,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2016</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,785,715</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2025</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2018</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,344,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2024</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2025</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"><tbody><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No./Class</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. Warrant </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Original </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amended </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-14-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,440,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-13-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-12-2017</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,200,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">12-11-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2016</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,785,715</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">08-04-2024</p></td></tr><tr style="height:15px"><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Clayton A. Struve Warrant</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2018</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1,344,000</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">$0.25</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2023</p></td><td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">02-28-2024</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants outstanding and exercisable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding October 1, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,786,313</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.029</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">980,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,582,727</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(297,273</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.103</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">September 30, 2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Shares</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Warrants</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Life ( In Years)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:20%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,649,381</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.16</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,649,381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6,512,207</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.37</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.20-1.85</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,512,207</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.20-1.85</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,694,725</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.59</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.00-3.00</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4,694,725</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">2.00-3.00</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">0.43</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4.080</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">10,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">4.080</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,886,313</p></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">2.07</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.163</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">20,886,313</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.163</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Dividend yield</p></td><td style="width:20%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">0%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected life</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">3-5 years</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected volatility</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">104%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Risk free interest rate</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2.96%</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529118160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK INCENTIVE PLANS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Options </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Price </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of October 1, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,315,120</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.565</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,636,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.815</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(26,293</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.376</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,132,457</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2.057</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,792,370</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.618</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,158,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.381</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(166,890</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(0.272</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Forfeitures</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,277,655</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1.647</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding as of September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,506,158</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1.546</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Stock options outstanding and exercisable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Weighted </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Average</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Range of</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Remaining Life </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Number</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Price</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercise Prices</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">In Years</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Outstanding</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$.88-1.25</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2,161,875</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">2.91</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1.105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1,946,758</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">1.107</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.28-1.67</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,754,283</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.473</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2,920,291</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.415</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">1.79-3.67</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2,590,000</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">3.05</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.186</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">1,213,750</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">2.151</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">14,506,158</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">3.00</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.546</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">6,080,800</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1.498</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772525433168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Schedule of deferred tax</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net operating loss carryforward</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,476,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,372,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Stock based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,174,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,677,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Research and Development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,460,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Accruals and reserves</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">46,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">97,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,156,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,367,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,156,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,367,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance during the year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(2,789,000</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,666,000</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Schedule of Effective tax rate</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Income tax provision at statutory rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Non deductible expenses </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other and prior year true up</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772525443168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT REPORTING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment reporting</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Operating</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Segment</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Revenue</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Profit (Loss)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Assets</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(14,298</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,266</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">274</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(14,024</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,266</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Year Ended September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Development of the Bio-RFID&#8482;&#8221; and &#8220;ChromaID&#8482;&#8221; technologies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,482</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,360</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Particle, Inc. technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(22</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Digital asset sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">398</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Total segments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,360</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(12,574</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">13,758</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524694640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AuthorizedSharesOfCapitalStock', window );">Authorized shares of capital stock</a></td>
<td class="nump">205,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AuthorizedSharesOfCapitalCommonStock', window );">Authorized shares of capital common stock</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Authorized shares of capital stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock share par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AuthorizedCommonStockIncreased', window );">Authorized common stock increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AuthorizedCommonStockIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AuthorizedCommonStockIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AuthorizedSharesOfCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AuthorizedSharesOfCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AuthorizedSharesOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AuthorizedSharesOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529059520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LIQUIDITY (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,023,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NetWorkingCapital', window );">Net working capital</a></td>
<td class="nump">$ 6,262,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524270432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit', window );">FDIC insurance</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SeveranceAndOtherExpenses', window );">Severance and other expenses</a></td>
<td class="nump">859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConvertibleDebentures', window );">Convertible debentures</a></td>
<td class="nump">2,761,931<span></span>
</td>
<td class="nump">$ 2,255,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">7,727,467<span></span>
</td>
<td class="nump">5,385,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">305,292<span></span>
</td>
<td class="nump">379,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market accounts</a></td>
<td class="nump">$ 7,836,393<span></span>
</td>
<td class="nump">$ 11,821,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">80,358,463<span></span>
</td>
<td class="nump">48,156,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">80,358,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Issuable upon conversion of convertible debentures</a></td>
<td class="nump">14,506,158<span></span>
</td>
<td class="nump">20,792,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="nump">$ 1.381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_PropertyPlantsAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=knwn_StockOption1Member', window );">Stock Option 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Unearned stock option grants</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=knwn_Warrant1Member', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">20,866,313<span></span>
</td>
<td class="nump">21,786,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">8,108,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">9,020,264<span></span>
</td>
<td class="nump">9,020,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReservedSharesToPaySeriesCAndDDividends', window );">Reserved shares to pay series C and D dividends</a></td>
<td class="nump">3,040,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,108,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConvertibleDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConvertibleDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_PropertyPlantsAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_PropertyPlantsAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ReservedSharesToPaySeriesCAndDDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ReservedSharesToPaySeriesCAndDDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SeveranceAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SeveranceAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481047/942-405-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=knwn_StockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=knwn_StockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=knwn_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=knwn_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772522210960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AI DEEP LEARNING PLATFORM (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling and Transactional Costs</a></td>
<td class="nump">$ 274,019<span></span>
</td>
<td class="nump">$ 3,430,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">94,062<span></span>
</td>
<td class="nump">462,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Technology Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_Revenue', window );">Revenue Digital Asset Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,360,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmountTotal', window );">Amount total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling and Transactional Costs</a></td>
<td class="nump">274,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 343,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AmountTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AmountTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524191952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment (2-3 years)</a></td>
<td class="nump">$ 213,330<span></span>
</td>
<td class="nump">$ 1,510,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements (5 years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures (3 years)</a></td>
<td class="nump">21,366<span></span>
</td>
<td class="nump">26,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(153,371)<span></span>
</td>
<td class="num">(677,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 81,325<span></span>
</td>
<td class="nump">$ 862,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524043872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AssetsNetBookValue', window );">Net book value of assets</a></td>
<td class="nump">$ 549,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">313,019<span></span>
</td>
<td class="nump">$ 320,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember', window );">Research And Development And Sellings General And Administrative [Mmber]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 295,260<span></span>
</td>
<td class="nump">$ 304,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AssetsNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AssetsNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523656480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_TotalRemainingPayments', window );">Total Remaining Payments</a></td>
<td class="nump">$ 153,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 154,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_TotalRemainingPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_TotalRemainingPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523583216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="nump">$ 268,000<span></span>
</td>
<td class="nump">$ 289,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_RightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_TotalLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 303,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_TotalLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_TotalLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772525774736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,023,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NetWorkingCapital', window );">Net working capital</a></td>
<td class="nump">6,262,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=knwn_ThirtyFirstDecemberTwentyTwentyThreeMember', window );">31 December,2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_GrossProceedFromPublicIssueStock', window );">Gross proceed from public issue stock</a></td>
<td class="nump">$ 8,280,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_GrossProceedFromPublicIssueStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_GrossProceedFromPublicIssueStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=knwn_ThirtyFirstDecemberTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=knwn_ThirtyFirstDecemberTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523968688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConvertibleNotesConversions', window );">less conversions of notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (14,209,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible notes, net</a></td>
<td class="nump">2,761,931<span></span>
</td>
<td class="nump">2,255,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteOneMember', window );">Convertibles Note - Clayton A. Struve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes, gross</a></td>
<td class="nump">1,301,005<span></span>
</td>
<td class="nump">1,071,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteTwoMember', window );">Convertibles Note - Ronald P. Erickson and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes, gross</a></td>
<td class="nump">1,460,926<span></span>
</td>
<td class="nump">1,184,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNotesFiveMember', window );">2021 Convertibles notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Convertible notes, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,209,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConvertibleNotesConversions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConvertibleNotesConversions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNoteTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNotesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNotesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524179360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 16, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Expensed</a></td>
<td class="nump">$ 230,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmortizationOfDebtDiscountPremiums', window );">Amortization related to the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,272,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">94,062<span></span>
</td>
<td class="nump">86,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote2Member', window );">Convertible Note - Ronald P. Erickson and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,039,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,460,926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote1Member', window );">Convertible Note - Clayton A. Struve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Expensed</a></td>
<td class="nump">276,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DepositLiabilitiesAccruedInterestsAmount', window );">Accrued interest amount</a></td>
<td class="nump">218,334<span></span>
</td>
<td class="nump">$ 287,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory or OID notes</a></td>
<td class="nump">$ 1,301,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote8Member', window );">Convertible Note - J3E2A2Z Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConvertibleRedeemablePromissoryNoteAmount', window );">Convertible redeemable promissory note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Convertible redeemable promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote7Member', window );">Convertible Note - J3E2A2Z Account Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ConvertibleRedeemablePromissoryNoteAmount', window );">Convertible redeemable promissory note amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Convertible redeemable promissory note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AmortizationOfDebtDiscountPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AmortizationOfDebtDiscountPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ConvertibleRedeemablePromissoryNoteAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ConvertibleRedeemablePromissoryNoteAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DepositLiabilitiesAccruedInterestsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DepositLiabilitiesAccruedInterestsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquipmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquipmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=knwn_ConvertibleNote7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523541040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,440,000<span></span>
</td>
<td class="nump">1,440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Aug. 14,  2017<span></span>
</td>
<td class="text">Aug. 14,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Aug. 13,  2024<span></span>
</td>
<td class="text">Aug. 13,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Aug. 13,  2025<span></span>
</td>
<td class="text">Aug. 13,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Dec. 12,  2017<span></span>
</td>
<td class="text">Dec. 12,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Dec. 11,  2024<span></span>
</td>
<td class="text">Dec. 11,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Dec. 11,  2025<span></span>
</td>
<td class="text">Dec. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,785,715<span></span>
</td>
<td class="nump">1,785,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Aug.  04,  2016<span></span>
</td>
<td class="text">Aug.  04,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Aug.  04,  2024<span></span>
</td>
<td class="text">Aug.  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Aug.  04,  2025<span></span>
</td>
<td class="text">Aug.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,344,000<span></span>
</td>
<td class="nump">1,344,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Feb. 28,  2018<span></span>
</td>
<td class="text">Feb. 28,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Feb. 28,  2024<span></span>
</td>
<td class="text">Feb. 28,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Feb. 28,  2025<span></span>
</td>
<td class="text">Feb. 28,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AmendedExpirationdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AmendedExpirationdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DateOfIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DateOfIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NumberOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NumberOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_OriginalExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_OriginalExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523987728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,440,000<span></span>
</td>
<td class="nump">1,440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Aug. 14,  2017<span></span>
</td>
<td class="text">Aug. 14,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Aug. 13,  2024<span></span>
</td>
<td class="text">Aug. 13,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Aug. 13,  2025<span></span>
</td>
<td class="text">Aug. 13,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Dec. 12,  2017<span></span>
</td>
<td class="text">Dec. 12,  2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Dec. 11,  2024<span></span>
</td>
<td class="text">Dec. 11,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Dec. 11,  2025<span></span>
</td>
<td class="text">Dec. 11,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,785,715<span></span>
</td>
<td class="nump">1,785,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Aug.  04,  2016<span></span>
</td>
<td class="text">Aug.  04,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Aug.  04,  2024<span></span>
</td>
<td class="text">Aug.  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Aug.  04,  2025<span></span>
</td>
<td class="text">Aug.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfWarrantShares', window );">Number of warrant shares</a></td>
<td class="nump">1,344,000<span></span>
</td>
<td class="nump">1,344,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DateOfIssue', window );">Issue date</a></td>
<td class="text">Feb. 28,  2018<span></span>
</td>
<td class="text">Feb. 28,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OriginalExpirationDate', window );">Original Expiration Date</a></td>
<td class="text">Feb. 28,  2024<span></span>
</td>
<td class="text">Feb. 28,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AmendedExpirationdate', window );">Amended Expiration Date</a></td>
<td class="text">Feb. 28,  2025<span></span>
</td>
<td class="text">Feb. 28,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AmendedExpirationdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AmendedExpirationdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DateOfIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DateOfIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NumberOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NumberOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_OriginalExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_OriginalExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772519703024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers', window );">Share Outstanding at beginning of period | shares</a></td>
<td class="nump">21,786,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued | shares</a></td>
<td class="nump">980,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="num">(2,582,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(297,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe', window );">Outstanding at end of period | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisableAtEndOfPeriod', window );">Exercisable at end of period | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OutstandingAtBegenningOfPeriod', window );">Outstanding at begin of period | $ / shares</a></td>
<td class="nump">$ 1.029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Issued | $ / shares</a></td>
<td class="nump">0.250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised | $ / shares</a></td>
<td class="num">(0.250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited | $ / shares</a></td>
<td class="num">(0.250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise PriceExpired | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OutstandingAtEndOfPeriod', window );">Outstanding at end of period | $ / shares</a></td>
<td class="nump">$ 1.103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExercisableAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExercisableAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_OutstandingAtBegenningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_OutstandingAtBegenningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_OutstandingAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_OutstandingAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772521944144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of warrants | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAveragesRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">2 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 1.163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Shares exercisable | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1.163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of warrants | shares</a></td>
<td class="nump">9,649,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAveragesRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 0.250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Shares exercisable | shares</a></td>
<td class="nump">9,649,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 0.250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of warrants | shares</a></td>
<td class="nump">6,512,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAveragesRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">1 year 4 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Shares exercisable | shares</a></td>
<td class="nump">6,512,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember', window );">Warrant Two [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">1.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember', window );">Warrant Two [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">1.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of warrants | shares</a></td>
<td class="nump">4,694,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAveragesRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">2 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Shares exercisable | shares</a></td>
<td class="nump">4,694,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember', window );">Warrant Three [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember', window );">Warrant Three [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of warrants | shares</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAveragesRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 4.080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Shares exercisable | shares</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 4.080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WeightedAveragesRemainingLifeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WeightedAveragesRemainingLifeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524035344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details 4)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_FederalFundsSoldAverageYield', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExpectedLifeMinimum', window );">Expected life minimum</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExpectedLifeMaximum', window );">Expected life Maximum</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Expected volatility</a></td>
<td class="nump">104.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Risk free interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExpectedLifeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExpectedLifeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExpectedLifeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExpectedLifeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_FederalFundsSoldAverageYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average yield on federal funds sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (2)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_FederalFundsSoldAverageYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772513182592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2016</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 20, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Jan. 05, 2022</div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
<th class="th"><div>Aug. 14, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average price of the common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,358<span></span>
</td>
<td class="nump">$ 48,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DescriptionOfAutomaticConversionOfConvertible', window );">Automatic conversion of Convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Money warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,866,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShrareIssuedWarrantToPurchasedPrice', window );">Shrare issued warrant to purchased price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Shrare issued warrant to purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,684,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,019<span></span>
</td>
<td class="nump">$ 244,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Authorized shares of capital stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock share par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,358,463<span></span>
</td>
<td class="nump">48,156,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DesignatedSeriesDConvertiblePreferredStocks', window );">Series D Convertible Preferred Stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember', window );">Three Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsToPurchaseCommonStock', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShrareIssuedWarrantToPurchasedPrice', window );">Shrare issued warrant to purchased price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=knwn_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReceivedOfWarrant', window );">warrants and received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387,334<span></span>
</td>
<td class="nump">$ 838,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632,727<span></span>
</td>
<td class="nump">389,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsToPurchaseCommonStock', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,273<span></span>
</td>
<td class="nump">122,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsExpiredPerSharePrice', window );">Warrants expired per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.250<span></span>
</td>
<td class="nump">$ 0.918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CommonStockSharesIssuedRelatedToWarrantExercises', window );">Common Stock Shares issued related to warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common Stock Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C PreferredStockMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Purchase preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="nump">$ 1,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Purchase preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_CommonPreferredStocksMember', window );">Common Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ProceedsFromIssuanceOfCommonStocks', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="nump">$ 26,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExerciseOfStockOption', window );">Exercise of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,687<span></span>
</td>
<td class="nump">26,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_AuthorizedCapitalStockMember', window );">Authorized Capital Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Authorized shares of capital stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock share par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DesignatedSeriesCConvertiblePreferredStock', window );">Series C Convertible Preferred Stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DesignatedSeriesDConvertiblePreferredStock', window );">Series D Convertible Preferred Stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesCMember', window );">Convertible Preferred Stock Series C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,358,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DesignatedSeriesDConvertiblePreferredStock', window );">Series D Convertible Preferred Stock designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_StockAtTwoMember', window );">Stock at 2.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants totaling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,439,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_StockAtOneMember', window );">Stock at 0.25</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants totaling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,424,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockDMember', window );">Convertible Preferred Stock D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_CommonStocksOfferingsMember', window );">Common Stock Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,472,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,424,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_GrossSales', window );">Gross proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=knwn_WarrantToPurchaseCommonStockMember', window );">Warrant To Purchase Common Stock Member | Boustead Securities LLC Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsIssuedValued', window );">Warrants valued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IssuedAmountReceived', window );">Issued amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common Stock Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember', window );">Mr. Struve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReceivedOfWarrant', window );">warrants and received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 387,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReceivedSeriesDPreferredStockDividendsShares', window );">Series D preferred stock dividends shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common Stock Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember', window );">Mr. Struve [Member] | Series C PreferredStockMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OwnershipInterestInPreferredStock', window );">Ownership interest</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cumulative Dividend</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Purchase preferred stock</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsToAcquireCommonStockShares', window );">Warrant to acquire common stock shares</a></td>
<td class="nump">1,785,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CommonStockSharePrice', window );">Share price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_PreferredStockConvertibleConversionPriceAdjusted', window );">Adjusted conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">1,785,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember', window );">Mr. Struve [Member] | Series D Preferred Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OwnershipInterestInPreferredStock', window );">Ownership interest</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CumulativeDividends', window );">Cumulative dividend cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cumulative Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average price of the common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Convertible common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,627,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Purchase preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_PreferredStockConvertibleConversionPriceAdjusted', window );">Adjusted conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember', window );">Mr. Struve [Member] | Series C and D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_OwnershipInterestInPreferredStock', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cumulative Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares of common stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfCommonStockSharesSettled', window );">Number of common stock shares settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DividendDistributedPerShare', window );">Dividend distributed per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The cumulative dividends accrued and paid in preferred stock will be determined based upon a $.70 stated value. The conversion from preferred stock into common stock is determined based dividing the $.70 stated value by the $.25 conversion price<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Convertible common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,526,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CumulativeDividendUnpaid', window );">Cumulative unpaid dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DeemedDividendsCumulative', window );">Cumulative deemed dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,526,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AccretedValueOfPreferredDividendIntoCommonStockShares', window );">Preferred dividend value accrete common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AccretedValueOfPreferredDividendIntoCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AccretedValueOfPreferredDividendIntoCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CommonStockSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CommonStockSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CommonStockSharesIssuedRelatedToWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CommonStockSharesIssuedRelatedToWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CumulativeDividendUnpaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CumulativeDividendUnpaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DeemedDividendsCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DeemedDividendsCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DescriptionOfAutomaticConversionOfConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DescriptionOfAutomaticConversionOfConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DesignatedSeriesCConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DesignatedSeriesCConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DesignatedSeriesDConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DesignatedSeriesDConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DesignatedSeriesDConvertiblePreferredStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DesignatedSeriesDConvertiblePreferredStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DividendDistributedPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DividendDistributedPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExerciseOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExerciseOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_GrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_GrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IssuedAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IssuedAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NumberOfCommonStockSharesSettled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NumberOfCommonStockSharesSettled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_OwnershipInterestInPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_OwnershipInterestInPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_PreferredStockConvertibleConversionPriceAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_PreferredStockConvertibleConversionPriceAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ProceedsFromIssuanceOfCommonStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ProceedsFromIssuanceOfCommonStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ReceivedOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ReceivedOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ReceivedSeriesDPreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ReceivedSeriesDPreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShrareIssuedWarrantToPurchasedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShrareIssuedWarrantToPurchasedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantIssuedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantIssuedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantsExpiredPerSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantsExpiredPerSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantsIssuedValued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantsIssuedValued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantsToAcquireCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantsToAcquireCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends distributed to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=knwn_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=knwn_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_CommonPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_CommonPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_AuthorizedCapitalStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_AuthorizedCapitalStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockSeriesCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_StockAtTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_StockAtTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_StockAtOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_StockAtOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_ConvertiblePreferredStockDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_CommonStocksOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_CommonStocksOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_WarrantToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_WarrantToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_BousteadSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_BousteadSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=knwn_SeriesCAndDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=knwn_SeriesCAndDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772522160000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(2,582,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(297,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="num">(0.250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 0.256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share Outstanding at beginning of period</a></td>
<td class="nump">20,792,370<span></span>
</td>
<td class="nump">15,315,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">4,158,333<span></span>
</td>
<td class="nump">6,636,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(166,890)<span></span>
</td>
<td class="num">(26,293)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(10,277,655)<span></span>
</td>
<td class="num">(1,132,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share Outstanding at ending of period</a></td>
<td class="nump">14,506,158<span></span>
</td>
<td class="nump">20,792,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at begin of period</a></td>
<td class="nump">$ 1.618<span></span>
</td>
<td class="nump">$ 1.565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">1.381<span></span>
</td>
<td class="nump">1.815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="num">(0.272)<span></span>
</td>
<td class="num">(1.376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeitures</a></td>
<td class="num">(1.647)<span></span>
</td>
<td class="num">(2.057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 1.546<span></span>
</td>
<td class="nump">$ 1.618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772513139040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding stock options | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price exerciseable</a></td>
<td class="nump">$ 1.163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=knwn_EmployeeStockOptionsOneMember', window );">Employee Stock Options One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding stock options | shares</a></td>
<td class="nump">14,506,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding</a></td>
<td class="nump">$ 1.546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">6,080,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price exerciseable</a></td>
<td class="nump">$ 1.498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=knwn_StockOptionsOneMember', window );">Stock Options 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding stock options | shares</a></td>
<td class="nump">2,161,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">2 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding</a></td>
<td class="nump">$ 1.105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">1,946,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price exerciseable</a></td>
<td class="nump">$ 1.107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=knwn_StockOptionsTwoMember', window );">Stock Options 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding stock options | shares</a></td>
<td class="nump">9,754,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding</a></td>
<td class="nump">$ 1.473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">2,920,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price exerciseable</a></td>
<td class="nump">$ 1.415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_StockOption3Member', window );">Stock Option 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of outstanding stock options | shares</a></td>
<td class="nump">2,590,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageRemainingLifeYears', window );">Weighted average remaining life (years)</a></td>
<td class="text">3 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WeightedAverageExercisePriceOutstanding', window );">Weighted average exercise price outstanding</a></td>
<td class="nump">$ 2.186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number exercisable | shares</a></td>
<td class="nump">1,213,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price exerciseable</a></td>
<td class="nump">$ 2.151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Option 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">1.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Option 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">1.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Option 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">0.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Option 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">1.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Option 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">3.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Option 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of exercise prices</a></td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WeightedAverageRemainingLifeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WeightedAverageRemainingLifeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=knwn_EmployeeStockOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=knwn_EmployeeStockOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=knwn_StockOptionsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=knwn_StockOptionsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=knwn_StockOptionsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=knwn_StockOptionsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_StockOption3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_StockOption3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_StockOption2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=knwn_StockOption2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=knwn_StockOption1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=knwn_StockOption1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772521270592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK INCENTIVE PLANS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_IntrinsicValue', window );">Intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockOptionGrants', window );">Stock option grants</a></td>
<td class="nump">14,906,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Average exercise price</a></td>
<td class="nump">$ 1.163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of common stock authorized shares</a></td>
<td class="nump">20,886,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned', window );">Unearned stock option grants</a></td>
<td class="nump">4,158,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="nump">$ 1.381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockIssuedDuringPeriodSharesStockOptionExercised', window );">Stock option grants share exercised</a></td>
<td class="nump">166,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExerciseStockOptionGrantsreceived', window );">Exercise stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option grants shares forfeitures</a></td>
<td class="nump">297,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember', window );">Ronald P Erickson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember', window );">Phillip A. Bosua [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember', window );">Peter Conley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common shares current price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantIssuedToCommonStock', window );">Warrant issued to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=knwn_TwoZeroTwoOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of common stock authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_NumberOfCommonStockSharesIncrease', window );">Number of common stock shares increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 0.272<span></span>
</td>
<td class="nump">$ 1.376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeitures</a></td>
<td class="nump">$ 1.647<span></span>
</td>
<td class="nump">$ 2.057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option grants shares forfeitures</a></td>
<td class="nump">10,277,655<span></span>
</td>
<td class="nump">1,132,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember', window );">Stock Option [Member] | Eight Employees And Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned', window );">Unearned stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember', window );">Stock Option [Member] | Nineteen Employees And Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned', window );">Unearned stock option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExerciseStockOptionGrantsreceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExerciseStockOptionGrantsreceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_IntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_IntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_NumberOfCommonStockSharesIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_NumberOfCommonStockSharesIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_StockIssuedDuringPeriodSharesStockOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_StockIssuedDuringPeriodSharesStockOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_StockOptionGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_StockOptionGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantIssuedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantIssuedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=knwn_TwoZeroTwoOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=knwn_TwoZeroTwoOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=knwn_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=knwn_EightEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=knwn_EightEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=knwn_NineteenEmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=knwn_NineteenEmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772520526064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 14, 2022</div></th>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Nov. 04, 2019</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Jan. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember', window );">Ronald P Erickson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ShareGrant', window );">No of share granted for stock option</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,207,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Share exercise price</a></td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DescriptionRelatedToCommonStock', window );">Company common stock description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">exceeds for 20 consecutive trading days starting at $100 million to $1 billion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CumulativeExpenses', window );">Cumulative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AdditionalStockOption', window );">Additional stock option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AdditionalExercisedPrice', window );">Additional exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsSharebasedCompensationStock', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AccruedCompensastionTravelAndInterest', window );">Accrued compensastion &amp; travel and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,334<span></span>
</td>
<td class="nump">295,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember', window );">Phillip A. Bosua [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Share exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DescriptionRelatedToCommonStock', window );">Company common stock description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">exceeds for 20 consecutive trading days starting at $100 million to $1 billion<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CumulativeExpenses', window );">Cumulative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AdditionalStockOption', window );">Additional stock option grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,132,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AdditionalExercisedPrice', window );">Additional exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_AIMindMember', window );">AI Mind [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember', window );">Three Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Share exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_WarrantsToPurchaseCommonStock', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember', window );">Mr. Struve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ReceivedSeriesDPreferredStockDividends', window );">Series D preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,627,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_ExercisePricePerShare', window );">Share exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AccruedCompensastionTravelAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AccruedCompensastionTravelAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AdditionalExercisedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AdditionalExercisedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AdditionalStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AdditionalStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CumulativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CumulativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DescriptionRelatedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DescriptionRelatedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ReceivedSeriesDPreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ReceivedSeriesDPreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_ShareGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_ShareGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsSharebasedCompensationStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsSharebasedCompensationStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquipmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquipmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_PhillipABosuaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_AIMindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_AIMindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=knwn_ThreeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=knwn_MrStruveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772519684032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 13, 2022</div></th>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Apr. 10, 2018</div></th>
<th class="th"><div>Apr. 13, 2017</div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th"><div>Oct. 11, 2021</div></th>
<th class="th"><div>May 18, 2021</div></th>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments', window );">Leases, net monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,334<span></span>
</td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 8,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_LeaseDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#8217;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company&#8217;s common stock exceeds $5.00 per share on the NYSE American (the &#8220;Stock Price Threshold&#8221;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=knwn_MrBosuaMember', window );">Mr. Bosua [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AnnualSalary', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_CommonStockPerShares', window );">Common stock per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember', window );">Ronald P Erickson [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AnnualSalary', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember', window );">Peter Conley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AnnualSalary', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_CommonStockPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_CommonStockPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_LeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_LeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481295/840-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=knwn_MrBosuaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=knwn_MrBosuaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_RonaldPEricksonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=knwn_PeterConleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772523569040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 10,476,000<span></span>
</td>
<td class="nump">$ 9,372,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">2,174,000<span></span>
</td>
<td class="nump">1,677,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment', window );">Research and Development</a></td>
<td class="nump">1,460,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and reserves</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">14,156,000<span></span>
</td>
<td class="nump">11,367,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(14,156,000)<span></span>
</td>
<td class="num">(11,367,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance during the year</a></td>
<td class="num">$ (2,789,000)<span></span>
</td>
<td class="num">$ (1,666,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529960912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non deductible expenses</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp', window );">Other and prior year true up</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772524540320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_FederalNetOperatingLossCarryforwardsExpired', window );">Federal net operating loss carryforwards expired</a></td>
<td class="text">expire in 2028-2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 49.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Gross deferred tax asset</a></td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_EffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_EffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_EffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_FederalNetOperatingLossCarryforwardsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_FederalNetOperatingLossCarryforwardsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772522089568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentRevenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentNetIncomeLoss', window );">Segment Operating Profit (Loss)</a></td>
<td class="num">(14,024,000)<span></span>
</td>
<td class="num">(12,574,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentAsset', window );">Segment assets</a></td>
<td class="nump">8,266<span></span>
</td>
<td class="nump">13,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember', window );">Development of the Bio-RFID and ChromaID Technologies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentRevenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentNetIncomeLoss', window );">Segment Operating Profit (Loss)</a></td>
<td class="num">(14,298,000)<span></span>
</td>
<td class="num">(13,482,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentAsset', window );">Segment assets</a></td>
<td class="nump">8,266,000<span></span>
</td>
<td class="nump">13,360,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=knwn_ParticleIncTechnologyMember', window );">Particle, Inc. Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentRevenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentNetIncomeLoss', window );">Segment Operating Profit (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentAsset', window );">Segment assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=knwn_DigitalassetsalesMember', window );">Digital asset sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentRevenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentNetIncomeLoss', window );">Segment Operating Profit (Loss)</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_SegmentAsset', window );">Segment assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SegmentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SegmentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SegmentNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SegmentNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_SegmentRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_SegmentRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=knwn_ParticleIncTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=knwn_ParticleIncTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=knwn_DigitalassetsalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=knwn_DigitalassetsalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772529904752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT REPORTING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash expenses</a></td>
<td class="nump">$ 4,767,809<span></span>
</td>
<td class="nump">$ 12,164,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139772513083024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockOptionGrantsToEmployeesAndDirectors', window );">Stock option grants to employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,909,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_StockOptionExpiryTerm', window );">Stock option expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_knwn_AdditionalSharePurchase', window );">Additional share purchase</a></td>
<td class="nump">883,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Additional warrants issued</a></td>
<td class="nump">61,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_AdditionalSharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_AdditionalSharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_StockOptionExpiryTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_StockOptionExpiryTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_knwn_StockOptionGrantsToEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">knwn_StockOptionGrantsToEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>knwn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>knwn_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:knwn="http://knwn.com/20230930"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="knwn-20230930.xsd" xlink:type="simple"/>
    <context id="From2022-10-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-26_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-26</instant>
        </period>
    </context>
    <context id="From2023-09-01to2023-10-26_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DigitalassetsalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:ParticleIncTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DigitalassetsalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:ParticleIncTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">knwn:DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-09-01to2022-09-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="From2022-05-01to2022-05-13_knwn_PeterConleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="From2021-04-01to2022-03-15_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="From2018-04-01to2018-04-10_knwn_MrBosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-10</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2021-03-31_knwn_MrBosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-01to2022-09-30_knwn_MrBosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:MrBosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-05-01to2021-03-31_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2018-04-01to2018-04-10_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-10</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_PeterConleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-11-01to2022-11-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="From2022-09-01to2022-09-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="From2021-09-11to2021-10-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2021-09-11</startDate>
            <endDate>2021-10-11</endDate>
        </period>
    </context>
    <context id="From2021-05-01to2021-05-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-18</endDate>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="From2017-04-01to2017-04-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-05_knwn_ThreeDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:ThreeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-05</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-14_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="AsOf2020-12-15_knwn_PhillipABosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-04_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="AsOf2020-12-15_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-12-01to2022-12-14_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_AIMindMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:AIMindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2019-11-01to2019-11-04_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_PeterConleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PeterConleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_PhillipABosuaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:PhillipABosuaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_RonaldPEricksonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:RonaldPEricksonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:NineteenEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:EightEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-01-01_knwn_TwoZeroTwoOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:TwoZeroTwoOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="AsOf2021-10-15_knwn_TwoZeroTwoOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:TwoZeroTwoOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:NineteenEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">knwn:EightEmployeesAndConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_EmployeeStockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:EmployeeStockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_StockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:EmployeeStockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockOptionsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockOptionsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">knwn:StockOptionsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:StockOption2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_knwn_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">knwn:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ConvertiblePreferredStockDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockAtOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:StockAtOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_StockAtTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:StockAtTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-01to2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="From2023-09-01to2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-20</instant>
        </period>
    </context>
    <context id="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">knwn:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-20_knwn_CommonStocksOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-20</instant>
        </period>
    </context>
    <context id="From2023-09-01to2023-09-29_knwn_CommonStocksOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-29_knwn_CommonStocksOfferingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonStocksOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:AuthorizedCapitalStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:CommonPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ThreeDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">knwn:ThreeDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-14</instant>
        </period>
    </context>
    <context id="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-14</instant>
        </period>
    </context>
    <context id="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-05</instant>
        </period>
    </context>
    <context id="AsOf2023-06-27_knwn_MrStruveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_MrStruveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_MrStruveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">knwn:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-12-01to2022-12-31_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-08-01to2023-08-31_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:SeriesCAndDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-05</endDate>
        </period>
    </context>
    <context id="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">knwn:MrStruveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">knwn:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-03-16_knwn_ConvertibleNote7Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote7Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-16</instant>
        </period>
    </context>
    <context id="AsOf2018-03-16_knwn_ConvertibleNote8Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote8Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-16</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertibleNote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertibleNote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-03-16_knwn_ConvertibleNote2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-16</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ConvertibleNote1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNote1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertibleNotesFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNotesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertibleNotesFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNotesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertibleNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertibleNoteTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertibleNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertibleNoteOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">knwn:ConvertibleNoteOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ThirtyFirstDecemberTwentyTwentyThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">knwn:ThirtyFirstDecemberTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">knwn:ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">knwn:ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_TechnologyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_TechnologyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_TechnologyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_StockOption1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">knwn:StockOption1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_Warrant1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">knwn:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_Warrant1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">knwn:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-10-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_knwn_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">knwn:SeriesCConvertiblesPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStocksSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">knwn:ConvertiblePreferredStocksSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2023-12-19</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074828</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-01to2023-09-30">0001074828</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-10-01to2023-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-10-01to2023-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2022-10-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      unitRef="Shares">30000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      unitRef="Shares">20000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="0" unitRef="Shares">80358463</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="0" unitRef="Shares">48156062</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-10-01to2023-09-30">  EstimatedUseful Lives June 30,2023  September 30,2022 Machinery and equipment 2-3 years $961,529  $1,510,265 Furniture and fixtures 5 years  26,855   26,855 Leasehold improvements 5 years  3,612   3,612 Less: accumulated depreciation    (691,899)  (677,755)    $300,097  $862,977 </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-10-01to2023-09-30">Year Ended June 30, 2024-   Total remaining payments $204,534 Less imputed interest  (1,822)Total lease liability $202,712 </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="AsOf2023-09-30" decimals="0" unitRef="Shares">80358463</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">213330</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1510265</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3612</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">21366</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">26855</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">153371</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">677755</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <knwn:TotalRemainingPayments contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">153401</knwn:TotalRemainingPayments>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1396</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">154797</us-gaap:OperatingLeaseLiability>
    <knwn:GrossProceedFromPublicIssueStock
      contextRef="From2022-10-01to2023-09-30_knwn_ThirtyFirstDecemberTwentyTwentyThreeMember"
      decimals="0"
      unitRef="USD">8280000</knwn:GrossProceedFromPublicIssueStock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="0"
      unitRef="Shares">4140000</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="0"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="0"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption1Member"
      decimals="INF"
      unitRef="USDPShares">0.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <knwn:StockOptionExpiryTerm contextRef="From2022-10-01to2023-09-30">P5Y</knwn:StockOptionExpiryTerm>
    <dei:DocumentType contextRef="From2022-10-01to2023-09-30">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2022-10-01to2023-09-30">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-10-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-10-01to2023-09-30">001-37479</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-10-01to2023-09-30">KNOW LABS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-01to2023-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-01to2023-09-30">90-0273142</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-01to2023-09-30">500 Union Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-01to2023-09-30">Suite 810</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-01to2023-09-30">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-01to2023-09-30">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-01to2023-09-30">98101</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-01to2023-09-30">206</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-01to2023-09-30">903-1351</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-10-01to2023-09-30">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-01to2023-09-30">KNW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-01to2023-09-30">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2022-10-01to2023-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2022-10-01to2023-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2022-10-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-10-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-10-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-10-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-01to2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2022-10-01to2023-09-30">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2022-10-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">32309758</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-12-19" decimals="INF" unitRef="Shares">81346524</dei:EntityCommonStockSharesOutstanding>
    <knwn:AnnualSalary
      contextRef="From2020-05-01to2021-03-31_knwn_MrBosuaMember"
      decimals="0"
      id="fid_1233"
      unitRef="USD">260000</knwn:AnnualSalary>
    <dei:AuditorFirmId contextRef="From2022-10-01to2023-09-30">207</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2022-10-01to2023-09-30">BPM LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2022-10-01to2023-09-30">Walnut Creek, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_434"
      unitRef="USD">8023716</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_435"
      unitRef="USD">12593692</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_436"
      unitRef="USD">8023716</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_437"
      unitRef="USD">12593692</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_438"
      unitRef="USD">81325</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_439"
      unitRef="USD">862977</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_441"
      unitRef="USD">15766</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_442"
      unitRef="USD">13767</us-gaap:OtherAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_443"
      unitRef="USD">145090</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_444"
      unitRef="USD">287930</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_445"
      unitRef="USD">8265897</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_446"
      unitRef="USD">13758366</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_449"
      unitRef="USD">1292861</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_450"
      unitRef="USD">526968</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_451"
      unitRef="USD">94062</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_452"
      unitRef="USD">462940</us-gaap:AccruedLiabilitiesCurrent>
    <knwn:AmountDueToRelatedPartiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_453"
      unitRef="USD">218334</knwn:AmountDueToRelatedPartiesCurrent>
    <knwn:AmountDueToRelatedPartiesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_454"
      unitRef="USD">348264</knwn:AmountDueToRelatedPartiesCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_455"
      unitRef="USD">2761931</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_456"
      unitRef="USD">2255066</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_457"
      unitRef="USD">154797</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_458"
      unitRef="USD">215397</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_459"
      unitRef="USD">4521985</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_460"
      unitRef="USD">3808635</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_462"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_463"
      unitRef="USD">87118</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_464"
      unitRef="USD">0</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_465"
      unitRef="USD">87118</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_466"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_467"
      unitRef="USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_486"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_492"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="INF"
      id="fid_487"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      id="fid_493"
      unitRef="Shares">30000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember"
      decimals="0"
      id="fid_506"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_469"
      unitRef="USD">1790</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_481"
      unitRef="USD">1790</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="INF"
      id="fid_488"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      id="fid_494"
      unitRef="Shares">20000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesDMember"
      decimals="0"
      id="fid_507"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_470"
      unitRef="USD">1015</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_482"
      unitRef="USD">1015</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_495"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_499"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_500"
      unitRef="Shares">80358463</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_501"
      unitRef="Shares">48156062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_471"
      unitRef="USD">80358</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_472"
      unitRef="USD">48158</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_473"
      unitRef="USD">125501537</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_474"
      unitRef="USD">111209388</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_475"
      unitRef="USD">-121840788</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_476"
      unitRef="USD">-101397738</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_477"
      unitRef="USD">3743912</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_478"
      unitRef="USD">9862613</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_479"
      unitRef="USD">8265897</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_480"
      unitRef="USD">13758366</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_512"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_513"
      unitRef="USD">4360087</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_515"
      unitRef="USD">7727467</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_516"
      unitRef="USD">5385586</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_517"
      unitRef="USD">6570597</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_518"
      unitRef="USD">8118137</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_519"
      unitRef="USD">274019</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_520"
      unitRef="USD">3430438</us-gaap:SellingExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_521"
      unitRef="USD">14024045</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_522"
      unitRef="USD">16934161</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_523"
      unitRef="USD">-14024045</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_524"
      unitRef="USD">-12574074</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_525"
      unitRef="USD">127145</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_526"
      unitRef="USD">15283</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_550"
      unitRef="USD">389626</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_551"
      unitRef="USD">8034081</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_527"
      unitRef="USD">-506865</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_528"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherIncome
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_529"
      unitRef="USD">-495776</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_530"
      unitRef="USD">521628</us-gaap:OtherIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_531"
      unitRef="USD">-1265122</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_532"
      unitRef="USD">-7497170</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_533"
      unitRef="USD">-15289167</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_534"
      unitRef="USD">-20071244</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_535"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_536"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_537"
      unitRef="USD">-15289167</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_538"
      unitRef="USD">-20071244</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_539"
      unitRef="USD">1627230</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsCommonStockStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_540"
      unitRef="USD">0</us-gaap:DividendsCommonStockStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_541"
      unitRef="USD">3526653</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_542"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <knwn:NetIncomeLossAvailableToCommonStockholders
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_543"
      unitRef="USD">-20443050</knwn:NetIncomeLossAvailableToCommonStockholders>
    <knwn:NetIncomeLossAvailableToCommonStockholders
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_544"
      unitRef="USD">-20071244</knwn:NetIncomeLossAvailableToCommonStockholders>
    <knwn:EarningsPerSharesBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_545"
      unitRef="USDPShares">-0.41</knwn:EarningsPerSharesBasicAndDiluted>
    <knwn:EarningsPerSharesBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_546"
      unitRef="USDPShares">-0.50</knwn:EarningsPerSharesBasicAndDiluted>
    <knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_547"
      unitRef="Shares">49581467</knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_548"
      unitRef="Shares">40370473</knwn:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1259"
      unitRef="Shares">17858</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1262"
      unitRef="USD">1790</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1260"
      unitRef="Shares">10161</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1263"
      unitRef="USD">1015</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1261"
      unitRef="Shares">35166551</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1264"
      unitRef="USD">35168</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1265"
      unitRef="USD">82530684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1266"
      unitRef="USD">-81326494</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1267"
      unitRef="USD">1242163</us-gaap:StockholdersEquity>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1268"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1269"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1270"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1271"
      unitRef="USD">4421634</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1272"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1273"
      unitRef="USD">4421634</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1277"
      unitRef="USD">0</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1278"
      unitRef="USD">0</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestShares
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1276"
      unitRef="Shares">7672860</knwn:ConversionOfDebtOfferingAndAccruedInterestShares>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1279"
      unitRef="USD">7673</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1280"
      unitRef="USD">15338047</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1281"
      unitRef="USD">0</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:ConversionOfDebtOfferingAndAccruedInterestAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1282"
      unitRef="USD">15345720</knwn:ConversionOfDebtOfferingAndAccruedInterestAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1286"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1287"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesShares
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1285"
      unitRef="Shares">26293</knwn:IssuanceOfCommonStockForStockOptionExercisesShares>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1288"
      unitRef="USD">26</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1289"
      unitRef="USD">26661</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1290"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1291"
      unitRef="USD">26687</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1295"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1296"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1294"
      unitRef="Shares">1045724</knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1297"
      unitRef="USD">1046</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1298"
      unitRef="USD">837441</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1299"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1300"
      unitRef="USD">838487</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1304"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1305"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1303"
      unitRef="Shares">104634</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1306"
      unitRef="USD">105</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1307"
      unitRef="USD">182895</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1308"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1309"
      unitRef="USD">183000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1310"
      unitRef="USD">0</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1311"
      unitRef="USD">0</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1312"
      unitRef="USD">0</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1313"
      unitRef="USD">451487</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1314"
      unitRef="USD">0</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IssuanceOfCommonStockWarrantForServices
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1315"
      unitRef="USD">451487</knwn:IssuanceOfCommonStockWarrantForServices>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1319"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1320"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <knwn:IsssuanceOfCommonStockForNyseUplistingShares
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1318"
      unitRef="Shares">4140000</knwn:IsssuanceOfCommonStockForNyseUplistingShares>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1321"
      unitRef="USD">4140</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1322"
      unitRef="USD">7420539</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1323"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <knwn:IsssuanceOfCommonStockForNyseUplistingAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1324"
      unitRef="USD">7424679</knwn:IsssuanceOfCommonStockForNyseUplistingAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1325"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1326"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1327"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1328"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1329"
      unitRef="USD">-20071244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1330"
      unitRef="USD">-20071244</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1331"
      unitRef="Shares">17858</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1334"
      unitRef="USD">1790</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1332"
      unitRef="Shares">10161</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1335"
      unitRef="USD">1015</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1333"
      unitRef="Shares">48156062</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1336"
      unitRef="USD">48158</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1337"
      unitRef="USD">111209388</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1338"
      unitRef="USD">-101397738</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1339"
      unitRef="USD">9862613</us-gaap:StockholdersEquity>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1340"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1341"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1342"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1343"
      unitRef="USD">2955933</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1344"
      unitRef="USD">0</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:StockCompensationExpenseEmployeeOptions
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1345"
      unitRef="USD">2955933</knwn:StockCompensationExpenseEmployeeOptions>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1349"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1350"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesShares
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1348"
      unitRef="Shares">166890</knwn:IssuanceOfCommonStockForStockOptionExercisesShares>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1351"
      unitRef="USD">166</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1352"
      unitRef="USD">4521</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1353"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForStockOptionExercisesAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1354"
      unitRef="USD">4687</knwn:IssuanceOfCommonStockForStockOptionExercisesAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1358"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1359"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1357"
      unitRef="Shares">2632727</knwn:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1360"
      unitRef="USD">2631</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1361"
      unitRef="USD">384703</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1362"
      unitRef="USD">0</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1363"
      unitRef="USD">387334</knwn:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1367"
      unitRef="USD">0</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1368"
      unitRef="USD">0</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockShares
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1366"
      unitRef="Shares">1402784</knwn:CommonStockDividendsOnSeriesDPreferredStockShares>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1369"
      unitRef="USD">1403</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1370"
      unitRef="USD">1625827</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1371"
      unitRef="USD">-1627230</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:CommonStockDividendsOnSeriesDPreferredStockAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1372"
      unitRef="USD">0</knwn:CommonStockDividendsOnSeriesDPreferredStockAmount>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1373"
      unitRef="USD">0</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1374"
      unitRef="USD">0</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1375"
      unitRef="USD">0</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1376"
      unitRef="USD">3526653</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1377"
      unitRef="USD">-3526653</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:DeemedDividendsOnSeriesCAndDPreferredStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1378"
      unitRef="USD">0</knwn:DeemedDividendsOnSeriesCAndDPreferredStock>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1382"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1383"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingShares
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1381"
      unitRef="Shares">28000000</knwn:IsssuanceOfCommonStockForCommonStockOfferingShares>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1384"
      unitRef="USD">28000</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1385"
      unitRef="USD">5444791</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1386"
      unitRef="USD">0</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1387"
      unitRef="USD">5472791</knwn:IsssuanceOfCommonStockForCommonStockOfferingAmount>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1388"
      unitRef="USD">0</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1389"
      unitRef="USD">0</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1390"
      unitRef="USD">0</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1391"
      unitRef="USD">349721</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1392"
      unitRef="USD">0</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <knwn:ExpensesForExtensionOfNotesAndWarrants
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1393"
      unitRef="USD">349721</knwn:ExpensesForExtensionOfNotesAndWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1394"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1395"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1396"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1397"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1398"
      unitRef="USD">-15289167</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1399"
      unitRef="USD">-15289167</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1400"
      unitRef="Shares">17858</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_knwn_SeriesCConvertiblesPreferredStockMember"
      decimals="0"
      id="fid_1403"
      unitRef="USD">1790</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1401"
      unitRef="Shares">10161</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_knwn_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      id="fid_1404"
      unitRef="USD">1015</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1402"
      unitRef="Shares">80358463</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_knwn_CommonStocksMember"
      decimals="0"
      id="fid_1405"
      unitRef="USD">80358</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1406"
      unitRef="USD">125501537</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1407"
      unitRef="USD">-121840788</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1408"
      unitRef="USD">3743912</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_703"
      unitRef="USD">-15289167</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_704"
      unitRef="USD">-20071244</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_706"
      unitRef="USD">313019</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_707"
      unitRef="USD">320995</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_708"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_709"
      unitRef="USD">183000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_710"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_711"
      unitRef="USD">451487</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <knwn:GainLossOnDebtSettlement
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_712"
      unitRef="USD">-50000</knwn:GainLossOnDebtSettlement>
    <knwn:GainLossOnDebtSettlement
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_713"
      unitRef="USD">-268872</knwn:GainLossOnDebtSettlement>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_714"
      unitRef="USD">549431</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_715"
      unitRef="USD">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_716"
      unitRef="USD">506865</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_717"
      unitRef="USD">0</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:InterestExpenseForeignDeposits
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_718"
      unitRef="USD">349721</us-gaap:InterestExpenseForeignDeposits>
    <us-gaap:InterestExpenseForeignDeposits
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_719"
      unitRef="USD">0</us-gaap:InterestExpenseForeignDeposits>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_720"
      unitRef="USD">2955933</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">4421634</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <knwn:GainLossOnForgivenessOfNotesPayablePppLoans
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_722"
      unitRef="USD">0</knwn:GainLossOnForgivenessOfNotesPayablePppLoans>
    <knwn:GainLossOnForgivenessOfNotesPayablePppLoans
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_723"
      unitRef="USD">-252700</knwn:GainLossOnForgivenessOfNotesPayablePppLoans>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_724"
      unitRef="USD">142840</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_725"
      unitRef="USD">35963</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_726"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_727"
      unitRef="USD">7272911</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_729"
      unitRef="USD">-1999</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_730"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_731"
      unitRef="USD">-147719</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_732"
      unitRef="USD">-22917</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_733"
      unitRef="USD">317085</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_734"
      unitRef="USD">1009935</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_735"
      unitRef="USD">-10353991</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_736"
      unitRef="USD">-6919808</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_738"
      unitRef="USD">80797</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_739"
      unitRef="USD">855468</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_740"
      unitRef="USD">-80797</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_741"
      unitRef="USD">-855468</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_743"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_744"
      unitRef="USD">8280000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <knwn:ProceedsFromIssuanceOfCommonStockOfferingNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_745"
      unitRef="USD">5472791</knwn:ProceedsFromIssuanceOfCommonStockOfferingNet>
    <knwn:ProceedsFromIssuanceOfCommonStockOfferingNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_746"
      unitRef="USD">0</knwn:ProceedsFromIssuanceOfCommonStockOfferingNet>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_747"
      unitRef="USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_748"
      unitRef="USD">855321</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_749"
      unitRef="USD">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_750"
      unitRef="USD">179103</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_777"
      unitRef="USD">4687</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_778"
      unitRef="USD">26687</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_751"
      unitRef="USD">387334</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_752"
      unitRef="USD">838487</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_753"
      unitRef="USD">5864812</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_754"
      unitRef="USD">8110750</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_755"
      unitRef="USD">-4569976</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_756"
      unitRef="USD">335474</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_757"
      unitRef="USD">12593692</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_758"
      unitRef="USD">12258218</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_759"
      unitRef="USD">8023716</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_760"
      unitRef="USD">12593692</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_762"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_763"
      unitRef="USD">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_764"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_765"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_767"
      unitRef="USD">0</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_768"
      unitRef="USD">14209000</us-gaap:DebtConversionOriginalDebtAmount1>
    <knwn:ConversionOfAccruedInterest
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_769"
      unitRef="USD">0</knwn:ConversionOfAccruedInterest>
    <knwn:ConversionOfAccruedInterest
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_770"
      unitRef="USD">1136720</knwn:ConversionOfAccruedInterest>
    <us-gaap:DividendsCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_771"
      unitRef="USD">1627230</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_772"
      unitRef="USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_773"
      unitRef="USD">3526653</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_774"
      unitRef="USD">0</us-gaap:DividendsPreferredStockStock>
    <knwn:IssuanceCostsFromCommonStockOffering
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_779"
      unitRef="USD">1527209</knwn:IssuanceCostsFromCommonStockOffering>
    <knwn:IssuanceCostsFromCommonStockOffering
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_780"
      unitRef="USD">0</knwn:IssuanceCostsFromCommonStockOffering>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_794">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1. ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;Know Labs, Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the State of Nevada in 1998. The Company currently has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.&#160;At the annual shareholder meeting held on October 15, 2021, the Company&#x2019;s authorized shares of common stock was increased to 200,000,000 shares of voting common stock, par value $0.001 per share. &#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique &#x201c;signature&#x201d; of said materials or analytes. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device will provide the user with real-time information on their blood glucose levels.&#160; We recently announced our Generation 1 working prototype device.&#160; This device embodies the sensor which has been used in internal clinical testing.&#160; We have also announced the work our R&amp;amp;D team is doing on the Generation 2 of our device, which is a wearable format and could be a final form factor, ready for commercial application. We are expanding our testing, both internally and externally, and will refine the device over time, which will require FDA clearance before entering the market.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <knwn:AuthorizedSharesOfCapitalStock
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_410"
      unitRef="Shares">205000000</knwn:AuthorizedSharesOfCapitalStock>
    <knwn:AuthorizedSharesOfCapitalCommonStock
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_411"
      unitRef="Shares">200000000</knwn:AuthorizedSharesOfCapitalCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_413"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_416"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_418"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <knwn:AuthorizedCommonStockIncreased
      contextRef="AsOf2021-10-15"
      decimals="0"
      id="fid_420"
      unitRef="Shares">200000000</knwn:AuthorizedCommonStockIncreased>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-10-15"
      decimals="INF"
      id="fid_414"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_781">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;2. LIQUIDITY&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The Company has cash and cash equivalents of $8,023,716 and net working capital of $6,262,662 (exclusive of convertible notes payable) as of September 30, 2023. The Company anticipates that it will record losses from operations for the foreseeable future. During the end of the year ended September 30, 2023, the Company made some adjustments to its staffing level and the impact of those adjustments, plus the departure of our chief technology and executive office, has significantly reduced our monthly burn rate. The Company will further adjust its cost structure if new debt or equity capital is not received. The Company&#x2019;s ability to transition profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company believes that it has enough available cash and flexibility with its operating expenses to operate until at least June 30, 2024. Based on current operating levels, the Company will need to raise additional funds by selling additional equity or incurring debt. To date, the Company has funded its operations primarily through issuance of equity securities, and proceeds from the exercise of warrants to purchase common stock and the sale of debt instruments. Additionally, future capital requirements will depend on many factors, including the rate of revenue growth, the selling price of the Company&#x2019;s products, the expansion of sales and marketing activities, the timing and extent of spending on research and development efforts and the continuing market acceptance of the Company&#x2019;s products. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for the twelve months from the date of this Report.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;Management of the Company intends to raise additional funds through the issuance of equity securities or debt. The Company is currently working on some capital fund raising transactions and while they expect to have something finalized by March 31, 2024, as of this date, there is no commitment. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company&#x2019;s ability to continue as a going concern has not been alleviated. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The proceeds of warrants currently outstanding, which could be exercised on a cash basis, may generate potential proceeds. &#160;The Company expects that portions of these warrants will be exercised but there is no guarantee any portion will be exercised. &lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <knwn:CashAndCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1"
      unitRef="USD">8023716</knwn:CashAndCashEquivalents>
    <knwn:NetWorkingCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_3"
      unitRef="USD">6262662</knwn:NetWorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_782">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt;&lt;/strong&gt; &#x2013;These unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt;&lt;/strong&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Particle and AI Mind. Intercompany items and transactions have been eliminated in consolidation. &#160;AI Mind was dissolved in July 2023.&#160; &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Cash and Cash Equivalents&lt;/em&gt;&lt;/strong&gt; &#x2013;&#160;The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Property and Equipment&lt;/em&gt;&lt;/strong&gt; &#x2013; Equipment consists of machinery, leasehold improvements and furniture and fixtures, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-5 years, except for leasehold improvements which are depreciated over 5 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Long-Lived Assets&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Revenue Recognition&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; The Company determines revenue recognition from contracts with customers through the following steps:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;identification of the contract, or contracts, with the customer;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;identification of the performance obligations in the contract;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;determination of the transaction price;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;allocation of the transaction price to the performance obligations in the contract; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;recognition of the revenue when, or as, the Company satisfies a performance obligation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Research and Development Expenses&lt;/em&gt;&lt;/strong&gt; &#x2013; Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s current research and development efforts are primarily focused on improving its radio frequency spectroscopy technology and its first focus on non-invasive monitoring of blood glucose levels; extending its capacity and developing new and unique applications for this technology. The Company believes that continued development of new and enhanced technologies is essential to its future success. The Company incurred expenses of $7,727,467 and $5,385,586 for the years ended September 30, 2023 and 2022, respectively, on development activities.&#160; Included in the expense for 2023 is approximately $859,000 related to severance and other expenses associated with the departure of the Company&#x2019;s former chief technology officer and chief executive officer, Philip A. Bosua, and other employees.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Advertising&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising and marketing costs for the year ended September 30, 2023 and 2022 were $305,292 and $379,724, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Fair Value Measurements and Financial Instruments&lt;/em&gt;&lt;/strong&gt; &#x2013;&lt;strong&gt;&#160;&lt;/strong&gt;ASC Topic 820, &lt;em&gt;Fair Value Measurement and Disclosures&lt;/em&gt;, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#x2019;s own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets and liabilities;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than level one inputs that are either directly or indirectly observable; and&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 3 &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities. The fair value of the Company&#x2019;s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has a money market account which is considered a Level 1 asset. The balance as of September 30, 2023 and 2022 was $7,836,393 and $11,821,931, respectively. No other assets or liabilities are required to&#160; be recorded at fair value on a recurring nature. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Derivative Financial Instruments&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &#x2013; &lt;/strong&gt;Pursuant to ASC 815 &#x201c;Derivatives and Hedging&#x201d;, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. &#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company determined that the conversion features for purposes of bifurcation within its &#160;convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and &#160;there was no derivative liability. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Stock Based Compensation&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. The Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Convertible Securities&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; Based upon ASC 815-15, the Company has adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. The Company will evaluate its contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company&#x2019;s inability to demonstrate it has sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Net Loss per Share&lt;/em&gt;&lt;/strong&gt; &#x2013; Under the provisions of ASC 260, &#x201c;Earnings Per Share,&#x201d; basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Deemed dividends to preferred shareholders increase the net loss available to common&#160; shareholders and impact the net loss per share calculation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2023, the Company had 80,358,463 shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of 14,506,158 shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 20,866,313 shares of our common stock, 8,108,356 shares of the Company&#x2019;s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 3,040,219 shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931.&#160; Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2022, the Company had 48,156,062 shares of common stock issued and outstanding. As of September 30, 2022, there were options outstanding for the purchase of 20,792,370 common shares (including unearned stock option grants totaling 9,704,620 shares related to performance targets), warrants for the purchase of 21,786,313 common shares, and 8,108,356&#160;shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2022, calculation of net loss per share because their impact is antidilutive.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Comprehensive loss&lt;/em&gt;&lt;/strong&gt; &#x2013; Comprehensive loss is defined as the change in equity of a business during a period from non-owner sources. There were no differences between net loss for the years ended September 30, 2023 and 2022 and comprehensive loss for those periods.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Dividend Policy&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of its business. The Company&#x2019;s future dividend policy will be determined by the board of directors on the basis of various factors, including results of operations, financial condition, capital requirements and investment opportunities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&lt;/strong&gt; &#x2013; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Recent Accounting Pronouncements &lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Based on the Company&#x2019;s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does believe such items are expected to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_795">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt;&lt;/strong&gt; &#x2013;These unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_796">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt;&lt;/strong&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Particle and AI Mind. Intercompany items and transactions have been eliminated in consolidation. &#160;AI Mind was dissolved in July 2023.&#160; &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_797">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Cash and Cash Equivalents&lt;/em&gt;&lt;/strong&gt; &#x2013;&#160;The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_7"
      unitRef="USD">250000</us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_798">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Property and Equipment&lt;/em&gt;&lt;/strong&gt; &#x2013; Equipment consists of machinery, leasehold improvements and furniture and fixtures, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-5 years, except for leasehold improvements which are depreciated over 5 years. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <knwn:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2022-10-01to2023-09-30_srt_MinimumMember"
      id="fid_34">P2Y</knwn:PropertyPlantsAndEquipmentUsefulLife>
    <knwn:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2022-10-01to2023-09-30_srt_MaximumMember"
      id="fid_35">P5Y</knwn:PropertyPlantsAndEquipmentUsefulLife>
    <knwn:PropertyPlantsAndEquipmentUsefulLife
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseholdImprovementsMember"
      id="fid_36">P5Y</knwn:PropertyPlantsAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_799">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Long-Lived Assets&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionLeases contextRef="From2022-10-01to2023-09-30" id="fid_800">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Revenue Recognition&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; The Company determines revenue recognition from contracts with customers through the following steps:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;identification of the contract, or contracts, with the customer;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;identification of the performance obligations in the contract;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;determination of the transaction price;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;allocation of the transaction price to the performance obligations in the contract; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;recognition of the revenue when, or as, the Company satisfies a performance obligation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. During the three months ended December 31, 2021, the Company generated revenue from digital asset sales of NFTs. The Company engineering team, using its research data, AI and proprietary algorithms, produced NFTs in the form of digital art. The NFTs produced had no recorded cost basis. The Company does not expect future activity or revenue from that source.&lt;/p&gt;</us-gaap:RevenueRecognitionLeases>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-10-01to2023-09-30" id="fid_801">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Research and Development Expenses&lt;/em&gt;&lt;/strong&gt; &#x2013; Research and development expenses consist of the cost of officers, employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s current research and development efforts are primarily focused on improving its radio frequency spectroscopy technology and its first focus on non-invasive monitoring of blood glucose levels; extending its capacity and developing new and unique applications for this technology. The Company believes that continued development of new and enhanced technologies is essential to its future success. The Company incurred expenses of $7,727,467 and $5,385,586 for the years ended September 30, 2023 and 2022, respectively, on development activities.&#160; Included in the expense for 2023 is approximately $859,000 related to severance and other expenses associated with the departure of the Company&#x2019;s former chief technology officer and chief executive officer, Philip A. Bosua, and other employees.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_12"
      unitRef="USD">7727467</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_13"
      unitRef="USD">5385586</us-gaap:ResearchAndDevelopmentExpense>
    <knwn:SeveranceAndOtherExpenses
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_8"
      unitRef="USD">859000</knwn:SeveranceAndOtherExpenses>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_802">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Advertising&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising and marketing costs for the year ended September 30, 2023 and 2022 were $305,292 and $379,724, respectively. &lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_14"
      unitRef="USD">305292</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_15"
      unitRef="USD">379724</us-gaap:AdvertisingExpense>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-10-01to2023-09-30" id="fid_803">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Fair Value Measurements and Financial Instruments&lt;/em&gt;&lt;/strong&gt; &#x2013;&lt;strong&gt;&#160;&lt;/strong&gt;ASC Topic 820, &lt;em&gt;Fair Value Measurement and Disclosures&lt;/em&gt;, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity&#x2019;s own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets and liabilities;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 2 &#x2013; Inputs other than level one inputs that are either directly or indirectly observable; and&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Level 3 &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of September 30, 2023 and 2022 are based upon the short-term nature of the assets and liabilities. The fair value of the Company&#x2019;s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company has a money market account which is considered a Level 1 asset. The balance as of September 30, 2023 and 2022 was $7,836,393 and $11,821,931, respectively. No other assets or liabilities are required to&#160; be recorded at fair value on a recurring nature. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_16"
      unitRef="USD">7836393</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_17"
      unitRef="USD">11821931</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DerivativesMethodsOfAccountingHedgeEffectiveness contextRef="From2022-10-01to2023-09-30" id="fid_804">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Derivative Financial Instruments&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &#x2013; &lt;/strong&gt;Pursuant to ASC 815 &#x201c;Derivatives and Hedging&#x201d;, the Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company then determines if an embedded derivative must be bifurcated and separately accounted for. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. &#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company determined that the conversion features for purposes of bifurcation within its &#160;convertible notes payable issued during 2020 and 2021 were immaterial and as of September 30, 2023 all such convertible notes have been converted to common stock and &#160;there was no derivative liability. &lt;/p&gt;</us-gaap:DerivativesMethodsOfAccountingHedgeEffectiveness>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-10-01to2023-09-30" id="fid_805">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Stock Based Compensation&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. The Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2022-10-01to2023-09-30" id="fid_806">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Convertible Securities&lt;/em&gt;&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;&#x2013; Based upon ASC 815-15, the Company has adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities to determine if an instrument should be accounted for as equity or a liability. The Company will evaluate its contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to the Company&#x2019;s inability to demonstrate it has sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_807">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Net Loss per Share&lt;/em&gt;&lt;/strong&gt; &#x2013; Under the provisions of ASC 260, &#x201c;Earnings Per Share,&#x201d; basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Deemed dividends to preferred shareholders increase the net loss available to common&#160; shareholders and impact the net loss per share calculation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2023, the Company had 80,358,463 shares of common stock issued and outstanding. As of September 30, 2023, there were options outstanding for the purchase of 14,506,158 shares of our common stock (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 20,866,313 shares of our common stock, 8,108,356 shares of the Company&#x2019;s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 3,040,219 shares of our common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931.&#160; Further, under the current terms of our&#160; Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock.&#160; All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2023, calculation of net loss per share because their impact is antidilutive&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;As of September 30, 2022, the Company had 48,156,062 shares of common stock issued and outstanding. As of September 30, 2022, there were options outstanding for the purchase of 20,792,370 common shares (including unearned stock option grants totaling 9,704,620 shares related to performance targets), warrants for the purchase of 21,786,313 common shares, and 8,108,356&#160;shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the September 30, 2022, calculation of net loss per share because their impact is antidilutive.&#160; &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_18"
      unitRef="Shares">80358463</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_25"
      unitRef="Shares">14506158</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30_knwn_Warrant1Member"
      decimals="0"
      id="fid_26"
      unitRef="Shares">20866313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="fid_20"
      unitRef="Shares">8108356</us-gaap:CommonStockSharesIssued>
    <knwn:ReservedSharesToPaySeriesCAndDDividends
      contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="fid_24"
      unitRef="Shares">3040219</knwn:ReservedSharesToPaySeriesCAndDDividends>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="fid_22"
      unitRef="Shares">9020264</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="fid_32"
      unitRef="USDPShares">0.25</us-gaap:SharesIssuedPricePerShare>
    <knwn:ConvertibleDebentures
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_9"
      unitRef="USD">2761931</knwn:ConvertibleDebentures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-10-01to2023-09-30_knwn_StockOption1Member"
      decimals="0"
      id="fid_30"
      unitRef="Shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_19"
      unitRef="Shares">48156062</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_421"
      unitRef="Shares">20792370</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30_knwn_Warrant1Member"
      decimals="0"
      id="fid_27"
      unitRef="Shares">21786313</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-10-01to2022-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="fid_28"
      unitRef="Shares">8108356</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="0"
      id="fid_23"
      unitRef="Shares">9020264</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-30_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="fid_33"
      unitRef="USDPShares">0.25</us-gaap:SharesIssuedPricePerShare>
    <knwn:ConvertibleDebentures
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_422"
      unitRef="USD">2255066</knwn:ConvertibleDebentures>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_808">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Comprehensive loss&lt;/em&gt;&lt;/strong&gt; &#x2013; Comprehensive loss is defined as the change in equity of a business during a period from non-owner sources. There were no differences between net loss for the years ended September 30, 2023 and 2022 and comprehensive loss for those periods.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <knwn:DividendPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_809">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Dividend Policy&lt;/em&gt;&lt;/strong&gt; &#x2013; The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of its business. The Company&#x2019;s future dividend policy will be determined by the board of directors on the basis of various factors, including results of operations, financial condition, capital requirements and investment opportunities.&lt;/p&gt;</knwn:DividendPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-10-01to2023-09-30" id="fid_810">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Use of Estimates&lt;/em&gt;&lt;/strong&gt; &#x2013; The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_811">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Based on the Company&#x2019;s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does believe such items are expected to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <knwn:AiDeepLearningPlatformDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_783">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;4. AI DEEP LEARNING PLATFORM&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;On September 17, 2021, the Company incorporated AI Mind, Inc. (&#x201c;AI Mind&#x201d;) in the State of Nevada. AI Mind was focused on monetizing intellectual property relating to the artificial intelligence utilized as a part of the data analytics performed with trade secret algorithms. Since incorporation, it focused on creating graphical images which were sold as Non Fungible Tokens (&#x201c;NFTs&#x201d;). During the year ended September 30, 2022,&#160;the&#160;Company began generating revenue from digital asset sales of NFTs and had sales of $4,360,087 of which substantially all were recorded in the three months ended December 31, 2021. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;After the sale of the NFT, the Ethereum was converted to US dollars as soon as practically possible. The Company recorded the total value of the gross NFT sale in revenue. Costs incurred in connection with the NFT transaction were recorded in the statement of operations as selling and transactional cost of digital assets and include costs to outside consultants, estimated employee and former CEO special bonus compensation, digital asset conversion losses and estimated sales and use tax. The amount totaled $3,430,438 for the year ended September 30, 2022. As of September &#160;30, 2023 and September 30, 2022, accrued expenses include $0 and $343,878 of expenses, respectively, primarily sales and use tax and other expenses. During the current year, based on new information, we revised our estimate downward for sales and use tax liability resulting in a $274,019 benefit that is recorded in Selling and Transactional Costs for Digital Assets in the consolidated statements of operations.&lt;/p&gt;</knwn:AiDeepLearningPlatformDisclosureTextBlock>
    <knwn:Revenue
      contextRef="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember"
      decimals="0"
      id="fid_37"
      unitRef="USD">4360087</knwn:Revenue>
    <knwn:AmountTotal
      contextRef="From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember"
      decimals="0"
      id="fid_38"
      unitRef="USD">3430438</knwn:AmountTotal>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30_us-gaap_TechnologyEquipmentMember"
      decimals="0"
      id="fid_41"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-09-30_us-gaap_TechnologyEquipmentMember"
      decimals="0"
      id="fid_42"
      unitRef="USD">343878</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SellingExpense
      contextRef="From2022-10-01to2023-09-30_us-gaap_TechnologyEquipmentMember"
      decimals="0"
      id="fid_423"
      unitRef="USD">274019</us-gaap:SellingExpense>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_784">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;5. PROPERTY AND EQUIPMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Property and equipment as of September 30, 2023 and 2022 was comprised of the following: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total depreciation expense was $313,019 and $320,995 for the years ended September 30, 2023 and 2022, respectively. All equipment is used primarily for research and development purposes and accordingly $295,260 and $304,637 in depreciation is classified in research and development expenses during the years ending September 30, 2023 and 2022. The Company retired assets with a net book value of $549,431 during the year ended September 30, 2023 related to the consolidation of leased offices and the reduction on headcount. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:Depreciation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_54"
      unitRef="USD">313019</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_55"
      unitRef="USD">320995</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-10-01to2023-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember"
      decimals="0"
      id="fid_56"
      unitRef="USD">295260</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-10-01to2022-09-30_knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember"
      decimals="0"
      id="fid_57"
      unitRef="USD">304637</us-gaap:Depreciation>
    <knwn:AssetsNetBookValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_53"
      unitRef="USD">549431</knwn:AssetsNetBookValue>
    <knwn:LeasesOfLesseDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_785">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;6. LEASES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The Company has entered into operating leases for office and development facilities which range from two to three years and include options to renew. The Company determines whether an arrangement is or contains a lease based upon the unique facts and circumstances at the inception of the lease. Operating lease liabilities and their corresponding right-of-use asses are recorded based upon the present value of the lease payments over the expected lease term. As of September 30, 2023 and 2022, total operating lease liabilities for remaining long term leases was approximately $155,000 and $303,000, respectively. Right of use assets totaled approximately $145,000 and $288,000 at September 30, 2023 and 2022, respectively. In the year ended September 30, 2023 and 2022, the Company recognized $268,000 and $289,000, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its estimated incremental borrowing rate to determine the present value of the lease payments.&#160; Recently the Company, as a result of certain headcount adjustments, has listed two of its leased premises as available for sublease.&#160; There can be no assurance such sublease will be successful or lead to a reduction in current on-going lease payments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The weighted average remaining lease term for the operating leases was 9 months at September 30, 2023 and the weighted average discount rate was 7%. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The minimum future lease payments as of September 30, 2023 are as follows: &lt;/p&gt;</knwn:LeasesOfLesseDisclosureTextBlock>
    <knwn:TotalLeaseLiability
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_428"
      unitRef="USD">155000</knwn:TotalLeaseLiability>
    <knwn:TotalLeaseLiability
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_429"
      unitRef="USD">303000</knwn:TotalLeaseLiability>
    <knwn:RightOfUseAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_426"
      unitRef="USD">145000</knwn:RightOfUseAssets>
    <knwn:RightOfUseAssets
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_427"
      unitRef="USD">288000</knwn:RightOfUseAssets>
    <us-gaap:LeaseCost
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_424"
      unitRef="USD">268000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_425"
      unitRef="USD">289000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="fid_431"
      unitRef="Pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <knwn:ConvertibleNotesPayableDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_786">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;7. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Convertible notes payable as of September 30, 2023 and 2022 consisted of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Convertible Promissory Notes with Clayton A. Struve&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company owes Clayton A. Struve, a significant stockholder, $1,301,005 under convertible promissory or OID notes. The Company recorded accrued interest of $94,062 and $86,562 as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company signed Amendments to the convertible promissory or OID notes, extending the due dates to September 30, 2023.&#160; On September 15, 2023, the due dates on the notes was further extended to September 30, 2024.&#160;The Company expensed $230,005 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Convertible Redeemable Promissory Notes with J3E2A2Z&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company owes Ronald P. Erickson and J3E2A2Z, an entity affiliated controlled by Ronald P. Erickson $1,460,926 under convertible promissory notes On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The Company recorded accrued interest of $218,334 and $287,290 as of September 30, 2023 and 2022, respectively. On December 7, 2022, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to January 30, 2023. On January 25, 2023, the Company approved Amendments to the convertible redeemable promissory notes with Ronald P. Erickson and J3E2A2Z, extending the due dates to September 30, 2023. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. The Company expensed $276,860 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Convertible Debt Offering &lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Beginning in 2019, the Company entered into a series of debt offerings with similar and consistent terms. The Company issued Subordinated Convertible Notes and Warrants in a private placement to accredited investors, pursuant to a series of substantially identical Securities Purchase Agreements, Common Stock Warrants, and related documents. As of September 30, 2022, all convertible notes and accrued interest had been converted to common stock. During the year ended September 30, 2022, amortization related to the debt offerings of $7,272,911 was recognized as interest expense in the consolidated statements of operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Convertible notes payable as of September 30, 2023 and 2022 are summarized below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;September 30,&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;September 30,&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Convertible note- Clayton A. Struve&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,301,005&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,071,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Convertible note- Ronald P. Erickson and affiliates&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,460,926&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,184,066&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021 Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;14,209,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less conversions of notes&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;(14,209,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,761,931&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,255,066&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</knwn:ConvertibleNotesPayableDisclosureTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-09-30_knwn_ConvertibleNote1Member"
      decimals="0"
      id="fid_1036"
      unitRef="USD">1301005</us-gaap:ConvertibleDebt>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1033"
      unitRef="USD">94062</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1034"
      unitRef="USD">86562</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:EquipmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1028"
      unitRef="USD">230005</us-gaap:EquipmentExpense>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member"
      decimals="0"
      id="fid_1042"
      unitRef="USD">1460926</us-gaap:ConvertibleLongTermNotesPayable>
    <knwn:ConvertibleRedeemablePromissoryNoteAmount
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote8Member"
      decimals="0"
      id="fid_1037"
      unitRef="USD">664233</knwn:ConvertibleRedeemablePromissoryNoteAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote8Member"
      decimals="0"
      id="fid_1039"
      unitRef="USD">664233</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <knwn:ConvertibleRedeemablePromissoryNoteAmount
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote7Member"
      decimals="0"
      id="fid_1038"
      unitRef="USD">519833</knwn:ConvertibleRedeemablePromissoryNoteAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote7Member"
      decimals="0"
      id="fid_1040"
      unitRef="USD">519833</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member"
      decimals="0"
      id="fid_1029"
      unitRef="Shares">1039666</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-03-16_knwn_ConvertibleNote2Member"
      decimals="INF"
      id="fid_1035"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <knwn:DepositLiabilitiesAccruedInterestsAmount
      contextRef="AsOf2023-09-30_knwn_ConvertibleNote1Member"
      decimals="0"
      id="fid_1030"
      unitRef="USD">218334</knwn:DepositLiabilitiesAccruedInterestsAmount>
    <knwn:DepositLiabilitiesAccruedInterestsAmount
      contextRef="AsOf2022-09-30_knwn_ConvertibleNote1Member"
      decimals="0"
      id="fid_1031"
      unitRef="USD">287290</knwn:DepositLiabilitiesAccruedInterestsAmount>
    <us-gaap:EquipmentExpense
      contextRef="From2022-10-01to2023-09-30_knwn_ConvertibleNote1Member"
      decimals="0"
      id="fid_1041"
      unitRef="USD">276860</us-gaap:EquipmentExpense>
    <knwn:AmortizationOfDebtDiscountPremiums
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1032"
      unitRef="USD">7272911</knwn:AmortizationOfDebtDiscountPremiums>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_814">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;September 30,&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;September 30,&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Convertible note- Clayton A. Struve&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,301,005&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,071,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Convertible note- Ronald P. Erickson and affiliates&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,460,926&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1,184,066&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021 Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;14,209,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less conversions of notes&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;(14,209,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,761,931&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2,255,066&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-09-30_knwn_ConvertibleNoteOneMember"
      decimals="0"
      id="fid_1022"
      unitRef="USD">1301005</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_knwn_ConvertibleNoteOneMember"
      decimals="0"
      id="fid_1023"
      unitRef="USD">1071000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-09-30_knwn_ConvertibleNoteTwoMember"
      decimals="0"
      id="fid_1024"
      unitRef="USD">1460926</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_knwn_ConvertibleNoteTwoMember"
      decimals="0"
      id="fid_1025"
      unitRef="USD">1184066</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-09-30_knwn_ConvertibleNotesFiveMember"
      decimals="0"
      id="fid_1026"
      unitRef="USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-09-30_knwn_ConvertibleNotesFiveMember"
      decimals="0"
      id="fid_1027"
      unitRef="USD">14209000</us-gaap:DebtInstrumentCarryingAmount>
    <knwn:ConvertibleNotesConversions
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1018"
      unitRef="USD">0</knwn:ConvertibleNotesConversions>
    <knwn:ConvertibleNotesConversions
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1019"
      unitRef="USD">-14209000</knwn:ConvertibleNotesConversions>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1020"
      unitRef="USD">2761931</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1021"
      unitRef="USD">2255066</us-gaap:DebtInstrumentFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_787">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;8. EQUITY&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Authorized Capital Stock&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following description summarizes important terms of the classes of our capital stock as of September 30, 2023. This summary does not purport to be complete and is qualified in its entirety by the provisions of our articles of incorporation as amended, restated and supplemented to date, or our articles of incorporation, and our second amended and restated bylaws, or our bylaws, which have been filed as exhibits to this Annual Report on Form 10-K.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Authorized Capital Stock&lt;/em&gt;.&#160; The Company&#x2019;s authorized capital stock currently consists of:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;200,000,000 shares of common stock, par value $0.001 per share; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;5,000,000 shares of &#x201c;blank check&#x201d; preferred stock, par value $0.001 per share, of which:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;30,000 shares have been designated as our Series C Convertible Preferred Stock, $0.001 par value per share; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;20,000 shares have been designated as our Series D Convertible Preferred Stock, $0.001 par value per share.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Outstanding Shares of Capital Stock&lt;/em&gt;. The Company&#x2019;s common stock is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. All outstanding shares of the Company&#x2019;s capital stock are fully paid and nonassessable. As of September 30, 2023, there were:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;80,358,643 shares of common stock issued and outstanding, held by holders of record;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;17,858 shares of Series C Convertible Preferred Stock issued and outstanding, held by one holder of record; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;10,161 shares of Series D Convertible Preferred Stock issued and outstanding, held by one holder of record.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Common Stock &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Holders of the Company&#x2019;s common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. The Company&#x2019;s articles of incorporation do not provide for cumulative voting in the election of directors.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Subject to any preferential rights of any outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors on the common stock out of legally available funds. In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of the Company&#x2019;s debts and other liabilities and the satisfaction of any preferential rights of any outstanding preferred stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock, including our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Preferred Stock &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company&#x2019;s articles of incorporation authorize its board of directors, without stockholder approval, to issue up to 5,000,000 shares of preferred stock in one or more series, and to determine the designation, preferences, limitations and relative rights thereof, including, without limitation, such matters as dividends, redemption, liquidation, conversion and voting. The Company&#x2019;s board of directors has the discretion to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock, or which could have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, a majority of the Company&#x2019;s outstanding voting stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In connection with the amendment and restatement of our preferred stock, we effected a reverse split of our outstanding Series C Convertible Preferred Stock and Series D Convertible Preferred Stock by a factor of 1-for-100. No changes were made to the 5 million total shares of &#x201c;blank-check&#x201d; preferred stock authorized in our Articles. Prior to such reverse split, there were 1,785,715 and 1,016,004 shares of Series C Convertible Preferred Stock and Series D Convertible Preferred Stock designated and outstanding, respectively. To account for the reverse split, but in order to provide the ability to issue &#x201c;pay in kind&#x201d; dividends in lieu of cash dividends, at the time of the reverse split, we designated 30,000 shares of Series C Convertible Preferred Stock&#160;and 20,000 shares of Series D Convertible Preferred Stock, of which 17,858 and 10,161 shares were, respectively, outstanding immediately after such reverse split. In order to maintain the economic rights of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, the definition of &#x201c;Stated Value&#x201d; was multiplied by 100, to offset the reverse split factor. All amount related to the preferred shares have been restated to reflect the reverse stock split as it occurred on the date of the first period presented. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Securities Subject to Price Adjustments&#160;&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;If in the future, the Company sells its common stock at a price below $0.25 per share, the conversion price of the Company&#x2019;s outstanding shares of series C convertible preferred stock and series D convertible preferred stock would adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 7,684,381 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Warrants totaling 4,439,707 would adjust below $1.20 per share and warrants totaling 4,424,425 would adjust below $2.40 per share, in each case pursuant to the documents governing such instruments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Series C and D Preferred Stock, Warrants and Dividends&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a cumulative dividend&#160; of 8% and an ownership blocker of 4.99%. Dividends are due and payable in cash when declared by the Company&#160; or when the stock&#160; is converted.&#160; Series&#160; C Preferred stock is senior to Series D Preferred stock and is entitled to receive&#160; equal&#160; dividends paid to Series D. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Stock and warrant and its conversion price, were adjusted to $0.25 per share pursuant to the documents governing such instruments. As of September 30, 2023, Mr. Struve owns all of the 1,785,715 issued and outstanding shares of Series C Preferred Stock.&#160; Each holder of Preferred Series C is allowed to vote as a common shareholder as if the shares were converted&#160; to common stock up to the ownership blocker of 4.99%.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In 2017 the Company closed a $750,000 Series D Preferred Stock and Warrant offering with Mr. Struve. As of September 30, 2023, Mr. Struve owns all of the 1,016,004 issued and outstanding shares of Series D Preferred Stock. Each outstanding share of series D preferred stock will accrue cumulative cash dividends at a rate equal to 8.0% per annum, subject to adjustment as provided in the series D preferred stock certificate of designations. Dividends are&#160; due and payable&#160; in cash when declared by the Company&#160; or when the stock&#160; is converted. In addition, On August 14, 2017, the price of the Series D Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. Each holder of Preferred Series D is allowed to vote as a common shareholder as if the shares were converted to common stock up to the ownership blocker of 4.99%.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In August, 2023, as part of a modification of the Series C and Series D Preferred certificates of designation,&#160; such preferred stock does not accrue or pay cash dividends. All future dividends will be accrued and paid in Series C or Series D stock, as applicable. As was the case prior to the modifications of the Series C and Series D preferred stock, although accrual of dividends is required as described below, no dividends are actually paid, and no shares actually issued, until a conversion of such stock or declaration of the dividend by the Board of Directors.&#160; Additionally the Series D Preferred stock will no longer be required to automatically convert to common stock based on listing of the Company&#x2019;s common stock on the NYSE American, except if the volume weighted average price of the common stock is at least $2.50 per share for 20 trading days and certain other requirements are satisfied.&#160; The cumulative dividends accrued and paid in preferred stock will be determined based upon a $.70 stated value. The conversion from preferred stock into common stock is determined based dividing the $.70 stated value by the $.25 conversion price. In June, 2023, as part of the anticipated modification of the certificates of designation of the Series C and Series D preferred stock, at Mr. Struve&#x2019;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#x2019;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.&#160; In connection with this transaction, the Company recorded $1,627,230 in dividends, representing the fair market value of the 1,402,784 shares issued.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Based upon the modified terms and conditions of Series C and D certificates of designations, it was determined that Series C and D preferred dividends need to be accreted going forward. As of September 30, 2023, cumulative unpaid Series C and D dividends totaled approximately $770,000, which on a converted-to-common-stock basis represents approximately 3,040,000 shares of common&#160; stock. The value of the 3.0 million shares of common totaled $3,526,653. The Company recorded $3,526,653in cumulative deemed dividends related to Series C and D Preferred Stock which have not been paid, net of the approximately $351,000 of accumulated dividends with respect to the Series D preferred that were settled for 1,402,784 shares of common stock as noted above.&#160; Mr. Struve is subject to an ownership blocker limiting his ownership to 4.99% and thus the amount of common shares he can receive for dividends.&#160; Unpaid accreted stock dividends will be issued to Mr. Struve if he converts preferred stock or if the Board declares a dividend thereon, limited to his 4.99% ownership blocker.&#160; Assuming no changes in the amount of outstanding Preferred Series&#160; C or D ownership, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2023&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 2,632,727 shares of common stock related to warrant exercises and received $387,334.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 27, 2023, at Mr. Struve&#x2019;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#x2019;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 3,750 shares related to the exercise of stock option grants and received $4,687.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 29, 2023, the Company closed an offering of our common stock pursuant to which the Company sold 28,000,000 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $5,472,791. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2022&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 1,045,724 shares of common stock related to warrant exercises and received $838,487.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 26,293 shares related to the exercise of stock option grants and received $26,887.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 104,634 shares each to three directors and three consultants at $1.749 per share. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 20, 2022, the Company completed a public offering of our common stock pursuant to which the Company sold 4,140,000 shares of common stock, at a purchase price of $2.00 per share, for total gross proceeds of $8,280,000. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $7,424,679.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Warrants to Purchase Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2023&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2022, the Company signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrant No./Class&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Current &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Amended &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-14-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-12-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2016&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,785,715&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2018&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recorded interest expense of $194,019 during the year ended September 30, 2023 related to the extension of the warrants. The Company recorded the original value of warrants in equity and as such, the Company recorded the extension value as an expense with an offset to additional paid in capital.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 19, 2023, the Company signed an Extension of Warrant Agreements with Ronald P. Erickson and an entity controlled by Mr. Erickson, extending the exercise dates from January 30, 2023 to January 30, 2024. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 2,632,727 shares of common stock related to warrant exercises and received $387,334.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Warrants to purchase 297,273 shares of common stock at $0.250 per share expired. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 29, 2023, pursuant to the Underwriting Agreement, the Company issued common stock purchase warrants to Boustead Securities, LLC and The Benchmark Company, LLC&#160;to purchase an aggregate of 1,960,000 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments. The Representatives&#x2019; Warrants are immediately exercisable, and may be exercised at any time and from time to time, in whole or in part, until September 26, 2028 and may be exercised on a cashless basis. The Representatives&#x2019; Warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the Representatives&#x2019; Warrants. The warrants were valued at $486,080 and recorded in additional paid in capital as costs form common stock offering. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2022&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 389,800 warrants to purchase common stock to three directors and four consultants at $1.899 per share. The warrants expire five years from the date of issuance.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 3, 2022, the Company signed an extension of warrant agreement with Clayton Struve, extending the exercise dates as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No./Class&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No. Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Original &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Amended &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-14-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-12-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2016&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,785,715&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2018&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company recorded interest expense of $244,260 during the year ended September 30, 2022 related to the extension of the warrants. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Warrants to purchase 122,018 shares of common stock at $0.918 per share expired. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company issued 1,045,724 shares of common stock related to warrant exercises and received $838,487. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A summary of the warrants outstanding as of September 30, 2023 were as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding October 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,786,313&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.029&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;980,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,582,727&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(297,273&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1.103&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes information about warrants outstanding and exercisable as of September 30, 2023: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number of&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Life ( In Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,649,381&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.16&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,649,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6,512,207&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.20-1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6,512,207&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.20-1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,694,725&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.00-3.00&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,694,725&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.00-3.00&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;0.43&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4.080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4.080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,886,313&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2.07&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.163&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.163&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The significant weighted average assumptions relating to the valuation of the Company&#x2019;s warrants for the year ended September 30, 2023 were as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;104%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2.96%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There were vested warrants of 20,866,313 with an aggregate intrinsic value of $0.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_975"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="INF"
      id="fid_963"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_973"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_965"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <knwn:DesignatedSeriesCConvertiblePreferredStock
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="0"
      id="fid_984"
      unitRef="Shares">30000</knwn:DesignatedSeriesCConvertiblePreferredStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_960"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <knwn:DesignatedSeriesDConvertiblePreferredStock
      contextRef="AsOf2023-09-30_knwn_AuthorizedCapitalStockMember"
      decimals="0"
      id="fid_985"
      unitRef="Shares">20000</knwn:DesignatedSeriesDConvertiblePreferredStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="fid_961"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"
      decimals="0"
      id="fid_1153"
      unitRef="Shares">80358643</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"
      decimals="0"
      id="fid_986"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember"
      decimals="0"
      id="fid_988"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_992"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesIssued>
    <knwn:ReverseStockSplit
      contextRef="From2022-10-01to2023-09-30_knwn_ConvertiblePreferredStockDMember"
      id="fid_991">1-for-100</knwn:ReverseStockSplit>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_969"
      unitRef="Shares">1785715</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_971"
      unitRef="Shares">1016004</us-gaap:PreferredStockSharesOutstanding>
    <knwn:DesignatedSeriesDConvertiblePreferredStocks
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1254"
      unitRef="Shares">30000</knwn:DesignatedSeriesDConvertiblePreferredStocks>
    <knwn:DesignatedSeriesDConvertiblePreferredStock
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"
      decimals="0"
      id="fid_1252"
      unitRef="Shares">20000</knwn:DesignatedSeriesDConvertiblePreferredStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"
      decimals="0"
      id="fid_987"
      unitRef="Shares">17858</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockDMember"
      decimals="0"
      id="fid_989"
      unitRef="Shares">10161</us-gaap:PreferredStockSharesOutstanding>
    <knwn:PreferredStockConvertibleConversionPriceAdjusted
      contextRef="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="fid_953"
      unitRef="USDPShares">0.25</knwn:PreferredStockConvertibleConversionPriceAdjusted>
    <knwn:PreferredStockConvertibleConversionPriceAdjusted
      contextRef="AsOf2017-08-14_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="fid_954"
      unitRef="USDPShares">0.25</knwn:PreferredStockConvertibleConversionPriceAdjusted>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_955"
      unitRef="Shares">7684381</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_knwn_StockAtTwoMember"
      decimals="INF"
      id="fid_980"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-09-30_knwn_StockAtTwoMember"
      decimals="0"
      id="fid_982"
      unitRef="USD">4439707</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_knwn_StockAtOneMember"
      decimals="INF"
      id="fid_981"
      unitRef="USDPShares">1.20</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-09-30_knwn_StockAtOneMember"
      decimals="0"
      id="fid_983"
      unitRef="USD">4424425</us-gaap:WarrantsAndRightsOutstanding>
    <knwn:ShrareIssuedWarrantToPurchasedPrice
      contextRef="From2022-10-01to2023-09-30_knwn_ThreeDirectorMember"
      decimals="INF"
      id="fid_956"
      unitRef="USDPShares">2.40</knwn:ShrareIssuedWarrantToPurchasedPrice>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_948"
      unitRef="USD">1250000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="fid_950"
      unitRef="USDPShares">0.70</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="fid_920"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <knwn:OwnershipInterestInPreferredStock
      contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="fid_915"
      unitRef="Pure">0.0499</knwn:OwnershipInterestInPreferredStock>
    <knwn:WarrantsToAcquireCommonStockShares
      contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_951"
      unitRef="Shares">1785714</knwn:WarrantsToAcquireCommonStockShares>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_knwn_ConvertiblePreferredStockSeriesCMember"
      decimals="INF"
      id="fid_979"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="fid_1253"
      unitRef="Shares">1785715</us-gaap:PreferredStockSharesIssued>
    <knwn:OwnershipInterestInPreferredStock
      contextRef="From2016-08-01to2016-08-05_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="fid_916"
      unitRef="Pure">0.0499</knwn:OwnershipInterestInPreferredStock>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_949"
      unitRef="USD">750000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_970"
      unitRef="Shares">1016004</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="fid_921"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <knwn:CommonStockSharePrice
      contextRef="AsOf2016-08-05_knwn_MrStruveMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="fid_952"
      unitRef="USDPShares">0.25</knwn:CommonStockSharePrice>
    <knwn:OwnershipInterestInPreferredStock
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="fid_917"
      unitRef="Pure">0.0499</knwn:OwnershipInterestInPreferredStock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-08-01to2023-08-31_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      id="fid_923"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <knwn:DividendDistributedPerShare
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      id="fid_927">The cumulative dividends accrued and paid in preferred stock will be determined based upon a $.70 stated value. The conversion from preferred stock into common stock is determined based dividing the $.70 stated value by the $.25 conversion price</knwn:DividendDistributedPerShare>
    <us-gaap:CommonStockDividendsShares
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_928"
      unitRef="Shares">1402784</us-gaap:CommonStockDividendsShares>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_932"
      unitRef="USD">1627230</us-gaap:CommonStockValue>
    <knwn:NumberOfCommonStockSharesSettled
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_926"
      unitRef="Shares">1402784</knwn:NumberOfCommonStockSharesSettled>
    <knwn:CumulativeDividendUnpaid
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_934"
      unitRef="USD">770000</knwn:CumulativeDividendUnpaid>
    <us-gaap:CommonStockDividendsShares
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_929"
      unitRef="Shares">3040000</us-gaap:CommonStockDividendsShares>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="-6"
      id="fid_924"
      unitRef="Shares">3000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_933"
      unitRef="USD">3526653</us-gaap:CommonStockValue>
    <knwn:DeemedDividendsCumulative
      contextRef="AsOf2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_935"
      unitRef="USD">3526653</knwn:DeemedDividendsCumulative>
    <us-gaap:CumulativeDividends
      contextRef="AsOf2023-08-30_knwn_MrStruveMember_us-gaap_SeriesDPreferredStockMember"
      decimals="0"
      id="fid_919"
      unitRef="USD">351000</us-gaap:CumulativeDividends>
    <knwn:NumberOfCommonStockSharesSettled
      contextRef="From2022-12-01to2022-12-31_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_925"
      unitRef="Shares">1402784</knwn:NumberOfCommonStockSharesSettled>
    <knwn:OwnershipInterestInPreferredStock
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="INF"
      id="fid_918"
      unitRef="Pure">0.0499</knwn:OwnershipInterestInPreferredStock>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="INF"
      id="fid_922"
      unitRef="Pure">0.0499</us-gaap:PreferredStockDividendRatePercentage>
    <knwn:AccretedValueOfPreferredDividendIntoCommonStockShares
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember_knwn_SeriesCAndDPreferredStockMember"
      decimals="0"
      id="fid_936"
      unitRef="Shares">160000</knwn:AccretedValueOfPreferredDividendIntoCommonStockShares>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2023-09-30_knwn_MrStruveMember"
      decimals="0"
      id="fid_1215"
      unitRef="Shares">2632727</knwn:WarrantIssuedToCommonStock>
    <knwn:ReceivedOfWarrant
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember"
      decimals="0"
      id="fid_1216"
      unitRef="USD">387334</knwn:ReceivedOfWarrant>
    <knwn:ReceivedSeriesDPreferredStockDividendsShares
      contextRef="AsOf2023-06-27_knwn_MrStruveMember"
      decimals="0"
      id="fid_942"
      unitRef="Shares">1402784</knwn:ReceivedSeriesDPreferredStockDividendsShares>
    <knwn:ProceedsFromIssuanceOfCommonStocks
      contextRef="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember"
      decimals="0"
      id="fid_958"
      unitRef="USD">3750</knwn:ProceedsFromIssuanceOfCommonStocks>
    <knwn:ExerciseOfStockOption
      contextRef="From2022-10-01to2023-09-30_knwn_CommonPreferredStocksMember"
      decimals="0"
      id="fid_978"
      unitRef="Shares">4687</knwn:ExerciseOfStockOption>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-29_knwn_CommonStocksOfferingsMember"
      decimals="0"
      id="fid_993"
      unitRef="Shares">28000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-29_knwn_CommonStocksOfferingsMember"
      decimals="INF"
      id="fid_994"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-09-01to2023-09-29_knwn_CommonStocksOfferingsMember"
      decimals="0"
      id="fid_995"
      unitRef="USD">5472791</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <knwn:DescriptionOfAutomaticConversionOfConvertible contextRef="From2021-10-01to2022-09-30" id="fid_996">The Company issued 7,672,860 shares of common stock related to the automatic conversion of convertible notes and interest from a private placement to accredited investors in 2021. The convertible notes and interest were automatically converted to common stock at $2.00 per share on the one-year anniversary in March 2022</knwn:DescriptionOfAutomaticConversionOfConvertible>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="0"
      id="fid_998"
      unitRef="Shares">1045724</us-gaap:SharesIssued>
    <knwn:IssuedAmountReceived
      contextRef="From2022-09-01to2022-09-20_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="0"
      id="fid_997"
      unitRef="USD">838487</knwn:IssuedAmountReceived>
    <knwn:ExerciseOfStockOption
      contextRef="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember"
      decimals="0"
      id="fid_1000"
      unitRef="Shares">26293</knwn:ExerciseOfStockOption>
    <knwn:ProceedsFromIssuanceOfCommonStocks
      contextRef="From2021-10-01to2022-09-30_knwn_CommonPreferredStocksMember"
      decimals="0"
      id="fid_1001"
      unitRef="USD">26887</knwn:ProceedsFromIssuanceOfCommonStocks>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_1002"
      unitRef="Shares">104634</us-gaap:SharesIssued>
    <knwn:ShrareIssuedWarrantToPurchasedPrice
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1003"
      unitRef="USDPShares">1.749</knwn:ShrareIssuedWarrantToPurchasedPrice>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-09-20_knwn_CommonStocksOfferingsMember"
      decimals="0"
      id="fid_1004"
      unitRef="Shares">4140000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2022-09-20_knwn_CommonStocksOfferingsMember"
      decimals="INF"
      id="fid_1005"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <knwn:GrossSales
      contextRef="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember"
      decimals="0"
      id="fid_1214"
      unitRef="USD">8280000</knwn:GrossSales>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-09-01to2022-09-20_knwn_CommonStocksOfferingsMember"
      decimals="0"
      id="fid_1006"
      unitRef="USD">7424679</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_815">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrant No./Class&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Current &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Amended &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Date &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-14-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-12-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2016&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,785,715&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:27%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2018&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2024&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:10%;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No./Class&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;No. Warrant &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Original &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Amended &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-14-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,440,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-13-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant &lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-12-2017&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12-11-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2016&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,785,715&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;08-04-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Clayton A. Struve Warrant&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2018&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1,344,000&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;$0.25&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2023&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-TOP: #000000 1px solid; BORDER-LEFT: #000000 1px solid;width:13%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;02-28-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock>
    <knwn:DateOfIssue
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember"
      id="fid_830">2017-08-14</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="0"
      id="fid_826"
      unitRef="Shares">1440000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="INF"
      id="fid_842"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember"
      id="fid_834">2024-08-13</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember"
      id="fid_838">2025-08-13</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember"
      id="fid_831">2017-12-12</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2023-09-30_knwn_WarrantTwoMember"
      decimals="0"
      id="fid_827"
      unitRef="Shares">1200000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2023-09-30_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_843"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember"
      id="fid_835">2024-12-11</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember"
      id="fid_839">2025-12-11</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember"
      id="fid_832">2016-08-04</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2023-09-30_knwn_WarrantThreeMember"
      decimals="0"
      id="fid_828"
      unitRef="Shares">1785715</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2023-09-30_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_844"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember"
      id="fid_836">2024-08-04</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember"
      id="fid_840">2025-08-04</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember"
      id="fid_833">2018-02-28</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="0"
      id="fid_829"
      unitRef="Shares">1344000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="INF"
      id="fid_845"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember"
      id="fid_837">2024-02-28</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember"
      id="fid_841">2025-02-28</knwn:AmendedExpirationdate>
    <us-gaap:InterestExpenseOther
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_959"
      unitRef="USD">194019</us-gaap:InterestExpenseOther>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_941"
      unitRef="Shares">2632727</knwn:WarrantIssuedToCommonStock>
    <knwn:ReceivedOfWarrant
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_938"
      unitRef="USD">387334</knwn:ReceivedOfWarrant>
    <knwn:WarrantsToPurchaseCommonStock
      contextRef="AsOf2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_943"
      unitRef="Shares">297273</knwn:WarrantsToPurchaseCommonStock>
    <knwn:WarrantsExpiredPerSharePrice
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="fid_957"
      unitRef="USDPShares">0.250</knwn:WarrantsExpiredPerSharePrice>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="0"
      id="fid_1007"
      unitRef="Shares">1960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="fid_1009"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <knwn:WarrantsIssuedValued
      contextRef="From2023-09-01to2023-09-29_knwn_WarrantToPurchaseCommonStockMember_knwn_BousteadSecuritiesLLCMember"
      decimals="0"
      id="fid_1011"
      unitRef="USD">486080</knwn:WarrantsIssuedValued>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_1012"
      unitRef="Shares">389800</knwn:WarrantIssuedToCommonStock>
    <knwn:DateOfIssue
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember"
      id="fid_850">2017-08-14</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2022-09-30_knwn_WarrantOneMember"
      decimals="0"
      id="fid_846"
      unitRef="Shares">1440000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-09-30_knwn_WarrantOneMember"
      decimals="INF"
      id="fid_862"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember"
      id="fid_854">2023-08-13</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantOneMember"
      id="fid_858">2024-08-13</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember"
      id="fid_851">2017-12-12</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2022-09-30_knwn_WarrantTwoMember"
      decimals="0"
      id="fid_847"
      unitRef="Shares">1200000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-09-30_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_863"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember"
      id="fid_855">2023-12-11</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantTwoMember"
      id="fid_859">2024-12-11</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember"
      id="fid_852">2016-08-04</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2022-09-30_knwn_WarrantThreeMember"
      decimals="0"
      id="fid_848"
      unitRef="Shares">1785715</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-09-30_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_864"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember"
      id="fid_856">2023-08-04</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantThreeMember"
      id="fid_860">2024-08-04</knwn:AmendedExpirationdate>
    <knwn:DateOfIssue
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember"
      id="fid_853">2018-02-28</knwn:DateOfIssue>
    <knwn:NumberOfWarrantShares
      contextRef="AsOf2022-09-30_knwn_WarrantFourMember"
      decimals="0"
      id="fid_849"
      unitRef="Shares">1344000</knwn:NumberOfWarrantShares>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-09-30_knwn_WarrantFourMember"
      decimals="INF"
      id="fid_865"
      unitRef="USDPShares">0.25</knwn:ExercisePricePerShare>
    <knwn:OriginalExpirationDate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember"
      id="fid_857">2023-02-28</knwn:OriginalExpirationDate>
    <knwn:AmendedExpirationdate
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantFourMember"
      id="fid_861">2024-02-28</knwn:AmendedExpirationdate>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1014"
      unitRef="USD">244260</us-gaap:InterestExpenseOther>
    <knwn:WarrantsToPurchaseCommonStock
      contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_1015"
      unitRef="Shares">122018</knwn:WarrantsToPurchaseCommonStock>
    <knwn:WarrantsExpiredPerSharePrice
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="fid_1013"
      unitRef="USDPShares">0.918</knwn:WarrantsExpiredPerSharePrice>
    <knwn:CommonStockSharesIssuedRelatedToWarrantExercises
      contextRef="AsOf2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_1017"
      unitRef="Shares">1045724</knwn:CommonStockSharesIssuedRelatedToWarrantExercises>
    <knwn:ReceivedOfWarrant
      contextRef="From2021-10-01to2022-09-30_knwn_WarrantsToPurchaseCommonStockMember"
      decimals="0"
      id="fid_1016"
      unitRef="USD">838487</knwn:ReceivedOfWarrant>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_816">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding October 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21,786,313&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.029&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;980,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,582,727&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(297,273&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.250&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1.103&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number of&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Life ( In Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,649,381&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.16&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,649,381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6,512,207&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.20-1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;6,512,207&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.20-1.85&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,694,725&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.59&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.00-3.00&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;4,694,725&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;2.00-3.00&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;0.43&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4.080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;10,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;4.080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,886,313&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;2.07&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.163&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;20,886,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.163&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_867"
      unitRef="Shares">21786313</knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers>
    <knwn:OutstandingAtBegenningOfPeriod
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="fid_873"
      unitRef="USDPShares">1.029</knwn:OutstandingAtBegenningOfPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_868"
      unitRef="Shares">980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_874"
      unitRef="USDPShares">0.250</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_869"
      unitRef="Shares">2582727</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_875"
      unitRef="USDPShares">0.250</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_870"
      unitRef="Shares">297273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <knwn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_876"
      unitRef="USDPShares">0.250</knwn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_877"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_878"
      unitRef="Shares">20886313</knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe>
    <knwn:OutstandingAtEndOfPeriod
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_880"
      unitRef="USDPShares">1.103</knwn:OutstandingAtEndOfPeriod>
    <knwn:ExercisableAtEndOfPeriod
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_879"
      unitRef="Shares">20886313</knwn:ExercisableAtEndOfPeriod>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="0"
      id="fid_881"
      unitRef="Shares">9649381</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAveragesRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantOneMember"
      id="fid_886">P2Y1M28D</knwn:WeightedAveragesRemainingLifeYears>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="INF"
      id="fid_891"
      unitRef="USDPShares">0.250</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="0"
      id="fid_897"
      unitRef="Shares">9649381</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_knwn_WarrantOneMember"
      decimals="INF"
      id="fid_902"
      unitRef="USDPShares">0.250</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_WarrantTwoMember"
      decimals="0"
      id="fid_882"
      unitRef="Shares">6512207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAveragesRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantTwoMember"
      id="fid_887">P1Y4M13D</knwn:WeightedAveragesRemainingLifeYears>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_892"
      unitRef="USDPShares">1.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_893"
      unitRef="USDPShares">1.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_WarrantTwoMember"
      decimals="0"
      id="fid_898"
      unitRef="Shares">6512207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_903"
      unitRef="USDPShares">1.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantTwoMember"
      decimals="INF"
      id="fid_904"
      unitRef="USDPShares">1.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_WarrantThreeMember"
      decimals="0"
      id="fid_883"
      unitRef="Shares">4694725</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAveragesRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantThreeMember"
      id="fid_888">P2Y7M2D</knwn:WeightedAveragesRemainingLifeYears>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_894"
      unitRef="USDPShares">2.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_909"
      unitRef="USDPShares">3.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_WarrantThreeMember"
      decimals="0"
      id="fid_899"
      unitRef="Shares">4694725</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_srt_MinimumMember_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_905"
      unitRef="USDPShares">2.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_srt_MaximumMember_knwn_WarrantThreeMember"
      decimals="INF"
      id="fid_908"
      unitRef="USDPShares">3.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="0"
      id="fid_884"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAveragesRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_WarrantFourMember"
      id="fid_889">P0Y5M4D</knwn:WeightedAveragesRemainingLifeYears>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="INF"
      id="fid_895"
      unitRef="USDPShares">4.080</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="0"
      id="fid_900"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30_knwn_WarrantFourMember"
      decimals="INF"
      id="fid_906"
      unitRef="USDPShares">4.080</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_885"
      unitRef="Shares">20886313</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAveragesRemainingLifeYears contextRef="From2022-10-01to2023-09-30" id="fid_890">P2Y25D</knwn:WeightedAveragesRemainingLifeYears>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_896"
      unitRef="USDPShares">1.163</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_901"
      unitRef="Shares">20886313</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_907"
      unitRef="USDPShares">1.163</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_817">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:20%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;3-5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;104%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2.96%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <srt:FederalFundsSoldAverageYield
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_910"
      unitRef="Pure">0</srt:FederalFundsSoldAverageYield>
    <knwn:ExpectedLifeMinimum contextRef="From2022-10-01to2023-09-30" id="fid_911">P3Y</knwn:ExpectedLifeMinimum>
    <knwn:ExpectedLifeMaximum contextRef="From2022-10-01to2023-09-30" id="fid_912">P5Y</knwn:ExpectedLifeMaximum>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_913"
      unitRef="Pure">1.04</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_914"
      unitRef="Pure">0.0296</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_940"
      unitRef="USD">20866313</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <knwn:SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_939"
      unitRef="USD">0</knwn:SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_788">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;9. EQUITY INCENTIVE PLANS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 12, 2021, the Company established its 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), which was adopted by stockholders on October 15, 2021. The Company initially had 20,000,000 shares of its common stock authorized as the maximum number of shares of common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to 22,000,000 shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase described below.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2023&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2023, the Company issued stock option grants to eighteen employees and consultants for 4,158,333 shares at an average exercise price of $1.381 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over two to four years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2023, stock option grants for 10,277,655 shares at an average exercise price of $1.647 per share were forfeited. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2023, stock option grants for 166,890 shares at an average exercise price of $0.272 per share were exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;&lt;span style="text-decoration:underline"&gt;Year Ended September 30, 2022&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 16, 2021, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 16, 2021, the Company issued a stock option grant to Phillip A. Bosua for 1,300,000 shares at an exercise price of $2.09 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 20, 2022, the Company issued a stock option grant to Peter Conley for 1,000,000 shares at an exercise price of $1.48 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years after two quarters.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2022, the Company also issued stock option grants to nineteen employees and consultants for 3,336,000 shares at an average exercise price of $1.726 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2022, the Company issued 26,293 shares related to the exercise of stock option grants and received $26,887.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the year ended September 30, 2022, eight employees and consultants forfeited stock option grants for 1,132,457 shares at an average of $2.057 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Stock option activity for the years ended September 30, 2023 and 2022 was as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;Options &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of October 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,315,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.565&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,636,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.815&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(26,293&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.376&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,132,457&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2.057&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,792,370&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.618&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,158,333&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(166,890&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.272&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(10,277,655&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1.647&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,506,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1.546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table summarizes information about stock options outstanding and exercisable as of September 30, 2023:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Range of&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Remaining Life &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Prices&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;In Years&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;$.88-1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2,161,875&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1.105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,946,758&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1.107&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.28-1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9,754,283&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.473&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,920,291&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.415&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.79-3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2,590,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2.186&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;1,213,750&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2.151&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;14,506,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;6,080,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.498&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;There were stock option grants of 14,906,158 with an aggregate intrinsic value of $0.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2021-10-15_knwn_TwoZeroTwoOneEquityIncentivePlanMember"
      decimals="0"
      id="fid_1094"
      unitRef="Shares">20000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:NumberOfCommonStockSharesIncrease
      contextRef="AsOf2022-01-01_knwn_TwoZeroTwoOneEquityIncentivePlanMember"
      decimals="0"
      id="fid_1095"
      unitRef="Shares">22000000</knwn:NumberOfCommonStockSharesIncrease>
    <knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1096"
      unitRef="Shares">4158333</knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1097"
      unitRef="USDPShares">1.381</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1099"
      unitRef="Shares">10277655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1093"
      unitRef="USDPShares">1.647</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <knwn:StockIssuedDuringPeriodSharesStockOptionExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1098"
      unitRef="Shares">166890</knwn:StockIssuedDuringPeriodSharesStockOptionExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1092"
      unitRef="USDPShares">0.272</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2022-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1100"
      unitRef="Shares">1000000</knwn:WarrantIssuedToCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-30_knwn_RonaldPEricksonMember"
      decimals="INF"
      id="fid_1103"
      unitRef="USDPShares">2.09</us-gaap:SharesIssuedPricePerShare>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2022-09-30_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1101"
      unitRef="Shares">1300000</knwn:WarrantIssuedToCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-30_knwn_PhillipABosuaMember"
      decimals="INF"
      id="fid_1104"
      unitRef="USDPShares">2.09</us-gaap:SharesIssuedPricePerShare>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2022-09-30_knwn_PeterConleyMember"
      decimals="0"
      id="fid_1102"
      unitRef="Shares">1000000</knwn:WarrantIssuedToCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-30_knwn_PeterConleyMember"
      decimals="INF"
      id="fid_1105"
      unitRef="USDPShares">1.48</us-gaap:SharesIssuedPricePerShare>
    <knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember"
      decimals="0"
      id="fid_1112"
      unitRef="Shares">3336000</knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-09-30_knwn_StockOptionsMember_knwn_NineteenEmployeesAndConsultantsMember"
      decimals="INF"
      id="fid_1110"
      unitRef="USDPShares">1.726</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <knwn:WarrantIssuedToCommonStock
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1106"
      unitRef="Shares">26293</knwn:WarrantIssuedToCommonStock>
    <knwn:ExerciseStockOptionGrantsreceived
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1107"
      unitRef="USD">26887</knwn:ExerciseStockOptionGrantsreceived>
    <knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember"
      decimals="0"
      id="fid_1111"
      unitRef="Shares">1132457</knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2022-09-30_knwn_StockOptionsMember_knwn_EightEmployeesAndConsultantsMember"
      decimals="INF"
      id="fid_1109"
      unitRef="USDPShares">2.057</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_818">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;Options &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Price &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of October 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,315,120&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.565&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,636,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.815&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(26,293&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.376&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,132,457&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2.057&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;20,792,370&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.618&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,158,333&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.381&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(166,890&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(0.272&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(10,277,655&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1.647&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding as of September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,506,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1.546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1043"
      unitRef="Shares">15315120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1052"
      unitRef="USDPShares">1.565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1045"
      unitRef="Shares">6636000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1054"
      unitRef="USDPShares">1.815</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1047"
      unitRef="Shares">26293</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1056"
      unitRef="USDPShares">1.376</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1049"
      unitRef="Shares">1132457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-01to2022-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1058"
      unitRef="USDPShares">2.057</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1044"
      unitRef="Shares">20792370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1053"
      unitRef="USDPShares">1.618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1046"
      unitRef="Shares">4158333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1055"
      unitRef="USDPShares">1.381</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1048"
      unitRef="Shares">166890</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1057"
      unitRef="USDPShares">0.272</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1050"
      unitRef="Shares">10277655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1059"
      unitRef="USDPShares">1.647</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_knwn_StockOptionsMember"
      decimals="0"
      id="fid_1061"
      unitRef="Shares">14506158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_knwn_StockOptionsMember"
      decimals="INF"
      id="fid_1062"
      unitRef="USDPShares">1.546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_819">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Weighted &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Range of&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Remaining Life &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Number&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercise Prices&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;In Years&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;$.88-1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2,161,875&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;2.91&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1.105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1,946,758&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;1.107&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.28-1.67&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9,754,283&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.473&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2,920,291&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.415&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;1.79-3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2,590,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;3.05&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2.186&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;1,213,750&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"&gt;2.151&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;14,506,158&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.546&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;6,080,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"&gt;1.498&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption1Member"
      decimals="INF"
      id="fid_1064"
      unitRef="USDPShares">1.25</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember"
      decimals="0"
      id="fid_1069"
      unitRef="Shares">2161875</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAverageRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsOneMember"
      id="fid_1073">P2Y10M28D</knwn:WeightedAverageRemainingLifeYears>
    <knwn:WeightedAverageExercisePriceOutstanding
      contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember"
      decimals="INF"
      id="fid_1077"
      unitRef="USDPShares">1.105</knwn:WeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember"
      decimals="0"
      id="fid_1081"
      unitRef="Shares">1946758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_StockOptionsOneMember"
      decimals="INF"
      id="fid_1086"
      unitRef="USDPShares">1.107</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption2Member"
      decimals="INF"
      id="fid_1065"
      unitRef="USDPShares">1.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption2Member"
      decimals="INF"
      id="fid_1066"
      unitRef="USDPShares">1.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember"
      decimals="0"
      id="fid_1070"
      unitRef="Shares">9754283</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAverageRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_StockOptionsTwoMember"
      id="fid_1074">P3Y</knwn:WeightedAverageRemainingLifeYears>
    <knwn:WeightedAverageExercisePriceOutstanding
      contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember"
      decimals="INF"
      id="fid_1078"
      unitRef="USDPShares">1.473</knwn:WeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember"
      decimals="0"
      id="fid_1082"
      unitRef="Shares">2920291</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_StockOptionsTwoMember"
      decimals="INF"
      id="fid_1087"
      unitRef="USDPShares">1.415</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MinimumMember_knwn_StockOption3Member"
      decimals="INF"
      id="fid_1067"
      unitRef="USDPShares">1.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-10-01to2023-09-30_srt_MaximumMember_knwn_StockOption3Member"
      decimals="INF"
      id="fid_1068"
      unitRef="USDPShares">3.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_StockOption3Member"
      decimals="0"
      id="fid_1071"
      unitRef="Shares">2590000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAverageRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_StockOption3Member"
      id="fid_1075">P3Y18D</knwn:WeightedAverageRemainingLifeYears>
    <knwn:WeightedAverageExercisePriceOutstanding
      contextRef="AsOf2023-09-30_knwn_StockOption3Member"
      decimals="INF"
      id="fid_1079"
      unitRef="USDPShares">2.186</knwn:WeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_StockOption3Member"
      decimals="0"
      id="fid_1083"
      unitRef="Shares">1213750</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_StockOption3Member"
      decimals="INF"
      id="fid_1088"
      unitRef="USDPShares">2.151</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember"
      decimals="0"
      id="fid_1072"
      unitRef="Shares">14506158</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <knwn:WeightedAverageRemainingLifeYears
      contextRef="From2022-10-01to2023-09-30_knwn_EmployeeStockOptionsOneMember"
      id="fid_1076">P3Y</knwn:WeightedAverageRemainingLifeYears>
    <knwn:WeightedAverageExercisePriceOutstanding
      contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember"
      decimals="INF"
      id="fid_1080"
      unitRef="USDPShares">1.546</knwn:WeightedAverageExercisePriceOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember"
      decimals="0"
      id="fid_1084"
      unitRef="Shares">6080800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember"
      decimals="INF"
      id="fid_1089"
      unitRef="USDPShares">1.498</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <knwn:StockOptionGrants
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1091"
      unitRef="Shares">14906158</knwn:StockOptionGrants>
    <knwn:IntrinsicValue
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1090"
      unitRef="USD">0</knwn:IntrinsicValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_790">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;10. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Transactions with Clayton Struve&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;See Notes 7 and 8 for related party transactions with Clayton A. Struve, a significant stockholder.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On June 27, 2023, at Mr. Struve&#x2019;s request, the Company settled all cash dividends with respect to the Series D preferred stock accrued and accumulated through December 31, 2022 in exchange for the issuance to Mr. Struve of 1,402,784 shares of the Company&#x2019;s common stock in reliance on the exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. In connection with this transaction, the Company recorded $1,627,230 in dividends, representing the fair market value of the 1,402,784 shares issued.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 7, 2022, we signed an Extension of Warrant Agreement with Clayton Struve, extending the exercise dates. We recorded interest expense of $194,019 during the year ended September 30, 2023 related to the extension of the warrants. We recorded the original value of warrants in equity and as such, we recorded the extension value as an expense with an offset to additional paid in capital.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Transactions with Ronald P. Erickson&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;See Notes 7, 8 and 9 for related party transactions with Ronald P. Erickson, the Company&#x2019;s Chairman and Chief Executive Officer and affiliated entities. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 14, 2022, the Company issued a stock option grant to Ronald P. Erickson for 1,000,000 shares at an exercise price of $1.41 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 4, 2019, the Company granted a stock option grant to Ronald P. Erickson for 1,200,000 shares with an exercise price of $1.10 per share. The performance grant expires November 4, 2024 and vests upon uplisting to the NASDAQ or NYSE exchanges. The Company&#x2019;s common stock began trading on NYSE American under the symbol &#x201c;KNW&#x201d; on September 16, 2022 and the Company expensed $1,207,200 during the year ended September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 15, 2020, the Company issued a stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vests in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; The Company estimated at grant date the fair value of these options at approximately $520,869 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $104,172 and a&#160; cumulative expense of $186,657, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 15, 2020, the Company issued an additional stock option grant to Ronald P. Erickson for 1,865,675 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The Company&#x2019;s common stock began trading on NYSE American under the symbol &#x201c;KNW&#x201d; on September 16, 2022 and the Company expensed $263,593 during the year ended September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Mr. Erickson was paid interest of $173,855 during the year ended September 30, 2023 and deferred compensation of $165,000 during the year ended September 30, 2022 that were previously accrued and reported but were deferred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $218,334 and $295,418 as of September 30, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Transactions with Phillip A. Bosua&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;See Notes 4, 8, 9 and 11 for related party transactions with Phillip A. Bosua. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 15, 2020, the Company issued a stock option grant to Phillip A. Bosua for 2,132,195 shares at an exercise price of $1.53 per share. The stock option grant expires in five years. The grant vested in increments if the market capitalization of our commons stock exceeds for 20 consecutive trading days starting at $100 million to $1 billion.&#160; The Company estimated at grant date the fair value of these options at approximately $595,277 which is being amortized over 5 years.&#160; As of September 30, 2023 and 2022, the Company recorded an expense of $37,370 and a cumulative expense of $231,321, respectively.&#160; The Company is valuing this stock option using the Monte Carlo pricing model which included key assumptions of 100% stock volatility, five year life and no forfeitures. The stock option grant was not vested as of September 30, 2023 and 2022. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On December 15, 2020, the Company issued another stock option grant to Phillip A. Bosua for 2,132,195 shares at an exercise price of $1.53 per share. The stock option grants expire in five years. The stock option grants vest when earned based on certain performance criteria. The Company&#x2019;s common stock began trading on NYSE American under the symbol &#x201c;KNW&#x201d; on September 16, 2022 and we expensed $301,249 during the year ended September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Mr. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer on January 23, 2023. Mr. Bosua was paid $400,000 in severance and $96,440 in rent and other costs during the year ended September 30, 2023. Mr. Bosua was paid $1,097,928 in compensation and $91,500 in rent expenses for services provided to AI Mind, a wholly owned subsidiary of the Company, in connection with the development of NFT sales for the year ended September 30, 2022.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Stock Issuances to Named Executive Officers and Directors&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 15, 2023, the Company issued stock option grants to two directors for a total of 50,000 shares at an exercise price of $1.24 per share. The stock option grant expires in five years. The stock option grants vested at issuance. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 5, 2022, the Company issued 30,000 shares each to three directors at an exercise price of $1.70 per share. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 5, 2022, the Company issued 20,000 warrants to purchase common stock each to three directors shares at $1.70 per share. The warrants expire on January 5, 2027. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-27_knwn_MrStruveMember"
      decimals="0"
      id="fid_1118"
      unitRef="Shares">1402784</us-gaap:SharesIssued>
    <knwn:ReceivedSeriesDPreferredStockDividends
      contextRef="AsOf2023-06-27_knwn_MrStruveMember"
      decimals="0"
      id="fid_1117"
      unitRef="USD">1627230</knwn:ReceivedSeriesDPreferredStockDividends>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-10-01to2023-09-30_knwn_MrStruveMember"
      decimals="0"
      id="fid_1119"
      unitRef="USD">194019</us-gaap:InterestExpenseDebt>
    <knwn:ShareGrant
      contextRef="From2022-12-01to2022-12-14_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1113"
      unitRef="Shares">1000000</knwn:ShareGrant>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-12-14_knwn_RonaldPEricksonMember"
      decimals="INF"
      id="fid_1114"
      unitRef="USDPShares">1.41</knwn:ExercisePricePerShare>
    <knwn:ShareGrant
      contextRef="From2019-11-01to2019-11-04_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1120"
      unitRef="Shares">1200000</knwn:ShareGrant>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2019-11-04_knwn_RonaldPEricksonMember"
      decimals="INF"
      id="fid_1121"
      unitRef="USDPShares">1.10</knwn:ExercisePricePerShare>
    <us-gaap:EquipmentExpense
      contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1122"
      unitRef="USD">1207200</us-gaap:EquipmentExpense>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1123"
      unitRef="Shares">1865675</us-gaap:StockIssuedDuringPeriodSharesOther>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2020-12-15_knwn_RonaldPEricksonMember"
      decimals="INF"
      id="fid_1124"
      unitRef="USDPShares">1.53</knwn:ExercisePricePerShare>
    <knwn:DescriptionRelatedToCommonStock
      contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember"
      id="fid_1125">exceeds for 20 consecutive trading days starting at $100 million to $1 billion</knwn:DescriptionRelatedToCommonStock>
    <knwn:CumulativeExpenses
      contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1126"
      unitRef="USD">186657</knwn:CumulativeExpenses>
    <knwn:AdditionalStockOption
      contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1127"
      unitRef="Shares">1865675</knwn:AdditionalStockOption>
    <knwn:AdditionalExercisedPrice
      contextRef="AsOf2020-12-15_knwn_RonaldPEricksonMember"
      decimals="INF"
      id="fid_1128"
      unitRef="USDPShares">1.53</knwn:AdditionalExercisedPrice>
    <us-gaap:EquipmentExpense
      contextRef="From2020-12-01to2020-12-15_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1129"
      unitRef="USD">263593</us-gaap:EquipmentExpense>
    <us-gaap:InterestPaid
      contextRef="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1130"
      unitRef="USD">173855</us-gaap:InterestPaid>
    <us-gaap:DividendsSharebasedCompensationStock
      contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1131"
      unitRef="USD">165000</us-gaap:DividendsSharebasedCompensationStock>
    <knwn:AccruedCompensastionTravelAndInterest
      contextRef="From2022-10-01to2023-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1132"
      unitRef="USD">218334</knwn:AccruedCompensastionTravelAndInterest>
    <knwn:AccruedCompensastionTravelAndInterest
      contextRef="From2021-10-01to2022-09-30_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1133"
      unitRef="USD">295418</knwn:AccruedCompensastionTravelAndInterest>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1134"
      unitRef="Shares">2132195</us-gaap:StockIssuedDuringPeriodSharesOther>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2020-12-15_knwn_PhillipABosuaMember"
      decimals="INF"
      id="fid_1136"
      unitRef="USDPShares">1.53</knwn:ExercisePricePerShare>
    <knwn:DescriptionRelatedToCommonStock
      contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember"
      id="fid_1137">exceeds for 20 consecutive trading days starting at $100 million to $1 billion</knwn:DescriptionRelatedToCommonStock>
    <us-gaap:EquipmentExpense
      contextRef="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1139"
      unitRef="USD">37370</us-gaap:EquipmentExpense>
    <knwn:CumulativeExpenses
      contextRef="From2021-10-01to2022-09-30_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1138"
      unitRef="USD">231321</knwn:CumulativeExpenses>
    <knwn:AdditionalStockOption
      contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1142"
      unitRef="Shares">2132195</knwn:AdditionalStockOption>
    <knwn:AdditionalExercisedPrice
      contextRef="AsOf2020-12-15_knwn_PhillipABosuaMember"
      decimals="INF"
      id="fid_1141"
      unitRef="USDPShares">1.53</knwn:AdditionalExercisedPrice>
    <us-gaap:EquipmentExpense
      contextRef="From2020-12-01to2020-12-15_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1140"
      unitRef="USD">301249</us-gaap:EquipmentExpense>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1143"
      unitRef="USD">400000</us-gaap:SeveranceCosts1>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2022-10-01to2023-09-30_knwn_PhillipABosuaMember"
      decimals="0"
      id="fid_1144"
      unitRef="USD">96440</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_knwn_AIMindMember"
      decimals="0"
      id="fid_1145"
      unitRef="USD">1097928</us-gaap:ShareBasedCompensation>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2022-10-01to2023-09-30_knwn_AIMindMember"
      decimals="0"
      id="fid_1146"
      unitRef="USD">91500</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PrepaidRent
      contextRef="AsOf2023-06-30_srt_DirectorMember"
      decimals="0"
      id="fid_1116"
      unitRef="USD">50000</us-gaap:PrepaidRent>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2023-06-30_srt_DirectorMember"
      decimals="INF"
      id="fid_1115"
      unitRef="USDPShares">1.24</knwn:ExercisePricePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember"
      decimals="0"
      id="fid_1147"
      unitRef="Shares">30000</us-gaap:TemporaryEquitySharesIssued>
    <knwn:ExercisePricePerShare
      contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember"
      decimals="INF"
      id="fid_1148"
      unitRef="USDPShares">1.70</knwn:ExercisePricePerShare>
    <knwn:WarrantsToPurchaseCommonStock
      contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember"
      decimals="0"
      id="fid_1149"
      unitRef="Shares">20000</knwn:WarrantsToPurchaseCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2022-01-05_knwn_ThreeDirectorMember"
      decimals="INF"
      id="fid_1150"
      unitRef="USDPShares">1.70</us-gaap:SharePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_791">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;11. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Legal Proceedings&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to the Company&#x2019;s business.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Employment Agreements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 10, 2018, the Company entered into an amended employment agreement for Ronald P. Erickson which amends our employment agreement with him dated July 1, 2017. The employment agreement provides for a base salary of $180,000 per year, which was increased to $215,000 from May 1, 2020 to March 31, 2021, to $300,000 from April 1, 2021 to March 15, 2022 and to $325,000 from March 15, 2022 to September 30, 2022. From December 14, 2022, Mr. Erickson has been compensated with an annual salary of $375,000. Mr. Erickson will be entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the company terminates Mr. Erickson&#x2019;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Erickson terminates his employment at any time for &#x201c;good reason&#x201d; or due to a &#x201c;disability,&#x201d; Mr. Erickson will be entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months. On January 23, 2023, the Board appointed Mr. Erickson to the position of Chief Executive Officer of the Company. Mr. Erickson was appointed to serve until his successor is duly elected.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 10, 2018, the Company entered into an employment agreement with Phillip A. Bosua reflecting his appointment as Chief Executive Officer. The employment agreement provided for a base salary of $225,000 per year, which was increased to $260,000 from May 1, 2020 to March 31, 2021 and to $350,000 from April 1, 2021 to January 23, 2023. Mr. Bosua also received 500,000 shares of common stock valued at $0.33 per share and was entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. Mr. Bosua was entitled to participate in all group employment benefits that are offered by us to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements. The employment agreement was for an initial term of 12 months (subject to earlier termination) and was automatically extended for additional 12-month terms unless either party notified the other party of its intention to terminate the employment agreement at least ninety (90) days prior to the end of the initial term or renewal term. If the Company terminated Mr. Bosua&#x2019;s employment at any time prior to the expiration of the term without cause, as defined in the employment agreement, or if Mr. Bosua terminated his employment at any time for &#x201c;good reason&#x201d; or due to a &#x201c;disability,&#x201d; Mr. Bosua was entitled to receive (i) his base salary amount for one year; and (ii) medical benefits for eighteen months.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On January 23, 2023, Mr. Bosua resigned from the Board and from his position as Chief Executive Officer of the Company.&#160; In connection with his resignation, we entered into a Separation and Release Agreement (the &#x201c;Separation Agreement&#x201d;) with Mr. Bosua containing customary terms and mutual releases, pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#x2019;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company&#x2019;s common stock exceeds $5.00 per share on the NYSE American (the &#x201c;Stock Price Threshold&#x201d;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 13, 2022, the Company entered into an employment agreement with Peter J. Conley reflecting his appointment as our Chief Financial Officer and Senior Vice President, Intellectual Property. The employment agreement provides for a base salary of $300,000. From December 14, 2022 to September 30, 2023, Mr. Conley has been compensated with an annual salary of $325,000, Mr. Conley may also be entitled to bonuses from time to time as determined by our Board or our compensation committee in their sole discretion. Mr. Conley is eligible to participate in all the Company&#x2019;s employee benefit plans, policies and arrangements that are applicable to other executive officers, as such plans, policies and arrangements may exist or change from time to time at our discretion. The Company will reimburse Mr. Conley for reasonable travel, entertainment and other expenses he incurs in the furtherance of his duties under the employment agreement. The employment agreement is at will, meaning either we or Mr. Conley may terminate the employment relationship at any time, with or without cause, upon written notice to the other party. The employment agreement provides for severance pay equal to 12 months of then-in-effect base salary if Mr. Conley is terminated without &#x201c;cause&#x201d; or voluntarily terminates his employment for &#x201c;good reason,&#x201d; as defined in the employment agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Properties and Operating Leases&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is obligated under the following leases for our various facilities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Corporate Offices&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $3,334. The monthly payment increases approximately 3% each year and the lease expired on May 31, 2022. On October 31, 2021, the Company extended the lease from June 1, 2022 to May 31, 2023 at $2,986&#160;per month. On April 26, 2023, the Company extended the lease from June 1, 2023 to May 31, 2024 at $2,908.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;em&gt;Lab Facilities and Executive Offices&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 18, 2021, the Company entered into a lease for its lab facilities located at 914 E Pine Street, Suite 212, Seattle, WA 98122 and leased 2,642 square feet. The net monthly lease payment was $8,697&#160;and&#160;increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 11, 2021, the Company entered into the First Amendment of Lease and added 2,485 square feet for $5,000&#160;per month.&#160; On September 20, 2022, the Company entered into the Second Amendment of Lease for additional space. The expanded space will be utilized for research and testing. The Amendment of Lease expires on December 31, 2023.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On September 22, 2022, the Company leased lab facilities and executive offices in Yucca Valley, CA from Phillip Bosua, our former CEO. The Company leased 1,700 square feet of the total 2,134 square feet of the premises and the current net monthly payment is $7,000. The lease was to expire September 30, 2023 and could be extended on a month to month basis. The Company paid $91,500&#160;in rent on September 28, 2022 for the period September 1, 2021 to September 30, 2022. The Company paid $28,000&#160;for the year ended September 30, 2023. &#160;The lease was terminated on January 23, 2023, the date of Mr. Bosua&#x2019;s resignation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 22, 2022, the Company leased an additional 1,800 square feet of lab facilities at 123 Boylston Ave, Suite C, Seattle, WA 98102 with a net monthly payment is $2,250. The lease was set to expire on November 21, 2023 and has been extended on a month-to-month basis.&#160; &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2018-04-01to2018-04-10_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1228"
      unitRef="USD">180000</us-gaap:OfficersCompensation>
    <knwn:AnnualSalary
      contextRef="From2020-05-01to2021-03-31_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1229"
      unitRef="USD">215000</knwn:AnnualSalary>
    <knwn:AnnualSalary
      contextRef="From2021-04-01to2022-03-15_knwn_RonaldPEricksonMember"
      decimals="0"
      id="fid_1235"
      unitRef="USD">300000</knwn:AnnualSalary>
    <us-gaap:OfficersCompensation
      contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember"
      decimals="0"
      id="fid_1234"
      unitRef="USD">225000</us-gaap:OfficersCompensation>
    <knwn:AnnualSalary
      contextRef="From2021-04-01to2022-09-30_knwn_MrBosuaMember"
      decimals="0"
      id="fid_1232"
      unitRef="USD">350000</knwn:AnnualSalary>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember"
      decimals="0"
      id="fid_1238"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <knwn:CommonStockPerShares
      contextRef="From2018-04-01to2018-04-10_knwn_MrBosuaMember"
      decimals="INF"
      id="fid_1239"
      unitRef="USDPShares">0.33</knwn:CommonStockPerShares>
    <knwn:LeaseDescription contextRef="From2022-10-01to2023-09-30" id="fid_1258">pursuant to which Mr. Bosua is entitled receive a $400,000 severance payment and benefits pursuant to his prior employment agreement. Pursuant to the Separation Agreement, Mr. Bosua&#x2019;s outstanding stock options ceased vesting as of January 23, 2023, and all vested stock options remain exercisable through January 23, 2024. Mr. Bosua has been engaged as a consultant to the Company for a period of one year at a rate of $10,000 per month. Mr. Bosua also entered into a lock up and leak out agreement with respect to 3,005,000 common shares owned by Mr. Bosua and shares issuable upon exercise of his vested option awards. During the period commencing March 17, 2023 through March 17, 2024, Mr. Bosua may sell no more than 1,500,000 shares. During the period commencing April 1, 2024 through June 30, 2026, Mr. Bosua may sell no more than 375,000 shares per quarter (or 1,500,000 shares per year), unless the stock price of the Company&#x2019;s common stock exceeds $5.00 per share on the NYSE American (the &#x201c;Stock Price Threshold&#x201d;), then Mr. Bosua may sell a maximum of 750,000 shares during any such quarter that the Stock Price Threshold is met. Notwithstanding the foregoing, any lock-up or leak-out restrictions are waived for any sales of shares from Mr. Bosua to Todd Baszucki.</knwn:LeaseDescription>
    <us-gaap:OfficersCompensation
      contextRef="From2022-05-01to2022-05-13_knwn_PeterConleyMember"
      decimals="0"
      id="fid_1240"
      unitRef="USD">300000</us-gaap:OfficersCompensation>
    <knwn:AnnualSalary
      contextRef="From2022-10-01to2023-09-30_knwn_PeterConleyMember"
      decimals="0"
      id="fid_1255"
      unitRef="USD">325000</knwn:AnnualSalary>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2017-04-01to2017-04-13"
      decimals="0"
      id="fid_1217"
      unitRef="USD">3334</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1218"
      unitRef="USD">2986</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2023-04-01to2023-04-26"
      decimals="0"
      id="fid_1219"
      unitRef="USD">2908</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2021-05-01to2021-05-18"
      decimals="0"
      id="fid_1220"
      unitRef="USD">8697</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <knwn:LeaseDescription contextRef="From2021-05-01to2021-05-18" id="fid_1224">increases by 3% annually. The lease expires on June 30, 2024. The lease can be extended for one additional three-year term</knwn:LeaseDescription>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2021-09-11to2021-10-11"
      decimals="0"
      id="fid_1221"
      unitRef="USD">5000</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2022-09-01to2022-09-22"
      decimals="0"
      id="fid_1222"
      unitRef="USD">7000</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-01to2022-09-28"
      decimals="0"
      id="fid_1225"
      unitRef="USD">91500</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1226"
      unitRef="USD">28000</us-gaap:PaymentsForRent>
    <us-gaap:SaleLeasebackTransactionMonthlyRentalPayments
      contextRef="From2022-11-01to2022-11-22"
      decimals="0"
      id="fid_1223"
      unitRef="USD">2250</us-gaap:SaleLeasebackTransactionMonthlyRentalPayments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_789">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;12. INCOME TAXES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The Company has incurred losses since inception, which have generated net operating loss carryforwards.&#160;&#160;The net operating loss carryforwards arise from United States sources.&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;Losses arising from United States taxable operations were approximately $4.2 million and $7.3 million for the years ended September 30, 2023 and 2022.&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;The Company has Federal net operating loss carryforwards of approximately $49.5 million which expire in 2028-2042. Because it is not more likely than not that sufficient tax earnings will be generated to utilize the net operating loss carryforwards, a corresponding valuation allowance equal to 100% of the gross deferred tax asset of approximately $14.2 million and $11.4 million was established as of September 30, 2023 and 2022, respectively.&#160; The Company does not recognize the majority of state tax loss operating loss carryforwards as a deferred tax asset given it no longer has any operation in those states. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;Under the Tax Reform Act of 1986, the amounts of, and benefits from, net operating losses may be limited in certain circumstances, including a change in control. Section&#160;382 of the Internal Revenue Code generally imposes an annual limitation on the amount of net operating loss carryforwards that may be used to offset taxable income when a corporation has undergone significant changes in its stock ownership. There can be no assurance that the Company will be able to utilize any net operating loss carryforwards in the future. The Company is subject to possible tax examination for the years 2017 through 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The principal components of the Company&#x2019;s deferred tax assets at September 30, 2023 and 2022 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,476,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,372,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,174,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,677,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,460,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;46,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;97,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,156,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,367,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,156,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(11,367,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in valuation allowance during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,789,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,666,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;A reconciliation of the United States Federal Statutory rate to the Company&#x2019;s effective tax rate for the years ended September 30, 2023 and 2022 are as follows. For the years ended September 30, 2023 and 2022, the Company&#x2019;s effective tax rate differs from the federal statutory rate principally due to nondeductible expenses plus an increase in the deferred tax asset valuation allowance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Income tax provision at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other and prior year true up&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;As of September 30, 2023, there were no uncertain tax positions. Management does not anticipate any future adjustments in&#160; the next twelve months which would result in a material change to its tax position. For the years ended September 30, 2023 and 2022, the Company did not have any interest and penalties.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="fid_1184"
      unitRef="USD">49500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <knwn:FederalNetOperatingLossCarryforwardsExpired contextRef="From2022-10-01to2023-09-30" id="fid_1187">expire in 2028-2042</knwn:FederalNetOperatingLossCarryforwardsExpired>
    <knwn:EffectiveTaxRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1183"
      unitRef="Pure">1</knwn:EffectiveTaxRate>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-09-30"
      decimals="-5"
      id="fid_1185"
      unitRef="USD">14200000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-09-30"
      decimals="-5"
      id="fid_1186"
      unitRef="USD">11400000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_821">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net operating loss carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,476,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9,372,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Stock based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,174,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,677,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Research and Development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,460,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;46,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;97,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,156,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,367,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,156,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(11,367,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in valuation allowance during the year&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,789,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,666,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1155"
      unitRef="USD">10476000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1164"
      unitRef="USD">9372000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1156"
      unitRef="USD">2174000</knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation>
    <knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1165"
      unitRef="USD">1677000</knwn:DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation>
    <knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1157"
      unitRef="USD">1460000</knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment>
    <knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1166"
      unitRef="USD">0</knwn:DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1158"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1167"
      unitRef="USD">221000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1159"
      unitRef="USD">46000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1168"
      unitRef="USD">97000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1160"
      unitRef="USD">14156000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1169"
      unitRef="USD">11367000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1161"
      unitRef="USD">14156000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1170"
      unitRef="USD">11367000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1162"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1171"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1163"
      unitRef="USD">2789000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1172"
      unitRef="USD">1666000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_822">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Income tax provision at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Non deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other and prior year true up&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1174"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1179"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1173"
      unitRef="Pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1180"
      unitRef="Pure">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1175"
      unitRef="Pure">0.18</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1178"
      unitRef="Pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1176"
      unitRef="Pure">0.02</knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp>
    <knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1181"
      unitRef="Pure">0.02</knwn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1177"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-10-01to2022-09-30"
      decimals="INF"
      id="fid_1182"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_792">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;13. SEGMENT REPORTING&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The management of the Company considers the business to currently have two operating segments (i) the development of the Bio-RFID&#x2122;&#x201d; and &#x201c;ChromaID&#x2122;&#x201d; technologies; (ii) Particle, Inc. technology; and (iii) AI sales of NFT products. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Particle commenced operations in the year ended September 30, 2020. AI commenced operations during the year ended September 30, 2021. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The reporting for the year ended September 30, 2023 and 2022 was as follows (in thousands): &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Operating&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Profit (Loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Development of the Bio-RFID&#x2122;&#x201d; and &#x201c;ChromaID&#x2122;&#x201d; technologies&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14,298&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,266&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Particle, Inc. technology&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Digital asset sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;274&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total segments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,024&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,266&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year Ended September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Development of the Bio-RFID&#x2122;&#x201d; and &#x201c;ChromaID&#x2122;&#x201d; technologies&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,482&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,360&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Particle, Inc. technology&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Digital asset sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;930&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;398&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total segments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(12,574&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,758&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During years ended September 30, 2023 and 2022, the Company incurred non-cash expenses related to operations of $4,767,809 and $12,164,418, respectively. &lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_820">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Operating&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Segment&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Profit (Loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Development of the Bio-RFID&#x2122;&#x201d; and &#x201c;ChromaID&#x2122;&#x201d; technologies&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(14,298&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,266&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Particle, Inc. technology&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Digital asset sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;274&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total segments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,024&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,266&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Year Ended September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Development of the Bio-RFID&#x2122;&#x201d; and &#x201c;ChromaID&#x2122;&#x201d; technologies&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(13,482&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,360&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Particle, Inc. technology&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Digital asset sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;930&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;398&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Total segments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,360&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(12,574&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;13,758&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <knwn:SegmentRevenues
      contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="0"
      id="fid_1191"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="-3"
      id="fid_1197"
      unitRef="USD">-14298000</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2022-10-01to2023-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="-3"
      id="fid_1203"
      unitRef="USD">8266000</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1192"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1198"
      unitRef="USD">0</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2022-10-01to2023-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1204"
      unitRef="USD">0</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1193"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1199"
      unitRef="USD">274</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2022-10-01to2023-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1205"
      unitRef="USD">0</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1206"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="-3"
      id="fid_1208"
      unitRef="USD">-14024000</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1210"
      unitRef="USD">8266</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="0"
      id="fid_1188"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="-3"
      id="fid_1194"
      unitRef="USD">-13482000</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2021-10-01to2022-09-30_knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember"
      decimals="-3"
      id="fid_1200"
      unitRef="USD">13360000</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1189"
      unitRef="USD">0</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1195"
      unitRef="USD">-22</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2021-10-01to2022-09-30_knwn_ParticleIncTechnologyMember"
      decimals="0"
      id="fid_1201"
      unitRef="USD">0</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1190"
      unitRef="USD">4360</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1196"
      unitRef="USD">930</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2021-10-01to2022-09-30_knwn_DigitalassetsalesMember"
      decimals="0"
      id="fid_1202"
      unitRef="USD">398</knwn:SegmentAsset>
    <knwn:SegmentRevenues
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1207"
      unitRef="USD">4360</knwn:SegmentRevenues>
    <knwn:SegmentNetIncomeLoss
      contextRef="From2021-10-01to2022-09-30"
      decimals="-3"
      id="fid_1209"
      unitRef="USD">-12574000</knwn:SegmentNetIncomeLoss>
    <knwn:SegmentAsset
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1211"
      unitRef="USD">13758</knwn:SegmentAsset>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1212"
      unitRef="USD">4767809</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2021-10-01to2022-09-30"
      decimals="0"
      id="fid_1213"
      unitRef="USD">12164418</us-gaap:OtherNoncashExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-10-01to2023-09-30" id="fid_793">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"&gt;&lt;strong&gt;14.&#160; SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to September 30, 2023, there were the following material transactions that require disclosure:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 12, 2023, the Company issued 30,000 shares each to three directors at $0.25 per share. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On October 26, 2023, the Company&#x2019;s underwriters exercised their over-allotment option under the Underwriting Agreement by and between the Company and the underwriters dated September 26, 2023, electing to purchase an additional 883,061 shares of Common Stock at a purchase price to the public of $0.25 per share. The Company also issued additional warrants to the Representatives to purchase an aggregate of 61,814 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments, with the same terms as the warrants issued in connection with the initial closing of the Offering. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 3, 2023,&#160; the Company appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan,&#160; as new non-employee members of the Board. Messrs. Ellingson, Cronin, and Londergan are deemed to qualify as independent under the director independence standards set forth in the rules and regulations of the SEC and applicable NYSE listing standards.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On November 28, 2023, the Board adopted, based on the recommendation of the Compensation Committee of the Board, the Know Labs Inc. Compensation Recovery Policy (the &#x201c;Policy&#x201d;) for the recovery of Erroneously Awarded Compensation in order to comply with Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act, and the listing standards of the New York Stock Exchange adopted pursuant thereto. &#160;The Board has designated the Compensation Committee of the Board as the administrator of the Policy.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Since September 30, 2023, the Company issued stock option grants to employees, directors and directors for 13,909,315 shares at an average exercise price of $0.256 per share. The stock option grants expire in five years. The stock option grants primarily vest quarterly over four years.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-10-12_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1242"
      unitRef="Shares">30000</us-gaap:SharesIssued>
    <us-gaap:SharePrice
      contextRef="AsOf2023-10-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1243"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <knwn:AdditionalSharePurchase
      contextRef="From2023-09-01to2023-10-26_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1244"
      unitRef="Shares">883061</knwn:AdditionalSharePurchase>
    <us-gaap:SharePrice
      contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1245"
      unitRef="USDPShares">0.25</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_1246"
      unitRef="Shares">61814</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-26_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_1247"
      unitRef="USDPShares">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <knwn:StockOptionGrantsToEmployeesAndDirectors
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1248"
      unitRef="Shares">13909315</knwn:StockOptionGrantsToEmployeesAndDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1249"
      unitRef="USDPShares">0.256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M7*WDP0]E08CZ*O0UDZDD+%3W!R,]F_[>WZ@=YVKZ(?GKZ-3U^B?'N'_6>ZT
M.T04P&44P(VBP#2;QU&@PC@GTD0'5FE+QZK:Y4;M9(>UASUG.#@^+5A7Z92.
M'S=R_'I\1I,LF9N3T1X1QW&[WJ _&!I16/7\MM2JN$K/CQMY_AL6<*&L&,FG
M8+07HZI'9DP*W3-#H]'8HSSY;H1G-0/84JO"*S, ;I0!'LD[N@G5H!^]1,&:
M(-#R8,FATW7PP'/[V$C/:A2PI5:E5T8!W"@*7(2A4D^+USMU&#(]SAGOT3MV
M'/2-K=NOH-0T*/JP1&N AT@%N$P%N-$C?B- 4_,9[]&;99'J]J>N8R1G-178
M4JN2*U,!;I0*ML1\O?%5H$?^QHS<8+49)5+&QNP.5[:F=H@T@,LT@&'[_A.U
M]5U"89L*_AJQP'R3@"6?+HS4K"8"6VI5:F4BP(UF!;;4IEQ9VAC]':WJ;ZRP
MX%#U4./C;KBN-;9#Q )<Q@*\9Y(@AR8HJ<<$"V#GQ C)ZJ2 +;7J@H(R"GAP
M%+CC>2I?<@:9W3TB0\?KNMZQL4G!I:W7$!QB,L KHX$'N_H9#3*AFY6+Y^@Q
M,@_9XSTBNSGU,UJI=/]*XHRB3\Z12@UH105*=7HUTK2:'&RI56F6R<&#_?VC
M(&'^X/8CF?/82!(6N)T\&2%930BVU*J0=I;\P':^:')7[\&2L 6M7;FR1VCR
M/+LRTK*[R.<0B< K$X$'._CBX=D%8YD:V-:S T9:L%#==!U<UIK6(>R_5]I_
MK^&D@.J)+(WRW D0@\5J9Y_@NM;(#N'[O=+W>XU\_PV35*S7F>II%+*=CC)R
M@Q5K9I_@JM;4#N'[O=+W>WM6_F1A)+E VFWH5F;$M,?GDYAE$ODJEZN[ID_B
MZ(4+%A$C.ZONWY9:E5WI_CW8K&_9U0[[</EX>H_N[J9&3%;=OBVU*J;2[7NP
M6=]BNHY$@FY"(ZE]=G]@I&35[MM2JZZ"+>U^'W;J.Y-+VH$F$ET)H:CY7 U?
MZ]7S=6OS]BC7#O]P7>L%L58#0&]GL;M>AI'_:"!%@7YNO5[W7NPM?IAPD2_'
M[Y6'KW_5<$_T*HX4Q?1%E3I' W6?$NL?"JPW)%_E2^?G7$J>Y&^7E(14Z /4
MYR^<R^V&_H+BYQJC_P%02P,$%     @ :("35WFC[016!@  H1L  !@   !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6RM66USHS80_BL:]Z;7SC@QDGA-$\\X
MCMMXFMBI[;1S'Q4CQ\QAQ(&<W/775\($# C%F?(A,9C=];-HM<^S</G*DJ_I
MEE(.ON_"*+WJ;3F/+P:#=+VE.Y*>LYA&XLJ&)3O"Q6GR/$CCA!(_<]J% V08
M]F!'@J@WO,R^>TB&EVS/PR"B#PE(][L=27Y<TY"]7O5@[^V+1?"\Y?*+P? R
M)L]T2?EC_)"(LT$1Q0]V-$H#%H&$;JYZ(W@QQD@Z9!9_!_0U/3H&,I4GQK[*
MDZE_U3,D(AK2-9<AB/AXH6,:AC*2P/$M#]HK?E,Z'A^_1?\]2UXD\T12.F;A
M/X'/MU<]MP=\NB'[D"_8ZRW-$[)DO#4+T^P_>,UMC1Y8[U/.=KFS0+ +HL,G
M^9[?B",':+8XH-P!G>J <P><)7I EJ5U0S@97B;L%2326D23!]F]R;Q%-D$D
MEW')$W$U$'Y\.)[/EO.[Z<UH-;D!UZ.[T6P\ <O;R62U!&?@<7D#?OGTZ^6
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M_9S3'%YYN./B3@8 "OV)PEB.K$"IY,*VY2* B,HSGD"LGZRXB*C22[&V92*
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MGK@=,=VY;-;>5OR85/=I48.,WK'&UFN7C9MJ<P%P\Z8I5]W]L]NR:<J\>_E
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M /Z_XM"['+Z('VC>8QK^'U!+ P04    " !H@)-7>0'!^?L$  #^"@  &
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M41N""16U\]:OMN*/'JCH4F:X,@5-)8W1K)S!+1BS6]!3=@5B82<-5R&>+;N
M1@DJ#RD6.JLN $#H<4DDA<=%3*$K!)&ID/T-("X11A"=I.TH A,YOYP5 K#R
M8(<GWUTN3I^]B$HOC64C4)6"1N.6QML&7\$'IV@O@W (-C@A+JFNE08-,M9,
MK>[)!4D!%ZZ# I"3+QUB8^>Q:UL?'HOB,/(E67C<4Q;S2,YW*Q3$6ALKH,;Z
MJ"P]F#Z$C4FU^.\A Q4] "Z+$0CR4U(=Y L1) #6P/%+YV@0U?E,W6)<($4.
MC3P$CG/G3 *,A[J31#F""78(VHB,2B%1<P9=&=5RJS#2K+"T>]<G"VDSCO?B
MUYQ(T.%5":"'&S$-[ X[[87(66F#P6PV$%.J@_!D8NRT*T2Q_381\@S8FH"?
M>4.""Z#NJU3J[H%"P?AAM-$!6L@%U':AP.;@W#=0+?+FB_NQAJ*V8B$2-(Z3
M*@4T4R_'4.UVVA?Z*,W L +E*A4.L["8^(;#K5"9/@ LR+%=.30'2>!.8FJ%
M)I[JS-3 ,?C(H:='Y(ZX482ISR+DH?.W"I9S*%$" YWW)"F7#Y">-C9(II''
M4O%)Y %#1LZ/Y9LGHFD569PE"\:W'*6B"GTOQ9$X=&'LT+%9W@Y[%6AR0]Z.
M@9>*049ZDGK=Q6Z)1@>OX+?T'?*AE_BD>]337M7W0(B;OU8K+V/$ P4:T]"R
MTX8L6EN3/QU&R91]-E*-SO">N+YGZJUV^#)L>F[V)6P<&"OCD4H9!"S=^9B(
MN6SZ8MG?( Y5BV(81B)+EN?"(#W>2?8737'+TT4N)$[-IC80-/;?2N_ > #:
M6J_S<$&@,,(HT=;\A4I$9;^5;)^=YOXQ[4>H,#(6,7=J[L520D8FC "7@G!H
M>?Q.(]X@ 7/G8^%GB:Z9R7T:^]J)!_0!DBL ;@H9 ,]XGXL+.^QZ)SI?HM#$
M07#\C+O_;HLI#Q8L0^G.U!O8<>EBR8I<;J&QXR%G&)ETX@KGA*\&_O3K+ \Y
M8*;S-%2EB44@>1^VNU(J?&?+3+Q&@0 PRUJ7^'*!2Q03I\:[?Q-WGD\D+3/+
MC[.&3R%'$8E:?B8Y87"[8O6#59P,^G;R_Y<3]W">R$LBQ^1B<B*R?C C&]EK
M;U'RX"KY*GIK6$OED%8@ K34M\_2B]/<*.&'O]#VOX%XCC9\T!&AX6,@1J;:
M_*,X(P;CH(4C062PX_C8'Q:[V@-/S%TI@D1)09$YH<O=G)%>K[-^<$8ST$NC
MMSN-M9[[*\<Z;'98[+D\^_BX]4@-YY8#B8RHA@+8[;O,61RK<M5I7DJ9N][5
MUW8S]=@I8KYWCFLHK.2TRI\X^,S(1[KQZ7@@?IG/@;OE^32-5K+"",5W1@73
MD]FSIQ,5\@DUWR3?RJEPZ1/.F')9XU!/@1?@?>7!67_#&XS_)KCY&U!+ P04
M    " !H@)-77-%QS-D*  !U'@  &    'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;,59;6_;.!+^*X2W6-P!JN.7V'&:-("3-+L!VC37I'N?:8FVB%*D2DI)
M?+_^GB$I6<K;8O>Z>T#1V"8Y+\_,/#.4CN^-_>9R(2KV4"CMW@_RJBK?[>VY
M-!<%=T-3"HV5M;$%K_#5;O9<:07/_*%"[4U&H_E>P:4>G!S[WZ[MR;&I*R6U
MN+;,U47![?94*'/_?C >-#]\D9N\HA_V3HY+OA$WHOI:7EM\VVNE9+(0VDFC
MF17K]X/E^-WI/NWW&WZ3XMYU/C/R9&7,-_IRF;T?C,@@H41:D02./W?B3"A%
M@F#&]RAST*JD@]W/C?0+[SM\67$GSHSZM\RJ_/U@,6"96/-:55_,_:\B^C,C
M>:E1SO_/[L/>^7S TMI5IHB'84$A=?C+'R(.G0.+T0L')O' Q-L=%'DKSWG%
M3XZMN6>6=D,:??"N^M,P3FH*RDUEL2IQKCJYN?SEZO+B\FQY=<N69V>?OU[=
M7E[]PJX_?[P\N_QPPY;GGZ]O+S]?L<\7W?6;V^75^?++^<WQ7@4K2-9>&C6>
M!HV3%S2.)^R3T57NV >=B:PO8 _FMSY,&A].)Z]*O!'ED$U'"9N,)M-7Y$U;
M3*9>WO1OQ"1HW']>(U7>.U?R5+P?H+2<L'=B</+S3^/YZ.@5?_9;?_9?D_Y[
M_KS[4PZ]KG(Z9/^S5G;*G73,K-DU8:(K[NOXVDJ=RE()OW1FM#-*9F'MC+N<
M<9V%#Q^^U_*.*YQT. 4>L]76K])""6:IV$>C-V\_@A<RMG1.8.,7<2=T+? W
M-1LMO5A$8C$]8C+#$;F6:5 &[54N6(IDMB"7A!G;?G$)ZKC*PP9?Q<(>O2X'
MYGF.U:E@9J7DQJ\Z)G5/32LE$Y6P8(2>$&S1C@?"*ZU,1;N=*V72U_>RROPQ
M2PC+*-YVX(KR;43R/A?:@\.!"BV<F:+D>LL<Y+JU1"#Y"SJ';3B0"%'%?Q K
M$AGL &$V^%E32(?%C3&9(WU41W#+T6'O[%I8BPW1S28NL J><?PK3(V<J')>
M4;^AQN$:CQV"9@-\71?$0QEV&;82C,):J: !(L5#FG.]$0R>X91QXJEM0W9>
M(Z$W(2*Y%8(5@1T%L2,[%ZDH5L*RZ=CSV[@/X49H,@L;&[37@(%E<B,KKH X
M<AHXQV*YNKB%PMNN_7J#RA7! L&+A-6./LN*\':"VS1G*"Z>L.6ECS=@1K*(
M"AT<.;4Q%FE> $+\GM4I#"$E3:I02$EQ:X^M@GZ_J3V2\XQIXP-LR>G4N(IZ
MK7QD;6;@AS95A)VMZZJV(G1VB=H&KCT8?"2=J6TJ*).B.^3%.;8I$SC@ X1I
M!\D=53__M)B,#XX<D@0IHZL=&'0ZZYP6:S@)M+BE%)28;*3:PG%D%SQ!NL@"
M?MZUH/),&E@GOM="IZ@!<L0:EYIRBPBDN3;*; )-T?ZUM,#"BR-AVNBW4M\!
MFCN?*+(R/G; >*606VRCZI0239&)[@A(54BD1GO*T61D9,'H!:UI3$_T4ZTE
M[&*\+%5D)Q>3ETJHM:X?E950$J)<@)NJ4B("?91@7Z-#Z)RJ/-O)DZ%$A2.2
MET@3*A_R/837U2D*Y5$JH ?4OIA%$SVH>'.0'$P.DOWY@=?T9I9,%[-DMIA'
M)P3;(HA-:6%LJ&)MQ=G!G\*'24+QIL@ 9K5-"/FN-S'A))7OI4Y53>)BRD=[
MO$8O$YX!3VL>D!L5I+$WB]EA,AJ-H$/YTH6[#M*M)S\RP4"0W7F&*C:I]%O;
MII*)$L5$\$3Z>YRX5'H0DN92K+N)9=9H/%@@/6%1/(BT)D^;M81=YU+)DBV'
M[-2X&L7?L:HHE=D*<GV9P6A0.&70!9>6_<85LN>3X Z&%;[OTL$+-"FT; 3V
M4KO*UF'E^1.A.J5+E:&?'/M(N+,Q\XZ-C]B_:D- ^(;E>2;,]9B)[3?JWX1[
M:+!I0X#!"B7Y"EY1U(ZBU$DK]5*7-?8%%Y''.A00 H_6$]9\=E.5"^EW91)\
M52G/.E+OOJV(VOE*B= ?@Z;I8TVQ!V$\J4-7*00Z1!:+'UIJO9/D!3F)YD=#
M [6H<'I-$-YY"(L=A*%06C(-Z\B2X-RZ#<;SV&!PR25XSO<\4,^.TR B;>8K
M_T'LYBMD2)I2]_1M6DAO=A)5-AP:%':VEGS;NH<?;=VMYT[1/':V'3":&GW!
M%_Q,>U\I= \UW>K ?67L[2X'H;^EX8IAN.J4V/-* MQ/K7O228SVY4(.HX>)
MCOO6_\+H4DU \SLNE5_9P+=@%)D35$-.YN<L/[<0^33C0]#@K\MKX2TGL"TM
MH&C%0Y]!<TYS%WJ(V,;B:0(3,T"Z=O !/+RM1 ]#D+7B*I#6[^)\CRV@Y\5T
MGDP/P^]OQN,$V"2'--IT^7;(KDQ,G0@Y2JP75DO!1_;%:6[527<4:3<6X =:
M0P;Z/N=1P<R%B>>.^\QYGIR::NU-'W'@)IW$!2] [AFHK&UI8E=:R34FD%#E
MQ-_@+-^+7\P'Z9SOGV$P!'RC!L<QNT<P,%)055A?Q%0Z+Z*O%'7/_!E=.8?O
M*Q'&:%H+2")3D!$,@W'ZS<NF* @?/0QHV0ZV)AP(UHW??.J+B+!"^<;;6$?K
M#<4@1.]*T+W+.9KYV4U.P5R^X$%_V*4Q<3%*IK,%6OP4=<IM0+AG=43/=RPP
M;<7]^#-\70?Y2/^9,@P]G9/M[("88IYWOL#'^\EL-$_&LT7'# R:?5/^L:O/
M6F/RH-0)*T$/VZ#G^V: X9AV39/%_!!%,6ND=D:$[@T)T_<&=?%/D#6W0<9S
M5DY&D(>"&T]?L3)ABV0\6@#6>6?7\PSV".9 \JE1:C<JM33:*8VH]0;I ^EG
MO<3 W3Y>RV[:I(L;SU_;&&:2_F0U34;[HV0R/GS5W;Z]\7%+@)AOVSZ48<+#
M&)'YL?N'6T]S(^-9(/)^EL=NJ0)#8U)$%"?S_8Y+@3VZA1K)*/;9<)FG>7@T
M1"I1F?G#.U\]=%:T00Q1ZT>LRQF96$%P'?6_F20'<\_;0W916RH?Q!TSM>V9
M$5K67QA[&%]X5@=O^8MV>^\T][@6NQPCK*]MLTYP\XZUC(K)0E_X7F.$%A9(
M^[MF+PKW$MQ)N0#29[Y3EJT-36JT$YP'NY^*X_G(S_C/DU0S9/5B(->!K'>9
MMT)3*\1N3G!MRH#Y=Y)WEKD=.E[4HQ46G.QROM2/6!]$J=IG*H!+!."B-LP'
M"L,W6HB_J<%13"PU((IW-2(Y;'>=I%O5<6Q^B!>E>#47SW(QAO:T5NUS*HU>
MH9I>$>6)E.-N31+0YG&[Q@7 7[)@D3>&VM,+9#]YVE#VP7ZS>3*:3WY00YG\
MJ8:"(C\XG"33@U&K/%CSAWO(87(PVD_FD]$/ZB'CY& 1>DC/L)!ES[6.)VVP
MSS)/>T/+#7\A>_9!_?L)<S*;(<?F_\_JFORHZAIZM*W(Z=T<S8(DXKPAQ6NC
M9+IE7T/Z?'"5IT1ZL)X2ULMPQR"OKZW1^)S&1P5A@NP_8&UG#RONZ!4?\>Q.
M@*\HHO.ZS+P.ZW4 MU"S27SJVNP+#P^WHGI\>^ 9BBF&F1YP&N>KK#G5U$4(
M0S_A_#/)^ @LD*X$["X&A>XT08L?N'GO%A_1?<'CM'VS05%M;RFPJ@J #9][
M-;37>158"%0XO?#TF:6K\%:P_;5]I[H,KQ)WV\,+V4\@" GJ4F*-HZ/AP6S
M;'C)&;Y4IO0O%E>FJDSA/^:XP@I+&["^-LCD^(44M&^:3_X+4$L#!!0    (
M &B DU>4A P@] 0  ! +   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;*U6;6_;-A#^*P<W*#9 L&793;PV,9#7+4"3!G&Z?::ELT24(C62LN/^^MV1
MLF*C:88!^V*+%._A<W?/G>YT8^PW5R%Z>*Z5=F>#ROOFXVCD\@IKX8:F04UO
M5L;6PM/2EB/76!1%,*K5*$O3XU$MI![,3\/>@YV?FM8KJ?'!@FOK6MCM!2JS
M.1N,![N-1UE6GC=&\]-&E+A _[5YL+0:]2B%K%$[:3187)T-SL<?+Z9\/ASX
M4^+&[3T#>[(TYALO;HNS0<J$4&'N&4'0WQHO42D&(AI_=YB#_DHVW'_>H=\$
MW\F7I7!X:=1?LO#5V6 V@ )7HE7^T6S^P,Z?#XR7&^7"+VSBV>QX 'GKO*D[
M8V)02QW_Q7,7ASV#6?H3@ZPSR +O>%%@>26\F)]:LP'+IPF-'X*KP9K(2<U)
M67A+;R79^?GY+5Q=7S_ Y^OSQ_O;^]_AX?/YT\V7Q[O3D2=X/C3*.ZB+")7]
M!&J<P9W1OG)PK0LL#@%&Q*LGE^W(761O(BZP&<(D32!+L\D;>)/>V4G F_P?
MSD:HZ>M07"L?72-R/!M0,3BT:QS,W[\;'Z>?WB Z[8E.WT+_;T3?AIH.X:=H
M\$4#Q=ACO40+XY,0Z'$"OD*X-'4C]!:DSHUMC!4>"T:ZD[I(X%;G0_CE_;M9
MEJ6?NMVP&G_ZE4P"PL*3#9@5W.-:%&*XLX:-<+ R)&Y"I,*LC48OOTM=DJ6G
M^J2";86"QE+KL7Y+M:^$Y]?>!&!AO5S)7-*9:"!+U#E"ZZ62WPF4\ 4T=(QO
M9XN"2@.$%FKK9>Z 8+F=T<F-]!5X*PH$A[FE)BA4:2SMUFX("\FP+Q&@-I*
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M=8MB<E$.X+)$&]HVMJ!$@ZYZ$?W73L..<88'T#@(/"#9?:D SBYQS-B)Z*@
MY<PVP%3YWSA\(L8@3A2CO?"3&0 '(1TCY<*BU%$4^-LH;23/6#O?+'>RPR"
M8C((?LFHC71.XT2PL$'9]H8X^XP1$ZQ"S'[5&!D)^)9+]L(X;[K3'&2S!BH%
M55N=K>V3")Y2E_'3QF-9NA.2PRWC4!.]Y/J=?C$I128?J.Q.NK>;-[P6*=>^
MJV7</4%Z_WU'"CNHRP9AF]"X%\-!O2E_)YH#68.KE+^FUXZCT<%5H&2WCA<>
M3Y%(=ROH5_L[U4UWE7@R[RYDGY5;RR VO()K.GQ_D72S</\2;!TO%DL;<$V)
MC]) [,0 WU?6AOV+!.AOFHM_ 5!+ P04    " !H@)-7;'3WI8,&  "7$P
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MOMIV>?-\ =2"A4B:TJB<(JHZ97U'8<RQ,+Q@SCJ<*,4I; .V31'&VIK$'I!
MY 5HMSXP6JNH/#C1#>I.S[00[.1V@;SYG]NS3X6+H4U[5;_4QF!5Y@WFD& 0
MMCS6KS0^_833).+C2-R"P7^N]%E=Y \K$DIY=0G>Q/ =0:5Y\ M>2+G9\&HU
M \OK71L/IZ4_ ^G_/'1H)US,O'!V\F4FWM@/.[UUA5Z/4/4$C.SOT/WDQFRK
M@:[>]+K["8EY=$\;O2EP9U F#I;VQ'??<0\()?E&Y?$&VXJ&-M]VUXPG5];
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MMO]'E3V<2RP-V&R[LVA1<^OW8I+=6DNMQ@&.Y$"-:Q3-*7'!8%7,LR_AXS;
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MXQ[3U:>ZZL&JPGT>NU76JLS]3 0'9=($O%\I;!OK!U+0?B\]_A=02P,$%
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M8/06\LFD'V]@I(X%J'(% )Q7B*5T7#AS LB3C6!.R@=<=*MT\*U9Z_&$<[.
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M<L1D.B1,V?PN3V<^.(6FMV3ZL#">A&NHQJ2D'0Y^J)T)AC\HKI7:8VBY44J
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MRBSYYT))5$BT ,]GQE3-!3%HO\E[^V]02P,$%     @ :("35]FV^$1]!@
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MA*T&;Y!3FHLR\Q9?%?S\Z>SV?#;]YW9Z]45,O^)W=CST@.6/PZ2!.*\A1L]
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MUE?J^L6;,EQCY\;C4AP>E_@OA"P;X/O"&-^^<(#N_YK3_P!02P,$%     @
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M3ZR31JR349H?Q(,H*L$^B$2M"[DO K^:"$,J+R:G3*8PGUS)Q,8C!6B9"98
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MS&/L,E(%"W%BD1\4RA>TIA\_= /G\Q&5O59E[QC[=$7VB\H40<2PD&1"J=^
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MKH6F-E"%"?5=E":!]F,A]&YB#F@[^?0W4$L#!!0    ( &B DU<=#BO=3@(
M !P%   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'U4VV[;, S]%<(;
MAA;(:D=Q+^@2 TW781M:H&BZ#7M4;#H6JHLGT4W[]Y.LQ,N -"^V2/$<'DJD
MIFMCGUR#2/"BI':SI"%J+]/4E0TJ[DY,B]KOU,8J3MZTJ]2U%GG5@Y1,69:=
MI8H+G133WG=OBZGI2 J-]Q9<IQ2WKW.49CU+QLG6\2!6#05'6DQ;OL(%TH_V
MWGHK'5@JH5 [8318K&?)U?ARGH?X/N"GP+7;64.H9&G,4S"^5;,D"X)08DF!
M@?O?,UZCE('(R_BSX4R&E &XN]ZR?^EK][4LN<-K(W^)BII9<I% A37O)#V8
M]5?<U',:^$HC7?^%=8S-?<:R<V34!NQM)73\\Y?-.>P +K(W &P#8+WNF*A7
M^9D3+Z;6K,&&:,\6%GVI/=J+$SI<RH*LWQ4>1\7MS=7B9@%'CWPIT1U/4_*D
M82LM-P3S2,#>(!@SN#.:&@<WNL+J?X+4JQDDL:VD.3O(N,#V!";9"%C&)@?X
M)D.)DYYO<K#$?95%7+X?%\;ATK6\Q%GB^]VA?<:D^/!N?)9].J J'U3EA]B+
M19P",'6X5J$Z!75'G460Z+L,6O[J>Y_</MT'F??K_HW<QAN"[YW&[?GF'P'@
MT1"7?L+"# N]&E+#>Y;EH]-)#K?H' C5=N3Q0A-Z7@(X&H\N&#N.^"A;"KX4
M4M!K +/1N6^/?8>5[G2L0KOJY])!:3I-L7D'[S#Z5['C_X7'=^..VY70SN>O
M/30[.3]-P,99C :9MN__I2$_3?VR\<\7VA#@]VMC:&N$!,.#6/P%4$L#!!0
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MCM(L(/U2"-U.S 9=TS__!U!+ P04    " !H@)-7M E/L8<#  !M"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R=5FUOVS80_BN$5@PIP$I\T6MF
M&TBR; O6)D:<M=A'6J)M(9+H472<_OL=*5FQ$]?M]L'2\73WW'/D0YQ'6Z4?
MVY64!CW75=..O94QZ_,@:/.5K$7KJ[5LX,M"Z5H86.IET*ZU%(5+JJN $1('
MM2@;;S)ROJF>C-3&5&4CIQJUF[H6^NNEK-1V[%%OY[@OERMC'<%DM!9+.9/F
MK_54PRH84(JREDU;J@9IN1A[%_3\,K+Q+N!S*;?MGHUL)W.E'NWBIAA[Q!*2
ME<R-11#P>I)7LJHL$-#XI\?TAI(V<=_>H?_F>H=>YJ*55ZKZ4A9F-?92#Q5R
M(3:5N5?;/V3?CR.8JZIU3[3M8J/00_FF-:KNDX%!73;=6SSW^["7D))O)+ ^
M@3G>72''\E=AQ&2DU19I&PUHUG"MNFP@5S;V4&9&P]<2\LQD]G!W]2>ZN;VZ
MOGVX^7R-IA\O;F?H[$',*]F^'P4&:MC((._Q+CL\]@T\RM GU9A5BZZ;0A:'
M  &0&QBR'<-+=A)Q)M<^X@0C1A@_@<>'CKG#X_^EXV.-=C#A<1A[6<[;M<CE
MV(/;T$K])+W)SS_1F/QR@F0XD Q/H4]F</F*32616J"94?DC4NL7%9?FZS'"
M)R&/$T9?G&QE@2Z>I(9;B.Y<'3B^9ZGSLI5HJLL<W!O3&M$49;-$HK6T[G*C
MYE(CZDZ&(AIA#C_*"'J'J!_%$?I=B\9BQSCF,2:$@#^ET8!=H#,68Y9Q]!Z=
M49\G,1APV1:R-!O@"$Y,.<-AE-@(YA-GO.4"&C&RMFQZH3!XX"1CF">V:$S3
M@4R(:91BSCGX>4KWR= XQFE&;"WBLX2]84,P2Q(<1U%'. Y_D [4"G%$8ENZ
MVYTP1B=D$@TRB?Z73(#%/JFF0++KTE[K8](Y6>9[TGEK[,3T^GTOFJ4C>[MQ
MVW,O[=RP'#^6"_E:<WW0*^_ALCW8_IL&_2V%/G1>O[1^8+_ST_0#]5F$&*8Q
MQ6D"EI^!DGU*(M!U%L8XZ0^,D@2>S";$"<K 'V*6<L1]I^HPX8"2@>B8 PA!
MY=1/L@_<AC,<9<3I'\)M$9K&@,\H!QQBUQ'=5X@#W<D$+DY*<-I[PBP]*IQ@
M;P344B_=H&M1KC:-Z:;!X!UFZ44W0E["NT'\2>AE"1*JY )2B9^ .'0WW+J%
M46LW4.;*P'ARY@K^#TAM ^#[0BFS6]@"PS^,R;]02P,$%     @ :("35ZAH
M*=M% P  F@<  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULG55M3]LP
M$/XKI^Q%( 7RTM ":RL!8QH?>!%E;%]-<FTB'#NSG1;^_<YV"$7KNFD?G/CL
MN\?/G>_.XY54C[I$-/!4<Z$G06E,<QQ%.B^Q9GI?-BAH9RY5S0R):A'I1B$K
MG%'-HS2.AU'-*A%,QV[M1DW'LC6\$GBC0+=US=3S*7*YF@1)\+)P6RU*8Q>B
MZ;AA"YRA^=;<*)*B'J6H:A2ZD@(4SB?!27)\>F#UG<)]A2N]-@?KR8.4CU:X
M*"9!; DAQ]Q8!$:_)9XAYQ:(:/SL,(/^2&NX/G]!_^)\)U\>F,8SR;]7A2DG
MP6$ !<Y9R\VM7'W%SA]',)=<NR^LO&XV""!OM9%U9TP,ZDKX/WOJXK!F<!C_
MP2#M#%+'VQ_D6'YFADW'2JY 66U"LQ/GJK,F<I6PES(SBG8KLC/3BZNSZ\MS
MN#OY<3Z#G3OVP%'OCB-#T%8ARCN84P^3_@$F2>%2"E-J.!<%%F\!(N+4$TM?
MB)VF6Q%GV.S#( XAC=/!%KQ![^C X0W^P=%-_GGK;+.U+8UCW; <)P'EOD:U
MQ&#Z\5TRC#]MX9;UW+)MZ-,9E5K1<@0YA_4Y91<JA048]K2)\W;4*RII*E[%
M3"46P*76D#.EGJF25TP5\!Z2.,Q&PS".8Q*.PL$H=?.9D?FCR_4"<EE3_6OF
M2B@-DU'F5))P.!JYV2U%@ZF\!"8*^(Q+*O.&BM:02C:,G<H>7 C#Q**RR452
MFB9N_23/5<NX=J9=5#5DGM"1A[^3AO$W@0"F-7F69&%RX%63)!P,O?H]XZWG
MRCCU&R9RA)TUU5V27K5WP<;H=W!-X=ASXZPDW@B5@.4&Y*)5-K2F1'BF()#%
M3AJ.#H\Z<!(I3L/NY"UY<M#GR<%_Y<GY?(ZNNSD7Z,)Q4[9LQ=Z<X:[X[">E
M*Z14\ <T2BXKUY69 6V8:8U4S^Y<2!/XX#]7M$^MH"5B=.^ 3S:/Z'[M'K6+
M#W^);7)(*B,:UQ1>Y5*D4954/M)&M0AM Q;'CM\C #$MT]@4]FBM7]:H%NY5
MH.J0K3"^=?:K_<-SXOOMJ[I_M2Z96E1" \<YF<;[(XJR\B^!%XQL7/=]D(9Z
MN9N6]'BBL@JT/Y?2O CV@/XYGOX"4$L#!!0    ( &B DU<X/?<PX (  . &
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;+5586_3,!#]*Z> T":5
M)76RKFQMI74;,(E!U0X0']WDFE@X=K#=%?X]9Z<-192*+ZAJ?#[?O7LOMB^C
MC39?;87HX'LME1U'E7/-91S;O,*:VS/=H**5E38U=S0U96P;@[P(2;6,69(,
MXIH+%4U&P3<SDY%>.RD4S@S8=5US\V.*4F_&43_:.>:BK)QWQ)-1PTM<H/O8
MS S-X@ZE$#4J*[0"@ZMQ=-V_G&8^/@1\$KBQ>S9X)4NMO_K)?3&.$D\()>;.
M(W :GO &I?1 1./;%C/J2OK$?7N'_CIH)RU+;O%&R\^B<-4X&D90X(JOI9OK
MS5O<ZCGW>+F6-CQAT\:F203YVCI=;Y.)02U4._+OV_>PES#\6P+;)K# NRT4
M6-YRQR<CHS=@?#2A>2-(#=E$3BB_*0MG:%50GILL[MX\W+U_A/G=[,/\\?[]
M&SAYY$N)]G04.\+W47&^Q9JV6.PO6'T&#UJYRL*=*K#X'2 F8AT[MF,W94<1
M%]B<09KT@"4L/8*7=FK3@)?^J]I#(EN([#"$OR27MN$YCB.Z!1;-$T:3%\_Z
M@^3J",&L(Y@=0Y\LZ-(5:XF@5[# DDZ_HZ/?:..$*@^1/0IWF&P'_*%!PSUP
MY]F-<WQ"M4:8&;T2#D[>:6M/X=I:=!:^(#?M#E-\X[!>HNDV"6XI5>HFP) (
M5R%,A7XY?WU_^^+9,!NR*QH8ZU\!5P4$.[FZJ8RN^1\1#O-*::E+@1:>PTOZ
MG_2S'GLUA%.RASTV&,",T\O))?;@7N5GOW)^4+S_W8I2."Z!>_9@.9UM\K*+
MC)Z/VJ_85O5^B81E>R6.*6;_7W':HY! A\QTD!R5?,)\Z&'96<A^E2:0TBO\
M0WR[["NRWOE%MJMX<3Z$0T<[WNLZ-9HR]%8+N5XKUS:@SMNU[^NV:_T*;WO_
M S>E4!8DKB@U.;LXC\"T_;2=.-V$'K;4CCIB,"OZ!*'Q ;2^TMKM)KY ]U&;
M_ 102P,$%     @ :("35WBYZ'C- @  7@L  !D   !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&ULK99=;YLP&(7_BL6F:9.V8#[RH8X@947;>K$V:O<A[<XE
M;X)5@YGM)-U^_6Q#$=DH(UURD6!XS\'GL2%OM.?B3F8 "MWGK)!S)U.J/'-=
MF6:0$SGB)13ZRIJ+G"@]%!M7E@+(RHIRYOH83]R<T,*)(WMN*>*(;Q6C!2P%
MDML\)^+G.V!\/W<\Y^'$-=UDRIQPXZ@D&[@!]:5<"CUR&Y<5S:&0E!=(P'KN
M++RS9&;J;<%7"GO9.D8FR2WG=V9PL9H[V$P(&*3*.!#]LX-S8,P8Z6G\J#V=
MYI9&V#Y^<']OL^LLMT3".6??Z$IE<V?FH!6LR9:I:[[_"'6>L?%+.9/V&^VK
MVG#BH'0K%<]KL9Y!3HOJE]S7'%H"+WQ$X-<"?Z@@J 7!4$%8"T)+IHIB.21$
MD3@2?(^$J=9NYL#"M&H=GQ9FV6^4T%>IUJGXZOK#XO+B^^+SQ=4E>IF (I1)
M=$F$(&9!7J$WZ#ERD<R( !FY2M_2"-VTMG]7V?N/V-] .4(!?HU\[ <=\O/A
M<K]#GO3+KU(U0M[8RKU#N:LY-;#\!I9O_8(!L+I85.JP6VT>X#-9DA3FCGY"
M)8@=./&+9]X$O^TB<TJSY$1F!]2"AEK0YQXOMBKC@OZ"5;V-$%^CE)14$8;T
M!D_ONEA6GF/K:=Y=N]C'8VP_D;MK@^J]^[&@3F1V "IL0(5/!Y7R/-?OR4=Y
MA1V\<">OWDD<R^M$9@>\Q@VO\7]N+%02@7:$;:$+6>4^;2'#(XR]/W -JDK^
M5740<-($G/0&7.K_0!#"Y+-IZI2DR=V5:O+71NA^; ;6);U3?.(*3QL T^,!
M]"_J=-"B#JI*>B?WQ.BS)OILZ.9N/_J(%JEN[V3WVO=:'OL'=$JS9#;@]51Q
M<EO-C.D\/Q&QH85$#-9:BT=3;2*J;JX:*%[:_N:6*]TMV<-,-\ @3(&^ON9<
M/0Q,R]2TU/%O4$L#!!0    ( &B DU?,!,1Z$ (  'T$   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;(5486_:,!#]*Y8W39TTX>#0M.J22 ,T#6FK
M6!F;]M$D!['JV*EM2/?O9SLA0AUE0DKN['OOWIGGI*W2CZ8"L.BY%M)DN+*V
MN2/$%!74S(Q4 ]+M;)6NF76IWA'3:&!E -6"T"A*2,VXQ'D:UI8Z3]7>"BYA
MJ9'9US73?Z8@5)OA,3XN//!=9?T"R=.&[6 %=MTLM<O(P%+R&J3A2B(-VPQ_
M&M]-)[X^%/SDT)J3&/E)-DH]^F119CCR@D! 83T#<Z\#S$ (3^1D//6<>&CI
M@:?QD?USF-W-LF$&9DK\XJ6M,GR+40E;MA?V0;5?H)_GVO,52ICP1&U7&T<8
M%7MC5=V#G8*:R^[-GOMS. %0^@J ]@ :='>-@LHYLRQ/M6J1]M6.S0=AU(!V
MXKCT?\K*:K?+'<[F7Q??UXOYXL=O=#4'R[@PZ)YIS?Q9O4^)=2U\(2EZNFE'
M1U^A6T$S0G'T =&(QFB]FJ.KMR]HB%,XR*2#3!IXX__)/">I@T[.0[VK[TS#
M"LBPLZT!?0"<OWLS3J*/%X3%@[#X$GL^8Z9"3):H\ $\[?F!"9#6G!/:426!
MRM^60W[KCNEFG*3D<$;#9- PN:CAWMU=[WTN=TY&PRT3Y[I/_NF>4/=+Z(ON
MY,1-_F)^8WK'I4$"M@X9C6ZN,=*=V;O$JB88;*.LLVL(*_=] .T+W/Y6*7M,
MO&>'+T[^%U!+ P04    " !H@)-7[Z8LFJ$%  "E&0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6RU6=MNXS80_17"+8I=H(U%RKHX=0PX]F9K8.,$
M<=)]*/J@2+0M1!)5DG*2O^_H$LFZF(D-)P^Q+ISA.1QRYI :/3/^)#:42O02
M!I&XZ&VDC,_[?>%N:.B(,Q;3"-ZL& \=";=\W1<QIXZ7&85!GVB:V0\=/^J-
M1]FS6SX>L40&?D1O.1))&#K\]9(&[/FBAWMO#^[\]4:F#_KC4>RLZ9+*A_B6
MPUV_].+Y(8V$SR+$Z>JB-\'G4V*G!EF+OWWZ+':N44KED;&G]&;N7?2T%!$-
MJ"M3%P[\;.F4!D'J"7#\5SCME7VFAKO7;]ZO,O) YM$1=,J"G[XG-Q<]NX<\
MNG*20-ZQY[]H0<A(_;DL$-E_]%RTU7K(381D86$,"$(_RG^=EV(@=@RPN<>
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MUTD=*%Y4'?F>*]W?JV&B;V 0)D&O+SA7+X%I\LV='OX%4$L#!!0    ( &B
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MF/\-$%JUK62RDSPD1Q'G6)U#-SH#$I$N/,['</+V] ANMRU%U^/V7L$=45T
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MZ9KCH]I^A$,]8\>7*V[\DVR;W&04D'QM4(D#V#H03#9ONCM\AQ- /#D#2 Z
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ME?]K1Q8MQ*%:@FH2U12EZ9%M6G&VN?/4N[N\K^I"]9%N;WK15ARJ>:CFHYI
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M/FR+8OMT^.UCECYD>?6"\N\_;K?%\0_5 %^V^:^'C_/V_P%02P,$%     @
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MM>."IE6R9)#&6?D;OE8/HI6 O8$$4B60;H(SD&!7"78AM&16R'H3BG V8?2
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M1K[<AJRLE<N.H'E1;CY3(8O7HKF%, *F N3]-:7BV%$#U/]8S/X!4$L#!!0
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M"]3Y>9[+S4[90;LT-OX/4$L#!!0    ( &B DU?0CG6FW 8  ,HU   9
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+6;77/B-A2&_XJ&=CJ[,RW8,AA(
M$V82T$[3=K/,LA\7G5XX1@1/;(N5!=ET^N,K?\1&QIS%[.E>;+#Q>8[\RASI
MM:W+)R$?DS7GBGR-PCBYZJR5VEST>HF_YI&7=,6&Q_J;E9"1I_2F?.@E&\F]
M9184A3UJ66XO\H*X,[G,]LWEY%)L51C$?"Y)LHTB3S[?\% \777LSLN.]\'#
M6J4[>I/+C?? %UQ]W,REWNJ5E&40\3@)1$PD7UUUKNT+Y@S2@.R(3P%_2O8^
MD_14[H5X3#=NEU<=*VT1#[FO4H2G_^SXE(=A2M+M^%) .V7.-'#_\PO]37;R
M^F3NO81/1?@Y6*KU56?4(4N^\K:A>B^>?N/%"64-]$689/^3I_Q85Q_L;Q,E
MHB)8MR *XORO][408B_ =H\$T"* U@/Z1P*<(L Y-:!?!/1/#1@4 =FI]_)S
MSX2;><J;7$KQ1&1ZM*:E'S+ULVBM5Q"G%\I"2?UMH./49/'AW?0/<GLW97<?
M;C\Q,O_S^FY!7LVX\H(P(7>>E%[:E:_)+^3C8D9>_?CZLJ=TXC2\YQ=);O(D
M]$@2FY*W(E;KA+!XR9<FH*=;7#:;OC3[AH+$!=]TB6/]3*A%G88&34\/IPWA
M,SC\=R_N$LL^&L[@\'>^ZA)[D(7;@!A.V8=.QNL?X=W&2@;ZI^N3G1=N>5/_
MY  W Z2U8S>Q+GN[?<' %&FYND@VGL^O.KH>)5SN>&?RTP^V:_W:)!\FC"'!
M#&G[I;1]4-J%$OXC$9NLJ#U(+U9)D[PY9+ GK]T?6ZX]&-54!K.U51D3QI!@
MALJ#4N4!J/+GK)SS);G><:F')\*^<ND'"2=S&?C5YK))^QP]W+^TNW10TQW,
MWU9W3!A#@AFZNZ7N+JC[B]S\1>Y-*G>3R.Z!R';7=IV:RF"VMBICPA@2S%!Y
M6*H\!%6^VT;W7!*Q(KZ((EU'DJRH>%NU%C+X1U_VR=K3:9MT'QX4%FJ-1JYC
MUZ4'F]!6>DP80X(9TH]*Z4>@]!]C[LDX5?BT.CXZD+NO:[CCU-4&L[95&Q/&
MD&"&VN-2[3&H]K2XO+.K64]>I>2QRFL*V>A?0/9%D^SCANKBC.R:Z&#RMJ)C
MPA@2S!#=MJH9O-5VCI)+7=;UQG&SH!J3%M<=C>L30SA[6]U1:0R+9BJ_YYUL
M4/ERFG)B>8%Q+4]^6M#V)_74'8V&9O_-4),R+)JI.*T4I_!,,?6CNJ@$2;+5
M95T)8TQMU!P$MM:<'@[(+AT[=<TQDS(LFJEYY2YMV%X>K2\)60FYXH':'IF]
M%&!#K?&0#NO#*=R UB4&U7UBT4SQ*_]IPP;TO8B]<$GFA.EA]#'1/?#76Y[.
M)_]N%!S3$DY1:3-4&L.BF=U2&58;=JQG3W5@;NL>RFFC_1]8UQK7JQ&J8<6B
MF<I7EM6&/>L9(P"FDYP6-&/:9&7_ZJJC&E@LFJEZ96%MV,/.UT$8!AMRW24W
M(MEZ<!7"](]35-H,E<:P:&:O5.[6ANWM^54(TW-."]JWJA"JS\6BF<I73M>&
MK>X950C3<4X+FE&%G,8JA&ITL6CF,Y_*Z5+8Z<ZYTE?U5,0A?P8K$,QI*S8J
M;89*8U@TLT<J!TQA!WQV!8*YK7O(/JA =K=?>_@R0\W)L&BF\I43IMA.& :V
MEOS0"3?/@U#3,BR:J7KEA2GLA=,GMH1]V0;JF=S&OK[8@QTG\]"#?1E,;2T]
MJEU&I3$LFMD_E5VFL%W^GF<M,+IU)Z&:9U0:HX?/JZE5^_&:'5 98PH;XR,=
M4 P00>Q+[B7-(P*J,T:ES0J:(1AMJG8,*Z\I?^6.*>R.\WMU[_)[=6!%0C7%
MJ+09*HUAT<P>J9PSA9WS=[W;4+!K+S<,:>W^:<-A=M<9NO61&-7[8M%,72OO
M2V'O^RU=W\"WI@NZ*9G;']:5/3Q,6]M!_1D+W-;6ROX?WI96WI;"WO;\^_VT
MP95:=#AT!_7W<9J.M!W:/U06U;]BT<S7]"K_ZISRI+96G<F_A*67,F'1)A3/
M7,M\'2]3EYML0Y6I#Q5R.&7;0HY*FZ'2&!;-[+S*ZCJPU3W]92D8U+I+[)-*
M$&I2AD4SM:[,K0.;V[;O[<"XUHHW6-O&XH2:EF'13,WW7B(^Y3'O87&ZT\<I
MSN-SZQ.J]46ES5!I#(MF]E]E?1W8^K:H3ZA&MZ"9,ZDAK4\^49,R+)JI=>5R
M'=CEMJY/J-[6.72CCN.XA[?>4-,R+%JN>6]OS4K$Y4.V6"@AOMC&*E\'4NXM
M%R1=9\MP:OMO[(MIOJRHPN2KG-YZ\B&($Q+RE49:W:$^ 9DO',HWE-AD*V/N
MA5(BRCZNN;?D,CU ?[\20KULI G*Y5N3_P!02P,$%     @ :("35VC3#M.Y
M"0  >&L  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULM9U=;Z-(&H7_
M2LD[&LU(NS$4^*LGB>0.!56K32:*,]L7J[T@IA*CML$+.$G_^P5,C OC"HS.
M]$7'8-[G+>SC^CI07+[%R?=T)65&WC?K*+T:K+)L^V4X3)<KN?'3BW@KH_R=
MYSC9^%F^F;P,TVTB_: ,VJR'U##&PXT?1H/KRW+??7)]&>^R=1C)^X2DN\W&
M3WY\E>OX[6I@#CYV/(0OJZS8,;R^W/HO<B&S/[;W2;XU/%""<".C-(PCDLCG
MJ\'<_")LHP@HC_AW*-_2H]>D.)6G./Y>;(C@:F 4)9)KN<P*A)__>94W<KTN
M2'DY_E=!!X><1>#QZP^Z6YY\?C)/?BIOXO6W,,A65X/I@ 3RV=^MLX?XC<OJ
MA$8%;QFOT_)_\E8=:PS(<I=F\:8*SDNP":/]7_^]^B". DS[3 "M F@C8#([
M$V!5 5;7#'858#<#QF<"1E7 J&N&<14P[AHPJ0(F70.F5<"T:\"L"IB5<MA_
M?^67[_B9?WV9Q&\D*8[.:<6+4D%E=/Z=AU$A]D66Y.^&>5QV_?LC9P]D(;P[
MX8J;^=TC>7R8WRWF-X_B][L%^28>.7E@_YH_,H?<SQ\>!5N07QR9^>$Z)7=^
MDOB%6'\E_R!_+!SRRT^_7@ZSO%@%?+BLBL#V1:!GBF!2<AM'V2HE+ IDH *&
M^?D<3HI^G-17JB4Z<GE!3/OOA!J4MA3HIDOXJ PW6L(=??A=_'I!C#*[.6O[
M./3A"[F]()919K=:PMWNX6WG[NG#_[F+M-EYAW Z.1LN/@GW\W!CU%9X10C6
M0=U6R;//\-A[WBBD34WM):2-+-J8+^G67\JK0=Z(I#)YE8/KG_]FCHW?V@2%
MA#E(&-O#QB6L:/E>KZEE&,;H<OAZ+"ID3@\)XTB8 ,$4,=H',=I:,3[$D;\.
MR#UA2;C\GN8M_7]NY>9))O]MDZ>6U5>>2)B#A#$DS$7"/"2,(V$"!%-$/#J(
M>*05\5U,XF>2KOQ$DI?$CS(9D+S+3?*.RO([B;=%#[9-SGOJZ*@:,HWRGUH/
MW6BS]U5J2U+:DI0AD[I(F(>$<21,@&"*",<'$8[_=+.NC>Q;;XY/&\^Q-9I9
MJGX<9$Z&A+FG)Y#_ B:T^0OPD$DY$B9 ,$5GDX/.)EJ=+<IJ3K[+9!FFDFSS
M=ENV:6Y/F1Y_RA>VV:C9V@X:-974=E #Q+1E[BL0),Q#PC@2)D P1473@XJF
M6A7=Q)M-WMG;MY!ERYFVB4@+Z5MQ34];ONEX-)XTNOT.,BE#PEPDS$/".!(F
M0#!%F+.#,&>?"7/K1S_(\EB@@4R727BV'Z<E]E6IOGCR?2EED);=2VKDI<R;
M_.6NF&XB6>('8?1" O]'FI?;3[)BR\_(3WFODFS"];J82,WB?)L\[;?:^H?(
MDV%(F(N$>4@81\($"*:HWS3JJ4]#K__=9K<NYR_S-K[L4;96S'I*7\U#:0Z4
MQJ TMZ(U&J'Q:-+H>T*S<BA-H&BJ0H\FYTVM0N=!$!8UL;]6!MC[D7>K5K6\
MWEHU.W8CH&D9E.9":1Z4QJ$T@:*I8J6U6&E7L7X^9-*S>@N5=AE<07,R*,V%
MTCPHC4-I D5355H[0J;>$A)1)G-N1K9^V#J!I(_OK4RH,P2EL8JF5.\3:SIJ
M>D/0K!Z4QJ$T@:*IVJP-(E/O$#GR62:)#(H16=$?]<^-PO2<WAJ%VD-0&H/2
MW(JF*'X\.C$$/&A6#J4)%$W5:.W_F'H#:+Y<)KLCB:9EA_1G?[/]K1B6O\HU
M\:. A%4UVZI>I!%Q Z4Y4!HS3QTH:DXMRV[6L"W'S4:V.6WJ$NH'06D"15-U
M65M"IMX3NE\5\SQ;,K\@7^-TYVO-=3VKMP*1- =*8U":"Z5Y4!J'T@2*IJJY
M-IY,O?.D<SCUH;W%.SFQ""W#I/:L.7A"9F50FEO1CJM/:V)-3EIUJ#\%I0D4
M3=5;;5&9>H^JJ].IQ_36WK33L!UJ4D%I+I3F06D<2A,HFBK0VJHR/_6JNIBH
M>DIO?<Y:NF\6-6<G\Y]0)PE*<Z$T#TKC4)I T=1KSFL[B7YB)_T).U6/[*O7
M3PKXUQNJT--A4)H+I7E0&H?2!(JF_@YJTXKJ3:N.MJJ>TEOZ2)H#I3$HS:UH
MZA7]1:O4Z.U"LW(H3:!HJD)KIXIV=JJZV:IZ7F^MTH[="FA:!J6Y4)H'I7$H
M3:!HJEAKPXKJ#:M>MJJ>U5NH5I?Q&30G@])<*,V#TCB4)E T5:6U=47UUM5"
MOLJ\]CRC2JA=!:4Y4!JCIP:3W7+'B0O-ZD%I'$H3*)JJR]JNHGJ[ZD%&66E(
MQ=E*)OF8)\W:>Z-03PI*<Z T1D^]IMG8MD\4"KV/"4KC4)I T52%UL85U1M7
M<T%NPUR@.K]*C^BM3JA?!:4Q*,V%TCPHC4-I D5315S[553O5]U\<L&*/KRW
M@)$T!TIC]-2+,HW99$:GS0H6>NL5E,:A-(&BJ=JLO2VJ][8Z=P&@WA:4YD!I
MC)[>'C8S1Z>=5*BY!:5Q*$V@:*I":W.+ZLVMQU4B)7'"1"ZS.-'W!* &%Y3F
M0&D,2G.A- ]*XU":0-'4!7=J%\S2FTQ=KR308_H*&4ISH#0&I;E0F@>E<2A-
M5#1U]K&^>4S59^U.67IW:J_/,$UW9Y:%@MI24)H#I3$HS872/"B-0VG".KTK
MSE*F^%1EUJZ4I7>EOA6KZ4596MCLVUVR7/EY_7E\,4&K7*'.%)3F0&D,2G.A
M- ]*XU":L%K<1HU<CY;6T_M2]T7+3K;YB*J\'*M5G-@U]K"+[&%7V8.Z5E":
M!Z5Q*$U8;0[CN3:^-J,LO1EUFUR0?'OW*K5C*3VEMSRAMA24QJ T%TKSH#0.
MI0D43=5Q;5Y9>O-J(9-0IL3)1U$?=P965Q6&KV$@HZ!U'DL/[2UKJ)4%I3$H
MS872/"B-5S1E(;<QG5"K,6<G4&E5Q=9FEO7)75@-H>ZOU-8-MZ#.%I3F0&D,
M2G.A- ]*XQ5-L4!L@TZF=E.L?X5I9=6FE:4WK0Y+ 527J;;J$VI<06D.E,:L
MTQO!S)E=+F&NKA0-]:V@- ZE"11-E6?M6UEZWZJ3'Z!G]-8GU+2"TAB4YD)I
M'I3&H32!HJDJKKTM2^]M=?8#H,86E.9 :0Q*<Z$TKZ*IXW'::+<Y-*= T=1%
M^6O#RM8;5L7E 6V"U(?U%224YD!I#$ISH32OHAWW2D:GU]-R:%*!HNT5.3QZ
M.L]&)B_EHYU2LHQW4;9_ILUA[^'Q4?/RH4F-_<S\XNX? E5C]L^DNO63ES!*
MR5H^YTCC8I+WO9/]8Y[V&UF\+9\!]!1G6;PI7ZZD'\BD."!__SF.LX^-(L'A
M85O7_P=02P,$%     @ :("35TG+*3:H"0  )%$  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3 N>&ULK9QK<^(X%H;_BHKIG>JI2@?;7-.=I"KA?K%)=3*[
MM;6U'Q2C@"N^,+9)FOGU>R2;B\$8J'V_)-CH?8ZD<W20A/#M9Q"^1W,A8O;+
M<_WHKC2/X\7W<CFRY\+CT76P$#Z]\Q:$'H_I,IR5HT4H^%2)/+=L:%J]['''
M+]W?JGM/X?UML(Q=QQ=/(8N6GL?#U:-P@\^[DEY:W_CIS.:QO%&^OUWPF7@6
M\9^+IY"NRAO*U/&$'SF!ST+Q=E=ZT+]/](84J!+_=,1GM/.:R::\!L&[O!A,
M[TJ:K)%PA1U+!*=_'Z(E7%>2J!Y_I=#2QJ84[KY>T[NJ\=285QZ)5N#^RYG&
M\[M2L\2FXHTOW?AG\-D7:8-JDF<';J3^LL^D;(,*V\LH#KQ43#7P'#_YSW^E
M';$CT"M'!$8J,/8%U2."2BJHG"NHIH+JN8):*JCM"VI'!/544#_70B,5-,X5
M-%-!\US!32JX.5>@:VO/:7N2IG9,LG'V@;?KQR1K=^MG^UM?.US?]_CQBJU=
MKA_X_&C%UDY/ KZ<1+P:+FT>\_O;,/ADH2Q///E"C3FEIU'B^#(]/,<AO>N0
M+KYO34QS\&)VK)=GUII8+P.KU[%:@\XS>[#:;-SI/8S9T\])J]-ITUO/[&M;
MQ-QQ(^;S,.1R:/_!OK$_G]OLZY<_;LLQ54F"RW9JOIN8-XZ8UYD9^/$\8AU_
M*J8Y^O$)_4F =0)@G ),3@":!8 R>6/C$F/MDD>CD&CR%=,K5\S0#".G/JUB
M=5O8UTRO*;F6(V\7RQ\6(<DU*=>;.?+..7)5>;V1%PYGR(VZJGPE1]XKEEO!
M!\F-HUW7+Y8_BP7)FT?E@W/DQZT/B^43.Z:NTY5<SY&/SHB:YE'U^)0ZW$1-
M7MW-,^25XW6WSNBYBG;4[9/SY4;! *QL<F)%\:I'>&-!\XWHBODT._/DV'97
M;,%7-"F*<RKW6 B3T[OOT8+;XJY$\[=(A!^B=/_[;WI=^Y$WN)&P-A+626!U
M!9.3SH_[2J52O2U_[ [OPT+&C=;,%NKE%#)J6K90'UGWP:'%AJ;M61P>%JH=
M%!H=%FK6;QK90F-DW4TDS,KS3[.>K?X$9#$S]JJ;L5<]/?9H?A_9H;.0"XB\
M$5>(N'3$(6%M)*R#A'61L!X2UD?"!DC8$ D;%<>]X]NA^MAAKRM6^0?COK_D
MKKNZ9B]SP5PU*L2OA4.&&*VJATM?K#_RJKME;.ZS5UDT%G(ZRMZ"D,H+QJ=3
M1PXG[K)X'@KQ;25XR&(1>GF3!63#323,*N[%Q3*,EMR/61RPS[ECSYE)$Y/'
M@&XR)V+T >[$+O5**&Q!2Q?&V9>JIEU1FF>1^! A]VVQ_J@G%TRI*WWQYL01
MVR7/";4('>I9X2W<("T]HUZ5KZ[9TT[9F#Q#\Q,NUTKDMX=UJ:MMS7[_K6GH
MC1_DUV4<Q635\6>,EG[V.PM4"HR8+7T[91\BBN6;G,J^L2&G$ E7S$C6"O17
MUIB"1I6CXEE&*.1N$46&"&TGXJ^ND)$0+&?S?1(%U+;;YF3L50@2^C,^(RI=
M<V83<>G&.XUL!=Z"^RL5<)PM!/7/5-92!I^*-4Y]Q*@;A+S[14]ZG<HE4ZQ=
MD]R- NDK$9(YQR<#G+FR*<N%:B)%^KOLK&V?T[(YGE,+HX6P58TJ1*\I"W;@
MD0$6S;D:.I\^,6F([5@C8OJN$]$-V3'+1;#I*55?Z?*T5Y/^9/R3A]/HFK67
MH72)[(*TT=*B\&UYE^;%%(-Z(W'0IK\SMZL[H4!+^Q5%(KG0#ZA?0NDB&M#Z
M56T=I:JB)ZS2*LIQ63(;KVZ=O),RZJ=M5AJU'8O*47]1D)!3V%=R\7Z55 'I
MYS^NV-)W112IRB4A2/6Q53?N!,HFZM<.4B7%+UN(:<2^U*[3Z%!XF?*DUOKW
M<X<]>-1BF>>^REN28V@_GI7\21EZH007S0-WJM[3?U"5J*2?UV3Y\I?C+3U9
MNT8MTZ)ITL<RJ*,E^6O=?.J>.!G7>39EGO$$90$KB&54;D:T5-#@$+. KJX4
M5@;U-PIJZD\9T]]D3!,F)F(R9F73/SEEJB21JZIP5ZCAG];R+0R\G991[+\$
MTRE[Y-'?2_O=N<Y;3H$R<F:"5]M,\&J%*?JG'*X+[N1MM3P62B^=V"%A;22L
M@X1UD; >$M:O'2PV;O3:_HIJ@#0Y1,)&2-@8"3.1,.O034;S8.$[ 9G,Y(SZ
M)F?4"W/&-KW]QQ3>JPC_FY<\"AF7)@\DK(V$=9"P+A+60\+Z2-@ "1LB82,D
M;(R$F4B8A81-0+!,*FIL4E&C,!4]J'6YG(71@BDO"Q7*+\U"2%@;">L@85TD
MK(>$]9&P 1(V1,)&2-@8"3,;AY.3NG8P.[&0-B>'-BNUC,U,YFAN,D>S,',\
MRNVYXWFC4'QIWD#"VLW<KVOV7=!!VNPB83TDK(^$#9"P(1(V0L+&2)B)A%E(
MV 0$RV27FTUVN2G,+JW=7;1D:R@ORQ1"+LTR2%@[@=7VOGT]R#)(FUTDK(>$
M]9&P 1(V1,)&2-@8"3.1, L)FX!@F2RC:YLT(\]7GIMG-OOSN;FFF'1ILH'2
MVBFMN9-NM.M*92_90&UVH;0>E-:'T@90VA!*&T%I8RC-A-(L*&V"HF7SSLXQ
M9;WX:R-Y=&'*GE@G=.SWB%)0T59P,>SBU(.DM:&T#I36A=)Z4%H?2AM :4,H
M;02EC:$T$TJSH+0)BI9-4<8V11G_W]9PL?[BK(2DM:&T#I36A=)Z4%H?2AM
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M)RP'9^T/!@1G(ZQ.TVG:DULK_,_2-$RM\PAT2E.'=-+D/2%^(\23A.M2?SB
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M;DKU1/'2UO455[I+V&&N^S@(8Z#?9YRKP\1LT/PSB/\ 4$L#!!0    ( &B
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MV9#DAY'L&8&I 'E]3:EX'*@;5%WH^#]02P,$%     @ :("35Z?'2--, @
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M3.EQ;KG6ZX5/R3X6ZH*]F!5DCQL4C\4#DRV[<8F2#'.>T!P8[N;6K7NS<K5
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M3TD<IZD? <SO((XQ!)Y&',$<@ <,B6/['MQY'T6K]U2T_@_F\#=02P,$%
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MW.&\R1K6*YG3(P,?<+Q12P*690<2AW.9[F0H82%[.,CV@#'UM3<'LH>#W:A
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M4$L! A0#%     @ :("35V5!_4=F P  '0\  !@              ("!/Q8
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &B DU>P25)#
M@@4  %84   8              " @=L9  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !H@)-79'TE';H(  "2.0  &
M@(&3'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :("3
M5PC2JOIB"   TR0  !@              ("!@R@  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( &B DU=Y <'Y^P0  /X*   8
M      " @1LQ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !H@)-7GOLNV=(&   R$   &               @(%,-@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ :("35US1<<S9"@  =1X  !@
M             ("!5#T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( &B DU>4A P@] 0  ! +   9              " @6-(  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ :("35SZ!%[X4 P
M)@<  !D              ("!CDT  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !H@)-7U:S_FW$$  !U"@  &0              @('9
M4   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &B DU=L
M=/>E@P8  )<3   9              " @8%5  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ :("35S>%R$9'%0  6TD  !D
M     ("!.UP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &B DU>S(7@3M ,  & )   9              "
M@5J5  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :("3
M5]ONDIF/!0  XPP  !D              ("!19D  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !H@)-7,B  8^D+   Z)P  &0
M        @($+GP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( &B DU<PA$FNO (  -4%   9              " @2NK  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ :("35QT.*]U. @  ' 4
M !D              ("!'JX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !H@)-7YMTB#:$"  #W!0  &0              @(&CL
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( &B DU>185.4
M/ 0    ,   9              " @7NS  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ :("35[0)3[&' P  ;0@  !D
M ("![K<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !H
M@)-7J&@IVT4#  ":!P  &0              @(&LNP  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &B DU<X/?<PX (  . &   9
M          " @2B_  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ :("35WBYZ'C- @  7@L  !D              ("!/\(  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !H@)-7S 3$>A "  !]
M!   &0              @(%#Q0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( &B DU?OIBR:H04  *49   9              " @8K'
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :("35S,"
M_T(# P  70D  !D              ("!8LT  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " !H@)-79L["\\4"  #?!P  &0
M    @(&<T   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M &B DU?85%M[Q0(  $0'   9              " @9C3  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ :("35QO@"[\@ @  Z@0  !D
M             ("!E-8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !H@)-7B1&E?:X"  "@!P  &0              @('KV   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &B DU?'5X4AA@(
M +P%   9              " @=#;  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ :("35W1U?GWC @  P D  !D              ("!
MC=X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !H@)-7
M5#=XGJH$  "-&   &0              @(&GX0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &B DU?)VU18/00  "$7   9
M      " @8CF  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ :("35S W[[,^!   (Q<  !D              ("!_.H  'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !H@)-7M\D9AC4#  "7"P
M&0              @(%Q[P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( &B DU? :+P>BP0  ,\9   9              " @=WR  !X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ :("35RA$.6QO
M @  A 8  !D              ("!G_<  'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " !H@)-7 P@58X(:  "3I@$ &0
M@(%%^@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &B
MDU=+"AQ+!00  +T0   9              " @?X4 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ :("35R06<8'W!   )AL  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( &B DU<]KYLJR@(  "4(   9
M  " @=\\ 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M:("35\EKD@K! @  *0@  !D              ("!X#\! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " !H@)-7>Q%O@J(#  "1#@  &0
M            @('80@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( &B DU>GQTC33 (  )0%   9              " @;%& 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ :("35Q911.F, P
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M2P$"% ,4    " !H@)-7##^0_.4!  !_(0  &@              @ 'M50$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !H@)-7C^&W
M:=,!   V(0  $P              @ $*6 $ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     0 !  '<1   .6@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - AI DEEP LEARNING PLATFORM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/AiDeepLearningPlatform</Role>
      <ShortName>AI DEEP LEARNING PLATFORM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://knwn.com/role/ConvertibleNotesPayableAndNotePayable</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EQUITY</Role>
      <ShortName>EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - STOCK INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/StockIncentivePlans</Role>
      <ShortName>STOCK INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties</Role>
      <ShortName>OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings</Role>
      <ShortName>COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/PropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/LEASES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/ConvertibleNotesPayableAndNotePayable</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityTables</Role>
      <ShortName>EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/EQUITY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/StockIncentivePlansTables</Role>
      <ShortName>STOCK INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/StockIncentivePlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://knwn.com/role/SegmentReporting</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>ORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/ORGANIZATION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/LIQUIDITY</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative</Role>
      <ShortName>AI DEEP LEARNING PLATFORM (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/AiDeepLearningPlatform</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/LeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/LeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative</Role>
      <ShortName>CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetails</Role>
      <ShortName>EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetails1</Role>
      <ShortName>EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetails2</Role>
      <ShortName>EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetails3</Role>
      <ShortName>EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetails4</Role>
      <ShortName>EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/EquityDetailsNarrative</Role>
      <ShortName>EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/EquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - STOCK INCENTIVE PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/StockIncentivePlansDetails</Role>
      <ShortName>STOCK INCENTIVE PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/StockIncentivePlansTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/StockIncentivePlansDetails1</Role>
      <ShortName>STOCK INCENTIVE PLANS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/StockIncentivePlansTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/StockIncentivePlansDetailsNarrative</Role>
      <ShortName>STOCK INCENTIVE PLANS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/StockIncentivePlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative</Role>
      <ShortName>OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative</Role>
      <ShortName>COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/IncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/IncomeTaxesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/SegmentReportingTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - SEGMENT REPORTING (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SegmentReportingDetailsNarrative</Role>
      <ShortName>SEGMENT REPORTING (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/SegmentReportingTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="knwn_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://knwn.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://knwn.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>knwn-20230930.xsd</File>
    <File>knwn-20230930_cal.xml</File>
    <File>knwn-20230930_def.xml</File>
    <File>knwn-20230930_lab.xml</File>
    <File>knwn-20230930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="knwn_10k.htm">knwn_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>knwn_10kimg32.jpg</File>
    <File>knwn_10kimg33.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="498">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "knwn_10k.htm": {
   "nsprefix": "knwn",
   "nsuri": "http://knwn.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "knwn-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "knwn-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "knwn-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "knwn-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "knwn-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "knwn_10k.htm"
     ]
    }
   },
   "keyStandard": 227,
   "keyCustom": 120,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 12,
   "memberCustom": 50,
   "hidden": {
    "total": 39,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://fasb.org/us-gaap/2023": 31,
    "http://knwn.com/20230930": 3
   },
   "contextCount": 194,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 487,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 498,
    "http://xbrl.sec.gov/dei/2023": 37,
    "http://fasb.org/srt/2023": 1
   },
   "report": {
    "R1": {
     "role": "http://knwn.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://knwn.com/role/ConsolidatedBalanceSheets",
     "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_knwn_ConvertiblePreferredStocksSeriesCMember",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://knwn.com/role/ConsolidatedStatementsOfOperations",
     "longName": "000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30_knwn_SeriesCConvertiblesPreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://knwn.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://knwn.com/role/ORGANIZATION",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://knwn.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards",
     "longName": "000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://knwn.com/role/AiDeepLearningPlatform",
     "longName": "000010 - Disclosure - AI DEEP LEARNING PLATFORM",
     "shortName": "AI DEEP LEARNING PLATFORM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:AiDeepLearningPlatformDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:AiDeepLearningPlatformDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://knwn.com/role/PropertyAndEquipment",
     "longName": "000011 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://knwn.com/role/LEASES",
     "longName": "000012 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:LeasesOfLesseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:LeasesOfLesseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://knwn.com/role/ConvertibleNotesPayableAndNotePayable",
     "longName": "000013 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE",
     "shortName": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:ConvertibleNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:ConvertibleNotesPayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://knwn.com/role/EQUITY",
     "longName": "000014 - Disclosure - EQUITY",
     "shortName": "EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://knwn.com/role/StockIncentivePlans",
     "longName": "000015 - Disclosure - STOCK INCENTIVE PLANS",
     "shortName": "STOCK INCENTIVE PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties",
     "longName": "000016 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES",
     "shortName": "OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings",
     "longName": "000017 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS",
     "shortName": "COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://knwn.com/role/IncomeTaxes",
     "longName": "000018 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://knwn.com/role/SegmentReporting",
     "longName": "000019 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://knwn.com/role/SubsequentEvents",
     "longName": "000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies",
     "longName": "000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://knwn.com/role/PropertyAndEquipmentTables",
     "longName": "000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://knwn.com/role/LeasesTables",
     "longName": "000023 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables",
     "longName": "000024 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)",
     "shortName": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://knwn.com/role/EquityTables",
     "longName": "000025 - Disclosure - EQUITY (Tables)",
     "shortName": "EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://knwn.com/role/StockIncentivePlansTables",
     "longName": "000026 - Disclosure - STOCK INCENTIVE PLANS (Tables)",
     "shortName": "STOCK INCENTIVE PLANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://knwn.com/role/IncomeTaxesTables",
     "longName": "000027 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://knwn.com/role/SegmentReportingTables",
     "longName": "000028 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://knwn.com/role/OrganizationDetailsNarrative",
     "longName": "000029 - Disclosure - ORGANIZATION (Details Narrative)",
     "shortName": "ORGANIZATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:AuthorizedSharesOfCapitalStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:AuthorizedSharesOfCapitalStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://knwn.com/role/LiquidityDetailsNarrative",
     "longName": "000030 - Disclosure - LIQUIDITY (Details Narrative)",
     "shortName": "LIQUIDITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
     "longName": "000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
     "longName": "000032 - Disclosure - AI DEEP LEARNING PLATFORM (Details Narrative)",
     "shortName": "AI DEEP LEARNING PLATFORM (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:SellingExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-01to2022-09-30_us-gaap_TechnologyEquipmentMember",
      "name": "knwn:Revenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "knwn:AiDeepLearningPlatformDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://knwn.com/role/PropertyAndEquipmentDetails",
     "longName": "000033 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:AssetsNetBookValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:AssetsNetBookValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://knwn.com/role/LeasesDetails",
     "longName": "000035 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://knwn.com/role/LeasesDetailsNarrative",
     "longName": "000036 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "knwn:LeasesOfLesseDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:LeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "knwn:LeasesOfLesseDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "longName": "000037 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails",
     "longName": "000038 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)",
     "shortName": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:ConvertibleNotesConversions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:ConvertibleNotesConversions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative",
     "longName": "000039 - Disclosure - CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)",
     "shortName": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EquipmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "knwn:ConvertibleNotesPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-01to2022-09-30",
      "name": "knwn:AmortizationOfDebtDiscountPremiums",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://knwn.com/role/EquityDetails",
     "longName": "000040 - Disclosure - EQUITY (Details)",
     "shortName": "EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_knwn_WarrantOneMember",
      "name": "knwn:NumberOfWarrantShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://knwn.com/role/EquityDetails1",
     "longName": "000041 - Disclosure - EQUITY (Details 1)",
     "shortName": "EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_knwn_WarrantOneMember",
      "name": "knwn:NumberOfWarrantShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "knwn:ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://knwn.com/role/EquityDetails2",
     "longName": "000042 - Disclosure - EQUITY (Details 2)",
     "shortName": "EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "knwn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://knwn.com/role/EquityDetails3",
     "longName": "000043 - Disclosure - EQUITY (Details 3)",
     "shortName": "EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:WeightedAveragesRemainingLifeYears",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://knwn.com/role/EquityDetails4",
     "longName": "000044 - Disclosure - EQUITY (Details 4)",
     "shortName": "EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "srt:FederalFundsSoldAverageYield",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "srt:FederalFundsSoldAverageYield",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://knwn.com/role/EquityDetailsNarrative",
     "longName": "000045 - Disclosure - EQUITY (Details Narrative)",
     "shortName": "EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://knwn.com/role/StockIncentivePlansDetails",
     "longName": "000046 - Disclosure - STOCK INCENTIVE PLANS (Details)",
     "shortName": "STOCK INCENTIVE PLANS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-09-30_knwn_StockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://knwn.com/role/StockIncentivePlansDetails1",
     "longName": "000047 - Disclosure - STOCK INCENTIVE PLANS (Details 1)",
     "shortName": "STOCK INCENTIVE PLANS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_knwn_EmployeeStockOptionsOneMember",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://knwn.com/role/StockIncentivePlansDetailsNarrative",
     "longName": "000048 - Disclosure - STOCK INCENTIVE PLANS (Details Narrative)",
     "shortName": "STOCK INCENTIVE PLANS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:IntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:IntrinsicValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
     "longName": "000049 - Disclosure - OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)",
     "shortName": "OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EquipmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "knwn:ConvertibleNotesPayableDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-12-01to2022-12-14_knwn_RonaldPEricksonMember",
      "name": "knwn:ShareGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
     "longName": "000050 - Disclosure - COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)",
     "shortName": "COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2017-04-01to2017-04-13",
      "name": "us-gaap:SaleLeasebackTransactionMonthlyRentalPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-04-01to2017-04-13",
      "name": "us-gaap:SaleLeasebackTransactionMonthlyRentalPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://knwn.com/role/IncomeTaxesDetails",
     "longName": "000051 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://knwn.com/role/IncomeTaxesDetails1",
     "longName": "000052 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://knwn.com/role/IncomeTaxesDetailsNarrative",
     "longName": "000053 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:FederalNetOperatingLossCarryforwardsExpired",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:FederalNetOperatingLossCarryforwardsExpired",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://knwn.com/role/SegmentReportingDetails",
     "longName": "000054 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:SegmentRevenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "knwn:SegmentRevenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://knwn.com/role/SegmentReportingDetailsNarrative",
     "longName": "000055 - Disclosure - SEGMENT REPORTING (Details Narrative)",
     "shortName": "SEGMENT REPORTING (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OtherNoncashExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:OtherNoncashExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://knwn.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000056 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:StockOptionGrantsToEmployeesAndDirectors",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "knwn:StockOptionGrantsToEmployeesAndDirectors",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "knwn_10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid In Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r517",
      "r676",
      "r677",
      "r678",
      "r725",
      "r745"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r636",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r741",
      "r745"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r242",
      "r243",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r388",
      "r390",
      "r391",
      "r393",
      "r396",
      "r500",
      "r502",
      "r517",
      "r745"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE), NET"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense), net",
        "label": "[Other Nonoperating Income (Expense)]",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r127",
      "r142",
      "r143",
      "r144",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r175",
      "r242",
      "r243",
      "r318",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r416",
      "r500",
      "r501",
      "r502",
      "r517",
      "r582"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r64",
      "r475",
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise prices",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to purchase common stock shares",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r117",
      "r118",
      "r120",
      "r121"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (expense) income, net",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r561",
      "r603",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ShortTermDebtInterestRateIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtInterestRateIncrease",
     "presentation": [
      "http://knwn.com/role/EquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares current price per share",
        "verboseLabel": "Common shares current price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment (2-3 years)",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals and reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r723"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://knwn.com/role/EquityDetails2",
      "http://knwn.com/role/StockIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued",
        "verboseLabel": "Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash (used in) operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r132",
      "r615"
     ]
    },
    "knwn_SeveranceAndOtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SeveranceAndOtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance and other expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares outstanding",
        "label": "[Common Stock, Other Shares, Outstanding]",
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock dividends on Series D Preferred Stock",
        "label": "[Dividends, Common Stock]",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r101"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "knwn_NetIncomeLossAvailableToCommonStockholders",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividends on Series C and D Preferred Stock",
        "label": "[Dividends, Preferred Stock]",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r101"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651"
     ]
    },
    "knwn_ReservedSharesToPaySeriesCAndDDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ReservedSharesToPaySeriesCAndDDividends",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserved shares to pay series C and D dividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of warrants",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "knwn_PropertyPlantsAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "PropertyPlantsAndEquipmentUsefulLife",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives of assets"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AmountTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AmountTotal",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount total"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "Revenue",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Digital Asset Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money warrants",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Dividend",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r591",
      "r593",
      "r594",
      "r602"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative",
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://knwn.com/role/SegmentReportingDetails",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetails1",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r175",
      "r457",
      "r507",
      "r528",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r562",
      "r563",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r582",
      "r639"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest paid",
        "label": "[Interest Paid, Including Capitalized Interest, Operating and Investing Activities]",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE- DIGITAL ASSET SALES",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r154",
      "r183",
      "r184",
      "r195",
      "r200",
      "r201",
      "r207",
      "r209",
      "r210",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r399",
      "r471",
      "r691"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r266",
      "r267",
      "r612",
      "r690"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, outstanding",
        "verboseLabel": "Weighted average exercise price exerciseable",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r136",
      "r137",
      "r138",
      "r154",
      "r169",
      "r170",
      "r172",
      "r173",
      "r176",
      "r177",
      "r241",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r301",
      "r302",
      "r305",
      "r308",
      "r316",
      "r399",
      "r508",
      "r509",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r539",
      "r560",
      "r582",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r656",
      "r673",
      "r679"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock par value",
        "verboseLabel": "Authorized shares of capital stock par value",
        "terseLabel": "Authorized shares of capital stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r83",
      "r110",
      "r182",
      "r196",
      "r202",
      "r205",
      "r471",
      "r483",
      "r620"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Goods And Nonemployee Services Transaction By Supplier Axis",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "knwn_ConvertibleDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleDebentures",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debentures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on debt extinguishment",
        "label": "[Extinguishment of Debt, Amount]",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercisable",
        "verboseLabel": "Average exercise price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "knwn_AmountDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AmountDueToRelatedPartiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses - related parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements and Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r15"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_IsssuanceOfCommonStockForCommonStockOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IsssuanceOfCommonStockForCommonStockOfferingShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Isssuance of common stock for common stock offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK INCENTIVE PLANS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "knwn_ExpensesForExtensionOfNotesAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExpensesForExtensionOfNotesAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses for extension of notes and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANISATION",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r104",
      "r505",
      "r506"
     ]
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base salary",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "knwn_SupplementalDisclosureOfNoncashFinancingActivityNewAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SupplementalDisclosureOfNoncashFinancingActivityNewAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash financing activity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AiDeepLearningPlatformDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AiDeepLearningPlatformDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatform"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AI DEEP LEARNING PLATFORM",
        "label": "[AI DEEP LEARNING PLATFORM]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_IssuanceCostsFromCommonStockOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceCostsFromCommonStockOffering",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs from common stock offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r187"
     ]
    },
    "knwn_ConversionOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConversionOfAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ProceedsFromIssuanceOfCommonStockOfferingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ProceedsFromIssuanceOfCommonStockOfferingNet",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock offering, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "knwn_GainLossOnForgivenessOfNotesPayablePppLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "GainLossOnForgivenessOfNotesPayablePppLoans",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on forgiveness of notes payable-PPP Loans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of convertible notes payable",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockStock",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "knwn_NetIncomeLossAvailableToCommonStockholders",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock dividends on Series D Preferred Stock",
        "label": "[Dividends, Common Stock, Stock]",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "knwn_GainLossOnDebtSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "GainLossOnDebtSettlement",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on debt settlement"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_IsssuanceOfCommonStockForCommonStockOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IsssuanceOfCommonStockForCommonStockOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Isssuance of common stock for common stock offering, amount"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockCompensationExpenseEmployeeOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockCompensationExpenseEmployeeOptions",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation expense - employee options",
        "documentation": "Custom Element."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_NetIncomeLossAvailableToCommonStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NetIncomeLossAvailableToCommonStockholders",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS",
        "label": "[NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_EarningsPerSharesBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "EarningsPerSharesBasicAndDiluted",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares issued",
        "verboseLabel": "Common stock shares issued",
        "terseLabel": "Common stock share issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price:"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares of common stock outstanding- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConversionOfDebtOfferingAndAccruedInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConversionOfDebtOfferingAndAccruedInterestShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt offering and accrued interest (Note 7), shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConversionOfDebtOfferingAndAccruedInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConversionOfDebtOfferingAndAccruedInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt offering and accrued interest (Note 7), amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory or OID notes",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r108",
      "r739"
     ]
    },
    "knwn_IssuanceOfCommonStockForStockOptionExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceOfCommonStockForStockOptionExercisesShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for stock option exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_IssuanceOfCommonStockForStockOptionExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceOfCommonStockForStockOptionExercisesAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for stock option exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetails2",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Issued",
        "verboseLabel": "Weighted average price of the common stock",
        "terseLabel": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "knwn_IssuanceOfCommonStockForExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceOfCommonStockForExerciseOfWarrantsShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for exercise of warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetails2",
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price Exercised",
        "label": "[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price]",
        "verboseLabel": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "knwn_IssuanceOfCommonStockForExerciseOfWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceOfCommonStockForExerciseOfWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for exercise of warrants, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "[Assets]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r135",
      "r154",
      "r182",
      "r197",
      "r203",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r383",
      "r385",
      "r399",
      "r474",
      "r551",
      "r634",
      "r645",
      "r691",
      "r692",
      "r730"
     ]
    },
    "knwn_IssuanceOfCommonStockWarrantForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuanceOfCommonStockWarrantForServices",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrant for services"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_IsssuanceOfCommonStockForNyseUplistingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IsssuanceOfCommonStockForNyseUplistingShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Isssuance of common stock for NYSE uplisting, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r539"
     ]
    },
    "us-gaap_DividendsPreferredStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStockStock",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed dividends on Series C and D Preferred Stock",
        "label": "[Dividends, Preferred Stock, Stock]",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r101"
     ]
    },
    "knwn_IsssuanceOfCommonStockForNyseUplistingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IsssuanceOfCommonStockForNyseUplistingAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Isssuance of common stock for NYSE uplisting, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r77",
      "r539",
      "r557",
      "r745",
      "r746"
     ]
    },
    "knwn_CommonStockDividendsOnSeriesDPreferredStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStockDividendsOnSeriesDPreferredStockShares",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends on Series D Preferred Stock, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price Forfeitures",
        "label": "[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price]",
        "verboseLabel": "Weighted Average Exercise Price Forfeitures",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "knwn_CommonStockDividendsOnSeriesDPreferredStockAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStockDividendsOnSeriesDPreferredStockAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock dividends on Series D Preferred Stock, amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise PriceExpired",
        "label": "[Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price]",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "knwn_DeemedDividendsOnSeriesCAndDPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DeemedDividendsOnSeriesCAndDPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deemed dividends on Series C and D Preferred Stock",
        "label": "[Deemed dividends on Series C and D Preferred Stock]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "knwn_AccretedValueOfPreferredDividendIntoCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AccretedValueOfPreferredDividendIntoCommonStockShares",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred dividend value accrete common stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNote1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNote1Member",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note - Clayton A. Struve"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ReceivedOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ReceivedOfWarrant",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "warrants and received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuable upon conversion of convertible debentures",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r45",
      "r76",
      "r100",
      "r311"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable - trade and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "knwn_ParticleIncTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ParticleIncTechnologyMember",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Particle, Inc. Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DesignatedSeriesCConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DesignatedSeriesCConvertiblePreferredStock",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertible Preferred Stock designated"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_PhillipABosuaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "PhillipABosuaMember",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phillip A. Bosua [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DesignatedSeriesDConvertiblePreferredStocks": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DesignatedSeriesDConvertiblePreferredStocks",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series D Convertible Preferred Stock designated",
        "label": "[Series D Convertible Preferred Stock designated]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNote2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNote2Member",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note - Ronald P. Erickson and Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r305",
      "r640",
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r531",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r597",
      "r598",
      "r599",
      "r600",
      "r636",
      "r638"
     ]
    },
    "knwn_ReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ReverseStockSplit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WeightedAverageRemainingLifeYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WeightedAverageRemainingLifeYears",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining life (years)",
        "label": "[Weighted average remaining life (years)]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WeightedAverageExercisePriceOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WeightedAverageExercisePriceOutstanding",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r60",
      "r529",
      "r531",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r597",
      "r598",
      "r599",
      "r600",
      "r617",
      "r636",
      "r638"
     ]
    },
    "knwn_EightEmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "EightEmployeesAndConsultantsMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eight Employees And Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r424"
     ]
    },
    "knwn_IntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic value",
        "label": "[Intrinsic value]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_NineteenEmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NineteenEmployeesAndConsultantsMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nineteen Employees And Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fin Stmt Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r653"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C PreferredStockMember",
        "verboseLabel": "Series C PreferredStockMember",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r694"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "knwn_ConvertibleNotesFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNotesFiveMember",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Convertibles notes"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DesignatedSeriesDConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DesignatedSeriesDConvertiblePreferredStock",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Convertible Preferred Stock designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock Member",
        "verboseLabel": "Series D Preferred Stock Member",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r694"
     ]
    },
    "knwn_PeterConleyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "PeterConleyMember",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peter Conley [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r134",
      "r473",
      "r645"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r328",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r360",
      "r361",
      "r362",
      "r363"
     ]
    },
    "knwn_SeriesCAndDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SeriesCAndDPreferredStockMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C and D Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNote8Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNote8Member",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note - J3E2A2Z Notes"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNoteTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNoteTwoMember",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertibles Note - Ronald P. Erickson and Affiliates"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DescriptionOfAutomaticConversionOfConvertible": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DescriptionOfAutomaticConversionOfConvertible",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Automatic conversion of Convertible"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantIssuedToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantIssuedToCommonStock",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued to common stock",
        "verboseLabel": "Warrant issued to common stock"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ThreeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ThreeDirectorMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNote7Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNote7Member",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note - J3E2A2Z Account Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TechnologyEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TechnologyEquipmentMember",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Equipment [Member]",
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible redeemable promissory note principal amount",
        "documentation": "Amount of the total principal payments made during the annual reporting period."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "knwn_ReceivedSeriesDPreferredStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ReceivedSeriesDPreferredStockDividendsShares",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D preferred stock dividends shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible common stock shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "knwn_CommonPreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonPreferredStocksMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantsToPurchaseCommonStock",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "verboseLabel": "Common Stock Shares issued",
        "terseLabel": "Preferred stock shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "knwn_StockOption2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOption2Member",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AuthorizedCapitalStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AuthorizedCapitalStockMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized Capital Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShrareIssuedWarrantToPurchasedPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShrareIssuedWarrantToPurchasedPrice",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shrare issued warrant to purchased price"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantsToAcquireCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantsToAcquireCommonStockShares",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to acquire common stock shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOption3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOption3Member",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes, gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r108",
      "r298"
     ]
    },
    "knwn_CommonStockSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStockSharePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r424"
     ]
    },
    "knwn_ConvertiblePreferredStockSeriesCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertiblePreferredStockSeriesCMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock Series C [Member]",
        "label": "[Convertible Preferred Stock Series C [Member]]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockAtTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockAtTwoMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock at 2.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK INCENTIVE PLANS",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r354",
      "r355",
      "r356",
      "r632"
     ]
    },
    "srt_FederalFundsSoldAverageYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "FederalFundsSoldAverageYield",
     "presentation": [
      "http://knwn.com/role/EquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "Average yield on federal funds sold."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126"
     ]
    },
    "knwn_StockOptionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionsOneMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "knwn_PreferredStockConvertibleConversionPriceAdjusted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "PreferredStockConvertibleConversionPriceAdjusted",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted conversion price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantsExpiredPerSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantsExpiredPerSharePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired per share"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockAtOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockAtOneMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock at 0.25"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOptionsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionsTwoMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ProceedsFromIssuanceOfCommonStocks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ProceedsFromIssuanceOfCommonStocks",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertibleNoteOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNoteOneMember",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertibles Note - Clayton A. Struve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/EQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EQUITY",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r153",
      "r300",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r395",
      "r585",
      "r587",
      "r611"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants totaling",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_GrossSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "GrossSales",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertiblePreferredStockDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertiblePreferredStockDMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable - trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19"
     ]
    },
    "knwn_WarrantsIssuedValued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantsIssuedValued",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants valued"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_CommonStocksOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStocksOfferingsMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_EmployeeStockOptionsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "EmployeeStockOptionsOneMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Options One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "knwn_ExerciseOfStockOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExerciseOfStockOption",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory notes",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "knwn_WarrantToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantToPurchaseCommonStockMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant To Purchase Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DevelopmentOfTheBioRFIDAndChromaIDTechnologiesMember",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development of the Bio-RFID and ChromaID Technologies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OPERATING LOSS",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r196",
      "r202",
      "r205",
      "r620"
     ]
    },
    "knwn_CommonStockSharesIssuedRelatedToWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStockSharesIssuedRelatedToWarrantExercises",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares issued related to warrant exercises"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_BousteadSecuritiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "BousteadSecuritiesLLCMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead Securities LLC Member"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_TwoZeroTwoOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "TwoZeroTwoOneEquityIncentivePlanMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "presentation": [
      "http://knwn.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average assumptions",
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "knwn_IssuedAmountReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "IssuedAmountReceived",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued amount received"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_RonaldPEricksonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "RonaldPEricksonMember",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ronald P Erickson [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r24",
      "r127",
      "r142",
      "r143",
      "r144",
      "r157",
      "r158",
      "r159",
      "r161",
      "r166",
      "r168",
      "r175",
      "r242",
      "r243",
      "r318",
      "r357",
      "r358",
      "r359",
      "r375",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r416",
      "r500",
      "r501",
      "r502",
      "r517",
      "r582"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r264",
      "r265",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r624",
      "r658",
      "r740"
     ]
    },
    "us-gaap_CumulativeDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CumulativeDividends",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative dividend cash",
        "documentation": "Amount of cumulative cash dividends distributed to shareholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock issued during period",
        "verboseLabel": "Common stock shares",
        "terseLabel": "Common stock shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RESEARCH AND DEVELOPMENT EXPENSES",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r366",
      "r738"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://knwn.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r425"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows",
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services, amount",
        "verboseLabel": "Issuance of common stock for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FDIC insurance",
        "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://knwn.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r152"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r119",
      "r122",
      "r123"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r724"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r101",
      "r478",
      "r503",
      "r504",
      "r512",
      "r540",
      "r634"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r41"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock for warrant exercise",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r420",
      "r421",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r556",
      "r558",
      "r589",
      "r729"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r131",
      "r154",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r384",
      "r385",
      "r386",
      "r399",
      "r634",
      "r691",
      "r730",
      "r731"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax provision at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r369",
      "r379"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://knwn.com/role/EquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r724"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent and other costs",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) INVESTING ACTIVITIES:",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH (USED IN) OPERATING ACTIVITIES",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "verboseLabel": "Purchase preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r476",
      "r634"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r724"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements (5 years)",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "[Liabilities, Noncurrent]",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r70",
      "r71",
      "r74",
      "r154",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r384",
      "r385",
      "r386",
      "r399",
      "r691",
      "r730",
      "r731"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOptionGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionGrants",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for stock for NYSE uplisting",
        "label": "[Payments for Repurchase of Common Stock]",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement of notes payable-PPP loans",
        "label": "[Repayments of Notes Payable]",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance during the year",
        "label": "[Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount]",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "knwn_DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStockBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "verboseLabel": "Minimum",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r322",
      "r456",
      "r499",
      "r530",
      "r531",
      "r590",
      "r592",
      "r595",
      "r596",
      "r601",
      "r613",
      "r614",
      "r621",
      "r630",
      "r631",
      "r635",
      "r693",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "knwn_DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r420",
      "r421",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r556",
      "r558",
      "r589"
     ]
    },
    "knwn_FederalNetOperatingLossCarryforwardsExpired": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "FederalNetOperatingLossCarryforwardsExpired",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Schedule of deferred tax",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r80",
      "r81",
      "r93",
      "r541",
      "r557",
      "r583",
      "r584",
      "r634",
      "r645",
      "r675",
      "r685",
      "r726",
      "r745"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Schedule of Effective tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET",
        "verboseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r472",
      "r482",
      "r634"
     ]
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositLiabilitiesAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "knwn_SegmentNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SegmentNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Operating Profit (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_SegmentRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SegmentRevenues",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_EffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "EffectiveTaxRate",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effective tax rate",
        "label": "[Effective tax rate]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r618"
     ]
    },
    "us-gaap_EquipmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expensed",
        "verboseLabel": "Expensed",
        "documentation": "This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsOtherAndPriorYearTrueUp",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other and prior year true up"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent paid",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r124",
      "r167",
      "r168",
      "r190",
      "r368",
      "r378",
      "r487"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r742"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r119",
      "r122",
      "r480"
     ]
    },
    "knwn_ExerciseStockOptionGrantsreceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExerciseStockOptionGrantsreceived",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise stock option grants"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_NumberOfCommonStockSharesIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NumberOfCommonStockSharesIncrease",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares increase"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_RevenueRecognitionLeases": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionLeases",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodUnearned",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unearned stock option grants",
        "label": "[Unearned stock option grants]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockIssuedDuringPeriodSharesStockOptionExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesStockOptionExercised",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option grants share exercised"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShareGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareGrant",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No of share granted for stock option"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DescriptionRelatedToCommonStock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DescriptionRelatedToCommonStock",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company common stock description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://knwn.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment reporting",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40"
     ]
    },
    "knwn_CumulativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CumulativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issued price",
        "verboseLabel": "Price per share",
        "terseLabel": "Price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument Axis",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r297",
      "r314",
      "r394",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r485",
      "r622",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "knwn_AdditionalStockOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AdditionalStockOption",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional stock option grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "knwn_NetIncomeLossAvailableToCommonStockholders",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows",
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r91",
      "r111",
      "r129",
      "r140",
      "r141",
      "r144",
      "r154",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r171",
      "r182",
      "r196",
      "r202",
      "r205",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r397",
      "r399",
      "r484",
      "r559",
      "r580",
      "r581",
      "r620",
      "r644",
      "r691"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r89"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r633"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AdditionalExercisedPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AdditionalExercisedPrice",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r297",
      "r314",
      "r394",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r485",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r194",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r514",
      "r515",
      "r516",
      "r564",
      "r565",
      "r566",
      "r586",
      "r588"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "verboseLabel": "Maximum",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r322",
      "r456",
      "r499",
      "r530",
      "r531",
      "r590",
      "r592",
      "r595",
      "r596",
      "r601",
      "r613",
      "r614",
      "r621",
      "r630",
      "r631",
      "r635",
      "r693",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "knwn_AccruedCompensastionTravelAndInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AccruedCompensastionTravelAndInterest",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensastion &amp; travel and interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r651"
     ]
    },
    "knwn_ReceivedSeriesDPreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ReceivedSeriesDPreferredStockDividends",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D preferred stock dividends"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AnnualSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AnnualSalary",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r319",
      "r322",
      "r350",
      "r351",
      "r352",
      "r432",
      "r456",
      "r499",
      "r530",
      "r531",
      "r590",
      "r592",
      "r595",
      "r596",
      "r601",
      "r613",
      "r614",
      "r621",
      "r630",
      "r631",
      "r635",
      "r638",
      "r689",
      "r693",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r89",
      "r151"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from isssuance of common stock for NYSE uplisting",
        "verboseLabel": "Net proceeds from sale",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shrare issued warrant to purchased",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_LeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "LeaseDescription",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_CommonStockPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStockPerShares",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock per shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r319",
      "r322",
      "r350",
      "r351",
      "r352",
      "r432",
      "r456",
      "r499",
      "r530",
      "r531",
      "r590",
      "r592",
      "r595",
      "r596",
      "r601",
      "r613",
      "r614",
      "r621",
      "r630",
      "r631",
      "r635",
      "r638",
      "r689",
      "r693",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737"
     ]
    },
    "knwn_AIMindMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AIMindMember",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AI Mind [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares issued",
        "verboseLabel": "Preferred stock shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r301"
     ]
    },
    "knwn_OriginalExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "OriginalExpirationDate",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original Expiration Date",
        "verboseLabel": "Original Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsSharebasedCompensationStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsSharebasedCompensationStock",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation",
        "documentation": "Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r408",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r674"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r539",
      "r557",
      "r745",
      "r746"
     ]
    },
    "knwn_DigitalassetsalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DigitalassetsalesMember",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Digital asset sales [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_OwnershipInterestInPreferredStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "OwnershipInterestInPreferredStock",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r136",
      "r137",
      "r138",
      "r154",
      "r169",
      "r170",
      "r172",
      "r173",
      "r176",
      "r177",
      "r241",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r301",
      "r302",
      "r305",
      "r308",
      "r316",
      "r399",
      "r508",
      "r509",
      "r510",
      "r511",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r539",
      "r560",
      "r582",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r656",
      "r673",
      "r679"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes, net",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r398",
      "r626",
      "r627"
     ]
    },
    "knwn_NumberOfCommonStockSharesSettled": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NumberOfCommonStockSharesSettled",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of common stock shares settled"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "terseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r539"
     ]
    },
    "knwn_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_DeemedDividendsCumulative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DeemedDividendsCumulative",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative deemed dividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r670"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r109",
      "r479",
      "r634",
      "r675",
      "r685",
      "r726"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://knwn.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of minimum future lease payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "knwn_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock for stock options exercise",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of operating lease right-of-use asset",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r633"
     ]
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "SELLING AND TRANSACTIONAL COSTS FOR DIGITAL ASSETS",
        "label": "[Selling Expense]",
        "verboseLabel": "Selling and Transactional Costs",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "knwn_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_CumulativeDividendUnpaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CumulativeDividendUnpaid",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative unpaid dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock par value",
        "verboseLabel": "Preferred stock share par value",
        "terseLabel": "Preferred stock share par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r301"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "knwn_DividendDistributedPerShare": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DividendDistributedPerShare",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend distributed per share"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AdditionalSharePurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AdditionalSharePurchase",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional share purchase"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_SegmentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SegmentAsset",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r723"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures (3 years)",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r723"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "knwn_AmendedExpirationdate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AmendedExpirationdate",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Expiration Date",
        "verboseLabel": "Amended Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r729"
     ]
    },
    "knwn_MrBosuaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "MrBosuaMember",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Bosua [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOptionGrantsToEmployeesAndDirectors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionGrantsToEmployeesAndDirectors",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option grants to employees and directors"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOptionExpiryTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOptionExpiryTerm",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option expiry term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r139",
      "r154",
      "r241",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r383",
      "r385",
      "r399",
      "r634",
      "r691",
      "r692",
      "r730"
     ]
    },
    "knwn_ExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExercisePricePerShare",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise price",
        "terseLabel": "Share exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax asset",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r723"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Axis",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r72",
      "r73",
      "r107",
      "r108",
      "r156",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r408",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r674"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash expenses",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "knwn_ExercisableAtEndOfPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExercisableAtEndOfPeriod",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable at end of period",
        "label": "[Exercisable at end of period]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AiDeepLearningPlatformAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AiDeepLearningPlatformAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AI DEEP LEARNING PLATFORM"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAbstract",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbers",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Share Outstanding at beginning of period",
        "label": "[Share Outstanding at beginning of period]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumbe",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding at end of period"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ThirtyFirstDecemberTwentyTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ThirtyFirstDecemberTwentyTwentyThreeMember",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "31 December,2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name Axis",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "knwn_Warrant1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "Warrant1Member",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation- stock option grants",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r54"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://knwn.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r633"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES-"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_StockOption1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "StockOption1Member",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option 1 [Member]",
        "verboseLabel": "Stock Option 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_OutstandingAtBegenningOfPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "OutstandingAtBegenningOfPeriod",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at begin of period",
        "label": "[Outstanding at begin of period]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r43",
      "r44"
     ]
    },
    "knwn_SeriesCConvertiblesPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SeriesCConvertiblesPreferredStockMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Convertibles Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ResearchAndDevelopmentAndSellingsGeneralAndAdministrativeMember",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development And Sellings General And Administrative [Mmber]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price Forfeited",
        "label": "[Weighted Average Exercise Price Forfeited]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r97"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r367",
      "r370",
      "r371",
      "r374",
      "r377",
      "r380",
      "r381",
      "r382",
      "r513"
     ]
    },
    "knwn_ConvertiblePreferredStocksSeriesCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertiblePreferredStocksSeriesCMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_OutstandingAtEndOfPeriod": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "OutstandingAtEndOfPeriod",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at end of period",
        "label": "[Outstanding at end of period]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ConvertiblePreferredStockSeriesDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertiblePreferredStockSeriesDMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_SeriesDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "SeriesDConvertiblePreferredStockMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_CommonStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CommonStocksMember",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_WeightedAveragesRemainingLifeYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WeightedAveragesRemainingLifeYears",
     "presentation": [
      "http://knwn.com/role/EquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life (years)"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_ExpectedLifeMinimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExpectedLifeMinimum",
     "presentation": [
      "http://knwn.com/role/EquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life minimum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://knwn.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants outstanding and exercisable",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "knwn_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r634",
      "r743"
     ]
    },
    "knwn_ExpectedLifeMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ExpectedLifeMaximum",
     "presentation": [
      "http://knwn.com/role/EquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type Axis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ]
    },
    "knwn_MrStruveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "MrStruveMember",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Struve [Member]",
        "verboseLabel": "Mr. Struve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "knwn_LeasesOfLesseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "LeasesOfLesseDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LEASES",
        "label": "[LEASES]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $0.001 par value, 200,000,000 shares authorized, 80,358,463 and 48,156,062 shares issued and outstanding at 9/30/2023 and 9/30/2022, respectively",
        "verboseLabel": "Common stock shares value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r477",
      "r634"
     ]
    },
    "knwn_ConvertibleNotesPayableDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNotesPayableDisclosureTextBlock",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE",
        "label": "[CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount to interest expense",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r86",
      "r296"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and marketing costs",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease right-of-use liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "knwn_ConvertibleRedeemablePromissoryNoteAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleRedeemablePromissoryNoteAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible redeemable promissory note amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r149",
      "r150"
     ]
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r623",
      "r686"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock warrants for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://knwn.com/role/EquityDetails2",
      "http://knwn.com/role/StockIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period]",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r76",
      "r77",
      "r101",
      "r334"
     ]
    },
    "knwn_DateOfIssue": {
     "xbrltype": "dateItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DateOfIssue",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue date",
        "verboseLabel": "Issue date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional warrants issued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "[Interest Expense]",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r113",
      "r145",
      "r186",
      "r407",
      "r567",
      "r644",
      "r744"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares exercisable",
        "verboseLabel": "Number exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "knwn_AmortizationOfDebtDiscountPremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AmortizationOfDebtDiscountPremiums",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization related to the debt"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual Axis",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r728"
     ]
    },
    "knwn_DepositLiabilitiesAccruedInterestsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DepositLiabilitiesAccruedInterestsAmount",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock options outstanding and exercisable",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_InterestExpenseForeignDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseForeignDeposits",
     "crdr": "debit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of notes and warrants - interest expense",
        "documentation": "Interest expense on all foreign deposits."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range Axis",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/StockIncentivePlansDetails1",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants",
        "verboseLabel": "Number of outstanding stock options",
        "terseLabel": "Number of common stock authorized shares",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "knwn_ConvertibleNotesConversions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ConvertibleNotesConversions",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "less conversions of notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "knwn_DividendPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "DividendPolicyTextBlock",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location Axis",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r263",
      "r566"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "[Interest Expense, Debt]",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r294",
      "r299",
      "r628",
      "r629"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r687",
      "r688"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r566"
     ]
    },
    "knwn_ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "ScheduleOfShareBasedCompensationWarrantActivityTableTextBlock",
     "presentation": [
      "http://knwn.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant activity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AuthorizedSharesOfCapitalStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AuthorizedSharesOfCapitalStock",
     "presentation": [
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized shares of capital stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://knwn.com/role/EquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://knwn.com/role/EquityDetails2",
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period]",
        "verboseLabel": "Stock option grants shares forfeitures",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned stock option grants",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "knwn_AuthorizedSharesOfCapitalCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AuthorizedSharesOfCapitalCommonStock",
     "presentation": [
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized shares of capital common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleLeasebackTransactionMonthlyRentalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionMonthlyRentalPayments",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, net monthly payment",
        "documentation": "The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://knwn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_AuthorizedCommonStockIncreased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AuthorizedCommonStockIncreased",
     "presentation": [
      "http://knwn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized common stock increased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r48"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r133",
      "r481"
     ]
    },
    "us-gaap_DerivativesMethodsOfAccountingHedgeEffectiveness": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesMethodsOfAccountingHedgeEffectiveness",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining hedging effectiveness and if hedge effectiveness was assessed on quantitative or qualitative basis."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "knwn_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://knwn.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "[Cash and cash equivalents]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Share Outstanding at beginning of period",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Share Outstanding at ending of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market accounts",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r458"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expenses",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at begin of period",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Outstanding at end of period",
        "verboseLabel": "Average exercise price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330"
     ]
    },
    "knwn_NumberOfWarrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NumberOfWarrantShares",
     "presentation": [
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrant shares",
        "verboseLabel": "Number of warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_NetWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "NetWorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://knwn.com/role/LiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net working capital",
        "verboseLabel": "Net working capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://knwn.com/role/AiDeepLearningPlatformDetailsNarrative",
      "http://knwn.com/role/CommitmentsContingenciesAndLegalProceedingsDetailsNarrative",
      "http://knwn.com/role/ConsolidatedBalanceSheets",
      "http://knwn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://knwn.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetails",
      "http://knwn.com/role/ConvertibleNotesPayableAndNotePayableDetailsNarrative",
      "http://knwn.com/role/EquityDetails",
      "http://knwn.com/role/EquityDetails1",
      "http://knwn.com/role/EquityDetails3",
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://knwn.com/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative",
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://knwn.com/role/SegmentReportingDetails",
      "http://knwn.com/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails",
      "http://knwn.com/role/StockIncentivePlansDetails1",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative",
      "http://knwn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r175",
      "r457",
      "r507",
      "r528",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r562",
      "r563",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r582",
      "r639"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://knwn.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Business Segments Axis",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r179",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r210",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r264",
      "r265",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r624",
      "r658",
      "r740"
     ]
    },
    "knwn_GrossProceedFromPublicIssueStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "GrossProceedFromPublicIssueStock",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceed from public issue stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://knwn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "knwn_AssetsNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "AssetsNetBookValue",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value of assets"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_TotalRemainingPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "TotalRemainingPayments",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Remaining Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://knwn.com/role/EquityDetailsNarrative",
      "http://knwn.com/role/StockIncentivePlansDetails1",
      "http://knwn.com/role/StockIncentivePlansDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://knwn.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://knwn.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "knwn_RightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "RightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://knwn.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "knwn_TotalLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://knwn.com/20230930",
     "localname": "TotalLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://knwn.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liability",
        "label": "[Total lease liability]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "30",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481295/840-40-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "79",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-79"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001654954-23-015760-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-23-015760-xbrl.zip
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MAX?Q*JJ3P)S#\HW1-$I&8)Z9C.[-"8O!!J/1$$"='E,]@N?S=VAEO23#+OM
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MYW^=(OR0GJ#\["T]D?R3;DXDH;GZI20TM0#)_42G&M]I?&?N.CJ#;7[[FD!
M?.<1S^-9#/\O<\>"I6&(5GY^F6W 8QAPL(S83Q<U\+#KLHVSGRX"$K)T@=T
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MS5U?.KIRCTZ-**&3LXF;$;S!GN5"JH6CES#:$CI+H6V2;,)/!SE'FIP,Q67
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M(DO:5AWJ\1;H;OC/$-=<8.36T<I%,_9;LB@\#S3GKQB%L/#JV&(=J]31\H4
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MQY=7>1P5D*C)6K/"J\VAXOCS*H_S J$J&K%6'0]C &FU2B2,=-<JD$'!J,H
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MA+.8Z;9(>%MPI9<]"W]E[^Y#MBUC=%'*EC'XD%Q;ADB9X&0B=^J%=>/JF@A
M!3/W[H5 U"/#UR),60OXOJ<6< Q\^R$^GTS= &XJXQ.W'7 V=.Q>2ME!-BL9
M].2B@ZXGT(NE&_@UWD1C]^J%,111.RI0)*YP&NF+ :I')K%EL+)F\<,IS6+@
MAQDLX=^><81_^7.%"JE2[![\/?.S&@8N3W-&X"<5*+6:$";O).6#N'8I+RRR
M( LE@C[V5)1]L!SBXLQ:@T\]W23AFTATI1-FKR.OGI!98^^5A#JK85&J<)2!
MM%>0B:S+0IU[L8^JH)FB(!)V5>=O7RB*?3"5IT R:V3/SWMJ9:N72L5'\/Z7
M2>6_(2?*"[:KK2:EI]Z+<V9MU&*CWDB5Y8;*1OP7&<"B;+\$7E(^ARU.4D/Y
M(A4YR)9*W!6XP')ML^(L9W]\"P6UC_:L'7*AB411%\\3I>UQ@50LSS93N'GR
M-!ZY\LPWZ;4\\Z1B>4HJ\1I'":)BG-/]P?<>DL0>WAK'["3?;%38J!46/"9C
M&"E);VQMX.YM# Y>8(>!#M<7_0X2>#V>CJ9N$/DHHV]F[VU22F,Z@O  \A$4
MCF(1YJE1=5]J57VX.T+?@#H6IR7@+#[:(DMOKX+(.2QT4<(WLP$=@SM(7,2K
M#5MJJXID*>3+?99T!0( F;U'"?<0><>+S6B*.=W2<+JI (D8)W(?)]6M6&,"
MV]UQ(2&U50@'$OER7R.]]5SP=&OXWT!X';D67'U&\$3W! F,*[C1D>!V5 @6
M+B]RGR4=7N_MSVNDV?(2<0IGK2=\:5W5Q(?&31<E<]%*YC^ M%[HQEL:3YEJ
M.L<:.Y3-E7!O%8"HQ)#<NKA4#VQV:G\^>)G"]#5<TZS!5 "T"7^28^5U-[0M
MVXF0DW,-S,BW4=KZY-%T(@M8UU 6Z,F.*#22E"+\0- RM1O4,D9XW]3.\ HI
M04L<-RNWV\[+2U=& *SLBRTZNC+8@>0B[KD)M%WHG_3OAF^EK[C<Q/6"IFY2
M4YBN'VU_1R%%:9OU9C6!6WVK:^G;)L :S0&?W$4U',E<=%(*..==#K+NY<\!
MV$;.S-Z29([ZBG550?;BW)1*_IZF8AFYR)-(^FVI=@.UZ-.05SODU;[0O-HA
MR+!VD*&LD\009-ABD*&LE-TAQK#]&,.^YOMN@'GO>HZW>SHRP N\8'21OVNL
M'W;!8*N39V]6X &XQ#N:Q#68_BI?I**^S)3@+H(<$H?(Q@L-AR*O7 M59)8C
MNE'H0O.M,' <D2O<8CL51$TA76Y40_I2Z\PV[FPG=@^.(M\'3#\JO8M",#"X
M*$8RG.:43JJJF)ZI24?S4LE"6EG%=(R358(4\2N4BA=RB!^<"H-3X64Y%9(2
MC\],HX\@*3.="<Q.2CD1F)Q(/G=2:..=.#G=>N$P$- Z,: *+@)9%8FZ@*I'
M;H&6X<HZ MYUXPA@!-R40T?AW]+-<' #7. ;#OP7W=I#60=ALMPS$[4:CRI_
MNRJDP,58G48\EU[-:>5@' 0@#.8@O/*\;[28S_BH26@H'P7!8S*!]D9>AA:*
MVQQ\8-JQRM"M7;Z5"M(F$EYT3)SF5)94CF><PTKUS''I^"[/73FJF">M4C7S
M GFG*F8-[=&-!^W3R'--X(M4X[XL%3A_KFV-3HDW"W3_/%K,1Y,5N3CW<%(<
M3HKJGQ3C.*LQY(1]-BPT4^HT6*!=\OGO2 WO&%%JV(LS'E%?: +OR3FNKLA[
M=%:K(79YY['-O>V'3]>V'X1C8,;;M<UW^(VG]/]A9_;1J\H \G><%/7*;NZK
M,-3)$0H]'PHW2>@_R)7^8#B _N0KK;%\40LF^%+H[^+2%A[8OGK^-[3W- XV
M_>J6T$X5<1)([R(#_<;W@B!]>0\E#RRC.\<VXVACUFOL_&ZJR)G/2?$R]V1/
M$O.?$F.<84O/-%5Y2^QXSAV.6\-Q2_WCUAC<A<_5E'G5ULMME3IXD1B0?/K*
MDS0W]@+%NFD]>G$>HRL4$XPL'Y)/9^U!TJ/S6F-8Y)W>"LO]PF6?U>C-Y>^[
M>*I%J0I4X*.; UG^<YOO7A4I9YHK+>4,'UC*756UBK>NU[Q+7U8'I26=XP3+
MNM5LS>('GU/_!>J(E7O(EW;E:F)E)F1?X&;5Y=JP?4[!)&H'%<#@\2 W]#Q/
M%J[=Q"LJP>ZE+"I%1OKOUV!>)9<>=J[AX!ANE@=7Q^#J>(FN#EE9RH.K@^KJ
M4-_[]%)='1UE$(L=62ZJ' TO7L2Q\*)P)&PW^[?P,?;#&+3&2LNW^#A&S9I5
M8O+]6$6^'U^$?#\6Y=NE2^-#%?E^>!'R_5"4KZ0"W,?\3V[N=KFE? "$=_YE
MXN5ZD(@O+<TCQ.QB^USS<02//<"Z>IH8YGV^+1VG%H96"-@6N.TBYB9]T".3
MIIXFKD_AWLL'01A0/52HOWAW%:"JQE&CP@KT"B#0]/Z=%DQ%9ANYE=#WEC[8
MVQ'1*Y/6V.!V5 4"$5[DO@;!51+6>8[;506<Q+F1^W0$T>Q.'H%OV@&(2Y@>
M?PS27X/SBFL6?SB%$*W)H>S')XY[UIGG[C; WV<=^@P\>1U50H['B^Q'*;*/
M+K'VA<6&:F*0T-[%\Q*9CZR !<#>B*OP>WL["#S_"8'.W+15Z*^"Z"NR)/>1
MB8*OU'4CPX%6U37M _Q#4OE<^):$TEL%T"HQ5+I'.<WU,#J+AT_TN/9W;XO7
MOJBRU.:/(69]N,A]41>YY.<;DL< ]"B\]WS[;V!]AM/*SSP+C6J3!E=/N;UC
M_%PO^R:XDX\I=97<B00D7WPVX*G,$>_.M)./]>(&O,.9V)X2TF4H.=% =27L
MT9V_THHH+[4"NU4X*17E9CW8TW<W>;(GN3+KG61?I)_A95V4F_UH0'2=H($_
MPRT)06KXPX%!*A/1Z@54^J%K+_)%T,BV^]' R/*.L:AW'T6K+)'>#J??2_B@
MX$%IVP-,Q"I,D,GOHEX'JM.RV,9%%6B7VMD6JD@P1W07D0(+W][9KN%,'@^V
MGU01A9^DB)#66!5ITNCOYLX_=D@^?\JBRY725A6Q4LAO=)E/D6K.H#/>YT2-
M*6U5D2J%_.+%NP2G^?$F/>LU/^=XS;7SP6\^^,T'O_G@-^^1WUQ6#I?J+LO!
M;]ZBWWRXO!G\YGWQFY\V3V_PF]?VF[>;T#?XS6O[S=O-_!O\Y@W]YNTF"@Y^
M\R9^\YI)A8/??/";#W[S/DES\)L/?G-EI-I?O_D%R6]^P?.;7W3RQ%:.L$L2
M8:6GHHN$70X._<&A/SCT!X?^X-!7WI<Z./0'A[YT)1P<^LHX],FZ&OAA1D_A
MWYYU%/[E3];J"']7;CW+T]S%Y!<1*-4QB<D[B4>2:^'SPB(+LN _;#6AJ$51
M]L%.B8MS2(OIO>]\2(OI"1!#6DR?P!C28OH#1GMI,;66YULHWGVT9RW0A282
M 2IN9TJK<X%4+,\VBZGQY&D\<N69;])K>>9)Q?*45+:LU8F)KX(741B$AFO9
M[BYIWXV+L1H!/3""PI[J4\FDBTOZKP 5Y .6_@!\8P>"%4"R@5^=V5OP!S!\
M6AR$2$<50!3E1>Y;4+$VW;6D8V7=*@@@U^4*[&P7">/*@,.9@%'LLE]4JJ!]
MO11<H]B+?JYQZ2_(U29GC2,1H)J"GD(F<LLTMSH/R^RQYN&IS&IEJE334FF"
MZD$8T#M2M,T[7K3-N^[#@%B/(;Y[SR-P>.AP" MZ46%!*^! -JREX8=/&Q^:
M'\.,+<S54_87=K1/E3'4N/2LP9CDL(@L0;RH!E+;7D3&5%=&!F ]*=S8#)@^
MW,)V!\X);FW;6[_2UR7B[1HG^I'>12GSQ^!#\J3*$L2;5*2VO;!V7,TB/V^2
M8R0S>=3#H4?&K3D665OVOJ>V3/]N^-8&?H!MOPK-E+)9!=HS@/3'@ZBCR^9=
MS I</9_;I(]&Q"P\\^%:R"T@\MYR-U_KA:TD:JZ09[ I^_AUJ$&#:GZM1U9>
MEA9EUX8//8I5WB#7UV([=2W[P;8BPZ''+5.:JK$VT.G/@")-Z%_M\#X^&Z'3
MU+U]V'@3-[09IT42.[Q!I,=%,W6-!12/,_Q,V0N'L ]FM#L8LQ;R4T]WST<;
MD]PGH.7!<]&"(.@-('=3PX**\=+%5*P 4($HWF:'TKP7^UTA72.\OT[@)S.K
M5 6E#[:O;6"R%N]<Y,I(MO,ZX_.M=1VDH+EC<I+%KD?85+EC('3KA?434#LQ
MI HV\%Q6YGP76/7(*+:,5\XT7IPTF^_67X=^],#.6RHVDA^71+]DS 87%^D^
M6K!Z<=S--]3 MT$P6L+1@.\#*_:F4R6/#3>KDWPDZ#<BQ:TTBX\C,K*"O&/B
MQG60H712#AD*'T=D6LW12Y5!=RU1F:-NW%XJ"%V(D:/46ZT7EV;]!1MO&?GF
MO1$ N$??>RY?\D(]Y4N_R\L#0OHD6QQ'#.ME %(PC/-GQ[8/3-B#B1FQI=R$
MOYI^Q*SHB5P=15TO.9 BZ@33_ 0-F")G]I _/<2,$Y.)HZ0_M%H>]!@A/C(.
M=F@X?(O$[J**K-E<'(7]L5VU=A^ ']IW#LB#G*Y*' T7ZZP* *+\'*'XU.HV
M*(ZZX9;P*#=31;QERAMZ)MB"Y!6E*3=33)"D)R-:34JFSH=Q/;,P5DW0?$Z.
M@I=T5JUV2.WK08EY35(XH++/2.T^#I'9R$-E@9^UW9W(IH_20[Z@JVSZ*$P<
M)=W%:;3V8;3G9U$QN8OP<A1_JP?)*R\*0F!8:V!&/I0-"&8S]MZ/V4.^P(7N
M'+*R9_)S%'JK1\K%=Q?XZ* [=4/@@R"<%@Y:%-$+]),/@."S$WQ6&E5;:1[C
M'^TC)\YY'2,O!7 MQMTOL;$*4+#HEUMPI;#M2LE:08:6P#<A3\:.D58KUELA
MA,08ZF/A$!&_:YK??Q.[4Z$E@!L/SV)E^S.N8TY)A$(*=%*Y2"XB@J9(_#Z4
M-8[0%C8A.2E#L0COF;=Y GU50EV G6+9C#9V.+C"3&8?FWQS#<+0>2Y?07G;
MC=Y-!=F+<8(S;-H4.UX7QG80^O9=A#;"[ >AF#U4$3:3"9SK(&D;^8S_<6M%
M?=X0[\88?52 1( -'#(M'90OAD-\';',0]I230!2XG%0=*NNLM+9X;-[,&R:
MB:<W5T&R; Z:/51$L^D DF0=9]#SUVD6G=Y>%0DS6.CDB6S=-'T %XUXEBRV
MQ[,6IF#JAEYI(:?=2-<;2Q5H:K+7R8/:*V "J!36\3%="B2$=JJ(FT!Z)X]A
MDPOW$4Z'=\7387*#,W7ASBN*&\:GBLV]X:;G1GVW\\$.,@M5 YY  MN,=><+
M"$+J.4 >.:HHACP)=?( ^!@$IF_'WU]L]2B$D@IM,[F%#>)_S-S(4A>^2F.H
M@G1%MC \;3XX4&%KG:P/2(Q[#Y+TMY'0C:I+>A'*%W,MN&;L[6@?3"'501BK
M('T#7G<\%=!MR")&NE4/0KK,)"ZC378I9U_#$CNH  */!RSE5B,=\;).C+GG
M^PFR.P.Q(51!HAI7&)M6 R.94=WL24#KHXKT.6Q@<==S'[1\(\AQW! ;JX #
MB_YFQ5:I6W\?SJ;$]I7B4"S:;5NR!Q7HJ8+,A9EI]H)?RS,@L^U[W@UR;D?%
M1U !M\I,=?GP'[2:N@G/5CX0=16)=%0!!E%>.GGGK_@=EL&BM%5%QA3RFSW9
M1Q&KZ)S2K?^)&(Z<ZL.H D9USKIX"K"MJ B\T"VV>A  UH&\XC JP%F/LV8O
M$7+6DLGC =K0XRTVRZBQNZ@@?SX76-:M'L*7OF<"8 77D&($.WI\*Q>P05NW
M13JJ(G<17K#T)=W6XPAAJ!K A3.0'<!%;JT"'$P&, :2SMX9A5@:_L*/N4DN
M 1D!1N4X!'IGA1 2XD?R4P'Y[4EUS$3[*P2;*$L8.5F)!\6#4[(E$9I>^0X*
M84/E 8,A+0N!LSRR9A"WJT( "7"#H6KU>'_C>T&P-ARJ$R7;0 5Y%FG&4NND
MQ$\RBV+[1CNADYNJ(DDR]5BFK8:T4TQ4FF^X\5)2<"8$35^K#Z,*%M4YPSBU
M>H1.OJKOT=TYODZD8$%NJHJ\R=1CF4J*=Q?;LBB[3R%O3B0=C NE:H0DS^JC
M$ XL-C JK4:Y8ZN5IO(GH7(4LT)IJX)X&>1+?G.-A/@B"H/0<"W;W573^%Q'
M%7 1Y06#U(L+ZN*[W]4PRO93'*(L*Q@A20?:TB9-!!YF)X6P8?*!@9&9/"^2
MVZ[0Q0Z!;"QE2:GA^+RHN]8*);"++2'L7@HAP68$8]/JL7D, GOGHA-@6DN1
M6EJ-LINJ,H *4%3E":/2;J)X@8 QE0":'Z/2"*KBPF0* ]/JI;0X!8UQ>8FP
M/*/2:DSX"J"0'I#L' Z.3<\T++531<8$TK$HCP?I?YP5F( C?DM^(?R08P\\
MAL"UGC>9.0;1]]^8WOXLYBJ)PW%142/[ : R[,$8A(;M/-.-"HC_]NHM_-^[
M7[37&DJ5<;P@\@'\RWJS&/VW-IV/)O/-],M$6\[T^5K[*1WBYU=20J]H"##>
MS<NTE1,N1GHIBD%OVJY+?3<<IXTPKSS!QZ!ZD=?(\.]0VX#UVZO0+Z<5G :>
M:]LU7-,VG.=$3O;S9-0.70+6^M-D5"Z:I48TAB.N- G7(;2SAFO4@VW"'?5B
M2R W0,]+!.2?> ]CM?N53E<FT3?/.'I<@+]= 4@.T5%/9WKT]IH\O<D^T_;N
MI*^T9=SQ[%K4I(;R]Z%=Z'NI.'Z!:\D)6]RBBYR:BQGW3%)0CN,;;/=3\E6F
MO>J6U;F76WZX*4/Y:IUQP%%WND/\V ^D/43^Y99/9B:S9"TEONUE16O4&$LE
M]&NPU_-"RQQ]O?;\+;##" 5-I$K;G7$@?DPE]>B"?\D%DMM;+3LJTMT6 3^0
MG@G+I%'AX:%(_% DOMTB\3(#59NP>HQCEJR*%>GXD;2QHFCD%J5NS"UAHR%)
M)2M3\B,I967A%(MVR[Z%/2==PWZH=@VKG0\7L<-%;&\O8@,_S$ #__8,"_S+
MGRLTURG7K?#WS,]J7*[F:6Y6Q;Z^0*E7&IB\DUQE<"\N\\(B"[)X_=!34?;A
M/D]<G-F+M\MN+MX:&^LQ7,\?XJ<*GJ^L5G;PC1V;P>ZEA@T18D5RE,8S<2.H
M-+YAANBBD7>#SN[5BR@*$;6C D7B2G)H1/M ]<'4=0/6">(1.CK;%G-P/L.C
MB9^Y<(D/'5=/N>,0:^O%/*$U_)A21K@3"4@V"0UX*G/$LR2=?*P7*T6',[$]
M):3+4'(2LNI*V*-54&E%S*ZY[WNZYB(&YL:>LUCF6RFURN5)SZ A4]J\25UL
MUXM%@:0J%&$7#/$O2HF[1^:OLLBS)N=#3TU.?,V!3B9LFU-HII31*= N>1K4
MOXQZYL.U1"=3-U_KA04D:FYK-W\L]C-3>M"@.E_KD5&7I479M>'C*=<&SEW$
M+41A'^U9MQ&%)A(# 8IW-Z6KB *IV/2W^A)QY@!R+IKB<]X#X0DYE?,2I7&!
MY=IFX#Q/3XU'KI[FF_1:3_.D8GFV^U[P,W 7HGIZT0/A=>F;8JKW11&.5NO]
M9CYT*0K'Y8\,QV41CE9K'F631A8N_3:^F+68:2L?%/*>CI9PF2$=B[35@D79
M;VV^>\(BS;153:09TK%(6RTU--D?'.\)@"K:RNDC7\1=GF=R15+9@L" ]2J6
MN*9!G7G?@9_\R=X32Q]U8<9+7^V!;C6+$6Y+$'U,3*[)6Y)KO=AF<I?2N70B
M+6,1\*,J'$LFC9*::8]5Y*/?5P")!GYT9F_!'\#PJ<^G\ONI *$@*XTRCL4D
MGU,%=F%4 M'TWHJB0&>HC]F[#2=[^@NZ^9!C@4D$J* XIY8)ON>6J'MW+;%9
M7F!8,_ *[&P7&<4KPT&O3YUS%+0W5*JFQ;T17#%177;BVQQ5ST;_>)1>)@'N
M8\4$N.-@0R+<D C7VT2X"O ,%4F)%4E;3:.K (=ZU25[$@K2@XJD0Q7;H2)I
MS8JD?4V,_&%# V7-9?4#NWJR'D@/#>Q7QI5*&M2CU:$/H8%]S0Y-7PA>&G[X
M%*^+AADSSEPIF)V46C>8G$BV 13:>).9TZT7=EU Z\2 ZDEN8A=0]<B M@R7
M"AE\S[;^QO,L=%*8>R[ @2?QH0$$&<[@ZA =#HX-?-$$^7KC*F5=FS(K.:^P
M*OF8>/'M5KUQ>V'"VYD@#16F*)G>I(3U26%ZM)#T4&E.D-LY/"DCZK 4?%+F
M?:MY/YOOWK^![\'_+%PP^2NRPZ?<%203&]'.\O$Z572NJ$0PEJW&LZT\UW"L
MY<2WS6^!QX:.TE8^4D*GB=S[H61.L(1;C5M;WMN.8Q_T*R^(#*9\B2T5E"Z1
M#RS;5E.)EB $_LAS'?#$EFRYG8IR+7.!I=IJ1M $!;[@G &T6L%O!G"7@JKE
MLQ,N!#K*EWL[F\Y<?H4 WQBI5A.-YK8+=0*X=< 2[/L2\1)D'4/6:B+3U U]
M&V[^S2^&$Y$"@U"K8J,>@" 4E%RDNU'V!_\4D#S@P3\$X':JB)% NN0'VH;W
M1WJK,))$T_-'Y8;W1UZ$4M9]?T1FMDM;(>GEA H6ZZ?*,*A,E6KJ*DU0/4B6
M&5)E>ZB0)TR5;?=PFGX/DK[WDCUM0OG4-7T F:(=3/G]5(!0D)5&#PO2CDB\
M9;?2PXB?76#X+O'-Y?BPTM''5,&X*_Y[\,!?D#PT'9L02%[\;QP#3NZB I9\
M+HIOV[7FS1!XSYOU\OG195!M'!5 J<E:LW0FFEL\';_DG?&!">P'*C0"_52!
M0H 5+/I6?7Y?4?ZI&R9*L/$RRRE%YJP.J@B;Q0.6<E_]@76>F:_M8:GS,164
MH$O^L0(=_7>GR5=?A/=P.;5WKKVU3:C<F6N;X*L=WF?N1&T@E,K^J9C*OMC\
M/EEIZ^G-?'H]'>GSC;99Z?.U/MI,%_.U]G6Z^5U;36;Z9C+6EOIJ,YT,B>Y#
MHCMAVKV(1'=*D$%P]93]I5;V"G$,I<*MJS F.4,^2U"5+(E>A4!75T8&8#U)
M0V\&3(]"C3L 1UJN-Z>$^@;M'Q;;J6O9#[85&0[]>6Q*4S7,')U^"6\]ER@Y
M[O>0EMW;AXTW<>'.CCZ+2.SP!I%K]^@ \('B<=9%LF4/(>R#A>P.QB'CN;_6
M<\AX[N%><<AX'C*>.TTRN_77\+3^P'Y9H-A(OC>1?@S)NI2+=&/SU6YZ&/P5
MC&T?F+ '.Q>,U%+N:T4UMSBY?"X25UC20_)6Q\E;ET/R5F?)6Y=MAE5RSAI<
M P(;]<AT")MA ME8NJTF<>G36]NUF"J;;](OX0GI:IX!+,9VGW)"-VOQ'3<K
M_"EM(%^$%4*64IK[^$!+U;M@-23/84%NA@_*.S\@\B>/B";&15ZYI4+"+Q/?
MQ5,EN=A;1N!<-J1&P8@Y!OF2TS!8$6-Q" +KGIK?5P5P*K#3*/& ,@7&(#!]
M.PY 29=UD; M;B\5)"_$2!<!]Z-H'SEQ]$IJW6BIL:2&JDB61'L7,?2Z9<7\
M&TXFV)&VD2:W546D%/(;!:!SI7J,UJ7E5^8I*S973[9%#AI%DS=>(J=N". *
M$"X-FQ%ZF6^E@LR)A$N.W1DC5R)PK8"27TA9$-/N8KT5PD:,H4[BR'73]*/G
MSP7H>QO?> ".[EI89VBV2*RO"D!48$=VH#E N;*N"49>$ :L'.=B0Q5PH-%>
M"LX^K=!G*#,1:L$*TH[6+8Y#@-)<(0 H'& 8))UB-V!_\'S#?TIJ F83T^A@
M,#LI! F3#PQ,JR?6--TFV'C+R#?OH48(IQG1^J@@;P$VL+CK'5;;\1&+5&%1
MZ&A (!M+N=XIMK&4ESXXP,WR"A!O.M)6N48*R3E'-Q9TJP?;59H N08^2ER"
M']P"WX=_1U/HN..EW<T+=E9!XE7XP4A(.@.+K:C*+J'$-5-6F@0^4:2;JS&X
M8Y@98F.%)$^D'P-P/)N<)N,2K>1V&-?:&GEN:+L[X)IV7/)R!G:&L_0]$P!4
M#$8DW?+]VV*ZY6AQ>SO=W$[FFS7\\WPSG=],YB.45*G/Q]IL<J//M.5J,9I,
MQO"G3*JE.Z1:#JF69()?5*KE$"??K^S)(4Y>*$Z^#_F40YQ\E3CY(<-RR+ <
M,BR'#,LAP_+$&99#=H9P=L9%J]>YP_,OJ51;S2JZ]?G9+H4VRN=L%?C!<I55
MW=YP0'PG>6>8WS*Z<0N-UKWSE%Q3II6^6'Z+:L/(GQ+B#H-JG'7Q#(GNNE#3
M("&&_T2+&,DU44&\9:H;92501!<CEXF0I8BOW$P5$98IE_M:QF*[M4W@!V(Y
M-N36*LB>R<"0DM 3>&2E)&1B&G"B"C5 GMA4!1G3J6^4<= \O"!=C*\]GQ-B
M4&RH@M1IM!<3$TYSY3=UX1_!QG@\5E EW>2=%V_RIO/1XG:B;?1_92JB_GPD
MO5,"STD47@A1J)V?B$;FO>BE&*V9^K(=T+Q.G!@K</!\=-/+0/]=D=[UY 9=
MXFJKR7*Q0K>X&148[F>'^UGU[V>/7%Q% 60X"-+I$K!O:#G=U+BG$.-%\M5?
M2@SOJJ_0K!>WL$*Z50K[S_$AN91<'>'WX>:@+0#DW1.,P0-PO+@JP6*[N0=7
MMK>ZGH[1F\3WD$UC.MX \][U'&]G _:;SO6&ZL$.FZ1\^7SJ.HQU<^F WB8P
M'0 WB,=O<JX?6#T4$#Z3_DZN(,;VS@X-QP@"$ :&P]-Z6FL%9$NEO=D5!*V:
M$3X@/  WHGH_2JUZ($>QND9%PCMY?SSYR!R$R1%QY@4<01::*B;- O5=7 BD
M7]+1)&"+,FVBF A3JHN7 *?Q!E&< DQOQGMQ[T#7+HWH+@!_1:ABTP/:SHE0
M_TN)^L]7Z\D_/R,&)E_B2/7AP9_!R_%"O1SY";.!G^+X-V@=U/)LT+B0[=,H
MT\4]8M.[],/7P=8P/C!]\7BT"$V?/"'MP*/"RQ0%XJF'1#*O/3HE\C21#5H[
M[HXAG;9&.JU,4?\P)1%:/6MFBMW%7TH+7E".G=36*DB4R8#<B+01\G@MMFGA
MD86_LG?WX6?7YA@/3C<50!'C1&ZP&I&X7*7?XX]!^BNK-E?-X51'D\]A%U%N
MI:?9-]YD?W"\)Q#G_..W!Z@N2^'N*L!3C2.Y$7)-G_E>1&$0&BZJY/ 5( T#
MEH[JRNU 3A$Y&X93$*""YIQ:)EV4,,YH_N3Q8/M/&^#O^?,^VU8%J!CD%TL8
MTSSNZ;^C_T/U2/_S_P-02P,$%     @ :("35_[FOPZ):P  /GL% !4   !K
M;G=N+3(P,C,P.3,P7VQA8BYX;6SMO>N2W#B2+OA_S?8=L+5K9ZK,4E5QO]2>
MF6.AS) Z=E(9.9FAZJDI6VMCD& F3T62V21#4O;3+RXD@R0N!!E! .H]/[I+
M4KB#'XB/@,/A</_O_^/;RP%\@7$21.&__C#\>? #@*$;>4'X]*\_')-W3N(&
MP0\@29W0<PY1"/_UAS>8_/ __NU__]_^^__Q[MU_OG^X!3>1>WR!80JN8^BD
MT -?@_09X)\^.4D*XW?O,NG?Z'-^!:.?QS\/%L6_OW<2I!6%1 ?]."Q^N4'M
M@<@'+FZ9J Y'OPR7OXP&HW$A]!CYZ5<GAL")W><@A6YZC)T#\& 2/(4  0>T
M0[^"U;^XX.;9B5^<UQB^."'N%%A]27\NVKJ.7M_BX.DY!3^Z/P'\&+!Y=[?>
M@??') AADH#'Z'#$4)(KL G=G\'J<  /6",!#S"!\1?H9<T=@O#/7_'_[5'_
M 'K18?+KMR3XUQ^>T_3UUU]^^?KUZ\]?QS]'\1/JSV#XRW]^NGUTGQ&N=T&(
M7[@+?\BU<"L\O>%RN?R%_)J+,I+?]O$A?\;XEQP.$D^"7Q/RN-O()2]700T(
M)?#?WN5B[_ _O1N.WHV'/W]+O!_0VP" OH\X.L 'Z ,"^M?T[14Q*@E>7@\8
M$OFWYQCZ?"B'./X%Z_\2PB=,-/R8)7[,<(8?\W]F_WSK[.'A!X E/S]LA+U:
M5MK*E'Y1A-JN\7L8!Y&W#O.G7*BC]695P5_T\8^I$Z>=7CFKK[D#NRAU#IV@
MES4U@[Z#W=[V24_W6T:S/NSVEDN:/8!.6<"M7RWOG1[P/]VB/U4 PF\I##WH
MY1!Q Y(9E[1/)G;2<M%VY%9:/>"Y.XK9?B>H5=)B MV?GZ(OOW@P(,LF_L,[
M_ ?29?27OUU'R !8[9,T=MPT;XETXE]_X/S^2Q40EEO%.2JT!#=T+)/XQ8W0
M O>:OCN4IT0_CEZX#\WZ''%^_-MA7^C3EX(>P859$8IA$AUC%[8:CS)6T1O*
M\+P<D 2VHF#X[O/C#_]&9, ?N=3_^]]_.;72^Q"OPS1(WQ[@4X"?'J9WS@OD
M](,OIF? 91#S<>?)6##\$EAU%E!1<)(%6-@ %ZZ1P8ZLY V:DK[].WP3]HJ1
MT\D& <@J'6I"UO"!CTM B$P8$&F Q+52(M_![5"+G/Y4?]9# !ZD?-S+OUDP
MW!PX]5$NMLA81NO0KM!C/?SH#P?GB0.^]KN>P>6"RD>W\J,%P\O#4Q_?0@9@
M(0/3^6_1X1BBG=3;A^" K&;AI,3(Z9S.!2"KTWE-R ("R' )IO-"&%!IK8RX
M/L8QIFN0N,[A=^C$Z]##CC2>X2H4U63E-T M#'Z!G 7L:(#&; .H.*#R "L
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MSO#A-1"'6KZ(.;F:.?;<1TGJ'/XK>)7NJ_C"!IC#A<OE3472-M;PP#5PAJH
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M.*=@',#D^AZU!I$=YQ%HGR#G5%Y)0R.OFH%7F"46)X.V'WHS?V(#MU2!LD=
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M<WN33B=W'\'Z/^_7=X_KQW?&YY4$HC>(RX#<H*_C$)&$\%FOA)^15$?G#*0
MOCHM212HRW'O.3,;MH MH+(3V.-Z]7#]%Q(F=(-FL]LMR==?D,YTK" \H.:>
M/L(0?40'U,&5]Q*$ ?Z <(R\G'RJRCJKWK7I3K4 GHHFG5(FPX$5J0^[8&8N
M@*UO;]$D> 4^KN_0A'A+B+JZ^;2YVSSN\ 3YVUJ!J_T/:?/0E;OK#^?3_N]6
M+>D0A? )GYG(@@YE$ 4C0@8"C<#=X^H:6[UH:*ZWC\@4_K!]J)I#ELPA2G.%
MN3FA'8%LN#\L@,5&%E,YD F:B1YFK# EBY+.3=Y^Z%D3']R D7\+X)2U[#)I
M/R^_.U'MK='=B#IG;"@K*D;&?**G5#&YK.&OE#IG;J-$_LY/8O2FYVPR@;I\
M2^I?J@BE>,MWNWTTO6I*AJ*YGT:^TFZ<L6$#)\,F^5:I-/@1R_]D.M:4E&VZ
MB\*HVI=L/E$IN*:@K+G,EG)WF I<C9IT)A@./<^&D+\NF/G%VS9WU]M/:_!C
MMB?[R8;"?YLPA>B-I;13I*_",P&.I,XC%B'0ZO$*(T:&9C\>#R<V9*QJ!%CG
M3JX  J)AQ/;(,4@V8C61S+6&Z-;[2U??RDLQ"M][MBVPY$.5;]49*?T?:$N.
M#&WZ*!E@C(51L*)YQZZ%%A^=($RPD0.3;;C^AM>G8Y \8R?WUK^!>Y%5H:"G
MCSK*G2B3J5&)9L_:#_75)9=1K"5<IFP7T@11"#PDB6:DLKH-QBU=S6065"ZA
MV4RM F-L4?HSW5",YJX5J6V$P/C58'_,UJ>?,@.AH>J#L7U!^_T 79^7H]E<
M5]1#L]^B!6"!N[$Z:%;4Z% :MU9OPI[M:$?:#6T(M%'%R?I!",G*FH5#)%.6
M^41Z#Y3#B]D'].\TK^H1P<L<-U&8O(=^%$,JMW.^P02ME;$3Q5X0.O';)H4O
M)-,OTD3//)!W0BTROL'9V^/HIFVQV$]UK1F-DY.VWC+&R?;Q$;Q??]@^K',G
MQV[UG\8#)#203=\(Z ]G_:?Y2H<V9/G5TDG.=K7D!@=XE,'IT>#T;+ G#\]7
M"?)XFB#]]#B0/\_TGK=X1=E:]AZ&T!>F2!1*Z_Z>A(#9;X$1I;>57&19CJSA
M<@-(UI]&J)4ZWYH]:CV.Q1U,Y8=A%0&:0F(_=,:Z*H WKO(2?$R1G?7.AN-2
M[BN7]4KGM]F!#T,;(A@$L)@5 ,E5#T.M2EQX$WP)/!AZ2?FJ)OX_WD@(A>E7
MX$V\1>\KO?IA@R):Z<U3+V\#N_Z*#$JUU$J&O^[&(51]+SJ_^@ORSHH:?PH0
MF9FAT+D"&>D>:4D \A_#\T'U@J-T5*JB]([:8.@Y-LX%,JSU ;J!\ 6GB.;,
M =<D=Z2U,P%_\-3>B9%9X#RV67&AH!&@[/NO\4COMT_2#U;,F=47)SA@\V07
ME>:S+,5J>71:JM)KT?,QU)9N46C-GX5<9.>#U6[WL'G_>;=Z?[L&NRW U:BV
M=^#Q+ZN'=9;CN)=LG^U'K]MKT);U4Q\=1\8SSG8!S&XS6E"PGXRS>3F&//59
M\MY) A??^PL.QY1)C:*HHXEOJN +EC4I9-5WYP/79 QE!ZAU9A%A8NYX5!P<
M<"C$*XQIWHI>N/17B.O!0F_U!<;.$[P[XHRU6Y_)LZ% L<Y-:6+>F5TM"-FQ
M'7ID[@R]I<D#U\OUH$[?O%'@T%:+9"L^<,L[_5+RE7=@7^>\Z5N">2(0]#:8
M9/>-E2.5='76+FG1F6HY$P5%>M5O.5MZ-N2FZ@"Y15:7Z[^L[CZN'\'FSL8J
M&D7?:6^1-?,:A:2@Z[= Y(5NT#% 4AEX+CEY"EDVC;T=-2M;0*V3,2N]<U(!
M?V"E?@S*K-Y"*:E];6\MKF&@K*IID6_9E6)15]2C2^!HZ1C-^M@=,7.-/_>R
ME9MA*AKT6C\CJ[H@K,K0Q+UF3:W44^U(C7E-:C0L:39?0I-'<IT!"WAW4^:=
M7MJ5]OR)K$0+*Z6M'(L(8*GT2EV$!B:,)Z.9KE-\(4V:P F. R\Y]&=;5H+:
MJUR^*.H8+X3+<DE)@:8-& RA8\,=DQ90):5QL2[8A"#3MH5U];*K4KJ)A,W5
MPA43C"])/?Z+X61B0R2Z"D99G=NL,*X"E_K<5#5DG&9S-T]GLX4NR^(5+?X1
MLA6<.)4=)8M!LIY3]%<77F4N)]/;\>8LY:;RDK?FA0TQF%Q0;'XI(G4%J)RA
MSTZI^J>@BN9PL?2'NKP6JI]@ U3AA^B\1,=S[VN*]HL8$_:+P# A(=U9:.[Z
MY?40O4&X?25QWMR=BZJJKAUCNZZ<MHQJ>O2>[6B_'YMTAG5'S&P:R=; +;62
MQU>#=P!F+8&(-M5CK<\$M4]O,F]]M&%%5@+.:NFZ,9IX\IL#=#KB[XO:MJ&U
M_F?[SM4J@:HW0#/).-Y\8/+:R@6@\ZN#XM;PZ1>YR!YE#9*S+H<V"8(\Q<*/
M=U$*P?RGRU@P9Y-W16;O\]Y3WH9UY*UVK@-Y:0-TDPF'[L*X)_@\Z!<D;X^K
M/C;KL&FQ]4M^I0]13/Y+5X_U-QB[00(3\=S;I15-!.[>P8+"[9O(F>#L31KZ
M%P'/7,+*VF/B#_PHSB,17C,;(FNVU]FW3?_$\V^75BPDL& .;M\$/41UX,0W
MZ96\"/B+$-C #)QW:NO_U8EC)TP[S+_B-@R3MZESC=05-4#SW2RGP[W)PJ<7
M@-Z*MCE3\8]?LT:-S+ILW]K/N>(VK"-MR_E6U$ V\D.+9ULUZ!<@[25FV@M$
M?B&0U.-Y<\06^CWUZY4\IG@%@O&7P!5F5V_;B,[8L"[=8WRMRBW0DA=+?S"U
MX=[S.=C;&1-9$[:<G_#[3:J]G\EI41O&*2WOG *C^0W0+=)D-K2B2/$9T#OR
M6;<YG*TY8GZV4S5I1XB[(C<?6#UZZV4X<D;&8Y(Z(5;F7F8<5#C8%_?XUL_=
M6P(_OQZ"!"?"DV[#6NCK8V'K3I6IJ*Q,1G<Z'$R7QB^,=8?-(:5D1KS[_7$-
MCGE[?>^X%+HDW6VUT+>*F^)=EK(RC7,9N //_3ZXR8-]'C>;UNP>C;,.&9(&
MP\ERJ&M=^P+C?91 6<2&!"%SEQZFY(9IW^'51?:%;9B%CO-JNO,/MEHWHC\X
MNUWW>+';:BW0%"KN<@R-+UMG8C\_$53/Y^3*O9,=E+=NQ#[J"H_*6[:0I6:9
M#VTX*S\+^R6H:V"!(UVG69:87E_C"][BM$ M5>G6R?=FVF8IR:)X%G;32:H$
MLU/[4>SV,K3-1_IH:31[56? ;#:KUD3LYP:=<(-0^EL>BM3!%R%IQ?2NK[&#
MS7L_81-99.%@;#3_\47 M]L'5I.$9,V:<55P^M?!82%IQ4("MW5>")N@,=S+
MZ;[_>GB7)# /_$4(W.,91%ZFF9Q[I^B/) 04AV,F:$7)#\!Y;T954U=2L%8=
M.:4&4U*CF\_I9.8;/W_H IC)#)*UD<4F9*U@1H:X'6(!Y&$*W\?E0SASYTM=
MMAF]^;0.I5ELQ1 [7SWL^TRYZ[6S@;\?:LO,J/;R&X#V>NGLDAG$KIWD^<,A
M^IJH)P[CJ!C)%R:$+D@3QLC3]!^3H>?X5D0>J")MDQ1L]?@7\.%V^U<+JD[@
M7MW'$=X1>N_?/B?XRD=1(G[EIFBOF*(-8@,1NS2DM7Y%QV[6CG!:MI)O:AS7
MAIQBY^)G"%ZP&'QXV'X"V_OUPVJWN?L(5M>[S6^;W6;]^.OW<AHWG8VFOJ[+
MA"E:GUJ>Q17X^CF+NT"^F_]Y3%(\42:[Z 'B00H.L-*/7729N::?1^G,KM/?
MJZHFY;G\<S)[RAE.;*@7UW\/V11 Q1-Q6: X?R:N4$N3+J-_Q7]VT5/!C\>$
M7'?\"9QJC#K%$TU7HH"O"'Y ;L.C/Q\@_@.^^/D2Q6GP#_+O@O>NIJJQ1D6+
MKE0*5BCH954]QTO'B@H6K1&SAU&G%NBMW)*JN4VHWL#FQ72^'.N*U%>(O3FC
M!YWBFTT7IRR<J_2X_.3 *G5S&U\?G.!%%*??L@V-A2R[=*Y2WK)- S0SXF((
MAS;LEL^ WC96.ND_6/JC$X38AMB&.#?"(TS3 W$%\/RS8EE-CO FL(7K6R1(
MKTTL'&]A_(J>&L0Z8[ 6/M$FB2>20LGP7%?J2Y"\1@G)(+GU5PE"*)K;&G3T
MS65*X,MSEU2!WEKWH.O8<$FN!52FECLV]#'3B*)SP'/4:XQM_/2-V%3P[\?@
M54Z^'D=M_0WO-(Y!\DP=E_@C8@]IFZ6S\POH:0LI5S"55.$*QPS/#K#2B.$9
MHGFXE%^!SKGAHBP;FJSPU08C$U-55<(S 5:[ E31=$+@/'U3=O2+K# 8/.&=
M(Y[OA*9U@Y+.HO J\*NUX64:]*KS!,X]DP?Z7;#6>?<I\@(_<.DVGGN"#]Z=
M$FTU%I/7=SW[(P;'V>:2@_.]DT"OG.Q1ME]NVY+FJ]K=.LKX-=HUD]4I\O:N
M#1FQS^X /X\G4:ID\WQ736OTU!#"<I$](?I<GX(O,(3H+S00Y]YYPU4A[U]?
M;R.'GT>VE;KVG:-RESB;R4;=[$H9G(Z-AZ=V1BW:<OJG9DZ3\2MMZ=W]_3T@
M;1F>?C\$(7:HW$+T^3S@BGM;_W,"R7Y'P>>OK*UOFFW9H?+4JJA*D_>[CN?:
M4+JB$VCF!*LDB;EZ.IDZX'9!C!M^%_GOCN@O#F[;],ER"3"UR=%^W<7&]7T,
M7X+CB^APL%E/XYFO:B<J![A-2M2#ZL_&GLF+G1WA-A&3;-2]K 5\K&J9-;L)
MW1A_,3>0_K=TJIQ5A6F(8VC3@,XM5]MN5;=?JMJ4#*/)P&@"V7-Q,S%1S^AO
M:.W'9L'IR)^X%,GF[! X^^! CO\EH5&F^)L^P_@.4>08QS!,I2YJ96VCS)5U
MJ(&V/%5ZLCZ$'C1Y0>4LT'7"$A5PB,*G=VAV?<FX:A\U\X^)&#^WV5?TUOYK
MKNM;,;'R.Z4XKU:5Z34DSY\X-I@$'6$S))79J/F4^F8=:5<NL5WR+>4IJ?[M
M:150?G%JC9FD<YONRKFMTA*-3?86<&##8>(E^L"I#4=:R!T)X!U %H@'*[44
M,EO8S/4A]8ARWKBK:]/CEQD<+76MNVF$3+Z&".U.X)GP[?6.7@?Y\?/C^@9L
M[G[BQM%_-_=$SGY==MX+N0!_M5V5D\U373 S1Y[XR@%N!>3-@/T;XF\>ZWQ:
MK4^MF3X'%?1[$WZ!R24N.DD;,DYHA6XJ$%O2"@V]& SVO@W'3N?B;[KHM+G[
M;?UHQ44G9%QDMQ]6[M^/00SOLRBD>]2!%-D<ZSP0B3?.ZMIT,I@M1I-QW^.[
MI.,;PB=<%%>V!'>%7Q_>>X3MV:%9^MM&<6F9O-J/<N<WI7.RTDM>&[R,73 S
MJV_>"':)9\V O)TK0%JZ(O0M&C-3TE9]%CYO#<I2;B_G4)>!U75ST A>87/0
M<NVQS+@Z^WW9:4Q=@,"CWA?6BQI.)\QM=P=%8_;O#NAY^P5V!]*&C!-:H9L*
MQ):T0LFR\,8C&RX-GXN_:7?P87.WNKNV:X9&G74A])(/B _<2A8B@Z593Z.]
MJ-J)BIG8I$2S*PS<Q<*&'!TMX3);F4P=X#<'@A;9\WL)EFSL39Y"#WV3O#B]
M=OJ:PB6[=*J(EVRCG-F& \\WGK:].^Q&AO()>DJ"&,H"T#3L3C]$\0-\S5P$
MS=--HQ8-ZW<6L_YS"K=WI:C"9D8UWY.>*LQ>>HJYF!>E>4!;OQP37I->>#FR
MX2RU#5:Q=P3S[Z2.)Y@LXWY37NL>QP[AR>!5@\UY(R:2I<>)D]G>M6C^4 /+
MW.8H[FCS@^8/%@3--PV9XHO0.4-<C&4C&TH_-B-DYH"3"N8540*9EFE/0]F0
MHH83N;&4Y,6'/=&<V*QG9B,F[81H(\95HA;&8CX9FBQ@UA%N1S/W9"[1FVM)
M43+:(IYF*5SRGHN<N'(5,^P401<1LRZ?5:<;C:8V!&^H(SV#CGDITF8B6N&I
M/,]#2=_:=#R:ZKH/WO7LJ!&\\.SH_F'[V^9F?0/>_\[U37XWOO>S7YB=OO8+
M,-AHO8QS,+<]/"H:4SL\ZG%\,4C\/WS(_L4Y8&/S 29I'+AHJX1_6(5>]1]*
MDO06?#UF>/W-/1P]U#GT!W*-Z %MN]:^#_GG,'H1T'O0B_$(ZG(1-,Z4)E\
M;[;]\69]_;!>/:[Q*3W]$_H#G817=S?T#^O_^+SY;76+,\$;GGC-,-CH&.I<
M /Y_.4$83>U@NM_,8H:;OJ++6>D)5^#T<$!%<+16[1^K&A05R&&AJ28#]M,5
M*+"!'!S Z "%]QVNCA?G,O5"NI/13)=#BU:K>4R=..UM!:OVBAN5P%MUKL >
M/@5AB F# UX)TN]Y*>KCW7XW"T4_W\K8AF"T"W6CMUGY?\VLV6N>P>%BIFOA
M5ZH#=L$^M9A7(>*++3/JX_'UE1ZM.0?</URW:A/Z4?Q"\JLTE153U=:84J]=
MARII]-14:6*/Y7P_M^$0O!-HYH"UU A)I7.(DB-"2AR_>#KS4:L@.#5K.DXQ
MSXAY[P0>&Q,FE-*?D+0&D)>!-!.ATXGOC&8VI1SE@F-2\.<)EUZ1M'%FX(H^
M.^<;/@"6DX,5U)H500"SEO&@)D6#YISI<FI#%&H3OCI1B.0%6"(((RU/8S?%
M+(;# 4(\B]4]S&]W\*M@@3N_.4U!IA?H<A%S>D9;68**F=F,_9?MA>(B24.2
MPG=TG2S.';+R76^F5TJ<7N\Z"K_ F%2"C@.TIT<OILA8/A1\V@IZ.NMV*7:B
M6K2K08G6;G G0\^&^*66<)G]1J&:YT3L98HM(?2S/#7YZL_[&*7BFJ9(!<C%
M%"B1S=*SN(.QR;"C=BCE),E3 ^7Y,HWX*6X"?'P;>DE#8#)/CG9VN!PN=47=
M*-0=:0;*CDHIM,;+U7&ZZ$<8!\A@N@'WZ)N$<8P&B[1G>DV1C)G"V]"Z<IQ+
MKXD-(1-R=(SGLA"_LB"6O0!3<)B :1X)CCSM\V@P]76Y$=M\\(V V1*;R)ST
MN)_\-?$J6_OA2\:RQ=LQ,A%<CH8V30Q2E+()HD:PJ\:IX@SC,;\1>!TE*0E.
MY5P,Y-D[:GJ:S,DVG2CL2A4E,EY+9P87QNM>M(<KK,KIXB9H.#'WXJ;A&6T;
M/SEAEDP>6<=)= @\)ZN5C#Z-!._V:9[ZS''@'![1OQ W0%.2APNUK6^.O.C+
M*$^F%VF8%O4<3YRI#3-O#UUBLAD_?%S=;?YKM=ML[[[GS^3DA=O!;^G[@]A8
MN/QCOI./1_**+O8=<9Y!*X1[SG)IPU%FO[WC?UV/-GQ=#T'R9X(Z^1F1+$Z=
M(%3((-2@H_$6J0KXRE52F0(]:-Q[_KCW6\LJ=TK5H3)E9#?_\7ESL]G];F33
M_7A$(!T$USG<1,=]NMI'Q_1CA*N48.4XE$XSZMI9EID!W.L:+H4->5?X'890
M4XQ.V\'L_$+T1NIHY*@-)F,'R.P99-$$(&T !S<"2"L@:P;\@1L"I"73]]BS
MV@2XHB=:SMWF=4VFH+$,6R/L2OTUH30U\)WYS+.A+J J3H9UFX]WFP^;Z]7=
M#JRNK[>?[TABT?OM[>9ZLWX$JYOM/3:CP/9#^??'W>KN9O5P8_H"TV/P%)(:
MR&'*OH'&N5-16>.\V:H[E3E329/:-:/)8FC#L7@7S"WY^VO/!!9X0U?!#82O
MM]")\1V+^X.3XO!*64!2DX8F#Z@:\,+W*1>G,\_0F2Y-WB5H#92IP;,!-^OU
M/;A=KQ[N"+EN5[L/VX=/6LU_23<:/ SM-.FM";1<+'2=CDK,_G.@7V 8+SX#
M-+O+VBH;G1<N3SSCQR/MX3(G<$*BF3;8A94&&NQV!3VMJ7W4.E'+[R-7H@4R
MO0%: RPPC%K"93+]/.#R8;O?R1TE?#WI_M/Z;F<F@ZJH)XI>\3;Z-(@2#N%0
M5P$B!8=5]PZ<.ZIFIQ3U@Z%V35@PT?1%71O\6)U <S*-E2O15 O1@%-+-CFS
M2"G:)@=674@?&?GPRG2K2M#K#B-O[NTM8)4,&^.9QSES)+OROBQ<BG'KW\(D
M@2J&;9,"7:,A7.YMV4BU0]QV8,[8+*F^^S:=T;8UZH<XQC="RBB9_0\EBND)
M'=^N.<%NF-A%PGJO08GAUN\^L9+9+=[IS(KT[2H8F:L2V[O?D'V[>7^[!G?;
MW?H1W*]^7^&_88,7_TO^#_H7!WJY)@WV!UC./ZWRM:NKTNQRH_U4VYVUI@6C
M*_8^AO;LBVUM1J_;2]!\[4T''8TO0QWPLME^E.EG>M'"NZ3TK6&QJ@OI6Z3X
M\,J+4U6"QN!,'<^UX8A<AJW.&>Q?,17?A6/HGZ.#!^.$0L;$5W0Z*"O3U/63
MY03J.IM3B>[JAK[MX.F)3&@[C%W?A=;X!'W<M,$;UAXQ$YY0:N%? &V#5".Q
MU U6SJIQ';V\PC A<=D/\(#K_Y!+0X_/3@SW:'?HY866FG979S:J\R;A);I?
MO6MX3HO4(S/W_*4-;KQ+]H7Y4';;ZW_'.;/7=[O-;VM\9GJGUPO8NI?OR[V4
MSGQG-DG/A<;0\W2E#U.Z&GW!/IW)!KNF1CDO+OL:K9P<]7X8-A@*E^H'\QU@
MG7=$"61:8(5K\SS1DGD660Y95^^=.'W;(80)SI(5A8UWG1K5=!;-4^M"M7B>
M7(<FS9M/AU9<PVN'EKE6M_O+^@&4(VYW#VA>QF6$MG>/X*^;W5_ P_IVM5O?
M@/O5@[RPD(%Q5-RGM%"G3H2Q \<6K<R=\?<ZWD8G(?5M=ZL6S$]-/5':AC6U
M"^8Z@[,V &D$E%NQ=/^-DW$$*=TWA<AN(%<B8(@O1"@?9K9L0V.5@RZ=J^2I
M;], /9(:+I>^#<[G,Z"SIVF?/FUV./CO$5QOR766]1V]K'5W V[7'U>WN.#?
M]7I]@WXR/24K=;QI5F[;B&6<EL[-[5K(CBV6CA4YJL[!+J'UU7? ZR(_MO*\
M+-4PD)Y<;<Z5B--XCK'O:/-+R;BH#)3)9W6'J+<&N]5_&MJO<)!+9PR9?&;1
MS\9[7?M-A1V).N!N8V/J@V]:MN0J1C_Y\PAFP]JC!)(M9X&5 -*R= /P")_P
M<OH 7Z,8+Z9-57J$XAH/A1L@5\Z !;+T0-^;3:U(IJ"&DG'6KC]BZP4\K.^W
M#]AZ,1,^4L.N>CC?K$:/; :+V<"S9VEIC?N,43,R ;2(&%'1-#<M7)B(-BQ!
M;; RO*.ZH%"V=4$Z[A/X]R."NOZB$.LA%M>;?4H&N9YKBB=+IWKH3,8V%&-2
M0\E0[//[Q_5_?,:SV_HW>;5QC:/1F/J+*TQ/IJ;.<*%K/!2ST2F@/6-<C'SB
M*CGG!/+F/O(S:&7%4M*(D)<OCFH JF+3JO'>28*$5+ IIW5ZH__?Q"]597UD
M:]>=,O/4-&GFFN726=JPVG3!7&<G:0-7(BIG]S5^%%%*/*Q&1;F*SF.&9NC5
M0P6Q?);M:NFX-M2_44?*IAD(0C=X/=!:MI5V3!.-EI>N%9569)R:KM[:],J=
MJ5<5;U2D%JP+X=Z&C(0=(#/'6+A6),YX4:\5;VNF%C5:JJM;D*%%@9RJNK2\
MFXNKWEK SVZH1?E9JHE93!^OO+PZ08R!;..;('F-$N>P]6^C\.DV^ *]59)
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M J^CEY<H;&"4DIJNF%[U+IR">IMUZ*;-'\SZSU?5&-7;%BUS )XU -((Y$T
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M/M+5TU-,JKRBKR(.PB1PR6?S&TQ2O@O''!:=I:X-ONQJX6L#0#)G^&P_-FZ
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M*VIG'RO%@_^$@MT&:X+UANE#9>NBTD#CCLC+%_09$\# LSQ)+% 4\E>M',-
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MA/OID[QJR8X$&,8!OG^>H]USML23S[;Y J5K%]W& ZX3V,+KY'3407I"+A;
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MQL0J.6LPR%@?HNT+'[Y?%!AX$V,('R2Q844DH/^%@%G\(%-CO)U<M@3(4,-
M$BVK+4^H8&2K=G#F.LMP)BL[>YS[6_F^$:A38U,SG*ZQ'SW=@P=X$F/X3.6/
MUZPGLJ:^P+2P BM+HI*V!R4_/&&Q#I1M>HTR/XURIXJ#),3C[=30"SAZ$!JR
ME%MKLW5Y@9U\_(=CQ=7N>;?)/2P.9SLM:+G:$&B!%P:2*.BM",[ ,H;S_3P(
M(D(-N"DY%M)4EKJV0/<0-*9V3C7#.7FNCT'LHQ\M+7KU?(+GS8&M*[8S1:6F
M$=')E5S$C;Z,L4R!LNT=C!BNB^56 (N:;BC;@Q+G+5T+I/2</C4'UFMBB$9Q
M4*K1<!;@1KF_#]UY>@/%0S+7L&2RNQ7 49S(Y[Z?[DY?S<AGURG\AC;S."A6
M(^TPY.D+;->V74D,:>U.QE;P2E[F0C0?1,*78Q_E%5%88>CG#4& +(1$>T]T
MU6DH6$K>U2)X<4/B,_$:N2<4W#3:?FJ;8^!J:$Y-/>%"5'!'4%7$-7I^25*8
MON[3;99CZ>@\8G0"AA'XH>C7WXZ<XL%5\&O0YYA#W$ZV3NYVJ?^$UPMW_%)]
M'RPM:8$L*=Y;W3-\L HN#%)Z3L S!4].H+WB$6B.9D_-3D"'43#.GA[C[E+T
M@A41<HS3.5=J!"P8*M7DQ--@71V.@G>#FASN#]&A#R@E05)WQ:+(]_M1(Z#Y
MOG!U!B'^I#VU)[T.^ H&";).\ D/9[<J-$/D2>(QT^ETNP12\D>>UF-1H<(=
MY--KY#%.N9K&0 O)&3]-5K+P%!P=Q#OS[8)3B=04;?.4>%=)O(WB1Q3[49YM
M]P8]PLU=FO@(D6Q(/)&IIG(9F7JU^O)EN?ZRN%T_X'_?KI>WGQ>W5R3^='Y[
M/;M9?)[?S.[N5U>+Q37^4RDJ-18:E5HBRS[O\(DR)WC-(:JMA@&NY5N^Z+C(
M=O&JKF*%@21FXV[$IKS[UJ*<>/"J88:F)IMUY)S";&Y4H<@:O-H]LD</?36<
M()-X,$D4CSI<9(^*#$_"*!,:#]HP[P+B%"-4#8@<0S;-@;6=&I'\JT2H0L_P
MJJ55)(@/.N-&,_,X8?9CZV@!0K;ONM7G.:F.MXM3JL8\PD164MQD*)ED!8%G
M21B6TH;@=%0%L0<-@_N2-L=AG;4!NFL$OHQG"^=A425Y/;Z"W(+>=!_@!N7/
MFA[T_R@MH"]8-WO:O.Y?.@])P%BJ3)MA@&IYH2N)2LK07.HUG4Y(>\73T%Q<
MXA@O1SP?F+[2/%E*34!@:ZXKR3W!374JBEX1,!2*YGPMN2%3J'K9#)B!JZI3
M6\],)*>(%A&'TBH,(Q^E&5_T5UUK$.B!&4IR1[<]8IB 3B$L[S 0Q0D5QY;7
MVYA],?##ZQJ(,DZ5@I)71A$P18U^J&D*= NZMB0)$5N=?DPTO:),^GLH' 2(
M3TG:X*5PWI 4PO"%J^0==Q -RV4PRML]O2UC_$^TAC^.25_K7M34RQ>UY>W5
MZLMBMI[_5RF)JY!'LB. -D]BC$Y ]2W#Z186U-_I_G!6XIG-LPQML]4+(@^0
M\>--DF57,$U?PR0EF8H9FDJ+08"!="V01(C@84KMKNH"> QUI<4\\B.9)_Y_
M'S;8<UR@6*KF2O(^T)[-P])@#+6JQ>SN,<TQO9[F<7"-OJ%-DL?;]^=\_;A
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MCWA9'OUMDSZ#!\U8PC'\>?L"O@QO]F!<29'V5,8?A\H/B+G@Y1_>C[TLGT3
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M)BDF5<8Q0AAD0\;.*:MT>JBFN:#T=*:>:[-&8.8GQQ.6!I(5/]$]U'0_.MT
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M&_BHGH]1J]PTOYDN)'"+>5S%0@.5&R 81G31_&60:*OM6)(BIZ*?4J,4A+K
M+Q PC2P<0K*@C@L&_\RLIKOR;@=H#8!'ZA.;1X2P[C'".H-C9)B7Z>I,E+4I
M315<!%T<MZ!&_4X]@W!B@:1[,F; ?^RV=K=V6YN;F[08_['3VG[SFCYJ;I_
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M"D%*$O^:]TD?0S)SKGU1V]$#GH;DHRD]>>&:\4\=JW[;Q*J?7-W Y?B*$8#
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M5L2VG)0WA1![F R6*MMH#X[!40B/2N*7;K*TV7!]/M!@,%B!3J9I(I)H+3:
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M0[A^S@., 4WYQ+;I@'+\F\2<*=>(Z^>9\I][0:*$R^E@1"DVUY'(J5\9 F:
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M%D;:IK&50%= ; V\A]\ FMALJFN@!O_<%RL8#<48,)>,-KCLA(P[C$_;[QG
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M_7?_9_;R>:(!9F=U\C_1J0^'/9YR[^IY(<2D!(ZY\@_QIV3QO"I>]!W-+8
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M;G?!XI(VBZ[K<T:3&C-HA,O@8U#N;5HT-9Z2<SQ4LR'0WG>4P^JX$9/^DUD
M^4@V4J:U%\UF0A'ACWG9!H3[RG]TO]_. *LHG$N4IDI":7U:^@&][?!AZ3N[
M-B^"@=Y1MU2A'6CQ$6RL?:QR:]Y<5!'1[2*9/0#N!8976?7Z+G"^UTU%-SZ
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MD@PM5//H\WV,/MMT" 8J2,'AC;RT%7ZW'=7H.*',71?1I1P>-\Q#,X*)7RB
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M%E$J%;QM[H:@]AMO]G>$+?(9P=EFSQG6)@-M](!BG735MI][G8@)DKSV2D7
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M?P"RW;CPRA8MC@3V"!X8G7\^%;O\K9-BSZ#6 [>N<F!]R?R#>N-9^6<+?QD
M.86"T1AQ=\9<#F7PF8_0(1$;0_E+?ZA$R.S@M/O=9[=!?$M:Q(##+1+"8&0$
M U_EW(%9N9RC:7]9@2K3*Y^%DT7[:8%US?2]#^B""P3MH\:53PC;!R'N%9,>
M$\S^[!1#@Q/TNJRV2/LRUO$+MZ0$7XTD'Z(I<OD[1DWKT%Z>I/22U(L03\8K
M#]*G3 E"7G2=+PA$'\>6:G.1L.@B,9BC;QQ<F(U?1 "T\=@*F9=EJ6$#>RZ<
MTS6I6?\L\U"VTY2G+(\U-H?&#+8FU5:+=4-%!B(S,FZ3/%U\;T&!.UQD\M48
MN8UH+:,C=9_Y45BSZ*7#A;V= HHQ/2PXYQD\5<(6IO6\9851M]DV0!%<,J@N
M@)>#&6889M/$(4*04?LSC[MB.2 .5F H7EV\Y6F$\)N =#<4+;WW4/<9F+H$
MOO(G\D)JY)P[Y"KW3<];&)*9(JSAEJAVFV0UKU:B:H@+F5;5XH8G+E#BQH8M
M#"8A(/=:<*W,H!4&&&5-3-(NP5R>65$X1HL#K9-6 '++ON"W/I3+M=9%IK\M
M.JYK\-9PR:N5&*2+\(X +U3 ;^,*L)\<#BO;8._6Q;-$HE:TWI%@MCQS=83R
MM)LFNQ'E)?@CFMEVL8&1U9/_-\);$R[!U).B]V%;OFJ=C<Z2#+F",I8Q%S$6
M!:"=4J$J\RY9IU& 56$<Y!A]P6C(5_I&JJ_\V:*"&[ZD4M]NU!<1-%%%LQ5:
M]2RB)/OSZVUU(3E\',C8S\U5X4HQ<@._8H#4E)H91XEIEP7R9&=Q1.[4-P'/
M4>%\2#<*<K %V#6XK95;E9U"BJ!R;6904OX6T8KJ:7C#5G:%IC%YP"5*3Y@"
M/<,H_9FBV _7U#A?H=1)Z\';H;## >#/Y!GME60%(RQ\K@=JVTIP@@QPQG:T
M N+M!^ 57LS^H9M.H;F("A2=9%?Z]A!PNRZ,Q4EY2^'$*.)M3']:*$,G3:*0
MHZ3[X0#'=LFIVS3U_7X#&G1*4,"';\Z(NE+)E^VP"(W_EA$^BUC]6]( <Z @
M\_)0'<KZHIV)$>"L5ICZSD*,[4]ZPV>CVU(=,K3O\DR.=M@<Q1C/$V$.#KSF
M=E($=<%G)OOY?L1BCK--IDS;%@1C.?';P/I2QT8*H"VA*1#S>R$@@'.LV7M7
M%_>]]]]&;&3S!CC6U#]*0-&!I\S;;VG\H_B7LA!>M$BFV'O?E-W<QZ\$?!Q^
MPERG&L8 JSLO6_Q_E2^D;H1WI:.$#"_=DBQEVZ/2E1:YV3F WZ',L>BK<*!"
MS"M#?M$-@YY.Z7T/5Z7C.T?4?+@#TGW#Y%LA:+L:W_00*3$?I($6L"4T[\_5
M/S=E'6MKUA^,;!&(;1*1(!QP^I)PWJ:.IZR2CQ90M4?>@ER]D.0(I!3JAB!/
M2*88GDU _,%F]$))=OM[DO.Z(=)-FT*AB(T>-O'"5AP)^:6K]VD.G;Z:2'H6
M:5<HPMXPR\0@8P+,\*&7AQQ1'=.XYQ#!_+%[$AY//0F_91Y<,A!>9Y+CC -8
ME6]=5:Z;QMM0+@'P80P=7V2=JA&'+?3IB9_8M.,.I:'3\&I94LN'WO\(0K\F
MAZ6V9P,#^C+&<0(KN"!<#][0AP7X+46OB>U=]=XE T%6(UWT_B<[R\ RUU=E
MTLT;-3SJI(I9T^5HM'DV$+PIYO5Q3U@9%C+QN36GCAI<U4"/]K6F!/(BWW+=
M/X*ENA@*&+QB<0?RHMEJ& ])&7Q'8X1,*@;&F]%[AO2&L1O1S4E)42KV3_8C
M:Q"\I:#*M1W,!OVX\6)=.O9W.B^Y=A !H?AYN+DVDGZ)G%[A/VN14%U[[57Q
M*CLBT;AF3_@(WPQ9VGQ;TFR,,&'#A6 1.</8EU9K6;JJD+8;:I-PWDU9!,;6
M#U]#N 7'%W%V-8S1A(\%0LO##^G8PV"XAD.18N9/W^*M$$)&U1%:O<2K=56S
M#=TH);5MZ8"C'.-0/SJ+H_#B**T!(G1M>_<^J-?AHG BY(+N,/+DZX;9$T"F
MQNL6VWU';A#H%B@H0#6RN/;R0"U2J MAH-3QZ%D%)QS$/\DF2<N==,GK321G
M0L\VULIR,7N92HA\U1#]4 Y1W'K)H%7[J.U- BVOI+'IFO-MQQ:3Q%_ZF#@?
MG2Z</@&WRF@QH[^SC.<[C->+BPV]W;WU9M1OW: 5FN(U8CB.)$B9KFAZ_M#J
ML:5"EJW&ZE?-V:[VW%=5V*(MTU!L\YU4Q!4<7%+W(QFK@\P-T7@CXG;D7A"G
M49OS)%.T]#HPI"6"3/XN5'N4O$ROZ%4]5C-T1\=.SPKX/.>4SE$;1_;N)V<D
MN755 (J>]5NB\7P'.3:,6(Q;2RV@CND9!%M!BF7Q#"HIKG6?HML$@DC>1G.M
MIAV]%#U/39" ;9P_B6--)"UW>2 [-IY9[X;$21_+'O6D[@V!"2=A+Z;;K.3%
M65ES-:9\+#J6AH%VT4,?TF.<-Z-MI9JHLON&X8NFZM-B6,C.DC4G#U.;<ZD.
MS/J TP('/U"5T=%5\3,K =*LR'RSE/()M*X;3HU(F5AC@+BMG"-A;IWX6I0$
M<KMP=R'LD;!DV-\;GQ&5?,DBB?9E?OI@,38^#FH*#@T:C@R"/6#5"  P_XSG
M4:OZ#__>3<MF)":'Z0RN<W($EUS-WVECL-4[-*K:M&_1DE%I8WE^Q[._R=&E
MA.(M[HG.PY0=5/O)\H[MAW)SAB[YPNN'!@F[SID'"]$94B#4%U)0QX:9A%/R
MPWS>.>DZ8D&0[_")8D$JZW4Y+W=2(16C3!>PKR.LTIR"Y2\BK2Y=].)PF./%
MX8PYNZ)_N4P3WT6>(59\S$_T''^(\A>O)A9K:M.LFSRCS@;2JOLKZWOTW5#S
M7@@[>6P-2+=1.YO\\C8W=90D[JGGE  UTXG7(R_.9:40[_)60GR#H]CIG?_#
M<8JBYSLDVD"F19)P(?B?_K85>*.-Y>G6>>@3M:\!A:L4C628ST(!#%P/KJ=P
ME03>7,=0,8.FLSR0I ^T->_A0%UC<1V&,"1M8<-*,RVMOB(W-?D]O1A8]3-8
M\#%;?MR21Q(0,_(D-CUTSQ9H#1,+GV% 0(ZY'3*&GMR'=KKPK<(?@6N!X0M^
M?Q@ZYLLN%*N/QS9"I8#'7RL9%))!S19\WZ%S1ENN2TX@HDCFOR7CEF$HDB6C
M.)CHHOJ8O\I&TJP#U3/[EHN@4MZ"KQ%"#T3"IKQMU0"U"3M7##C%B2U7AG*]
MD$LJ[1RD[GM;/(UI@> 923.#/[K^Q$KTIIJ>;F27_/OA*>5-5'B+FH=[.!!(
M6A":831?>T>1&E9''B@P;[]/N7"#@@;62&'%4!]=4>K;Q:C9L=_!'8..9<!;
MHZ9&3MW0?ML!=IC:Q(\>#/$/4PQ';OP4$);2%D<#=Q*B#[Z8#=\>$GLC],GT
MN[%EPRO!X*+WQ-_E;=W<5*Y LD9*%I0L<%I^SP8IEU=().R:.$BI6_>>G?"*
MA[KV;Y6NV!#HSV*S2PU!< +BB.'.Q43.M9?I(A]RI793_# 54V\OIGXY%5-_
M6[LCI@"L:+UCS 1'>4TR()*QSP=FQI*I^1-+MFC.K:>N#9&AUH/&,UKTZ2)^
MR?X8.H)&I'<ZXYIH/.B;PT#GB-HSAI [!V,Y<:3'?,XU2T)X2(; R\&W=6!H
MA1RQ+</$VY6VF(JN(JT3IBOAU9OZZD'ET3A%3+K!.V?/!_GU$/<+#PBTV?MJ
MCN?@*%T%=U$2(B,Y2>_G.'84FC9-4'*KC#LZ2<W].YA[IED);0C>RPXQ=2#7
M949^/'<R(KD,UAU=9QH)0.I,3Q5%KL$QOVG:JLA,6*UMW&A-=865JZ'D8GR;
M(%#BV2-G>>PAQX^B"."0S#RBB G\ !W =X*I=12SSZ[XL)/^$_<_S:0,I^F>
MI(26+!FV47NP=0,U,17?(&T-P-.#CH<"$WOH35[$^VQ-CTE?'Z-$Y"$94IQ[
MV?1'\F+V8^6E'\ VF>A*[Y;NI.E$_+ ENX-YW;'DC#PR+ZM[MX";C!!Q9&&"
MZBAT)-)[J^'*9Z$81A(EH4)%<O76[6.I[@^2M\!TMA73PM'<"Z?*^$0K+$N8
MZ=863UHO/OO!X@HB5:QW(J# R#$-2ZCY#&I3AF7([OEX#J HBF'.-PT"R@9=
M3D1X#1D5CMO(-97:&;# M),!0%HQT!4W!C/X1F_&YM*##@?H98[@?)P($W+;
M#T@'KF!1:*_T:WQ2\4/3ZA]SVOQS<JH(@TV7,^3K=\V*N[U"Z$JJF(8+=R[?
M<&I:XZGTH;V=:7M*A>N#Q%U+Q/_C*>/;=+&52+3E#M)I40[LBA8HLGNE*!F#
M;+8NJ1Z-=N1L=(ND348+]7 (J622B0#3RPVF*0^GKZG,#2B@F-(#[E!0&4@,
MH%3OGU]:U3LKBA!8I- Z*6'<H60J6T8I.6[Q8*]%>P^"H^>_^B]_#W^0R;>-
M#_7"LA0'AVC$AY&"C=Q/@W:^#_[+>I5UOYE3^7AI;AJ6U6J =+A$YM1&\J2V
MX4>\<$4L-+43^.XD/.MR*_TF8[TBIDSS!I;S]@:.6/CZ-))QR^M+^P:]?<Q2
MF-K4X;KPM49QCL>&B+B'GT[?.1IQM%>('D<M:!\@[I=Q?KH3)*@V64*29H=^
M4/RDQ$B3Q&Q(+G%F2++K^Q3>P>N:+H!UT;0"LL\XN[A]+])IGH$Z,>@1SM"U
M>+-.QH</P@^>9J+0P [$=.+6LH6,:82@6LSBP2GM*,@E;$GQI!O9NCV2P2H+
M-44Y-/I$H+L!BU+VMXF3463PS!U"5:8W4QOI@/W@M736W7_KK1N!E+QQL3@R
M;#-&7Z3(2MZVU!^)=N7QZ,O\[. 7XG*P%?7?';Q6<+H$).V(1E;5<?%9Y.4W
M2 242PL!ETAG +C+!F$<^Y@UC8*B?PX!L/Y7Z/;W41+\CV-\K?J#&\* ON\]
M+Y&UF\\2[UH<#&/T(UZ(WAFJ\2\T .!=3+]09&+3E])\0VZ=R[Q8!S2HT&EH
M&_ YO:\WY"OQ,*V)/J5:H^1%*1:!]C'X/X1>,WT6<U,J,G*+_SJOT H)]#4I
M0J8GF9H3EP0W -C8*RZML;OF0W,"+YH0)3Y ^P.[129"(6EYX;UX.Y>,.<70
M4&JW0N%Z@_Z=NWVCN4Y&\SS$ &>(D%9;?]S61P6;<B%&MI;_P$@X)]P.P=.B
M4:!*)F8ZX%8C$P3&JH7?I]A89*15YG1VSFO9-F#P^<_]F\$3'V2&6;#B#>FY
MM!XY=%),A8M7(+0OLR\[ .W0W'B X@G[ )P=S3)&FSHP#[:9)CZ@S ]T,K**
MK!' :8"I-0 ERB,I->,/D9;-!FML@<E"]R)_*DU)C#LG3IR_!'6G,DXJT$-L
MUYBZ>.GZ9%RV#@!G.+DK_URD\+;>8U@#EW:V;6ZTBM>SOM#>>+FN=0H8>XS0
MD2B&!"-VMSLC(TDB-2B])@=#>TL&?JP!J I[MLR]R0#*;M";7@&#"^=:]>58
MI\QV//LZ% 8>3@NX%[8436A2>.WXZ S!'\G2?Y-M^V-7;;^:JK8G /(T@ 72
M'".R-KMC< P\KI!DQP<_TFJ/#9YNG$1FH800X)S#P1R/;\3.O^<F<A%%A-0.
MC:(E]X&Z9.KP8X*/JZAE8TR/H& S6)>D$*LZIL@WX,>)"9XQX%7.(PS8%33-
M%EMU)A_R _(Z20-4)"U*6XH9%EP@J@ZZ?0UFE01\2=*;Y[^8P^K<TC&Z@.$=
M-8)"7E!60?\6P;]2<BC3U3OV%9VIOI@]Q09DL[7WJZ!R;ML*/A2H1>(*>V%3
MZ8;I<(Z[Y+.  <^>-&\YQVU)(S*+PD<+K&\Y<]*WGKCY=#V5V5^]] C6CU'7
M#1/7X2[)Y<].(1R,6MBZEY(0*TO@(1'QS?&,^<AHJKFV6D\TT/!_'),2&1D9
MU<YGJ%XTUYK3LLV5-\B_.,^AHAA7 $98RIKTGS0AXP47&%&9Z)AZR?6\8+87
M/@"/%$/OV5FFF/8JB*(\K0%ILE1J5EAWG8\E7,:EUSL-*G$; %%RKW22!)V]
MXJ\3Q ^7G+AE-$D+B+81S\$TF<G8?EE'I.W05I0FP@-Q&E7*#:H'98P!GEH<
MS21+X2@ALN2'5F[OE"S,?*1J5BZA5[[.JYZ'JT*O=#TS#&=YZSV9-AX5GJG6
MB>,;KH?$I$; (]!9<RKX,K855//2A_:"#9<B=Y)K"+"6/<=V>")^?D&5XBQ,
M2!CIY#N!>T"8*#_"6RH0(4T7HEO_>U=WG$YI##JH<*\$0D#.VW*O0WO86T[(
MHF4AW0<M@,L@I?(CY6/&TJ1I91)LU&/+K6TT\RXD9[-:OJ!AXG(%.#04%L8R
M*:J@TBJ^T2,W>PE#(##//AQOPZ!^FINVH&$4(.,>E5OY_UPZE];*PC=3"KEP
M&N 6RR'C<POTTI_&9-I\-]E12")A+U*B2.P]&.E)5,BM8&PT;_BKKLG>JQ=&
M %:YU4$Y=]RAVZA''X=$#D@HH83?060I%;T*D#[ 84S*PG;O4.[)NQE9,W_V
MZ69N!LO0.LIK9O@$@A"\)OF8(-@S@<7;S58M-Y,Q,/N81-"!W 8D^($ />M;
M[)?"!"38HF?A-[Q!.4*XWPYJ<G\[I>3/_:[\Q2$#].]F?.3O?)7'_SOANA[<
MR=)I#U_0*X]56?_M 5WV.!MXN,M[2+9_Y8T_.?GWKWPN,W\56DZVJBN&<\US
M8NFM9.0%Q<>H.WX5V_M'V\7?QS5_@X7YM-)SJE*=2/#<,<Y#$<C;U+ [;FVW
MUGH2XTF,3T:,,=4L6/45AG/8 [> K"K$B<C#)3=]C>+/TI9Y?WQ%$"<Q$.TG
MH9^$_G2$/H91!_H[$'F5F[RU/(U,'W!0\ND:X*0(Y/4@]R+1%%H%+""=IH=#
MA/^-__UT0*8#<BH'9 QOOC'SH*4SI$-EO:1^)!?&0N1DT04X:T!C_W6I'"=G
M6SN.!5JAP5!C2B!_P^'] :3N " @=+ G2XX>K;1R$WCJN.2*[QPR$+UU2<JJ
M;?9YQ5S!IA,V:8(?GW6[T80.M;^ZXBSR'B_G(>=]D ,_2'X3@'U9=<D68&JQ
M&X X43JLW06N3/D*3W;[)P1H95$N^'ZN1IYE"2A^[SVY&TDD4I:W[BFQRO^E
M'=@CQ+3(.S9U.'W2DYJD"8L>:=/0#2X 1PJ!4Y5+!R2*4(X8O4PVY 4%=W;>
M=<VBQ!QDZ-^O]N!KI/\,O>5:J>"LXS5(K>G)VL#C?9#?U$['T).+W+V4L@-#
MW;9OO05/\_HAGXJX+$[SF"3U8<>A9-*[<M?G@1&&"Q*F?1>'*HX;[P-F=MW4
M0YJ/R/QEX+5+JRU#,R?EWPQ!S=RO?\-XZ?[25;[ME)$PP)8>KE<F5^!^77[M
MG*DA4$+9.4+B[N(VJZ,BCT24*>28)$E.[3^)"^Z7=-4<IJZA@2B4B$]I]S(^
ML;\$OY#?.6)\D#ER5"RIY+A#1VB6="LB/:PI6CN-,D&*?*;FM+].S6F_F:GZ
M!RI,RHL7:>]L74B.LN3QV?#HK!U3!1(+))?M"NI0[:0 G7@5<3J9'G.T*[M*
M'B:4>OHZ#F':L3LFCU'%)F/Y@FMD$$/4=VQ'N$[WTOPF;TU;>B>3,*PWQ:)A
M[+ Q'&'(;*A36VB_BSR94.4P(L F0!((4\XOHG\+3F9C)CG:1>LHP,Y2*%CN
M%-_-NW)4&18[* 2(UR47UU(JY1!DMD,IN+6LE\)'W$FO?BC)V=%V#KQUZ!,X
M!\?1-MH\#;UTEH5JT)@M81)/11A);X2\Y):=2]CUJ!T,<44Z#Z)PXO1OA0\8
M1G IHQ8%$QP+2'3A_5/TL0^KV[A;>HPLHB#1#C3U?7G#!,YM?X9M/"\PZTTO
MOG=YVZG3N,X)I\:ED$5FT4:+SI&4UWC<=Y"(H/CH24H&+HX8F<CH!DSCJ,L"
M.L7XI35B]U=_%@EHN\AF*B N4IR3\1)I<_B9$[U#Z@P(D'0<@M)"FAX9R;8-
M&M2'!S2K'^P([<M]AMZ1'B*:A*/Y& -/QVP+<8TS-FG2HK;;24])$IEE,MD4
MAG?6)4LQ9NM&3@E<'P:>T,"YT788G#L"_I")O=?TBN_Y%JJ:&I]G"8R!PC0C
ME>+:33<S+->A>9NZ=ZHJXD?SKQW@Z_/#'HMYGXBA]';$T?T!_>\'V!,V/VDK
M$&1#&7'M)!A^W9:<K= +1('[1_J$\!>2QPP2$&DO6"K1<\02KH&2N!;T&+;Y
MQ1A .2("MG3XALD5!RR^C4$):08-EKSA3@Z9GKL4E%'S.T$^DB:X$#WG+;9=
M6<MS \S]L5ITSQ/J@$:SO -;[;NR&W98A4R.EXM7^>YUG6]G/UAH\W+[--^6
ME%'Y>]OT6T7*R=7?U>NB%9XP<>H!79J,P1IB-"8*TL:IF]A%U,TV= XXE\ 4
M6GG+!-/J;=8D+W0;X'QY(2QW/6&PSM#')-J\03ZGDGN% ESJ4Y_%UEJ?ZS8J
MCW%8D?=2=XS]RE)UQ'%KRF@?1<F[,W/'.3I'"4N<4;@PHP'F#Y0ZWAQ0)V?"
M:Y- -+ Q#K ZMV/%<"_AO"^K0CJ81[Y..CDGFEGAXM$&81G["*B$1[?P$!)8
M0Z1;NN6C)C[0N(R^<ZB?S^*X_C1Z/(Q#-=CZX"/=S0%*LA)./-8;9V\ GS,!
M/TJ;BG7L!(G;,$X74N(0H<S(#T] =0'0S03I$0EAT!@+5#'VKF0DPI)F$<7P
M=1G1>!372TL'@K=X[.)\WEPE?;I1L=U9_G6'&%:1E"=G J[I<?VW:GZRLC-
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MDUKF*1M\UR<6G'ND#*E[GG'JBL0\'*:)3W7?S_=N)[7,T_&ZZQ.'2J>"1 [
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M42<$EC7!5]WUB9FTBBR?=PP*+<U. C<)W"=Z8I.,%>:LLAWV4+0Y=8R9B _
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M47D:G2(P_ZT]YQH%W8_(W*<VA,_6AO!H:D,XB1SC&T;@;Q<$N<H4&);2,J:
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MD=J8!(! 5(Y9O4_>,*$#0Z%-K!CW$NS/KQ(S($\N&B;QJ7<E=7/LL /,7DP
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M'#["$Z4JN0[Z*J675[T=:%!V5/$4;WZOA2M]$/83#P8HH( ,-X)K>&%4,*,
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M,#*;V*V*B,5XUUX0DD@FR86Q$%$)07P&8>D"VBO!3A#D-ED9\U,T:KB@.,\
M@2*?@GMVX"*3;#]F^SZIS02X$"TW4IM=0,QIH;M/8GP,G>!Z3;H2P Y\$WQV
M'?CDWI"T![HCQ 8F!TK1DOT1?O0*J>.OQ'5H$["8)-SA],E I2:;887,/_2
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MZH3G7"?->__BU#["-TY8^6[0!OOY9BI"-<*3M;0*$BE6>@@#+:3KQ3DCF!8
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MPW'94ICDR226;ER:HLD_R6LO'LK+0W3U<"$0(74M2QK<'3,8F_QSTBT6J@'
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M,MI6Y(TE7A,1?>,E W:?HKR^0*Z+[JP+%4]"HA^QHA G82GYB^6MJU^!&V@
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MN9X$F:(]J;= [=>)?)1K=BHF-$<E/@+@:6_&;O?T:'O"CNZH,G]^U6_(_EJ
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M.$$?B$S3U_W>;EG+L:7>+<)9 VV[>_3^O0-@]%'-8F#E>!-X-3!*R;M#!S+
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MB*,I[' $2RI)$?K\C :^ $613N+0'(R]H9A 5+5%_.?W8)J3S;N_6]J!3CA
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M$F=N4=SXF5L4-W[F%L6-G_DEH;C^$2C3"IE:U9ZIY-]YD )HTKKDZ[9TVGA
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MYI>$XOI'GSZ8=NDR\L692OZ=!RF )JU+759+IXT'=(OBQ@.Z17'C =VBN/&
M;E%<.YMQ(QE4?U<RS"9D,5ZK<"P396_=J0, V_AS?8BYQ46+BQ87+2Y:7#PG
M7-0_;'4T&B6Y\L65'/'5=C-9W=Q\8[1T2QNKI[W"^"%-L^Y\@W&OO96ZQ6B+
MT1:C+49;C+88?588;3/1VDCFRP!TB^+& [I%<>,!W:*X\8!N45P[PV\C(;V+
M.%MQ:6M=?(\!+-6/\V&HUN)\+$WWJ-['H/4G6YRV.-TT3@\/#ZJJ!5O,MIAM
M,5M3S-92#I.!]V,VC/TY_E?"UIQ)'G[E3>F:FS_R- O&\W=F>F<1-*.9;A@G
MODIHTT%T^;;K0C%48]XE[7=I;@VW;O>'5P(Q.).^#V/\_*J+]BAO[_9+;'B4
MG26D+MJMCPZ7%=WLU[V,KVH<JA&6=9@V^^,X$=FU"J^4F +P)VGG+L[!8O#W
MSRSTXN1_+K8_G7X\.;T %KF-M%PH/CTAWQD6FT+HBKXP&Z.K;*+$E8*?HTL1
MCV&^HHF-N$QDE*7;(.PB,9+IQ+NKE/I3HE#0+$^W]9_2+(FCR_<?@P0@ -QT
M7&H6J)\^\2(<:GVZ2;[DB0@B7\'N?!5EB,=M-9V%\5PIX>OM@VA)E)@E 6 "
M$%2T3E2^N ZR215)4,HP_ZY_R&(ALRR1HXR>)2J3023^G<.2Q@&,-()? Q\&
MI5=3E8#X@N&0^C[$,O$]6*A #4&SX&CB=:_O[7:[1'EZ0(7[@15&:0!JB1.&
M@&B'. (-&HQ4VA&?(O@C(Y(VNRQUA/3$M;*CT!I2 !PL%%8)ZY_&.?P'QD60
MPV.9.<!2WQ&:N(QQ'HZ#,,198(@@$7Z>!;R_.&>JDM%<R!23JT/\+\WT#;[9
M#M65"F%3_\YA8%\,Y_3)5$V'"N; J0U@.NLCQ)LU_Y-I>G-[X&PX28KUW$.$
M+YB$PU "718GOF5]A9"HNN]OKW]/%?K7F;Q4V\-$R6_;<@R#O!4RO);S]*_O
M[Z&0U?3]3U),$C7^^=5?+KX<OWI_05@ $C@&@,/JTI]^E# 0OK@Y^_")B? "
MJ)VI;ZC"^!JY-T5#!Z0/,H++NV(F ]_PV J!YN>)YDHQ#E+0JF*N9")0"OKB
M7,TRXC,P73R!USMVQ-<XDJ$OSCKB) E&WU*8ALIH)\C?,W'4 5Y,<PE3^#!G
M!HP[4MAF%OF[M#@RSD@8&&F$?&]7UA$7B]OQ88%AS-UK:<7G^72*=IZKE003
MA1S&,&FB9HE*5:25=X;AUN55?$X6-H,_T"YJ(U'6Y4L\J=^][D,.<\GJ39>@
MW?E>U4<A@SO<&8^6PF:AUZ+K[NCZ,EO9-KO%5PWQ]8M2U?5Z+;:>_/1WTX>^
M-QG"A0E<3;'KHL]3.56U(I?;P'5_3M_ !>5'U^ =5O)]>_M\0Y KMG8J@X4M
M@I\]@D]D$BF_16XCD;LR VJ#N*U_-XI?XTB<J=E,)>U5TG4M**[5S)O%16_7
M.SQH[\JM$4+HN*B&8'FI".D?>#N;YY#Z)TQ_&DV")!87\IM*Y;>XQE?'U":E
MO]68-9^YU;(-F+G5S V8^05K\XVXL;]CSH"<8M+ EVN%-\$-:J;.;^_$L&GJ
M;'KWAI8*6BIHJ6#M5%!MA[2DT))"C4CAH?&*9A)E;6BOF=T$7NC,+8H;/W.+
MXL;/_))07/^X1]OVI?&EZ2U._Q1.!SWO<.]6GZ-%[/-#[/Y=G,D6L<\.L7N'
MWDX].;;M$K),W"^W2PA6E2Z7Z5,=:+_K=;M=D4YDHJBR?!1/I_ &OWXM4Q&D
M*=[  ;_]HH9)CK6GO5VNC,4Z6ZP;U6F9=%$8?'$E0_Q"9E2 RO76Z6@2ATH_
MPWE>=SO[AX<"OZ/).^Y(. H5\IHB?USJ8AG_$:UWN5[7<T>:P$A5'0IPP'V2
MRZOVSKM);/^"69Z,8#15?@N^VG%!V'9;:;NMU(X_;>K8(W"H'>L1>-2.U7)I
MRZ4W<&EUAL2ZEX$4RRD;CT#Z/-!-=-^2_$LF^>K*O@TH)J K[GB4BH2;@I'.
M8 V%'9L$^"'?5*;UADQ+;8N^JLL\Y*XCY]O_$)^ %X L^UO1&U"]'K4ER3-N
M;B)'(_ 39#12W%?JEZ/S#^+H_%A<Q+-@)/9[!\!3U"@IS:?$+2E,[2O3& 7G
ME_PS=JP:@4^!+:%\XA=?I:,D&/),XSC.HAA6?H#L@]_J9DS_YR\'_=[^.^"_
M((*%!#($R,(6I\HPY2_<+X:4:S$#K2!(Q5$4Y?#TJYK%248:.4ZF@ K8N>[\
M<L>&,V@0&*BGD_@Z,IMDO\I%!/=W&<L@,9J;WR34@!!@1!$,8FI.$RD03RDW
M\W('DJ,,%T^#>"(88_<:C]M;3>5<#'%:H(__,&+QBS!($7?JNQKE67"U+&.>
M9P,X%,_'21P%$8OJWV+ 4W(IX4_3*.>$^GIAZYQK!;2FY&@BY&P6!Q$"Q&WI
M@X@[C:\8P2S^4>;G(VI=-#>M@K!O4+E)S^(@"/";J:8)+>E,\SW84$^<@!S)
MYN)3A)63V$_I+)0-Z\ 7B:/\$OX48$@@%GO4>TZER#!!.@%$(][_$<77XC<Y
M3#T$1D>LAH[8PO=1CO6[[^@U_)7^[KT#@7L]"8#RT'Z1/I@<16\Y,AK  ?"I
MP5PDO@#A(75I5Z+',FD<AV%\C<VS4MV&:I@$($/F5L!RTZE9$H#XG*%@4C++
MM16#3^R:B)= 9A8] ('( Y!WN)M$P<Z&))^ OU E:$$]SD$#("B7QC-["U!Z
MA\R%,(OZ/@F&0<;?!ZB<4#8W@E=T$P!70I.P)U".PMQ7;\66?,-K"2R9N/8F
M$-364+^!S=(L,OBGQ5=';]S?0>"!? I87%%(%-_Q]3N \RP)1B0/::'P3.EG
MX%*"/IR2KB?KU+Z"1+$UKGBM+!OI;2+)U'P+! &T0K0,_P(3/('A3/.WU*-^
MCGF8V?:4A7 E@HW3%.@D1(X"RAKG2+1&%W*'3.J RG(X!/FSG:EDJM<)^U1E
M<, 8N)(ENYT4+:Y7,*]9BP.-B2#*B;78A6 K2(^"U@F;/YKN 3;3 -<,YD V
MGS&#:4CDD>E;Z7 ;;*=D!$UC^@4LF)"[ZC6")XS^P,:)9WD":&7(6$"\U:T2
M]7LDU6;.B\M0JVY=6D%C"V2%%I^#/7I*DC8?IH$?@ &FTG> !F!*--5@XBF*
MO*F2$2,3Z"D&TL*'EGNYD^IH$J@K38; \9>*87L9RQ"&A,^N M_YJ,P\\0PE
M8!X%&2T ES7.$Y@^$01-W: 031GDX93I,)L A Q9EY1%-DGB_')2GH2$$HC;
MH4PY-K7(#8VCMB-_&D1@$!=M9TND5$5W!9T%J(_Y>^4T?"V!%*$79)E28DMK
M<<7ZD4A"BS$BVF(E<?(&I 8 '40781AT(-BMWHJ7*1Y!(BH'?"<H#*D;+_D(
M('%2=*ZN)S&01!@672ZU[ 9A@D(I4NR7+ @E(_VBG*Q6["7-X0V888@D>F5V
M[NH">&B-(1X6IF!ISKV X=\E-0&+5L SGC#ZAQU"Y#T" #%'2C_:M;%MLP(<
M)5#8M<#JIMCGER5".@KPOWFHA4!BO5XT./!?V&XT+E-$;?IL/MGI6TTZ]P[N
M&?5J._<^C80\@6=DKWP%,VD6( 06I>*9EC'*O I,4Q8SE<8-B:.ALDKJ9O//
M6U#4A:VV4D^3T$-C@&5A$0)9%AJ-4VSG+*:/KL!2) K^YS(&%O#(:^2CJX7C
MJR6KF (H(& O@TB&X$AJ>?L?]N!PEJG\'DSSZ;+FJ!K.]89\("/6*A@EEQ@Z
M!9\4'8 *(O(0X7]0, Q0[2,L,.Q'9AQ0$QE]HQ@,Q00-LM$$S2Z0]N!TC#+3
M39K7Y7%XQX;VTQFX%:1D0,WK3=#!730"&9/R\OK]"F"5W0?ZZ5<9\1$?N>5]
M\G)1 P%M&YL#( AXALUJWPJ[06,_?3,?]93.4YR8#7_!^-*(=L&@7:U*ID/
ML"%2.#6PP1'J8?"_/7QAK )D%GA3?9\%.+J\1$ .%6P-/K(TA8/ILX^*N3KB
MAK494Q-;^H?LV]"5 "04,.!IIN1H\=WG/+(.@8FE.A$$$"(PO$95HJ8X17EH
M/)<EFZ1R\++]!W9[7%!^6OZ>* OH'Q:P=?2&FHK?P@">)A9W[8[-SJX%.+<5
M092)O,(NZRHR9 -$DF<$1WW0#-X2+DPCP9AK-O3 N\5E];N]GJ#>SHM!*O+R
M/]RZ%0?;I4@$TE,:3 '6R4-FUQ!"S?X0"#$EXQK(HKP.4K9*07YE[+3' #"
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M['%:D;0<T5F,CM(/L*^583N$-/ V!^%P;_=8DAX;O]+8Z53E1WFN5T3SL;O
MF6VDD36\BK.-7O\=V\@N@1 BR^_H\Y,BKK J#E N^K\U?&B=>UWYPZ+?H+4B
MNDFI!$T] ^1BFTH^_EI4NICS]D2M/*[3,=3%C#29<05@"H[Z\H C5-WR&].;
M086M>[%6!7[ ;C7+C43-,(LGLKD[G-MXI]-NYP@%&)I<]B*Y.DZ6YA1849 N
MSUPZZC04?].!O9OU T2?CN7(#8\M+@;)$[,^D:'TZ9"I0"[*=G5U#2A(&P(
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MK%C-UW!%/U_@QWI+,BZ>^*P&BY%KZ(9&<]:$]^H/:,-I;.<M4I$GN[W!_Y-
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MHW3_;&J;(#THE'[@S:RDF?)PO@%2@>?[<\.BNCT>*@XK]@;@"I""<(5LR!'
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M#HHB%[6X"C]UX-U@K6=D[T?@9_JE>$65-".]HC!.#0Q96!I7Z8YM*I0/"-_
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MTN'KN+EP28@]@_8[*.X,/<B3^#Z8SA!/XLHYMV;C_6L_R2L.[54%PBW^>/\
MT2H<?+K\!KPWQL0+96Z$&1=0C:>MPSLK&/W1'/397=PJIQN]3PPAE;FY< 7
MZ:D:,10^DV&U,S$#WQN;3+#F)B:*A=DG8VS@ITG PZ&BT!)?\Z,$Z"3HNI,L
M(K)VGIBL<K0Q'Y\A?'3^LFN@1VLHB>R.%13D)_DZ@DNE=&<2?4=!3A&_<'VW
MQE<(,]NA:!EN$TY(%^%(^K7'M!E(+$QDAZ&4!<6SU\Z&+Y,+GFSQT_.]H>
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MI"H;WZ>9*E&Y_#Y\^=;"F]H.4$#?(6;HOT%5+10*^-_Z6[CT$44+EE&5 7/
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M^Y/?!<-*_7[N*TN)<]XK'T'B[)1TVTL 7 J<_*U\!,!6CA)27 ?GFX/?1;5
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MV'I6M C1R%]H9#LZ<P@F\"X?"X0#0L3:*@)9A<+?@". V^::CAWU$*7P4 Z
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MQF=D8NYWGX5'6E3KC0T>Z1(]N%#>>"CQK3;B#F5'@_'4![79A>5B=$ML9=G
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M2D:<+)FA(V9Q@T),@<?G)ZICY_G"/#LX<)@Q#'+94T&B.?_<$J,_T&'-/V,
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M2<_$(*W$0D+%<-4SK!3^[S?=8J@T_*]EIQ0@20;1'PW&N>5IA; HN'(]P*@
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M#04>7\Y\X2-$%Q3L"D0$O0F_-=WO9@!-V)HW=JT')&ESYCPWJL 8_V[.010
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MBTF@D:-_X5J.RX;DH%M862Y*@KBO,?\P@\@VGK44;[>^#841D@SMR0VBR!^
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M^R]XTI+9-(C&;Y$G<M8P)J&'S>%2'.W9H_KO2Z,X[>\P!+#:-NM42 P\?,3
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MN?M/WSS)=N(X9(FM"+(HUF1\S@1+M8-KQCFY;;0E\[5P9#%9T MCW;8])F8
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M&[N2,9L7PO97 5]4X6JCWSZA!9F]O%NR8^F]!ZX9=&M70!T'C/<GH?;7^C6
M-@_(/9TE?EOW1TDY!R2G9;]-.IH)/_C0@ 4%&E"BD@.4_AK*_\=()C0RL!R[
M<E/'LXSI3/=22UQG9VE;_0P/F3?W+S*9#HG<9M)!"X;U[C2@0,WQ@P;-$0-Q
M/J<#,2?<G2WKI;!W?LVVQJ_$WMGR*FSC>F%,/YQW#SMQCAG>,UW0FECS2PLL
M/W_+F^ZFJ<Z978QU*QY8P3!*^TD#C1\3YU-M3F9IX%=*=ZR/6W$;-$\4G<A
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M;%;WLZ>9:9HGQ2-B'M<JN^\B3^?X0VD?",9M? :2PI&S&Y\8LY;$PS-7E\E
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M'? /;KP&X-_97_7OO7@-Q7\T_Y03U*AJ\?[A8M MQ(-:F52?@).\"A)L4O<
M2ET%VC87U8B$\(A=-% 21]GQUF>,..;4>N[+ =]>H'>V=WS#0HG/PIX]T[.S
M4W!'R^3JW(;E"&[TL6K]OJNW?[-K9Q\)+3R:!R/CH7-><+:S>VCK#LQ,7;9F
MJ>Y[.;^*O0#K_70-4L:5/2RIP<'!N]V]IM_FY[=>4"#?/APB*Z#8,HL.5<.^
M@DAA9\N-4.I@>X+RS2&$3=<VO-2(_OSEOG8A#W\_/^CCMCIG]F:36)R9WA1W
M<XK.87QA'OX4%6Z^>'D M,GOG$(SUC-K=ELXVT-7@04]]]\ 4$L#!!0    (
M &B DU?'R-"&ZAL  &H@   1    :VYW;E\Q,&MI;6<S,RYJ<&?5> =05&O3
MYAF&)$$DAR$J2<E!@F25."*(!,E*AB%*$! <1 ')24#A2DX2)0P#PY"SY P#
M@@P"DAF2(R"SW*]V[_7?^K[:;_^_=K>V3]6IMT[WZ;>?#N_I/H09PE?@BHZ&
MM@8  H& QQ<70)@#[@ DQ!<$_O-.2D)"2DY-3DY&1GZ%DNH2-?T5!GJZ*W1T
M#,P<K Q,[$QT=&S7V-@YN7AX>!A8>05XN?DYN'FX_U0"(B$E)2<CIR$GI^%F
MI&/D_M\F0BM 2PYH@)3!H*L $2T(3 LB= )<   B ?V#@/].("(P,0DI&?DE
M"LH+ <05@ @$!A-=V'\!X((;?,$'B&E)Z'@DU$CI'SPAN^K%(/DR,8?\VNVJ
M-D:#T3U>*9NGH9<HF)A96-GX^ 4$K]^0OBDC*R=_Z\Y==0U-+6V=AX9&QB:/
M3,UL[>P=')V<7;Q]?/V>^0<$OGH=%A[Q)C(J*?EM2FK:N_?IN7GY!85%Q1]+
MJFMJ$77(^@94>T=G5W=/;]_GL?&)R:GIF5G,$G;YV\KJVO?U#=S^P>'1\0_\
MSY,_<8$ ,.A_T#_%17N!B^@B+,1D?^("$3W[4X"6F(1'@I1.[0'9$R_ZJY(O
MR1EN)^94M5VZ)F6PQVCS=)2"B5=ZB0_W)[1_(/OW@(7^IY#]!>QO7!B "@RZ
M"!Z8%E !3FQ^6"''?,LI-1OV?LWWE\DF<YS9<-5T"<9FV67DTR1=27PM?S+Y
MA?2$([#7A4PMZ_Z=:\(P'V[;&Z\ZHVR>0?1<$[36.(28L?QIP:5!"@U58X?F
MY>;Z/I'EN8AT.;LXH\?]W &\JHU:P]19MA:+733D&PNB:1WEES^4]!6J497>
M#(N>$>DJ&Z#_G";+LTPBWM\LU?3,_M)JB-*SK=26@VWF7WM"X$[,AY;P,UEX
MI7;N8/$=6]K,1\)C8M*Y^P.*/>IRK')?,N7ZL.AXL[WX*%%E?@+@#F^GA:ND
M\28@SC.\'9(LS9L2H\6\>->]ZN4MK@IKU8N$NXK/CYQ=+W92J7$]YZS><QW!
MQVWJP!1*Y5;J#HKJ)7Y:V7ZVGVFE8D_CY08N$XV0>2TU.2-PUQOVW(MRN&/Y
M8RO'9E-]77^-$U=3Q3R%D"5V^11.31"]&&3F.AQ@V^-XV'YK93?4=F3K!2>^
M6=&%B3DY8_=*^WY#Y(A<[/G,X*>K$J _GD2Y66TJ9EZ:+K>=.MQ6:;4_DU34
MO9SS*Y07H86 J/ \F)(^"*J*--0QT'WY2:KO:HB2><>MG43L(/.IX[WQU?"Y
M;7KSK<:Z_?PO#+$0>QJASW^ 7VV L/'TFQB5,%?AG2,AU@)HXXRP+=/4@@-O
M2OMUVU$3@22M0U9>,)9KKSQ(^]F2KH!V_5Y%9=&ZL<E)LNC[HO["@$\!XP&I
M!SGO^MB(#?K>"MV@?]N[6;XL1HQ/.NV231OWYSB#^B QEJOO2WN\7*R&6-BD
M;M9+:4.N\]FYYF[#I5:[!<$3:#6LKHK:Q%9MUX@' MI?_*U>XI%Y7JV^AJ%B
M&6N:)\F$F^Z0]_['\EC19;W)VN<BQ@L#O,R>^;BR*A+/LNP03=MAG>475YV>
MW5J>@7<)%6]\=$UJ:CJ.AC-F%A3-BU.4TZ.K*L8*D$2=[*)&$>"WDXHTR[KF
M70O,DXIW,>%Y2@6Q)1GEDE"6U*$=>4J=G7$->Z,$1N*YKY\,\A_' ,_ALVZJ
M!"#>J>K\:PF;#T:CO+"MV+E9?3!_$W7] >DT9UY<RE=KFJ!KG$7%ZC<KP];J
MF&Y-E7.L(I][L6\6FTDG]QSKI6NF3-0(,2;>7F%]*1P0<<[H7K]X^8PK![ID
M>;M]\5Z<O]A6;>$XDS&*1\9:2+=)8O_3 <@T31Y<G$V3W]P'(P#*H_!%HH8Y
MD>?:$XKVI?[&$-:D4V@H)#(_=<[N7O7.7%7\XFD$+Y7?D!JXMP /*[;P1VU@
M?[3)IGVRV#2AU_7R#2;I^>#B>MM-877>]GD(35HM& &]$0:8$( P.%;I-CEI
MTU>%<IWCM0Z90#MF>JLYQK%=FP/#89X#)%%!2JI6JB98KHU7GVR$ -@A"$"6
M4\ON2\.*J86IS[#*+0*@\OGV@H5XQ+,>>XZ^2D@3_AGVNC*OU>:MF,#58NR,
M".(H=C*E6AINOY])ZD>T_JAYE:+BFO!&U]M06 G>.6?P:\MKE._'O=BNNAK&
MW."ZSY=$!@<G/N=(VA_X27!3%^2SZ).QM )( G"I.]VG%D4 7NL9WDI>T+9!
M:::XN\<4%\P[#NY_NN+^9=66W?%9OZ5&8D ^+%T]L[*P["G&ZF[-[56E_%*J
MF%!)FJI*V?$S6:P;DQ#'BVG-B2/&FHD=4;=:\SG\6A,RU/^VY,\QG0?OH U[
M]M=L$U@RA0KV1+?)H(@]I4[1:8Q1S$,+BVO=-@X)53>RY;U"(9!)-7"HIR>P
MBAL*<R[>D+DU%%'LU#XT>$2^BJZ+M_]&/F>*)1^8):[LW8@_$.L?5+M @"AU
MEDU+\!<SJV_^E- 34*#IX>[N%J+&O\K_@)6$58MBJT<.2&CU/D'$1RE:BC:0
M3+_<K9W-1SR'03[<WAB9*W/YO%$?;LI>6U':>(.H).[IY?5OUJSF_ WE:E^;
MC"J"M+T9GIJV>=LYCF\OA]F*0H>N.;K*C)2UVC%]-PSQ]?8OZH#!EDK?+$MI
M8EEIA>]YQMW1L*.:[9YL79M_N8"JK#8C ,.UUC]:*P4F% 66H:4$@-+EUKU
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M0H?R1N%D:.VVZL:^G0W=LQ,N#R4..0).'FX)G,/=6W;7"(!9=@0T?($Q:B$
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M    " !H@)-7\W1MET4"  "4!   #@   &MN=VY?97@R,S$N:'1MI51=;]I
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M.8?9;/E?2\@*VFKP)>)S&WSSG6R$),[^DO+&TIK[\M/PO@-02P,$%     @
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MI>OIH5@J7>G.W4HJGI3#*=EGQ&!+\'5PHE@V=A0^<!3"$<US%=3H0>JVOH=
M_6E/@,I?[1BH;6'0A'RUXN[+8"J1[O1Y;C8?0@)P* ",PI.3E#I'+N0@J8DT
MEOK02RAKA\X(%J2Y3+RIB+A%6J$I%V@I%:1,C1($BEB,CF1@#UA-/C0RD#R5
M- 'IE*^5 HHLY8;4J-V;C)6NEBBU$0@H S'3H(33-Y)'G/@=T[)!+%0M1CB-
MO"SM<344U!$4C/$BV$?*W1<D#_]92-Z8M!X!>G.ZVQC7V LF,B"X<J.534)N
M '4J,0G#/ WF> +")1_*2&8STKGKW-+N8J%G4>4VA@==ETI4*Q_NB@DE>9H
MU<;J<M]'_ML ;+$Z$@IR.P*XT2(2VC6H"PIQ!V#L+C(!@S<>(OCS0/"Q&29<
MO3EX?? P,PE53P2+#<+<2[SZN\9K9\*CW-(3);,(0U2&<H(T-&LJO'L%O0'=
MNMOU19^%)P:"*HTK+8<ZSSX=P2:"@-_W%E0WAU\^[6'#>45N=QSA5@+Q-*SQ
M%Y)\KJ +=@VZMLOGQ[B@4]>B6K,M:\'W%=1($E;[?IY2]B_IQ3568VTR/*>7
M=+!EL [LSQQR$Z8//S$D!(Q!6BN]B\!]@,L>&*N';T)>N:C&W-R+:Z(["WL1
M6!U@UZ/@Z!F+Y*V(BM/CE?ZEO[U$^PKU?3F".OW7'D'9-XK!?*,H+<B*N',9
MK O>(KA]A>)^5+W>1\=1P68Z-?<BUSZ R3B662;$9Y3!4$-&4WL@$9\U<@A(
M@X@-$3W^ISIZO@^)/W.)\.V>DRO?GC._>CEI>KYXW/E)DQ>A,D.C!-SH>),.
M2GTI (Y"L]Z?^$P%OR41ZBHU*T-MC6E?><[?BGP5Y(K#&7>XO(;?>("!1MS3
MVR?A652F& *,(4%+3@D;R&"3QY@N5LI.II 5:]\?[2OU[0O4=GX4Y$',ABFH
MHX3$%Y;P !W[CK[ 6,EI0:DF.IH($H2*CXJ?&J0%1XHXB?1,H'4ZUHX5^0,$
M W'?1"T?+?V8='>(V)Z7-A:]SMH0#?$0*U#];XG5*K63W0'Q].2O(W%#V)WU
M^NU.OWS6&PQZ[^OL^XK]QZK)';/G\L543DZ_*3"7@SLVQZL_0_S,!E&M;65)
MOGSZMMVO84MK^[EU?5G$#3V>CZ4(V<7]?MASA<C*;O07C3=%W#J\=L?6L+WP
M0M+#6YQL%T[!6!BP9@VV]&W.-W?[]PVM_P-02P,$%     @ :("35ZW0/\;0
M!   :1(   X   !K;G=N7V5X,S(Q+FAT;>U886_B.!#]*W-4K5J)0(!CKPLL
M4DK3;K0M5)!*W?MR,HE#?)O86=LI<+_^QDG84K;=JU:ETIVNJJH23^8]/X\]
MSPQBG2;#04Q).!QHIA,Z_,*7_ ^ZZK1;#1P<-,NG@U\LZUP$>4JYAD!2HFD(
MN6)\ >[YI3.])DI3:5G#0;-,-A?A&I1>)_1#S7?O?,NY\B['/?@S5YI%ZSY<
M3,9^#UIVID&SE"K@= E2I(37AH-L\ZJ)LF;>[VX96KYF73C7WM7GWNZ+?;AV
MII<>HMC9J@^:KK1%$K;@O0UJ;7C$YRKKPZ"9#>'5821;Q!I!!DI+P1=#]^ZC
M=^;YT&DW6H-F]7"_T.7\]H,1X.)3N36_D3OUO0MOY/C>9 PWM]/9K3/VP9]
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M4R+?RD;2KSF3U+0E9;1Y4/J8X$)):'6/PQ,HY[%1]:'4OI59)6WK?>?7OBG
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M'L05>A%LQ0\WP[\!4$L! A0#%     @ :("35Q/3)KJQ%@  ?_T  !$
M         ( !     &MN=VXM,C R,S Y,S N>'-D4$L! A0#%     @ :("3
M5Q35X+]^$   2+@  !4              ( !X!8  &MN=VXM,C R,S Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( &B DU>.N\DDB#   -8_ P 5
M  "  9$G  !K;G=N+3(P,C,P.3,P7V1E9BYX;6Q02P$"% ,4    " !H@)-7
M_N:_#HEK   ^>P4 %0              @ %,6   :VYW;BTR,#(S,#DS,%]L
M86(N>&UL4$L! A0#%     @ :("35_0Q?*N=60  G.H$ !4
M ( !",0  &MN=VXM,C R,S Y,S!?<')E+GAM;%!+ 0(4 Q0    ( &B DU>*
M]SE@$Z(" ,>*&@ ,              "  =@= 0!K;G=N7S$P:RYH=&U02P$"
M% ,4    " !H@)-7C!=:8W,_  !630  $0              @ $5P , :VYW
M;E\Q,&MI;6<S,BYJ<&=02P$"% ,4    " !H@)-7Q\C0ANH;  !J(   $0
M            @ &W_P, :VYW;E\Q,&MI;6<S,RYJ<&=02P$"% ,4    " !H
M@)-7\9?OPJ$!  !S!@  #@              @ '0&P0 :VYW;E]E>#(Q,2YH
M=&U02P$"% ,4    " !H@)-7\W1MET4"  "4!   #@              @ &=
M'00 :VYW;E]E>#(S,2YH=&U02P$"% ,4    " !H@)-7R1/0/(H'  ":,0
M#@              @ $.( 0 :VYW;E]E>#,Q,2YH=&U02P$"% ,4    " !H
M@)-7=%]WMHT'   _,0  #@              @ '$)P0 :VYW;E]E>#,Q,BYH
M=&U02P$"% ,4    " !H@)-7K= _QM $  !I$@  #@              @ %]
M+P0 :VYW;E]E>#,R,2YH=&U02P$"% ,4    " !H@)-7),C#,,\$   8$@
M#@              @ %Y- 0 :VYW;E]E>#,R,BYH=&U02P4&      X #@!K
) P  =#D$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
